Rank,Sponsor/Collaborators,Title,Status,Study Results,Conditions,Interventions,Funded Bys,Study Type,Locations,URL
1,"University of Wisconsin, Madison|Dendreon",Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer,"Active, not recruiting",Has Results,Prostate Cancer,Biological: sipuleucel-T|Biological: DNA Vaccine,Other|Industry,Interventional,"University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT01706458
2,Cedars-Sinai Medical Center|Merck Sharp & Dohme Corp.,A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer,"Active, not recruiting",Has Results,Ovarian Cancer,Drug: Pembrolizumab|Drug: Gemcitabine|Drug: Cisplatin,Other|Industry,Interventional,"Cedars-Sinai Medical Center, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT02608684
3,University of Kansas Medical Center|AstraZeneca,Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.,"Active, not recruiting",Has Results,Invasive Breast Cancer,Drug: Fulvestrant|Drug: Anastrazole,Other|Industry,Interventional,"University of Kansas Medical Center, Kansas City, Kansas, United States",https://ClinicalTrials.gov/show/NCT00921115
4,H. Lee Moffitt Cancer Center and Research Institute|Merck Sharp & Dohme Corp.|Prometheus Laboratories,Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer,"Active, not recruiting",Has Results,Kidney Cancer,Drug: Pembrolizumab|Drug: Interleukin-2,Other|Industry,Interventional,"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",https://ClinicalTrials.gov/show/NCT02964078
5,H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb,Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers,"Active, not recruiting",Has Results,Biliary Tract Cancer|Biliary Tract Neoplasms,Drug: Nivolumab,Other|Industry,Interventional,"City of Hope Cancer Center, Duarte, California, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Winship Cancer Institute, Atlanta, Georgia, United States",https://ClinicalTrials.gov/show/NCT02829918
6,"H. Lee Moffitt Cancer Center and Research Institute|Genentech, Inc.",Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer,"Active, not recruiting",Has Results,Breast Cancer,Drug: Gemcitabine|Drug: Trastuzumab|Drug: Pertuzumab,Other|Industry,Interventional,"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",https://ClinicalTrials.gov/show/NCT02139358
7,Duke University|Janssen Pharmaceuticals,"Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer","Active, not recruiting",Has Results,Prostate Cancer,Drug: Abiraterone acetate|Drug: Androgen deprivation|Radiation: Radiation Therapy|Drug: Prednisone,Other|Industry,Interventional,"Durham Regional Hospital, Durham, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|MD Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT01717053
8,H. Lee Moffitt Cancer Center and Research Institute|Bayer,Single Agent Regorafenib in Refractory Advanced Biliary Cancers,"Active, not recruiting",Has Results,Cancer of the Bile Duct,Drug: Regorafenib,Other|Industry,Interventional,"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|VCU Massey Cancer Center, Richmond, Virginia, United States",https://ClinicalTrials.gov/show/NCT02115542
9,H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb,Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer,"Active, not recruiting",Has Results,Small Cell Lung Cancer|Extensive-stage Small Cell Lung Cancer,Radiation: Thoracic Radiation Therapy|Drug: Ipilimumab|Drug: Nivolumab,Other|Industry,Interventional,"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",https://ClinicalTrials.gov/show/NCT03043599
10,Dana-Farber Cancer Institute|Bristol-Myers Squibb,Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity,"Active, not recruiting",Has Results,Head and Neck Cancer,Drug: Nivolumab|Drug: Ipilimumab|Procedure: Standard of Care Surgery,Other|Industry,Interventional,"Dana Farber Cancer Institute, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT02919683
11,University of Florida|Bristol-Myers Squibb,"Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma","Active, not recruiting",Has Results,Pancreatic Cancer Metastatic,Drug: Dasatinib|Drug: mFOLFOX6,Other|Industry,Interventional,"UF Health Cancer Center, Gainesville, Florida, United States",https://ClinicalTrials.gov/show/NCT01652976
12,Sidney Kimmel Cancer Center at Thomas Jefferson University|Pfizer|Thomas Jefferson University,A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer,"Active, not recruiting",Has Results,Advanced Hepatocellular Carcinoma|HCC|Liver Cancer,Drug: PD-0332991,Other|Industry,Interventional,"Thomas Jefferson University, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT01356628
13,"University of Washington|Janssen Scientific Affairs, LLC|National Cancer Institute (NCI)","A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy","Active, not recruiting",Has Results,Stage III Prostate Adenocarcinoma AJCC v7|Stage III Prostate Cancer AJCC v7|Stage IV Prostate Adenocarcinoma AJCC v7|Stage IV Prostate Cancer AJCC v7,Drug: Abiraterone Acetate|Drug: Apalutamide|Drug: Degarelix|Drug: Indomethacin|Other: Laboratory Biomarker Analysis|Drug: Prednisone,Other|Industry|NIH,Interventional,"Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT02849990
14,"Andrew Sikora|Advaxis, Inc.|Baylor College of Medicine","ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer","Active, not recruiting",Has Results,Head and Neck Cancer|Squamous Cell Carcinoma of the Head and Neck|HPV Positive Oropharyngeal Squamous Cell Carcinoma,Biological: ADXS11-001 (ADXS-HPV),Other|Industry,Interventional,"Icahn School of Medicine at Mount Sinai, New York, New York, United States|Baylor College of Medicine, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT02002182
15,Northwestern University|Bristol-Myers Squibb|National Cancer Institute (NCI),Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery,"Active, not recruiting",Has Results,Recurrent Non-Small Cell Lung Carcinoma|Stage III Non-Small Cell Lung Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer,Other: Laboratory Biomarker Analysis|Drug: Metformin Hydrochloride|Biological: Nivolumab,Other|Industry|NIH,Interventional,"Northwestern University, Chicago, Illinois, United States|Northwestern University- Lake Forest Hospital, Lake Forest, Illinois, United States",https://ClinicalTrials.gov/show/NCT03048500
16,"Memorial Sloan Kettering Cancer Center|Astellas Pharma US, Inc.",Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT),"Active, not recruiting",Has Results,Hematologic Malignancy|Myeloproliferative Disorder,Drug: Isavuconazole,Other|Industry,Interventional,"Memorial Sloan Kettering Cancer Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT03149055
17,Northwestern University|Merck Sharp & Dohme Corp.|National Cancer Institute (NCI),Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery,"Active, not recruiting",Has Results,Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma,Drug: Capecitabine|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab,Other|Industry|NIH,Interventional,"Northwestern University, Chicago, Illinois, United States|Northwestern Lake Forest Hospital, Lake Forest, Illinois, United States",https://ClinicalTrials.gov/show/NCT03044730
18,"Dana-Farber Cancer Institute|Medivation, Inc.",Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate,"Active, not recruiting",Has Results,Prostate Adenocarcinoma|Prostate Cancer|High Risk Prostate Cancer,Drug: Enzalutamide|Drug: Abiraterone Acetate|Drug: Prednisone|Drug: Leuprolide Acetate,Other|Industry,Interventional,"Johns Hopkins University, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Washington, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT02268175
19,UNC Lineberger Comprehensive Cancer Center|GlaxoSmithKline,Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery,"Active, not recruiting",Has Results,Head and Neck Cancer|Squamous Cell Carcinoma of the Head and Neck,Drug: Carboplatin|Drug: Paclitaxel|Drug: Lapatinib|Drug: Cisplatin|Radiation: Ipsilateral Radiation|Radiation: Bilateral Radiation|Procedure: Transoral Surgery,Other|Industry,Interventional,"The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",https://ClinicalTrials.gov/show/NCT01612351
20,Georgetown University|Merck Sharp & Dohme Corp.|Incyte Corporation,Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma,"Active, not recruiting",Has Results,Thymic Carcinoma|Thymus Neoplasms|Thymus Cancer,Drug: Pembrolizumab|Drug: Epacadostat,Other|Industry,Interventional,"Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States",https://ClinicalTrials.gov/show/NCT02364076
21,UNC Lineberger Comprehensive Cancer Center|Celgene Corporation,Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck,"Active, not recruiting",Has Results,Head and Neck Cancer,Drug: Cetuximab|Drug: Nab-paclitaxel|Drug: Carboplatin,Other|Industry,Interventional,"University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Vanderbilt University, Nashville, Tennessee, United States|University of Washington, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT01412229
22,"Washington University School of Medicine|BioLineRx, Ltd.",Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies,"Active, not recruiting",Has Results,Acute Myelogenous Leukemia|Acute Lymphoblastic Leukemia|Chronic Myelogenous Leukemia|Non-Hodgkin's Lymphoma|Non-Hodgkin Lymphoma|Hodgkin Disease|Hodgkins Disease|Hodgkin's Disease|Multiple Myeloma|Myelodysplastic Syndrome|Myeloproliferative Neoplasm,Drug: BL-8040|Procedure: Leukapheresis|Procedure: Hematopoietic cell transplant,Other|Industry,Interventional,"Northside Hospital Cancer Institute, Atlanta, Georgia, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Ohio State University, Columbus, Ohio, United States",https://ClinicalTrials.gov/show/NCT02639559
23,Eli Lilly and Company,A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors,"Active, not recruiting",Has Results,Malignant Solid Tumor,Biological: ramucirumab (IMC-1121B)|Drug: paclitaxel,Industry,Interventional,"ImClone Investigational Site, Ann Arbor, Michigan, United States|ImClone Investigational Site, Detroit, Michigan, United States|ImClone Investigational Site, New Brunswick, New Jersey, United States|ImClone Investigational Site, Cleveland, Ohio, United States|ImClone Investigational Site, Philadelphia, Pennsylvania, United States|ImClone Investigational Site, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT01515306
24,"Daiichi Sankyo, Inc.|AstraZeneca|Daiichi Sankyo Co., Ltd.",A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1),"Active, not recruiting",Has Results,Breast Cancer,Drug: DS-8201a,Industry,Interventional,"Alaska Urological Institute dba Alaska Clinical Research Center, Anchorage, Alaska, United States|Arizona Oncology Associates, Tucson, Arizona, United States|The Regents of the University of California, Los Angeles, California, United States|Sharp Clinical Oncology Research, San Diego, California, United States|University of California San Francisco, San Francisco, California, United States|Sansum Clinic, Santa Barbara, California, United States|Innovative Clinical Research Institute, LLC, Whittier, California, United States|Sylvester Comprehensive Cancer Center - Deerfield Beach, Boca Raton, Florida, United States|Specialist Global Research, Hialeah, Florida, United States|Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States|Piedmont Cancer Institute, Atlanta, Georgia, United States|Straub Medical Center, Honolulu, Hawaii, United States|University of Hawaii, Honolulu, Hawaii, United States|Norton Healthcare, Louisville, Kentucky, United States|University of Louisville Research Foundation, Louisville, Kentucky, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|North Shore Hematology Oncology Associates PC DBA NY Cancer and Blood Specialists, East Setauket, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Aultman Hospital Cancer Center, Canton, Ohio, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|St Francis Hospital, Greenville, South Carolina, United States|Accurate Clinical Research, Baytown, Texas, United States|Texas Oncology, P.A., Dallas, Texas, United States|Texas Oncology - Memorial City, Houston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|The Methodist Hospital Research Institute, Houston, Texas, United States|Texas Oncology, P.A. - Longview, Tyler, Texas, United States|The University of Texas Health Science Center at Tyler, Tyler, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Providence Regional Medical Center - Everett, Everett, Washington, United States|Imeldaziekenhuis, Bonheiden, Belgium|Grand Hôpital de Charleroi, Charleroi, Belgium|UZ Leuven, Leuven, Belgium|CHU Sart Tilman, Liège, Belgium|AZ Sint-Maarten, Mechelen, Belgium|University of Calgary, Calgary, Alberta, Canada|Institut Sainte Catherine, Avignon, France|CHU Besançon - Hôpital Jean Minjoz, Besançon, France|Centre Georges François Leclerc, Dijon, France|CHU Bordeaux - Hôpital Saint André, Gironde, France|CH de la Rochelle - Hopital St Louis, La Rochelle, France|Clinique Victor Hugo - Centre Jean Bernard, Le Mans, France|Hôpital Nord - CHU Marseille, Marseille, France|Institut Régional du Cancer de Montpellier, Montpellier, France|Centre Catherine de Sienne, Nantes, France|Hôpital Saint-Louis - Paris, Paris, France|Centre Hospitalier Lyon Sud, Pierre-Bénite, France|CRLCC Eugene Marquis, Rennes, France|Hôpital d'Instruction des Armees Begin, Saint-Mandé, France|Centre Paul Strauss, Strasbourg, France|Institut Gustave Roussy, Villejuif, France|Ospedale San Raffaele, Milano, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|IEO Istituto Europeo di Oncologia, Milano, Italy|Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo), Monza, Italy|Ospedale degli Infermi, Rimini, Italy|Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Torrette, Italy|NHO Shikoku Cancer Center, Matsuyama, Ehime-Ken, Japan|Toranomon Hospital, Minato-Ku, Tokyo-To, Japan|Aichi Cancer Center Hospital, Aichi, Japan|National Cancer Center Hospital East, Chiba, Japan|NHO Kyushu Cancer Center, Fukuoka, Japan|Hakuaikai Sagara Hospital, Kagoshima, Japan|Kanagawa Cancer Center, Kanagawa, Japan|Kindai University Hospital, Osaka, Japan|National Cancer Center Hospital, Tokyo, Japan|St. Luke's International Hospital, Tokyo, Japan|Cancer Institute Hospital of JFCR, Tokyo, Japan|Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Hospital Infanta Cristina, Badajoz, Spain|Hospital Universitari Quiron Dexeus, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|ICO l´Hospitalet - Hospital Duran i Reynals, Barcelona, Spain|Hospital Quiron Barcelona, Barcelona, Spain|MD Anderson Cancer Centre, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria, Málaga, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Instituto Valenciano de Oncologia IVO, Valencia, Spain|Derriford Hospital, Plymouth, Devon, United Kingdom|Queen Mary University of London, London, Greater London, United Kingdom|University College London Hospitals, London, Greater London, United Kingdom|Western General Hospital, Edinburgh, Lothian Region, United Kingdom|Nottingham University Hospitals City Campus, Nottingham, Nottinghamshire, United Kingdom|Royal Surrey County Hospital, Guildford, Surrey, United Kingdom",https://ClinicalTrials.gov/show/NCT03248492
25,"Pfizer|Astellas Pharma Inc|Medivation LLC, a wholly owned subsidiary of Pfizer Inc.","Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer","Active, not recruiting",Has Results,"Advanced, Androgen Receptor Positive Triple Negative Breast Cancer",Drug: Enzalutamide,Industry,Interventional,"Rocky Mountain Cancer Centers, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers, Lone Tree, Colorado, United States|Florida Cancer Specialists, Altamonte Springs, Florida, United States|Florida Cancer Specialists, Bonita Springs, Florida, United States|Florida Cancer Specialists, Bradenton, Florida, United States|Florida Cancer Specialists, Brandon, Florida, United States|Florida Cancer Specialists, Cape Coral, Florida, United States|Florida Cancer Specialists, Clearwater, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists, Gainesville, Florida, United States|Florida Cancer Specialists, Hudson, Florida, United States|Florida Cancer Specialists, Largo, Florida, United States|Florida Cancer Specialists, Naples, Florida, United States|Florida Cancer Specialists, New Port Richey, Florida, United States|Florida Cancer Specialists, Orange City, Florida, United States|Florida Cancer Specialists, Orlando, Florida, United States|Florida Cancer Specialists, Port Charlotte, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Florida Cancer Specialists, Sarasota, Florida, United States|Florida Cancer Specialists, Sarasota, Florida, United States|Florida Cancer Specialists, Spring Hill, Florida, United States|Florida Cancer Specialists, Tampa, Florida, United States|Florida Cancer Specialists, Tavares, Florida, United States|Florida Cancer Specialists, Venice, Florida, United States|Florida Cancer Specialists, Venice, Florida, United States|Northwestern Medical Faculty Foundation(NMFF)/ Women's Cancer Center Shared Laboratories, Chicago, Illinois, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|The University of Chicago Medical Center, Investigational Drug Service Department of Pharmacy, Chicago, Illinois, United States|The University of Chicago, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center at Silver Cross Hospital, New Lenox, Illinois, United States|Indiana University Health Hospital, Indianapolis, Indiana, United States|Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Investigational Drug Services, Indianapolis, Indiana, United States|Sidney and Lois Eskenazi Hospital, Indianapolis, Indiana, United States|Springmill Medical Clinic, Indianapolis, Indiana, United States|Oncology Hematology Care, Inc., Crestview Hills, Kentucky, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|The West Clinic, PC, Corinth, Mississippi, United States|The West Clinic, PC, Southaven, Mississippi, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Washington University Infusion Center Pharmacy, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, United States|Siteman Cancer Center-West County, Saint Louis, Missouri, United States|Siteman Cancer Center, Saint Peters, Missouri, United States|Hematology Oncology Associates of Northern NJ, Morristown, New Jersey, United States|Memorial Sloan Kettering - I Chemotherapy Practice/Investigational Drug Service, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Cone Health Cancer Center, Greensboro, North Carolina, United States|Wesley Long Community Hospital, Greensboro, North Carolina, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Oncology Hematology Care, Inc., Fairfield, Ohio, United States|Greenville Health System, Greenville, South Carolina, United States|Greenville Health System, Seneca, South Carolina, United States|Greenville Health System, Spartanburg, South Carolina, United States|Tennessee Oncology, PLLC, Dickson, Tennessee, United States|Tennessee Oncology, PLLC, Franklin, Tennessee, United States|Tennessee Oncology, PLLC, Gallatin, Tennessee, United States|Tennessee Oncology, PLLC, Hermitage, Tennessee, United States|Tennessee Oncology, PLLC, Lebanon, Tennessee, United States|The West Clinic, PC, Memphis, Tennessee, United States|The West Clinic, PC, Memphis, Tennessee, United States|Tennessee Oncology, PLLC, Murfreesboro, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|The Sarah Cannon Research Institute, Nashville, Tennessee, United States|Vanderbilt Breast Center at One Hundred Oaks, Nashville, Tennessee, United States|Vanderbilt Health Pharmacy One Hundred Oaks, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Henry-Joyce Cancer Clinic, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Smyrna, Tennessee, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology - Longview Cancer Center, Longview, Texas, United States|Texas Oncology-Tyler, Tyler, Texas, United States|Virginia Cancer Institute, Mechanicsville, Virginia, United States|Virginia Cancer Institute, Midlothian, Virginia, United States|Virginia Oncology Associates, Newport News, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Virginia Oncology Associates, Virginia Beach, Virginia, United States|Institut Jules Bordet, Brussels, Belgium|British Columbia Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|Sunnybrook Research Institute, Toronto, Ontario, Canada|McGill University Health Centre-Cedars Cancer Centre, Montreal, Quebec, Canada|Pharmacy Department, Dublin 4, Ireland|3rd Floor,Oncology Link office, Dublin, Ireland|Department of Radiology, Dublin, Ireland|Institute for Cancer Research, Dublin, Ireland|Mater Private Hospital, Dublin, Ireland|Pharmacy Department, Dublin, Ireland|Radiology Department, Dublin, Ireland|U.O Farmaceutica, Nuovo Ospedale di Prato Palazzina dei servizi, Prato, Italy|Hospital Universitario HM Monteprincipe, Boadilla del Monte, Madrid, Spain|Grupo Hospitalario Quiron - Hospital Quiron Barcelona, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario Ramon Y Cajal, Madrid, Spain|Hospital Universitario 12 Octubre, Madrid, Spain|Centro Intergral Oncologico Clara Campal, Madrid, Spain|Hospital de Madrid Norte-Sanchinarro., Madrid, Spain|Clinical Investigation and Research Unit, Brighton, England, United Kingdom|Pharmacy Department, Brighton, England, United Kingdom|Radiation Safety Service, Medical Physics Department, Brighton, England, United Kingdom|Histopathology Department, Nottingham, England, United Kingdom|Nottingham University Hospital, Nottingham, England, United Kingdom|Pharmacy Department, Nottingham, England, United Kingdom|Radiology Department, Nottingham, England, United Kingdom|Royal Cornwall Hospitals NHS trust, Truro, Cornwall, England, United Kingdom|Department of Radiology, Truro, England, United Kingdom|Pharmacy Department, Truro, England, United Kingdom",https://ClinicalTrials.gov/show/NCT01889238
26,"Pfizer|Astellas Pharma Inc|Medivation, Inc.",Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer,"Active, not recruiting",Has Results,Breast Cancer,Drug: Enzalutamide|Drug: exemestane|Drug: Placebo (for enzalutamide),Industry,Interventional,"ATTN-Research Pharmacist, Aurora, Colorado, United States|University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States|University of Colorado Hospital, Anschutz Outpatient Pavilion, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers, Lone Tree, Colorado, United States|Florida Cancer Specialists, Altamonte Springs, Florida, United States|Florida Cancer Specialists, Bonita Springs, Florida, United States|Florida Cancer Specialists, Bradenton, Florida, United States|Florida Cancer Specialists, Brandon, Florida, United States|Florida Cancer Specialists, Cape Coral, Florida, United States|Florida Cancer Specialists, Clearwater, Florida, United States|Florida Cancer Specialists, Englewood, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists, Gainesville, Florida, United States|Florida Cancer Specialists, Hudson, Florida, United States|Florida Cancer Specialists, Largo, Florida, United States|Florida Cancer Specialists, Naples, Florida, United States|Florida Cancer Specialists, New Port Richey, Florida, United States|Florida Cancer Specialists, Orange City, Florida, United States|Florida Cancer Specialists, Orlando, Florida, United States|Florida Cancer Specialists, Port Charlotte, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Florida Cancer Specialists, Sarasota, Florida, United States|Florida Cancer Specialists, Sarasota, Florida, United States|Florida Cancer Specialists, Spring Hill, Florida, United States|Florida Cancer Specialists, Tampa, Florida, United States|Florida Cancer Specialists, Tavares, Florida, United States|Florida Cancer Specialists, Venice, Florida, United States|Florida Cancer Specialists, Venice, Florida, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|The University of Chicago Medical Center,, Chicago, Illinois, United States|The University of Chicago, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center at Silver Cross Hospital, New Lenox, Illinois, United States|Indiana University Health Hospital, Indianapolis, Indiana, United States|Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Investigational Drug Services, Indianapolis, Indiana, United States|Sidney and Lois Eskenazi Hospital, Indianapolis, Indiana, United States|Springmill Medical Clinic, Indianapolis, Indiana, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Minnesota Oncology Hematology, P.A, Minneapolis, Minnesota, United States|Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|Allina Health System DBA Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Dr.Michaela Tsai, Minneapolis, Minnesota, United States|The West Clinic, P.C., Corinth, Mississippi, United States|The West Clinic, P.C. d/b/a West Cancer Center, Southaven, Mississippi, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Washington University Infusion Center Pharmacy, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, United States|Siteman Cancer Center- West County, Saint Louis, Missouri, United States|Siteman Cancer Center, Saint Peters, Missouri, United States|Hematology Oncology Associates of Northern NJ, Morristown, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Oncology Hematology Care, Inc., Fairfield, Ohio, United States|Greenville Health System, Greenville, South Carolina, United States|Greenville Health System, Seneca, South Carolina, United States|Greenville Health System, Spartanburg, South Carolina, United States|The West Clinic, P.C. d/b/a West Cancer Center, Germantown, Tennessee, United States|The West Clinic, P.C. d/b/a West Cancer Center, Memphis, Tennessee, United States|The Sarah Cannon Research Institute, Nashville, Tennessee, United States|Vanderbilt Breast Center at One Hundred Oaks, Nashville, Tennessee, United States|Vanderbilt Health Pharmacy One Hundred Oaks, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Henry-Joyce Cancer Clinic, Nashville, Tennessee, United States|Investigational Products Center (IPC), Fort Worth, Texas, United States|Investigational Products Center(IPC), Fort Worth, Texas, United States|Investigational Products center, Fort Worth, Texas, United States|lnvestigational Products Center (IPC), Fort Worth, Texas, United States|Texas Oncology - Memorial City, Houston, Texas, United States|Texas Oncology-Longview Cancer Center, Longview, Texas, United States|Texas Oncology - Tyler, Tyler, Texas, United States|Virginia Cancer Institute, Mechanicsville, Virginia, United States|Virginia Cancer Institute, Midlothian, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|UZA, Edegem, Antwerpen, Belgium|GZA, Wilrijk, Antwerpen, Belgium|Institut Jules Bordet, Brussels, Belgium|Sunnybrook Research Institute, Toronto, Ontario, Canada|McGill University Health Center- Cedars Cancer Center, Montreal, Quebec, Canada|McGill University Health Centre - Cedars Cancer Centre, Montreal, Quebec, Canada|Institute for Cancer Research, Dublin 7, Ireland|Mater Private Hospital, Dublin 7, Ireland|Pharmacy Department, Dublin, Ireland|Radiology Department, Dublin, Ireland|St Vincent's University Hospital, Dublin, Ireland|Institute for Cancer Research, Dublin, Ireland|Mater Private Hospital, Dublin, Ireland|Pharmacy Department, Dublin, Ireland|Radiology Department, Dublin, Ireland|Cancer Clinical Trials Unit, Dublin, Ireland|Pharmacy Department, Dublin, Ireland|Radiology Department, Dublin, Ireland|Pharmacy Department, Dublin, Ireland|Radiology Department, Dublin, Ireland|IRCCS Ospedale San Raffaele, Milano, MI, Italy|Divisione di Senologia Medica; Istituto Europeo di Oncologia, Milano, MI, Italy|A.O.di Perugia S. Maria Della Misericoridia, Perugia, PG, Italy|Azienda Ospedaliera S.Orsola Malpighi, Bologna, Italy|U.O. Farmaceutica, Nuovo Ospedale di Prato, Prato, Italy|U.O. Oncologia Medica, Nuovo Ospedale di Prato, Prato, Italy|Dipartimento di Oncologia Medica, Istituto Nazionale Tumori Regina Elena, Roma, Italy|Hospital Universitario HM Monteprincipe, Boadilla del Monte, Madrid, Spain|Grupo Hospitalario Quiron - Hospital Universitari Quiron Dexeus, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario Ramon Y Cajal, Madrid, Spain|Hospital Universitario 12 Octubre, Madrid, Spain|Centro Integral Oncologico Clara Campal, Madrid, Spain|Hospital de Madrid Norte Sanchinarro, Madrid, Spain|Brighton and Sussex University Hospital NHS Trust, Brighton, England, United Kingdom|Pharmacy Department, Brighton, England, United Kingdom|Radiation Safety Service, Medical Physics Department, Brighton, England, United Kingdom|Histopathology Department, Nottingham, England, United Kingdom|Nottingham University Hospital, Nottingham, England, United Kingdom|Pharmacy Department, Nottingham, England, United Kingdom|Radiology Department, Nottingham, England, United Kingdom|Radiology Department, Nottingham, England, United Kingdom|Department of Radiology, Truro, England, United Kingdom|Pharmacy Department, Truro, England, United Kingdom|Royal Cornwall Hospitals NHS trust, Truro, England, United Kingdom|Clinical Investigation & Research Unit, Brighton, Sussex, United Kingdom",https://ClinicalTrials.gov/show/NCT02007512
27,AstraZeneca|KuDOS Pharmaceuticals Limited,Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer,"Active, not recruiting",Has Results,Breast Neoplasms,Drug: KU-0059436 (AZD2281) (PARP inhibitor),Industry,Interventional,"Research Site, Duarte, California, United States|Research Site, Los Angeles, California, United States|Research Site, Boston, Massachusetts, United States|Research Site, New York, New York, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Dallas, Texas, United States|Research Site, Melbourne, Australia|Research Site, Randwick, Australia|Research Site, Köln, Germany|Research Site, Haifa, Israel|Research Site, Tel-Aviv, Israel|Research Site, Hospitalet deLlobregat, Spain|Research Site, Lund, Sweden|Research Site, Cambridge, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom",https://ClinicalTrials.gov/show/NCT00494234
28,"AstraZeneca|Myriad Genetic Laboratories, Inc.|Merck Sharp & Dohme Corp.",Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer,"Active, not recruiting",Has Results,Recurrent Platinum Resistant Ovarian Cancer,Drug: cediranib and olaparib,Industry,Interventional,"Research Site, Mobile, Alabama, United States|Research Site, Anchorage, Alaska, United States|Research Site, Downey, California, United States|Research Site, Greenbrae, California, United States|Research Site, Los Angeles, California, United States|Research Site, Orange, California, United States|Research Site, San Diego, California, United States|Research Site, San Francisco, California, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Newnan, Georgia, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Westwood, Kansas, United States|Research Site, Covington, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Billings, Montana, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT02889900
29,"Bayer|Janssen Research & Development, LLC","Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms","Active, not recruiting",Has Results,Prostatic Neoplasms,"Drug: Radium-223 dichloride (Xofigo, BAY88-8223)|Drug: Matching placebo (normal saline)|Drug: Abiraterone|Drug: Prednisone/Prednisolone",Industry,Interventional,"Anchorage, Alaska, United States|Tucson, Arizona, United States|Tucson, Arizona, United States|Oceanside, California, United States|Denver, Colorado, United States|Washington, District of Columbia, United States|Fort Myers, Florida, United States|Atlanta, Georgia, United States|Jeffersonville, Indiana, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Rockville, Maryland, United States|Towson, Maryland, United States|Boston, Massachusetts, United States|Burlington, Massachusetts, United States|Detroit, Michigan, United States|Traverse City, Michigan, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Hackensack, New Jersey, United States|Poughkeepsie, New York, United States|Syracuse, New York, United States|Bala-Cynwyd, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Norfolk, Virginia, United States|Seattle, Washington, United States|Spokane, Washington, United States|Wheeling, West Virginia, United States|St Leonards, New South Wales, Australia|Adelaide, South Australia, Australia|East Bentleigh, Victoria, Australia|Heidelberg, Victoria, Australia|Melbourne, Victoria, Australia|Darlinghurst, Australia|East Melbourne, Australia|Randwick, Australia|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Edegem, Belgium|Gent, Belgium|Belo Horizonte, Minas Gerais, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Barretos, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Sao Paulo, Brazil|Calgary, Alberta, Canada|Vancouver, British Columbia, Canada|Winnipeg, Manitoba, Canada|Hamilton, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Quebec, Canada|Helsinki, Finland|Kuopio, Finland|Seinäjoki, Finland|Tampere, Finland|Besancon, France|Bordeaux Cedex, France|Paris, France|Paris, France|POITIERS cedex, France|Saint Herblain, France|Toulouse Cedex 9, France|Ulm, Baden-Württemberg, Germany|München, Bayern, Germany|Marburg, Hessen, Germany|Münster, Nordrhein-Westfalen, Germany|Dresden, Sachsen, Germany|Jena, Thüringen, Germany|Berlin, Germany|Afula, Israel|Beer Sheva, Israel|Haifa, Israel|Jerusalem, Israel|Kfar Saba, Israel|Petah Tikva, Israel|Ramat Gan, Israel|Tel Aviv, Israel|Zerifin, Israel|Modena, Emilia-Romagna, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Genova, Liguria, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Cagliari, Sardegna, Italy|Arezzo, Toscana, Italy|Trento, Trentino-Alto Adige, Italy|Nagoya, Aichi, Japan|Hirosaki, Aomori, Japan|Kashiwa, Chiba, Japan|Matsuyama, Ehime, Japan|Sapporo, Hokkaido, Japan|Kobe, Hyogo, Japan|Tsukuba, Ibaraki, Japan|Kanazawa, Ishikawa, Japan|Kita, Kagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Sendai, Miyagi, Japan|Matsumoto, Nagano, Japan|Kurashiki, Okayama, Japan|Osakasayama, Osaka, Japan|Hamamatsu, Shizuoka, Japan|Bunkyo-ku, Tokyo, Japan|Bunkyo-ku, Tokyo, Japan|Koto-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Ube, Yamaguchi, Japan|Chiba, Japan|Chiba, Japan|Fukuoka, Japan|Fukuoka, Japan|Kumamoto, Japan|Miyazaki, Japan|Nagasaki, Japan|Okayama, Japan|Amsterdam, Netherlands|Nijmegen, Netherlands|Zwolle, Netherlands|Bodø, Norway|Lørenskog, Norway|Oslo, Norway|Gdansk, Poland|Gdynia, Poland|Gliwice, Poland|Poznan, Poland|Moscow, Russian Federation|Obninsk, Russian Federation|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Badalona, Barcelona, Spain|Hospitalet de Llobregat, Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Málaga, Spain|Oviedo, Spain|Pamplona, Spain|Sevilla, Spain|Linköping, Sweden|Stockholm, Sweden|Sundsvall, Sweden|Umeå, Sweden|Växjö, Sweden|Edinburgh, Lothian, United Kingdom|Bebington, Merseyside, United Kingdom|Northwood, Middlesex, United Kingdom|Guildford, Surrey, United Kingdom|Sutton, Surrey, United Kingdom|Newcastle Upon Tyne, Tyne And Wear, United Kingdom|Coventry, Warwickshire, United Kingdom|Belfast, United Kingdom|Leeds, United Kingdom|London, United Kingdom|Romford, United Kingdom",https://ClinicalTrials.gov/show/NCT02043678
30,Incyte Corporation|Merck Sharp & Dohme Corp.,Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05),"Active, not recruiting",Has Results,Lung Cancer,Drug: Pembrolizumab|Drug: Epacadostat|Drug: Placebo,Industry,Interventional,"Pacific Cancer Medical Center, Inc., Anaheim, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Florida Cancer Specialists (South Region), Fort Myers, Florida, United States|Florida Cancer Specialists (North Region), Saint Petersburg, Florida, United States|Southeastern Regional Medical Center, Inc., Newnan, Georgia, United States|Anne Arundel Health System Research Institute, Annapolis, Maryland, United States|Weinberg Cancer Institute at Franklin Square, Baltimore, Maryland, United States|Maryland Oncology Hematology, P.A., Rockville, Maryland, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|Minnesota Oncology Hematology, PA, Coon Rapids, Minnesota, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Tennessee Oncology, PLLC/The Sarah Cannon Research Institute, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC/The Sarah Cannon Research Institute, Nashville, Tennessee, United States|Texas Oncology-South Austin, Austin, Texas, United States|Austin Health-Austin Hospital, Heidelberg, Victoria, Australia|St John of God Murdoch Medical Clinic, Murdoch, Western Australia, Australia|Cross Cancer Institute, Edmonton, Alberta, Canada|Moncton Hospital - Horizon Health Network, Moncton, New Brunswick, Canada|William Osler Health System, Brampton, Ontario, Canada|Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Ontario, Canada|Sault Area Hospital, Sault Ste Marie, Ontario, Canada|Rigshospitalet, Copenhagen, Denmark|Regionshospitalet Herning, Herning, Denmark|Odense Universitetshospital, Odense, Denmark|SA Tartu Ulikooli Kliinikum, Tartu, Estonia|Galway University Hospital, Galway, Connacht, Ireland|St Vincents University Hospital, Dublin, Ireland|Soroka Medical Center, Beer Sheva, Israel|Rambam Medical Center, Haifa, Israel|Meir Medical Center, Kfar Saba, Israel|Rabin Medical Center, Petah Tikva, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|IRCCS A.O.U. San Martino - IST, Genova, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Kanagawa Cancer Center, Yokohama, Kanagawa, Japan|Sendai Kousei Hospital, Sendai, Miyagi, Japan|Kansai Medical University Hospital, Hirakata, Osaka, Japan|Kindai University Hospital, Osakasayama, Osaka, Japan|Shizuoka Cancer Center, Nagaizumi-chō, Shizuoka Prefecture, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Kyushu University Hospital, Fukuoka, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|National Cancer Center Hospital, Tokyo, Japan|Nippon Medical School Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Wakayama Medical University Hospital, Wakayama, Japan|Chungbuk National University Hospital, Cheongju si, Chungcheongbuk Do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Gacheon University Gil Medical Center, Incheon, Korea, Republic of|Hospital Tengku Ampuan Afzan, Kuantan, Pahang, Malaysia|Institut Kanser Negara - National Cancer Institute, Putrajaya, Wilayah Persekutuan, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia|Sarawak General Hospital, Kuching, Malaysia|Swietokrzyskie Centrum Onkologii SPZOZ, Kielce, Swietokrzyskie, Poland|Centrum Onkologii im. Prof. Franciszka Lukaszczyka, Bydgoszcz, Poland|Centrum Onkologii. Instytut im. Marii Sklodowskiej-Curie, Gliwice, Poland|Swietokrzyskie Centrum Onkologii SPZOZ, Kielce, Poland|Przychodnia Lekarska Komed, Konin, Poland|Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc, Olsztyn, Poland|Wojewodzki Szpital im. Zofii z Zamoyskich Tarnowskiej w Tarnobrzegu, Tarnobrzeg, Poland|Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie, Warszawa, Poland|Belgorod Regional Oncology Dispensary, Belgorod, Russian Federation|Central Clinical Hospital with polyclinic, Moscow, Russian Federation|Moscow Research Oncology Institute named after P.A. Hertsen, Moscow, Russian Federation|SBHI Leningrad Regional Clinical Hospital, Saint Petersburg, Russian Federation|SBHI Samara Regional Clinical Oncology Dispensary, Samara, Russian Federation|Republican Clinical Oncology Dispensary of Republic of Bashkortostan, Ufa, Russian Federation|Hospital Alvaro Cunqueiro, Vigo, Pontevedra, Spain|Hospital General de Alicante, Alicante, Spain|Hospital del Mar, Barcelona, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Clinico de Valencia, Valencia, Spain|Oncological Institute of Southern Switzerland, Bellinzona, Switzerland|Inselspital Universitatsspital Bern, Bern, Switzerland|Hopitaux Universitaires de Geneve HUG., Geneva, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|Universitaetsspital Zuerich, Zuerich, Switzerland|Basken Uni. Adana Dr.Turgut Noyan Uygulama ve Arastirma Merkezi, Adana, Turkey|Ankara University Medical Faculty, Ankara, Turkey|Akdeniz Universitesi Tip Fakultesi, Antalya, Turkey|Erciyes Universitesi Tip Fakultesi, Kayseri, Turkey|Necmettin Erbakan Universitesi Meram Tip Fakultesi Hastanesi, Konya, Turkey|MI Kryviy Rih Center of Dnipropetrovsk Regional Council, Kryvyi Rih, Dnipropetrovsk Region, Ukraine|Dnipropetrovsk City Multidiscipline Clinical Hosp.4 of DRC, Dnipropetrovsk, Ukraine|Grigoriev Institute for medical Radiology NAMS of Ukraine, Kharkiv, Ukraine|PP PPC Acinus Medical and Diagnostic Centre, Kirovohrad, Ukraine|Kyiv City Clinical Oncological Center, Kyiv, Ukraine|Dobryi Prognoz, Kyiv, Ukraine|Volyn Regional Oncological Dispensary, Lutsk, Ukraine|MI Odessa Regional Oncological Centre, Odesa, Ukraine|Zaporizhzhya Regional Clinical Oncology Center, Zaporizhzhya, Ukraine|Leeds Teaching Hospital NHS Trust. St. James University Hospital, Leeds, United Kingdom",https://ClinicalTrials.gov/show/NCT03322540
31,AstraZeneca|Parexel,AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,"Active, not recruiting",Has Results,Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer,Drug: AZD9291 80 mg/40 mg + placebo|Drug: Placebo Erlotinib 150/100mg|Drug: Placebo Gefitinib 250 mg|Drug: Erlotinib 150/100 mg|Drug: Gefitinib 250 mg|Drug: Placebo AZD9291 80 mg/ 40 mg,Industry,Interventional,"Research Site, Anaheim, California, United States|Research Site, Santa Rosa, California, United States|Research Site, West Hills, California, United States|Research Site, Tampa, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Marietta, Georgia, United States|Research Site, Louisville, Kentucky, United States|Research Site, Bethesda, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Salisbury, North Carolina, United States|Research Site, Burlington, Vermont, United States|Research Site, Camperdown, Australia|Research Site, Chermside, Australia|Research Site, Clayton, Australia|Research Site, Heidelberg, Australia|Research Site, Kogarah, Australia|Research Site, Nedlands, Australia|Research Site, Woolloongabba, Australia|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Roeselare, Belgium|Research Site, Porto Alegre, Brazil|Research Site, Sofia, Bulgaria|Research Site, Edmonton, Alberta, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Changchun, China|Research Site, Chongqing, China|Research Site, Chongqing, China|Research Site, Chongqing, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Nanjing, China|Research Site, Nanning, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Suzhou, China|Research Site, Wuhan, China|Research Site, Xi'an, China|Research Site, Xi'an, China|Research Site, Yangzhou, China|Research Site, Ürümqi, China|Research Site, Ostrava, Czechia|Research Site, Caen, France|Research Site, Creteil, France|Research Site, Lyon Cedex 08, France|Research Site, Nantes, France|Research Site, Toulon Naval, France|Research Site, Villejuif, France|Research Site, Bad Berka, Germany|Research Site, Berlin, Germany|Research Site, Gauting, Germany|Research Site, Halle, Germany|Research Site, Heidelberg, Germany|Research Site, Karlsruhe, Germany|Research Site, Lübeck, Germany|Research Site, München, Germany|Research Site, Villingen-Schwenningen, Germany|Research Site, Farkasgyepü, Hungary|Research Site, Miskolc, Hungary|Research Site, Mátraháza, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Tatabánya, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Haifa, Israel|Research Site, Kfar-Saba, Israel|Research Site, Petach Tikva, Israel|Research Site, Tel Hashomer, Israel|Research Site, Cremona, Italy|Research Site, Lecce, Italy|Research Site, Lecco, Italy|Research Site, Orbassano, Italy|Research Site, Parma, Italy|Research Site, Roma, Italy|Research Site, Sondrio, Italy|Research Site, Terni, Italy|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Hirakata-shi, Japan|Research Site, Kanazawa-shi, Japan|Research Site, Kashiwa, Japan|Research Site, Kobe-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Natori-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osakasayama-shi, Japan|Research Site, Sagamihara-shi, Japan|Research Site, Sakai-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Sunto-gun, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Cheongju-si, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Kuala Lumpur, Malaysia|Research Site, Kuantan, Malaysia|Research Site, Kuching, Malaysia|Research Site, Cebu, Philippines|Research Site, Manila, Philippines|Research Site, Quezon City, Philippines|Research Site, Brzozoów, Poland|Research Site, Otwock, Poland|Research Site, Poznań, Poland|Research Site, Szczecin, Poland|Research Site, Warszawa, Poland|Research Site, Amadora, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Vila Nova de Gaia, Portugal|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Craiova, Romania|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Coruña, Spain|Research Site, Lugo, Spain|Research Site, Lérida, Spain|Research Site, Madrid, Spain|Research Site, Málaga, Spain|Research Site, Sevilla, Spain|Research Site, Zaragoza, Spain|Research Site, Linköping, Sweden|Research Site, Luzern, Switzerland|Research Site, Winterthur, Switzerland|Research Site, Zürich, Switzerland|Research Site, Kaohsiung, Taiwan|Research Site, Taichung City, Taiwan|Research Site, Tainan City, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taoyuan City, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Muang, Thailand|Research Site, Songkla, Thailand|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Dnipro, Ukraine|Research Site, Kryvyi Rih, Ukraine|Research Site, Lviv, Ukraine|Research Site, Sumy, Ukraine|Research Site, Edinburgh, United Kingdom|Research Site, London, United Kingdom|Research Site, Maidstone, United Kingdom|Research Site, Withington, United Kingdom|Research Site, Hanoi, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh City, Vietnam",https://ClinicalTrials.gov/show/NCT02296125
32,"AstraZeneca|Merck Sharp & Dohme Corp.|Foundation Medicine, Inc.|Myriad Genetics, Inc.",Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study),"Active, not recruiting",Has Results,Metastatic Castration-resistant Prostate Cancer,Drug: olaparib|Drug: enzalutamide|Drug: abiraterone acetate,Industry|Other,Interventional,"Research Site, Anchorage, Alaska, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Duarte, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Barbara, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Tampa, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Jeffersonville, Indiana, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Albany, New York, United States|Research Site, Bronx, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Salisbury, North Carolina, United States|Research Site, Gahanna, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Springfield, Oregon, United States|Research Site, Tualatin, Oregon, United States|Research Site, Charleston, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Myrtle Beach, South Carolina, United States|Research Site, Germantown, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, San Antonio, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Spokane, Washington, United States|Research Site, Wheeling, West Virginia, United States|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, La Rioja, Argentina|Research Site, Rosario, Argentina|Research Site, Adelaide, Australia|Research Site, Box Hill, Australia|Research Site, Clayton, Australia|Research Site, Greenslopes, Australia|Research Site, Herston, Australia|Research Site, Macquarie University, Australia|Research Site, Melbourne, Australia|Research Site, Nedlands, Australia|Research Site, Randwick, Australia|Research Site, Waratah, Australia|Research Site, Graz, Austria|Research Site, Linz, Austria|Research Site, Salzburg, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Barretos, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Curitiba, Brazil|Research Site, Florianópolis, Brazil|Research Site, Passo Fundo, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Recife, Brazil|Research Site, Ribeirao Preto, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Santo Andre, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Edmonton, Alberta, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Quebec, Canada|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changsha, China|Research Site, Chongqing, China|Research Site, Guang Zhou, China|Research Site, Hangzhou, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Odense C, Denmark|Research Site, BESANCON Cedex, France|Research Site, Bordeaux, France|Research Site, Caen, France|Research Site, Lille, France|Research Site, Lyon Cedex 08, France|Research Site, Marseille cedex 09, France|Research Site, Montpellier, France|Research Site, Paris, France|Research Site, Poitiers Cedex, France|Research Site, Saint Herblain, France|Research Site, Toulouse Cedex 09, France|Research Site, Vandoeuvre les Nancy, France|Research Site, Villejuif, France|Research Site, Bergisch Gladbach, Germany|Research Site, Berlin, Germany|Research Site, Bremen, Germany|Research Site, Duisburg, Germany|Research Site, Düsseldorf, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research Site, Holzminden, Germany|Research Site, Jena, Germany|Research Site, Köln, Germany|Research Site, Magdeburg, Germany|Research Site, Nürnberg, Germany|Research Site, Nürtingen, Germany|Research Site, Tübingen, Germany|Research Site, Wuppertal, Germany|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Kfar Saba, Israel|Research Site, Petach-Tikva, Israel|Research Site, Ramat Gan, Israel|Research Site, Zerifin, Israel|Research Site, Ancona, Italy|Research Site, Arezzo, Italy|Research Site, Bari, Italy|Research Site, Brescia, Italy|Research Site, Meldola, Italy|Research Site, Milano, Italy|Research Site, Milan, Italy|Research Site, Modena, Italy|Research Site, Napoli, Italy|Research Site, Trento, Italy|Research Site, Bunkyo-ku, Japan|Research Site, Bunkyo-ku, Japan|Research Site, Bunkyo-ku, Japan|Research Site, Fukuoka, Japan|Research Site, Hirosaki-shi, Japan|Research Site, Kanazawa-shi, Japan|Research Site, Kashihara-shi, Japan|Research Site, Kashiwa, Japan|Research Site, Kawagoe-shi, Japan|Research Site, Kita-gun, Japan|Research Site, Koto-ku, Japan|Research Site, Kyoto-shi, Japan|Research Site, Maebashi-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Minato-ku, Japan|Research Site, Mitaka-shi, Japan|Research Site, Miyazaki-shi, Japan|Research Site, Nagasaki-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osakasayama-shi, Japan|Research Site, Sagamihara-shi, Japan|Research Site, Sakura-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Suita-shi, Japan|Research Site, Sunto-gun, Japan|Research Site, Yokohama-shi, Japan|Research Site, Busan, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Amsterdam, Netherlands|Research Site, Hilversum, Netherlands|Research Site, Leiden, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Zwolle, Netherlands|Research Site, Lørenskog, Norway|Research Site, Barcelona, Spain|Research Site, Gerona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Malaga, Spain|Research Site, Oviedo, Spain|Research Site, Sevilla, Spain|Research Site, Göteborg, Sweden|Research Site, Solna, Sweden|Research Site, Changhua City, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan City, Taiwan|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Edirne, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Karsiyaka, Turkey|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Romford, United Kingdom|Research Site, Sutton, United Kingdom",https://ClinicalTrials.gov/show/NCT02987543
33,Novartis Pharmaceuticals|GlaxoSmithKline|Novartis,"A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer","Active, not recruiting",Has Results,"Neoplasms, Breast",Drug: lapatinib|Drug: trastuzumab|Drug: Aromatase inhibitor,Industry,Interventional,"Novartis Investigative Site, La Jolla, California, United States|Novartis Investigative Site, Pleasant Hill, California, United States|Novartis Investigative Site, Hollywood, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Augusta, Georgia, United States|Novartis Investigative Site, Lawrenceville, Georgia, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Goshen, Indiana, United States|Novartis Investigative Site, Waterloo, Iowa, United States|Novartis Investigative Site, Grand Rapids, Michigan, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, Billings, Montana, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Cary, North Carolina, United States|Novartis Investigative Site, Dayton, Ohio, United States|Novartis Investigative Site, Germantown, Tennessee, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Milwaukee, Wisconsin, United States|Novartis Investigative Site, Berazategui, Buenos Aires, Argentina|Novartis Investigative Site, Capital Federal, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Aut6noma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, La Plata, Buenos Aires, Argentina|Novartis Investigative Site, Viedma, Río Negro, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, La Rioja, Argentina|Novartis Investigative Site, Quilmes, Argentina|Novartis Investigative Site, San Miguel de Tucuman, Argentina|Novartis Investigative Site, Box Hill, Victoria, Australia|Novartis Investigative Site, Wodonga, Victoria, Australia|Novartis Investigative Site, Adelaide, Australia|Novartis Investigative Site, Douglas, Australia|Novartis Investigative Site, Ringwood East, Australia|Novartis Investigative Site, Tweed Heads, Australia|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Fortaleza, Ceará, Brazil|Novartis Investigative Site, Goiania, Goiás, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Barretos, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Rio de Janeiro, Brazil|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Fuzhou, Fujian, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Changchun, Jilin, China|Novartis Investigative Site, Harbin, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Monteria, Colombia|Novartis Investigative Site, Osijek, Croatia|Novartis Investigative Site, Pula, Croatia|Novartis Investigative Site, Zagreb, Croatia|Novartis Investigative Site, Besancon, France|Novartis Investigative Site, Le Mans, France|Novartis Investigative Site, Lille, France|Novartis Investigative Site, Montpellier Cedex 5, France|Novartis Investigative Site, Nancy, France|Novartis Investigative Site, Paris Cedex 20, France|Novartis Investigative Site, Heidelberg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Tuebingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Regensburg, Bayern, Germany|Novartis Investigative Site, Rosenheim, Bayern, Germany|Novartis Investigative Site, Fuerstenwalde, Brandenburg, Germany|Novartis Investigative Site, Rostock, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Goslar, Niedersachsen, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Aachen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Bottrop, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Troisdorf, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Velbert, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Halle, Sachsen-Anhalt, Germany|Novartis Investigative Site, Kiel, Schleswig-Holstein, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Chania, Greece|Novartis Investigative Site, Heraklion, Greece|Novartis Investigative Site, Perioxi Dragana, Alexandroupolis, Greece|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Kowloon, Hong Kong|Novartis Investigative Site, Pokfulam, Hong Kong|Novartis Investigative Site, Tuen Mun, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Gyor, Hungary|Novartis Investigative Site, Gyula, Hungary|Novartis Investigative Site, Kaposvar, Hungary|Novartis Investigative Site, Miskolc, Hungary|Novartis Investigative Site, Nyiregyhaza, Hungary|Novartis Investigative Site, Pecs, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Szolnok, Hungary|Novartis Investigative Site, Veszprem, Hungary|Novartis Investigative Site, Zalaegerszeg, Hungary|Novartis Investigative Site, Bangalore, India|Novartis Investigative Site, Chennai, India|Novartis Investigative Site, Delhi, India|Novartis Investigative Site, Nagpur, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Pune, India|Novartis Investigative Site, Surat, India|Novartis Investigative Site, Dublin 7, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Galway, Ireland|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Petah-Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Rehovot, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Parma, Emilia-Romagna, Italy|Novartis Investigative Site, Piacenza, Emilia-Romagna, Italy|Novartis Investigative Site, Monza, Lombardia, Italy|Novartis Investigative Site, Pavia, Lombardia, Italy|Novartis Investigative Site, Rozzano (MI), Lombardia, Italy|Novartis Investigative Site, San Giovanni Rotondo, Italy|Novartis Investigative Site, Aichi, Japan|Novartis Investigative Site, Chiba, Japan|Novartis Investigative Site, Ehime, Japan|Novartis Investigative Site, Kagoshima, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Saitama, Japan|Novartis Investigative Site, Saitama, Japan|Novartis Investigative Site, Shizuoka, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, Lorenskog, Norway|Novartis Investigative Site, Miraflores, Lima, Peru|Novartis Investigative Site, San Borja, Lima, Peru|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, Arequipa, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Trujillo, Peru|Novartis Investigative Site, Makati City, Philippines|Novartis Investigative Site, Quezon City, Philippines|Novartis Investigative Site, Konin, Poland|Novartis Investigative Site, Lubin, Poland|Novartis Investigative Site, Otwock, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wieliszew, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Coimbra, Portugal|Novartis Investigative Site, Evora, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisbon, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, San Juan, Puerto Rico|Novartis Investigative Site, San Juan, Puerto Rico|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Arkhangelsk, Russian Federation|Novartis Investigative Site, Kazan, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Tver, Russian Federation|Novartis Investigative Site, Belgrade, Serbia|Novartis Investigative Site, Kragujevac, Serbia|Novartis Investigative Site, Sremska Kamenica, Serbia|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Durban, South Africa|Novartis Investigative Site, Port Elizabeth, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Saxonwold, Johannesburg, South Africa|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Castellon, Spain|Novartis Investigative Site, Cordoba, Spain|Novartis Investigative Site, La Coruna, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Santa Cruz de Tenerife, Spain|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Kaohsiung Hsien, Taiwan|Novartis Investigative Site, Taipei City, Taiwan|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Chernivtsi, Ukraine|Novartis Investigative Site, Dnipropetrovsk, Ukraine|Novartis Investigative Site, Kharkiv, Ukraine|Novartis Investigative Site, Khmelnytskyi, Ukraine|Novartis Investigative Site, Lyutizh, Ukraine|Novartis Investigative Site, Sumy, Ukraine|Novartis Investigative Site, Uzhgorod, Ukraine|Novartis Investigative Site, Vinnitsia, Ukraine|Novartis Investigative Site, Chelmsford, Essex, United Kingdom|Novartis Investigative Site, Birmingham, West Midlands, United Kingdom|Novartis Investigative Site, Huddersfield, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Maidstone, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom|Novartis Investigative Site, Peterborough, United Kingdom|Novartis Investigative Site, Sutton, United Kingdom",https://ClinicalTrials.gov/show/NCT01160211
34,Incyte Corporation|Merck Sharp & Dohme Corp.,A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06),"Active, not recruiting",Has Results,Lung Cancer,Drug: Pembrolizumab|Drug: Epacadostat|Drug: Platinum-based chemotherapy|Drug: Placebo,Industry,Interventional,"Southern Cancer Center, PC, Daphne, Alabama, United States|Western Regional Medical Center, Inc., Goodyear, Arizona, United States|Arizona Oncology Associates PC- HOPE, Tucson, Arizona, United States|Lynn Cancer Institute, Boca Raton, Florida, United States|Florida Cancer Specialists (South Region), Fort Myers, Florida, United States|Florida Cancer Specialists (North Region), Saint Petersburg, Florida, United States|PPG-Oncology, Fort Wayne, Indiana, United States|University of Michigan, Ann Arbor, Michigan, United States|MMCORC, Saint Louis Park, Minnesota, United States|St. Vincent Healthcare Frontier Cancer Center, Billings, Montana, United States|New York Oncology Hematology P.C, Albany, New York, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Southwestern Regional Medical Center, Inc., Tulsa, Oklahoma, United States|St. Luke's Hospital - Anderson Campus, Easton, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Tennessee Oncology, PLLC/The Sarah Cannon Research Institute, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC/The Sarah Cannon Research Institute, Nashville, Tennessee, United States|Texas Oncology-Denton South, Denton, Texas, United States|Oncology & Hematology Assoc. SW Virginia, Inc., DBA Blue Ridge Cancer Care, Blacksburg, Virginia, United States|Emily Couric Clinical Cancer Center, Charlottesville, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|MNCCI Port Macquarie Base Hospital, Port Macquarie, New South Wales (Australia), Australia|Blacktown Hospital, Blacktown, New South Wales, Australia|Chris OBrien Lifehouse, Camperdown, New South Wales, Australia|The Crown Princess Mary Cancer Centre Westmead, Westmead, New South Wales, Australia|Southern Medical Day Care Centre, Wollongong, New South Wales, Australia|Cairns Base Hospital, Cairns, Queensland, Australia|BCCA-Cancer Centre of the Southern Interior, Kelowna, British Columbia, Canada|Lions Gate Hospital, North Vancouver, British Columbia, Canada|CISSS de la Monteregie-Centre, Greenfield Park, Quebec, Canada|CSSS de Laval- Hopital de la Cite de la Sante, Laval, Quebec, Canada|CIUSSS Ouest de l'Ile - St-Mary's Hospital, Montréal, Quebec, Canada|CIUSSS du Nord-de-l'ILe-de-Montreal Hopital du Sacre-Coeur de Montreal, Montréal, Quebec, Canada|CIUSSS de la Mauricie-et-du-Centre-du-Quebec, Trois-Rivières, Quebec, Canada|CHU de Quebec - Hotel-Dieu de Quebec, Quebec, Canada|Zala Megyei Korhaz Pozvai Telephely, Pozva, Zalaegerszeg, Hungary|Orszagos Koranyi TBC es Pulmonologiai Intezet, Budapest, Hungary|Veszprem Megyei Tudogyogyintezet, Farkasgyepű, Hungary|Bekes Megyei Pandy Kalman Korhaz, Gyula, Hungary|CRU Hungary Kft., Miskolc, Hungary|Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet, Szolnok, Hungary|St Vincents University Hospital, Dublin, Ireland|Ha Emek Medical Center, Afula, Israel|Soroka Medical Center, Be'er Sheva, Israel|Rambam Medical Center, Haifa, Israel|Meir Medical Center, Kfar Saba, Israel|Rabin Medical Center, Petah Tikva, Israel|Chaim Sheba Medcal Center, Ramat Gan, Israel|Centro Di Riferimento Oncologico, Aviano, Italy|A.O.U. Policlinico Vittorio Emanuele - Presidio Gaspare Rodolico, Catania, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|Istituto Europeo di Oncologia, Milano, Italy|Ospedale San Gerardo - ASST Monza, Monza, Italy|National Cancer Center, Goyang-si, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Medical Care Research S.A. de C.V., Mérida, Yucatan, Mexico|Oaxaca Site Management Organization S.C., Oaxaca, Mexico|FAICIC Clinical Research, Veracruz, Mexico|Belgorod Regional Oncology Dispensary, Belgorod, Russian Federation|Udmurtia Republic Regional Clinical Oncology Dispensary, Izhevsk, Russian Federation|Republican Clinical Oncology Dispensary of Tatarstan MoH, Kazan, Russian Federation|Central Clinical Hospital with polyclinic, Moscow, Russian Federation|Moscow Research Oncology Institute, Moscow, Russian Federation|SBI of Stavropol region Pyatigorskiy Oncologic dispensary, Pyatigorsk, Russian Federation|SBHI Leningrad Regional Clinical Hospital, Saint Petersburg, Russian Federation|SBHI Samara Regional Clinical Oncology Dispensary, Samara, Russian Federation|Oncological Dispensary #2 of Ministry of Health of Krasnodar region, Sochi, Russian Federation|Tomsk Scientific Research Institute of Oncology, Tomsk, Russian Federation|Hospital Universitario Insular de Gran Canaria, Las Palmas De Gran Canaria, Gran Canaria, Spain|Hospital Juan Ramón Jimenez, Huelva, Spain|Institut Catala Oncologia de Bellvitge - ICO, L'Hospitalet De Llobregat, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario La Fe, Valencia, Spain|Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain|Chang Gung Medical Foundation, Kaohsiung Branch, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Chang Gung Medical Foundation, Linkou Branch, Taoyuan, Taiwan|Ege Universitesi Tip Fakultesi Hastanesi, İzmir, Bornova, Turkey|Baskent Universitesi Adana Uygulama ve Arastirma Hastanesi, Adana, Turkey|Cukurova Universitesi Tıp Fakultesi Balcalı Hastanesi, Adana, Turkey|Hacettepe Universitesi Tip Fakultesi Hastanesi, Ankara, Turkey|Uludag Universitesi Tip Fakultesi, Bursa, Turkey|Pamukkale Unv. Tip Fak, Denizli, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi, Istanbul, Turkey|Samsun Medical Park Hastanesi, Samsun, Turkey|Namık Kemal University Medical Faculty, Tekirdağ, Turkey|Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|North Middlesex Hospital, London, United Kingdom|Freeman Hospital Newcastle upon Tyne Foundation NHS Trust, Newcastle Upon Tyne, United Kingdom",https://ClinicalTrials.gov/show/NCT03322566
35,Pfizer|AstraZeneca,Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3),"Active, not recruiting",Has Results,Metastatic Breast Cancer,Drug: Palbociclib|Drug: Fulvestrant|Drug: Placebo,Industry,Interventional,"University of Alabama at Birmingham, The Kirklin Clinic, Birmingham, Alabama, United States|UAB Hospital-Investigational Drug Service, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Southern Cancer Center, PC, Daphne, Alabama, United States|Southern Cancer Center, PC, Mobile, Alabama, United States|Southern Cancer Center, PC, Mobile, Alabama, United States|Southern Cancer Center,PC, Mobile, Alabama, United States|Arizona Center for Cancer Care, Avondale, Arizona, United States|Ironwood Physicians P.C dba Ironwood Cancer & Research Centers, Chandler, Arizona, United States|Arizona Oncology Associates, PC- HAL, Flagstaff, Arizona, United States|Ironwood Physicians P.C dba Ironwood Cancer & Research Centers, Gilbert, Arizona, United States|Palo Verde Hematology Oncology, Glendale, Arizona, United States|Arizona Center for Cancer Care, Glendale, Arizona, United States|Western Regional Medical Center, Inc., Goodyear, Arizona, United States|Ironwood Physicians P.C dba Ironwood Cancer & Research Centers, Mesa, Arizona, United States|Ironwood Physicians P.C dba Ironwood Cancer & Research Centers, Mesa, Arizona, United States|Arizona Oncology Associates, PC- HAL, Prescott Valley, Arizona, United States|Arizona Oncology Associates, PC- HAL, Sedona, Arizona, United States|Arizona Center for Cancer Care, Surprise, Arizona, United States|The University of Arizona Cancer Center- North Campus, Tucson, Arizona, United States|The University of Arizona Cancer Center, Tucson, Arizona, United States|CBCC Global Research Inc. at Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Administrative Management Only: Translational Research Management, Culver City, California, United States|Administrative Management Only, Culver City, California, United States|City of Hope, Duarte, California, United States|St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare, Fullerton, California, United States|Global Research Management, Glendale, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|UC San Diego Medical Center-La Jolla, La Jolla, California, United States|Keck Hospital of USC, Los Angeles, California, United States|LAC & USC Medical Center, Los Angeles, California, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Drug Management only: UCLA West Medical Pharmacy, Los Angeles, California, United States|TRIO-US Pharmacy, UCLA West Medical Pharmacy, Los Angeles, California, United States|UCLA West Medical Pharmacy, Attn: Steven L. Wong, Pharm. D., Los Angeles, California, United States|UCLA West Medical Pharmacy, Attn: Steven L. Wong, Pharm. D, Los Angeles, California, United States|UCLA West Medical Pharmacy, attn:, Los Angeles, California, United States|UCLA West Medical Pharmacy, Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Drug Information Center, Los Angeles, California, United States|TRIO -US Central Administration, Los Angeles, California, United States|TRIO- US Central Administration, Los Angeles, California, United States|TRIO-US Central Administration, Los Angeles, California, United States|UCLA Hematology Oncology, Los Angeles, California, United States|UCLA West Medical Pharmacy, Los Angeles, California, United States|Breastlink Medical Group, Inc., Orange, California, United States|Hematology Oncology Medical Group of Orange County, Inc. (HOMG), Orange, California, United States|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States|UCLA Hematology/Oncology - Pasadena, Pasadena, California, United States|Torrance Health Association, DBA Torrance Memorial Physician Network/Cancer Care Associates, Redondo Beach, California, United States|UC San Diego Medical Center-Hillcrest, San Diego, California, United States|University of California, San Francisco: Helen Diller Comprehensive Cancer Center, San Francisco, California, United States|San Luis Obispo Oncology and Hematology Health Center/Pacific Central Coast Health Centers, San Luis Obispo, California, United States|Breastlink Medical Group, Inc., Santa Ana, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, United States|City of Hope, South Pasadena, California, United States|Wellness Oncology & Hematology, West Hills, California, United States|ATTN - Research Pharmacist, Aurora, Colorado, United States|University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora, Colorado, United States|University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP), Aurora, Colorado, United States|Mount Sinai Medical Center- Aventura, Aventura, Florida, United States|University of Miami Hospitals and Clinics (UHMC) Sylvester at Deerfield Beach, Deerfield Beach, Florida, United States|Holy Cross Hospital/Michael and Dianne Bienes Comprehensive Cancer Center, Fort Lauderdale, Florida, United States|Memorial Breast Cancer Center at Memorial Regional Hospital, Hollywood, Florida, United States|Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States|Memorial Regional Hospital, Hollywood, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Sylvester Comprehensive Cancer Center/ University of Miami Hospitals and Clinics, Miami, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|Memorial Breast Cancer Center at Memorial Hospital West, Pembroke Pines, Florida, United States|Memorial Cancer Institute at Memorial Hospital West, Pembroke Pines, Florida, United States|Memorial Hospital West, Pembroke Pines, Florida, United States|Sylvester at Plantation, Plantation, Florida, United States|Piedmont Cancer Institute, PC, Atlanta, Georgia, United States|Piedmont Cancer Institute, PC, Fayetteville, Georgia, United States|Northwest Georgia Oncology Centers, PC, Marietta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Cancer Treatment Centers of America at Midwestern Regional Medical Center, Zion, Illinois, United States|Maine Center for Cancer Medicine, dba: New England Cancer Specialists, Brunswick, Maine, United States|Maine Center for Cancer Medicine, dba: New England Cancer Specialists, Kennebunk, Maine, United States|Maine Center for Cancer Medicine, dba: New England Cancer Specialists, Scarborough, Maine, United States|Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins, Green Spring Station, Lutherville, Maryland, United States|University of Michigan Health System/Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States|Fairview Southdale Oncology Clinic, Edina, Minnesota, United States|University of Minnesota Medical Center, Fairview IDS Pharmacy, Minneapolis, Minnesota, United States|University of Minnesota Medical Center, Fairview, Minneapolis, Minnesota, United States|University of Minnesota Physicians, Masonic Cancer Center, Minneapolis, Minnesota, United States|Mercy Clinic St. Louis Cancer and Breast Institute, Ballwin, Missouri, United States|Mercy Ministry Office, Chesterfield, Missouri, United States|Mercy Clinic St. Louis Cancer and Breast Institute, Saint Louis, Missouri, United States|Mercy Hospital St. Louis, Saint Louis, Missouri, United States|Mercy Hospital St.Louis- David C. Pratt Cancer Center, Saint Louis, Missouri, United States|Mercy Clinic Mercy Oncology, Washington, Missouri, United States|Mercy Hospital Washington, Washington, Missouri, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada Research Department, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|CareMount Medical, Brewster, New York, United States|ProHEALTHCARE Associates, LLP, Lake Success, New York, United States|CareMount Medical, Mount Kisco, New York, United States|Northern Westchester Hospital, Mount Kisco, New York, United States|Hope Women's Cancer Centers, Asheville, North Carolina, United States|Mission Hospital, Inc., Asheville, North Carolina, United States|UPMC Cancer Center, Monroeville, Monroeville, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Investigational Drug Services, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Kimmel Cancer Center, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Magee Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute, Investigational Drug Service, William M. Cooper Pavilion, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, William M. Cooper Pavilion, Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|The Jones Clinic, PC, Germantown, Tennessee, United States|Texas Oncology- Dallas Presbyterian Hospital, Dallas, Texas, United States|Investigational Products Center (IPC), Fort Worth, Texas, United States|Texas Oncology- Longview Cancer Center, Longview, Texas, United States|Texas Oncology- McAllen South Second Street, McAllen, Texas, United States|Cancer Care Centers of South Texas, San Antonio, Texas, United States|Cancer Care Centers of South Texas, San Antonio, Texas, United States|Cancer Care Centers of South Texas, San Antonio, Texas, United States|Texas Oncology- Tyler, Tyler, Texas, United States|Texas Oncology- Weslaco, Weslaco, Texas, United States|Huntsman Cancer Hospital, Salt Lake City, Utah, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Virginia Cancer Specialists, PC, Arlington, Virginia, United States|Emily Couric Clinical Cancer Center, Charlottesville, Virginia, United States|University of Virginia Cancer Center IDS Pharmacy, Charlottesville, Virginia, United States|UVA Health System, Charlottesville, Virginia, United States|IFH Prosperity Infusion Pharmacy, Fairfax, Virginia, United States|Inova Medical Group, Fairfax, Virginia, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Cancer Specialists, PC, Leesburg, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Virginia Oncology Associates, Virginia Beach, Virginia, United States|Shenandoah Oncology, P.C., Winchester, Virginia, United States|Swedish Cancer Institute, Seattle, Washington, United States|Swedish Medical Center First Hill IDS Pharmacy, Seattle, Washington, United States|Swedish Medical Center, Seattle, Washington, United States|Columbia St. Mary's, Mequon, Wisconsin, United States|Columbia St. Mary's, Milwaukee, Wisconsin, United States|Bankstown - Lidcombe Hospital, Bankstown, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|River City Pharmacy, Auchenflower, Queensland, Australia|Sunshine Coast Hospital and Health Service, Nambour, Queensland, Australia|Icon Cancer Care Southport, Southport, Queensland, Australia|Cabrini Brighton, Brighton, Victoria, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia|Western Health, Western Hospital-Clinical Trials Pharmacy, Footscray, Victoria, Australia|Peninsula and Southeast Oncology, Frankston, Victoria, Australia|Barwon Health - The Geelong Hospital, Geelong, Victoria, Australia|Cabrini Hospital, Malvern, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Sunshine Hospital, St Albans, Victoria, Australia|Fiona Stanley Hospital - Cancer Centre, Murdoch, Western Australia, Australia|UZ Antwerpen, Edegem, Antwerpen, Belgium|Clinique Saint-Pierre, Ottignies, Brabant Wallon, Belgium|Institut Jules Bordet, Bruxelles, Bruxelles Capitale, Belgium|Grand Hôpital de Charleroi - Site Notre Dame, Charleroi, Hainaut, Belgium|INDC Entité Jolimontoise - CH de Jolimont-Lobbes, Haine St. Paul, Hainaut, Belgium|CHWaPi - Site IMC, Tournai, Hainaut, Belgium|C.H. de l'Ardenne - site Libramont, Libramont-Chevigny, Luxembourg, Belgium|Hopital Erasme, Bruxelles, Region DE Bruxelles-capital, Belgium|Imelda Ziekenhuis, Bonheiden, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|UZ Leuven - Campus Gasthuisberg, Leuven, Belgium|Clinique et Maternité Sainte-Elisabeth, Namur, Belgium|GZA Ziekenhuizen - Campus St Augustinus, Wilrijk, Belgium|British Columbia Cancer Agency - Sindi Ahluwalia Hawkins Centre for the Southern Interior, Kelowna, British Columbia, Canada|British Columbia Cancer Agency - Fraser Valley Centre, Surrey, British Columbia, Canada|Royal Victoria Regional Health Centre, Barrie, Ontario, Canada|Cancer Centre of Southeastern Ontario @ Kingston Health Sciences Centre, Kingston, Ontario, Canada|Lakeridge Health Oshawa, R.S. McLaughlin Durham Regional Cancer Centre, Oshawa, Ontario, Canada|The Ottawa Hospital Cancer Centre, General Campus, Ottawa, Ontario, Canada|Niagara Health System Walker Family Cancer Center, St. Catharines, Ontario, Canada|Toronto East General Hospital, Toronto, Ontario, Canada|Sunnybrook Research Institute, Toronto, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Universitaetsklinikum Leipzig AoeR, Leipzig, Germany|Zentrum fuer Radiologie und Nuklearmedizin am Johannisplatz, Leipzig, Germany|Klinikum der Universität München, München, Germany|Klinikum der Universität München, München, Germany|Bon Secours Hospital, Cork, Ireland|Azienda Sanitaria Firenze, c/o Ospedale S. M. Annunziata Farmacia Interna, Bagno A Ripoli (FI), Italy|S.O.C. Oncologia Medica I, Azienda Sanitaria Firenze, c/o Ospedale S. M. Annunziata, Bagno A Ripoli (FI), Italy|A.O.U. Policlinico SantOrsola, Bologna, Italy|SSD Oncologia Medica Addarii-Zamagni, Bologna, Italy|U.O. di Oncologia Medica P.O. Policlinico G. Rodolico"", Catania, Italy|Azienda U.L.S.S. n. 21 di Legnago, Presidio Ospedaliero Mater Salutis, Legnago (VR), Italy|Farmacia Ospedaliera-Azienda U.L.S.S. n. 21 di Legnago, Legnago (VR), Italy|IRST, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (FC), Italy|Farmacia IRCCS Ospedale San Raffaele, Milano, Italy|IRCCS Ospedale S. Raffaele, Milano, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|Istituto Europeo di Oncologia, Milano, Italy|Servizio di Farmacia - Istituto Europeo di Oncologia, Milano, Italy|Policlinico di Modena Dipartimento ad attivita integrata di Oncologia,, Modena, Italy|IRCCS Istituto Nazionale per lo Studio e la Cura dei Tumori, Napoli, Italy|Farmacia - Fondazione Policlinico Universitario A. Gemelli, Roma, Italy|Fondazione Policlinico Universitario A. Gemelli, Roma, Italy|S.C. Oncologia, Terni, Italy|Aichi Cancer Center Hospital, Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama-city, Ehime, Japan|Saitama Cancer Center, Kita-adachi-gun, Saitama,japan, Japan|Chiba Cancer Center, Chiba, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Hakuaikai Medical Corporation Sagara Hospital, Kagoshima, Japan|National Hospital Organization, Osaka, Japan|National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Academisch Ziekenhuis Maastricht, Maastricht, Limburg, Netherlands|Orbis Medisch Centrum, Sittard-Geleen, Limburg, Netherlands|TweeSteden Ziekenhuis, Tilburg, Noord-brabant, Netherlands|Haga Ziekenhuis, Den Haag, Zuid-holland, Netherlands|Leids Universitair Medisch Centrum, Leiden, Zuid-holland, Netherlands|Ikazia Ziekenhuis, Rotterdam, Zuid-holland, Netherlands|Champalimaud Cancer Center/ Breast Unit, Lisboa, Portugal|Instituto Português de Oncologia, Porto, Portugal|Spitalul Clinic CF nr.2 Bucuresti, Bucharest, Romania|Spitalul Municipal Ploiesti, Ploiesti, Romania|Spitalul Judetean de Urgente ""Sf. Ioan cel Nou"", Suceava, Romania|Spitalul Clinic Judetean Mures, Tg Mures, Romania|OGBUZ Belgorod Oncology Dispensary, Belgorod,, Belgorodskaya Oblast',, Russian Federation|OGBUZ Belgorod Oncology Dispensary, Stariy Oskol, Belgorodskaya Oblast', Russian Federation|GBUZ Leningrad regional oncological dispensary, Village Kuzmolovsky, Leningradskaya Oblast', Russian Federation|GBUZ Republican Clinical Oncology Dispensary of Ministry of Health of the Republic of Bashkortostan, Ufa, Republic OF Bashkortostan, Russian Federation|FGBUZ Clinical Hospital 101 of the Federal Medical and Biological Agency"", Lermontov, Stavropol Territory, Russian Federation|GBUZ of Stavropol Territory ""Pyatigorsk Oncology Dispensary"", Pyatigorsk,, Stavropol Territory, Russian Federation|GBUZ Chelyabinsk regional clinical center of oncology and nuclear medicine, Chelyabinsk, Russian Federation|FSBSI Russian Cancer Research Center n.a.NN Blokhin, Moscow, Russian Federation|Saint Petersburg GBUZ ""City Clinical Oncology Dispensary"", Saint Petersburg, Russian Federation|Saint Petersburg GBUZ City Clinical Oncology Dispensary, Saint Petersburg, Russian Federation|GBUZ of Stavropol Territory ""Stavropol Regional Clinical Oncology Dispensary"", Stavropol, Russian Federation|FGBU Russian Research Center for Radiology and Surgical Technologies, Village Pesochny, Russian Federation|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Ege University Medical Faculty, Izmir, Bornova, Turkey|Komunalna ustanova ""Chernivetskyi oblasnyi klinichnyi onkolohichnyi dyspanser"", Chernivtsi, Ukraine|Komunalnyi zaklad 'Miska klinichna likarnia No.4' Dniprovskoi miskoi rady,, Dnipro, Ukraine|Komunalne nekomertsiyne pidpryiemstvo ""Oblasnyi, Kharkiv, Ukraine|KNP Lvivskoi oblasnoi rady Lvivskyi onkolohichnyi, Lviv, Ukraine|Komunalna ustanova ""Odeska oblasna klinichna likarnia"", Odesa, Ukraine|Podilskyi rehionalnyi tsentr onkolohii,, Vinnytsia, Ukraine|Queen Alexandra Hospital, Portsmouth Hospitals NHS Trust Portsmouth Haematology and Oncology Centre, Portsmouth, Hampshire, United Kingdom|Velindre Cancer Centre, Cardiff, South Glamorgan, United Kingdom|Royal Hallamshire Hospital, Sheffield, South Yorkshire, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust, Weston Park Hospital, Sheffield, South Yorkshire, United Kingdom|The Royal Marsden NHS Foundation Trust, London, United Kingdom|The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom",https://ClinicalTrials.gov/show/NCT01942135
36,"Hoffmann-La Roche|Genentech, Inc.|Breast International Group",A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer,"Active, not recruiting",Has Results,Breast Cancer,Drug: 5-Fluorouracil|Drug: Carboplatin|Drug: Cyclophosphamide|Drug: Docetaxel|Drug: Doxorubicin|Drug: Epirubicin|Drug: Paclitaxel|Drug: Pertuzumab|Drug: Placebo|Drug: Trastuzumab,Industry|Other,Interventional,"HonorHealth Research Institute - Bisgrove, Scottsdale, Arizona, United States|Providence Regional Medical Center, Everett, California, United States|Marin Cancer Care Inc, Greenbrae, California, United States|Kaiser Permanente - Hayward, Hayward, California, United States|UCSD Moores Cancer Center, La Jolla, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Kaiser Permanente - Oakland, Oakland, California, United States|Kaiser Permanente - Roseville, Roseville, California, United States|Kaiser Permanente Sacramento Medical Center, Sacramento, California, United States|Sutter Cancer Center, Sacramento, California, United States|Southern California Kaiser Permanente, San Diego, California, United States|K. Permanente - San Fransisco, San Francisco, California, United States|K. Permanente - San Jose, San Jose, California, United States|K. Permanente - Santa Clara, Santa Clara, California, United States|K. Permanente - S. San Fran, South San Francisco, California, United States|Kaiser Permanente; Oncology Clinical Trials, Vallejo, California, United States|K. Permanente - Walnut Creek, Walnut Creek, California, United States|Rocky Mountain Cancer Center - Denver, Littleton, Colorado, United States|Lutheran Hematology &Oncology, Wheat Ridge, Colorado, United States|Eastern Ct Hema/Onco Assoc; Dept of Oncology, Norwich, Connecticut, United States|Washington Cancer Institute at MedStar Washington Hospital Center., Washington, District of Columbia, United States|Georgetown U; Lombardi Comp Can, Washington, District of Columbia, United States|Florida Cancer Specialists; SCRI, Fort Myers, Florida, United States|Memorial Cancer Institute, Hollywood, Florida, United States|Mayo Clinic-Jacksonville, Jacksonville, Florida, United States|Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy), Jacksonville, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Memorial Breast Cancer Center, Pembroke Pines, Florida, United States|Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida, United States|Florida Cancer Specialists; Saint Petersburg, Saint Petersburg, Florida, United States|Florida Cancer Specialists, Research Department, West Palm Beach, Florida, United States|Phoebe Putney Memorial Hospital, Albany, Georgia, United States|Georgia Cancer Specialists, Atlanta, Georgia, United States|Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Rush University Medical Center, Chicago, Illinois, United States|Uni of Chicago, Chicago, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Loyola University Med Center, Maywood, Illinois, United States|Edward Cancer Center Naperville, Naperville, Illinois, United States|Illinois Cancer Care, Peoria, Illinois, United States|Edward Cancer Center Plainfield, Plainfield, Illinois, United States|Quincy Medical Group; Canc Ctr at Blessing Hosp, Quincy, Illinois, United States|Carle Foundation, Urbana, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Cancer Center of Acadiana at Lafayette General, Lafayette, Louisiana, United States|Cancer Care of Maine, Brewer, Maine, United States|New England Cancer Specialists, Scarborough, Maine, United States|Mercy Medical Center, Baltimore, Maryland, United States|Weinberg CA Inst Franklin Sq, Baltimore, Maryland, United States|Maryland Oncology & Hematology, PA, Bethesda, Maryland, United States|Massachusetts General Hospital., Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute at Faulkner Hospital, Boston, Massachusetts, United States|Beth Israel Deac Med Ctr; East Campus Rsch Pharmacy, Boston, Massachusetts, United States|Dana Farber Can Ins, Boston, Massachusetts, United States|Berkshire Hematology, Oncology Pc, Pittsfield, Massachusetts, United States|Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Southdale Cancer Clinic, Edina, Minnesota, United States|US Oncology Research at Minnesota Oncology, Minneapolis, Minnesota, United States|Coborn Cancer Center, Saint Cloud, Minnesota, United States|Jackson Oncology Associates, PLLC, Jackson, Mississippi, United States|University of Missouri-Columbia; Ellis Fischel Cancer Center, Columbia, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Heartland CCOP/Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Cancer Alliance of Nebraska, Lincoln, Nebraska, United States|Cancer Alliance of Nebraska, Omaha, Nebraska, United States|Dartmouth Hitchcock Med Center, Lebanon, New Hampshire, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|New York Oncology Hematology, P.C., Albany, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Roswell Park Cancer Inst., Buffalo, New York, United States|Mount Sinai Beth Israel Medical Center, New York, New York, United States|Mount Sinai Beth Israel Comprehensive Cancer Center, New York, New York, United States|Mount Sinai West, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, United States|Carolina Oncology Specialists, PA - Hickory, Hickory, North Carolina, United States|Oncology Hematology Care Inc, Cincinnati, Ohio, United States|The Mark H. Zangmeister Ctr; Mid Ohio Onc/Hem Inc., Columbus, Ohio, United States|Dayton Clinical Oncology Prog, Dayton, Ohio, United States|Toledo Clinic Cancer Center-Oregon, Oregon, Ohio, United States|Northwest Cancer Specialists - Portland (NE Hoyt St), Portland, Oregon, United States|Abramson Cancer Center; Univ of Pennsylvania, Philadelphia, Pennsylvania, United States|Albert Einstein Healthcare Network ; Cancer Center, Philadelphia, Pennsylvania, United States|Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|Charleston Cancer Center, Charleston, South Carolina, United States|Charleston Oncology, P .A, Charleston, South Carolina, United States|South Carolina Oncology Associates - SCRI, Columbia, South Carolina, United States|Cancer Centers of the Carolina; Eastside Medical Center, Greenville, South Carolina, United States|Sanford USD School of Medicine, Sioux Falls, South Dakota, United States|Chattanooga Oncology and Hematology Associates, PC, Chattanooga, Tennessee, United States|Tennessee Onc., PLLC - SCRI, Nashville, Tennessee, United States|Vanderbilt Breast Center at One Hundred Oaks, Nashville, Tennessee, United States|Texas Oncology-Medical City Dallas, Dallas, Texas, United States|Texas Oncology - Dallas Presbyterian Hospital, Dallas, Texas, United States|Texas Oncology-Baylor Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology-El Paso Cancer Treatment Center Grandview, El Paso, Texas, United States|Texas Oncology, P.A. - Fort Worth, Fort Worth, Texas, United States|The Center for Cancer and Blood Disorders - Fort Worth, Fort Worth, Texas, United States|Texas Oncology, P.A. - Garland, Garland, Texas, United States|Texas Oncology - Houston (Gessner), Houston, Texas, United States|Texas Oncology-Tyler, Irving, Texas, United States|Cancer Care Centers of South Texas-HOAST - San Antonio, New Braunfels, Texas, United States|Texas Oncology-Plano East, Plano, Texas, United States|Community Cancer Trials of Utah, Ogden, Utah, United States|Wellmonth Physician Services, Bristol, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Providence St. Mary Regional Cancer Center, Walla Walla, Washington, United States|West Virginia University Hospitals Inc, Morgantown, West Virginia, United States|Green Bay Oncology/St. Mary's Hospital, Green Bay, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Centro Medico San Roque, San Miguel de Tucuman, Argentina|Isis Centro Especializado de Luces; Oncology, Santa Fe, Argentina|Lismore Base Hospital; Cancer Care & Haematology Unit, Lismore, New South Wales, Australia|Mater Misericordiae Hospital; Chemotherapy Cottage, Sydney, New South Wales, Australia|Newcastle Mater Misericordiae Hospital; Oncology, Waratah, New South Wales, Australia|Westmead Hospital; Medical Oncology and Pallative Care, Westmead, New South Wales, Australia|Wesley Medical Centre; Clinic For Haematology and Oncology, Auchenflower, Queensland, Australia|Mater Hospital; Oncology, Brisbane, Queensland, Australia|Royal Adelaide Hospital; Oncology, Adelaide, South Australia, Australia|Royal Hobart Hospital; Medical Oncology, Hobart, Tasmania, Australia|Monash Medical Centre; Oncology, Clayton, Victoria, Australia|Geelong Hospital; Andrew Love Cancer Centre, Geelong, Victoria, Australia|Austin Hospital; Medical Oncology, Heidelberg, Victoria, Australia|Peter Maccallum Cancer Institute; Medical Oncology, Melbourne, Victoria, Australia|Sir Charles Gairdner Hospital; Medical Oncology, Perth, Western Australia, Australia|Lkh-Univ. Klinikum Graz; Klinik Für Innere Medizin I, Graz, Austria|Tiroler Landeskrankenanstalten Ges.M.B.H.; Abt. Für Gynäkologie, Innsbruck, Austria|Ordensklinikum Linz Barmherzige Schwestern; Abt. fur Innere Medizin 1, Linz, Austria|Lhk Feldkirch; Interne Medizin Abt., Rankweil, Austria|Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt., Salzburg, Austria|A. Ö. Krankenhaus Der Barmherzigen Brüder; Interne Abt., St Veit An Der Glan, Austria|Lkh Vöcklabruck; I. Abt. Für Innere Medizin, Vöcklabruck, Austria|Klinikum Kreuzschwestern Wels; Iii. Interne Abt., Wels, Austria|Medizinische Universität Wien; Univ.Klinik für Frauenheilkunde - Klinik für Gynäkologie, Wien, Austria|Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie, Wien, Austria|Krankenhaus Der Stadt Wien-Hietzing; Abt. Für Gynäkologie U. Geburtshilfe, Wien, Austria|Institut Jules Bordet, Bruxelles, Belgium|GHdC Site Notre Dame, Charleroi, Belgium|UZ Antwerpen, Edegem, Belgium|Jessa Zkh (Campus Virga Jesse), Hasselt, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|CHU Sart-Tilman, Liège, Belgium|Clinique Ste-Elisabeth, Namur, Belgium|Sint Augustinus Wilrijk, Wilrijk, Belgium|UMHAT Tsaritsa Yoanna - ISUL; Clinic of Oncotherapy, Sofia, Bulgaria|SHATO - Sofia, Sofia, Bulgaria|SHATOD Dr. Marko Antonov Markov-Varna, EOOD, Varna, Bulgaria|Tom Baker Cancer Centre; Dept of Medicine, Calgary, Alberta, Canada|Cross Can Inst, Edmonton, Alberta, Canada|BC Cancer Agency, CSI, Kelowna, British Columbia, Canada|BC Cancer Agency - Fraser Valley Centre, Surrey, British Columbia, Canada|BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Bcca - Vancouver Island Cancer Centre; Oncology, Victoria, British Columbia, Canada|CancerCare Manitoba; Neuro-Oncology, Winnipeg, Manitoba, Canada|Atlantic Health Science Corporation; Saint John Regional Hospital Facility, Saint John, New Brunswick, Canada|Queen Elizabeth II Health Sciences Centre; Oncology, Halifax, Nova Scotia, Canada|Hamilton Health Sciences - Juravinski Cancer Centre, Hamilton, Ontario, Canada|Cancer Centre of Southeastern Ontario; Kingston General Hospital, Kingston, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Credit Valley Hospital/Carlo Fidani Peel Regional Cancer Centre, Mississauga, Ontario, Canada|Southlake Regional Health Center, Newmarket, Ontario, Canada|Ottawa Regional Cancer Centre, Ottawa, Ontario, Canada|Niagara Health Systems - St. Catherines General Site; Niagara Health System-St. Catharines Site, St. Catharines, Ontario, Canada|Northeastern Ontario; Regional Cancer Centre, Sudbury, Ontario, Canada|Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Princess Margaret Cancer Center, Toronto, Ontario, Canada|Hopital Maisonneuve- Rosemont; Oncology, Montreal, Quebec, Canada|Chum Hopital Notre Dame; Centre D'Oncologie, Montreal, Quebec, Canada|Hopital Sacre-Coeur Research Centre, Montreal, Quebec, Canada|Hopital du Saint Sacrement, Quebec City, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|Fundacion Arturo Lopez Perez, Santiago, Chile|INTOP, Santiago, Chile|Cancer Hospital Chinese Academy of Medical Sciences., Beijing, China|The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA), Beijing, China|the First Hospital of Jilin University, Changchun, China|Jilin Cancer Hospital, Changchun, China|Hu Nan Provincial Cancer Hospital, Changsha, China|Sichuan Provincial People's Hospital, Chengdu, China|Fujian Medical University Union Hospital, Fujian, China|Fuzhou General Hospital, PLA Nanjing Military Area Command, Fuzhou, China|Sun Yet-sen University Cancer Center, Guangzhou, China|Guangdong General Hospital, Guangzhou, China|The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|The 1st Affiliated Hospital of Nanchang Unversity, Nanchang, China|Shanghai Jiao Tong University School of Medicine (SJTUSM) - Ruijin Hospital (GuangCi Hospital), Shanghai, China|Shanghai First People's Hospital, Shanghai, China|Fudan University Shanghai Cancer Center, Shanghai, China|Changhai Hospital of Shanghai, Shanghai, China|Hebei Medical University Fourth Hospital;(Tumor Hospital of Hebei Province), Shijiazhuang, China|Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology, Wuhan, China|Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech, Wuhan, China|Hubei Cancer Hospital, Wuhan, China|Inst. Nacional de Cancerologia; Clinica de Seno, Bogota, Colombia|Fundacion Cardioinfantil, Bogota, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|Oncomedica S.A., Monteria, Colombia|Uni Hospital Split; Oncology & Radiotherapy, Split, Croatia|General Hospital Varazdin, Varazdin, Croatia|Clinical Hospital Centre Zagreb, Zagreb, Croatia|Masarykuv onkologicky ustav, Brno, Czechia|Fakultni Nemocnice Hradec Kralove; Dept of Radiotherapy & Oncology, Hradec Kralove, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|MULTISCAN, s.r.o., Radiologicke centrum Pardubice, Pardubice, Czechia|Aalborg Universitetshospital, Klinik Kirurgi-Kræft, Onkologisk afd., Aalborg, Denmark|Sydvestjysk Sygehus Esbjerg; Onkologisk afdeling, Esbjerg, Denmark|Herlev Hospital; Afdeling for Kræftbehandling, Herlev, Denmark|Nordsjællands Hospital, Hillerød, Onkologisk Afdeling, Hillerod, Denmark|Rigshospitalet; Onkologisk Klinik, København Ø, Denmark|Sjællands Universitetshospital, Næstved; Onkologisk Afdeling, Naestved, Denmark|Odense Universitetshospital, Onkologisk Afdeling R, Odense C, Denmark|Sygehus Syd Roskilde; Onkologisk/haematologisk ambulatorium, Roskilde, Denmark|Vejle Sygehus; Onkologisk Afdeling, Vejle, Denmark|Hospital Oncologia; Oncology, Salvador, El Salvador|Hospital Diagnostico Escalón, San Salvador, El Salvador|Clinique De L Europe; Pmsi, Amiens, France|ICO Paul Papin; Oncologie Medicale., Angers, France|HOP Prive Arras Les Bonnettes; Chimiotherapie, Arras, France|Institut Sainte Catherine, Avignon, France|Institut Bergonie; Oncologie, Bordeaux, France|Polyclinique Bordeaux Nord, Bordeaux, France|Hopital Augustin Morvan; Federation De Cancerologie, Brest, France|Centre Francois Baclesse; Recherche Clinique, Caen, France|Centre Jean Perrin; Hopital De Jour, Clermont Ferrand, France|Centre Leonard De Vinci;Chimiotherapie, Dechy, France|Centre Georges-François Lecler; Ctr de Lutte Contre le Canc, Dijon, France|Institut Daniel Hollard, Grenoble, France|Centre Hospitalier Departemental Les Oudairies, La Roche Sur Yon, France|Clinique des Ormeaux; Oncologie, Le Havre, France|Centre Oscar Lambret; Cancerologie Gynecologique, Lille, France|Hopital Dupuytren; Oncologie Medicale, Limoges, France|Centre Leon Berard; Departement Oncologie Medicale, Lyon, France|Institut Paoli Calmettes; Oncologie Medicale, Marseille, France|Institut régional du Cancer Montpellier, Montpellier, France|Polyclinique De Gentilly; Hemodialyse, Nancy, France|Centre Antoine Lacassagne; Hopital De Jour A2, Nice, France|Institut de cancerologie du Gard, Nimes, France|Institut Curie; Oncologie Medicale, Paris, France|Ch Pitie Salpetriere; Cmrr Ile De France Salpetriere, Paris, France|Polyclinique Francheville; MED CHIMIOTHERAPIE RADIOTHERAPIE, Perigueux, France|Clinique Armoricaine Radiologie; Hopital de Jour, Plerin, France|Chu De Poitiers; Chu La Miletrie, Poitiers, France|Institut Jean Godinot; Hopital De Jour, Reims, France|Polyclinique De Courlancy; Centre Radiotherapie Oncologie, Reims, France|Centre Eugene Marquis; Unite Huguenin, Rennes, France|Centre Henri Becquerel; Oncologie Medicale, Rouen, France|Ico Rene Gauducheau; Oncologie, Saint Herblain, France|ICL; Hematologie, Saint-Priest en Jarez, France|Centre Rene Huguenin; CONSULT SPECIALISEES, St Cloud, France|Institut d'oncologie de l'Orangerie; Chimiotherapie, Strasbourg, France|Hopital Hautepierre; Hematologie Oncologie, Strasbourg, France|Institut Claudius Regaud; Departement Oncologie Medicale, Toulouse, France|Clinique Pasteur; Pneumologie, Toulouse, France|Centre Alexis Vautrin; Oncologie Medicale, Vandoeuvre-les-nancy, France|Institut Gustave Roussy; Oncologie Medicale, Villejuif, France|Gesundheitszentrum St. Marien GmbH; Med. II, Hämatologie/Onkologie, Amberg, Germany|Hochwaldkrankenhaus, Bad Nauheim, Germany|Evang. Krankenhaus Frauenklinik, Bergisch Gladbach, Germany|Praxisklinik Krebsheilkunde für Frauen / Brustzentrum (Dres. Kittel/Klare), Berlin, Germany|Praxis Dr. Schoenegg, Berlin, Germany|HELIOS Klinikum Berlin-Buch; Klinik für Gynäkologie und Geburtshilfe, Berlin, Germany|Frauenarzt-Zentrum Zehlendorf an der Teltower Eiche, Berlin, Germany|Onkologische Schwerpunktpraxis Bielefeld; Haemotologie & Internistische onkologie, Bielefeld, Germany|Universitätsklinikum Bonn; Zentrum für Geburtshilfe und Frauenheilkunde, Bonn, Germany|Praxis Dr. Ralf Lorenz, Braunschweig, Germany|Hämato-Onkologie im Medicum/Home, Bremen, Germany|Klinikum Sindelfingen-Böblingen; Frauenklinik, Böblingen, Germany|Klinikum Chemnitz gGmbH; Frauen- und Kinderklinik, Chemnitz, Germany|DONAU ISAR Klinikum Deggendorf; Frauenklinik, Deggendorf, Germany|St. Johannes-Hospital, Dortmund, Germany|Universitätsklinikum ""Carl Gustav Carus""; Frauenheilkunde und Geburtshilfe, Dresden, Germany|Universitätsklinikum Düsseldorf; Frauenklinik, Düsseldorf, Germany|Luisenkrankenhaus GmbH & Co. KG., Brustzentrum, Düsseldorf, Germany|Praxis für Hamatologie und Onkologie, Erfurt, Germany|Universitätsklinikum Erlangen; Frauenklinik, Erlangen, Germany|Klinikum Esslingen; Klinik für Frauenheilkunde und Geburtshilfe, Esslingen, Germany|Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt am Main, Germany|Klinik Johann Wolfgang von Goethe Uni; Klinik für Frauenheilkunde und Geburtshilfe, Frankfurt, Germany|Städtische Kliniken Frankfurt am Main Höchst, Frankfurt, Germany|Praxis für Interdisziplinäre Onkologie und Hämatologie GbR, Freiburg, Germany|Dres.Jochen Wilke und Harald Wagner, Fürth, Germany|Universitätsklinikum Greifswald; Klinik für Frauenheilkunde und Brustzentrum, Greifswald, Germany|Universitätsklinikum Halle (Saale); Universitätsklinik Und Poliklinik Für Gynäkologie, Halle, Germany|Universitätsklinikum Hamburg-Eppendorf; Frauenklinik, Hamburg, Germany|SANA Klinikum Hameln-Pyrmont; Frauenklinik / Brustzentrum, Hameln, Germany|Gynaekologisch-Onkologische Schwerpunktpraxis Prof. Dr. med. Lueck, Dr. Schrader und Dr. Noeding, Hannover, Germany|Diakovere Henriettenstift, Frauenklinik, Hannover, Germany|Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg, Heidelberg, Germany|Praxisgemeinschaft; Frauenärzte am Bahnhofsplatz, Hildesheim, Germany|Universitätsklinikum des Saarlandes; Klinik f. Frauenheilkunden und Geburtshilfe, Homburg/Saar, Germany|ViDia Christliche Kliniken Karlsruhe, Vincentius-Diakonissen-Kliniken gAG; Frauenklinik, Karlsruhe, Germany|Elisabeth-Krankenhaus Brustzentrum, Kassel, Germany|Klinikum Kassel GmbH; Klinik für Frauenheilkunde und Geburtshilfe, Kassel, Germany|UNI-Klinikum Campus Kiel Klinik für Gynäkologie und Geburtshilfe, Kiel, Germany|St. Elisabeth Krankenhaus Köln GmbH; Gynäkologie und Geburtshilfe, Koeln, Germany|Uniklinik Köln, Klinik und Poliklinik und Geburtshilfe; Brustzentrum Köln, Köln, Germany|Klinikum Landshut Frauenklinik, Landshut, Germany|Sankt Elisabeth Krankenhaus; Gynaekology, Leipzig, Germany|Evangelisches Krankenhaus; Abt. Gynäkologie und Geburtshilfe, Ludwigsfelde, Germany|Universitätsklinikum Schleswig-Holstein / Campus Lübeck; Klinik für Frauenheilkunde und Geburtshilfe, Lübeck, Germany|Universitätsmedizin Mainz; Klinik u. Poliklinik f. Geburtshilfe u. Frauenheilkunde, Mainz, Germany|Rotkreuzklinikum München; Frauenklinik, Muenchen, Germany|Brustzentrum Rhein-Ruhr Servicegesellschaft mbH, Mönchengladbach, Germany|Klinikum der Universität München; Frauenklinik - Onkologie II, München, Germany|Klinikum rechts der Isar der TU München; Klinik und Poliklinik für Frauenheilkunde, München, Germany|Universitätsklinikum Münster; Klinik für Frauenheilkunde und Geburtshilfe, Münster, Germany|Sana Klinikum Offenbach GmbH; Klinik für Gynäkologie & Geburtshilfe, Offenbach, Germany|Medizinisches Versorgungszentrum am Klinikum Oldenburg GmbH, Oldenburg, Germany|Hämatologisch/Onkologische Praxis Dr. Herbrick - Zipp/Prof. Dr. Decker, Studienzentrum, Ravensburg, Germany|Oncologianova GmbH, Recklinghausen, Germany|RoMed Klinikum Rosenheim; Klinik für Gynäkologie und Geburtshilfe, Rosenheim, Germany|Universitätsfrauen- und Poliklinik am Klinikum Suedstadt, Rostock, Germany|MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken, Stade, Germany|Klinikum Mutterhaus der Borromaeerinnen gGmbH; Haematologie/Onkologie, Trier, Germany|Universitätsklinik Tübingen; Frauenklinik, Tübingen, Germany|Universitätsklinikum Ulm Am Michelsberg; Frauenklinik, Ulm, Germany|Dres. Arnd Nusch Naser Ali-Mohammad Kalhori und Werner Langer, Velbert, Germany|Schwarzwald-Baar Klinikum Klinik für Frauenheilkunde und Geburtshilfe, Villingen-Schwenningen, Germany|St. Josefs-Hospital Wiesbaden GmbH; Klinik für Frauenheilkunde und Geburtshilfe, Wiesbaden, Germany|Marien-Hospital Witten; Frauenklinik Brustzentrum, Witten, Germany|Hämatologisch-Onkologische Schwerpunktpraxis; Dres. Schlag & Schöttker, Würzburg, Germany|Grupo Angeles, Guatemala City, Guatemala|Centro Oncológico Sixtino / Centro Oncológico SA, Guatemala, Guatemala|Queen Mary Hospital; Surgery, Hong Kong, Hong Kong|Queen Mary Hospital; Dept of Medicine, Hong Kong, Hong Kong|Semmelweis Egyetem Onkologiai Központ, Budapest, Hungary|Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly, Budapest, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont; Fázis I-es Klinikai Farmakológiai Vizsgálóhely, Budapest, Hungary|Debreceni Egyetem, Klinikai Kozpont, Onkologiai Klinika, Debrecen, Hungary|Petz Aladar Megyei Oktato Korhaz; Oncoradiologia, Gyor, Hungary|Békés Megyei Pándy Kálmán Kórház; Onkologiai tanszek, Gyula, Hungary|Bacs-Kiskun Megyei Korhaz, SZTE AOK Oktato Korhaza, Onkoradiologiai Kozpont, Kecskemet, Hungary|Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika, Szeged, Hungary|Veszprem Megyei Csolnoky; Ferenc Korhaz, Veszprem, Hungary|Cork Uni Hospital; Oncology Dept, Cork, Ireland|St Vincent'S Uni Hospital; Medical Oncology, Dublin, Ireland|Mater Misericordiae Uni Hospital; Oncology, Dublin, Ireland|St. James Hospital; Oncology, Dublin, Ireland|Beaumont Hospital; Cancer Clinical Trials Unit, Dublin, Ireland|Galway University Hospital; Clinical Trials Department, Galway, Ireland|University Hospital Limerick - Oncology, Limerick, Ireland|Rambam Medical Center; Oncology, Haifa, Israel|Rabin MC; Davidof Center - Oncology Institute, Petach Tikva, Israel|Chaim Sheba Medical Center; Oncology Dept, Ramat Gan, Israel|Kaplan Medical Center; Oncology Inst., Rehovot, Israel|Sourasky / Ichilov Hospital; Oncology Department, Tel Aviv, Israel|Campus Universitario S.Venuta; Centro Oncologico T.Campanella, Catanzaro, Calabria, Italy|AORN'S.G.Moscati; Oncologia, Avellino, Campania, Italy|IRCCS Istituto Nazionale Tumori Fondazione Pascale; Oncologia Medica A, Napoli, Campania, Italy|Ist. Uni Federico Ii; Divisione Di Oncologia Medica - Dpt. Di Medicina Interna, Napoli, Campania, Italy|Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica, Bologna, Emilia-Romagna, Italy|Ospedale Ramazzini, Carpi, Emilia-Romagna, Italy|Arcispedale Santa Maria Nuova; Oncologia, Reggio Emilia, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica, Aviano, Friuli-Venezia Giulia, Italy|Divisione Onc Med dell'Azienda, Udine, Friuli-Venezia Giulia, Italy|Ospedale Belcolle Di Viterbo; Oncologia, Viterbo, Lazio, Italy|Ente Ospedaliero Ospedali Galliera; S.C. Oncologia Medica, Genova, Liguria, Italy|Az. Osp. Uni Ria San Martino; Cliniche Uni Rie Convenzionate U.O. Oncologia Medical, Genova, Liguria, Italy|IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A, Genova, Liguria, Italy|ASST DEGLI SPEDALI CIVILI DI BRESCIA; Oncologia Medica, Brescia, Lombardia, Italy|ASST DI LECCO; Oncologia Medica, Lecco, Lombardia, Italy|Ospedale Mater Salutis; Dept of Oncology, Legnago, Lombardia, Italy|Irccs Istituto Europeo Di Oncologia (IEO); Ricerca Di Senologia Medica, Milano, Lombardia, Italy|Policlinico di Monza; Istituto di Oncologia, Monza, Lombardia, Italy|IRCCS Fondazione Maugeri; Oncologia Medica I, Pavia, Lombardia, Italy|IRCCS Istituto Clinico Humanitas; Oncologia, Rozzano, Lombardia, Italy|Az. Osp. Di Busto P.O. Di Saronno; U.O. Di Oncologia Medica, Saronno, Lombardia, Italy|Ospedale S. Croce Di Fano; Servizio Oncologia, Fano, Marche, Italy|Fondazione Del Piemonte Per L'oncologia Ircc Di Candiolo; Dipartimento Oncologico, Candiolo, Piemonte, Italy|Ospedale Antonio Perrino; Oncologia Medica, Brindisi, Puglia, Italy|Ospedale della Misericordia e Dolce; Radiologia, Prato, Toscana, Italy|Ospedale Di Bolzano; Dept. Di Oncologia, Bolzano, Trentino-Alto Adige, Italy|Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica, Perugia, Umbria, Italy|Azienda Ospedaliera S. Maria - Terni; Oncologia, Terni, Umbria, Italy|Aichi Cancer Center Hospital, Breast Oncology, Aichi, Japan|Chiba Cancer Center; Breast Surgical Oncology, Chiba, Japan|National Cancer Center Hospital East; Breast and Medical Oncology, Chiba, Japan|Natl Hosp Org Shikoku; Cancer Ctr, Surgery, Ehime, Japan|National Hospital Organization Kyushu Cancer Center;Breast Oncology, Fukuoka, Japan|Gunma University Hospital; Department of Thoracic and Visceral Organ Surgery, Gunma, Japan|Hiroshima City Hiroshima Citizens Hospital; Breast Surgery, Hiroshima, Japan|Iwate Med Univ School of Med; Surgery, Iwate, Japan|Sagara Hospital; Breast Surgery, Kagoshima, Japan|St. Marianna University School of Medicine Hospital, Breast and Endocrine Surgery, Kanagawa, Japan|Tokai University Hospital, Breast and Endocrine Surgery, Kanagawa, Japan|Kumamoto City Hospital, Breast and Endocrine Surgery, Kumamoto, Japan|Kumamoto Shinto General Hospital; Breast Cancer Center, Kumamoto, Japan|Kyoto University Hospital; Breast Surgery, Kyoto, Japan|Niigata Cancer Ctr Hospital; Breast Surgery, Niigata, Japan|National Hospital Organization Osaka National Hospital; Breast Surgery, Osaka, Japan|Osaka International Cancer Institute; Breast and Endocrine Surgery, Osaka, Japan|Saitama Medical University International Medical Center; Breast Oncology, Saitama, Japan|Saitama Cancer Center, Breast Oncology, Saitama, Japan|Shizuoka Cancer Center; Female Internal Medicine, Shizuoka, Japan|Shizuoka General Hospital; Breast Surgery, Shizuoka, Japan|Jichi Medical School ; Surgery, Tochigi, Japan|National Cancer Center Hospital; Breast and Medical Oncology, Tokyo, Japan|Tokyo Metropolitan; Komagome Hospital, Surgery, Tokyo, Japan|The Cancer Inst. Hosp. of JFCR; Breast Oncology Center, Tokyo, Japan|Tokyo Medical Uni. Hospital; Breast Oncology, Tokyo, Japan|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Seoul National Uni Hospital; Dept. of Internal Medicine/Hematology/Oncology, Seoul, Korea, Republic of|Yonsei University Severance Hospital; Medical Oncology, Seoul, Korea, Republic of|Kyunghee University Hospital; Endocrinology, Seoul, Korea, Republic of|Samsung Medical Centre; Division of Hematology/Oncology, Seoul, Korea, Republic of|Korea University Anam Hospital; Oncology Haemotology, Seoul, Korea, Republic of|Hospital Angeles Metropolitano; Room 220, Mexico City, Mexico CITY (federal District), Mexico|Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico|Centro Estatal de Oncología de Campeche, Campeche, Mexico|Centro Estatal De Cancerologia De Durango; Oncology, Durango, Mexico|Núcleo de Especialidades Oncológicas, Guadalajara, Mexico|Fundacion Rodolfo Padilla Padilla A.C., León, Mexico|Hospital General de México; Unidad de Oncologia, Mexico DF, Mexico|Centro Universitario Contra El Cancer, Monterrey, Mexico|Centro de Diagnóstico y Tratamiento Integral de Mama, Hospital San José Tec de Monterrey, Monterrey, Mexico|Oaxaca Site Management Organization, Oaxaca, Mexico|Cancerologia de Queretaro; Oncologia, Queretaro, Queretaro, Mexico|Centro Regional de Enfermedades Oncológicas, S.A., San Luis Potosi, Mexico|Medisch Centrum Alkmaar, Alkmaar, Netherlands|Amphia ziekenhuis, locatie langendijk, Breda, Netherlands|Reinier de Graaf Gasthuis, Delft, Netherlands|Academish Ziekenhuis Maastricht (Azm); Inwendige Geneeskunde, Maastricht, Netherlands|Isala Klinieken, Zwolle, Netherlands|Waikato Hospital; Dept of Medical Oncology, Hamilton, New Zealand|Palmerston North Hospital; Regional Cancer Treatment Service, Palmerston North, New Zealand|Centro Hemato Oncologico Panama, Panama, Panama|Centro Oncologico America, Panama, Panama|Clinica Anglo Americana - Centro de Investigacion Oncologia CAA, Lima, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Clinica El Golf, San Isidro, Peru|Clinica Peruana Americana, Trujillo, Peru|University Of Santo Tomas; Oncology; Benavides Cancer Institute, Manila, Philippines|Rizal Medical Center, Pasig City, Philippines|Veterans Memorial Medical Ctr; Cancer Research Centre, Quezon City, Philippines|Bialostockie Ctr Onkologii; Oddzial Chemioterapii Dziennej, Bialystok, Poland|Centrum Onkologii;Im. Franciszka Lukaszczyka;Onkologii, Bydgoszcz, Poland|Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii, Gdansk, Poland|Opolskie Centrum Onkologii;Oddzial Onkologii Klinicznej, Opole, Poland|Narodowy Inst.Onkologii im.Sklodowskiej-Curie Panstw.Inst.Bad; Klinika Nowtw.Piersi i Chir.Rekonstr, Warszawa, Poland|NZOZ Mazowiecki Szpital Onkologiczny Uczelni Warszawskiej im. M. Skłodowskiej-Curie, Wieliszew, Poland|Emergency University Bucharest Hospital; Oncology Department, Bucharest, Romania|Prof. Dr. I. Chiricuta Institute of Oncology, Cluj Napoca, Romania|Oncology Inst. Cluj-Napoca; Cancer Dept, Cluj-Napoca, Romania|Euroclinic Center of Oncology SRL, Iasi, Romania|Clinical Oncology Dispensary of Ministry of Health of Tatarstan, Kazan, Russian Federation|S.I. Russian Oncological Research Center n.a. N.N. Blokhin, Moscow, Russian Federation|State Budget Institution of Healthcare of Stavropol region Pyatigorsk Oncology Dispensary, Pyatigorsk, Russian Federation|SBI of Healthcare Samara Regional Clinical Oncology Dispensary, Samara, Russian Federation|SBI of Healthcare of Stavropol region Stavropol Regional Clinical Oncology Dispensary, Stavropol, Russian Federation|Tula Regional Oncology Dispensary, Tula, Russian Federation|Institute of Oncology Ljubljana, Ljubljana, Slovenia|National Hospital; Oncotherapy Dept, Bloemfontein, South Africa|Wits Donald Gordon Clinical Trial Centre; Medical Oncology, Parktown, Johannesburg, South Africa|Steve Biko Academic Hospital; Oncology, Pretoria, South Africa|Hospital General Universitario de Elche; Servicio de Oncologia, Elche, Alicante, Spain|Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Badalona, Barcelona, Sp",
37,"Astellas Pharma Global Development, Inc.|Medivation LLC, a wholly owned subsidiary of Pfizer Inc.|Astellas Pharma Inc",A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC),"Active, not recruiting",Has Results,Metastatic Hormone Sensitive Prostate Cancer,Drug: Enzalutamide|Drug: Placebo,Industry,Interventional,"Site US10016, Homewood, Alabama, United States|Site US10007, Anchorage, Alaska, United States|Site US10008, Tucson, Arizona, United States|Site US10034, Fountain Valley, California, United States|Site US10056, La Jolla, California, United States|Site US10026, Santa Rosa, California, United States|Site US10035, Aurora, Colorado, United States|Site US10050, Denver, Colorado, United States|Site US10048, Saint Petersburg, Florida, United States|Site US10054, Thomasville, Georgia, United States|Site US10015, Chicago, Illinois, United States|Site US10043, Springfield, Illinois, United States|Site US10045, Jeffersonville, Indiana, United States|Site US10020, West Des Moines, Iowa, United States|Site US10055, Kansas City, Kansas, United States|Site US10017, Towson, Maryland, United States|Site US10036, Omaha, Nebraska, United States|Site US10018, Lawrenceville, New Jersey, United States|Site US10025, Newburgh, New York, United States|Site US10029, Syracuse, New York, United States|Site US10068, Charlotte, North Carolina, United States|Site US10009, Concord, North Carolina, United States|Site US10014, Durham, North Carolina, United States|Site US10060, Greenville, North Carolina, United States|Site US10044, Middleburg Heights, Ohio, United States|Site US10011, Lancaster, Pennsylvania, United States|Site US10012, Myrtle Beach, South Carolina, United States|Site US10059, Nashville, Tennessee, United States|Site US10046, Dallas, Texas, United States|Site US10004, Dallas, Texas, United States|Site US10040, Virginia Beach, Virginia, United States|Site US10002, Burien, Washington, United States|Site US10013, Seattle, Washington, United States|Site US10028, Wenatchee, Washington, United States|Site AR54002, Rosario, Santa Fe, Argentina|Site AR54007, San Miguel de Tucuman, Tucuman, Argentina|Site AR54010, Buenos Aires, Argentina|Site AU61016, Camperdown, New South Wales, Australia|Site AU61007, St Leonards, New South Wales, Australia|Site AU61006, Sydney, New South Wales, Australia|Site AU61009, Tweed Heads, New South Wales, Australia|Site AU61013, Waratah, New South Wales, Australia|Site AU61001, Woodville South, South Australia, Australia|Site AU61004, Ballarat, Victoria, Australia|Site AU61015, Clayton, Victoria, Australia|Site AU61017, Parkville, Victoria, Australia|Site AU61008, St. Albans, Victoria, Australia|Site BE32001, Mons, Hainaut, Belgium|Site BE32012, Gent, Oost-Vlaanderen, Belgium|Site BE32005, Kortrijk, West-Vlaanderen, Belgium|Site BE32008, Liege, Belgium|Site BE32007, Yvoir, Belgium|Site CA15016, Edmonton, Alberta, Canada|Site CA15024, Abbotsford, British Columbia, Canada|Site CA15003, Kelowna, British Columbia, Canada|Site CA15022, Kelowna, British Columbia, Canada|Site CA15010, Brampton, Ontario, Canada|Site CA15021, Kingston, Ontario, Canada|Site CA15013, Oakville, Ontario, Canada|Site CA15020, Toronto, Ontario, Canada|Site CA15023, Granby, Quebec, Canada|Site CA15004, Montreal, Quebec, Canada|Site CL56002, Temuco, IX Region, Chile|Site CL56001, Santiago, RM, Chile|Site CL56007, Providencia, Santiago, Chile|Site CL56005, Viña Del Mar, Valparaiso, Chile|Site CL56004, Reñaca, Viña Del Mar, Chile|Site CL56003, Santiago, Chile|Site DK45002, Copenhagen, Hovestaden, Denmark|Site DK45005, Aarhus, Midtjylland, Denmark|Site DK45008, Holstebro, Midtjylland, Denmark|Site DK45004, Aalborg, Nordjylland, Denmark|Site DK45003, Herlev, Denmark|Site DK45001, Odense C, Denmark|Site FI35802, Helsinki, Etelä-Suomen Lääni, Finland|Site FI35804, Pori, Länsi-Suomen Lääni, Finland|Site FI35803, Seinäjoki, Länsi-Suomen Lääni, Finland|Site FI35801, Tampere, Oulun Laani, Finland|Site FI35805, Oulu, Finland|Site FI35806, Pietarsaari, Finland|Site FI35807, Turku, Finland|Site FR33010, Angers, Maine-et-Loire, France|Site FR33003, Creteil, Val-de-Marne, France|Site FR33006, Bordeaux, France|Site FR33014, Caen Cedex 05, France|Site FR33005, La Roche sur Yon, France|Site FR33015, Le Mans Cedex 2, France|Site FR33012, Lille Cedex, France|Site FR33007, Lyon Cedex 3, France|Site FR33011, Nimes, France|Site FR33001, Pierre Benite, France|Site FR33009, Quimper, France|Site FR33013, Saint Mande, France|Site DE49002, Freiburg, Baden-Württemberg, Germany|Site DE49004, Nürtingen, Baden-Württemberg, Germany|Site DE49005, Bonn, Germany|Site DE49014, Hamburg, Germany|Site DE49013, Heidelberg, Germany|Site IL97201, Kfar-Saba, HaMerkaz, Israel|Site IL97211, Zerifin, HaMerkaz, Israel|Site IL97210, Beer-Sheva, Israel|Site IL97202, Haifa, Israel|Site IL97205, Haifa, Israel|Site IL97206, Jerusalem, Israel|Site IT39005, Meldola, Emilia-Romagna, Italy|Site IT39004, Cremona, Lombardia, Italy|Site IT39003, Milano, Lombardia, Italy|Site IT39012, Milano, Lombardia, Italy|Site IT39007, Novara, Piemonte, Italy|Site IT39008, Pisa, Toscana, Italy|Site IT39011, Trento, Trentino-Alto Adige, Italy|Site IT39006, Padova, Veneto, Italy|Site IT39009, Candiolo, Italy|Site JP81003, Sakura, Chiba, Japan|Site JP81001, Maebashi, Gunma, Japan|Site JP81013, Kita-gun, Kagawa, Japan|Site JP81007, Yokohama, Kanagawa, Japan|Site JP81016, Sendai, Miyagi, Japan|Site JP81010, Abeno-ku, Osaka, Japan|Site JP81011, Chuo-ku, Osaka, Japan|Site JP81012, Osakasayama, Osaka, Japan|Site JP81006, Bunkyo-ku, Tokyo, Japan|Site JP81004, Koto-ku, Tokyo, Japan|Site JP81005, Shinjuku-ku, Tokyo, Japan|Site JP81017, Ube, Yamaguchi, Japan|Site JP81002, Chiba, Japan|Site JP81014, Fukuoka, Japan|Site JP81015, Fukuoka, Japan|Site JP81008, Kyoto, Japan|Site JP81018, Nagasaki, Japan|Site JP81020, Niigata, Japan|Site JP81019, Yamagata, Japan|Site KR82008, Seongnam-si, Gyeonggi-do, Korea, Republic of|Site KR82007, Busan, Korea, Republic of|Site KR82004, Incheon, Korea, Republic of|Site KR82001, Seoul, Korea, Republic of|Site KR82002, Seoul, Korea, Republic of|Site KR82003, Seoul, Korea, Republic of|Site NL31002, Sneek, Friesland, Netherlands|Site NL31003, Nijmegen, Gelderland, Netherlands|Site NL31007, Nijmegen, Gelderland, Netherlands|Site NL31005, Eindhoven, Noord-Brabant, Netherlands|Site NL31010, Alkmaar, Noord-Holland, Netherlands|Site NL31008, Amsterdam, Noord-Holland, Netherlands|Site NL31009, Zwolle, Overijssel, Netherlands|Site NL31006, Rotterdam, Zuid-Holland, Netherlands|Site NZ64003, Tauranga, Bay Of Plenty, New Zealand|Site NZ64008, Kensington, Northland, New Zealand|Site NZ64002, Dunedin, South Island, New Zealand|Site NZ64005, Nelson, Tasman District, New Zealand|Site NZ64004, Hamilton, New Zealand|Site PL48003, Wroclaw, Dolnoslaskie, Poland|Site PL48007, Krakow, Malopolskie, Poland|Site PL48011, Warszawa, Mazowieckie, Poland|Site PL48005, Gdańsk, Pomerania, Poland|Site PL48010, Slupsk, Pomorskie, Poland|Site PL48001, Myslowice, Poland|Site RO40008, Cluj-Napoca, Cluj, Romania|Site RO40009, Cluj-Napoca, Cluj, Romania|Site RO40002, Floresti, Cluj, Romania|Site RO40011, Timisoara, Timis, Romania|Site RO40007, Brasov, Romania|Site RO40003, Bucharest, Romania|Site RO40006, Bucharest, Romania|Site RU70013, Ivanovo, Russian Federation|Site RU70001, Moscow, Russian Federation|Site RU70003, Moscow, Russian Federation|Site RU70014, Moscow, Russian Federation|Site RU70006, Omsk, Russian Federation|Site RU70005, Penza, Russian Federation|Site RU70007, St. Petersburg, Russian Federation|Site RU70008, St. Petersburg, Russian Federation|Site RU70009, St. Petersburg, Russian Federation|Site RU70012, St. Petersburg, Russian Federation|Site RU70016, St. Petersburg, Russian Federation|Site SK42110, Bratislava, Slovakia|Site SK42109, Kosice, Slovakia|Site SK42102, Michalovce, Slovakia|Site SK42103, Nitra, Slovakia|Site SK42101, Poprad, Slovakia|Site SK42107, Trencin, Slovakia|Site SK42106, Žilina, Slovakia|Site ES34011, Salamanca, A Coruña, Spain|Site ES34020, Oviedo, Asturias, Spain|Site ES34010, Sabadell, Barcelona, Spain|Site ES34012, Barcelona, Cataluña, Spain|Site ES34014, Barcelona, Cataluña, Spain|Site ES34013, Valencia, Comunidad Valenciana, Spain|Site ES34006, Pamplona, Navarra, Spain|Site ES34001, Avila, Spain|Site ES34007, Barcelona, Spain|Site ES34004, Madrid, Spain|Site ES34019, Madrid, Spain|Site SE46002, Örebro, Orebro Län, Sweden|Site SE46001, Malmö, Skåne Län, Sweden|Site SE46006, Stockholm, Sodermanlands Lan, Sweden|Site SE46004, Sundsvall, Vasternorrlands Lan, Sweden|Site SE46007, Goteborg, Vastra Gotalands Lan, Sweden|Site TW88601, Kaohsiung, Taiwan|Site TW88606, Taichung, Taiwan|Site TW88605, Taipei, Taiwan|Site TW88607, Taoyuan, Taiwan|Site GB44002, Withington, Manchester, United Kingdom",https://ClinicalTrials.gov/show/NCT02677896
38,"Pfizer|Merck KGaA, Darmstadt, Germany|Pierre Fabre Medicament|Ono Pharmaceutical Co. Ltd",Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer,"Active, not recruiting",Has Results,BRAF V600E-mutant Metastatic Colorectal Cancer,Drug: Encorafenib|Drug: Binimetinib|Drug: Cetuximab|Drug: Irinotecan|Drug: Folinic Acid|Drug: 5-Fluorouracil,Industry,Interventional,"Mayo Clinic Hospital, Phoenix, Arizona, United States|Compassionate Cancer Care Medical Group, Inc. - Corona, Corona, California, United States|City of Hope - Comprehensive Cancer Center, Duarte, California, United States|Compassionate Care Research Group, Inc., Fountain Valley, California, United States|St. Jude Heritage Healthcare, Fullerton, California, United States|University of Southern California (USC) Norris Comprehensive Cancer Center, Los Angeles, California, United States|Compassionate Cancer Care Medical Group, Riverside, California, United States|University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Broward General Medical Center, Fort Lauderdale, Florida, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Emory University Winship Cancer Institute, Atlanta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Illinois Cancer Center, Peoria, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Baptist Health Cancer Center, New Albany, Indiana, United States|University of Iowa Health Care - University of Iowa Hospital, Iowa City, Iowa, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|John Hopkins Hospital, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital (MGH), Boston, Massachusetts, United States|St. Joseph Mercy Hospital, Ypsilanti, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Saint Louis University Hospital, Saint Louis, Missouri, United States|Washington University, Saint Louis, Missouri, United States|Dartmouth Hitchcock, Lebanon, New Hampshire, United States|New Mexico Cancer Care, Albuquerque, New Mexico, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Gabrail Cancer CTR Research, Canton, Ohio, United States|Cleveland Clinic Taussig, Cleveland, Ohio, United States|Toledo Clinic Cancer Center, Toledo, Ohio, United States|Oregon Health and Science University Knight Cancer Institute, Portland, Oregon, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Vanderbilt Ingram Cancer CTR, Nashville, Tennessee, United States|MD Anderson, Houston, Texas, United States|Baylor Scott & White Health, Temple, Texas, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Medical Oncology Associates, P.S., Spokane, Washington, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Pfizer Investigative Site, Pergamino, Buenos Aires, Argentina|Pfizer Investigative Site, Córdoba, Cordoba, Argentina|Pfizer Investigative Site, Santa Rosa, La Pampa, Argentina|Pfizer Investigative Site, San Miguel De Tucumán, Tucuman, Argentina|Pfizer Investigative Site, La Rioja, Argentina|Pfizer Investigative Site, Darlinghurst, New South Wales, Australia|Pfizer Investigative Site, Adelaide, South Australia, Australia|Pfizer Investigative Site, East Bentleigh, Victoria, Australia|Pfizer Investigative Site, Heidelberg, Victoria, Australia|Pfizer Investigative Site, Parkville, Victoria, Australia|Pfizer Investigative Site, Adelaide, Australia|Pfizer Investigative Site, Steyr, Oberösterreich, Austria|Pfizer Investigative Site, Wels, Oberösterreich, Austria|Pfizer Investigative Site, Vienna, Austria|Pfizer Investigative Site, Bonheiden, Antwerpen, Belgium|Pfizer Investigative Site, Edegem, Antwerp, Belgium|Pfizer Investigative Site, Charleroi, Hainaut, Belgium|Pfizer Investigative Site, Verviers, Liege, Belgium|Pfizer Investigative Site, Libramont-Chevigny, Luxembourg, Belgium|Pfizer Investigative Site, Gent, Oost-Vlaanderen, Belgium|Pfizer Investigative Site, Brugge, West-Vlaanderen, Belgium|Pfizer Investigative Site, Roeselare, West-Vlaanderen, Belgium|Pfizer Investigative Site, Leuven, Belgium|Pfizer Investigative Sites (2), Liège, Belgium|Pfizer Investigative Site, Cachoeiro de Itapemirim, Espírito Santo, Brazil|Pfizer Investigative Site, Belo Horizonte, Minas Gerais, Brazil|Pfizer Investigative Site, Caxias do Sul, Rio Grande Do Sul, Brazil|Pfizer Investigative Site, Lajeado, Rio Grande Do Sul, Brazil|Pfizer Investigative Site, Pelotas, Rio Grande Do Sul, Brazil|Pfizer Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Pfizer Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Pfizer Investigative Site, Itajaí, Santa Catarina, Brazil|Pfizer Investigative Site, São Paulo, Sao Jose Do Rio Preto, Brazil|Pfizer Investigative Site, Barretos, São Paulo, Brazil|Pfizer Investigative Site, Santo André, São Paulo, Brazil|Pfizer Investigative Site, Sorocaba, São Paulo, Brazil|Pfizer Investigative Site, Passo Fundo, Brazil|Pfizer Investigative Site, Pôrto Alegre, Brazil|Pfizer Investigative Site, São Paulo, Brazil|Pfizer Investigative Site, Ottawa, Ontario, Canada|Pfizer Investigative Site, Toronto, Ontario, Canada|Pfizer Investigative Site, Montréal, Quebec, Canada|Pfizer Investigative Site, Toronto, Canada|Pfizer Investigative Site, Temuco, Araucanía, Chile|Pfizer Investigative Site, Brno, Brno-město, Czechia|Pfizer Investigative Site, Hradec Králové, Královéhradecký Kraj, Czechia|Pfizer Investigative Site, Olomouc, Czechia|Pfizer Investigative Site, Praha, Czechia|Pfizer Investigative Site, Odense, South Denmark, Denmark|Pfizer Investigative Site, Reims, Cedex, France|Pfizer Investigative Site, Villejuif, Il-de-France, France|Pfizer Investigative Site, Lyon, Rhone, France|Pfizer Investigative Site, Avignon, Vaucluse, France|Pfizer Investigative Site, Besançon, France|Pfizer Investigative Site, Brest, France|Pfizer Investigative Site, La Tronche, France|Pfizer Investigative Site, Lyon, France|Pfizer Investigative Site, Montpellier, France|Pfizer Investigative Site, Paris, France|Pfizer Investigative Site, Périgueux, France|Pfizer Investigative Site, Toulouse, France|Pfizer Investigative Site, Ulm, Baden-Württemberg, Germany|Pfizer Investigative Site, München, Bayern, Germany|Pfizer Investigative Site, Schweinfurt, Bayern, Germany|Pfizer Investigative Site, Hannöver, Niedersachsen, Germany|Pfizer Investigative Site, Oldenburg, Niedersachsen, Germany|Pfizer Investigative Site, Essen, Nordrhein-Westfalen, Germany|Pfizer Investigative Site, Essen, Nordrhein-Westfalen, Germany|Pfizer Investigative Site, Worms, Rheinland-Pfalz, Germany|Pfizer Investigative Site, Dresden, Sachsen, Germany|Pfizer Investigative Site, Kiel, Schleswig-Holstein, Germany|Pfizer Investigative Site, Tübingen, Württemberg, Germany|Pfizer Investigative Site, Berlin, Germany|Pfizer Investigative Site, Hamburg, Germany|Pfizer Investigative Site, Mönchengladbach, Germany|Pfizer Investigative Site, Pécs, Baranya, Hungary|Pfizer Investigative Site, Debrecen, Hajdú-Bihar, Hungary|Pfizer Investigative Site, Kaposvár, Somogy, Hungary|Pfizer Investigative Site, Budapest, Hungary|Pfizer Investigative Site, Budapest, Hungary|Pfizer Investigative Site, Budapest, Hungary|Pfizer Investigative Site, Budapest, Hungary|Pfizer Investigative Site, Zalaegerszeg, Hungary|Pfizer Investigative Site, Beer Sheva, HaDarom, Israel|Pfizer Investigative Site, Kfar Saba, HaMerkaz, Israel|Pfizer Investigative Site, Petah Tikva, HaMerkaz, Israel|Pfizer Investigative Site, Ramat Gan, Hamerkaz, Israel|Pfizer Investigative Site, Ashkelon, Israel|Pfizer Investigative Site, Jerusalem, Israel|Pfizer Investigative Site, Tel Aviv, Israel|Pfizer Investigative Site, Treviglio, Bergamo, Italy|Pfizer Investigative Site, Monserrato, Cagliari, Italy|Pfizer Investigative Site, Monza, Milano, Italy|Pfizer Investigative Site, Milano, MI, Italy|Pfizer Investigative Site, Aviano, Pordenone, Italy|Pfizer Investigative Site, Ancona, Italy|Pfizer Investigative Site, Bergamo, Italy|Pfizer Investigative Site, Bologna, Italy|Pfizer Investigative Site, Cremona, Italy|Pfizer Investigative Site, Firenze, Italy|Pfizer Investigative Sites (2), Milano, Italy|Pfizer Investigative Site, Milano, Italy|Pfizer Investigative Site, Milano, Italy|Pfizer Investigative Site, Modena, Italy|Pfizer Investigative Sites (2), Napoli, Italy|Pfizer Investigative Site, Padova, Italy|Pfizer Investigative Site, Pisa, Italy|Pfizer Investigative Site, Roma, Italy|Pfizer Investigative Site, Roma, Italy|Pfizer Investigative Site, Roma, Italy|Pfizer Investigative Site, Rozzano, Italy|Pfizer Investigative Site, Nagoya, Aichi, Japan|Pfizer Investigative Site, Kashiwa, Chiba, Japan|Pfizer Investigative Site, Sapporo, Haikodo, Japan|Pfizer Investigative Site, Kanazawa, Isikawa, Japan|Pfizer Investigative Site, Kawasaki, Kanagawa, Japan|Pfizer Investigative Site, Yokohama, Kanagawa, Japan|Pfizer Investigative Site, Amagasaki, Osaka, Japan|Pfizer Investigative Site, Suita, Osaka, Japan|Pfizer Investigative Site, Tsukiji, Tokyo, Japan|Pfizer Investigative Site, Fukuoka, Japan|Pfizer Investigative Site, Busan, Busan Gwang'yeogsi, Korea, Republic of|Pfizer Investigative Site, Anyang-si, Gyeonggido, Korea, Republic of|Pfizer Investigative Site, Seongnam-si, Gyeonggido, Korea, Republic of|Pfizer Investigative Site, Jeollanam-do, Jeonranamdo, Korea, Republic of|Pfizer Investigative Site, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Pfizer Investigative Site, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Pfizer Investigative Site, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Pfizer Investigative Site, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Pfizer Investigative Site, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Pfizer Investigative Site, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Pfizer Investigative Site, Seoul, Teugbyeolsi, Korea, Republic of|Pfizer Investigative Site, Incheon, Korea, Republic of|Pfizer Investigative Site, Distrito Federal, Col Roma, Mexico|Pfizer Investigative Site, México, Mexico|Pfizer Investigative Site, Noord-Holland, Amsterdam, Netherlands|Pfizer Investigative Site, Amhem, Gelderland, Netherlands|Pfizer Investigative Site, Den Haag, Netherlands|Pfizer Investigative Site, Heidelberglaan, Netherlands|Pfizer Investigative Site, Limburg, Netherlands|Pfizer Investigative Site, Oslo, Norway|Pfizer Investigative Site, Otwock, Mazowieckie, Poland|Pfizer Investigative Sites (2), Warszawa, Mazowieckie, Poland|Pfizer Investigative Site, Brzozów, Podkarpackie, Poland|Pfizer Investigative Site, Elbląg, Warminsko-mazurskie, Poland|Pfizer Investigative Site, Poznan, Wielkopolskie, Poland|Pfizer Investigative Site, Krakow, Poland|Pfizer Investigative Site, Obninsk, Kaluzhskaya Oblast', Russian Federation|Pfizer Investigative Site, Kursk, Kurski Region, Russian Federation|Pfizer Investigative Site, Chelyabinsk, Russian Federation|Pfizer Investigative Sites (2), Moscow, Russian Federation|Pfizer Investigative Site, Saint Petersburg, Russian Federation|Pfizer Investigative Site, Sabadell, Barcelona, Spain|Pfizer Investigative Site, San Sebastián, Guipúzcoa, Spain|Pfizer Investigative Site, Palma de Mallorca, Illes Balears, Spain|Pfizer Investigative Site, Madrid, Sancchinarro, Spain|Pfizer Investigative Site, Reus, Tarragona, Spain|Pfizer Investigative Site, Barcelona, Spain|Pfizer Investigative Sites (2), Barcelona, Spain|Pfizer Investigative Site, Burgos, Spain|Pfizer Investigative Site, Córdoba, Spain|Pfizer Investigative Site, Jaén, Spain|Pfizer Investigative Site, Madrid, Spain|Pfizer Investigative Site, Madrid, Spain|Pfizer Investigative Sites (2), Madrid, Spain|Pfizer Investigative Site, Madrid, Spain|Pfizer Investigative Site, Madrid, Spain|Pfizer Investigative Site, Sevilla, Spain|Pfizer Investigative Site, Valencia, Spain|Pfizer Investigative Site, Valencia, Spain|Pfizer Investigative Site, Valencia, Spain|Pfizer Investigative Site, Zaragoza, Spain|Pfizer Investigative Site, Taichung, Changhua, Taiwan|Pfizer Investigative Site, Linkou, Taoyuan, Taiwan|Pfizer Investigative Site, Kaohsiung, Taiwan|Pfizer Investigative Site, Taichung, Taiwan|Pfizer Investigative Site, Tainan, Taiwan|Pfizer Investigative Site, Taipei, Taiwan|Pfizer Investigative Site (2), Ankara, Turkey|Pfizer Investigative Site, Bursa, Turkey|Pfizer Investigative Site, Edime, Turkey|Pfizer Investigative Site, İstanbul, Turkey|Pfizer Investigative Site, İzmir, Turkey|Pfizer Investigative Site, İzmir, Turkey|Pfizer Investigative Site, Malatya, Turkey|Pfizer Investigative Site, Dnipropetrovsk, Dnipropetrovs'ka Oblast', Ukraine|Pfizer Investigative Site, Vinnytsya, Vinnyts'ka Oblast', Ukraine|Pfizer Investigative Site, Uzhgorod, Zakarpats'ka Oblast', Ukraine|Pfizer Investigative Site, Kyiv, Ukraine|Pfizer Investigative Site, Aberdeen, Aberdeenshire, United Kingdom|Pfizer Investigative Site, Hammersmith, London, United Kingdom|Pfizer Investigative Site, Glasgow, Scotland, United Kingdom|Pfizer Investigative Site, Guildford, Surrey, United Kingdom|Pfizer Investigative Site, London, United Kingdom|Pfizer Investigative Site, London, United Kingdom|Pfizer Investigative Site, Manchester, United Kingdom",https://ClinicalTrials.gov/show/NCT02928224
39,"Tesaro, Inc.|Facing Our Risk of Cancer Empowered|Myriad Genetics, Inc.",A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens,"Active, not recruiting",Has Results,Ovarian Neoplasms|Ovarian Cancer,Drug: Niraparib,Industry|Other,Interventional,"GSK Investigational Site, Chandler, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Burbank, California, United States|GSK Investigational Site, Duarte, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, San Francisco, California, United States|GSK Investigational Site, Santa Barbara, California, United States|GSK Investigational Site, Stanford, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, New Haven, Connecticut, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, West Palm Beach, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Covington, Louisiana, United States|GSK Investigational Site, New Orleans, Louisiana, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Burlington, Massachusetts, United States|GSK Investigational Site, Ann Arbor, Michigan, United States|GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Rochester, Minnesota, United States|GSK Investigational Site, Springfield, Missouri, United States|GSK Investigational Site, Hackensack, New Jersey, United States|GSK Investigational Site, Morristown, New Jersey, United States|GSK Investigational Site, East Setauket, New York, United States|GSK Investigational Site, Jamaica, New York, United States|GSK Investigational Site, Lake Success, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Corvallis, Oregon, United States|GSK Investigational Site, Medford, Oregon, United States|GSK Investigational Site, Wynnewood, Pennsylvania, United States|GSK Investigational Site, Providence, Rhode Island, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Fort Worth, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, The Woodlands, Texas, United States|GSK Investigational Site, Tyler, Texas, United States|GSK Investigational Site, Spokane, Washington, United States|GSK Investigational Site, Tacoma, Washington, United States|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada",https://ClinicalTrials.gov/show/NCT02354586
40,Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd,Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer,"Active, not recruiting",Has Results,Lung Cancer,Drug: Nivolumab|Drug: Topotecan|Drug: Amrubicin,Industry,Interventional,"Univ Of Ark For Med Sci, Little Rock, Arkansas, United States|Smilow Cancer Hospital. At Yale New Haven, New Haven, Connecticut, United States|Emory University, Atlanta, Georgia, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Nebraska Hematology Oncology Pc, Lincoln, Nebraska, United States|Broome Oncology, Johnson City, New York, United States|Duke University, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|St. Luke's University Health Network, Bethlehem, Pennsylvania, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Tennessee Oncology, Pllc, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Local Institution, Waratah, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Kurralta Park, South Australia, Australia|Local Institution, Perth, Western Australia, Australia|Local Institution, Murdoch, Australia|Local Institution, Graz, Austria|Local Institution, Wels, Austria|Akh Wien, Wien, Austria|Local Institution, Bruxelles, Belgium|Local Institution, Edegem, Belgium|Local Institution, Leuven, Belgium|Local Institution, Yvoir, Belgium|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Recoleta, Santiago DE Chile, Chile|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Guanzhou, Guangdong, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Xian, Shaanxi, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Urumqi, Xinjiang, China|Local Institution, Beijing, China|Local Institution, Guangzhou, China|Local Institution, Hangzhou, China|Local Institution, Hangzhou, China|Local Institution, Shanghai, China|Local Institution, Brno, Czechia|Klinika komplexni onkologicke pece, Brno, Czechia|Klinika plicnich nemoci a tuberkulozy, Olomouc, Czechia|Pneumologicka klinika 1. LF a TN, Praha 4, Czechia|Local Institution, Copenhagen, Denmark|Local Institution, Herlev, Denmark|Local Institution, Odense, Denmark|Chu Brest Hopital Morvan, Brest, France|CHRU Lille - Hopital Calmette, Lille Cedex, France|Hopital Cochin, Paris Cedex 14, France|Centre Hospitalier D'Annecy, Pringy Cedex, France|Polyclinique De Courlancy, Reims, France|Hopital Sainte Musse, Toulon Cedex, France|Local Institution, Bamberg, Germany|Local Institution, Berlin, Germany|Local Institution, Essen, Germany|Local Institution, Frankfurt am Main, Germany|Local Institution, Gera, Germany|Local Institution, Gerlingen, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Halle (saale), Germany|Local Institution, Hamburg, Germany|Local Institution, Heidelberg, Germany|Local Institution, Immenstadt, Germany|Local Institution, Koeln, Germany|Local Institution, Muenchen, Germany|Local Institution, Oberhausen, Germany|Local Institution, Regensburg, Germany|University Hospital Of Heraklion, Heraklion, Creta, Greece|Sotiria General Hospital, Athens, Greece|Papageorgiou General Hospital, Thessaloniki, Greece|Pulmonologiai Klinika, Budapest, Hungary|Orsz.Koranyi Tbc es Pulm.Int., Budapest, Hungary|Local Institution, Beer Sheva, Israel|Local Institution, Kfar Saba, Israel|Local Institution, Ramat -Gan, Israel|Ospedale Bellaria-Maggiore, Bologna, Italy|Ospedale Civile Di Livorno, Livorno, Italy|Ospedale San Luca, Lucca, Italy|IRST Meldola, Meldola, Italy|Local Institution, Milano, Italy|Azienda Ospedaliera - Nuovo Ospedale San Gerardo, Monza, Italy|Ospedale Degli Infermi, Rimini, Italy|Azienda Ospedaliera S. Andrea, Roma, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Nagoya, Aichi, Japan|Local Institution, Kashiwa, Chiba, Japan|Local Institution, Matsuyama, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Akashi-shi, Hyogo, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Natori-shi, Miyagi, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Habikino-shi, Osaka, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Osaka-sayama, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Sakai, Osaka, Japan|Local Institution, Kitaadachigun, Saitama, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Wakayama, Japan|Local Institution, Cheongju-si, Chungcheonbuk-do, Korea, Republic of|Local Institution, Suwon, Gyeonggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Bergen, Norway|Local Institution, Oslo, Norway|Wojewodzki Szpital Zespolony W Elblagu, Elblag, Poland|Klinika Onkologii I Radioterapii Am, Gdansk, Poland|Oddzial Onkologiczny, Krakow, Poland|Regionalny Osrodek Onkologiczny, Lodz, Poland|Oddzial Onkologii Klinicznej, Poznan, Poland|Klinika Nowotworow Pluca i Klatki Piersiowej, Warszawa, Poland|Local Institution, Bucharest, Romania|Local Institution, Craiova, Romania|Local Institution, Romania, Romania|Local Institution, Timisoara, Timis, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Ryazan, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, Basel, Switzerland|Centre hospitalier universitaire Vaudois (CHUV), Lausanne, Switzerland|Local Institution, Winterthur, Switzerland|Local Institution, Zurich, Switzerland|Local Institution, Taichung, Taiwan|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Maidstone, Kent, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom",https://ClinicalTrials.gov/show/NCT02481830
41,Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd,"An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy","Active, not recruiting",Has Results,Lung Cancer,Biological: Nivolumab|Biological: Ipilimumab|Other: Placebo,Industry,Interventional,"Sutter Cancer Center, Sacramento, California, United States|Yale University, New Haven, Connecticut, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|Cancer Specialists of North FL, Jacksonville, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|University of Kansas Cancer Center - Clinical Research Center, Fairway, Kansas, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Memorial Sloan Kettering Nassau, New York, New York, United States|Duke University, Durham, North Carolina, United States|Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States|Sanford Health, Fargo, North Dakota, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Donald Guthrie Foundation, Sayre, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Sanford Health, Sioux Falls, South Dakota, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Local Institution, Berazategui, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Tucuman, Argentina|Local Institution, Kogarah, New South Wales, Australia|Local Institution, Wollongong, New South Wales, Australia|Local Institution, Birtinya, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, East Melbourne, Victoria, Australia|Local Institution, Innsbruck, Austria|Local Institution, Salzburg, Austria|Local Institution, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Charleroi, Belgium|Local Institution, Roeselare, Belgium|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Itajai, Santa Catarina, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Salvador, Brazil|Local Institution, Edmonton, Alberta, Canada|Local Institution, Moncton, New Brunswick, Canada|Local Institution, Oshawa, Ontario, Canada|Local Institution, Sudbury, Ontario, Canada|Local Institution, Windsor, Ontario, Canada|Local Institution, Hefei, Anhui, China|Local Institution, Hefei, Anhui, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Harbin, Heilongjiang, China|Local Institution, Wuhang, Hubei, China|Local Institution, Changsha, Hunan, China|Local Institution, Nantong, Jiangsu, China|Local Institution, Nanchang, Jiangxi, China|Local Institution, Changchun, Jilin, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Kunming, Yunnan, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Wenzhou, Zhejiang, China|Local Institution, Guangzhou, China|Local Institution, Monteria, Cordoba, Colombia|Local Institution, Bogota, Colombia|Local Institution, Medellin, Colombia|Local Institution, Oulu, Finland|Local Institution, Tampere, Finland|Local Institution, Turku, Finland|Local Institution, Vaasa, Finland|Local Institution, Avignon Cedes 9, France|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 20, France|Local Institution, Paris Cedex 20, France|Local Institution, Pierre Benite, France|Local Institution, Rennes Cedex 9, France|Local Institution, Saint Herblain, France|Nouvel Hopital Civil Chru De Strasbourg, Strasbourg, France|Local Institution, Toulouse, France|Local Institution, Augsburg, Germany|Local Institution, Bad Berka, Germany|Local Institution, Berlin, Germany|Local Institution, Bochum, Germany|Local Institution, Gauting, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Immenhausen, Germany|Local Institution, Tuebingen, Germany|General Oncology Hospital of Kifissia Agioi Anargyroi, N.Kifissia, Greece|Interbalkan European Medical Center, Thessaloniki, Greece|Local Institution, Hong Kong, Hong Kong|Local Institution, Wilton, Cork, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Limerick, Ireland|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Petach Tikva, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Zerifin, Israel|Local Institution, Avellino, Italy|Local Institution, Bologna, Italy|Local Institution, Messina, Italy|Local Institution, Milan, Italy|Local Institution, Perugia, Italy|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Kurume-shi, Fukuoka, Japan|Local Institution, Gifu-shi, Gifu, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Kurashiki-shi, Okayama, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Osaka-sayama-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Takatsuki-shi, Osaka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Wakayama-shi, Wakayama, Japan|Local Institution, Seongnam-si, Gyeonggi-do, Korea, Republic of|Local Institution, Suwon-si, Gyeonggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Leon de los Aldama, Guanajuato, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Queretaro, Mexico|Local Institution, 's-Hertogenbosch, Netherlands|Local Institution, Eindhoven, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Miraflores, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Gdansk, Poland|Local Institution, Gdynia, Poland|Local Institution, Olsztyn, Poland|Local Institution, Warszawa, Poland|Local Institution, Bucharest, Romania|Local Institution, Bucharest, Romania|Local Institution, Craiova, Romania|Local Institution, Lasi, Romania|Local Institution, Romania, Romania|Local Institution, Timisoara, Timis, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Sandton, Gauteng, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, George, Western CAPE, South Africa|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Sevilla, Spain|Local Institution, Lund, Sweden|Local Institution, Uppsala, Sweden|Local Institution, Aarau, Switzerland|Local Institution, Geneve, Switzerland|Local Institution, St. Gallen, Switzerland|Local Institution, Tainan, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Truro, Cornwall, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Oxford, Oxfordshire, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom|Local Institution, Sheffield, United Kingdom|Local Institution, Wirral, United Kingdom",https://ClinicalTrials.gov/show/NCT02538666
42,"Pfizer|Astellas Pharma Inc|Medivation LLC, a wholly owned subsidiary of Pfizer Inc.",Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer,"Active, not recruiting",Has Results,Nonmetastatic Castration-Resistant Prostate Cancer|Prostate Cancer|Cancer of the Prostate,Drug: Enzalutamide|Drug: Placebo,Industry,Interventional,"Urological Associates of Southern Arizona, PC, Tucson, Arizona, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UCLA Clark Urology Center, Los Angeles, California, United States|University of California, Irvine Medical Center, Orange, California, United States|Urology Associates of San Luis Obispo, a Medical Group, Inc, San Luis Obispo, California, United States|Urology Associates, P.C., Englewood, Colorado, United States|c/o Lynn Buchwalder, New Haven, Connecticut, United States|C/O Thomas Ferencz, RPh, BCOP, Smilow Cancer Hospital at Yale-New Haven, New Haven, Connecticut, United States|Smilow Cancer Center at Yale New Haven-Hospital, New Haven, Connecticut, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Lakeland Regional Cancer Center, Lakeland, Florida, United States|Urology of Indiana, LLC, Carmel, Indiana, United States|First Urology, PSC, Jeffersonville, Indiana, United States|IU Health Arnett Cancer Care, Lafayette, Indiana, United States|Kansas City Urology Care, PA, Overland Park, Kansas, United States|GU Research Network/ Wichita Urology Group, Wichita, Kansas, United States|Chesapeake Urology Research Associates, Baltimore, Maryland, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Michigan Institute of Urology, Troy, Michigan, United States|GU Research Network, Omaha, Nebraska, United States|Brooklyn Urology Research Group, Brooklyn, New York, United States|Premier Medical Group of the Hudson Valley, Newburgh, New York, United States|Duke University Medical Center, Cary, North Carolina, United States|Carolina Urology Partners, PLLC, Charlotte, North Carolina, United States|Carolina Urology Partners, PLLC, Gastonia, North Carolina, United States|Gaston Medical Associates, Gastonia, North Carolina, United States|Carolina Urology Partners, PLLC, Huntersville, North Carolina, United States|Duke Women's Cancer Care Raleigh, Raleigh, North Carolina, United States|Clinical Research Solutions, Middleburg Heights, Ohio, United States|Oregon Urology Institute, Springfield, Oregon, United States|Lancaster Urology, Lancaster, Pennsylvania, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|Vanderbilt University Medical Center, Dept. of Urologic Surgery, Nashville, Tennessee, United States|Vanderbilt University Medical Center, The Urologic Clinic, Nashville, Tennessee, United States|Urology San Antonio, San Antonio, Texas, United States|Urology of Virginia, PLLC, Virginia Beach, Virginia, United States|COIBA(Centro de Oncologia e Investigacion Buenos Aires), Berazategui, Buenos Aires, Argentina|Centro Medico Austral(OMI), Caba, Buenos Aires, Argentina|Centro de Urologia, Caba, Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Caba, Buenos Aires, Argentina|Sanatorio Parque, Rosario, Santa FE, Argentina|Instituto De Oncologia De Rosario, Rosario, Santa FE, Argentina|Clinica Universidad Reina Fabiola, Cordoba, Argentina|Hospital Privado Centro Medico de Cordoba, Cordoba, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina|The Canberra Hospital, Garran, Australian Capital Territory, Australia|Border Medical Oncology Research Unit, Albury, New South Wales, Australia|The Border Cancer Hospital Dispensary, Albury, New South Wales, Australia|The Border Cancer Hospital, Albury, New South Wales, Australia|Sydney cancer centre, Concord, New South Wales, Australia|Epic pharmacy, Lismore, New South Wales, Australia|North Coast Cancer Institute, Lismore, New South Wales, Australia|Macquarie University Hospital, North Ryde, New South Wales, Australia|Macquarie University, North Ryde, New South Wales, Australia|Epic Pharmacy Port Macquarie base hospital, Port Macquarie, New South Wales, Australia|Mid North Coast Cancer Institute, Port Macquarie, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|The Tweed Hospital, Tweed Heads, New South Wales, Australia|Australian Clinical Trials, Wahroonga, New South Wales, Australia|Sydney Adventist Hospital, Wahroonga, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Icon Cancer Care Wesley, Auchenflower, Queensland, Australia|River City Pharmacy - APHS, Auchenflower, Queensland, Australia|Icon Cancer Care Chermside, Chermside, Queensland, Australia|Icon Cancer Care South Brisbane, South Brisbane, Queensland, Australia|Integrated Clinical Oncology Network (ICON), South Brisbane, Queensland, Australia|Icon Cancer Care Southport, Southport, Queensland, Australia|Tasman Oncology Research Pty Ltd, Southport, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Adelaide Cancer Centre, Kurralta Park, South Australia, Australia|Ashford Cancer Centre Research, Kurralta park, South Australia, Australia|Cancer Care SA Pty Ltd, Kurralta Park, South Australia, Australia|Tenpharm Pty Ltd trading as EPIC Pharmacy Tennyson, Kurralta Park, South Australia, Australia|Box Hill Hospital (Eastern health), Box Hill, Victoria, Australia|Eastern Clinical Research Unit (Eastern Health), Box Hill, Victoria, Australia|Cabrini Hospital Brighton, Brighton, Victoria, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Austin Health, Austin Hospital, Heidelberg, Victoria, Australia|Cabrini Hospital Malvern, Malvern, Victoria, Australia|Cabrini Hospital- Education and Research Precinct, Malvern, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Sunshine Hospital, St Albans, Victoria, Australia|Krankenhaus Barmherzige Schwestern Linz, Abteilung Radiologie, Linz, Upper Austria, Austria|Krankenhaus Barmherzige Schwestern Linz, Abteilung Urologie, Linz, Upper Austria, Austria|St. Vincent's Hospital, PET - CT Center, Linz, Upper Austria, Austria|Isotopix, Ambulatorium fuer Nuklearmedizin, Vienna, Austria|Medizinische Universitaet Wien, Universitaetsklinik fuer Innere Medizin I, Vienna, Austria|Diagnosezentrum Meidling GesmbH, Vienna, Austria|Algemeen Ziekenhuis Groeninge, Kortrijk, West-vlaanderen, Belgium|Clinique Universitaire de Bruxelles Hopital Erasme, Bruxelles, Belgium|Vzw Algemeen Ziekenhuis Maria Middelares, Gent, Belgium|Universitaire Ziekenhuizen Leuven, Leuven, Belgium|Centre Hospitalier Universitaire de Liege, Site du Sart-Tilman, Liege, Belgium|Hospital Sao Rafael, Salvador, Bahia, Brazil|Liga Paranaense de Combate ao cancer / Hospital Erasto Gaertner, Curitiba, Parana, Brazil|Associacao Hospital de Caridade de Ijui, Ijui, RIO Grande DO SUL, Brazil|Hospital da Cidade de Passo Fundo, Passo Fundo, RIO Grande DO SUL, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, RIO Grande DO SUL, Brazil|CLINIONCO - Clinica de Oncologia de Porto Alegre Ltda., Porto Alegre, RIO Grande DO SUL, Brazil|Hospital Sao Lucas da PUCRS, Porto Alegre, RIO Grande DO SUL, Brazil|Instituto D'or de Pesquisa e Ensino, Rio de Janeiro, RJ, Brazil|Hospital Amaral Carvalho - Fundacao Dr. Amaral Carvalho, Jau, SAO Paulo, Brazil|Fundacao Dr. Amaral Carvalho, Jau, SAO Paulo, Brazil|Fundacao Dr.Amaral Carvalho, Jau, SAO Paulo, Brazil|Hospital Israelita Albert Einstein, Sao Paulp, SAO Paulo, Brazil|Hospital das Clinicas da Faculdade de Ciencias Medicas da UNICAMP, Campinas, SP, Brazil|Centro de Estudos e Pesquisas em Hematologia e Oncologia (CEPHO), Santo Andre, SP, Brazil|IAMSPE-Inst. de Assist. ao Servidor Publico Estadual, Sao Paulo, SP, Brazil|Hospital Universitario Pedro Ernesto - UERJ, Rio de Janeiro, Brazil|Oncologia Rede D'Or, Rio de Janeiro, Brazil|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Vancouver Prostate Centre, Vancouver, British Columbia, Canada|Manitoba Prostate Centre CancerCare Manitoba, Winnipeg, Manitoba, Canada|NS Health Authority, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|The Male/Female Health and Research Centre, Barrie, Ontario, Canada|McMaster Institute of Urology @ St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|Urology Associates / Urologic Medical Research, Kitchener, Ontario, Canada|London Regional Cancer Program - Victoria Hospital, London Health Sciences Centre(LHSC), London, Ontario, Canada|Urology Reasearch - Victoria Hospital, London Health Sciences Centre(LHSC), London, Ontario, Canada|SunnyBrook Health Sciences Centre, Toronto, Ontario, Canada|University Health Network- Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Urology South Shore Research, Greenfield Park, Quebec, Canada|Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|McGill University Health Centre, Montreal, Quebec, Canada|CHU de Quebec, Quebec, Canada|Fundacion Arturo Lopez Perez, Santiago, Chile|Centro de Investigaciones Clinicas Vina del Mar, Santiago, Chile|Instituto Clinico Oncologico del Sur (ICOS), Temuco, Chile|Instituto Oncologico Ltda., Vina del Mar, Chile|Centro de Investigaciones Clinicas, Vina del Mar, Chile|Peking University First Hospital, Beijing, Beijing, China|Beijing Cancer Hospital, Beijing, Beijing, China|Peking University Third Hospital, Beijing, Beijing, China|Beijing Hospital, Beijing, Beijing, China|Peking Union Medical College Hospital, Beijing, Beijing, China|Chongqing Cancer Hospital, Chongqing, Chongqing, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Office of Hongqian Guo, Nanjing, Jiangsu, China|Jiangsu Cancer Hospital, Nanjing, Jiangsu, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China|Wuxi People's Hospital, Wuxi, Jiangsu, China|Qingdao Municipal Hospital (East Hospital), Qingdao, Shandong, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China|Huashan Hospital Fudan University, Shanghai, Shanghai, China|Shanghai First People's Hospital, Shanghai, Shanghai, China|Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China|Shanghai Changhai Hospital, Shanghai, Shanghai, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|The First Affiliated Hosptial of Wenzhou Medical University, Wenzhou, Zhejiang, China|UNIMED Medical Institute Limited, Hong Kong, China|The Second Hospital of Tianjin Medical University, Tianjin, China|Rigshospitalet 7521, Copenhagen, Norrebro, Denmark|Copenhagen Prostate Cancer Center, Copenhagen, N, Denmark|Aarhus University Hospital, Arhus N, Denmark|Rigshospitalet, Copenhagen, Denmark|Frederiksberg Hospital, Frederiksberg, Denmark|Herlev Hospital, Herlev, Denmark|Odense University Hospital, Odense C, Denmark|Vejle Sygehus, Vejle, Denmark|Docrates Syopasairaala, Helsinki, Finland|Helsingin yliopistollinen keskussairaala, Meilahden sairaala, Helsinki, Finland|Oulun yliopistollinen sairaala, Oulu, Finland|Satakunnan keskussairaala, Pori, Finland|Tampereen yliopistollinen Sairaala, Tampere, Finland|Hopitaux Universitaires de Strasbourg - Hopital Civil, STRASBOURG Cedex, Alsace, France|Centre Paul Strauss, Strasbourg, Bas-rhin, France|Clinique Sainte Anne, Strasbourg, Bas-rhin, France|Societe MIM, Clinique Sainte Anne, Strasbourg, Bas-rhin, France|Institut Curie, Paris Cedex, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite Cedex, Rhone, France|Institut Gustave Roussy, Villejuif Cedex, VAL DE Marne, France|Institut de Cancerologie de l'Ouest - Paul Papin, Angers Cedex 2, France|Institut Sainte Catherine, Avignon, Cedex 9, France|Institut Bergonie, Bordeaux Cedex, France|Urologic Oncology Department- Institut Bergonie - Centre regional de Lutte contre le Cancer, Bordeaux Cedex, France|Cabinet de Radiologie, Brest, France|CHU Brest Hopital Morvan, Brest, France|Clinique pasteur Lancroze, Brest, France|Clinique Pasteur-Lanroze, Brest, France|CHRU de Brest, Brest, France|Hopital Pasteur, Colmar Cedex, France|Hopitaux Civils de Colmar, Colmar, France|Centre Regional de lutte Contre le Cancer Georges Francois Leclerc, Dijon, France|Clinique Victor Hugo, Le Mans,Cedex, France|Hopital Calude Huriez - CHU Lille, Lille, France|Hopital Edouard Herriot - CHU Lyon, Lyon Cedex 03, France|Centre Leon Berard, Lyon Cedex, France|Centre de Medecine Nucleaire LUMEN, Lyon, France|Hopital Nord, Marseille, France|ICM Val D'Aurelle, Montpellier Cedex, France|Hopital Europeen Georges Pompidou, Paris, Cedex 15, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|CHU Poitiers - Hopital la Miletrie, Poitiers, Cedex, France|Institut de Cancerologie de I'Ouest - Rene Gauducheau, Saint-Herblain Cedex, France|Clinique Pasteur - CIMOF, Toulouse Cedex 3, France|Clinique Pasteur- Service Imagerie et Radiologie, Toulouse Cedex 3, France|Clinique Pasteur, Toulouse Cedex 3, France|IUCT-Oncopole, Toulouse Cedex 9, France|Institut Claudius Regaud, Toulouse, France|Studienpraxis Urologie, Nuertingen, Baden-wuerttemberg, Germany|Universitatsmedizin Mannheim, Medizinische Fakultat Mannheim der Universitat Heidelberg, Mannheim, Baden-wurttemberg, Germany|MVZ Zentrum fuer Diagnostische Radiologie und Nuklearmedizin Braunschweig GmbH, Braunschweig, Niedersachsen, Germany|Staedtisches Klinikum Braunschweig, Braunschweig, Niedersachsen, Germany|Hannover Medical School, Hannover, Niedersachsen, Germany|Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|RWTH University Aachen, Aachen, Nordrhein-westfalen, Germany|Uniklinik der RWTH Aachen, Aachen, Nordrhein-westfalen, Germany|Clinic of Radiology, Aachen, Nordrhein-westfalen, Germany|Universitaetsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Saxony, Germany|Charite, Campus Benjamin Franklin, Berlin, Germany|Charite, Universitaetsmedizin Berlin, Berlin, Germany|Martini-Klinik am UKE GmbH, Hamburg, Germany|Diagnostikzentrum Esslingen, Kirchheim, Germany|University General Hospital of Heraklion, Urology Clinic, Heraklion, Crete, Greece|General Hospital of Athens""Korgialeneio-Benakeio EES"".Urology Clinic, Athens, Greece|General Hospital of Athens ""Alexandra"", Therapeutic Clinic, Athens, Greece|University General Hospital of Larissa, Urology Department, Larissa, Greece|University General Hospital of Patras, Oncology Department, Internal Medicine Clinic, Patra, Greece|General Hospital"" Papageorgiou"",B' Univ.Urology Clinic, Thessaloniki, Greece|Queen Mary Hospital, Hong Kong, Hong Kong|Tuen Mun Hospital, Hong Kong, Hong Kong|Prince of Wales Hospital, Shatin, Hong Kong|Laboratorio Medicina Nucleare-Ospedale G.B. Morgagni-Pierantoni, Forli, FC, Italy|Farmacia, Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Italy|Medicina Nucleare, Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Italy|Servizio di Radiologia, Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Italy|Struttura Complessa di Oncologia, Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Italy|U.O. di Oncologia, Ospedale Civile Degli Infermi, Faenza (RA), Italy|U.O. di Radiologia, Ospedale Civile degli Infermi, Faenza (RA), Italy|U.O. di Oncologia, Ospedale Civile Umberto I, Lugo (RA), Italy|U.O. di Radiologia, Ospedale Civile Umberto I, Lugo (RA), Italy|Laboratorio Farmaci Antiblastici, Meldola (FC), Italy|U.O. Oncologia Medica, Meldola (FC), Italy|UO Radiologia, Meldola (FC), Italy|Dipartimento di Radiologia, Ospedale San Raffaele, Milano, Italy|Servizio di Farmacia, Ospedale San Raffaele, Milano, Italy|U.O. di Medicina Nucleare e Centro PET, Ospedale San Raffaele, Milano, Italy|U.O. di Urologia, Ospedale San Raffaele, Milano, Italy|Farmacia Studi Clinici e Sperimentali, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|S.C. di Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|S.C. Diagnostica Radiologica 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|Divisione di Radiologia, Istituto Europeo di Oncologia, Milano, Italy|Reparto Oncologia Medica Urogenitale e Cervico Facciale, Istituto Europeo di Oncologia, Milano, Italy|Servizio Farmacia, Istituto Europeo di Oncologia, Milano, Italy|Farmacia Interna, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy|Medicina Nucleare, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy|Radiologia I, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy|U.O.S.C. di Oncologia Medica, A.O.R.N. ""A. Cardarelli"", Napoli, Italy|Farmacia Ospedaliera, AOU San Luigi Gonzaga, Orbassano (TO), Italy|SCDU Oncologia Medica II Pad, AOU San Luigi Gonzaga, Orbassano (TO), Italy|SCDU Radiodiagnostica, AOU San Luigi Gonzaga, Orbassano (TO), Italy|SS Medicina Nucleare, AOU San Luigi Gonzaga, Orbassano (TO), Italy|Farmacia, Istituto Oncologico Veneto (IOV), Padova, Italy|IRCCS - Istituto Oncologico Veneto (IOV), UOC Oncologia Medica 1, Padova, Italy|Medicina Nucleare, Istituto Oncologico Veneto (IOV), Padova, Italy|UOC Radiodiagnostica Oncologica, Istituto Oncologico Veneto (IOV), Padova, Italy|Ospedale Santa Maria delle Croci, Ravenna, Italy|Servizio di Farmacia, AUSL di Ravenna, Ravenna, Italy|Servizio di Radiologia, AUSL di Ravenna, Ravenna, Italy|Azienda Ospedaliera S. Camillo Forlanini, UOC per il governo clinico in Oncologia Medica, Roma, Italy|U.O. di Oncologia Medica, Ospedale Santa Chiara, Trento, Italy|U.O. Farmacia, Ospedale Santa Chiara, Trento, Italy|U.O. Radiologia, Ospedale Santa Chiara, Trento, Italy|National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun-gun, Jeonnam, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Universiti Kebangsaan Malaysia Medical Centre, Cheras, Kuala Lumpur, Malaysia|Sarawak General Hospital, Kuching, Sarawak, Malaysia|Subang Jaya Medical Centre Sdn. Bhd., Subang Jaya, Selangor Darul Ehsan, Malaysia|Hospital Kuala Lumpur, Kuala Lumpur, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Maastricht University Medical Centre, Maastricht, AZ, Netherlands|Catharina Ziekenhuis, Eindhoven, Noord-brabant, Netherlands|Netherlands Cancer Institute, Amsterdam, Netherlands|Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands|Canterbury District Health Board, Christchurch, Canterbury, New Zealand|Palmerston North Hospital, Palmerston North, Manawatu, New Zealand|Waikato Urology Research LTD, Hamilton, Waikato, New Zealand|Regional Blood and Cancer Services, Auckland, New Zealand|Greenlane Clinical Centre, Auckland, New Zealand|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|UROMEDYK, Poradnia Urologiczna, Kielce, Poland|Malopolskie Centrum Medyczne s.c., Krakow, Poland|Wojewodzki Szpital Specjalistyczny im. Stefana Kardynala Wyszynskiego SPZOZ, Lublin, Poland|Wojewodzki Szpital Specjalistyczny im. Janusza. Korczaka, Slupsk, Poland|Profesorskie Centrum Medyczne Optimum, Wroclaw, Poland|Centrum Medyczne Melita Medical, Wroclaw, Poland|Wro Medica, Wroclaw, Poland|Lexmedica, Wroclaw, Poland|Federal State Budgetary Institution ""N.N. Blokhin Russian Cancer Research Center"", Moscow, Russian Federation|P. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research, Moscow, Russian Federation|State Budgetary Healthcare Institution City Multifield Hospital No.2, Saint-Petersburg, Russian Federation|SBEI HPE ""First Pavlov State Medical University of St. Petersburg"" of, Saint-Petersburg, Russian Federation|SBEI HPE ""First Pavlov State Medical University of St. Petersburg"" of, Saint-Petersburg, Russian Federation|Saint-Petersburg State Budgetary Healthcare Institution ""Hospital for Veterans of War"", Saint-Petersburg, Russian Federation|SBHI ""Saint-Petersburg clinical scientific, Saint-Petersburg, Russian Federation|SBEI of HPE ""Bashkir State Medical University"" of MoH of the RF, Ufa, Russian Federation|Clinical Center Of Serbia, Clinic of Urology, Belgrade, Serbia|Clinical Center ""Dr Dragisa Misovic -Dedinje"", Clinic of Urology, Belgrade, Serbia|Clinical Center ""Bezanijska Kosa"", Department of Urology, Belgrade, Serbia|Clinical Center Zemun, Belgrade, Serbia|National University Hospital, Singapore, Singapore|National Cancer Centre Singapore, Singapore, Singapore|Fakultna nemocnica s poliklinikou F.D. Roosevelta, Banska Bystrica, Slovakia|Institut nuklearnej a molekularnej mediciny, Banska Bystrica, Slovakia|Bratislavske radiodiagnosticke centrum, a.s., Bratislava, Slovakia|CUIMED, s.r.o., Urologicka ambulancia, Bratislava, Slovakia|Vychodoslovensky onkologicky ustav, a.s., Kosice, Slovakia|Vychodoslovensky onkologicky ustav, a.s., Kosice, Slovakia|Institut nuklearnej a molekularnej mediciny, Kosice, Slovakia|Univerzitna nemocnica Martin, Martin, Slovakia|IZOTOPCENTRUM, s.r.o., Nitra, Slovakia|Jessenius-diagnosticke centrum, a.s., Nitra, Slovakia|UROEXAM spol. s r.o. urologicka ambulancia, Nitra, Slovakia|Alfamedis, s.r.o., Presov, Slovakia|MILAB s.r.o., UROCENTRUM, Presov, Slovakia|Vivamed, s.r.o, Presov, Slovakia|UVN SNP - FN Ruzomberok, Pracovisko Nuklearnej mediciny CCSR, Ruzomberok, Slovakia|Fakultna nemocnica s Poliklinikou Skalica a.s, Skalica, Slovakia|GAMMALAB, spol. s.r.o., Oddelenie nuklearnej mediciny, Trnava, Slovakia|GAMMALAB, spol.s.r.o., Oddelenie nuklearnej mediciny, Trnava, Slovakia|KK MED s.r.o., Zilina, Slovakia|Fakultna nemocnica s poliklinikou Zilina, Urologicke oddelenie, Zilina, Slovakia|Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, A Coruna, Spain|Hospital Universitari Son Espases,, Palma de Mallorca, Baleares, Spain|Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain|ALTAHIA. Xarxa Assistencial Universitaria de Manresa, Manresa, Barcelona, Spain|Hospital Universitario Parc Tauli, Sabadell, Barcelona, Spain|ICO Girona-Hospital Universitari de Girona Dr. Josep Trueta, Gerona, Cataluna, Spain|Hospital de Navarra, Pamplona, Navarra, Spain|Complejo Hospitalario Universitario A Coruna, A Coruna, Spain|Hospital Del Mar, Barcelona, Spain|Cetir Centre Medic, S.L., Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario de la Princesa, Madrid, Spain|MD Anderson Cancer Center, Madrid, Spain|Hospital Universitario 12 de octubre, Madrid, Spain|Urologmottagningen, Goteborg, Sweden|Diagnostiskt centrum for bild- och funktionsmedicin, Malmo, Sweden|Urologiska Kliniken, Malmo, Sweden|Apoteket AB Kliniska Provningar Molnlycke, Molnlycke, Sweden|Karolinska Universitetssjukhuset, Solna, Sweden|Urologmottagningen, Stockholm, Sweden|Urologkliniken, Umea, Sweden|Urologiska Kliniken, Örebro, Sweden|Chang Gung Medical Fundation, Chiayi Branch(Chiayi Chang Gung Memorial Hospital), Chiayi County, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|Chang Gung Medical Fundation,Kaohsiung (Kaohsiung Chang Gung Memorial Hospital), Kaohsiung, Taiwan|Chang Gung Memorial Hospital, Keelung Branch (Keelung Chang Gung Memorial Hospital), Keelung City, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Chi Mei Medical Centre, Tainan City, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang-Gung Memorial Hospital at Linkuo, Taoyuan County, Taiwan|Maharaj Nakorn Chiang Mai Hospital, Muang, Chiang MAI, Thailand|Songklanagarind Hospital, Hat Yai, Songkla, Thailand|King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand|Rajavithi Hospital, Bangkok, Thailand|Cukurova Universitesi Tip Fakultesi, Adana, Turkey|Hacettepe Universitesi Tip Fakultesi, Ankara, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi, Istanbul, Turkey|Izmir Bozyaka Egitim Arastirma Hastanesi, Izmir, Turkey|Celal Bayar Universitesi Tip Fakultesi, Manisa, Turkey|RCI Chernivtsi Regional Clinical Hospital, Chernivtsi, Ukraine|CI Dnipropetrovsk I.I. Mechnykov RCH, Department of Urology #2, Dnipropetrovsk, Ukraine|CHI V.I.Shapoval RCC of Urology and Nephrology, Dep. Of Urology#4, Kharkiv, Ukraine|Kyiv City Clinical Hospital #3, Department of Urology, Kyiv, Ukraine|Central City Clinical Hospital, City Oncological Center, Uzhgorod, Ukraine|CI Zaporizhzhia Regional Clinical Hospital, Dep. Of Urology,, Zaporizhzhia, Ukraine|East and North Hertfordshire NHS Trust, Northwood, Middlesex, United Kingdom|Belfast Health and Social Care Trust, Belfast, Northern Ireland, United Kingdom|Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom|The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, Tyne and Wear, United Kingdom|University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom|University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom|Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom|University College Hospitals NHS Trust, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|University College London Hospitals NHS Foundation Trust, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Oxford University Hospitals NHS Trust, Oxford, United Kingdom",https://ClinicalTrials.gov/show/NCT02003924
43,"Clovis Oncology, Inc.|Foundation Medicine|Myriad Genetics, Inc.","A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer","Active, not recruiting",Has Results,Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer,Drug: Rucaparib|Drug: Placebo,Industry,Interventional,"University of Arizona Cancer Center, Tucson, Arizona, United States|Saint Jude Heritage Medical Center, Fullerton, California, United States|UC Davis Comprehensive Cancer Center, Sacramento, California, United States|University of California San Francisco (UCSF), San Francisco, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Medical Oncology, Santa Maria, California, United States|University of California Los Angeles (UCLA), Santa Monica, California, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, United States|Memorial Healthcare System, Hollywood, Florida, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Florida Hospital, Orlando, Florida, United States|Johns Hopkins Universty, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Karmanos Cancer Institute - Wayne State University, Detroit, Michigan, United States|Washington University School of Medicine - Division of Gynaecological Oncology, Saint Louis, Missouri, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Hope Women's Cancer Centers, Asheville, North Carolina, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|University of Washington at Seattle, Seattle, Washington, United States|Prince of Wales Hospital, Sydney, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Royal Brisbane & Women's Hospital, Herston, Queensland, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|St John of God Hospital Subiaco, Subiaco, Western Australia, Australia|AZ St Augustinus, Antwerpen, Belgium|UZ Gent, Gent, Belgium|UZ Leuven, Leuven, Belgium|Clinique Sainte-Elisabeth, Namur, Belgium|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|London Regional Cancer Centre, London, Ontario, Canada|Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CHUM Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada|Centre Hospitalier Universitaire de Québec, Quebec, Canada|Centre Francois Baclesse, Caen Cedex 05, Basse-Normandie, France|Institut Gustave Roussy, Villejuif, Ile De France, France|Hôpital Européen Georges-Pompidou, Paris, Ile-de-France, France|Institut Claudius Regaud, Toulouse, Midi-Pyrenees, France|Centre Catherine de Sienne, Nantes Cedex, Pays De La Loire, France|Centre Leon Berard, Lyon, Rhone-Alpes, France|Centre Hospitalier Lyon Sud, Pierre Benite, Rhone-Alpes, France|Institute Bergonie, Bordeaux, France|Hospital Tenon, Paris, France|Klinikum Stuttgart, Stuttgart, Baden-Wuerttemberg, Germany|Klinikum Ludwigsburg-Bietigheim gGmbH, Ludwigsburg, Baden-Wuerttembert, Germany|Rotkreuzklinikum Muenchen gGmbH, Munich, Bavaria, Germany|Universitätsklinikum Frankfurt, Frankfurt am Main, Hessen, Germany|Dr. Horst Schmidt Klinik, Klinik fuer Gynaekologie und Gyn. Onkologie, Wiesbaden, Hessen, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Sachsen, Germany|Technische Universität Dresden, Dresden, Sachsen, Germany|Rambam Health Care Campus, Haifa, Israel|Lady Davis Carmel Medical Center, Haifa, Israel|Rabin Medical Center, Petach-Tikva, Israel|Oncology Institute, Sheba Medical Center, Ramat Gan, Israel|Sourasky Medical Center, Tel-Aviv, Israel|Assaf Harofeh M.C., Zerifin, Israel|Oncology Unit City Hospital degli Infermi, Faenza, Ravenna, Italy|Arcispedale Santa Maria Nuova IRCCS, Reggio Emilia, Reggio Nella Emilia, Italy|Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi, Bologna, Italy|Fondazione IRCCS National Cancer Institute, Milan, Italy|Instituto Europeo di Oncologia, Milan, Italy|Azienda Ospedaliero Universitaria Policlinico di Modena, Modena, Italy|Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Auckland City Hospital, Auckland, Grafton, New Zealand|Palmsteron North Hospital, Palmerston North, Manawatu, New Zealand|Wellington Hospital, Newtown, Wellington, New Zealand|Hospital Central de Asturias, Oviedo, Asturias, Spain|Centro Oncologico de Galica, A Coruna, Spain|Hospital Vall D'Hebron, Barcelona, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario San Carlos, Madrid, Spain|Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-San Chinarro, Madrid, Spain|Hospital Regional Universitario Carlos Haya de Malaga, Malaga, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Instituto Valencia de Oncologia-Fundacion, Valencia, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Royal Marsden Hospital, London, England, United Kingdom|Belfast City Hospital, Belfast, Northern Ireland, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, Scotland, United Kingdom|The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom|St. James University Hospital, Leeds, West Yorkshire, United Kingdom|Addenbrookes Hospital, Cambridge, United Kingdom|Barts Health NHS Trust, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|Sarah Cannon Reserach Institute UK, London, United Kingdom|University College London, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Sir Bobby Robson Cancer trials research Centre, Northern Centre For Cancer Care, Newcastle Upon Tyne, United Kingdom",https://ClinicalTrials.gov/show/NCT01968213
44,"Tesaro, Inc.|Gynecologic Oncology Group|European Network of Gynaecological Oncological Trial Groups (ENGOT)|Myriad Genetics, Inc.",A Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy,"Active, not recruiting",Has Results,Ovarian Neoplasms|Ovarian Cancer,Drug: Niraparib|Drug: Placebo,Industry|Other,Interventional,"GSK Investigational Site, Mesa, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, San Francisco, California, United States|GSK Investigational Site, San Francisco, California, United States|GSK Investigational Site, Santa Rosa, California, United States|GSK Investigational Site, Hartford, Connecticut, United States|GSK Investigational Site, New Haven, Connecticut, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Augusta, Georgia, United States|GSK Investigational Site, Savannah, Georgia, United States|GSK Investigational Site, Geneva, Illinois, United States|GSK Investigational Site, Hinsdale, Illinois, United States|GSK Investigational Site, Warrenville, Illinois, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Baton Rouge, Louisiana, United States|GSK Investigational Site, Covington, Louisiana, United States|GSK Investigational Site, New Orleans, Louisiana, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Silver Spring, Maryland, United States|GSK Investigational Site, Burlington, Massachusetts, United States|GSK Investigational Site, Springfield, Massachusetts, United States|GSK Investigational Site, Grand Rapids, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Middletown, New Jersey, United States|GSK Investigational Site, Neptune, New Jersey, United States|GSK Investigational Site, Teaneck, New Jersey, United States|GSK Investigational Site, Buffalo, New York, United States|GSK Investigational Site, Harrison, New York, United States|GSK Investigational Site, Mineola, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Rochester, New York, United States|GSK Investigational Site, Chapel Hill, North Carolina, United States|GSK Investigational Site, Wilmington, North Carolina, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Mayfield Heights, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Tulsa, Oklahoma, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Springfield, Oregon, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Willow Grove, Pennsylvania, United States|GSK Investigational Site, Providence, Rhode Island, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Sioux Falls, South Dakota, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Fort Worth, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, The Woodlands, Texas, United States|GSK Investigational Site, Tyler, Texas, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Kennewick, Washington, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Spokane, Washington, United States|GSK Investigational Site, Morgantown, West Virginia, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States|GSK Investigational Site, Bonheiden, Belgium|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Charleroi, Belgium|GSK Investigational Site, Gent, Belgium|GSK Investigational Site, Hasselt, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Libramont, Belgium|GSK Investigational Site, Namur, Belgium|GSK Investigational Site, Sint-Niklaas, Belgium|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Kelowna, British Columbia, Canada|GSK Investigational Site, Surrey, British Columbia, Canada|GSK Investigational Site, Vancouver, British Columbia, Canada|GSK Investigational Site, Barrie, Ontario, Canada|GSK Investigational Site, London, Ontario, Canada|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Montréal, Quebec, Canada|GSK Investigational Site, Brno, Czechia|GSK Investigational Site, Plzen-Lochotin, Czechia|GSK Investigational Site, Prague, Czechia|GSK Investigational Site, Prague, Czechia|GSK Investigational Site, Aalborg, Denmark|GSK Investigational Site, Copenhagen, Denmark|GSK Investigational Site, Herlev, Denmark|GSK Investigational Site, Odense, Denmark|GSK Investigational Site, Kuopio, Finland|GSK Investigational Site, Oulu, Finland|GSK Investigational Site, Tampere, Finland|GSK Investigational Site, Turku, Finland|GSK Investigational Site, Angers, France|GSK Investigational Site, Caen Cedex 05, France|GSK Investigational Site, Montpellier Cedex 5, France|GSK Investigational Site, Nice Cedex 2, France|GSK Investigational Site, Paris Cedex 15, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Pierre-Benite cedex, France|GSK Investigational Site, Rennes Cedex, France|GSK Investigational Site, Saint-Herblain, France|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Karlsruhe, Baden-Wuerttemberg, Germany|GSK Investigational Site, Mannheim, Baden-Wuerttemberg, Germany|GSK Investigational Site, Schwaebisch Hall, Baden-Wuerttemberg, Germany|GSK Investigational Site, Fuerth, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Goettingen, Niedersachsen, Germany|GSK Investigational Site, Hildesheim, Niedersachsen, Germany|GSK Investigational Site, Aachen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Ludwigshafen, Rheinland-Pfalz, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Debrecen, Hungary|GSK Investigational Site, Gyor, Hungary|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Galway, Ireland|GSK Investigational Site, Waterford, Ireland|GSK Investigational Site, Wilton, Cork, Ireland|GSK Investigational Site, Beer Sheva, Israel|GSK Investigational Site, Haifa, Israel|GSK Investigational Site, Haifa, Israel|GSK Investigational Site, Holon, Israel|GSK Investigational Site, Petach Tikva, Israel|GSK Investigational Site, Tel Aviv, Israel|GSK Investigational Site, Tel Hashomer, Israel|GSK Investigational Site, Napoli, Campania, Italy|GSK Investigational Site, Meldola (FC), Emilia-Romagna, Italy|GSK Investigational Site, Modena, Emilia-Romagna, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Candiolo (TO), Piemonte, Italy|GSK Investigational Site, Lecce, Puglia, Italy|GSK Investigational Site, Mirano, Veneto, Italy|GSK Investigational Site, Bergen, Norway|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Lodz, Poland|GSK Investigational Site, Lublin, Poland|GSK Investigational Site, Olsztyn, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Arkhangelsk, Russian Federation|GSK Investigational Site, Chelyabinsk, Russian Federation|GSK Investigational Site, Irkutsk, Russian Federation|GSK Investigational Site, Ivanovo, Russian Federation|GSK Investigational Site, Kazan, Russian Federation|GSK Investigational Site, Krasnoyarsk, Russian Federation|GSK Investigational Site, Orenburg, Russian Federation|GSK Investigational Site, Pyatigorsk, Russian Federation|GSK Investigational Site, Saint-Petersburg, Russian Federation|GSK Investigational Site, St-Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Badalona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Cordoba, Spain|GSK Investigational Site, Elche, Spain|GSK Investigational Site, Girona, Spain|GSK Investigational Site, Hospitalet de Llobregat, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, San Sebastián, Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Zaragoza, Spain|GSK Investigational Site, Stockholm, Sweden|GSK Investigational Site, Uppsala, Sweden|GSK Investigational Site, Basel, Switzerland|GSK Investigational Site, Bern, Switzerland|GSK Investigational Site, Frauenfeld, Switzerland|GSK Investigational Site, Zurich, Switzerland|GSK Investigational Site, Dnipropetrovsk, Ukraine|GSK Investigational Site, Dnipro, Ukraine|GSK Investigational Site, Ivano-Frankivsk, Ukraine|GSK Investigational Site, Kherson, Ukraine|GSK Investigational Site, Krivoy Rog, Ukraine|GSK Investigational Site, Kyiv, Ukraine|GSK Investigational Site, Vinnitsia, Ukraine|GSK Investigational Site, Zaporizhzhia, Ukraine|GSK Investigational Site, Portsmouth, Hampshire, United Kingdom|GSK Investigational Site, Bath, Somerset, United Kingdom|GSK Investigational Site, Stoke-on-Trent, Staffordshire, United Kingdom|GSK Investigational Site, Blackburn, United Kingdom|GSK Investigational Site, Exeter, United Kingdom|GSK Investigational Site, Glasgow, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Sheffield, United Kingdom|GSK Investigational Site, Truro, United Kingdom",https://ClinicalTrials.gov/show/NCT02655016
45,"Bayer|Orion Corporation, Orion Pharma",Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Nonmetastatic Castration-resistant Prostate Cancer,"Active, not recruiting",Has Results,Prostate Cancer Non-Metastatic|Castration-Resistant,"Drug: Darolutamide (Nubeqa, BAY1841788)|Drug: Placebo",Industry,Interventional,"Homewood, Alabama, United States|Anchorage, Alaska, United States|Tucson, Arizona, United States|Fountain Valley, California, United States|La Jolla, California, United States|Laguna Hills, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|San Diego, California, United States|Whittier, California, United States|Denver, Colorado, United States|Denver, Colorado, United States|Parker, Colorado, United States|Boca Raton, Florida, United States|Orlando, Florida, United States|Port Saint Lucie, Florida, United States|Coeur d'Alene, Idaho, United States|Chicago, Illinois, United States|Evanston, Illinois, United States|Springfield, Illinois, United States|Greenwood, Indiana, United States|Indianapolis, Indiana, United States|Jeffersonville, Indiana, United States|West Des Moines, Iowa, United States|Wichita, Kansas, United States|New Orleans, Louisiana, United States|Annapolis, Maryland, United States|Baltimore, Maryland, United States|Salisbury, Maryland, United States|Boston, Massachusetts, United States|Grand Rapids, Michigan, United States|Royal Oak, Michigan, United States|Omaha, Nebraska, United States|Omaha, Nebraska, United States|Lebanon, New Hampshire, United States|Voorhees, New Jersey, United States|Bronx, New York, United States|Bronx, New York, United States|Syracuse, New York, United States|Asheboro, North Carolina, United States|Charlotte, North Carolina, United States|Canton, Ohio, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Gahanna, Ohio, United States|Middleburg Heights, Ohio, United States|Oklahoma City, Oklahoma, United States|Bala-Cynwyd, Pennsylvania, United States|Bryn Mawr, Pennsylvania, United States|Myrtle Beach, South Carolina, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Fairfax, Virginia, United States|Richmond, Virginia, United States|Virginia Beach, Virginia, United States|Wheeling, West Virginia, United States|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Santa Fé, Santa Fe, Argentina|San Miguel de Tucumán, Tucuman, Argentina|Córdoba, Argentina|Córdoba, Argentina|Córdoba, Argentina|La Rioja, Argentina|Randwick, New South Wales, Australia|St Leonards, New South Wales, Australia|Douglas, Queensland, Australia|South Brisbane, Queensland, Australia|Fitzroy, Victoria, Australia|Kurralta Park, Australia|Wien, Austria|Wien, Austria|Lesnoy, Belarus|Minsk, Belarus|Bonheiden, Belgium|Kortrijk, Belgium|Libramont, Belgium|Liege, Belgium|Sint-truiden, Belgium|Salvador, Bahia, Brazil|Fortaleza, Ceará, Brazil|Goiânia, Goiás, Brazil|Belo Horizonte, Minas Gerais, Brazil|Juiz de Fora, Minas Gerais, Brazil|Uberlandia, Minas Gerais, Brazil|Curitiba, Parana, Brazil|Recife, Pernambuco, Brazil|Passo Fundo, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Itajaí, Santa Catarina, Brazil|Barretos, Sao Paulo, Brazil|Jau, Sao Paulo, Brazil|Ribeirao Preto - SP, Sao Paulo, Brazil|Sorocaba, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Sofia, Bulgaria|Varna, Bulgaria|Calgary, Alberta, Canada|Halifax, Nova Scotia, Canada|Burlington, Ontario, Canada|Hamilton, Ontario, Canada|Kingston, Ontario, Canada|London, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Granby, Quebec, Canada|Pointe-Claire, Quebec, Canada|Medellín, Antioquia, Colombia|Montería, Córdoba, Colombia|Floridablanca, Santander, Colombia|Jablonec nad Nisou, Czechia|Kolin, Czechia|Olomouc, Czechia|Opava, Czechia|Praha 2, Czechia|Praha 2, Czechia|Praha 6, Czechia|Praha 8, Czechia|Tallinn, Estonia|Helsinki, Finland|Kuopio, Finland|Seinäjoki, Finland|Tampere, Finland|Turku, Finland|Angers, France|Bayonne, France|Besancon, France|Bordeaux Cedex, France|CAEN cedex 05, France|Cergy Pontoise, France|Clermont Ferrand Cedex 1, France|Creteil, France|Dijon, France|LA ROCHE SUR YON cedex, France|Limoges Cedex, France|Montpellier Cedex, France|Montpellier Cedex, France|Nancy, France|Nantes Cedex, France|Paris, France|Paris, France|Pierre Benite, France|POITIERS cedex, France|REIMS cedex, France|Rennes Cedex, France|Rouen Cedex, France|Saint Mande, France|Strasbourg, France|Suresnes, France|Tours, France|Villejuif Cedex, France|Emmendingen, Baden-Württemberg, Germany|Kirchheim unter Teck, Baden-Württemberg, Germany|Mühlacker, Baden-Württemberg, Germany|Nürtingen, Baden-Württemberg, Germany|Reutlingen, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|Zirndorf, Bayern, Germany|Frankfurt, Hessen, Germany|Marburg, Hessen, Germany|Hagenow, Mecklenburg-Vorpommern, Germany|Herzberg Am Harz, Niedersachsen, Germany|Holzminden, Niedersachsen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Mülheim, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Wuppertal, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Magdeburg, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Berlin, Germany|Hamburg, Germany|Hamburg, Germany|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Gyor, Hungary|Nyiregyhaza, Hungary|Szeged, Hungary|Szekszard, Hungary|Szolnok, Hungary|Zalaegerszeg, Hungary|Haifa, Israel|Chieti, Abruzzo, Italy|Catanzaro, Calabria, Italy|Napoli, Campania, Italy|Forlì Cesena, Emilia-Romagna, Italy|Modena, Emilia-Romagna, Italy|Parma, Emilia-Romagna, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Torino, Piemonte, Italy|Torino, Piemonte, Italy|Lecce, Puglia, Italy|Messina, Sicilia, Italy|Palermo, Sicilia, Italy|Arezzo, Toscana, Italy|Nagoya, Aichi, Japan|Kashiwa, Chiba, Japan|Kurume, Fukuoka, Japan|Koriyama, Fukushima, Japan|Maebashi, Gunma, Japan|Otake, Hiroshima, Japan|Sapporo, Hokkaido, Japan|Kobe, Hyogo, Japan|Higashiibaraki, Ibaraki, Japan|Kanazawa, Ishikawa, Japan|Sagamihara, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokosuka, Kanagawa, Japan|Sendai, Miyagi, Japan|Ueda, Nagano, Japan|Kashihara, Nara, Japan|Yufu, Oita, Japan|Osakasayama, Osaka, Japan|Wako, Saitama, Japan|Hamamatsu, Shizuoka, Japan|Utsunomiya, Tochigi, Japan|Bunkyo-ku, Tokyo, Japan|Bunkyo-ku, Tokyo, Japan|Itabashi-ku, Tokyo, Japan|Minato-ku, Tokyo, Japan|Mitaka, Tokyo, Japan|Nakano-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Sumida-ku, Tokyo, Japan|Ube, Yamaguchi, Japan|Chiba, Japan|Fukui, Japan|Hiroshima, Japan|Kyoto, Japan|Nagasaki, Japan|Nagasaki, Japan|Okayama, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Toyama, Japan|Cheongju, Chungcheongbugdo, Korea, Republic of|Donggu,, Gwangju Gwang''yeogsi, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Daegu, Korea, Republic of|Daegu, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Daugavpils, Latvia|Jelgava, Latvia|Leipaja, Latvia|Riga, Latvia|Riga, Latvia|Riga, Latvia|Kaunas, Lithuania|Kaunas, Lithuania|Klaipeda, Lithuania|Vilnius, Lithuania|Vilnius, Lithuania|La Victoria, Arequipa, Peru|Lima, Peru|Lima, Peru|San Isidro, Peru|Elblag, Poland|Gdansk, Poland|Lodz, Poland|Lublin, Poland|Otwock, Poland|Rzeszow, Poland|Siedlce, Poland|Warszawa, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Guimaraes, Braga, Portugal|Almada, Lisboa, Portugal|Matosinhos, Porto, Portugal|Braga, Portugal|Lisboa, Portugal|Lisboa, Portugal|Lisboa, Portugal|Lisboa, Portugal|Porto, Portugal|Porto, Portugal|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Cluj-Napoca, Romania|Craiova, Romania|Craiova, Romania|Oradea, Romania|Ploiesti, Romania|Targu-Mures, Romania|Chelyabinsk, Russian Federation|Ivanovo, Russian Federation|Kazan, Russian Federation|Krasnoyarsk, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Novosibirsk, Russian Federation|Obninsk, Russian Federation|Omsk, Russian Federation|Orenburg, Russian Federation|Pyatigorsk, Russian Federation|Rostov-on-Don, Russian Federation|Saratov, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Tyumen, Russian Federation|Ufa, Russian Federation|Vladimir, Russian Federation|Belgrade, Serbia|Belgrade, Serbia|Nis, Serbia|Bratislava, Slovakia|Bratislava, Slovakia|Martin, Slovakia|Trencin, Slovakia|George, Eastern Cape, South Africa|Port Elizabeth, Eastern Cape, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Paarl, Western Cape, South Africa|Rondebosch, Western Cape, South Africa|Cape Town, South Africa|Cape Town, South Africa|Elche, Alicante, Spain|Cádiz, Andalucía, Spain|L'Hospitalet de Llobregat, Barcelona, Spain|Sabadell, Barcelona, Spain|Terrassa, Barcelona, Spain|Jerez de la Frontera, Cádiz, Spain|Manacor, Illes Baleares, Spain|Palma de Mallorca, Illes Baleares, Spain|Alcorcón, Madrid, Spain|Barcelona, Spain|Barcelona, Spain|Bilbao, Spain|Córdoba, Spain|Granada, Spain|Lugo, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Málaga, Spain|Salamanca, Spain|Sevilla, Spain|Sevilla, Spain|Valencia, Spain|Valencia, Spain|Valencia, Spain|Göteborg, Sweden|Stockholm, Sweden|Uppsala, Sweden|Örebro, Sweden|Kaohsiung City ,, Taiwan|Kaoshiung, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Ankara, Turkey|Istanbul, Turkey|Izmir, Turkey|Izmir, Turkey|Manisa, Turkey|Sivas, Turkey|Chernivtsi, Ukraine|Dnipro, Ukraine|Kharkiv, Ukraine|Kryvyi Rih, Ukraine|Kyiv, Ukraine|Kyiv, Ukraine|Uzhgorod, Ukraine|Zaporozhye, Ukraine|Reading, Berkshire, United Kingdom|Llanelli, Carmarthenshire, United Kingdom|Romford, Essex, United Kingdom|Stevenage, Hertfordshire, United Kingdom|Dartford, Kent, United Kingdom|Maidstone, Kent, United Kingdom|Preston, Lancashire, United Kingdom|Bebington, Merseyside, United Kingdom|Scunthorpe, North East Lincolnshire, United Kingdom|Bath, Somerset, United Kingdom|Stoke-on-Trent, Staffordshire, United Kingdom|Dudley, West Midlands, United Kingdom|Huddersfield, West Yorkshire, United Kingdom|Wakefield, West Yorkshire, United Kingdom|Cardiff, United Kingdom|Glasgow, United Kingdom|London, United Kingdom",https://ClinicalTrials.gov/show/NCT02200614
46,"Pfizer|Medivation, Inc.","A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)","Active, not recruiting",Has Results,Breast Neoplasms|BRCA 1 Gene Mutation|BRCA 2 Gene Mutation,Drug: talazoparib|Drug: Physician's-Choice,Industry,Interventional,"Arizona Oncology Associates P.C. - NAHOA, Flagstaff, Arizona, United States|HonorHealth, Scottsdale, Arizona, United States|Virginia G. Piper Cancer Pharmacy, Scottsdale, Arizona, United States|Kaiser Permanente Medical Center Lab Drawing Station, Antioch, California, United States|Kaiser Permanente Medical Center Lab Drawing Station, Antioch, California, United States|CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Kaiser Permanente Medical Center Lab Drawing Station, Fairfield, California, United States|St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare, Fullerton, California, United States|Kaiser Permanente Medical Center Lab Drawing Station, Gilroy, California, United States|Los Angeles Hematology Oncology Medical Group, Glendale, California, United States|Los Angeles Hematology Oncology Medical Group, Glendale, California, United States|Marin Specialty Care, Greenbrae, California, United States|Los Angeles Hematology Oncolgy Medical Group, Los Angeles, California, United States|Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States|Drug Management Only: UCLA West Medical Pharmacy, Attn:Steven L. Wong, Pharm.D., Los Angeles, California, United States|Drug Management only: UCLA West Medical Pharmacy, Los Angeles, California, United States|UCLA West Medical Pharmacy, Attn: Steven L. Wong, Pharm. D., Los Angeles, California, United States|UCLA West Medical Pharmacy, Attn: Steven L. Wong, Pharm.D., Los Angeles, California, United States|UCLA West Medical Pharmacy, Attn:Steven L. Wong, Pharm.D., Los Angeles, California, United States|Regulatory Managment Only: TRIO-US Central Administration, Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|TRIO-US Central Administration, Los Angeles, California, United States|UCLA West Medical Pharmacy, Attn: Steven L. Wong, Pharm.D., Los Angeles, California, United States|University of California Los Angeles, Los Angeles, California, United States|Kaiser Permanente Medical Center Lab Drawing Station, Martinez, California, United States|Kaiser Permanente Medical Center Lab Drawing Station, Milpitas, California, United States|Kaiser Permanente Medical Center Lab Drawing Station, Modesto, California, United States|Kaiser Permanente Medical Center Lab Drawing Station, Mountain View, California, United States|Kaiser Permanente Medical Center Lab Drawing Station, Napa, California, United States|Kaiser Permanente Medical Center (clinic+DSL), Oakland, California, United States|Kaiser Permanente Medical Center (Radiology), Oakland, California, United States|Kaiser Permanente Medical Center Lab Drawing Station, Pleasanton, California, United States|Torrance Health Association, DBA Torrance Memorial Physician Network/Cancer care Associates, Redondo Beach, California, United States|Kaiser Permanente Medical Center Lab Drawing Station, Redwood City, California, United States|Kaiser Permanente Medical Center (clinic+DSL), Roseville, California, United States|Southern California Permanente Medical Group, San Diego, California, United States|University of California, San Francisco: Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|UCSF Helen Diller Comprehensive Cancer Centre - Precision Cancer Medicine Building, San Francisco, California, United States|Kaiser Permanente Mission Bay Medical Center Lab Drawing Station, San Francisco, California, United States|Kaiser Permanente Medical Center Lab Drawing Station, San Jose, California, United States|Kaiser Permanente Medical Center (clinic+DSL), San Leandro, California, United States|Pacific Central Coast Health Centers - San Luis Obispo Oncology and Hematology Health Center, San Luis Obispo, California, United States|Ridley Tree Cancer Center, Santa Barbara, California, United States|Santa Barbara Cottage Hospital, Santa Barbara, California, United States|Kaiser Permanente Medical Center (clinic+DSL), Santa Clara, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|UCLA Hematology Oncology, Santa Monica, California, United States|UCLA Hematology/Oncology - Parkside, Santa Monica, California, United States|UCLA Santa Monica Medical Center & Orthopaedic Hospital, Santa Monica, California, United States|Sutter North Bay Health Plaza, Santa Rosa, California, United States|Sutter Pacific Medical Foundation, Santa Rosa, California, United States|Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States|Ridley Tree Cancer Center, Solvang, California, United States|Kaiser Permanente Medical Center (clinic+DSL), South San Francisco, California, United States|Stanford Cancer Institute, Stanford, California, United States|Stanford Women's Cancer Center, Stanford, California, United States|UCLA Hematology/Oncology - Santa Clarita, Valencia, California, United States|Kaiser Permanente Medical Center (clinic+DSL), Vallejo, California, United States|Kaiser Permanente Medical Center (clinic+DSL), Walnut Creek, California, United States|Kaiser Permanente Medical Center, Walnut Creek, California, United States|Southern California Permanente Medical Group, Woodland Hills, California, United States|Rocky Mountain Cancer Centers, Aurora, Colorado, United States|University of Colorado Cancer Center - Anschutz Cancer Pavilion (ACP), Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|Rocky Mountain Cancer Centers, Littleton, Colorado, United States|Rocky Mountain Cancer Centers, Longmont, Colorado, United States|Rocky Mountain Cancer Centers, Parker, Colorado, United States|Rocky Mountain Cancer Centers, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers, Thornton, Colorado, United States|Cancer Center of Central Connecticut, Plainville, Connecticut, United States|Florida Cancer Specialists, Altamonte Springs, Florida, United States|Florida Cancer Specialists, Brandon, Florida, United States|Florida Cancer Specialists, Clearwater, Florida, United States|Sylvester Comprehensive Cancer Center Deerfield Beach, Deerfield Beach, Florida, United States|Florida Cancer Specialists, Gainesville, Florida, United States|Memorial Healthcare System, Hollywood, Florida, United States|Memorial Regional Hospital, Hollywood, Florida, United States|Florida Cancer Specialists, Hudson, Florida, United States|Cancer Specialists of North Florida, Jacksonville Beach, Florida, United States|Cancer Specialists of North Florida, Jacksonville, Florida, United States|Cancer Specialists of North Florida, Jacksonville, Florida, United States|Cancer Specialists of North Florida, Jacksonville, Florida, United States|Cancer Specialists of North Florida, Jacksonville, Florida, United States|Cancer Specialists of North Florida, Jacksonville, Florida, United States|Florida Cancer Specialists, Lady Lake, Florida, United States|Florida Cancer Specialists, Largo, Florida, United States|Florida Cancer Specialists, Lecanto, Florida, United States|""University of Miami Hospital & Clinics,Sylvester Comprehensive Cancer Center/UMHC"", Miami, Florida, United States|Sylvester Comprehensive Cancer Center Kendall, Miami, Florida, United States|Florida Cancer Specialists, New Port Richey, Florida, United States|Florida Cancer Specialists, Orange City, Florida, United States|Florida Cancer Specialists, Orlando, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|Sylvester Comprehensive Cancer Center Plantation, Plantation, Florida, United States|Cancer Specialists of North Florida (CSNF) (Florida Oncology Associates (FOA)), Saint Augustine, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Florida Cancer Specialists, Spring Hill, Florida, United States|Florida Cancer Specialists, Tampa, Florida, United States|Florida Cancer Specialists, Tavares, Florida, United States|Central Georgia Cancer Care, PC, Macon, Georgia, United States|Central Georgia Cancer Care, PC, Warner Robins, Georgia, United States|Indiana University- Melvin and Bren Simon Cancer Center (IUSCC), Indianapolis, Indiana, United States|IU Health University Hospital, Indianapolis, Indiana, United States|Sidney and Lois Eskenazi Hospital, Indianapolis, Indiana, United States|Springmill Medical Clinic, Indianapolis, Indiana, United States|The University of Kansas Cancer Center (Regulatory Office), Fairway, Kansas, United States|The University of Kansas Cancer Center, Kansas City, Kansas, United States|The University of Kansas Cancer Center, Overland Park, Kansas, United States|The University of Kansas Cancer Center - Investigational Drug Services, Westwood, Kansas, United States|University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Cancer And Hematology Centers Of Western Michigan, Grand Rapids, Michigan, United States|Minnesota Oncology Hematology, P.A., Coon Rapids, Minnesota, United States|Minnesota Oncology Hematology, P.A., Edina, Minnesota, United States|Minnesota Oncology Hematology, P.A., Fridley, Minnesota, United States|Minnesota Oncology Hematology, P.A., Maplewood, Minnesota, United States|Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States|Minnesota Oncology Hematology, P.A., Saint Paul, Minnesota, United States|Minnesota Oncology Hematology, P.A., Woodbury, Minnesota, United States|The West Clinic, P.C., Corinth, Mississippi, United States|The West Clinic, P.C. d/b/a West Cancer Center, Southaven, Mississippi, United States|The University of Kansas Cancer Center, Kansas City, Missouri, United States|The University of Kansas Cancer Center, Kansas City, Missouri, United States|The University of Kansas Cancer Center, Lee's Summit, Missouri, United States|Comprehensive Cancer Centers Of Nevada, Henderson, Nevada, United States|New York Oncology Hematology, P.C., Albany, New York, United States|Eastchester Center for Cancer Care, Bronx, New York, United States|New York Oncology Hematology, P.C., Clifton Park, New York, United States|New York University Langone Medical Center, New York, New York, United States|Perlmutter Cancer Center, New York, New York, United States|Weill Cornell Medical College - New York Presbyterian Hospital, New York, New York, United States|Weill Cornell Medical College - New York-Presbyterian Hospital, New York, New York, United States|New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States|Weill Cornell Breast Center, New York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|Weill Cornell Medical College - New York Presbyterian Hospital, New York, New York, United States|Hope Women's Cancer Centers, Asheville, North Carolina, United States|MH Mission Hospital, LLLP, Asheville, North Carolina, United States|Novant Health Cancer Specialists, Charlotte, North Carolina, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|Southern Oncology Specialists, Charlotte, North Carolina, United States|Lake Norman Hematology Oncology Specialists, Huntersville, North Carolina, United States|Novant Health Huntersville Medical Center, Huntersville, North Carolina, United States|Southern Oncology Specialists, Huntersville, North Carolina, United States|Novant Health Cancer Specialists, Matthews, North Carolina, United States|Novant Health Matthews Medical Center, Matthews, North Carolina, United States|Lake Norman Hematology Oncology Specialists, Mooresville, North Carolina, United States|Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa, Oklahoma, United States|Northwest Cancer Specialists, P.C., Portland, Oregon, United States|Northwest Cancer Specialists, P.C., Portland, Oregon, United States|Northwest Cancer Specialists, P.C., Tigard, Oregon, United States|Upmc Cancer Centers - The Regional Cancer Center, Erie, Pennsylvania, United States|Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, William M. Cooper Pavilion, Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Tennessee Oncology, PLLC, Dickson, Tennessee, United States|Tennessee Oncology, PLLC, Franklin, Tennessee, United States|Tennessee Oncology PLLC, Gallatin, Tennessee, United States|The West Clinic, P.C. d/b/a West Cancer Center, Germantown, Tennessee, United States|Tennessee Oncology, PLLC, Hermitage, Tennessee, United States|University of Tennessee Medical Center, Knoxville, Tennessee, United States|Tennessee Oncology, PLLC, Lebanon, Tennessee, United States|The West Clinic, P.C. d/b/a West Cancer Center, Memphis, Tennessee, United States|Tennessee Oncology PLLC, Murfreesboro, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Shelbyville, Tennessee, United States|Tennessee Oncology PLLC, Smyrna, Tennessee, United States|The Center for Cancer and Blood Disorders, Arlington, Texas, United States|Texas Oncology-South Austin, Austin, Texas, United States|The Center for Cancer and Blood Disorders (Huguley), Burleson, Texas, United States|Texas Oncology - Cedar Park, Cedar Park, Texas, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology-El Paso Cancer Treatment Center Grandview, El Paso, Texas, United States|Texas Oncology-El Paso Cancer Treatment Center Gateway, El Paso, Texas, United States|Texas Oncology - El Paso Cancer Treatment Center Joe Battle, El Paso, Texas, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States|Investigational Products Center (IPC), Fort Worth, Texas, United States|Texas Oncology-Memorial City, Houston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|University Of Texas, Md Anderson Cancer Center, Houston, Texas, United States|UT MD Anderson Cancer Center, Houston, Texas, United States|US Oncology Investigational Products Center (IPC), Irving, Texas, United States|US Oncology Investigational Products Center(IPC), Irving, Texas, United States|Texas Oncology-Plano East, Plano, Texas, United States|Texas Oncology-Seton Williamson, Round Rock, Texas, United States|Texas Oncology - Waco, Waco, Texas, United States|Texas Oncology-Waco, Waco, Texas, United States|The Center for Cancer and Blood Disorders, Weatherford, Texas, United States|Virginia Cancer Specialists, PC, Alexandria, Virginia, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Oncology Associates, Newport News, Virginia, United States|Swedish Cancer Institute, Seattle, Washington, United States|Swedish First Hill IDS Pharmacy, Seattle, Washington, United States|Swedish Medical Center, Seattle, Washington, United States|Northwest Cancer Specialists, P.C.(Admin Only), Vancouver, Washington, United States|Northwest Cancer Specialists, P.C., Vancouver, Washington, United States|Concord Repatriation General Hospital, Concord, New South Wales, Australia|ICON Cancer Care (Haematology And Oncology Clinics Of Australasia (Hoca))-Milton, Milton, Queensland, Australia|Icon Cancer Care, Corporate Office, South Brisbane, Queensland, Australia|ICON Cancer Care, South Brisbane, Queensland, Australia|ICON Cancer Foundation, South Brisbane, Queensland, Australia|Mater Adult Hospital, South Brisbane, Queensland, Australia|Icon Cancer Care South Brisbane, South Brisbane, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Adelaide Cancer Centre, Kurralta Park, South Australia, Australia|Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia|Cancer Care SA PTY Ltd, Kurralta Park, South Australia, Australia|Cancer Care SA trading as Icon Pharmacy Adelaide, Kurralta Park, South Australia, Australia|Victoria Breast and Oncology Care, East Melbourne, Victoria, Australia|Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia|Barwon Health, University Hospital Geelong, Geelong, Victoria, Australia|Austin Health, The Austin Hospital, Melbourne, Victoria, Australia|Slade Pharmacy Mount Waverley, Mount Waverley, Victoria, Australia|Nova Pharmacy, Wendouree, Victoria, Australia|Ballarat Oncology & Haematology Services Clinical Trials Unit, Wendouree, Victoria, Australia|Ballarat Oncology & Haematology Services, Wendouree, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Sir Charles Gairdner Hospital Lung Institute Of Western Australia, Nedlands, Western Australia, Australia|River City Pharmacy, Auchenflower, Australia|Icon Cancer Care, Milton, Australia|Universitair Ziekenhuis Gent, Gent, Belgium|CHU Sart Tilman Liege, Liege, Belgium|Hospital do Cancer III - INCA / Instituto Nacional do Cancer / MS INCA HCIII, Rio de Janeiro, RJ, Brazil|Hopital da Cidade de Passo Fundo, Passo Fundo, RS, Brazil|Hospital da Cidade de Passo Fundo - HCPF, Passo Fundo, RS, Brazil|Associacao Hospitalar Moinhos de Vento, Porto Alegre, RS, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil|Uniao Brasileira de Educacao E Assistencia, Porto Alegre, RS, Brazil|Inst de Oncologia Clínica de Piracicaba S/S Ltda. CECAN - Centro do Cancer Santa Casa de Piracicaba, Piracicaba, SAO Paulo, Brazil|Hospital do Cancer de Barretos - Fundacao Pio XII, Barretos, SP, Brazil|Fundacao Hospital Amaral Carvalho, Jau, SP, Brazil|Instituto de Oncologia de Piracicaba S/S Ltda., Piracicaba, SP, Brazil|Centro de Referencia da Saude da Mulher - Hospital Perola Byington, Sao Paulo, SP, Brazil|Clinica de Pesquisas e Centro de Estudos em Oncologia Ginecologica e Mamária Ltda., Sao Paulo, SP, Brazil|CHRU Jean Minjoz, Besancon, France|Centre Leon Berard, LYON cedex 08, France|Institut Paoli Calmettes, Marseille, France|Hopital Prive du Confluent, Nantes BP 20215, France|Hopital Saint Louis, Paris, France|Hopital Tenon, Paris, France|Institut de Cancerologie de l'Ouest - Site Rene Gauducheau, Saint Herblain, France|Hopitaux Universitaires de Strasbourg - Hopital Civil, Strasbourg, France|Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France|CHU Bretonneau Centre Henry Kaplan, Tours Cedex 9, France|Institut Gustave Roussy, Villejuif cedex, France|Medizinisches Zentrum fur Hamatologie und Onkologie Munchen MVZ, Munich, Bavaria, Germany|Radiologicum, Munich, Bavaria, Germany|IOZ Muenchen, Munich, Bavaria, Germany|University of Munich (LMU), Grosshadern Hospital, Munich, Bavaria, Germany|Radiologicum, Munich, Bavaria, Germany|Universitaetsklinikum Carl Gustav Carus an der Technischen Universitaet Dresden, Dresden, Saxony, Germany|HELIOS Klinikum Berlin-Buch, Berlin, Germany|Praxisklinik Krebsheilkunde fuer Frauen/Brustzentrum, Berlin, Germany|University Hospital Duesseldorf, Duesseldorf, Germany|Universitaetsklinikum Erlangen, Erlangen, Germany|Kliniken Essen-Mitte, Klinik für Senologie / Brustzentrum, Essen, Germany|Universitaetsklinikum Freiburg, Klinik fuer Frauenheilunde, Freiburg, Germany|Oncologie Unter Ems, Leer, Germany|Klinikum rechts der Isar, TUM, Frauenklinik und Poliklinik, Munich, Germany|Unifrauenklinik am Klinikum Suedstadt, Rostock, Germany|Universitaetsfrauenklinik, Ulm, Germany|St. Vincent's University Hospital, Dublin 4, Ireland|Mater Misericordiae University Hospital, Dublin 7, Ireland|University Hospital Galway, Galway, Ireland|Soroka University Medical Center, Beer Sheva, Israel|Oncology Institute, Rambam Health Care Campus, Haifa, Israel|Oncology Institute, Davidoff Center, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel|Division of Oncology Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Assuta Medical Center, Tel Aviv, Israel|The Chaim sheba Medical Center, Tel Hashomer, Israel|Oncology Institute, Assuta Medical Center, Tel-Aviv, Israel|Assaf Harofeh Medical Center, Zerifin, Israel|A.O.S.G. Moscati - Contrada Amoretta, Avellino, AV, Italy|Ospedale S. Raffaelle di Milano, Milano, MI, Italy|A.S.S.T. Monza, Monza, Monza AND Brianza, Italy|A.S.S.T. Monza, Oncologia Medica, Ospedale San Gerardo, Monza, Monza Brianza, Italy|La Maddalena Clinic For Cancer University Of Palermo, Palermo, PA, Italy|A.O.U. Pisana, DAI Oncologia, U.O. Oncologia Med. 2 Univ., Pisa, PI, Italy|Ospendale Sant'Andrea, Roma, RM, Italy|Ospedale Mater Salutis, Legnago, VR, Italy|S.S.D. Oncologia Medica Addarii - A.O.U. di Bologna - Policlinico Sant'Orsola-Malpighi, Bologna, Italy|Senologia Medica, IRCCS-Instituto Oncologico Europeo (IEO), Milano, Italy|Universita Campus Bio-Medico di Roma, Dipartimento Oncologia Medica, Roma, Italy|Seoul National University Bundang Hospital, Bundang-gu, Gyeonggi-do, Korea, Republic of|National Cancer Centre, Goyang-si, Gyeonggi-do, Korea, Republic of|Ajou University Hospital, Suwon, Gyeonggi-do, Korea, Republic of|Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Republic of|Centrum Terapii Wspolczesnej J.M. Jasnorzewska Spolka Komandytowo-Akcyjna, Lodz, LODZ Province, Poland|NZOZ Innowacyjna Medycyna, Dobra, Poland|Uniwersyteckie Centrum Kliniczne, Zaklad Medycyny Nuklearnej, Gdansk, Poland|Uniwersyteckie Centrum Kliniczne Klinika Onkologii i Radioterapii, Gdansk, Poland|Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii, Gdansk, Poland|Uniwersyteckie Centrum Kliniczne, Zaklad Radiologii, Gdansk, Poland|Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie, Oddzial w Gliwicach, Gliwice, Poland|NU-MED Centrum Diagnostyki i Terapii Onkologicznej Katowice, Katowice, Poland|Uniwersyteckie Centrum Kliniczne im. Prof. K. Gibinskiego Slaskiego Uniwersytetu, Katowice, Poland|Europejskie Centrum Zdrowia Otwock Szpital im.F.Chopina, Otwock, Poland|Szpital Kliniczny im. Heliodora Swiecickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego, Poznan, Poland|Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Pozna, Poznan, Poland|Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola, Poznan, Poland|Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Pozna, Poznan, Poland|Wielkopolskie Centrum Onkologii im. Marii Sklodowskiej-Curie, Poznan, Poland|Oddzial Onkologii Klinicznej, Samodzielny Publiczny Szpital Kliniczny Nr 2 PUM w Szczecinie, Szczecin, Poland|Pracownia Tomografii Komputerowej , Samodzielny Publiczny Szpital Kliniczny Nr 2 PUM w Szczecinie, Szczecin, Poland|Pracownia Medycyny Nuklearnej, 109 Szpital Wojskowy z Przychodnia SP ZOZ, Szczecin, Poland|Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie Klinika Nowotworow Piersi i, Warszawa, Poland|Klinika Onkologii, Wojskowy lnstytut Medyczny, Warszawa, Poland|Gbuz Lood, Leningrad, Leningrad Region, Russian Federation|State Budgetary Institution of Healthcare ""Republican Oncology dispensary""', Petrozavodsk, Russian Federation|City Clinical Oncology Dispensary, St. Petersburg, Russian Federation|Hospital Nuestra Senora de Sonsoles(Complejo Asistencial de Avila), Avila, Spain|Hospital Universitari Germans Trias i Pujol, Badalona Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic I Provincial, Barcelona, Spain|Consorcio Hospitalario Provincial de Castellon, Castellon, Spain|Complejo Hospitalario de Jaen, Jaen, Spain|Centro Oncologico de Galicia, La Coruna, Spain|Hospital Universitario de Canarias, La Laguna Santa Cruz De Tenerife, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario Ramon Y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario Quiron Madrid, Pozuelo De Alarcon (Madrid), Spain|Corporacio Sanitaria Parc Tauli, Sabadell Barcelona, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Changhua Christian Hospital, Changhua, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan|Communal Institution ""Krivorizhskiy Oncology Dispensary"" of Dnipropetrovsk Regional Council, Kriviy Rig, Ukraine|Regional Municipal Institution ""Sumy Regional Clinical Oncology Dispensary"", Thoracic Department, Sumy, Ukraine|Sarah Cannon Research Institute UK, London, England, United Kingdom|Nottingham University Hospital NHS Trust, Nottingham, Nottinghamshire, United Kingdom|Sussex Cancer Centre, Royal Sussex County Hospital, Brighton, Sussex, United Kingdom|Royal Sussex County Hospital, Royal Alexandra Children's Hospital L10, Brighton, United Kingdom|St James University Hospital, Leeds, United Kingdom|Impretial College Healthcare NHS Trust, London, United Kingdom|Cancer Research UK, Department of Medical Oncology - The Christie NHS Foundation Trust, Manchester, United Kingdom",https://ClinicalTrials.gov/show/NCT01945775
47,Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd,"An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)","Active, not recruiting",Has Results,Stage IV or Recurrent Non-Small Cell Lung Cancer,Biological: Nivolumab|Drug: Gemcitabine|Drug: Cisplatin|Drug: Carboplatin|Drug: Paclitaxel|Drug: Pemetrexed,Industry,Interventional,"Southern Cancer Center, Inc., Mobile, Alabama, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Arizona Oncol Assoc Dba (Hem Onc Physicians&Extenders) Hope, Tucson, Arizona, United States|Stanford Cancer Institute, Stanford, California, United States|University Of Colorado Hosp, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|Baptist Health Medical Group Oncology, Miami, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Emory University - Winship Cancer Institute, Atlanta, Georgia, United States|Northwest Georgia Oncology Center, P.C., Marietta, Georgia, United States|Rush University Med Ctr, Chicago, Illinois, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Crescent City Research Consortium, LLC, Marrero, Louisiana, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center., Boston, Massachusetts, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|New York University Clinical Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University Of North Carolina At Chapel Hill, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States|University Hospitals, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|Hollings Cancer Center, Charleston, South Carolina, United States|St Francis Hospital, Greenville, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University Of Texas Southwestern Medical Center, Dallas, Texas, United States|Univ Of Tx. Md Anderson, Houston, Texas, United States|Cancer Centers of South Texas, San Antonio, Texas, United States|Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington, United States|COIBA, Berazategui, Buenos Aires, Argentina|Instituto Medico Especializado Alexander Fleming, Capital Federal, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Clinica Colombo, Cordoba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Camperdown, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Fitzroy, Victoria, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Wels, Austria|Local Institution, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Edegem, Belgium|Local Institution, Gent, Belgium|Local Institution, Leuven, Belgium|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Centre Hospitalier De L'Universite De Montreal, Montreal, Canada|Local Institution, Olomouc, Czechia|Local Institution, Ostrava - Poruba, Czechia|Local Institution, Praha 8, Czechia|Local Institution, Usti nad Labem, Czechia|Local Institution, Helsinki, Finland|Local Institution, Tampere, Finland|Local Institution, Vaasa, Finland|Hopital Cote De Nacre C H U Caen, Caen, France|Local Institution, Lille, France|Local Institution, Marseille Cedex 20, France|Local Institution, Pontoise Cedex, France|Local Institution, Rennes Cedex 9, France|Local Institution, Strasbourg, France|Sozialstiftung Bamberg, Bamberg, Germany|Klinik Schillerhoehe GmbH, Gerlingen, Germany|LungenClinic Grosshansdorf GmbH, Grosshansdorf, Germany|Thoraxklinik-Heidelberg gGmbH, Heidelberg, Germany|Local Institution, Koeln, Germany|Local Institution, Wiesbaden, Germany|University Hospital Of Heraklion, Heraklion, Creta, Greece|Sotiria General Hospital, Athens, Greece|Local Institution, Budapest, Hungary|Local Institution, Debrecen, Hungary|Local Institution, Matrahaza, Hungary|Azienda Ospedaliera Moscati, Avellino, Italy|Local Institution, Livorno, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Perugia, Italy|Local Institution, Terni, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Nagoya, Aichi, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Kobe City, Hyogo, Japan|Local Institution, Natori-shi, Miyagi, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Habikino-city, Osaka, Japan|Local Institution, Osaka-sayama, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Sakai-shi, Osaka, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Akashi, Hyogo, Japan|Local Institution, Ota, Gunma, Japan|Local Institution, Sapporo, Hokkaido, Japan|Local Institution, Tokyo, Japan|Local Institution, Wakayama, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Bydgoszcz, Poland|Local Institution, Krakow, Poland|Local Institution, Lodz, Poland|Local Institution, Warszawa, Poland|Local Institution, Wodzislaw Slaski, Poland|Local Institution, Cluj Napoca, Romania|Local Institution, Cluj-napoca, Romania|Local Institution, Ploiesti, Romania|Local Institution, Barcelona, Spain|Local Institution, Las Palmas De Gran Canaria, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, Stockholm, Sweden|Local Institution, Uppsala, Sweden|Local Institution, Chur, Switzerland|Local Institution, Lausanne, Switzerland|Local Institution, Zuerich, Switzerland|Local Institution, Taipei, Taiwan|Local Institution, Kayseri, Turkey|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Leeds, Yorkshire, United Kingdom",https://ClinicalTrials.gov/show/NCT02041533
48,Eli Lilly and Company,Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer,"Active, not recruiting",Has Results,Breast Cancer,Biological: ramucirumab (IMC-1121B)|Drug: docetaxel|Other: Placebo,Industry,Interventional,"ImClone Investigational Site, Birmingham, Alabama, United States|ImClone Investigational Site, Mobile, Alabama, United States|ImClone Investigational Site, Chandler, Arizona, United States|ImClone Investigational Site, Gilbert, Arizona, United States|ImClone Investigational Site, Mesa, Arizona, United States|ImClone Investigational Site, Alhambra, California, United States|ImClone Investigational Site, Bakersfield, California, United States|ImClone Investigational Site, Chula Vista, California, United States|ImClone Investigational Site, La Mesa, California, United States|ImClone Investigational Site, Los Angeles, California, United States|ImClone Investigational Site, Oceanside, California, United States|ImClone Investigational Site, Pasadena, California, United States|ImClone Investigational Site, Pasadena, California, United States|ImClone Investigational Site, San Diego, California, United States|ImClone Investigational Site, Santa Barbara, California, United States|ImClone Investigational Site, Santa Maria, California, United States|ImClone Investigational Site, Santa Monica, California, United States|ImClone Investigational Site, Solvang, California, United States|ImClone Investigational Site, Valencia, California, United States|ImClone Investigational Site, Aurora, Colorado, United States|ImClone Investigational Site, Fort Lauderdale, Florida, United States|ImClone Investigational Site, Gainesville, Florida, United States|ImClone Investigational Site, New Port Richey, Florida, United States|ImClone Investigational Site, Atlanta, Georgia, United States|ImClone Investigational Site, Atlanta, Georgia, United States|ImClone Investigational Site, Macon, Georgia, United States|ImClone Investigational Site, Marietta, Georgia, United States|ImClone Investigational Site, Alton, Illinois, United States|ImClone Investigational Site, Chicago, Illinois, United States|ImClone Investigational Site, Chicago, Illinois, United States|ImClone Investigational Site, Skokie, Illinois, United States|ImClone Investigational Site, Elkhart, Indiana, United States|ImClone Investigational Site, Mishawaka, Indiana, United States|ImClone Investigational Site, South Bend, Indiana, United States|ImClone Investigational Site, Westville, Indiana, United States|ImClone Investigational Site, Lexington, Kentucky, United States|ImClone Investigational Site, Lansing, Michigan, United States|ImClone Investigational Site, Saint Joseph, Michigan, United States|ImClone Investigational Site, Minneapolis, Minnesota, United States|ImClone Investigational Site, Southaven, Mississippi, United States|ImClone Investigational Site, Saint Louis, Missouri, United States|ImClone Investigational Site, Grand Island, Nebraska, United States|ImClone Investigational Site, Kearney, Nebraska, United States|ImClone Investigational Site, Henderson, Nevada, United States|ImClone Investigational Site, New York, New York, United States|ImClone Investigational Site, Charlotte, North Carolina, United States|ImClone Investigational Site, Charlotte, North Carolina, United States|ImClone Investigational Site, Charlotte, North Carolina, United States|ImClone Investigational Site, Charlotte, North Carolina, United States|ImClone Investigational Site, Charlotte, North Carolina, United States|ImClone Investigational Site, Charlotte, North Carolina, United States|ImClone Investigational Site, Bismarck, North Dakota, United States|ImClone Investigational Site, Oklahoma City, Oklahoma, United States|ImClone Investigational Site, Portland, Oregon, United States|ImClone Investigational Site, West Reading, Pennsylvania, United States|ImClone Investigational Site, Bartlett, Tennessee, United States|ImClone Investigational Site, Germantown, Tennessee, United States|ImClone Investigational Site, Memphis, Tennessee, United States|ImClone Investigational Site, Memphis, Tennessee, United States|ImClone Investigational Site, Memphis, Tennessee, United States|ImClone Investigational Site, Niles, Tennessee, United States|ImClone Investigational Site, Oxford, Tennessee, United States|ImClone Investigational Site, Lubbock, Texas, United States|ImClone Investigational Site, Temple, Texas, United States|ImClone Investigational Site, Salt Lake City, Utah, United States|ImClone Investigational Site, Fitzroy, Victoria, Australia|ImClone Investigational Site, Frankston, Victoria, Australia|ImClone Investigational Site, Bankstown, Australia|ImClone Investigational Site, Bedford Park, Australia|ImClone Investigational Site, Box Hill, Australia|ImClone Investigational Site, Darlinghurst, Australia|ImClone Investigational Site, East Bentleigh, Australia|ImClone Investigational Site, East Melbourne, Australia|ImClone Investigational Site, Herston, Australia|ImClone Investigational Site, Hobart, Australia|ImClone Investigational Site, Milton, Australia|ImClone Investigational Site, Nambour, Australia|ImClone Investigational Site, New Lambton Heights, Australia|ImClone Investigational Site, Perth, Australia|ImClone Investigational Site, Ringwood East, Australia|ImClone Investigational Site, Subiaco, Australia|ImClone Investigational Site, Sydney, Australia|ImClone Investigational Site, Tweed Heads, Australia|ImClone Investigational Site, Wendouree, Australia|ImClone Investigational Site, Brasschaat, Belgium|ImClone Investigational Site, Charleroi, Belgium|ImClone Investigational Site, Edegem, Belgium|ImClone Investigational Site, Gent, Belgium|ImClone Investigational Site, Kortrijk, Belgium|ImClone Investigational Site, Liege, Belgium|ImClone Investigational Site, Namur, Belgium|ImClone Investigational Site, Yvoir, Belgium|ImClone Investigational Site, Ijui, Brazil|ImClone Investigational Site, Porto Alegre, Brazil|ImClone Investigational Site, Porto Alegre, Brazil|ImClone Investigational Site, Porto Alegre, Brazil|ImClone Investigational Site, Rio de Janeiro, Brazil|ImClone Investigational Site, San Paulo, Brazil|ImClone Investigational Site, San Paulo, Brazil|ImClone Investigational Site, Santo Andre, Brazil|ImClone Investigational Site, Sao Paulo, Brazil|ImClone Investigational Site, Sao Paulo, Brazil|ImClone Investigational Site, Sao Paulo, Brazil|ImClone Investigational Site, Calgary, Alberta, Canada|ImClone Investigational Site, Edmonton, Alberta, Canada|ImClone Investigational Site, Vancouver, British Columbia, Canada|ImClone Investigational Site, Toronto, Ontario, Canada|ImClone Investigational Site, Weston, Ontario, Canada|ImClone Investigational Site, Greenfield Park, Quebec, Canada|ImClone Investigational Site, Quebec, Canada|ImClone Investigational Site, Osijek, Croatia|ImClone Investigational Site, Praha, Motol, Czechia|ImClone Investigational Site, Brno, Czechia|ImClone Investigational Site, Kutna Hora, Czechia|ImClone Investigational Site, Pardubice, Czechia|ImClone Investigational Site, Prague, Czechia|ImClone Investigational Site, Prague, Czechia|ImClone Investigational Site, Videnska, Czechia|ImClone Investigational Site, Alexandria, Egypt|ImClone Investigational Site, Cairo, Egypt|ImClone Investigational Site, Cairo, Egypt|ImClone Investigational Site, Chemnitz, Germany|ImClone Investigational Site, Hamburg, Germany|ImClone Investigational Site, Hamburg, Germany|ImClone Investigational Site, Kiel, Germany|ImClone Investigational Site, Lubeck, Germany|ImClone Investigational Site, Munchen, Germany|ImClone Investigational Site, Munich, Germany|ImClone Investigational Site, Oldenburg, Germany|ImClone Investigational Site, Saarbrucken, Germany|ImClone Investigational Site, Trier, Germany|ImClone Investigational Site, Tubingen, Germany|ImClone Investigational Site, Cork, Ireland|ImClone Investigational Site, Dublin, Ireland|ImClone Investigational Site, Dublin, Ireland|ImClone Investigational Site, Erlangen, Ireland|ImClone Investigational Site, Limerick, Ireland|ImClone Investigational Site, Beersheva, Israel|ImClone Investigational Site, Jerusalem, Israel|ImClone Investigational Site, Petach-Tikva, Israel|ImClone Investigational Site, Rehovot, Israel|ImClone Investigational Site, Tel Aviv, Israel|ImClone Investigational Site, Incheon, Korea, Republic of|ImClone Investigational Site, Seoul, Korea, Republic of|ImClone Investigational Site, Seoul, Korea, Republic of|ImClone Investigational Site, Seoul, Korea, Republic of|ImClone Investigational Site, Beirut, Lebanon|ImClone Investigational Site, Bsalim, Lebanon|ImClone Investigational Site, Metn, Lebanon|ImClone Investigational Site, Saïda, Lebanon|ImClone Investigational Site, Zgharta, Lebanon|ImClone Investigational Site, Auckland, New Zealand|ImClone Investigational Site, Auckland, New Zealand|ImClone Investigational Site, Palmerston North, New Zealand|ImClone Investigational Site, Arequipa, Peru|ImClone Investigational Site, Lima, Peru|ImClone Investigational Site, Lima, Peru|ImClone Investigational Site, Lima, Peru|ImClone Investigational Site, Lima, Peru|ImClone Investigational Site, Lima, Peru|ImClone Investigational Site, Bytom, Poland|ImClone Investigational Site, Olsztyn, Poland|ImClone Investigational Site, Olsztyn, Poland|ImClone Investigational Site, Engels, Russian Federation|ImClone Investigational Site, Kazan, Russian Federation|ImClone Investigational Site, Kursk, Russian Federation|ImClone Investigational Site, Leningrad Region, Russian Federation|ImClone Investigational Site, Lipetsk, Russian Federation|ImClone Investigational Site, Magnitogorsk, Russian Federation|ImClone Investigational Site, Moscow, Russian Federation|ImClone Investigational Site, Moscow, Russian Federation|ImClone Investigational Site, Moscow, Russian Federation|ImClone Investigational Site, Novosibirsk, Russian Federation|ImClone Investigational Site, Omsk, Russian Federation|ImClone Investigational Site, Orenburg, Russian Federation|ImClone Investigational Site, Perm, Russian Federation|ImClone Investigational Site, Samara, Russian Federation|ImClone Investigational Site, Saratov, Russian Federation|ImClone Investigational Site, St. Petersburg, Russian Federation|ImClone Investigational Site, St. Petersburg, Russian Federation|ImClone Investigational Site, Tambov, Russian Federation|ImClone Investigational Site, Ufa, Russian Federation|ImClone Investigational Site, Kragujevac, Serbia|ImClone Investigational Site, Nis, Serbia|ImClone Investigational Site, Sremska Kamenica, Serbia|ImClone Investigational Site, Bratislava, Slovakia|ImClone Investigational Site, Trnava, Slovakia|ImClone Investigational Site, Zilina, Slovakia|ImClone Investigational Site, Parktown, Johannesburg, South Africa|ImClone Investigational Site, Amanzimtoti, South Africa|ImClone Investigational Site, Bloemfontein, South Africa|ImClone Investigational Site, Durban, South Africa|ImClone Investigational Site, Durban, South Africa|ImClone Investigational Site, Lynnwood, South Africa|ImClone Investigational Site, Port Elizabeth, South Africa|ImClone Investigational Site, Pretoria, South Africa|ImClone Investigational Site, Pretoria, South Africa|ImClone Investigational Site, Pretoria, South Africa|ImClone Investigational Site, Sandton, South Africa|ImClone Investigational Site, Alicante, Spain|ImClone Investigational Site, Badalona, Spain|ImClone Investigational Site, Barbastro, Spain|ImClone Investigational Site, Barcelona, Spain|ImClone Investigational Site, Barcelona, Spain|ImClone Investigational Site, Girona, Spain|ImClone Investigational Site, Jaen, Spain|ImClone Investigational Site, La Caruna, Spain|ImClone Investigational Site, La Coruna, Spain|ImClone Investigational Site, La Laguna - Tenerife, Spain|ImClone Investigational Site, Lleida, Spain|ImClone Investigational Site, Madrid, Spain|ImClone Investigational Site, Madrid, Spain|ImClone Investigational Site, Madrid, Spain|ImClone Investigational Site, Madrid, Spain|ImClone Investigational Site, Madrid, Spain|ImClone Investigational Site, Malaga, Spain|ImClone Investigational Site, Palma de Mallorca, Spain|ImClone Investigational Site, Salamanca, Spain|ImClone Investigational Site, San Sebastian, Spain|ImClone Investigational Site, Santander, Spain|ImClone Investigational Site, Sevilla, Spain|ImClone Investigational Site, Toledo, Spain|ImClone Investigational Site, Valencia, Spain|ImClone Investigational Site, Valencia, Spain|ImClone Investigational Site, Zaragoza, Spain|ImClone Investigational Site, Changhua, Taiwan|ImClone Investigational Site, Taipei, Taiwan|ImClone Investigational Site, Taoyuan County, Taiwan|ImClone Investigational Site, Bournemouth, United Kingdom|ImClone Investigational Site, Edinburgh, United Kingdom|ImClone Investigational Site, Huddersfield, United Kingdom|ImClone Investigational Site, Hull, United Kingdom|ImClone Investigational Site, Manchester, United Kingdom|ImClone Investigational Site, Nottingham, United Kingdom",https://ClinicalTrials.gov/show/NCT00703326
49,AstraZeneca,Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.,"Active, not recruiting",Has Results,Breast Cancer,Drug: Fulvestrant,Industry,Interventional,"Research Site, New Britain, Connecticut, United States|Research Site, Crystal River, Florida, United States|Research Site, Urbana, Illinois, United States|Research Site, Baltimore, Maryland, United States|Research Site, Detroit, Michigan, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Greenville, North Carolina, United States|Research Site, Pasadena, Texas, United States|Research Site, West Bend, Wisconsin, United States|Research Site, Brasschaat, Belgium|Research Site, Brussels, Belgium|Research Site, Brussels, Belgium|Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Hasselt, Belgium|Research Site, Liege, Belgium|Research Site, Liège, Belgium|Research Site, Turnhout, Belgium|Research Site, Londrina, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Recife, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Bogota, Colombia|Research Site, Cali, Colombia|Research Site, Brno, Czechia|Research Site, Ceske Budejovice, Czechia|Research Site, Pardubice, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 8, Czechia|Research Site, Tabor, Czechia|Research Site, V Uvalu 84, Czechia|Research Site, Szombathely, Hungary|Research Site, Hyderabad, India|Research Site, Jaipur, India|Research Site, Kolkata, India|Research Site, Marg Jaipur, India|Research Site, Pune, India|Research Site, Trivandrum, India|Research Site, Vellore, India|Research Site, Aviano, Italy|Research Site, Bergamo, Italy|Research Site, Carpi, Italy|Research Site, Prato, Italy|Research Site, Reggio Emilia, Italy|Research Site, Varese, Italy|Research Site, Floriana, Malta|Research Site, Mexico Distrito Federal, Mexico|Research Site, Mexico, Mexico|Research Site, Białystok, Poland|Research Site, Poznań, Poland|Research Site, Łódź, Poland|Research Site, Ivanovo, Russian Federation|Research Site, Kazan, Tatarstan, Russian Federation|Research Site, Kazan, Tatarstan, Russian Federation|Research Site, Lipetsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, St-Petersburg, Russian Federation|Research Site, St.-Petersburg, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Bardejov, Slovakia|Research Site, Madrid, Spain|Research Site, Malaga, Spain|Research Site, Oviedo, Spain|Research Site, Salamanca, Spain|Research Site, Sevilla, Spain|Research Site, Cherkasy, Ukraine|Research Site, Dnipro, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Sumy, Ukraine|Research Site, Uzhhorod, Ukraine|Research Site, Caracas, Venezuela",https://ClinicalTrials.gov/show/NCT00099437
50,Novartis Pharmaceuticals|NCIC Clinical Trials Group|Novartis,Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer,"Active, not recruiting",Has Results,Breast Cancer,Biological: trastuzumab|Drug: docetaxel|Drug: lapatinib ditosylate|Drug: paclitaxel,Industry|Other,Interventional,"Novartis Investigative Site, Anchorage, Alaska, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Hot Springs, Arkansas, United States|Novartis Investigative Site, Berkeley, California, United States|Novartis Investigative Site, Highland, California, United States|Novartis Investigative Site, Montebello, California, United States|Novartis Investigative Site, Colorado Springs, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Greenwich, Connecticut, United States|Novartis Investigative Site, Southington, Connecticut, United States|Novartis Investigative Site, Stamford, Connecticut, United States|Novartis Investigative Site, Trumbull, Connecticut, United States|Novartis Investigative Site, Waterbury, Connecticut, United States|Novartis Investigative Site, Kissimmee, Florida, United States|Novartis Investigative Site, Loxahatchee Groves, Florida, United States|Novartis Investigative Site, New Port Richey, Florida, United States|Novartis Investigative Site, Augusta, Georgia, United States|Novartis Investigative Site, Lawrenceville, Georgia, United States|Novartis Investigative Site, Savannah, Georgia, United States|Novartis Investigative Site, Post Falls, Idaho, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Oak Lawn, Illinois, United States|Novartis Investigative Site, Evansville, Indiana, United States|Novartis Investigative Site, Goshen, Indiana, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Munster, Indiana, United States|Novartis Investigative Site, New Albany, Indiana, United States|Novartis Investigative Site, Towson, Maryland, United States|Novartis Investigative Site, Wheaton, Maryland, United States|Novartis Investigative Site, Bozeman, Montana, United States|Novartis Investigative Site, Grand Island, Nebraska, United States|Novartis Investigative Site, Kearney, Nebraska, United States|Novartis Investigative Site, Kearney, Nebraska, United States|Novartis Investigative Site, Denville, New Jersey, United States|Novartis Investigative Site, Parsippany, New Jersey, United States|Novartis Investigative Site, Cooperstown, New York, United States|Novartis Investigative Site, Greensboro, North Carolina, United States|Novartis Investigative Site, Canton, Ohio, United States|Novartis Investigative Site, Wooster, Ohio, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, United States|Novartis Investigative Site, Columbia, South Carolina, United States|Novartis Investigative Site, Memphis, Tennessee, United States|Novartis Investigative Site, Chesapeake, Virginia, United States|Novartis Investigative Site, Salem, Virginia, United States|Novartis Investigative Site, Bellevue, Washington, United States|Novartis Investigative Site, Kirkland, Washington, United States|Novartis Investigative Site, Mount Vernon, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Sequim, Washington, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Wenatchee, Washington, United States|Novartis Investigative Site, Milwaukee, Wisconsin, United States|Novartis Investigative Site, Capital Federal, Buenos Aires, Argentina|Novartis Investigative Site, Capital Federal, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, La Plata, Buenos Aires, Argentina|Novartis Investigative Site, Cipolletti, Río Negro, Argentina|Novartis Investigative Site, Viedma, Río Negro, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Tucuman, Argentina|Novartis Investigative Site, Garran, Australian Capital Territory, Australia|Novartis Investigative Site, Liverpool, New South Wales, Australia|Novartis Investigative Site, North Sydney, New South Wales, Australia|Novartis Investigative Site, Tweed Heads, New South Wales, Australia|Novartis Investigative Site, Woolloongabba, Queensland, Australia|Novartis Investigative Site, Adelaide, South Australia, Australia|Novartis Investigative Site, Bedford Park, South Australia, Australia|Novartis Investigative Site, Kurralta Park, South Australia, Australia|Novartis Investigative Site, Hobart, Tasmania, Australia|Novartis Investigative Site, Box Hill, Victoria, Australia|Novartis Investigative Site, Fitzroy, Victoria, Australia|Novartis Investigative Site, Wodonga, Victoria, Australia|Novartis Investigative Site, Subiaco, Western Australia, Australia|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Jette, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Kelowna, British Columbia, Canada|Novartis Investigative Site, Surrey, British Columbia, Canada|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Victoria, British Columbia, Canada|Novartis Investigative Site, Winnipeg, Manitoba, Canada|Novartis Investigative Site, Moncton, New Brunswick, Canada|Novartis Investigative Site, Saint John, New Brunswick, Canada|Novartis Investigative Site, Barrie, Ontario, Canada|Novartis Investigative Site, Hamilton, Ontario, Canada|Novartis Investigative Site, Kingston, Ontario, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Newmarket, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Sault Ste. Marie, Ontario, Canada|Novartis Investigative Site, St Catharines, Ontario, Canada|Novartis Investigative Site, Sudbury, Ontario, Canada|Novartis Investigative Site, Thunder Bay, Ontario, Canada|Novartis Investigative Site, Charlottetown, Prince Edward Island, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Regina, Saskatchewan, Canada|Novartis Investigative Site, Saskatoon, Saskatchewan, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Angers, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Caen Cedex 05, France|Novartis Investigative Site, Marseille cedex 9, France|Novartis Investigative Site, Metz-Tessy, France|Novartis Investigative Site, Nantes cedex, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Heidelberg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Stuttgart, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Coburg, Bayern, Germany|Novartis Investigative Site, Eggenfelden, Bayern, Germany|Novartis Investigative Site, Fuerth, Bayern, Germany|Novartis Investigative Site, Regensburg, Bayern, Germany|Novartis Investigative Site, Rosenheim, Bayern, Germany|Novartis Investigative Site, Weiden, Bayern, Germany|Novartis Investigative Site, Fuerstenwalde, Brandenburg, Germany|Novartis Investigative Site, Frankfurt, Hessen, Germany|Novartis Investigative Site, Fulda, Hessen, Germany|Novartis Investigative Site, Lich, Hessen, Germany|Novartis Investigative Site, Goslar, Niedersachsen, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Leer, Niedersachsen, Germany|Novartis Investigative Site, Bielefeld, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Bonn, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Coesfeld, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Porta Westfalica, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Troisdorf, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Velbert, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Witten, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koblenz, Rheinland-Pfalz, Germany|Novartis Investigative Site, Saarbruecken, Saarland, Germany|Novartis Investigative Site, Halle, Sachsen-Anhalt, Germany|Novartis Investigative Site, Dresden, Sachsen, Germany|Novartis Investigative Site, Luebeck, Schleswig-Holstein, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Brandenburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Bangalore, India|Novartis Investigative Site, Nagpur, India|Novartis Investigative Site, Pune, India|Novartis Investigative Site, Beer-Sheva, Israel|Novartis Investigative Site, Holon, Israel|Novartis Investigative Site, Petah-Tikva, Israel|Novartis Investigative Site, Poriya, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Aviano (pn), Friuli-Venezia-Giulia, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Sora (FR), Lazio, Italy|Novartis Investigative Site, Genova, Liguria, Italy|Novartis Investigative Site, Lecce, Puglia, Italy|Novartis Investigative Site, Sassari, Sardegna, Italy|Novartis Investigative Site, Prato (PO), Toscana, Italy|Novartis Investigative Site, Chieti, Italy|Novartis Investigative Site, Aichi, Japan|Novartis Investigative Site, Chiba, Japan|Novartis Investigative Site, Ehime, Japan|Novartis Investigative Site, Kagoshima, Japan|Novartis Investigative Site, Kanagawa, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Saitama, Japan|Novartis Investigative Site, Saitama, Japan|Novartis Investigative Site, Shizuoka, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Songpa-gu, Seoul, Korea, Republic of|Novartis Investigative Site, Cuernavaca, Morelos, Mexico|Novartis Investigative Site, Ciudad Obregon, Sonora, Mexico|Novartis Investigative Site, Mexico City, Mexico|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Delft, Netherlands|Novartis Investigative Site, Dordrecht, Netherlands|Novartis Investigative Site, Maastricht, Netherlands|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Lodz, Poland|Novartis Investigative Site, Olsztyn, Poland|Novartis Investigative Site, Olsztyn, Poland|Novartis Investigative Site, Plock, Poland|Novartis Investigative Site, Rzeszow, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Arkhangelsk, Russian Federation|Novartis Investigative Site, Ivanovo, Russian Federation|Novartis Investigative Site, Kazan, Russian Federation|Novartis Investigative Site, Kirov, Russian Federation|Novartis Investigative Site, Lipetsk, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Stavropol, Russian Federation|Novartis Investigative Site, Ufa,, Russian Federation|Novartis Investigative Site, Ufa, Russian Federation|Novartis Investigative Site, Alcorcon, Spain|Novartis Investigative Site, Alicante, Spain|Novartis Investigative Site, Badalona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Elche, Spain|Novartis Investigative Site, Girona, Spain|Novartis Investigative Site, Jaen, Spain|Novartis Investigative Site, La Coruna, Spain|Novartis Investigative Site, Lugo, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Majadahonda (Madrid), Spain|Novartis Investigative Site, Pozuelo De Alarcon (Madrid), Spain|Novartis Investigative Site, Sevilla, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Tainan County, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiangmai, Thailand|Novartis Investigative Site, Dnepropetrovsk, Ukraine|Novartis Investigative Site, Dnipropetrovsk, Ukraine|Novartis Investigative Site, Lviv, Ukraine|Novartis Investigative Site, Sumy, Ukraine|Novartis Investigative Site, Bournemouth, United Kingdom|Novartis Investigative Site, Brighton, United Kingdom|Novartis Investigative Site, Chelmsford, United Kingdom|Novartis Investigative Site, Cheltenham, United Kingdom|Novartis Investigative Site, Colchester, United Kingdom|Novartis Investigative Site, Cottingham, Hull, United Kingdom|Novartis Investigative Site, Derby, United Kingdom|Novartis Investigative Site, Edmonton, United Kingdom|Novartis Investigative Site, Guildford, United Kingdom|Novartis Investigative Site, Harrogate, United Kingdom|Novartis Investigative Site, Huddersfield, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Newcastle upon Tyne, United Kingdom|Novartis Investigative Site, Norwich, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom|Novartis Investigative Site, Oxford, United Kingdom|Novartis Investigative Site, Poole, Dorset, United Kingdom|Novartis Investigative Site, Sheffield, United Kingdom|Novartis Investigative Site, Shrewsbury, United Kingdom|Novartis Investigative Site, Sutton, United Kingdom|Novartis Investigative Site, Whitchurch, Cardiff, United Kingdom|Novartis Investigative Site, York, United Kingdom",https://ClinicalTrials.gov/show/NCT00667251
51,"Astellas Pharma Global Development, Inc.|Medivation LLC, a wholly owned subsidiary of Pfizer Inc.|Astellas Pharma Inc","A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer","Active, not recruiting",Has Results,HER2 Amplified|Advanced Breast Cancer|Human Epidermal Growth Factor Receptor 2 (HER2),Drug: Enzalutamide|Drug: Trastuzumab,Industry,Interventional,"Site US10051, Anaheim, California, United States|Site US10028, Los Angeles, California, United States|Site US10035, San Francisco, California, United States|Site US10079, Fort Myers, Florida, United States|Site US10074, Gainesville, Florida, United States|Site US10081, Chicago, Illinois, United States|Site US10004, Indianapolis, Indiana, United States|Site US10070, Boston, Massachusetts, United States|Site US10078, Saint Louis, Missouri, United States|Site US10072, Cincinnati, Ohio, United States|Site US10048, Pittsburgh, Pennsylvania, United States|Site US10029, Knoxville, Tennessee, United States|Site US10042, Nashville, Tennessee, United States|Site US10077, Nashville, Tennessee, United States|Site US10076, Fort Worth, Texas, United States|Site US10082, Houston, Texas, United States|Site BE32003, Edegem, Antwerp, Belgium|Site BE32013, Brasschaat, Belgium|Site BE32016, Bruxelles, Belgium|Site BE32001, Charleroi, Belgium|Site BE32009, Leuven, Belgium|Site BE32007, Liege, Belgium|Site CA15022, Ottawa, Ontario, Canada|Site CA15023, Toronto, Ontario, Canada|Site CA15028, Regina, Saskatchewan, Canada|Site CA15026, Saskatoon, Saskatchewan, Canada|Site CA15001, Quebec, Canada|Site IT39005, Meldola, Forli, Italy|Site IT39008, Lecce, Italy|Site IT39002, Milano, Italy|Site IT39003, Milan, Italy|Site IT39001, Sondrio, Italy|Site IT39021, Udine, Italy|Site ES34014, Pozuelo de Alarcon, Madrid, Spain|Site ES34010, Barcelona, Spain|Site ES34013, Madrid, Spain|Site GB44003, Edinburgh, United Kingdom|Site GB44013, Manchester, United Kingdom|Site GB44001, Nottingham, United Kingdom",https://ClinicalTrials.gov/show/NCT02091960
52,"AstraZeneca|Myriad Genetic Laboratories, Inc.|Merck Sharp & Dohme Corp.",Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,"Active, not recruiting",Has Results,"Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity",Drug: OLAPARIB|Drug: Single agent chemotherapy,Industry,Interventional,"Research Site, Birmingham, Alabama, United States|Research Site, Sacramento, California, United States|Research Site, San Francisco, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Littleton, Colorado, United States|Research Site, Hartford, Connecticut, United States|Research Site, Augusta, Georgia, United States|Research Site, Covington, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Detroit, Michigan, United States|Research Site, Albany, New York, United States|Research Site, Mineola, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Columbus, Ohio, United States|Research Site, Springfield, Oregon, United States|Research Site, Abington, Pennsylvania, United States|Research Site, Bedford, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Caba, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Ijui, Brazil|Research Site, Passo Fundo, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Hradec Kralove, Czechia|Research Site, Ostrava-Poruba, Czechia|Research Site, Praha 2, Czechia|Research Site, Zlin, Czechia|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyor, Hungary|Research Site, Afula, Israel|Research Site, Haifa, Israel|Research Site, Holon, Israel|Research Site, Petah Tikva, Israel|Research Site, Ramat Gan, Israel|Research Site, Rehovot, Israel|Research Site, Tel-Aviv, Israel|Research Site, Meldola, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Goyang-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Mexico, Mexico|Research Site, Oaxaca, Mexico|Research Site, Gdańsk, Poland|Research Site, Lublin, Poland|Research Site, Olsztyn, Poland|Research Site, Poznan, Poland|Research Site, Warszawa, Poland|Research Site, Łódź, Poland|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Córdoba, Spain|Research Site, Gerona, Spain|Research Site, Granada, Spain|Research Site, Madrid, Spain",https://ClinicalTrials.gov/show/NCT02282020
53,"AstraZeneca|Myriad Genetic Laboratories, Inc.|Merck Sharp & Dohme Corp.",Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.,"Active, not recruiting",Has Results,Breast Cancer Metastatic|BRCA 1 Gene Mutation|BRCA 2 Gene Mutation,Drug: Olaparib|Drug: Physician's choice chemotherapy,Industry,Interventional,"Research Site, San Diego, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Whittier, California, United States|Research Site, Denver, Colorado, United States|Research Site, New Haven, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Jacksonville, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Plantation, Florida, United States|Research Site, Columbus, Georgia, United States|Research Site, Marietta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Niles, Illinois, United States|Research Site, Wichita, Kansas, United States|Research Site, Lafayette, Louisiana, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Rochester, Minnesota, United States|Research Site, Saint Louis Park, Minnesota, United States|Research Site, Jackson, Mississippi, United States|Research Site, Columbia, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Commack, New York, United States|Research Site, Harrison, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Rockville Centre, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Sayre, Pennsylvania, United States|Research Site, Germantown, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Burlington, Vermont, United States|Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Vratza, Bulgaria|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Dalian, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Harbin, China|Research Site, Nanjing, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Tianjin, China|Research Site, Brno, Czechia|Research Site, Olomouc, Czechia|Research Site, Praha 2, Czechia|Research Site, Caen Cedex, France|Research Site, Montpellier, France|Research Site, Rouen, France|Research Site, Strasbourg Cedex, France|Research Site, Villejuif, France|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Veszprém, Hungary|Research Site, Bologna, Italy|Research Site, Napoli, Italy|Research Site, Padova, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Rozzano, Italy|Research Site, Chuo-ku, Japan|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Suita-shi, Japan|Research Site, Cheongju-si, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Estado de México, Mexico|Research Site, Merida, Mexico|Research Site, Merida, Mexico|Research Site, Mexico, Mexico|Research Site, Mérida, Mexico|Research Site, San Juan del Rio, Mexico|Research Site, Cusco, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, San Borja, Peru|Research Site, Elbląg, Poland|Research Site, Gdańsk, Poland|Research Site, Grzepnica, Poland|Research Site, Tarnobrzeg, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Łódź, Poland|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj Napoca, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Arkhangelsk, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saransk, Russian Federation|Research Site, St-Petersburg, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Barcelona, Spain|Research Site, Córdoba, Spain|Research Site, Granada, Spain|Research Site, Madrid, Spain|Research Site, Majadahonda, Spain|Research Site, Oviedo, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Zaragoza, Spain|Research Site, Bern, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Zürich, Switzerland|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Edirne, Turkey|Research Site, Gaziantep, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Kayseri, Turkey|Research Site, Konya, Turkey|Research Site, Mersin, Turkey|Research Site, Aberdeen, United Kingdom|Research Site, Colchester, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Plymouth, United Kingdom",https://ClinicalTrials.gov/show/NCT02000622
54,Advanced Accelerator Applications,"A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours","Active, not recruiting",Has Results,Carcinoid Tumor of the Small Bowel|Neuroendocrine Tumour,Drug: Octreotide LAR|Drug: 177Lu-DOTA0-Tyr3-Octreotate,Industry,Interventional,"Cedars-Sinai Medical Center Samuel Oschin Cancer Center, Los Angeles, California, United States|Stanford Cancer Center, Palo Alto, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Duke University Medical Center, Durham, North Carolina, United States|Kettering Medical Center, Kettering, Ohio, United States|Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States|Henry-Joyce Cancer Clinic, Nashville, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Excel Diagnostics and Nuclear Oncology Center, Houston, Texas, United States|Digestive Oncology, Leuven Cancer Institute, Leuven, Brabant Flamand, Belgium|Institut Gustave Roussy, Villejuif Cedex, Ile De France, France|Institut Claudius Regaud, Toulouse, Midi-Pyrénées, France|Hotel Dieu/CHU Nantes, Nantes, Pays De La Loire, France|Hôpital la Timone /CHU Marseille, Marseille, Provence-Alpes-Côte d'Azur, France|Centre Hospitalier Lyon-Sud, Lyon, Rhône-Alpes, France|Hôpital Beaujon AP-HP, Clichy Cedex, France|Klinikum Rechts Isar, Nuclear Medicine, Munich, Bayern, Germany|Universitätsmedizin Mainz, Medizinische Klinik I Schwerpunkt Endokrinologie, Mainz, Rheinland-Pfalz, Germany|Zentralklinik Bad Berka, Bad Berka, Thüringen, Germany|Charité, Virchow-Klinikum, Gastroentrology, Hepatology & Endocrinology, Berlin, Germany|Istituto Oncologico Romagnolo per lo Studio dei Tumori, Meldola, Emilia-Romagna, Italy|IEO Istituto Europeo di Oncologia, Milano, Lombardia, Italy|Presidio Osp. Di Macerata, Macerata, Marche, Italy|Azienda Ospedaliero - Universitaria Pisana (Presidio Ospedaliero S. Chiara), Pisa, Toscana, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|Università ""Sapienza"" di Roma, Facoltà di Medicina e Psicologia, Ospedale S. Andrea-Roma, Roma, Italy|Centro Hospitalar e Universitario de Coimbra, Coimbra, Centro, Portugal|Instituto Português de Oncologia, Porto, Norte, Portugal|University Hospital of Bellvitge, Hospitalet de Llobregat (Barcelona), Cataluña, Spain|Ramon y Cajal University Hospital, Madrid, Spain|University of Oxford, Oxford, South East England, United Kingdom|Beatson Oncology Centre, Glasgow, United Kingdom|Royal Free Hospital, London, United Kingdom|Imperial College Healthcare Trust, Hammersmith Hospital, London, United Kingdom|The Christie NHS foundation Trust, Manchester, United Kingdom",https://ClinicalTrials.gov/show/NCT01578239
55,H. Lee Moffitt Cancer Center and Research Institute|Bayer,Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma,"Active, not recruiting",Has Results,Biliary Carcinoma|Gall Bladder Carcinoma|Cholangiocarcinoma|Gastrointestinal Tumor,Drug: Cisplatin|Drug: Gemcitabine|Drug: Copanlisib,Other|Industry,Interventional,"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",https://ClinicalTrials.gov/show/NCT02631590
56,AstraZeneca|Merck Sharp & Dohme Corp.,Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.,"Active, not recruiting",Has Results,Metastatic Castration-resistant Prostate Cancer,Drug: Olaparib|Drug: Placebo|Drug: Abiraterone|Drug: Prednisone or prednisolone,Industry,Interventional,"Research Site, San Diego, California, United States|Research Site, Lake Success, New York, United States|Research Site, Edegem, Belgium|Research Site, Liège, Belgium|Research Site, Wilrijk, Belgium|Research Site, London, Ontario, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Liberec, Czechia|Research Site, Angers, France|Research Site, Dijon, France|Research Site, LYON cedex 08, France|Research Site, Lecce, Italy|Research Site, Mirano, Italy|Research Site, Napoli, Italy|Research Site, Parma, Italy|Research Site, Pisa, Italy|Research Site, Arnhem, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Gdańsk, Poland|Research Site, Warszawa, Poland|Research Site, Moscow, Russian Federation|Research Site, Badalona, Spain|Research Site, Córdoba, Spain|Research Site, Gerona, Spain|Research Site, L'Hospitalet de Llobregat, Spain|Research Site, Madrid, Spain|Research Site, Palma de Mallorca, Spain|Research Site, Valencia, Spain|Research Site, Cardiff, United Kingdom|Research Site, Exeter, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Torquay, United Kingdom|Research Site, Westcliff-on-Sea, United Kingdom",https://ClinicalTrials.gov/show/NCT01972217
57,AstraZeneca,"Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","Active, not recruiting",Has Results,"Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation",Drug: Adavosertib|Drug: Paclitaxel|Drug: Carboplatin|Drug: Gemcitabine|Drug: PLD,Industry,Interventional,"Research Site, Gilbert, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, La Jolla, California, United States|Research Site, Los Angeles, California, United States|Research Site, San Francisco, California, United States|Research Site, Tampa, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Boston, Massachusetts, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Cleveland, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Toronto, Ontario, Canada|Research Site, Amsterdam, Netherlands",https://ClinicalTrials.gov/show/NCT02272790
58,"Genzyme, a Sanofi Company|Sanofi","Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer","Active, not recruiting",Has Results,Differentiated Thyroid Cancer,Drug: Vandetanib (SAR390530)|Drug: Placebo,Industry,Interventional,"Research Site, Little Rock, Arkansas, United States|Research Site, Torrance, California, United States|Research Site, Lexington, Kentucky, United States|Research Site, Boston, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Washington University, Saint Louis, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, New York, New York, United States|Research Site, Portland, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Porto Alegre, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, São Paulo, Brazil|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Chengdu, China|Research Site, Huangzhou, China|Research Site, Shanghai, China|Research Site, Tianjin, China|Research Site, Wuhan, China|Research Site, Olomouc, Czechia|Research Site, Praha, Czechia|Research Site, Odense, Denmark|Research Site, Angers Cedex 01, France|Research Site, Bordeaux Cedex, France|Research Site, Caen Cedex 5, France|Research Site, Paris Cedex 13, France|Research Site, Villejuif Cedex, France|Research Site, Catania, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Siena, Italy|Research Site, Bunkyo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Fukushima-shi, Japan|Research Site, Kashiwa-shi, Japan|Research Site, Kobe-shi, Japan|Research Site, Koto-ku, Japan|Research Site, Matsumoto-shi, Japan|Research Site, Nagasaki-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Niigata-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Yokohama-shi, Japan|Research Site, Gliwice, Poland|Research Site, Kielce, Poland|Research Site, Warszawa, Poland|Research Site, Zgierz, Poland|Research Site, Barnaul, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Barcelona, Spain|Research Site, Gerona, Spain|Research Site, Hospitalet de Llobregat(Barcel, Spain|Research Site, Madrid, Spain|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden",https://ClinicalTrials.gov/show/NCT01876784
59,Novartis Pharmaceuticals|Novartis,Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.,"Active, not recruiting",Has Results,Breast Cancer,Drug: Fulvestrant|Drug: Alpelisib|Drug: Alpelisib placebo,Industry,Interventional,"Ironwood Cancer and Research Centers Chandler 2, Chandler, Arizona, United States|Mayo Clinic - Arizona, Scottsdale, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|Beverly Hills Cancer Center, Beverly Hills, California, United States|City of Hope National Medical Center, Duarte, California, United States|Scripps Clinic SC, La Jolla, California, United States|Kaiser Permanente - California Southern, San Diego, California, United States|University of California San Francisco, San Francisco, California, United States|Florida Cancer Specialists FL Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists - North SC, Saint Petersburg, Florida, United States|Rush University Medical Center Rush Uni Medical Center, Chicago, Illinois, United States|North Shore University Health System NorthShore University, Evanston, Illinois, United States|Edward Cancer Center SC, Naperville, Illinois, United States|Fort Wayne Medical Oncology/Hematology, Inc. Dept.of Fort Wayne Med Onc/Hem, Fort Wayne, Indiana, United States|St. Francis Health Comprehensive Cancer Center SC, Topeka, Kansas, United States|Mercy Medical Center SC-2, Baltimore, Maryland, United States|Massachusetts General Hospital Updated Regulatory, Boston, Massachusetts, United States|Lahey Clinic, Burlington, Massachusetts, United States|Detroit Clinical Research Center, Owosso, Michigan, United States|St. Luke's Cancer Institute SC, Kansas City, Missouri, United States|St Vincent Frontier Cancer Center, Billings, Montana, United States|Rutgers Cancer Institute of New Jersey SC-2, New Brunswick, New Jersey, United States|University Hospitals of Cleveland Seidman Cancer Center SC, Cleveland, Ohio, United States|Good Samaritan Regional Medical Center Good Samaritan Reg Med Ctr, Corvallis, Oregon, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|Greenville Health System SC-2, Greenville, South Carolina, United States|Avera Cancer SC, Sioux Falls, South Dakota, United States|Tennessee Oncology SC-3, Nashville, Tennessee, United States|Texas Oncology PA Dallas Presbyterian Hospital SC-1, Dallas, Texas, United States|El Paso, Texas Oncology, El Paso, Texas, United States|Cancer Therapy and Research Center UT Health Science Center InstituteForDrugDevelopment(4), San Antonio, Texas, United States|US Oncology P A, Tyler, Texas, United States|Virginia Cancer Specialists SC, Fairfax, Virginia, United States|Wenatchee Valley Medical Center SC-2, Wenatchee, Washington, United States|Novartis Investigative Site, Berazategui, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Rio Negro, Viedma, Argentina|Novartis Investigative Site, La Rioja, Argentina|Novartis Investigative Site, Wahroonga, New South Wales, Australia|Novartis Investigative Site, Wooloongabba, Queensland, Australia|Novartis Investigative Site, Elizabeth Vale, South Australia, Australia|Novartis Investigative Site, Melbourne, Victoria, Australia|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Edegem, Antwerpen, Belgium|Novartis Investigative Site, Jette, Brussel, Belgium|Novartis Investigative Site, Sint Niklaas, Vlaams Brabant, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Libramont, Belgium|Novartis Investigative Site, Ottignies, Belgium|Novartis Investigative Site, Verviers, Belgium|Novartis Investigative Site, Natal, RN, Brazil|Novartis Investigative Site, Lajeado, RS, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Jose do Rio Preto, Brazil|Novartis Investigative Site, Sao Paulo, Brazil|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Cambridge, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Temuco, Araucania, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Vina del Mar, Chile|Novartis Investigative Site, Hradec Kralove, Czech Republic, Czechia|Novartis Investigative Site, Praha 4, Czech Republic, Czechia|Novartis Investigative Site, Zlin, Czech Republic, Czechia|Novartis Investigative Site, Prague 8, Czechia|Novartis Investigative Site, Marseille cedex 20, Bouches Du Rhone, France|Novartis Investigative Site, Angers cedex 02, France|Novartis Investigative Site, Avignon Cedex, France|Novartis Investigative Site, Caen Cedex, France|Novartis Investigative Site, Clermont-Ferrand, France|Novartis Investigative Site, Creteil, France|Novartis Investigative Site, La Roche sur Yon cedex 9, France|Novartis Investigative Site, Le Chesnay, France|Novartis Investigative Site, Levallois-Perret, France|Novartis Investigative Site, Lyon Cedex 08, France|Novartis Investigative Site, Montpellier, France|Novartis Investigative Site, Nimes, France|Novartis Investigative Site, Rouen Cedex 1, France|Novartis Investigative Site, Saint-Herblain Cédex, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Recklinghausen, North Rhine-westphalia, Germany|Novartis Investigative Site, Leipzig, Sachsen, Germany|Novartis Investigative Site, Luebeck, Schleswig-holstein, Germany|Novartis Investigative Site, Aschaffenburg, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Friedrichshafen, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Homburg, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Potsdam, Germany|Novartis Investigative Site, Rostock, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Velbert, Germany|Novartis Investigative Site, Thessaloniki, GR, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Nyiregyhaza, Hungary|Novartis Investigative Site, Szekszard, Hungary|Novartis Investigative Site, Vijayawada, Andhra Pradesh, India|Novartis Investigative Site, Nagpur - Maharashtra, Maharashtra, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Beer-Sheva, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Chieti, CH, Italy|Novartis Investigative Site, Meldola, FC, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Pontedera, PI, Italy|Novartis Investigative Site, Aviano, PN, Italy|Novartis Investigative Site, Rionero in Vulture, PZ, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Sassari, SS, Italy|Novartis Investigative Site, Savona, SV, Italy|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Negrar, VR, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Matsuyama, Ehime, Japan|Novartis Investigative Site, Maebashi city, Gunma, Japan|Novartis Investigative Site, Sapporo-city, Hokkaido, Japan|Novartis Investigative Site, Akashi, Hyogo, Japan|Novartis Investigative Site, Kagoshima-city, Kagoshima, Japan|Novartis Investigative Site, Isehara, Kanagawa, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, Japan|Novartis Investigative Site, Kumamoto City, Kumamoto, Japan|Novartis Investigative Site, Osaka-city, Osaka, Japan|Novartis Investigative Site, Osaka-city, Osaka, Japan|Novartis Investigative Site, Kitaadachi-gun, Saitama, Japan|Novartis Investigative Site, Chuo ku, Tokyo, Japan|Novartis Investigative Site, Minato ku, Tokyo, Japan|Novartis Investigative Site, Bundang Gu, Gyeonggi Do, Korea, Republic of|Novartis Investigative Site, Gyeonggi do, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Ashrafieh, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Saida, Lebanon|Novartis Investigative Site, Monterrey, N.L., Monterrey, Mexico|Novartis Investigative Site, San Luis Potosi, Mexico|Novartis Investigative Site, Venray, CE, Netherlands|Novartis Investigative Site, Terneuzen, Netherlands|Novartis Investigative Site, San Borja, Lima, Peru|Novartis Investigative Site, Surquillo, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Floresti, Cluj, Romania|Novartis Investigative Site, Craiova, Dolj, Romania|Novartis Investigative Site, Iasi, Romania|Novartis Investigative Site, Arkhangelsk, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Jerez, Cadiz, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Alicante, Comunidad Valenciana, Spain|Novartis Investigative Site, Castellon, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Badajoz, Extremadura, Spain|Novartis Investigative Site, Caceres, Extremadura, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, Palma De Mallorca, Islas Baleares, Spain|Novartis Investigative Site, Pozuelo de Alarcon, Madrid, Spain|Novartis Investigative Site, El Palmar, Murcia, Spain|Novartis Investigative Site, La Laguna, Santa Cruz De Tenerife, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Gavle, Sweden|Novartis Investigative Site, Oerebro, Sweden|Novartis Investigative Site, Vasteras, Sweden|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Bangkok, THA, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Plymouth, Devon, United Kingdom|Novartis Investigative Site, Leicester, United Kingdom|Novartis Investigative Site, London, United Kingdom",https://ClinicalTrials.gov/show/NCT02437318
60,"Aragon Pharmaceuticals, Inc.",A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer,"Active, not recruiting",Has Results,Prostatic Neoplasms,Drug: Apalutamide|Drug: Placebo,Industry,Interventional,"Birmingham, Alabama, United States|Anchorage, Alaska, United States|Chandler, Arizona, United States|Tucson, Arizona, United States|Duarte, California, United States|Fullerton, California, United States|Laguna Woods, California, United States|Los Angeles, California, United States|Orange, California, United States|Roseville, California, United States|Sacramento, California, United States|San Bernardino, California, United States|San Diego, California, United States|San Francisco, California, United States|Santa Monica, California, United States|Sherman Oaks, California, United States|Stanford, California, United States|Tarzana, California, United States|Torrance, California, United States|Denver, Colorado, United States|Englewood, Colorado, United States|Glenwood Springs, Colorado, United States|Grand Junction, Colorado, United States|Washington, District of Columbia, United States|Aventura, Florida, United States|Boca Raton, Florida, United States|Bradenton, Florida, United States|Daytona Beach, Florida, United States|Fort Myers, Florida, United States|Hialeah, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|New Port Richey, Florida, United States|Orlando, Florida, United States|Saint Petersburg, Florida, United States|Sarasota, Florida, United States|Wellington, Florida, United States|Meridian, Idaho, United States|Chicago, Illinois, United States|Decatur, Illinois, United States|Maywood, Illinois, United States|Melrose Park, Illinois, United States|Carmel, Indiana, United States|Jeffersonville, Indiana, United States|Muncie, Indiana, United States|West Des Moines, Iowa, United States|Westwood, Kansas, United States|Wichita, Kansas, United States|Metairie, Louisiana, United States|New Orleans, Louisiana, United States|Annapolis, Maryland, United States|Baltimore, Maryland, United States|Rockville, Maryland, United States|Towson, Maryland, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Lansing, Michigan, United States|Minneapolis, Michigan, United States|Royal Oak, Michigan, United States|Duluth, Minnesota, United States|Bay Saint Louis, Mississippi, United States|Southaven, Mississippi, United States|Kansas City, Missouri, United States|Missoula, Montana, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Hooksett, New Hampshire, United States|Hackensack, New Jersey, United States|Lawrenceville, New Jersey, United States|Morristown, New Jersey, United States|Mount Laurel, New Jersey, United States|New Brunswick, New Jersey, United States|Voorhees, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Bronx, New York, United States|Mineola, New York, United States|New York, New York, United States|Oneida, New York, United States|Poughkeepsie, New York, United States|Syracuse, New York, United States|Concord, North Carolina, United States|Greensboro, North Carolina, United States|Greenville, North Carolina, United States|Salisbury, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Middleburg Heights, Ohio, United States|Middletown, Ohio, United States|Bend, Oregon, United States|Portland, Oregon, United States|Tualatin, Oregon, United States|Bala-Cynwyd, Pennsylvania, United States|Bryn Mawr, Pennsylvania, United States|Lancaster, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Warwick, Rhode Island, United States|Charleston, South Carolina, United States|Greenville, South Carolina, United States|Myrtle Beach, South Carolina, United States|West Columbia, South Carolina, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Abilene, Texas, United States|Amarillo, Texas, United States|Dallas, Texas, United States|Fort Sam Houston, Texas, United States|Houston, Texas, United States|McAllen, Texas, United States|San Antonio, Texas, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Virginia Beach, Virginia, United States|Burien, Washington, United States|Edmonds, Washington, United States|Seattle, Washington, United States|Tacoma, Washington, United States|Green Bay, Wisconsin, United States|Madison, Wisconsin, United States|Milwaukee, Wisconsin, United States|Adelaide, Australia|Box Hill, Australia|Camperdown, Australia|Darlinghurst, Australia|Geelong, Australia|Gosford, Australia|Hobart, Australia|Kogarah, Australia|Liverpool, Australia|Melbourne, Australia|Nedlands, Australia|Parkville, Australia|South Woodville, Australia|Southport, Australia|Sydney, Australia|Tweed Heads, Australia|Wollongong, Australia|Graz, Austria|Innsbruck, Austria|Linz, Austria|Wien, Austria|Brussels, Belgium|Brussel, Belgium|Gent, Belgium|Kortrijk, Belgium|Leuven, Belgium|Liege, Belgium|Ottignies, Belgium|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Abbotsford, British Columbia, Canada|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|Moncton, New Brunswick, Canada|Saint John, New Brunswick, Canada|Halifax, Nova Scotia, Canada|Barrie, Ontario, Canada|Brampton, Ontario, Canada|Brantford, Ontario, Canada|Hamilton, Ontario, Canada|London, Ontario, Canada|North York, Ontario, Canada|Oakville, Ontario, Canada|Ottawa, Ontario, Canada|Owen Sound, Ontario, Canada|Toronto, Ontario, Canada|Gatineau, Quebec, Canada|Granby, Quebec, Canada|Greenfield Park, Quebec, Canada|Laval, Quebec, Canada|Montreal, Quebec, Canada|Pointe-Claire, Quebec, Canada|Sherbrooke, Quebec, Canada|Kelowna, Canada|Montrel, Canada|Quebec, Canada|Toronto, Canada|Liberec, Czechia|Olomouc, Czechia|Opava, Czechia|Plzen, Czechia|Praha 2, Czechia|Praha 4, Czechia|Praha 5, Czechia|Praha, Czechia|Aalborg C, Denmark|Copenhagen, Denmark|Odense N/a, Denmark|Roskilde, Denmark|Helsinki, Finland|Oulu, Finland|Seinäjoki, Finland|Tampere, Finland|Turku, Finland|Angers Cedex 9, France|Angers, France|Besancon, France|Bordeaux, France|Caen Cédex 05, France|Clermont Ferrand, France|Hyers, France|La Roche sur Yon Cedex 9, France|Le Mans, France|Lille Cedex N/a, France|Lyon, France|Marseille cedex 5, France|Marseille Cedex 9, France|Nice Cedex 2, France|Nîmes Cedex 9, France|Paris 75, France|Paris Cedex 15, France|Paris, France|Reims Cedex, France|Rennes Cedex, France|Rouen, France|Saint Gregoire, France|Saint Herblain, France|Strasbourg, France|Suresnes, France|Tours, Cedex 9, France|Vandoeuvre Les Nancy Cedex, France|Aachen, Germany|Bergisch Gladbach, Germany|Berlin, Germany|Braunschweig, Germany|Duisburg, Germany|Emmendingen, Germany|Frankfurt / Main, Germany|Greifswald, Germany|Göttingen, Germany|Hamburg, Germany|Hannover, Germany|Heidelberg, Germany|Heinsberg, Germany|Homburg/Saar, Germany|Jena, Germany|Kiel, Germany|Kirchheim unter Teck, Germany|Köln, Germany|Magdeburg, Germany|Mainz, Germany|Mannheim, Germany|Marburg, Germany|Mettmann, Germany|Müllheim, Germany|Münster, Germany|Nuertingen, Germany|Regensburg, Germany|Rostock, Germany|Tübingen, Germany|Weiden, Germany|Wilhelmshaven, Germany|Wuppertan, Germany|Zirndorf, Germany|Budapest, Hungary|Miskolc, Hungary|Nyíregyhá, Hungary|Sopron, Hungary|Szentes, Hungary|Haifa, Israel|Jeruselem, Israel|Kfar-Saba, Israel|Petah-Tikva, Israel|Ramat Gan, Israel|Tel Aviv, Israel|Zerifin, Israel|Akita, Japan|Fukuoka-shi, Japan|Gifu, Japan|Hakodate, Japan|Hiroshima, Japan|Hokkaido, Japan|Kanazawa, Japan|Kashiwa, Japan|Kita-Gun, Japan|Kobe, Japan|Koshigaya, Japan|Kumamoto, Japan|Kurume, Japan|Matsuyama, Japan|Nagano, Japan|Nagasaki, Japan|Nagoya, Japan|Niigata, Japan|Osaka-Sayama, Japan|Osaka, Japan|Sagamihara, Japan|Sakura, Japan|Sapporo, Japan|Shinjuku-Ku, Japan|Tokushima, Japan|Tokyo, Japan|Ube, Japan|Wakayama, Japan|Yokohama, Japan|Daegu, Korea, Republic of|Gwangju-si, Korea, Republic of|Pusan, Korea, Republic of|Seongnam, Korea, Republic of|Seoul, Korea, Republic of|Alkmaar, Netherlands|Eindhoven, Netherlands|Hoofddorp, Netherlands|Leidschendam, Netherlands|Nijmegen, Netherlands|Rotterdam, Netherlands|Auckland, New Zealand|Christchurch, New Zealand|Hamilton, New Zealand|Nelson City, New Zealand|Tauranga, New Zealand|Whangarei, New Zealand|Nordbyhagen, Norway|Bialystok, Poland|Bydgoszcz, Poland|Gdansk, Poland|Kutno, Poland|Lodz, Poland|Poznan, Poland|Szczecin, Poland|Torun, Poland|Warszawa, Poland|Wroclaw, Poland|Baia Mare, Romania|Brasov, Romania|Bucharest, Romania|Cluj- Napoca, Romania|Targu Mures, Romania|Barnaul, Russian Federation|Ekaterinburg, Russian Federation|Ivanovo, Russian Federation|Moscow, Russian Federation|Obninsk, Kaluga Region, Russian Federation|Omsk, Russian Federation|Ryazan, Russian Federation|Saint Petersburg, Russian Federation|St. Petersburg, Russian Federation|Ufa, Russian Federation|Yaroslavl, Russian Federation|Banska Bystrica, Slovakia|Bratislava, Slovakia|Martin, Slovakia|Nitra, Slovakia|Trenčín, Slovakia|Badalona, Spain|Barcelona, Spain|Castellon, Spain|Coruña, Spain|Girona, Spain|Guadalajara, Spain|Jerez de la Frontera, Spain|Las Palmas De Gran Canaria, Spain|Madrid, Spain|Murcia, Spain|Málaga, Spain|Palma de Mallorca, Spain|Pamplona, Spain|Sabadell, Spain|Salamanca, Spain|San Sebastian de los Reyes, Spain|Santander, Spain|Sevilla N/a, Spain|Sevilla, Spain|Valencia, Spain|Goteborg, Sweden|Stockholm, Sweden|Umea, Sweden|Uppsala, Sweden|Örebro, Sweden|Kaohsiung, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Taoyuan County, Taiwan|Blackburn, United Kingdom|Cambridge, United Kingdom|Cardiff, United Kingdom|Dundee, United Kingdom|Glasgow, United Kingdom|Guildford, United Kingdom|Leeds, United Kingdom|London, United Kingdom|Maidstone, United Kingdom|Nottingham, United Kingdom|Plymouth, United Kingdom|Southampton, United Kingdom|Surrey, United Kingdom|Swansea, United Kingdom|Wirral, United Kingdom|Wolverhampton, United Kingdom",https://ClinicalTrials.gov/show/NCT01946204
61,Pfizer,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,"Active, not recruiting",Has Results,Kidney Neoplasms,Drug: Axitinib (AG-013736)|Drug: Sorafenib,Industry,Interventional,"Advanced Medical Specialties, Miami, Florida, United States|Advanced Medical Specialties, Miami, Florida, United States|Illinois Cancer Specialists, Arlington Heights, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Indiana University Health Central Indiana Cancer Centers, Carmel, Indiana, United States|Indiana University Health Central Indiana Cancer Centers, Fishers, Indiana, United States|Indiana University Health Central Indiana Cancer Centers, Greenfield, Indiana, United States|Indiana University Health Central Indiana Cancer Centers, Indianapolis, Indiana, United States|Indiana University Health Central Indiana Cancer Centers, Indianapolis, Indiana, United States|Missouri Cancer Associates, Columbia, Missouri, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|US Oncology West Region, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Hematology-Oncology Associates of Northern NJ, PA, Morristown, New Jersey, United States|Hematology-Oncology Associates of Northern NJ, PA, Parsippany, New Jersey, United States|New York Oncology Hematology, PC, Albany, New York, United States|New York Oncology Hematology, PC, Albany, New York, United States|New York Oncology Hematology, PC, Latham, New York, United States|New York Oncology Hematology, PC, Rexford, New York, United States|New York Oncology Hematology, PC, Troy, New York, United States|Raleigh Hematology Oncology Associates, Cary, North Carolina, United States|Raleigh Hematology Oncology Associates, Raleigh, North Carolina, United States|Raleigh Hematology Oncology Associates, Raleigh, North Carolina, United States|Northwest Cancer Specialists, PC, Portland, Oregon, United States|Northwest Cancer Specialists, PC, Portland, Oregon, United States|Northwest Cancer Specialists, PC, Portland, Oregon, United States|Northwest Cancer Specialists, PC, Tualatin, Oregon, United States|Penn State Milton S. Hershey Medical Center, Penn State Cancer Institute, Hershey, Pennsylvania, United States|Medical University of South Carolina University Hospital, Charleston, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Texas Oncology- Amarillo, Amarillo, Texas, United States|Texas Oncology-Beaumont, Mamie McFaddin Ward Cancer Center, Beaumont, Texas, United States|Texas Oncology- Bedford, Bedford, Texas, United States|Texas Oncology- Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology- Fort Worth 12th Avenue, Fort Worth, Texas, United States|Texas Oncology- Southwest Fort Worth, Fort Worth, Texas, United States|Investigational Products Center (IPC), Fort Worth, Texas, United States|Investigational Products Center (lPC), Fort Worth, Texas, United States|US Oncology Research and Clinical Pharmacy, Fort Worth, Texas, United States|Texas Oncology - Grapevine, Grapevine, Texas, United States|Cancer Care Centers of South Texas, Kerrville, Texas, United States|Texas Oncology- McAllen South Second Street, McAllen, Texas, United States|Texas Oncology- Midland Allison Cancer Center, Midland, Texas, United States|Cancer Care Centers of South Texas, San Antonio, Texas, United States|Cancer Care Centers of South Texas, San Antonio, Texas, United States|Texas Oncology-Deke Slayton Cancer Center, Webster, Texas, United States|Texas Oncology-Weslaco, Weslaco, Texas, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Christiansburg, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Low Moor, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Roanoke, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Salem, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Wytheville, Virginia, United States|Northwest Cancer Specialists, PC, Vancouver, Washington, United States|Northwest Cancer Specialists, PC, Vancouver, Washington, United States|Wenatchee Valley Medical Center, Wenatchee, Washington, United States|Clinic of Oncology, Banja Luka, Bosnia and Herzegovina|Institute of Oncology, University Hospital Center Sarajevo, Sarajevo, Bosnia and Herzegovina|University Clinical Center Tuzla, Clinic for Oncology, Hematology and Radiotherapy, Tuzla, Bosnia and Herzegovina|Spetsializirana Bolnitsa za Aktivno Lechenie po Onkologiya, EAD, Klinika po Himioterapiya, Sofia, Bulgaria|SBALOZ D-r Marko Markov-Varna, Varna, Bulgaria|Instituto Clinico Oncologico del Sur, Temuco, Cautin, Chile|Instituto Clinico Oncologico del Sur, Temuco, IX Region, Chile|Instituto de Terapias Oncologicas Providencia, Providencia, Santiago, Chile|Private Office, Santiago, Chile|Cancer Institute and Hospital ,Chinese Academy of Medical Sciences, Beijing, Beijing, China|Chinese PLA General Hospital, Haidian District, Beijing, China|The Fuzhou General Hospital, PLA Nanjing Military Area Command, Fuzhou, Fujian, China|Nanfang Hospital, Guangzhou, Guang DONG, China|Urology Department, Sun Yet-Sen University Cancer Center, Guangzhou, Guangdong, China|Nanjing Bayi Hospital, Nanjing, Jiangsu, China|The Oncology Department, Jiangsu Province Hospital, Nanjing, Jiangsu, China|Jilin Provincial Cancer Hospital, Changchun, Jilin, China|Urology Department, 1st Hospital of China Medical University, Shen Yang, LIAO NING, China|Xijing Hospital, The Fourth Military Medical University,Oncology Department, Xi'an, Shaanxi, China|Urology Department, Renji Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Sir Run Run Shaw Hospital of College of Medicine of Zhejiang University, Center for Oncology, Hangzhou, Zhejiang, China|Department of Urology,Peking University First Hospital, Beijing, China|Beijing Cancer Hospital/Department of Renal Cancer and Melanoma, Beijing, China|South-Western Hospital, 3rd Military Medical University, Chongqing, China|Jiangsu Cancer Hospital, Nanjing, China|Fudan University, Cancer Hospital, Department of Urology, Shanghai, China|Tianjin Oncology Hospital,biology treatment department, Tianjin, China|Urology Department, The Second Hospital of Tianjin Medical University, Tianjin, China|BIBI General Hospital and Cancer Centre,, Hyderabad, Andhra Pradesh, India|Chinmaya Mission Hospital, Bangalore, Karnataka, India|Sri Venkateshwara Hospital, Bangalore, Karnataka, India|NU Hospitals, Bangalore, Karnataka, India|Cancer Care Clinic and Hospitals, Nagpur, Maharashtra, India|Shatabdi Superspeciality Hospital, Nashik, Maharashtra, India|Curie Manavata Cancer Centre, Nashik, Maharashtra, India|Deenanath Mangeshkar Hospital and Research Centre, Pune, Maharashtra, India|Sahyadri Speciality Hospital, Pune, Maharashtra, India|Shettys hospital, Bangalore, India|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, DF, Mexico|Hospital General de Mexico O.D., Mexico City, Distrito Federal, Mexico|Centro Hemato-Oncologico Privado, Toluca, Estado DE Mexico, Mexico|Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico|Oaxaca Site Management Organization, Oaxaca, Mexico|Rm. 3227 Doctors Clinic, Annex II Bldg., National Kidney & Transplant Institute, Quezon City, Diliman, Philippines|St. Lukes Medical Center, Quezon City, Metro Manila, Philippines|University of the East Ramon Magsaysay Memorial Medical Center, Quezon City, Metro Manila, Philippines|Makati Medical Center, Makati City, Philippines|Room 805, Committee on Research Room, Manila Doctors Hospital, Manila, Philippines|Oncomed SRL, Timisoara, JUD. Timis, Romania|Institutul Oncologic ""Prof.Dr.I.Chiricuta"" Cluj-Napoca, Cluj-Napoca, Romania|Institutul Oncologic ''Prof.Dr. I. Chiricuta'' Cluj Napoca, Cluj-Napoca, Romania|Moscow State Healthcare Institution Oncology Clinical Dispensary #1, Moscow, Russian Federation|P.A. Herzen Moscow Oncology Research Institute,, Moscow, Russian Federation|GBU RO ""Ryazan Regional Clinical Oncology Dispensary"", Ryazan, Russian Federation|FGBOU VO ""Ryazan State Medical University named after academician I.P.Pavlov"", Ryazan, Russian Federation|FGBOU VO ""First Saint-Petersburg State Medical University n.a. I.P.Pavlov"", Saint-Petersburg, Russian Federation|Republican Clinical Oncology Dispensary of the Ministry of Health of Bashkortostan Republic, Ufa, Russian Federation|GVI Oncology, Port Elizabeth, South Africa|Taichung Veterans General Hospital, Taichung, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|MI Dnipropetrovsk Regional Clinical Hospital n a I.I. Mechnikov, Dnipropetrovsk, Ukraine|Kharkiv Regional Clinical Center of Urology and Nephrology, Kharkiv, Ukraine|State Enterprise ""Institute of Urology of NAMS of Ukraine"", Kyiv, Ukraine|Komunalne nekomertsiine pidpryiemstvo Lvivskoi oblasnoi rady ""Lvivskyi onkolohichnyi rehionalnyi li, Lviv, Ukraine|SI ""Zaporizhzhya Medical Academy of Postgraduate Education of the Ministry of Health of Ukraine"", Zaporizhzhya, Ukraine",https://ClinicalTrials.gov/show/NCT00920816
62,Novartis Pharmaceuticals|Novartis,Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.,"Active, not recruiting",Has Results,Advanced Breast Cancer,Drug: Ribociclib|Drug: fulvestrant|Drug: Ribociclib placebo,Industry,Interventional,"Southern Cancer Center PC SC-2, Mobile, Alabama, United States|Ironwood Cancer and Research Centers SC-2, Chandler, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|UCLA Medical Center, Los Angeles, California, United States|Central Coast Medical Oncology Corporation SC, Santa Maria, California, United States|St Joseph Heritage Healthcare, Santa Rosa, California, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Florida Cancer Research Institute Dept of Oncology, Davie, Florida, United States|Florida Hospital Cancer Institute SC, Orlando, Florida, United States|UF Health Cancer Center at Orlando Health, Orlando, Florida, United States|John D Archbold Memorial Hospital Main, Thomasville, Georgia, United States|Moanalua Medical Center. Attn: Oncology Dept SC, Honolulu, Hawaii, United States|Oncology Specialists, SC Advocate Medical Group-Niles, Park Ridge, Illinois, United States|Jackson Oncology Associates SC, Jackson, Mississippi, United States|Southeast Nebraska Oncology SC, Lincoln, Nebraska, United States|Meridian Health Systems Regulatory, Neptune, New Jersey, United States|University of New Mexico Cancer Center SC, Albuquerque, New Mexico, United States|CR Wood Cancer Center SC, Glens Falls, New York, United States|Clinical Research Alliance, Lake Success, New York, United States|NYU Langone Medical Center CV Research center NYU Langone Medical Center, New York, New York, United States|Genesis Cancer Services SC, Zanesville, Ohio, United States|St. Charles Cancer Center SC, Bend, Oregon, United States|Penn State University Milton S Hershey Medical Center SC, Hershey, Pennsylvania, United States|Millennium Oncology SC, Houston, Texas, United States|Northern Utah Cancer Associates SC, Ogden, Utah, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Providence Regional Cancer System SC, Lacey, Washington, United States|Virginia Mason Medical Center-Oncology SC, Seattle, Washington, United States|Novartis Investigative Site, Buenos Aires, Caba, Argentina|Novartis Investigative Site, St Leonards, New South Wales, Australia|Novartis Investigative Site, Herston, Queensland, Australia|Novartis Investigative Site, East Melbourne, Victoria, Australia|Novartis Investigative Site, Nedlands, Western Australia, Australia|Novartis Investigative Site, Innsbruck, Tyrol, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Aalst, Belgium|Novartis Investigative Site, Charleroi, Belgium|Novartis Investigative Site, Hasselt, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Surrey, British Columbia, Canada|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Victoria, British Columbia, Canada|Novartis Investigative Site, Moncton, New Brunswick, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Brampton, Ontario, Canada|Novartis Investigative Site, Kingston, Ontario, Canada|Novartis Investigative Site, Newmarket, Ontario, Canada|Novartis Investigative Site, Montréal, Quebec, Canada|Novartis Investigative Site, Rimouski, Quebec, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, Trois Rivieres, Quebec, Canada|Novartis Investigative Site, Regina, Saskatchewan, Canada|Novartis Investigative Site, Bogota, Colombia|Novartis Investigative Site, Monteria, Colombia|Novartis Investigative Site, Brno Bohunice, Czech Republic, Czechia|Novartis Investigative Site, Liberec, Czech Republic, Czechia|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, Prague 8, Czechia|Novartis Investigative Site, Praha, Czechia|Novartis Investigative Site, Aalborg, Denmark|Novartis Investigative Site, Aarhus, Denmark|Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Herlev, Denmark|Novartis Investigative Site, Odense C, Denmark|Novartis Investigative Site, Vejle, Denmark|Novartis Investigative Site, Strasbourg Cedex, Cedex, France|Novartis Investigative Site, Saint-Cloud, Hauts De Seine, France|Novartis Investigative Site, Reims Cedex, Marne, France|Novartis Investigative Site, Besancon Cedex, France|Novartis Investigative Site, Bordeaux Cedex, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Brest, France|Novartis Investigative Site, Creteil, France|Novartis Investigative Site, Le Mans Cedex, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Limoges, France|Novartis Investigative Site, Paris Cedex 13, France|Novartis Investigative Site, Pierre Benite, France|Novartis Investigative Site, Saint-gregoire, France|Novartis Investigative Site, Thonon-les-Bains Cedex, France|Novartis Investigative Site, Toulon La Seyne Sur Mer, France|Novartis Investigative Site, Langen, Hessen, Germany|Novartis Investigative Site, Georgsmarienhuette, Lower Saxony, Germany|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bielefeld, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Fuerth, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Lubeck, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Mühlhausen, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Ravensburg, Germany|Novartis Investigative Site, Saarbruecken, Germany|Novartis Investigative Site, Troisdorf, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Velbert, Germany|Novartis Investigative Site, Weiden, Germany|Novartis Investigative Site, Kecskemet, Bacs Kiskun, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Szolnok, Hungary|Novartis Investigative Site, L'Aquila, AQ, Italy|Novartis Investigative Site, Brescia, BS, Italy|Novartis Investigative Site, Catania, CT, Italy|Novartis Investigative Site, Lecce, LE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Pontedera, PI, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Amman, Jordan|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Ashrafieh, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Johor Bahru, Johor, Malaysia|Novartis Investigative Site, Kuching, Sarawak, Malaysia|Novartis Investigative Site, Oaxaca, Mexico|Novartis Investigative Site, Amersfoort, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Breda, Netherlands|Novartis Investigative Site, Den Haag, Netherlands|Novartis Investigative Site, Deventer, Netherlands|Novartis Investigative Site, Enschede, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Hoofddorp, Netherlands|Novartis Investigative Site, Maastricht, Netherlands|Novartis Investigative Site, Nieuwegein, Netherlands|Novartis Investigative Site, Roermond, Netherlands|Novartis Investigative Site, Sittard-Geleen, Netherlands|Novartis Investigative Site, Tilburg, Netherlands|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Konin, Poland|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Guimaraes, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Arkhangelsk, Russian Federation|Novartis Investigative Site, Tambov, Russian Federation|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Granada, Andalucia, Spain|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Sant Joan Despi, Barcelona, Spain|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, A Coruna, Galicia, Spain|Novartis Investigative Site, Alcorcon, Madrid, Spain|Novartis Investigative Site, San Sebastian de los Reyes, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Eskilstuna, Sweden|Novartis Investigative Site, Sundsvall, Sweden|Novartis Investigative Site, Umea, Sweden|Novartis Investigative Site, Vaxjo, Sweden|Novartis Investigative Site, Aarau, Switzerland|Novartis Investigative Site, Basel, Switzerland|Novartis Investigative Site, Zuerich, Switzerland|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Plymouth, Devon, United Kingdom|Novartis Investigative Site, Newcastle Upon Tyne, United Kingdom",https://ClinicalTrials.gov/show/NCT02422615
63,"Tesaro, Inc.|European Network of Gynaecological Oncological Trial Groups (ENGOT)|Myriad Genetics, Inc.|US Oncology Research|Sarah Cannon|Cooperative Ovarian Cancer Group (COGI)|Facing Our Risk of Cancer Empowered",A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer,"Active, not recruiting",Has Results,Ovarian Neoplasms|Platinum Sensitive Ovarian Cancer,Drug: Active comparator: Niraparib|Drug: placebo,Industry|Other,Interventional,"GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, La Jolla, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, San Francisco, California, United States|GSK Investigational Site, Stanford, California, United States|GSK Investigational Site, New Haven, Connecticut, United States|GSK Investigational Site, Sarasota, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Burlington, Massachusetts, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Rochester, Minnesota, United States|GSK Investigational Site, Morristown, New Jersey, United States|GSK Investigational Site, Farmington, New Mexico, United States|GSK Investigational Site, Lake Success, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Toledo, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Abington, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Providence, Rhode Island, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Fort Worth, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, The Woodlands, Texas, United States|GSK Investigational Site, Vancouver, Washington, United States|GSK Investigational Site, Graz, Austria|GSK Investigational Site, Innsbruck, Austria|GSK Investigational Site, Wien, Austria|GSK Investigational Site, Edegem, Belgium|GSK Investigational Site, Kortrijk, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Liège, Belgium|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Kelowna, British Columbia, Canada|GSK Investigational Site, Vancouver, British Columbia, Canada|GSK Investigational Site, Hamilton, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada|GSK Investigational Site, Aalborg, Denmark|GSK Investigational Site, Copenhagen, Denmark|GSK Investigational Site, Herlev, Denmark|GSK Investigational Site, Odense, Denmark|GSK Investigational Site, Besançon Cedex, France|GSK Investigational Site, Lille Cedex, France|GSK Investigational Site, Montpellier Cedex 5, France|GSK Investigational Site, Nice, France|GSK Investigational Site, Saint Brieuc, France|GSK Investigational Site, Saint-Herblain cedex, France|GSK Investigational Site, Strasbourg Cedex, France|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Goettingen, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Duesseldorf, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Kiel, Schleswig-Holstein, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Miskolc, Hungary|GSK Investigational Site, Szolnok, Hungary|GSK Investigational Site, Haifa, Israel|GSK Investigational Site, Holon, Israel|GSK Investigational Site, Jerusalem, Israel|GSK Investigational Site, Jerusalem, Israel|GSK Investigational Site, Kfar-Saba, Israel|GSK Investigational Site, Rehovot, Israel|GSK Investigational Site, Tel Hashomer, Israel|GSK Investigational Site, Tel-Aviv, Israel|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Brescia, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Monza, Lombardia, Italy|GSK Investigational Site, Catania, Sicilia, Italy|GSK Investigational Site, Pisa, Toscana, Italy|GSK Investigational Site, Aviano (pn), Veneto, Italy|GSK Investigational Site, MIlano, Italy|GSK Investigational Site, Bergen, Norway|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Bialystok, Poland|GSK Investigational Site, Gdansk, Poland|GSK Investigational Site, Gdansk, Poland|GSK Investigational Site, Lodz, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Oviedo, Asturias, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Palma de Mallorca, Spain|GSK Investigational Site, Linköping, Sweden|GSK Investigational Site, Lund, Sweden|GSK Investigational Site, Stockholm, Sweden|GSK Investigational Site, Rhyl, Flintshire, United Kingdom|GSK Investigational Site, Nottingham, Nottinghamshire, United Kingdom|GSK Investigational Site, Yeovil, Somerset, United Kingdom|GSK Investigational Site, Sutton, Surrey, United Kingdom|GSK Investigational Site, Birmingham, West Midlands, United Kingdom|GSK Investigational Site, Bebington, Wirral, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Maidstone, United Kingdom|GSK Investigational Site, Taunton, United Kingdom",https://ClinicalTrials.gov/show/NCT01847274
64,Pfizer,A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2),"Active, not recruiting",Has Results,Breast Neoplasms,Drug: PD-0332991|Drug: Letrozole|Drug: Placebo,Industry,Interventional,"Southern California Permanente Medical Group, Bellflower, California, United States|Beverly Hills Cancer Center, Beverly Hills, California, United States|St. Joseph Heritage Healthcare, Fullerton, California, United States|Los Angeles Hematology/Oncology Medical Group, Glendale, California, United States|UCLA Hematology/ Oncology- Irvine, Irvine, California, United States|UCLA Hematology Oncology- Laguna Hills, Laguna Hills, California, United States|Los Angeles Hematology/Oncology Medical Group, Los Angeles, California, United States|Southern California Permanente Medical Group, Los Angeles, California, United States|Translational Research Management, Los Angeles, California, United States|Drug Management Only: UCLA West Medical Pharmacy, Attn: Steven L Wong, Pharm.D., Los Angeles, California, United States|UCLA West Medical Pharmacy, Attn: Steven L. Wong, Los Angeles, California, United States|UCLA West Medical Pharmacy: Drug Management Only, Los Angeles, California, United States|UCLA West Medical Pharmacy; Drug Management Only, Los Angeles, California, United States|UCLA West Medical Pharmacy, Los Angeles, California, United States|Administrative Address: UCLA Hematology/Oncology, Los Angeles, California, United States|Drug Management Only: TRIO-US Pharmacy UCLA Medical Plaza, Attn: Steven L Wong, Pharm.D., Los Angeles, California, United States|Regulatory Management Only: TRIO-US Central Administration, Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|TRIO-US Central Administration: Regulatory Management Only, Los Angeles, California, United States|TRIO-US Central Administration, Los Angeles, California, United States|UCLA Hematology Oncology, Los Angeles, California, United States|Freidenrich Center for Translational Research, Palo Alto, California, United States|UCLA Hematology/ Oncology- Pasadena, Pasadena, California, United States|Torrance Health Association, DBa Torrance Memorial Physician Network, Redondo Beach, California, United States|Southern California Permanente Medical Group, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|University of California, San Francisco, San Francisco, California, United States|San Luis Obispo Oncology and Hematology Health Center/ Pacific Central Coast Health Centers, San Luis Obispo, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|UCLA Santa Monica Medical Center and Orthopaedic Hospital, Santa Monica, California, United States|Stanford Women's Cancer Center, Stanford, California, United States|Wellness Oncology & Hematology, West Hills, California, United States|UCLA Hematology/Oncology- Westlake, Westlake Village, California, United States|St. Mary's Hospital Regional Cancer Center, Grand Junction, Colorado, United States|Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States|Whittingham Cancer Center @ Norwalk Hospital, Norwalk, Connecticut, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Sylvester at Deerfield Beach, Deerfield Beach, Florida, United States|Memorial Breast Cancer Center at Memorial Regional Hospital, Hollywood, Florida, United States|Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States|Memorial Regional Hospital, Hollywood, Florida, United States|Cancer Specialist of North Florida, Pharmacy, Jacksonville, Florida, United States|Cancer Specialists of North Florida-Southpoint, Jacksonville, Florida, United States|Orlando Health, Inc., Orlando, Florida, United States|Memorial Breast Cancer Center at Memorial Hospital West, Pembroke Pines, Florida, United States|Memorial Cancer Institute at Memorial Hospital West, Pembroke Pines, Florida, United States|Memorial Hospital West, Pembroke Pines, Florida, United States|Sylvester Comprehensive Cancer Center Plantation, Plantation, Florida, United States|Cancer Specialists of North Florida - St. Augustine, Saint Augustine, Florida, United States|Grady Health System, Atlanta, Georgia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|The Emory Clinic, Atlanta, Georgia, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Northwest Georgia Oncology Centers, PC, Marietta, Georgia, United States|Kootenai Clinic Cancer Services, Coeur d'Alene, Idaho, United States|Kootenai Clinic Cancer Services, Post Falls, Idaho, United States|The Mark M. Connolly Center for Cancer and Specialty Care, Chicago, Illinois, United States|Carle Foundation Hospital DBA Carle Cancer Center, Danville, Illinois, United States|Carle Foundation Hospital DBA Carle Cancer Center, Effingham, Illinois, United States|Presence Infusion Care- Evanston, Evanston, Illinois, United States|Carle Foundation Hospital DBA Carle Cancer Center, Mattoon, Illinois, United States|Presence Infusion Care- Skokie, Skokie, Illinois, United States|Carle Foundation Hospital DBA Carle Cancer Center, Urbana, Illinois, United States|James Graham Brown Cancer Center and University Hospital, Louisville, Kentucky, United States|James Graham Brown Cancer Center, Louisville, Kentucky, United States|University of Maryland, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Park Nicollet Frauenshuh Cancer Center, Saint Louis Park, Minnesota, United States|The West Clinic, PC, Corinth, Mississippi, United States|The West Clinic, PC dba West Cancer Centre, Southaven, Mississippi, United States|Mercy Clinic St. Louis Cancer and Breast Institute, Ballwin, Missouri, United States|Mercy Clinic St. Louis Cancer and Breast Institute, Saint Louis, Missouri, United States|Mercy Hospital St. Louis - David C. Pratt Cancer Center, Saint Louis, Missouri, United States|Mercy Hospital St. Louis, Saint Louis, Missouri, United States|Saint Francis Medical Center, Grand Island, Nebraska, United States|Saint Francis Medical Center, Saint Francis Cancer Treatment Center, Grand Island, Nebraska, United States|Saint Francis Medical Center, Hastings, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Regulatory Office: Comprehensive Cancer Centers of Nevada Research Department, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|CUMC Herbert Irving Pavilion, Fort Lee, New Jersey, United States|Mount Kisco Medical Group, Brewster, New York, United States|Mount Kisco Medical Group, Mount Kisco, New York, United States|Northern Westchester Hospital, Mount Kisco, New York, United States|CUMC Herbert Irving Pavilion, New York, New York, United States|Milstein Hospital, New York, New York, United States|Stony Brook University- Cancer Center, Stony Brook, New York, United States|Northwest Cancer Specialists, PC, Portland, Oregon, United States|Kaiser Permanente Northwest Region, Portland, Oregon, United States|Northwest Cancer Specialists, P.C., Portland, Oregon, United States|OHSU Center for Health and Healing, Portland, Oregon, United States|OHSU Research Pharmacy Services, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Tennessee Oncology, PLLC, Dickson, Tennessee, United States|Tennessee Oncology PLLC, Franklin, Tennessee, United States|Tennessee Oncology, PLLC, Gallatin, Tennessee, United States|The West Clinic, PC dba West Cancer Centre, Germantown, Tennessee, United States|Tennessee Oncology PLLC, Hermitage, Tennessee, United States|Tennessee Oncology, PLLC, Lebanon, Tennessee, United States|The West Clinic, PC dba West Cancer Centre, Memphis, Tennessee, United States|Tennessee Oncology PLLC, Murfreesboro, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Shelbyville, Tennessee, United States|Tennessee Oncology PLLC, Smyrna, Tennessee, United States|Texas Oncology-Dallas Presbyterian Hospital, Dallas, Texas, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology-El Paso Cancer Treatment Center Grandview, El Paso, Texas, United States|Texas Oncology- El Paso Cancer Treatment Center Gateway, El Paso, Texas, United States|Texas Oncology-El Paso Cancer Treatment Center Joe Battle, El Paso, Texas, United States|Investigational Products Center (IPC), Fort Worth, Texas, United States|The University of Texas MD Anderson Cancer Center, Department of Breast Medical Oncology, Houston, Texas, United States|The University of Texas MD Anderson Cancer Center., Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|US Oncology Investigational Products Center, Irving, Texas, United States|Oncology & Hematology Associates of Southwest Virginia, INC., D.B.A. Blue Rigde Cancer Care, Blacksburg, Virginia, United States|Oncology & Hematology Associates of Southwest Virginia, Inc. D.B.A Blue Ridge Cancer Care, Low Moor, Virginia, United States|Virginia Oncology Associates, Newport News, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Oncology & Hematology Associates of Southwest Virginia, Inc. D.B.A Blue Ridge Cancer Care, Roanoke, Virginia, United States|Oncology & Hematology Associates of Southwest Virginia, Inc. D.B.A Blue Ridge Cancer Care, Salem, Virginia, United States|Virginia Oncology Associates, Virginia Beach, Virginia, United States|Shenandoah Oncology PC, Winchester, Virginia, United States|Oncology & Hematology Associates of Southwest Virginia, INC., D.B.A. Blue Rigde Cancer Care, Wytheville, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Northwest Cancer Specialists, P.C., Vancouver, Washington, United States|Northwest Cancer Specialists P.C., Vancouver, Washington, United States|West Virginia University, Morgantown, West Virginia, United States|University of Wisconsin, Madison, Wisconsin, United States|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Laverty Pathology, Port Macquarie, New South Wales, Australia|Mid Coast North Diagnostic Imaging, Port Macquarie, New South Wales, Australia|North Coast Cancer Institute/Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Icon Cancer Care, Auchenflower, Queensland, Australia|River City Pharmacy, Auchenflower, Queensland, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Icon Cancer Care Corporate Office, South Brisbane, Queensland, Australia|Icon Cancer Foundation Corporate Office, South Brisbane, Queensland, Australia|Princess Alexandra Hospital, Wooloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Bendigo Health Care Group, The Bendigo Hospital Campus, Bendigo, Victoria, Australia|Day Oncology, Northern Hospital, Epping, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Epworth Hospital, Richmond, Victoria, Australia|Maroondah Hospital, Ringwood East, Victoria, Australia|Goulburn Valley Health, Shepparton, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Gasthuis Zusters Antwerpen - Campus Sint- Augustinus, Wilrijk, Antwerpen, Belgium|Institut Jules Bordet, Brussels, Belgium|Oncologie, Brussels, Belgium|UZ Brussel, Brussel, Belgium|Grand Hopital de Charleroi / Service d'Hematologie et Oncologie, Charleroi, Belgium|Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgium|CHU Start Tilman, Liege, Belgium|CHR East Belgium - Verviers, Verviers, Belgium|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|BC Cancer Agency-Fraser Valley Centre, Surrey, British Columbia, Canada|British Columbia Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada|QEII Health Sciences Centre, Victoria General Site, Halifax, Nova Scotia, Canada|London Regional Cancer Program, London, Ontario, Canada|Southlake Regional Health Centre- Stronach Regional Cancer Centre, Newmarket, Ontario, Canada|Sunnybrook Research Institute, Toronto, Ontario, Canada|St. Michaels Hospital, Toronto, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|McGill University Health Centre (MUHC), Glen Site, Cedars Cancer Centre, Montreal, Quebec, Canada|Hopital du Sacre-Coeur, Montreal, Quebec, Canada|Center Hospitalier Affilie Universitaire de Quebec, Universite Laval, Hopital du Saint Sacrement, Quebec City, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|Fakultni nemocnice Hradec Kralove, Klinika onkologie a radiologie, Hradec Kralove, Czechia|Institut de Cancerologie de l'Ouest- Paul Papin, Anger Cedex 02, France|Centre François Baclesse, Caen Cedex 5, France|Centre Georges François Leclerc, Dijon, France|CHD Vendée, La Roche Sur Yon, France|Centre Val d'Aurelle,, Montpellier CEDEX 5, France|Centre Antoine Lacassagne, Nice cedex 2, France|Institut Curie, Departement d'Oncologie Medicale, Paris Cedex 05, France|Centre Eugene Marquis, Rennes, France|Hopital Rene Huguenin/Institut Curie, Saint-Cloud, France|Institut de Cancérologie de l'Ouest-Rene Gauducheau, St Herblain, France|Institut Claudius Regaud- Cancer Comprehensive Center- IUCT-O-Medical Oncology Department, Toulouse CEDEX-9, France|Institut Gustave Roussy, Villejuif, France|IOZ- Munchen, PGM- Studien GmbH, Muenchen, Bavaria, Germany|University of Kiel, Kiel, SH, Germany|Klinikverbund Sudwest - Kliniken Sidelfingen-Boblingen, Boblingen, Germany|University Hospital Carl Gustav Carus - Department for Obstetrics and Gynecology., Dresden, Germany|Universitatsklinikum Erlangen, Frauenklinik, Erlangen, Germany|Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitaetsklinikum Magdeburg AOR Universitaetsfrauenklinik, Magdeburg, Germany|Katholisches Klinikum Mainz, Mainz, Germany|Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universitaet Muenchen, Muenchen, Germany|Rotkreuzklinikum Munchen, Frauenklinik,, Munich, Germany|Breast Cancer, University of Munich, Grosshadern Hospital, Munich, Germany|Klinikum Mutterhaus, Trier, Germany|Szent Margit Korhaz, Budapest, Hungary|Affidea Diagnosztika Kft., Budapest, Hungary|Orszagos Onkologiai Intezet ,, Budapest, Hungary|Országos Onkológiai Intézet ""B"" Belgyogyaszati osztaly, Budapest, Hungary|Országos Onkológiai Intézet, Nuklearis Medicina Osztaly, Budapest, Hungary|Országos Onkológiai Intézet, Radiologiai Diagnosztikai Osztily, Budapest, Hungary|Petz Aladar Megyei Oktato Korhaz Izotopdiagnosztikai es Terapias Szakambulancia, Gyor, Hungary|Petz Aladar Megyei Oktato Korhaz, Onkoradiologiai Osztaly, Gyor, Hungary|Josa Andras Teaching Hospital,, Nyiregyhaza, Hungary|Szegedi Tudomanyegyetem Altalanos Orvosi Kar, Patologia Intezet, Szeged, Hungary|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont, Altalanos Orvostudomanyi Kar, Szeged, Hungary|Diagnoscan Magyarorszag Kft., Szeged, Hungary|Bon Secours Hospital, Cork, Ireland|St Vincents University Hospital, Dublin 4, Ireland|St. James Hospital, Dublin, Ireland|Beaumont Hospital, Dublin, Ireland|Mater Misericordiae University Hospital, Dublin, Ireland|Department of Medical Oncology, Galway, Ireland|Mid Western Regional Hospital, Limerick, Ireland|Waterford Regional Hospital, Waterford, Ireland|Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi, Bologna, BO, Italy|Irccs Irst, Meldola, Forli, Italy|IRCCS - Istituto Europeo di Oncologia, Milano, Milan, Italy|Azienda Ospedaliera San Giuseppe Moscati, Avellino, Italy|Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy|Istituti Fisioterapici Ospitalieri, Roma, Italy|Ospedale SS Trinita, Sora (FR), Italy|Aichi Cancer Center Hospital, Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama-city, Ehime, Japan|National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan|Saitama Cancer Center, Kita-adachi-gun, Saitama, Japan|National Cancer Center Hospital, Chuo-Ku, Tokyo, Japan|Chiba Cancer Center, Chiba, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan|Iwate Medical University Hospital, Iwate, Japan|Hakuaikai Medical Corporation Sagara Hospital, Kagoshima, Japan|Kumamoto University Hospital, Kumamoto, Japan|Kumamoto City Hospital, Kumamoto, Japan|Niigata Cancer Center Hospital 2-15-3, Niigata, Japan|National Hospital Organization Osaka National Hospital, Osaka, Japan|National Cancer Center, Center for Breast Cancer, Goyang-si, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seodaemun-gu, Seoul, Korea, Republic of|Seoul National University Hospital / Department of Internal Medicine, Seoul, Korea, Republic of|Asan Medical Center, Division of Oncology, Department of Internal Medicine, Seoul, Korea, Republic of|Samsung Medical Center, Division of Hematology-Oncology, Department of Medicine, Seoul, Korea, Republic of|Europejskie Centrum Zdrowia Otwock, Otwock, Mazovia, Poland|Oncology and Radiotherapy Clinic, Gdańsk, Poland|Gabinet Okulistyczny ""Focus"", Warsaw, Poland|Niepubliczny Zakład Opieki Zdrowotnej ""Onko-Dent"" SP.P. G.L. Słomian, Zory, Poland|Regional Budgetary Healthcare Institution Kursk Regional Clinical, Kursk, Kursk Region, Russian Federation|State Budget Healthcate Institution ""Leningrad Region Oncology Dispensary"", Kuzmolovo, Leningrad Region, Russian Federation|GUZ Republic Clinical Oncology Dispensary of Ministry of Health of Republic of Tatarstan, Kazan, Russian Federation|State Budget Healthcare Institution Moscow City Oncology Hospital, Moscow Area, Russian Federation|Federal State Budget Institution, Moscow, Russian Federation|Budget Institution of Healthcare, Omsk, Russian Federation|Budget Institution of Healthcare, Omsk, Russian Federation|Ryazan Regional Clinical Oncology Dispensary, Ryazan, Russian Federation|Saint-Petersburg State Budget Healthcare Institution (SBHCI), Saint-Petersburg, Russian Federation|Non-State Health Care agency ""Road Clinical Hospital of PLC"" Russian Railways, St Petersburg, Russian Federation|Republican Clinical Hospital n.a. G.G. Kuvatov, Ufa, Russian Federation|State Budget Medical Institution Republican Clinical Oncology, Ufa, Russian Federation|SBHI of Republic of Bashkortostan Emergency Hospital, Ufa, Russian Federation|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain|Hospital Universitari Son Espases, Palma de Mallorca, Islas Baleares, Spain|Hospital Universitario Fundacion de Alcorcon, Alcorcon, Madrid, Spain|Hospital Universitario de Canarias, La Laguna, Santa CRUZ DE Tenerife, Spain|Hospital Universitario Infanta Cristina, Badajoz, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic I Provincial, Barcelona, Spain|Hospital de Donostia, Donostia- San Sebastian, Spain|Complejo Hospitalario de Jaen, Jaen, Spain|Instituto Catalan de Oncologia L'Hospitalet, L'Hospitalet De Llobregat (Barcelona), Spain|Centro Oncologico de Galicia, La Coruna, Spain|Hospital Universitario Arnau De Vilanova de Lleida, Lleida, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Centro Oncologico MD Anderson Internacional España, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|HOSPITAL Universitario 12 DE OCTUBRE, Madrid, Spain|Hospital Madrid Universitario Sanchinarro, Madrid, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Instituto Valenciano de Oncologia, Valencia, Spain|National Taiwan University Hospital, Taipei City, Taiwan|Veterans General Hospital-Taipei, Taipei City, Taiwan|Mackay Memory Hospital, Taipei, Taiwan|MI ""Dnipropetrovsk City Multidisciplinary Clinical Hospital No.4"" of the Dnipropetrovsk City Council, Dnipro, Ukraine|State Institution Dnipropetrovsk Medical Academy at the Ministry of Health of Ukraine, Dnipro, Ukraine|Municipal Non-profit Enterprise ""Regional Centre of Oncology"", Kharkiv, Ukraine|Lviv State Oncologic Regional Treatment and Diagnostic Center, Chemotherapy Department, Lviv, Ukraine|Municipal Medical Institution ""Makiivka City Hospital No.2 of Donetsk Region"", Makiivka, Ukraine|Regional Municipal Establishment ""Sumy Regional Clinical Oncology Dispensary"", Thoracic Department, Sumy, Ukraine|City Oncology Centre of Central Municipal Clinical Hospital, Uzhgorod, Ukraine|Institute of Postgraduate education and preuniversity preparing of Uzhgorod National Univ., Uzhgorod, Ukraine|MI ""Zaporizhzhia Regional Clinical Oncology Dispensary"" Zaporizhzhia Regional Assembly,, Zaporizhzhia, Ukraine|State institution ""Zaporizhzhia Medical Academy of Postgraduate Education MOH Ukraine"",, Zaporizhzhya, Ukraine|Kent Oncology Center, Maidstone, Kent, United Kingdom|Edinburgh Cancer Centre, Western General Hospital, Edinburgh, Scotland, United Kingdom|Beatson Institute for Cancer Research, Glasgow, Scotland, United Kingdom|Guys Hospital, London, United Kingdom|The Royal Marsden NHS Foundation Trust, London, United Kingdom|Charing Cross Hospital, London, United Kingdom|Christie Hospital NHS Foundation Trust, Manchester, United Kingdom|The Research And Development Office, The Christie NHS Foundation Trust, Manchester, United Kingdom",https://ClinicalTrials.gov/show/NCT01740427
65,Hoffmann-La Roche,"A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread","Active, not recruiting",Has Results,Breast Cancer,Drug: Cobimetinib|Drug: Paclitaxel|Drug: Placebo|Drug: Atezolizumab|Drug: Nab-Paclitaxel,Industry,Interventional,"Long Beach Memorial Medical Center; Oncology, Long Beach, California, United States|Mercy Hospital, a Campus of Plantation General Hospital, Miami, Florida, United States|Cancer Specialists of North Florida, Orange Park, Florida, United States|Florida Hospital Cancer Inst, Orlando, Florida, United States|Florida Cancer Research Institute, Plantation, Florida, United States|Cancer Treatment Centers of America, Newnan, Georgia, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|St. Luke's Cancer Institute, Kansas City, Missouri, United States|Montefiore Einstein Cancer Center, Bronx, New York, United States|Oregon Health and Science University, Portland, Oregon, United States|Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Northwest Medical Specialties, Tacoma, Washington, United States|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Mater Adult Hospital, South Brisbane, Queensland, Australia|Peter MacCallum Cancer Centre; Medical Oncology, Melbourne, Victoria, Australia|St John of God Murdoch Hospital; Oncology West, Murdoch, Western Australia, Australia|Clinique Edith Cavell, Bruxelles, Belgium|AZ Sint Lucas (Sint Lucas), Gent, Belgium|Jessa Zkh (Campus Virga Jesse), Hasselt, Belgium|AZ Groeninge, Kortrijk, Belgium|AZ Sint Augustinus Veurne, Veurne, Belgium|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Multiscan s.r.o., Pardubice, Czechia|Centre Oscar Lambret, Lille, France|Centre Régional de Lutte Contre Le Cancer Val D'aurelle Paul Lamarque, Montpellier, France|Hopital Tenon, Paris, France|Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer, Rennes, France|Chaim Sheba Medical Center, Ramat Gan, Israel|Azienda Ospedaliero Universitaria Seconda Università Degli Studi Di Napoli, Napoli, Campania, Italy|A.O.U Policlinico S. Orsola Malpighi di Bologna U.O di Medicina Interna Borghi - Pad.2, Bologna, Emilia-Romagna, Italy|Centro Di Riferimento Oncologico; SOC Oncologia Medica C, Aviano, Friuli-Venezia Giulia, Italy|Policlinico Universitario Agostino Gemelli, Roma, Lazio, Italy|Istituto Europeo Di Oncologia, Milano, Lombardia, Italy|Azienda Ospedaliero - Universitaria Pisana U.O. Oncologia Medica 2 Universitaria - Polo Oncologico, Pisa, Toscana, Italy|National Cancer Center; Medical Oncology, Gyeonggi-do, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Yonsei University Health System/Severance Hospital, Seoul, Korea, Republic of|Riga East Clinical University Hospital Latvian Oncology Centre, Riga, Latvia|Pauls Stradins Clinical University Hospital, Rīga, Latvia|Prof. Dr. I. Chiricuta Institute of Oncology, Cluj Napoca, Romania|Oncology Center Sf. Nectarie, Craiova, Romania|Corporacio Sanitaria Parc Tauli; Servicio de Oncologia, Sabadell, Barcelona, Spain|Organización Sanitaria Integrada Bilbao Basurto, Bilbao, Vizcaya, Spain|Hospital Universitario Infanta Cristina; Servicio de Oncologia, Badajoz, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Fundacion Jimenez Diaz; Servicio de Oncologia, Madrid, Spain|Hospital Clinico San Carlos; Servicio de Nefrologia, Madrid, Spain|Hosp. Regional Univ. de Malaga - Hospital Materno Infantil; Hospital Materno Infantil de Malaga, Malaga, Spain|Chang Gung Memorial Hospital, Kaohsiung Country, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology, Taipei City, Taiwan|Nuffield Health Bournemouth Hospital, Bournemouth, United Kingdom|Mount Vernon Hospital, Middlesex, United Kingdom|Nottingham University Hospitals City Campus, Nottingham, United Kingdom",https://ClinicalTrials.gov/show/NCT02322814
66,Hoffmann-La Roche,A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1),"Active, not recruiting",Has Results,Bladder Cancer,Drug: Atezolizumab,Industry,Interventional,"University of Alabama At Birmingham, Birmingham, Alabama, United States|Pinnacle Oncology Hematology, Scottsdale, Arizona, United States|Arizona Oncology - HOPE Wilmot, Tucson, Arizona, United States|UCLA, Los Angeles, California, United States|The Angeles Clinic and Research Institute - W LA Office, Los Angeles, California, United States|USC Norris Cancer Center, Los Angeles, California, United States|UCSF, San Francisco, California, United States|Kaiser Permanente - San Marcos, San Marcos, California, United States|Stanford Cancer Center, Stanford, California, United States|Kaiser Permanente; Oncology Clinical Trials, Vallejo, California, United States|Rocky Mountain Cancer Center - Aurora, Aurora, Colorado, United States|University Of Colorado, Aurora, Colorado, United States|University of Connecticut Health Center, Farmington, Connecticut, United States|Yale Cancer Center ; Medical Oncology, New Haven, Connecticut, United States|Georgetown University Medical Center Lombardi Cancer Center, Washington, District of Columbia, United States|Mayo Clinic Cancer Center, Jacksonville, Florida, United States|Piedmont Cancer Institute, PC, Atlanta, Georgia, United States|University of Chicago; Hematology/Oncology, Chicago, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Indiana University Health; Goshen Center for Cancer Care, Goshen, Indiana, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Massachusetts General Hospital;Oncology, Boston, Massachusetts, United States|Dana Farber Cancer Inst. ; Dept. of Medical Oncology, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Harvard Medical School; Department of Medicine, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Minnesota Oncology Minneapolis, Minneapolis, Minnesota, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|Urology Cancer Center & GU Research Network, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|New York Oncology Hematology, P.C., Albany, New York, United States|NYU Langone Medical Center, New York, New York, United States|Mount Sinai School of Medicine - Tisch Cancer Institute, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Oncology Hematology Care Inc, Cincinnati, Ohio, United States|Case Western Reserve Univ; Hem/Onc, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States|Kimmel Cancer Center Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Sarah Cannon Cancer Center - Tennessee Oncology, Pllc, Nashville, Tennessee, United States|Ctr for Cancer and Blood Disorders, Fort Worth, Texas, United States|Texas Oncology - Houston (Gessner), Houston, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Oncology Associates - Lake Wright Cancer Center, Norfolk, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Bcca - Cancer Center Southern Interior, Kelowna, British Columbia, Canada|BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Lakeridge Health Oshawa; Oncology, Oshawa, Ontario, Canada|The Ottawa Hospital Cancer Centre; Oncology, Ottawa, Ontario, Canada|Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada|University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada|APHP - Hospital Saint Louis, Paris, France|Hopital Foch; Oncologie, Suresnes, France|Institut Gustave Roussy; Oncologie Medicale, Villejuif, France|Charité - Universitätsmedizin Berlin; CC 8: Chirurgische Medizin; Klinik für Urologie, Berlin, Germany|Universitätsklinikum Düsseldorf; Urologische Klinik, Düsseldorf, Germany|Universitätsklinikum Freiburg; Chirurgische Klinik; Abteilung Urologie, Freiburg, Germany|Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II, Hamburg, Germany|Klinikum rechts der Isar der TU München; Urologische Klinik und Poliklinik, München, Germany|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, Milano, Lombardia, Italy|Azienda USL8 Arezzo-Presidio Ospedaliero 1 San Donato;U.O.C. Oncologia, Arezzo, Toscana, Italy|The Netherlands Cancer Institute - Antoni Van Leeuwenhoekziekenhuis, Amsterdam, Netherlands|Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Institut Catala d Oncologia Hospital Duran i Reynals, Barcelona, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|University Hospital Birmingham The Cancer Centre, Queen Elizabeth Hospital, Birmingham, United Kingdom|Barts and The London, London, United Kingdom|Sarah Cannon Research Institute, London, United Kingdom|Royal Marsden Hospital; Dept of Medical Oncology, Sutton, United Kingdom|The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, United Kingdom",https://ClinicalTrials.gov/show/NCT02951767
67,Eli Lilly and Company,A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer,"Active, not recruiting",Has Results,Breast Cancer,Drug: Abemaciclib|Drug: Anastrozole|Drug: Letrozole|Drug: Placebo,Industry,Interventional,"Ironwood Cancer & Research Centers, Chandler, Arizona, United States|Arizona Oncology Associates, PC - CASA, Tucson, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|California Cancer Associates Research and Excellence (cCARE), Fresno, California, United States|St. Joseph Heritage Medical Group, Fullerton, California, United States|UCLA Medical Center, Los Angeles, California, United States|TRIO - Translational Research in Oncology-US, Inc., Los Angeles, California, United States|North Valley Hematology/Oncology Medical Group, Northridge, California, United States|Central Coast Medical Oncology Corporation, Santa Monica, California, United States|Catholic Health Initiatives (CHI), Englewood, Colorado, United States|St Mary's Hospital Regional Cancer Center, Grand Junction, Colorado, United States|Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States|Lakeland Regional Cancer Center, Lakeland, Florida, United States|Lakes Research LLC, Miami Lakes, Florida, United States|Moroose, Reynolds and Castillo, Orlando, Florida, United States|Georgia Regents University, Augusta, Georgia, United States|Summit Cancer Care, Savannah, Georgia, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|IU Health Ball Memorial Hospital, Muncie, Indiana, United States|Office: Dr Jayne S Gurtler, Metairie, Louisiana, United States|Walter Reed National Military Medical Center IRB, Bethesda, Maryland, United States|Mayo Clinic, Rochester, Minnesota, United States|St. Francis Medical Center, Grand Island, Nebraska, United States|Nebraska Hematology-Oncology, Lincoln, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Broome Oncology, Johnson City, New York, United States|Beth Israel Medical Center, New York, New York, United States|Mid Ohio Oncology Hematology, Columbus, Ohio, United States|Kaiser Permanente / Central Interstate Medical Office, Portland, Oregon, United States|University of Tennessee Medical Center, Knoxville, Tennessee, United States|Oncology Consultants Cancer Center, Houston, Texas, United States|Joe Arrington Cancer Center, Lubbock, Texas, United States|Scott & White Healthcare, Round Rock, Texas, United States|Scott & White Memorial Hosptial & Clinic, Temple, Texas, United States|Cancer Care Northwest, Valley, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Camperdown, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fitzroy, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Geelong, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Murdoch, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., South Brisbane, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wahroonga, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wollongong, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Woodville, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Woolloongabba, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Innsbruck, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Linz, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wien, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussels, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleroi, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Namur, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roeselare, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wilrijk, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edmonton, Alberta, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oshawa, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ottawa, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montreal, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bordeaux, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brest, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dijon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Roche Sur Yon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lyon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montpellier, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Saint Herblain Cedex, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint-Brieuc, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aachen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Düsseldorf, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lubeck, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ludwigsburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munich, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., München, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulm, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wiesbaden, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heraklion, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beer Sheva, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haifa, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jerusalem, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kfar Saba, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Petah Tiqva, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ramat Gan, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rehovot, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Aviv Jaffa, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bergamo, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bologna, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brindisi, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Candiolo, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cona, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Genova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Messina, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Negrar, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prato, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Terni, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aichi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiba, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ehime, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hiroshima, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hokkaido, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kagoshima, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Niigata, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saitama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shinjuku-ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shizuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tochigi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daegu, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Goyang-Si, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gyeonggi-do, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Incheon, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulsan-si, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cuernavaca, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guadalajara, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Juchitan, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leon, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Queretaro, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Torreon, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Den Haag, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eindhoven, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leiden, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rotterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Auckland, New Zealand|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wellington, New Zealand|San Juan Ccop, San Juan, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Arkhangelsk, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kaznan, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint-Petersburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Volzhskiy, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bratislava, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kosice, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Badajoz, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lleida, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Sebastian, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gavle, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orebro, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vasteras, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jhonghe City, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kuei Shan Hsiang, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pei-Tou, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ankara, Turkey|For additional information regarding investigative ",
68,AstraZeneca,A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer,"Active, not recruiting",Has Results,Non-Small Cell Lung Cancer,Drug: MEDI4736,Industry,Interventional,"Research Site, Goodyear, Arizona, United States|Research Site, Santa Rosa, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Port Saint Lucie, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Lawrenceville, Georgia, United States|Research Site, Waterloo, Iowa, United States|Research Site, Topeka, Kansas, United States|Research Site, Bethesda, Maryland, United States|Research Site, Burlington, Massachusetts, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Saint Louis Park, Minnesota, United States|Research Site, Bronx, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Huntersville, North Carolina, United States|Research Site, Bismarck, North Dakota, United States|Research Site, Fargo, North Dakota, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Middleton, Ohio, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Fort Worth, Texas, United States|Research Site, Spokane, Washington, United States|Research Site, Wenatchee, Washington, United States|Research Site, Wien, Austria|Research Site, Bruxelles, Belgium|Research Site, Gent, Belgium|Research Site, Gilly, Belgium|Research Site, Kortrijk, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Hamilton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Regina, Saskatchewan, Canada|Research Site, Brno, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 8, Czechia|Research Site, Praha, Czechia|Research Site, Bordeaux Cedex, France|Research Site, Brest Cedex, France|Research Site, Creteil, France|Research Site, Dijon, France|Research Site, Le Mans Cedex 02, France|Research Site, Marseille, France|Research Site, Pessac, France|Research Site, Rennes Cedex 09, France|Research Site, Saint Herblain Cedex, France|Research Site, Toulouse Cedex 9, France|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Borstel, Germany|Research Site, Dortmund, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Freiburg, Germany|Research Site, Großhansdorf, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research Site, Köln, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Győr, Hungary|Research Site, Szolnok, Hungary|Research Site, Tatabanya, Hungary|Research Site, Torokbalint, Hungary|Research Site, Candiolo, Italy|Research Site, Catania, Italy|Research Site, Milano, Italy|Research Site, Monza, Italy|Research Site, Orbassano, Italy|Research Site, Perugia, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Rozzano, Italy|Research Site, Akashi-shi, Japan|Research Site, Bunkyo-ku, Japan|Research Site, Chuo-ku, Japan|Research Site, Habikino-shi, Japan|Research Site, Hidaka-shi, Japan|Research Site, Hirakata-shi, Japan|Research Site, Kashiwa, Japan|Research Site, Kitaadachi-gun, Japan|Research Site, Kobe-shi, Japan|Research Site, Koto-ku, Japan|Research Site, Kurume-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Natori-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osakasayama, Japan|Research Site, Sakai-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Sunto-gun, Japan|Research Site, Ube-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Goyang-si, Korea, Republic of|Research Site, Hwasun-gun, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Cebu City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Gdańsk, Poland|Research Site, Warszawa, Poland|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Barcelona, Spain|Research Site, Gerona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Málaga, Spain|Research Site, Sevilla, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Hat Yai, Thailand|Research Site, Muang, Thailand|Research Site, Edinburgh, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Stoke-on-Trent, United Kingdom",https://ClinicalTrials.gov/show/NCT02087423
69,Novartis Pharmaceuticals|Novartis,Lapatinib and Bevacizumab for Metastatic Breast Cancer,"Active, not recruiting",Has Results,"Neoplasms, Breast",Drug: lapatinib|Drug: bevacizumab,Industry,Interventional,"Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Hollywood, Florida, United States|Novartis Investigative Site, Tampa, Florida, United States|Novartis Investigative Site, Basking Ridge, New York, United States|Novartis Investigative Site, Commack, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Rockville Centre, New York, United States|Novartis Investigative Site, Sleepy Hollow, New York, United States",https://ClinicalTrials.gov/show/NCT00444535
70,Hoffmann-La Roche,A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2),"Active, not recruiting",Has Results,Bladder Cancer,Drug: Atezolizumab,Industry,Interventional,"University of Alabama At Birmingham, Birmingham, Alabama, United States|Pinnacle Oncology Hematology, Scottsdale, Arizona, United States|Arizona Oncology - HOPE Wilmot, Tucson, Arizona, United States|UCLA, Los Angeles, California, United States|The Angeles Clinic and Research Institute - W LA Office, Los Angeles, California, United States|USC Norris Cancer Center, Los Angeles, California, United States|UCSF, San Francisco, California, United States|Kaiser Permanente - San Marcos, San Marcos, California, United States|Stanford Cancer Center, Stanford, California, United States|Kaiser Permanente; Oncology Clinical Trials, Vallejo, California, United States|Rocky Mountain Cancer Center - Aurora, Aurora, Colorado, United States|University Of Colorado, Aurora, Colorado, United States|University of Connecticut Health Center, Farmington, Connecticut, United States|Yale Cancer Center ; Medical Oncology, New Haven, Connecticut, United States|Georgetown University Medical Center Lombardi Cancer Center, Washington, District of Columbia, United States|Mayo Clinic Cancer Center, Jacksonville, Florida, United States|Piedmont Cancer Institute, PC, Atlanta, Georgia, United States|University of Chicago; Hematology/Oncology, Chicago, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Indiana University Health; Goshen Center for Cancer Care, Goshen, Indiana, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Massachusetts General Hospital;Oncology, Boston, Massachusetts, United States|Dana Farber Cancer Inst. ; Dept. of Medical Oncology, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Harvard Medical School; Department of Medicine, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Minnesota Oncology Minneapolis, Minneapolis, Minnesota, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|Urology Cancer Center & GU Research Network, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|New York Oncology Hematology, P.C., Albany, New York, United States|NYU Langone Medical Center, New York, New York, United States|Mount Sinai School of Medicine - Tisch Cancer Institute, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Oncology Hematology Care Inc, Cincinnati, Ohio, United States|Case Western Reserve Univ; Hem/Onc, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States|Kimmel Cancer Center Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Sarah Cannon Cancer Center - Tennessee Oncology, Pllc, Nashville, Tennessee, United States|Ctr for Cancer and Blood Disorders, Fort Worth, Texas, United States|Texas Oncology - Houston (Gessner), Houston, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Oncology Associates - Lake Wright Cancer Center, Norfolk, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Bcca - Cancer Center Southern Interior, Kelowna, British Columbia, Canada|BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Lakeridge Health Oshawa; Oncology, Oshawa, Ontario, Canada|The Ottawa Hospital Cancer Centre; Oncology, Ottawa, Ontario, Canada|Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada|University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada|APHP - Hospital Saint Louis, Paris, France|Hopital Foch; Oncologie, Suresnes, France|Institut Gustave Roussy; Oncologie Medicale, Villejuif, France|Charité - Universitätsmedizin Berlin; CC 8: Chirurgische Medizin; Klinik für Urologie, Berlin, Germany|Universitätsklinikum Düsseldorf; Urologische Klinik, Düsseldorf, Germany|Universitätsklinikum Freiburg; Chirurgische Klinik; Abteilung Urologie, Freiburg, Germany|Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II, Hamburg, Germany|Klinikum rechts der Isar der TU München; Urologische Klinik und Poliklinik, München, Germany|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, Milano, Lombardia, Italy|Azienda USL8 Arezzo-Presidio Ospedaliero 1 San Donato;U.O.C. Oncologia, Arezzo, Toscana, Italy|The Netherlands Cancer Institute - Antoni Van Leeuwenhoekziekenhuis, Amsterdam, Netherlands|Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Institut Catala d Oncologia Hospital Duran i Reynals, Barcelona, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|University Hospital Birmingham The Cancer Centre, Queen Elizabeth Hospital, Birmingham, United Kingdom|Barts and The London, London, United Kingdom|Sarah Cannon Research Institute, London, United Kingdom|Royal Marsden Hospital; Dept of Medical Oncology, Sutton, United Kingdom|The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, United Kingdom",https://ClinicalTrials.gov/show/NCT02108652
71,Novartis Pharmaceuticals|Novartis,"Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer","Active, not recruiting",Has Results,Advanced Metastatic Breast Cancer,Drug: LEE011|Drug: Tamoxifen|Drug: Letrozole|Drug: Anastrozole|Drug: Goserelin|Drug: LEE011 Placebo,Industry,Interventional,"Comprehensive Blood and Cancer Center SC-2, Bakersfield, California, United States|University of California at Los Angeles Dept of Onc, Los Angeles, California, United States|Comprehensive Cancer Center at Saint Joseph Hospital SC, Denver, Colorado, United States|Danbury Hospital SC, Danbury, Connecticut, United States|Florida Cancer Specialists Onc Dept, Fort Myers, Florida, United States|Florida Cancer Specialists SC-2, Fort Myers, Florida, United States|Memorial Cancer Institute SC, Hollywood, Florida, United States|University of Miami Univ Miami 2, Miami, Florida, United States|NorthWest Georgia Oncology Centers NW Georgia Oncology, Marietta, Georgia, United States|Moanalua Medical Center. Attn: Oncology Dept SC, Honolulu, Hawaii, United States|University of Chicago SC-3, Chicago, Illinois, United States|Norton Cancer Institute SC, Louisville, Kentucky, United States|Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Med Dept of Onc., Baltimore, Maryland, United States|Massachusetts General Hospital Onc Dept, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center Onc Dept, Ann Arbor, Michigan, United States|Washington University School of Medicine SC, Saint Louis, Missouri, United States|Meridian Health Systems SC, Neptune, New Jersey, United States|University of New Mexico Hospital SC-2, Albuquerque, New Mexico, United States|Clinical Research Alliance, Lake Success, New York, United States|Duke University Medical Center Duke (SC), Durham, North Carolina, United States|Penn State University Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|Bon Secours Cancer Center SC, Greenville, South Carolina, United States|Erlanger Medical Center SC, Chattanooga, Tennessee, United States|Tennessee Oncology Tennessee Oncology (3), Nashville, Tennessee, United States|The Center for Cancer and Blood Disorders SC, Fort Worth, Texas, United States|Methodist Hospital / Methodist Cancer Center Dept of Oncology, Houston, Texas, United States|University of Texas MD Anderson Cancer Center SC-5, Houston, Texas, United States|Cancer Therapy and Research Center UT Health Science Center SC-4, San Antonio, Texas, United States|Brooke Army Medical Center SC, San Antonio, Texas, United States|Northern Utah Cancer Associates, Ogden, Utah, United States|Bon Secours Virginia Health System, Midlothian, Virginia, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Kadlec Clinic Hematology and Oncology Kadlec Clinic Hematology & Onc, Kennewick, Washington, United States|Northwest Medical Specialties Dept of Onc, Tacoma, Washington, United States|University of Wisconsin / Paul P. Carbone Comp Cancer Center Univ Wisc 3, Madison, Wisconsin, United States|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Jujuy, Argentina|Novartis Investigative Site, La Rioja, Argentina|Novartis Investigative Site, Waratah, New South Wales, Australia|Novartis Investigative Site, Box Hill, Victoria, Australia|Novartis Investigative Site, Heidelberg, Victoria, Australia|Novartis Investigative Site, Murdoch, Western Australia, Australia|Novartis Investigative Site, Nedlands, Western Australia, Australia|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Londrina, PR, Brazil|Novartis Investigative Site, Ljui, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Passo Fundo, RS, Brazil|Novartis Investigative Site, Barretos, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Bogota, Colombia|Novartis Investigative Site, Monteria, Colombia|Novartis Investigative Site, Strasbourg Cedex, Cedex, France|Novartis Investigative Site, Caen Cedex, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Montpellier Cedex 5, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Rouen Cedex 1, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Muehlhausen, Thueringen, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Esslingen, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Offenbach, Germany|Novartis Investigative Site, Ravensburg, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Thessaloniki, GR, Greece|Novartis Investigative Site, Heraklion Crete, Greece|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Kowloon, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Szolnok, Hungary|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Nashik, Maharashtra, India|Novartis Investigative Site, Kolkatta, West Bengal, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, L'Aquila, AQ, Italy|Novartis Investigative Site, Benevento, BN, Italy|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Cremona, CR, Italy|Novartis Investigative Site, Catania, CT, Italy|Novartis Investigative Site, Meldola, FC, Italy|Novartis Investigative Site, Cona, FE, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Lecce, LE, Italy|Novartis Investigative Site, Lucca, LU, Italy|Novartis Investigative Site, Macerata, MC, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Perugia, PG, Italy|Novartis Investigative Site, Prato, PO, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Candiolo, TO, Italy|Novartis Investigative Site, Terni, TR, Italy|Novartis Investigative Site, Udine, UD, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Bundang Gu, Gyeonggi Do, Korea, Republic of|Novartis Investigative Site, Gyeonggi do, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, El Chouf, LBN, Lebanon|Novartis Investigative Site, Ashrafieh, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Saida, Lebanon|Novartis Investigative Site, Johor Bahru, Johor, Malaysia|Novartis Investigative Site, Kuala Lumpur, Malaysia|Novartis Investigative Site, Metepec, Edo. De México, Mexico|Novartis Investigative Site, Leon, Guanajuato, Mexico|Novartis Investigative Site, Monterrey Nuevo Leon, Monterrey, Mexico|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Konin, Poland|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Arkhangelsk, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Riyadh, Saudi Arabia|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Elche, Alicante, Spain|Novartis Investigative Site, Almeria, Andalucia, Spain|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Sabadell, Barcelona, Spain|Novartis Investigative Site, Sant Joan Despi, Barcelona, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, Mallorca, Islas Baleares, Spain|Novartis Investigative Site, Alcorcon, Madrid, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, Spain|Novartis Investigative Site, Baracaldo, Vizcaya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Geneve, Switzerland|Novartis Investigative Site, New Taipei City, TWN, Taiwan|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Kaohsiung City, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taoyuan, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Istanbul, TUR, Turkey|Novartis Investigative Site, Adana, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Diyarbakir, Turkey|Novartis Investigative Site, Edirne, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Al Ain Abu Dhabi, United Arab Emirates",https://ClinicalTrials.gov/show/NCT02278120
72,Eli Lilly and Company,"A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer","Active, not recruiting",Has Results,Hormone Receptor Positive Breast Cancer|HER-2 Positive Breast Cancer,Drug: Abemaciclib|Drug: Trastuzumab|Drug: Fulvestrant|Drug: Standard of Care Single Agent Chemotherapy,Industry,Interventional,"Comprehensive Blood and Cancer Center, Bakersfield, California, United States|St Jude Medical Center, Fullerton, California, United States|TRIO - Translational Research in Oncology-US, Inc., Los Angeles, California, United States|USC Norris Cancer Hospital, Los Angeles, California, United States|UCLA Medical Center, Los Angeles, California, United States|Cancer Care Associates Medical Group, Redondo Beach, California, United States|Central Coast Medical Oncology Corporation, Santa Monica, California, United States|Catholic Health Initiatives (CHI), Englewood, Colorado, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|MD Anderson Cancer Center Orlando, Orlando, Florida, United States|University of Miami Plantation, Plantation, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Winship Cancer Center Emory University, Atlanta, Georgia, United States|Northside Hospital Cancer Institute, Atlanta, Georgia, United States|Fort Wayne Medical Oncology & Hematology, Inc., Fort Wayne, Indiana, United States|St Joseph Cancer Center, Lexington, Kentucky, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Billings Clinic Research Center, Billings, Montana, United States|Brookdale Hospital Medical Center, Brooklyn, New York, United States|North Shore Hematology Oncology Associates, East Setauket, New York, United States|Clinical Research Alliance, Inc, Lake Success, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States|Northwest Medical Specialties, PLLC, Puyallup, Washington, United States|Swedish Medical Center, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Caba, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cordoba, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cordoba, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Rioja, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rosario, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rosario, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Miguel De Tucuman, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Viedma, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kurralta Park, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nedlands, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St. Leonards, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleroi, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gent, Belgium|Universitair Ziekenhuis Leuven - Gasthuisberg, Leuven, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Namur, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Porto Alegre, Brazil|Instituto COI de Pesquisa Educação e Gestão, Rio de Janeiro, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sao Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|Fundação Antonio Prudente - Hospital do Câncer A.C Camargo, São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Calgary, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Calgary, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Newmarket, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Ottawa, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Angers, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Besancon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lyon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montpellier, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nice, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Cloud, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Villejuif, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt am Main, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Freiburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., München, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Achaia, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Genova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sora, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daegu, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Goyang-si, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seongnam-si, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., México City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Badajoz, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leicester, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sutton, United Kingdom",https://ClinicalTrials.gov/show/NCT02675231
73,AstraZeneca,A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.,"Active, not recruiting",Has Results,Hormone Receptor Positive Breast Cancer,Drug: faslodex 500mg|Drug: arimidex 1mg|Drug: faslodex dummy|Drug: arimidex dummy,Industry,Interventional,"Research Site, Modesto, California, United States|Research Site, Savannah, Georgia, United States|Research Site, Auburn, Maine, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Somerset, New Jersey, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Nashville, Tennessee, United States|Research Site, Murray, Utah, United States|Research Site, La Rioja, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Pergamino, Argentina|Research Site, Rosario, Argentina|Research Site, Porto Alegre, Brazil|Research Site, Santo Andre, Brazil|Research Site, Abbotsford, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, Thunder Bay, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Chengdu, China|Research Site, Dalian, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Suzhou, China|Research Site, Tianjin, China|Research Site, Praha 5, Czechia|Research Site, Pribram, Czechia|Research Site, Avellino, Italy|Research Site, Bari, Italy|Research Site, Benevento, Italy|Research Site, Catania, Italy|Research Site, Genova, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Treviglio, Italy|Research Site, Fukuoka-shi, Japan|Research Site, Hamamatsu-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Mitaka-shi, Japan|Research Site, Nishinomiya-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Sakai-shi, Japan|Research Site, Suita-shi, Japan|Research Site, Merida, Mexico|Research Site, Mexico, D.F., Mexico|Research Site, Monterrey, Mexico|Research Site, Monterrey, Mexico|Research Site, Monterrey, Mexico|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Katowice, Poland|Research Site, Lublin, Poland|Research Site, Łódź, Poland|Research Site, Braila, Romania|Research Site, Craiova, Romania|Research Site, Onesti, Romania|Research Site, Timisoara, Romania|Research Site, Barnaul, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, St-Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Bardejov, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Trencin, Slovakia|Research Site, Cape Town, South Africa|Research Site, Cape town, South Africa|Research Site, Cape Town, South Africa|Research Site, Pietermaritzburg, South Africa|Research Site, Pretoria, South Africa|Research Site, Pretoria, South Africa|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Pamplona, Spain|Research Site, Pozuelo de Alarcon, Spain|Research Site, Sabadell, Spain|Research Site, Sevilla, Spain|Research Site, Sevilla, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Valencia, Spain|Research Site, Taichung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Ankara, Turkey|Research Site, Gaziantep, Turkey|Research Site, Cherkasy, Ukraine|Research Site, Dnipro, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Mariupol, Ukraine|Research Site, Uzhhorod, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Airdrie, United Kingdom|Research Site, Derby, United Kingdom|Research Site, Stoke-on-Trent, United Kingdom",https://ClinicalTrials.gov/show/NCT01602380
74,AbbVie|Gynecologic Oncology Group;Australia New Zealand Gynaecological Oncology Group,"Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","Active, not recruiting",Has Results,Ovarian Cancer|Ovarian Neoplasm,Drug: Veliparib|Drug: Paclitaxel|Drug: Carboplatin|Other: Placebo to Veliparib,Industry|Other,Interventional,"University of Alabama at Birmingham - Main /ID# 138087, Birmingham, Alabama, United States|Tennessee Valley Gyn-Onc /ID# 139548, Huntsville, Alabama, United States|University of South Alabama /ID# 138091, Mobile, Alabama, United States|Alaska Womens Cancer Care /ID# 138231, Anchorage, Alaska, United States|Arizona Oncology Associates, PC-HOPE /ID# 142002, Tucson, Arizona, United States|Arizona Oncology Associates, PC-HOPE /ID# 143805, Tucson, Arizona, United States|Arizona Oncology Associates, PC-HOPE /ID# 143806, Tucson, Arizona, United States|Arizona Oncology Associates, PC-HOPE /ID# 143808, Tucson, Arizona, United States|University of Arizona Cancer Center - North Campus /ID# 138084, Tucson, Arizona, United States|University of Arizona Cancer Center - North Campus /ID# 139495, Tucson, Arizona, United States|University of Arkansas for Medical Sciences /ID# 138253, Little Rock, Arkansas, United States|John Muir Medical Center /ID# 139618, Concord, California, United States|Ucsd /Id# 140323, La Jolla, California, United States|Long Beach Memorial Medical Ct /ID# 147526, Long Beach, California, United States|Kaiser Permanente /ID# 141305, Los Angeles, California, United States|University of California, Los Angeles /ID# 138179, Los Angeles, California, United States|Medical Oncology Care Assoc /ID# 139498, Orange, California, United States|Univ CA, Irvine Med Ctr /ID# 139613, Orange, California, United States|UC Davis Comprehensive Cancer Center - Main /ID# 144439, Sacramento, California, United States|California Pacific Medical Ctr /ID# 138177, San Francisco, California, United States|Kaiser Permanente - San Francisco /ID# 142051, San Francisco, California, United States|Univ California, San Francisco /ID# 138178, San Francisco, California, United States|Kaiser Permanente-Santa Clara /ID# 142053, Santa Clara, California, United States|Stanford University School of Med /ID# 139450, Stanford, California, United States|Palo Alto Medical Foundation /ID# 139452, Sunnyvale, California, United States|Kaiser Permanente Medical Ctr-Vallejo /ID# 139492, Vallejo, California, United States|Kaiser Permanente- Walnut Creek /ID# 142052, Walnut Creek, California, United States|Kaiser Permanente, Waterpark III Institute for Health Research /ID# 139499, Aurora, Colorado, United States|Univ of Colorado Cancer Center /ID# 138016, Aurora, Colorado, United States|Hartford Healthcare /ID# 138184, New Britain, Connecticut, United States|Yale University /ID# 138056, New Haven, Connecticut, United States|University of Miami /ID# 139457, Miami, Florida, United States|Women's Cancer Associates /ID# 140321, Saint Petersburg, Florida, United States|Sarasota Memorial Health Care /ID# 138180, Sarasota, Florida, United States|Moffitt Cancer Center /ID# 138061, Tampa, Florida, United States|Georgia Regents University /ID# 138085, Augusta, Georgia, United States|IACT Health /ID# 138058, Columbus, Georgia, United States|Memorial Health Univ Med Ctr /ID# 138019, Savannah, Georgia, United States|St. Joseph's/Candler /ID# 138090, Savannah, Georgia, United States|The Queens Medical Center /ID# 141709, Honolulu, Hawaii, United States|Kapiolani Medical Center /ID# 140319, Honolulu, Hawaii, United States|Rush University Medical Center /ID# 143491, Chicago, Illinois, United States|University of Chicago /ID# 139612, Chicago, Illinois, United States|NorthShore University HealthSystem - Evanston Hospital /ID# 139451, Evanston, Illinois, United States|Sharma, Hinsdale, IL /ID# 140326, Hinsdale, Illinois, United States|Advocate Lutheran General Hosp /ID# 139489, Park Ridge, Illinois, United States|Indiana Univ School Medicine /ID# 139610, Indianapolis, Indiana, United States|Saint Vincent /ID# 139537, Indianapolis, Indiana, United States|McFarland Clinic, PC /ID# 139455, Ames, Iowa, United States|University of Iowa Hospitals and Clinics /ID# 138082, Iowa City, Iowa, United States|Univ Kansas Med Ctr /ID# 140322, Kansas City, Kansas, United States|Baptist Health Lexington /ID# 139542, Lexington, Kentucky, United States|University of Kentucky Chandler Medical Center /ID# 138060, Lexington, Kentucky, United States|Norton Cancer Institute /ID# 139567, Louisville, Kentucky, United States|MMP Women's Health /ID# 139544, Portland, Maine, United States|Greater Baltimore Medical Ctr /ID# 138049, Baltimore, Maryland, United States|Sinai Hospital of Baltimore /ID# 141306, Baltimore, Maryland, United States|Weinberg Cancer Inst Franklin /ID# 138235, Rossville, Maryland, United States|Baystate Medical Center /ID# 139456, Springfield, Massachusetts, United States|UMass Memorial Medical Center /ID# 139458, Worcester, Massachusetts, United States|Wayne State University /ID# 139601, Detroit, Michigan, United States|Henry Ford Health System /ID# 139536, Detroit, Michigan, United States|William Beaumont Hospital /ID# 139550, Royal Oak, Michigan, United States|Mayo Clinic - Rochester /ID# 139565, Rochester, Minnesota, United States|Mmcorc /Id# 139534, Saint Louis Park, Minnesota, United States|St. Dominic Hospital /ID# 138241, Jackson, Mississippi, United States|Ellis Fischel Cancer Center /ID# 139571, Columbia, Missouri, United States|Washington University-School of Medicine /ID# 138089, Saint Louis, Missouri, United States|Cancer Research For the Ozarks /ID# 139538, Springfield, Missouri, United States|Ferrell-Duncan Clinic /ID# 143484, Springfield, Missouri, United States|Nebraska Methodist Hospital /ID# 139600, Omaha, Nebraska, United States|Womens Cancer Center of Nevada /ID# 138092, Las Vegas, Nevada, United States|Renown Regional Medical Center /ID# 138237, Reno, Nevada, United States|Dartmouth-Hitchcock Medical Center /ID# 139502, Lebanon, New Hampshire, United States|MD Anderson Cancer Ctr at Coop /ID# 139616, Camden, New Jersey, United States|Hackensack Univ Med Ctr /ID# 143776, Hackensack, New Jersey, United States|University of New Mexico /ID# 144220, Albuquerque, New Mexico, United States|SW Gynecologic Oncology Assoc /ID# 147097, Albuquerque, New Mexico, United States|Women's Cancer Care Associates /ID# 138234, Albany, New York, United States|Montefiore Medical Center /ID# 139585, Bronx, New York, United States|SUNY Downstate Medical Center /ID# 139533, Brooklyn, New York, United States|Roswell Park Comprehensive Cancer Center /ID# 138052, Buffalo, New York, United States|Northwell Health /ID# 139572, Lake Success, New York, United States|Icahn School of Med Mt. Sinai /ID# 139617, New York, New York, United States|Columbia University Medical Center /ID# 138252, New York, New York, United States|Memorial Sloan Kettering Cancer Center /ID# 138017, New York, New York, United States|Memorial Sloan Kettering Cancer Center /ID# 154464, New York, New York, United States|SUNY Upstate Medical University - Downtown /ID# 139513, Syracuse, New York, United States|Hope Womens Cancer Centers /ID# 139614, Asheville, North Carolina, United States|Univ NC Chapel Hill /ID# 138547, Chapel Hill, North Carolina, United States|Atrium Health Carolinas Medical Center /ID# 139568, Charlotte, North Carolina, United States|Presbyterian Cancer Center /ID# 139590, Charlotte, North Carolina, United States|Duke University Medical Center /ID# 138048, Durham, North Carolina, United States|Wake Forest Baptist Medical Center /ID# 139588, Winston-Salem, North Carolina, United States|University of Cincinnati /ID# 139619, Cincinnati, Ohio, United States|Univ Hosp Cleveland /ID# 139615, Cleveland, Ohio, United States|Fairview Hospital /ID# 144403, Cleveland, Ohio, United States|Cleveland Clinic Main Campus /ID# 139501, Cleveland, Ohio, United States|The Ohio State University - Columbus /ID# 138053, Columbus, Ohio, United States|Columbus NCORP /ID# 139587, Columbus, Ohio, United States|Womens Cancer Center /ID# 138062, Kettering, Ohio, United States|Hillcrest Hospital /ID# 144404, Mayfield Heights, Ohio, United States|Univ Oklahoma HSC /ID# 138020, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists /ID# 138059, Tulsa, Oklahoma, United States|Willamette Valley Cancer Institute /ID# 140318, Eugene, Oregon, United States|Kaiser Permanente, NW /ID# 138249, Portland, Oregon, United States|Abington Memorial Hospital /ID# 138086, Abington, Pennsylvania, United States|University of Pennsylvania /ID# 140079, Philadelphia, Pennsylvania, United States|Thomas Jefferson University /ID# 138239, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center /ID# 149479, Philadelphia, Pennsylvania, United States|University of Pittsburgh MC /ID# 138054, Pittsburgh, Pennsylvania, United States|Reading Hospital /ID# 138057, Reading, Pennsylvania, United States|Women and Infants Hospital /ID# 138083, Providence, Rhode Island, United States|Medical University of South Carolina /ID# 138181, Charleston, South Carolina, United States|Sanford Research/USD /ID# 139624, Sioux Falls, South Dakota, United States|Chattanoogas Program in Womens /ID# 139545, Chattanooga, Tennessee, United States|Texas Oncology - Austin Central /ID# 143817, Austin, Texas, United States|Texas Oncology - South Austin /ID# 143818, Austin, Texas, United States|Texas Oncology - Bedford /ID# 143814, Bedford, Texas, United States|Texas Oncology - Medical City Dallas /ID# 143809, Dallas, Texas, United States|Texas Oncology - Medical City Dallas /ID# 143812, Dallas, Texas, United States|Texas Oncology - Forth Worth /ID# 143811, Fort Worth, Texas, United States|Houston Methodist Hospital - Scurlock Tower /ID# 138232, Houston, Texas, United States|Memorial Hermann Hospital /ID# 138238, Houston, Texas, United States|Texas Oncology - The Woodlands /ID# 142003, The Woodlands, Texas, United States|Texas Oncology - Tyler /ID# 143810, Tyler, Texas, United States|University of Utah /ID# 138250, Salt Lake City, Utah, United States|University of Vermont Medical Center /ID# 138251, Burlington, Vermont, United States|University of Virginia /ID# 138088, Charlottesville, Virginia, United States|Carilion Roanoke Memorial Hosp /ID# 139602, Roanoke, Virginia, United States|Skagit Valley Medical Center /ID# 139586, Mount Vernon, Washington, United States|MultiCare Regional Cancer Ctr /ID# 149872, Puyallup, Washington, United States|Multicare Institute for Research and Innovation /ID# 143485, Tacoma, Washington, United States|HSHS St. Vincent Hospital /ID# 139453, Green Bay, Wisconsin, United States|Froedtert & the Medical College of Wisconsin /ID# 139449, Milwaukee, Wisconsin, United States|Coffs Harbour Health Campus /ID# 145132, Coffs Harbour, New South Wales, Australia|Gosford Hospital /ID# 145299, Gosford, New South Wales, Australia|St George Hospital /ID# 145138, Kogarah, New South Wales, Australia|Newcastle Private Hospital /ID# 145834, Lambton Heights, New South Wales, Australia|The Prince of Wales Hospital /ID# 145134, Randwick, New South Wales, Australia|Northern Cancer Institute /ID# 145681, St Leonards, New South Wales, Australia|Calvary Mater Newcastle /ID# 145139, Waratah, New South Wales, Australia|Westmead Hospital /ID# 145137, Westmead, New South Wales, Australia|Southern Medical Day Care Ctr /ID# 145133, Wollongong, New South Wales, Australia|The Townsville Hospital /ID# 149163, Douglas, Queensland, Australia|Royal Brisbane and Women's Hospital /ID# 145135, Herston, Queensland, Australia|Icon Cancer Centre /ID# 148208, South Brisbane, Queensland, Australia|Mater Misericordiae Limited /ID# 145682, South Brisbane, Queensland, Australia|Royal Adelaide Hospital /ID# 150071, Adelaide, South Australia, Australia|Monash Health /ID# 145297, Clayton, Victoria, Australia|Cabrini Health /ID# 145142, Malvern, Victoria, Australia|Royal Womens Hospital /ID# 145136, Parkville, Victoria, Australia|Sir Charles Gairdner Hospital /ID# 145140, Nedlands, Western Australia, Australia|St. John of God Subiaco Hosp /ID# 147742, Subiaco, Western Australia, Australia|Hc Ufmg /Id# 137156, Belo Horizonte, Minas Gerais, Brazil|Hospital Sao Lucas da PUCRS /ID# 137157, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital de Cancer de Barretos /ID# 137121, Barretos, Sao Paulo, Brazil|Centro de Referencia da Saude da Mulher - Hospital Perola Byington /ID# 137120, São Paulo, Sao Paulo, Brazil|Instituto Nacional de Câncer José de Alencar Gomes da Silva (INCA) /ID# 137155, Rio de Janeiro, Brazil|Vejle Sygehus /ID# 137262, Vejle, Syddanmark, Denmark|Regionshospitalet Herning /ID# 137260, Herning, Denmark|Rambam Health Care Campus /ID# 137434, Haifa, Israel|The Lady Davis Carmel MC /ID# 137537, Haifa, Israel|Shaare Zedek Medical Center /ID# 137435, Jerusalem, Israel|Meir Medical Center /ID# 139397, Kfar Saba, Israel|Sheba Medical Center /ID# 137436, Ramat Gan, Israel|Kaplan Medical Center /ID# 137536, Rehovot, Israel|Aichi Cancer Center Hospital /ID# 148398, Nagoya-shi, Aichi, Japan|National Hospital Organization Kyushu Cancer Center /ID# 149133, Fukuoka-shi, Fukuoka, Japan|Kurume University Hospital /ID# 148697, Kurume-shi, Fukuoka, Japan|Iwate Medical University Hospital /ID# 147721, Shiwa-gun, Iwate, Japan|Kumamoto University Hospital /ID# 154169, Kumamoto-shi, Kumamoto, Japan|Mie University Hospital /ID# 149169, Tsu-shi, Mie, Japan|Tohoku University Hospital /ID# 149818, Sendai-shi, Miyagi, Japan|Niigata University Medical & Dental Hospital /ID# 149488, Niigata-shi, Niigata, Japan|Kindai University Hospital /ID# 154947, Osaka-sayama, Osaka, Japan|Shizuoka Cancer Center /ID# 147723, Sunto-gun, Shizuoka, Japan|The Cancer Institute Hosp JFCR /ID# 148436, Koto-ku, Tokyo, Japan|Keio University Hospital /ID# 148326, Shinjuku-ku, Tokyo, Japan|Yamagata University Hospital /ID# 153646, Yamagata-shi, Yamagata, Japan|Hyogo Cancer Center /ID# 148327, Akashi, Japan|Kansai Rosai Hospital /ID# 149237, Amagasaki, Japan|The Jikei Univ. Kashiwa Hosp. /ID# 149238, Kashiwa-shi, Japan|St. Marianna Univ Hospital /ID# 149327, Kawasaki, Japan|NHO Kure Medical Center and Ch /ID# 148569, Kure, Japan|Shikoku Cancer Center /ID# 148382, Matsuyama, Japan|Osaka International Cancer Institute /ID# 150778, Osaka, Japan|Hokkaido Cancer Center /ID# 148570, Sapporo, Japan|The Jikei University Hospital /ID# 148691, Tokyo, Japan|National Cancer Center /ID# 139404, Goyang, Gyeonggido, Korea, Republic of|Korea University Anam Hospital /ID# 136908, 성북구, Gyeonggido, Korea, Republic of|Gangnam Severance Hospital /ID# 136835, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 136834, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul National University Hospital /ID# 136909, Seoul, Korea, Republic of|Asan Medical Center /ID# 136836, Seoul, Korea, Republic of|Auckland City Hospital /ID# 145123, Auckland, New Zealand|Uniwersyteckie C. Kliniczne /ID# 138021, Gdańsk, Poland|Hospital Duran i Reynals /ID# 137298, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Univ Vall d'Hebron /ID# 137297, Barcelona, Spain|Hospital Clinic de Barcelona /ID# 137300, Barcelona, Spain|Hospital Clin Univ San Carlos /ID# 137402, Madrid, Spain|Hosp Univ 12 de Octubre /ID# 137299, Madrid, Spain|Hosp Univ Madrid Sanchinarro /ID# 137414, Madrid, Spain|Fundacion Inst Valenciano Onc /ID# 137403, Valencia, Spain|Norfolk and Norwich Univ Hosp /ID# 137969, Norwich, Norfolk, United Kingdom|Beatson west of scotland cancer center /ID# 137965, Glasgow, Scotland, United Kingdom|Ninewells Hospital /ID# 137967, Dundee, United Kingdom|James Paget University Hosp /ID# 137970, Great Yarmouth, United Kingdom|Imanova Limited, Hammersmith Hospital /ID# 137966, London, United Kingdom|Oxford Univ Hosp NHS Trust /ID# 137973, Oxford, United Kingdom",https://ClinicalTrials.gov/show/NCT02470585
75,Eli Lilly and Company,A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer,"Active, not recruiting",Has Results,Breast Neoplasms,Drug: Abemaciclib|Drug: Fulvestrant|Drug: Placebo,Industry,Interventional,"Highlands Oncology Group, Fayetteville, Arkansas, United States|Clopton Clinic, Jonesboro, Arkansas, United States|Southern California Permanente Medical Group, Bellflower, California, United States|Univ of California San Francisco, San Francisco, California, United States|Southern California Permanente Medical Group, San Marcos, California, United States|Stanford University Clinic, Stanford, California, United States|Rocky Mountain Cancer Center, Aurora, Colorado, United States|Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Advanced Medical Specialties, Miami, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|H Lee Moffitt Cancer Center, Tampa, Florida, United States|Palm Beach Cancer Institue, West Palm Beach, Florida, United States|Northeast Georgia Cancer Care, LLC, Athens, Georgia, United States|Harbin Clinic, Rome, Georgia, United States|Quincy Medical Group, Quincy, Illinois, United States|Community Clinical Research Center, Anderson, Indiana, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Breslin Cancer Center, Lansing, Michigan, United States|Minnesota Oncology/Hematology PA, Minneapolis, Minnesota, United States|Freeman Cancer Institute, Joplin, Missouri, United States|St Lukes Hospital, Kansas City, Missouri, United States|Washington University Medical Center, Saint Louis, Missouri, United States|Billings Clinic Research Center, Billings, Montana, United States|Oncology Hematology West, Omaha, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Mount Sinai School of Medicine Dermatology Clinical Trials, New York, New York, United States|Columbia University College of Phys & Surgeons, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Rochester General Hospital, Rochester, New York, United States|Novant Health, Oncology Research Institute, Winston-Salem, North Carolina, United States|Sandford Research/USD, Sioux Falls, North Dakota, United States|SMO Sanford Research, Sioux Falls, North Dakota, United States|Tulsa Cancer Institute, PLLC, Tulsa, Oklahoma, United States|Sanford Research/USD, Sioux Falls, South Dakota, United States|The Jones Clinic, Germantown, Tennessee, United States|The Boston Baskin Cancer Group, Memphis, Tennessee, United States|SMO Sarah Cannon Research Inst., Nashville, Tennessee, United States|Texas Oncology Cancer Center, Austin, Texas, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Bedford, Texas, United States|Texas Oncology Fort Worth, Fort Worth, Texas, United States|Texas Oncology-Memorial City, Houston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Oncology Consultants Cancer Center, Houston, Texas, United States|Texas Oncology-Plano East, Plano, Texas, United States|SMO US Oncology, The Woodlands, Texas, United States|Tyler Cancer Center, Tyler, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|Oncology and Hematology Associates of Southwest Virginia Inc, Salem, Virginia, United States|Columbia Basin Hematology & Oncology, Kennewick, Washington, United States|St Mary Regional Cancer Center, Walla Walla, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., East Bentleigh, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kurralta Park, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., South Brisbane, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Southport, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Subiaco, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussel, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edegem, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liège, Belgium|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Calgary, Alberta, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., London, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Toronto, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aalborg, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Herlev, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roskilde, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oulu, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampere, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Turku, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Besancon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Clermont-Ferrand, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Chaussee Saint Victor, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Le Mans, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Augsburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ludwigsburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munich, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tübingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chania, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heraklion, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Patras, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bologna, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cona, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Padova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bunkyo-ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiba, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chuo-Ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kagoshima, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kashiwa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kawasaki, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kitaadachi-Gun, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Koto-ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kurume, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Matsuyama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nagoya, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Niigata, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nishinomiya, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sapporo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shimotsuke, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chungbuk, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gyeonggi-Do, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Incheon, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulsan-Si, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leon, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nuevo Leon, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tijuana, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bialystok, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gdansk, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lodz, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wieliszew, Poland|Puerto Rico Hematology/Oncology Group, Bayamon, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bucharest, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cluj-Napoca, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Craiova, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Arkhangelsk, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kursk, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Petersburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Elche, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lleida, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Murcia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Basel, Switzerland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Genève, Switzerland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Thun, Switzerland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kaohsiung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kuei Shan Hsiang, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taoyuan, Taiwan",https://ClinicalTrials.gov/show/NCT02107703
76,Eli Lilly and Company,A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer,"Active, not recruiting",Has Results,Metastatic Breast Cancer,Drug: Abemaciclib|Drug: Tamoxifen|Drug: Prophylactic Loperamide,Industry,Interventional,"Arizona Cancer Center, Tucson, Arizona, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States|University of Wisconsin-Madison Hospital and Health Clinic, Madison, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Caba, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Rosario, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Salta, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, San Salvador de Jujuy, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Tucuman, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Viedma, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Graz, Steiermark, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Innsbruck, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleroi, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gent, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liege, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sint-Niklaas, Belgium|Fundação PIO XII, Barretos, Brazil|Hospital São Lucas da PUCRS, Porto Alegre, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sao Paulo, Brazil|Clinica de Pesquisas e Centro de Estudos em Oncologia Ginecológica e Mamária LTDA, São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brno, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Praha 10, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Praha 2, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Praha 4, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Praha 5, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marseille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulm, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bologna, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Napoli, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Negrar, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roma, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Culiacan, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oaxaca, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Bernardino, Mexico|Republic Oncology Dispensary of MoH of Republic Tatarstan, Kazan, Russian Federation|St-Petersburg scientifical practical center of specialized kinds of medical care (oncological), Saint Petersburg, Russian Federation|Saint-Petersburg city clinical oncology dispensary, Saint Petersburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taoyuan City, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Adana, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ankara, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Istanbul, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Istanbul, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kayseri, Turkey",https://ClinicalTrials.gov/show/NCT02747004
77,Novartis Pharmaceuticals|Novartis,Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2),"Active, not recruiting",Has Results,"Advanced, Metastatic Breast Cancer",Drug: LEE011|Drug: Letrozole|Drug: LEE011 Placebo,Industry,Interventional,"Ironwood Cancer and Research Centers SC, Chandler, Arizona, United States|Arizona Oncology Associates PC HAL, Sedona, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|NEA Baptist Cancer Center, Jonesboro, Arkansas, United States|Alta Bates Cancer Center Oncology Dept., Berkeley, California, United States|City of Hope National Medical Center SC-5, Duarte, California, United States|Glendale-Adventist Medical Center Dept of Oncology, Glendale, California, United States|The Angeles Clinic and Research Institute SC-3, Los Angeles, California, United States|Cedars Sinai Medical Center SC-5, Los Angeles, California, United States|UC Davis Comprehensive Cancer Center SC-2, Sacramento, California, United States|University of Colorado School of Medicine Onc Dept., Aurora, Colorado, United States|Rocky Mountain Cancer Centers RMCC - Aurora, Greenwood Village, Colorado, United States|University Cancer Institute SC, Boynton Beach, Florida, United States|Florida Cancer Research Institute Dept of Oncology, Davie, Florida, United States|Florida Cancer Specialists FL Cancer Specialists, Fort Myers, Florida, United States|Memorial Hospital SC, Hollywood, Florida, United States|University of Miami Univ Miami 2, Miami, Florida, United States|Florida Retina Institute SC-3, Orlando, Florida, United States|Florida Retina Institute SC-5, Orlando, Florida, United States|Sacred Heart Medical Oncology SC, Pensacola, Florida, United States|Florida Cancer Specialists - North, Saint Petersburg, Florida, United States|Georgia Cancer Specialists Georgia Cancer Spec, Decatur, Georgia, United States|Lewis Hall Singletary Onc Ctr at John D. Archbold Mem Hosp. Onc Dept, Thomasville, Georgia, United States|Moanalua Medical Center. Attn: Oncology Dept, Honolulu, Hawaii, United States|University of Illinois Cancer Center at Chicago, Chicago, Illinois, United States|University of Chicago Dept. of Oncology, Chicago, Illinois, United States|North Shore University Health System, Evanston, Illinois, United States|Ingalls Memorial Hospital Ingalls Mem Hosp, Harvey, Illinois, United States|Edward Hospital Dept of Oncology, Naperville, Illinois, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Med SC-3, Baltimore, Maryland, United States|Frederick Memorial Hospital SC, Frederick, Maryland, United States|Dana Farber Cancer Institute Dana Farber-9, Boston, Massachusetts, United States|Virginia Piper Cancer Institute, Allina Health, Minneapolis, Minnesota, United States|Jackson Oncology Associates, Jackson, Mississippi, United States|Saint Luke's Hospital/Marion Bloch Neuroscience Institute Oncology Dept, Kansas City, Missouri, United States|Mercy Medical Research Institute SC-1, Manchester, Missouri, United States|Foundation Medical Partners, Nashua, New Hampshire, United States|Hackensack Meridian Health, Brick, New Jersey, United States|Cooper Cancer Center Cooper Cancer Center, Camden, New Jersey, United States|Cancer Institute of New Jersey Onc Dept, New Brunswick, New Jersey, United States|Montefiore Medical Center SC-8, Bronx, New York, United States|CR Wood Cancer Center, Glens Falls, New York, United States|Winthrop University Hospital Onc Dept, Mineola, New York, United States|NYU Langone Medical Center CV Research center SC-2, New York, New York, United States|Mount Sinai School of Medicine SC, New York, New York, United States|Duke University Medical Center SC-8, Durham, North Carolina, United States|Oncology Hematology Care Inc Oncology Hematology Care (3), Cincinnati, Ohio, United States|The Ohio State University Comprehensive Cancer Center Ohio State-2, Columbus, Ohio, United States|Mercy Clinic Oklahoma Communities Mercy Oncology, Oklahoma City, Oklahoma, United States|Lehigh Valley Hospital Onc Dept, Allentown, Pennsylvania, United States|Penn State University Milton S Hershey Medical Center SC-3, Hershey, Pennsylvania, United States|Avera Cancer SC-2, Sioux Falls, South Dakota, United States|Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology, Chattanooga, Tennessee, United States|Sarah Cannon Research Institute SC-2, Nashville, Tennessee, United States|Vanderbilt University Medical Center SC-4, Nashville, Tennessee, United States|Texas Oncology, P.A., Bedford, Texas, United States|Texas Oncology P A SC-3, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Center for Cancer and Blood Disorders SC, Fort Worth, Texas, United States|Texas Oncology, P.A., Fort Worth, Texas, United States|Texas Oncology Houston Memorial City SC, Houston, Texas, United States|University of Texas MD Anderson Cancer Center UT MDAnderson, Houston, Texas, United States|Millennium Oncology SC, Houston, Texas, United States|Texas Oncology, McAllen, Texas, United States|Richardson Hematology Oncology Associates, Richardson, Texas, United States|Texas Oncology P A, San Antonio, Texas, United States|US Oncology P A, Tyler, Texas, United States|Utah Cancer Specialists Utah Cancer Specialists (11), Salt Lake City, Utah, United States|Virginia Cancer Specialists Fairfax Northern Virginia, Fairfax, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia Inc, Salem, Virginia, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Northwest Medical Specialties Dept of Onc, Tacoma, Washington, United States|Dean Health System Onc Dept, Madison, Wisconsin, United States|Novartis Investigative Site, San Miguel De Tucuman, Tucuman, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, La Rioja, Argentina|Novartis Investigative Site, Kurralta Park, South Australia, Australia|Novartis Investigative Site, East Melbourne, Victoria, Australia|Novartis Investigative Site, Nedlands, Western Australia, Australia|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Sint Niklaas, Vlaams Brabant, Belgium|Novartis Investigative Site, Hasselt, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Ribeirao Preto, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Burnaby, British Columbia, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Hamilton, Ontario, Canada|Novartis Investigative Site, Kitchener, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Brno Bohunice, Czech Republic, Czechia|Novartis Investigative Site, Brno, Czech Republic, Czechia|Novartis Investigative Site, Liberec, Czech Republic, Czechia|Novartis Investigative Site, Olomouc, CZE, Czechia|Novartis Investigative Site, Aarhus, Denmark|Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Odense C, Denmark|Novartis Investigative Site, Vejle, Denmark|Novartis Investigative Site, Helsinki, Finland|Novartis Investigative Site, Turku, Finland|Novartis Investigative Site, Nice Cedex 2, Alpes Maritimes, France|Novartis Investigative Site, France, Villejuif, France|Novartis Investigative Site, Angers Cedex 02, France|Novartis Investigative Site, Avignon Cedex, France|Novartis Investigative Site, Besancon Cedex, France|Novartis Investigative Site, Bordeaux Cedex, France|Novartis Investigative Site, Creteil, France|Novartis Investigative Site, Le Mans Cedex, France|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Pierre Benite Cedex, France|Novartis Investigative Site, Rouen Cedex 1, France|Novartis Investigative Site, Saint-Herblain Cédex, France|Novartis Investigative Site, Recklinghausen, North Rhine-westphalia, Germany|Novartis Investigative Site, Aschaffenburg, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bielefeld, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Bottrop, Germany|Novartis Investigative Site, Duesseldorf, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Fuerth, Germany|Novartis Investigative Site, Goslar, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Offenbach, Germany|Novartis Investigative Site, Ravensburg, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Velbert, Germany|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Gyor, Hungary|Novartis Investigative Site, Gyula, Hungary|Novartis Investigative Site, Cork, Ireland|Novartis Investigative Site, Dublin 4, Ireland|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Brescia, BS, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Lecco, LC, Italy|Novartis Investigative Site, Macerata, MC, Italy|Novartis Investigative Site, Messina, ME, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Perugia, PG, Italy|Novartis Investigative Site, Pisa, PI, Italy|Novartis Investigative Site, Aviano, PN, Italy|Novartis Investigative Site, Reggio Calabria, RC, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Candiolo, TO, Italy|Novartis Investigative Site, Terni, TR, Italy|Novartis Investigative Site, Viterbo, VT, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Bundang Gu, Gyeonggi Do, Korea, Republic of|Novartis Investigative Site, Gyeonggi do, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Ashrafieh, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Saida, Lebanon|Novartis Investigative Site, Maastricht, AZ, Netherlands|Novartis Investigative Site, Alkmaar, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Deventer, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Leiden, Netherlands|Novartis Investigative Site, Sittard-Geleen, Netherlands|Novartis Investigative Site, Tilburg, Netherlands|Novartis Investigative Site, Zwolle, Netherlands|Novartis Investigative Site, Bergen, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Arkhangelsk, Russian Federation|Novartis Investigative Site, Nizhniy Novgorod, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Pretoria, Gauteng, South Africa|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, La Laguna, Santa Cruz De Tenerife, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Eskilstuna, Sweden|Novartis Investigative Site, Goteborg, Sweden|Novartis Investigative Site, Joenkoeping, Sweden|Novartis Investigative Site, Lund, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Vaxjo, Sweden|Novartis Investigative Site, Kuei-Shan Chiang, Taoyuan/ Taiwan ROC, Taiwan|Novartis Investigative Site, New Taipei City, TWN, Taiwan|Novartis Investigative Site, Kaohsiung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Diyarbakir, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Truro, Cornwall, United Kingdom|Novartis Investigative Site, Newcastle upon Tyne, United Kingdom",https://ClinicalTrials.gov/show/NCT01958021
78,"Genentech, Inc.",A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy,"Active, not recruiting",Has Results,Metastatic Breast Cancer,Drug: Pertuzumab|Drug: Trastuzumab,Industry,Interventional,"Arizona Cancer Center, Tucson, Arizona, United States|City of Hope National Medical Center, Duarte, California, United States|Stanford Cancer Institute, Stanford, California, United States|University of Miami Hospital & Clinics, Miami, Florida, United States|H. Lee Moffitt Cancer Center and Research Inst., Tampa, Florida, United States|Northwestern University, Chicago, Illinois, United States|University of Maryland Medical Center; Department of Neurology, Baltimore, Maryland, United States|Associates in Oncology-Hematology, PC, Bethesda, Maryland, United States|Dana Farber Cancer Inst., Boston, Massachusetts, United States|Allina Health System, Saint Paul, Minnesota, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Mid Ohio Oncology Hematology;ZangMeister Center (West), Columbus, Ohio, United States|Temple Cancer Center; Oncology, Philadelphia, Pennsylvania, United States|Methodist Hospital Research Institute, Houston, Texas, United States|Huntsman Cancer Institute; University of Utah, Salt Lake City, Utah, United States|Northwest Medical Specialties, PLLC, Tacoma, Washington, United States",https://ClinicalTrials.gov/show/NCT02536339
79,Bristol-Myers Squibb,"A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks","Active, not recruiting",Has Results,Lung Cancer,Biological: Nivolumab,Industry,Interventional,"Alabama Oncology, Birmingham, Alabama, United States|Arizona Oncology Assoc, Pc-Hal, Phoenix, Arizona, United States|Arizona Oncology Associates PC - NAHOA, Phoenix, Arizona, United States|CBCC Global Research, Inc., Bakersfield, California, United States|Southern California Permanente Medical Group, Bellflower, California, United States|St Jude Hospital Yorba Linda, Fullerton, California, United States|UCLA Hematology/Oncology Clinic, Los Angeles, California, United States|Torrance Health Association, Redondo Beach, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Sansum Clinic, Santa Barbara, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|Kaiser Permanente Medical Center (clinic+DSL), Vallejo, California, United States|Rocky Mountain Cancer Centers Llp, Denver, Colorado, United States|Poudre Valley Health Care, Fort Collins, Colorado, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States|Ocala Oncology Center, Pl, Ocala, Florida, United States|Sacred Heart Medical Oncology Group, Pensacola, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|University Cancer Blood Ctr, Athens, Georgia, United States|John B. Amos Cancer Center, Columbus, Georgia, United States|Northwest Georgia Oncology Ctr, Marietta, Georgia, United States|Ingalls Health System, Harvey, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Illinois Cancercare, PC, Peoria, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Innova Schar Cancer Institute, Indianapolis, Indiana, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Oncology Associated Of Western Kentucky, Paducah, Kentucky, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Cancer Care Of Maine, Brewer, Maine, United States|Center For Cancer And Blood Disorders, Bethesda, Maryland, United States|Providence Cancer Center, Southfield, Michigan, United States|Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States|North Mississippi Med Center, Tupelo, Mississippi, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|Oncology Hematology West PC, Omaha, Nebraska, United States|New York Oncology Hematology, P.C., Clifton Park, New York, United States|Broome Oncology, Johnson City, New York, United States|First Health Of The Carolinas, Pinehurst, North Carolina, United States|Hematology And Oncology Associates, Canton, Ohio, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|MetroHealth Cancer Care Center, Cleveland, Ohio, United States|Tri-County Hematology & Oncology Associates, Inc, Massillon, Ohio, United States|Hematology Oncology Consultants, Pc, Medford, Oregon, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Jones Clinic PC, Germantown, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Texas Oncology, P.A., Abilene, Texas, United States|Texas Oncology - Amarillo, Amarillo, Texas, United States|Texas Oncology, P.A., Dallas, Texas, United States|Texas Oncology, P.A., Dallas, Texas, United States|Texas Oncology, P.A., Denton, Texas, United States|Texas Oncology, P.A., El Paso, Texas, United States|Texas Oncology, P.A., Flower Mound, Texas, United States|Texas Oncology, P.A., Houston, Texas, United States|Texas Oncology, P.A., Longview, Texas, United States|Texas Oncology-Midland Allison Cancer Center, Midland, Texas, United States|Texas Oncology, P.A., Plano, Texas, United States|Texas Oncology, P.A., San Antonio, Texas, United States|Texas Oncology, P.A., Sherman, Texas, United States|Texas Oncology, P.A., Sugar Land, Texas, United States|Texas Oncology, Wichita Falls, Texas, United States|Innova Schar Cancer Institute, Falls Church, Virginia, United States|Shenandoah Oncology, Winchester, Virginia, United States|Cancer Care Northwest, Spokane Valley, Washington, United States|Northwest Cancer Specialists, P.C., Vancouver, Washington, United States|Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington, United States|Local Institution, Waratah, New South Wales, Australia|Local Institution, Westmead,, New South Wales, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Bedford Park, South Australia, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Kurralta Park, South Australia, Australia|Local Institution, Hobart, Tasmania, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Murdoch, Australia|Local Institution, St Leonards, Australia|Local Institution, Wien, Austria|Local Institution, Newmarket, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, St. Jerome, Quebec, Canada|Local Institution, Quebec, Canada|Local Institution, Angers, France|Local Institution, Bayonne, France|Local Institution, Clermont-Ferrand, France|Local Institution, Le Mans, France|Local Institution, Mulhouse, France|Local Institution, Nimes, France|Local Institution, Paris, France|Local Institution, Paris, France|Local Institution, Pontoise, France|Local Institution, Suresnes, France|Local Institution, Tours, France|Local Institution, Vandoeuvre-les-Nancy, France|Local Institution, Villefranche-sur-Saone, France|Local Institution, Bad Berka, Germany|Local Institution, Berlin, Germany|Local Institution, Dresden, Germany|Local Institution, Freiburg, Germany|Local Institution, Gauting, Germany|Local Institution, Greifenstein, Germany|Local Institution, Hamburg, Germany|Local Institution, Hannover, Germany|Local Institution, Kassel, Germany|Local Institution, Kiel, Germany|Local Institution, Leipzig, Germany|Local Institution, Lostau, Germany|Local Institution, Moers, Germany|Local Institution, Nurnberg, Germany|Local Institution, Localita San Filippo Lucca, Italy|Local Institution, Monza, Italy|Local Institution, Napoli, Italy|Local Institution, Roma, Italy|Local Institution, Barcelona, Spain|Local Institution, El Palmar, Spain|Local Institution, Las Palmas de Gran Canaria, Spain|Local Institution, Sevilla, Spain",https://ClinicalTrials.gov/show/NCT02713867
80,Eisai Inc.|Merck Sharp & Dohme Corp.,Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC),"Active, not recruiting",Has Results,Breast Neoplasm,Drug: Eribulin Mesylate|Drug: Pembrolizumab,Industry,Interventional,"Facility #1, Duarte, California, United States|Facility #1, Santa Barbara, California, United States|Facility #1, Denver, Colorado, United States|Facility #1, Miami, Florida, United States|Facility #1, West Palm Beach, Florida, United States|Facility #1, Boston, Massachusetts, United States|Facility #2, Boston, Massachusetts, United States|Facility #1, Minneapolis, Minnesota, United States|Facility #1, Saint Louis, Missouri, United States|Facility #1, Lebanon, New Hampshire, United States|Facility #1, New York, New York, United States|Facility #2, New York, New York, United States|Facility #1, Chattanooga, Tennessee, United States|Facility #1, Nashville, Tennessee, United States|Facility #1, Austin, Texas, United States|Facility #1, Fort Worth, Texas, United States|Facility #1, San Antonio, Texas, United States|Facility #2, San Antonio, Texas, United States|Facility #1, Sherman, Texas, United States|Facility #1, Salem, Virginia, United States|Facility #1, Winchester, Virginia, United States|Facility #1, Madison, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT02513472
81,"Eli Lilly and Company|Parexel|PPD|Medidata Solutions|Laboratory Corporation of America|University of Colorado, Denver|Thermo Fisher Scientific|ICON Clinical Research|Pacific Biomarkers|Sysmex Inostics GmbH|Intertek",First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin,"Active, not recruiting",Has Results,Non Small Cell Lung Cancer,Biological: Necitumumab|Drug: Gemcitabine|Drug: Cisplatin,Industry|Other,Interventional,"ImClone Investigational Site, Chandler, Arizona, United States|ImClone Investigational Site, Fayetteville, Arkansas, United States|ImClone Investigational Site, Sacramento, California, United States|ImClone Investigational Site, Galesburg, Illinois, United States|ImClone Investigational Site, Goshen, Indiana, United States|ImClone Investigational Site, Wichita, Kansas, United States|ImClone Investigational Site, Hazard, Kentucky, United States|ImClone Investigational Site, Baltimore, Maryland, United States|ImClone Investigational Site, Jefferson City, Missouri, United States|ImClone Investigational Site, Lincoln, Nebraska, United States|ImClone Investigational Site, New York, New York, United States|ImClone Investigational Site, Akron, Ohio, United States|ImClone Investigational Site, Camp Hill, Pennsylvania, United States|ImClone Investigational Site, Memphis, Tennessee, United States|ImClone Investigational Site, Fairfax, Virginia, United States|ImClone Investigational Site, Garran, New South Wales, Australia|ImClone Investigational Site, Westmead, New South Wales, Australia|ImClone Investigational Site, Wollongong, New South Wales, Australia|ImClone Investigational Site, East Bentleigh, Victoria, Australia|ImClone Investigational Site, Geelong, Victoria, Australia|ImClone Investigational Site, Linz, Austria|ImClone Investigational Site, Wien, Austria|ImClone Investigational Site, Wien, Austria|ImClone Investigational Site, Duffel, Belgium|ImClone Investigational Site, Liege, Belgium|ImClone Investigational Site, Namur, Belgium|ImClone Investigational Site, Barretos, Brazil|ImClone Investigational Site, Brasilia, Distrito Federal, Brazil|ImClone Investigational Site, Goiania, Brazil|ImClone Investigational Site, Ijui, Brazil|ImClone Investigational Site, Itajai, Brazil|ImClone Investigational Site, Lajeado, Brazil|ImClone Investigational Site, Porto Alegre/RS, Brazil|ImClone Investigational Site, Salvador, Brazil|ImClone Investigational Site, Santo Andre, Brazil|ImClone Investigational Site, Sao Paulo, Brazil|ImClone Investigational Site, São Paulo - SP, Brazil|ImClone Investigational Site, Saint John, New Brunswick, Canada|ImClone Investigational Site, Brampton, Ontario, Canada|ImClone Investigational Site, Saskatoon, Saskatchewan, Canada|ImClone Investigational Site, Dubrovnik, Croatia|ImClone Investigational Site, Pula, Croatia|ImClone Investigational site, Zagreb, Croatia|ImClone Investigational Site, Brest Cedex, France|ImClone Investigational Site, Caen, France|ImClone Investigational Site, Draguignan, France|ImClone Investigational Site, Grenoble, France|ImClone Investigational Site, Le Mans Cedex, France|ImClone Investigational Site, Le Mans, France|ImClone Investigational Site, Lille, France|ImClone Investigational Site, Lyon, France|ImClone Investigational Site, Marseille, France|ImClone Investigational Site, Paris, France|ImClone Investigational Site, Paris, France|ImClone Investigational Site, Paris, France|ImClone Investigational Site, Paris, France|ImClone Investigational Site, Rennes, France|ImClone Investigational Site, Saint-Jean, France|ImClone Investigational Site, Toulon Armées, France|ImClone Investigational Site, Berlin, Germany|ImClone Investigational Site, Essen, Germany|ImClone Investigational Site, Essen, Germany|ImClone Investigational Site, Frankfurt, Germany|ImClone Investigational Site, Gauting, Germany|ImClone Investigational Site, Großhansdorf, Germany|ImClone Investigational Site, Halle, Germany|ImClone Investigational Site, Hamburg, Germany|ImClone Investigational Site, Hamburg, Germany|ImClone Investigational Site, Heidelberg, Germany|ImClone Investigational Site, Hemer, Germany|ImClone Investigational Site, Hofheim, Germany|ImClone Investigational Site, Karlsruhe, Germany|ImClone Investigational Site, Lostau, Germany|ImClone Investigational Site, Löwenstein, Germany|ImClone Investigational Site, München, Germany|ImClone Investigational Site, Münster, Germany|ImClone Investigational Site, Regensburg, Germany|ImClone Investigational Site, Regensburg, Germany|ImClone Investigational Site, Ulm, Germany|ImClone Investigational Site, Athens, Greece|ImClone Investigational Site, Heraklion, Crete, Greece|ImClone Investigational Site, Patras, Greece|ImClone Investigational Site, Thessaloniki, Greece|ImClone Investigational Site, Budapest, Hungary|ImClone Investigational Site, Budapest, Hungary|ImClone Investigational Site, Deszk, Hungary|ImClone Investigational Site, Farkasgyepü, Hungary|ImClone Investigational Site, Mosonmagyaróvár, Hungary|ImClone Investigational Site, Szombathely, Hungary|ImClone Investigational Site, Székesfehérvár, Hungary|ImClone Investigational Site, Törökbálint, Hungary|ImClone Investigational Site, Lido di Camaiore, Lucca, Italy|ImClone Investigational Site, Aviano, Pordenone, Italy|ImClone Investigational Site, Frosinone, Italy|ImClone Investigational Site, Genova, Italy|ImClone Investigational Site, Milano, Italy|ImClone Investigational Site, Milano, Italy|ImClone Investigational Site, Monza, Italy|ImClone Investigational Site, Parma, Italy|ImClone Investigational Site, Perugia, Italy|ImClone Investigational Site, Incheon, Korea, Republic of|ImClone Investigational Site, Jeonju-si, Korea, Republic of|ImClone Investigational Site, Seongnam, Korea, Republic of|ImClone Investigational Site, Seoul, Korea, Republic of|ImClone Investigational Site, Seoul, Korea, Republic of|ImClone Investigational Site, Seoul, Korea, Republic of|ImClone Investigational Site, Suwon, Korea, Republic of|ImClone Investigational Site, Cebu City, Philippines|ImClone Investigational Site, Cebu, Philippines|ImClone Investigational Site, Davao City, Philippines|ImClone Investigational Site, Makati City, Philippines|ImClone Investigational Site, Manila, Philippines|ImClone Investigational Site, Quezon City, Philippines|ImClone Investigational Site, Quezon City, Philippines|ImClone Investigational Site, Olsztyn, Poland|ImClone Investigational Site, Otwock, Poland|ImClone Investigational Site, Poznan, Poland|ImClone Investigational Site, Radom, Poland|ImClone Investigational Site, Rzeszow, Poland|ImClone Investigational Site, Szczecin, Poland|ImClone Investigational Site, Torun, Poland|ImClone Investigational Site, Wroclaw, Poland|ImClone Investigational Site, Coimbra, Portugal|ImClone Investigational Site, Lisboa, Portugal|ImClone Investigational Site, Lisboa, Portugal|ImClone Investigational Site, Porto, Portugal|ImClone Investigational Site, Brasov, Romania|ImClone Investigational Site, Bucharest, Romania|ImClone Investigational Site, Bucharest, Romania|ImClone Investigational Site, Cluj-Napoca, Romania|ImClone Investigational Site, Craiova, Dolj, Romania|ImClone Investigational Site, Iasi, Romania|ImClone Investigational Site, Piatra Neamt, Romania|ImClone Investigational Site, Sibiu, Romania|ImClone Investigational Site, Ivanovo, Russian Federation|ImClone Investigational Site, Kirov, Russian Federation|ImClone Investigational Site, Krasnodar, Russian Federation|ImClone Investigational Site, Moscow, Russian Federation|ImClone Investigational Site, Omsk, Russian Federation|ImClone Investigational Site, Smolensk, Russian Federation|ImClone Investigational Site, St. Petersburg, Russian Federation|ImClone Investigational Site, St. Petersburg, Russian Federation|ImClone Investigational Site, St. Petersburg, Russian Federation|ImClone Investigational Site, St. Petersburg, Russian Federation|ImClone Investigational Site, Ufa, Russian Federation|ImClone Investigational Site, Yaroslavl, Russian Federation|ImClone Investigational Site, Belgrade, Serbia|ImClone Investigational Site, Kragujevac, Serbia|ImClone Investigational Site, Nis, Serbia|ImClone Investigational Site, Sremska Kamenica, Serbia|ImClone Investigational Site, Singapore, Singapore|ImClone Investigational Site, Bratislava, Slovakia|ImClone Investigational Site, Nitra, Slovakia|ImClone Investigational Site, Poprad, Slovakia|ImClone Investigational Site, Bloemfontein, Free State, South Africa|ImClone Investigational Site, Pretoria, Gauteng, South Africa|ImClone Investigational Site, Durban, Kwazulu-Natal, South Africa|ImClone Investigational Site, Sevilla, Andalucía, Spain|ImClone Investigational Site, Avila, Castilla Y Leon, Spain|ImClone Investigational Site, Barcelona, Cataluña, Spain|ImClone Investigational Site, Barcelona, Cataluña, Spain|ImClone Investigational Site, Terrassa, Cataluña, Spain|ImClone Investigational Site, Madrid, Communidad De Madrid, Spain|ImClone Investigational Site, Madrid, Communidad De Madrid, Spain|ImClone Investigational Site, Majadahonda, Communidad De Madrid, Spain|ImClone Investigational Site, Barcelona, Spain|ImClone Investigational Site, L'Hospitalet de Llobregat, Spain|ImClone Investigational Site, Madrid, Spain|ImClone Investigational Site, Taichung, Taiwan|ImClone Investigational Site, Taichung, Taiwan|ImClone Investigational Site, Chiang Mai, Thailand|ImClone Investigational Site, Songkhla, Thailand|ImClone Investigational Site, Aberdeen, United Kingdom|ImClone Investigational Site, Bournemouth, United Kingdom|ImClone Investigational Site, Dundee, United Kingdom|ImClone Investigational Site, Edinburgh, United Kingdom|ImClone Investigational Site, Guildford, United Kingdom|ImClone Investigational Site, Liverpool, United Kingdom|ImClone Investigational Site, London, United Kingdom|ImClone Investigational Site, Manchester, United Kingdom|ImClone Investigational Site, Manchester, United Kingdom|ImClone Investigational Site, Preston, United Kingdom",https://ClinicalTrials.gov/show/NCT00981058
82,Novartis Pharmaceuticals|Novartis,Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.,"Active, not recruiting",Has Results,Cancer,Drug: Dabrafenib|Device: Trametinib,Industry,Interventional,"Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Orange, California, United States|Novartis Investigative Site, Aurora, Colorado, United States|Novartis Investigative Site, Tampa, Florida, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Rochester, Minnesota, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Lebanon, New Hampshire, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Syracuse, New York, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Madison, Wisconsin, United States|Novartis Investigative Site, Caen Cedex 9, France|Novartis Investigative Site, Lille cedex, France|Novartis Investigative Site, Marseille cedex 20, France|Novartis Investigative Site, Paris Cedex 12, France|Novartis Investigative Site, Pierre Benite, France|Novartis Investigative Site, Saint-Herblain cedex, France|Novartis Investigative Site, Strasbourg cedex, France|Novartis Investigative Site, Toulouse cedex 9, France|Novartis Investigative Site, Villejuif, France|Novartis Investigative Site, Heidelberg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Gauting, Bayern, Germany|Novartis Investigative Site, Frankfurt/Main, Hessen, Germany|Novartis Investigative Site, Moers, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Grosshansdorf, Schleswig-Holstein, Germany|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Orbassano (TO), Piemonte, Italy|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Alicante, Spain|Novartis Investigative Site, Badalona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Granada, Spain|Novartis Investigative Site, La Coruna, Spain|Novartis Investigative Site, Las Palmas De Gran Canaria, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Malaga, Spain|Novartis Investigative Site, Oviedo, Spain|Novartis Investigative Site, Palma de Mallorca, Spain|Novartis Investigative Site, Pamplona, Spain|Novartis Investigative Site, Sevilla, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Sutton, Surrey, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom|Novartis Investigative Site, Oxford, United Kingdom",https://ClinicalTrials.gov/show/NCT01336634
83,"Millennium Pharmaceuticals, Inc.|European Network of Translational Research in Ovarian Cancer - EUTROC|European Network of Individualized Treatment in Endometrial Cancer - ENITEC|Takeda","A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer","Active, not recruiting",Has Results,Endometrial Neoplasms,Drug: Paclitaxel|Drug: Sapanisertib|Drug: MLN1117,Industry|Other,Interventional,"University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States|University of Arizona Cancer Center, Phoenix, Arizona, United States|Marin Cancer Care, Greenbrae, California, United States|University of California San Diego Medical Center, La Jolla, California, United States|University of California at San Francisco (PARENT), San Francisco, California, United States|Stanford School of Medicine, Stanford, California, United States|H. Lee Moffitt Cancer Center and Research Institute, Inc, Tampa, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|Augusta University, Augusta, Georgia, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|University of Kansas Medical Center Research Institute, Inc., Westwood, Kansas, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|NYU Langone Medical Center Clinic, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center Cancer Center at Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|St George Hospital, Kogarah, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Monash Medical Centre Clayton, Clayton, Victoria, Australia|Sunshine Hospital, Footscray, Victoria, Australia|Cabrini Hospital Malvern, Malvern, Victoria, Australia|Peter MacCallum Cancer Centre-East Melbourne, Melbourne, Victoria, Australia|UZ Antwerpen, Edegem, Antwerpen, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|UZ Leuven, Leuven, Belgium|Centre Hospitalier Universitaire de Liege Site Sart Tilman, Liege, Belgium|GasthuisZusters Antwerpen Sint-Augustinus, Wilrijk, Belgium|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Juravinski Cancer Clinic, Hamilton, Ontario, Canada|LHSC - Victoria Hospital, London, Ontario, Canada|Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CHUM Hopital Notre-Dame, Montreal, Quebec, Canada|Universitaetsmedizin Greifswald, Greifswald, Mecklenburg Vorpommern, Germany|Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden, Sachsen, Germany|Universitaetsklinikum Schleswig-Holstein - Campus Luebeck, Luebeck, Schleswig Holstein, Germany|Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum, Berlin, Germany|Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori, Meldola, Forli - Cesena, Italy|Spedali Civili di Brescia, Brescia, Italy|Ente Ospedaliero Ospedali Galliera, Genova, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|IEO Istituto Europeo di Oncologia, Milano, Italy|Istituto Tumori Napoli Fondazione G. Pascale, Napoli, Italy|Azienda Unita Sanitaria Locale di Ravenna, Ravenna, Italy|Istituto Nationale Tumori Regina Elena, Roma, Italy|Universita degli Studi di Roma ""La Sapienza"" - Umberto I Policlinico di Roma, Roma, Italy|Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy|Maastricht Universitair Medisch Centrum, Maastricht, Limburg, Netherlands|Academisch Medisch Centrum, Amsterdam, Noord-holland, Netherlands|Erasmus Medisch Centrum Daniel den Hoed, Rotterdam, Zuid-holland, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Haukeland universitetssykehus, Kvinneklinikken, Bergen, Norway|Radiumhospitalet, Oslo, Norway|Stavanger University Hospital, Stavanger, Norway|Hospital Universitari Vall d'Hebron, Barcelona, Spain|MD Anderson Cancer Centre, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario Clinico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Centro Integral Oncologico Clara Campal, Madrid, Spain|Instituto Valenciano de Oncologia IVO, Valencia, Spain|Bristol Haematology and Oncology Centre, Bristol, Avon, United Kingdom|Royal Devon and Exeter Hospital (Wonford), Exeter, Devon, United Kingdom|University College London Hospitals, London, Greater London, United Kingdom|Royal Marsden Hospital, London, Greater London, United Kingdom|Hammersmith Hospital, London, Greater London, United Kingdom|The Christie, Manchester, Greater Manchester, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom",https://ClinicalTrials.gov/show/NCT02725268
84,"Celgene|Agios Pharmaceuticals, Inc.",Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation,"Active, not recruiting",Has Results,Hematologic Neoplasms,Drug: Enasidenib,Industry,Interventional,"City of Hope, Duarte, California, United States|Stanford Cancer Center, Stanford, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|University of Miami Sylvester Cancer Center, Miami, Florida, United States|Florida Cancer Specialists, Sarasota, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Northwestern University, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Cornell University Weill Medical College, New York, New York, United States|Memorial Sloan-Kettering Cancer Center - NYC, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University, Gahanna, Ohio, United States|Oregon Health and Science University OHSU, Portland, Oregon, United States|Sarah Cannon Research Institute Drug Development Unit, Nashville, Tennessee, United States|UT Southwestern Medical Center at Dallas, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Institut Bergonie Department Oncologie, Bordeaux, France|Hospital Saint Louis, Paris, France|Hospital haut leveque, Pessac, France|CHU Purpan, Toulouse, France|Institut Gustave Roussy, Villejuif, France",https://ClinicalTrials.gov/show/NCT01915498
85,Hoffmann-La Roche|NSABP Foundation Inc|German Breast Group,A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE),"Active, not recruiting",Has Results,Breast Cancer,Drug: trastuzumab|Drug: trastuzumab emtansine,Industry|Other,Interventional,"Providence Alaska Medical Center, Anchorage, Alaska, United States|Todd Cancer Institute at Long Beach Memorial Medical Center, Long Beach, California, United States|Chao Family Comprehensive Cancer Center; UC Irvine Medical Center, Orange, California, United States|Kaiser Permanente - San Diego, San Diego, California, United States|Breastlink Medical Group Inc, Santa Ana, California, United States|Stanford University Medical Center, Stanford, California, United States|Kaiser Permanente - Vallejo, Vallejo, California, United States|Kaiser Permanente - Franklin, Denver, Colorado, United States|Colorado Cancer Research Program/Admin, Denver, Colorado, United States|Rocky Mountain Cancer Centers - Colorado Springs (Circle), Lone Tree, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|Yale Cancer Center, New Haven, Connecticut, United States|Washington Cancer Institute; Washington Hospital Center, Washington, District of Columbia, United States|University of Florida; Davis Cancer Pavilion and Shands Medical Plaza, Gainesville, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|UF Health Orlando, Orlando, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Edward Cancer Center Naperville, Naperville, Illinois, United States|Edward Cancer Center Plainfield, Plainfield, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|University of Kentucky Medical Center, Lexington, Kentucky, United States|Norton Healthcare Inc., Louisville, Kentucky, United States|Cancer Care of Maine, Brewer, Maine, United States|New England Cancer Specialists, Scarborough, Maine, United States|Mercy Medical Center; Medical Oncology & Hematology, Baltimore, Maryland, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Med Star Franklin Square Medical Center/Weinburg Cancer Institute, Baltimore, Maryland, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Spectrum Health Hospitals, Grand Rapids, Michigan, United States|Breslin Cancer Center, Lansing, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|US Oncology Research at Minnesota Oncology, Minneapolis, Minnesota, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Sparta Cancer Center, Sparta, New Jersey, United States|Columbia University Medical Center, New York, New York, United States|Troy Cancer Treatment Program, Troy, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Batte Cancer Center - Carolinas Medical Center, Concord, North Carolina, United States|Sanford Roger Maris Cancer Center, Fargo, North Dakota, United States|Aultman Hospital; Aultman Hospital Cancer Center, Canton, Ohio, United States|Fairview Hospital; Cleveland Clinic Cancer Center, Cleveland, Ohio, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University, Arthur James Cancer Hospital, Columbus, Ohio, United States|Lake Health/University Hospitals - Mentor Campus, Mentor, Ohio, United States|Columbia River Oncology Program, Portland, Oregon, United States|Kimmel Cancer Center Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Allegheny Cancer Center, Pittsburgh, Pennsylvania, United States|Uni of Pittsburgh; Magee-Women'S Hospital, Pittsburgh, Pennsylvania, United States|York Hospital, York, Pennsylvania, United States|Medical University of South Carolina; Hollings Cancer Center, Charleston, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States|Houston Methodist Hospital Outpatient Center, Houston, Texas, United States|Uni of Texas - Md Anderson Cancer Center; Dept of Breast Medical Oncology, Houston, Texas, United States|Joe Arrington Cancer Research & Treatment Center, Lubbock, Texas, United States|Hematology Oncology Associates of Fredericksburg, Inc., Fredericksburg, Virginia, United States|Lynchburg Hem Onc Clinic Inc, Lynchburg, Virginia, United States|Virginia Commonwealth University - Massey Cancer Center, Richmond, Virginia, United States|Swedish Cancer Institute - Issaquah, Issaquah, Washington, United States|PeaceHealth St. John Medical Center - Lower Columbia Cancer Center, Longview, Washington, United States|Cancer Care Northwest, Spokane, Washington, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina|Instituto de Oncología de Rosario, Rosario, Argentina|Tiroler Landeskrankenanstalten Ges.M.B.H.; Abt. Für Gynäkologie, Innsbruck, Austria|Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt., Salzburg, Austria|Medizinische Universität Wien; Univ.Klinik für Frauenheilkunde - Klinik für Gynäkologie, Wien, Austria|Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie, Wien, Austria|Cliniques Universitaires St-Luc, Bruxelles, Belgium|AZ Sint Lucas (Sint Lucas), Gent, Belgium|CHU Sart-Tilman, Liège, Belgium|Sint Augustinus Wilrijk, Wilrijk, Belgium|Iop Instituto de Oncologia Do Parana, Curitiba, PR, Brazil|Instituto Nacional de Cancer - INCa; Oncologia, Rio de Janeiro, RJ, Brazil|Clinicas Oncologicas Integradas - COI, Rio De Janeiro, RJ, Brazil|UPCO - Unidade de Pesquisas Clínicas em Oncologia, Pelotas, RS, Brazil|Hospital Moinhos de Vento, Porto Alegre, RS, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil|Hospital de Cancer de Barretos, Barretos, SP, Brazil|Instituto de Ensino e Pesquisa Sao Lucas - IEP, Sao Paulo, SP, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, Brazil|Hospital Perola Byington, Sao Paulo, SP, Brazil|Hospital Sao Jose, São Paulo, SP, Brazil|Tom Baker Cancer Centre; Dept of Medicine, Calgary, Alberta, Canada|Cross Cancer Institute ; Dept of Medical Oncology, Edmonton, Alberta, Canada|Bcca-Fraser Valley Cancer Centre, Surrey, British Columbia, Canada|British Columbia Cancer Agency (Bcca) - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|London Regional Cancer Centre, London, Ontario, Canada|The Ottawa Hospital; Division of Infectious Diseases, Ottawa, Ontario, Canada|University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada|CSSS champlain - Charles-Le Moyne, Greenfield Park, Quebec, Canada|Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada|McGill University Health Center, Cedar Cancer Center, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Hopital du Saint Sacrement, Quebec City, Quebec, Canada|the First Hospital of Jilin University, Changchun, China|Sun Yet-sen University Cancer Center, Guangzhou, China|Guangdong General Hospital, Guangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Shandong Cancer Hospital, Jinan, China|Shanghai Jiao Tong University School of Medicine (SJTUSM) - Ruijin Hospital (GuangCi Hospital), Shanghai, China|Fudan University Shanghai Cancer Center, Shanghai, China|Clinica del Country, Bogota, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|Oncomedica S.A., Monteria, Colombia|Fakultni Nemocnice Hradec Kralove; Dept of Radiotherapy & Oncology, Hradec Kralove, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|Institut Sainte Catherine;Recherche Clinique, Avignon, France|HOPITAL JEAN MINJOZ; Oncologie, Besancon, France|Institut Bergonie; Oncologie, Bordeaux, France|Centre Hospitalier Fleyriat; Oncologie/Hematologie, Bourg En Bresse, France|Centre Francois Baclesse; Comite Sein, Caen, France|Centre Jean Perrin; Oncologie, Clermont Ferrand, France|Clinique Victor Hugo; Chimiotherapie, Le Mans, France|Institut Paoli Calmettes; Oncologie Medicale, Marseille, France|Centre Val Aurelle Paul Lamarque; Recherche Clinique, Montpellier, France|Institut Curie; Oncologie Medicale, Paris, France|Hopital Saint Louis; Oncologie Medicale, Paris, France|HOPITAL TENON; Cancerologie Medicale, Paris, France|Centre Henri Becquerel; Oncologie Medicale, Rouen, France|Centre Rene Huguenin; CONSULT SPECIALISEES, St Cloud, France|Centre Paul Strauss; Oncologie Medicale, Strasbourg, France|Institut Gustave Roussy; Departement Oncologie Medicale, Villejuif, France|Hämatologisch-onkologische Praxis Dr. med. - Heinrich, - Bangerter, Augsburg, Germany|Praxisklinik Krebsheilkunde für Frauen / Brustzentrum (Dres. Kittel/Klare), Berlin, Germany|Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, Germany|HELIOS Klinikum Berlin-Buch; Klinik für Gynäkologie und Geburtshilfe, Berlin, Germany|Studienzentrum Berlin City, Berlin, Germany|Onkologische Schwerpunktpraxis Bielefeld, Bielefeld, Germany|Klinikum Sindelfingen-Böblingen; Frauenklinik, Böblingen, Germany|St. Johannes-Hospital, Dortmund, Germany|Luisenkrankenhaus GmbH & Co. KG., Brustzentrum, Düsseldorf, Germany|Universitätsklinikum Erlangen; Frauenklinik, Erlangen, Germany|Universitätsklinikum Essen; Zentrum Für Frauenheilkunde, Essen, Germany|Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH; Klinik für Senologie / Brustzentrum, Essen, Germany|Klinikum Esslingen; Klinik für Frauenheilkunde und Geburtshilfe, Esslingen, Germany|Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt am Main, Germany|Klinik Johann Wolfgang von Goethe Uni; Klinik für Frauenheilkunde und Geburtshilfe, Frankfurt, Germany|Universitätsklinikum Freiburg; Frauenklinik, Freiburg, Germany|Evangelische Kliniken Gelsenkirchen GmbH; Brustzentrum, Gelsenkirchen, Germany|Universitätsklinikum Greifswald; Klinik für Frauenheilkunde und Brustzentrum, Greifswald, Germany|Krankenhaus St. Elisabeth und St. Barbara, Klinik für Frauenheilkunde und Geburtshilfe, Halle, Germany|Universitätsklinikum Halle (Saale); Universitätsklinik Und Poliklinik Für Gynäkologie, Halle, Germany|Kooperatives Mammazentrum Hamburg Krankenhaus Jerusalem, Hamburg, Germany|St. Barbara-Klinik Hamm-Heessen GmbH; Frauenklinik, Hamm, Germany|Gynaekologisch-Onkologische Schwerpunktpraxis Prof. Dr. med. Lueck, Dr. Schrader und Dr. Noeding, Hannover, Germany|Diakovere Henriettenstift, Frauenklinik, Hannover, Germany|Medizinische Hochschule Hannover, Klinik für Frauenheilkunde und Geburtshilfe, Hannover, Germany|Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg, Heidelberg, Germany|Elisabeth-Krankenhaus Brustzentrum, Kassel, Germany|Klinikum Kassel GmbH; Klinik für Frauenheilkunde und Geburtshilfe, Kassel, Germany|UNI-Klinikum Campus Kiel Klinik für Gynäkologie und Geburtshilfe, Kiel, Germany|St. Elisabeth Krankenhaus Köln GmbH; Gynäkologie und Geburtshilfe, Koeln, Germany|Kliniken der Stadt Köln gGmbH Krankenhaus Holweide; Brustzentrum, Köln, Germany|Gemeinschaftspraxis; Onkologisches Zentrum Lebach; Caritas Krankenhaus Lebach, Lebach, Germany|Klinikum der Universität München; Frauenklinik - Onkologie II, München, Germany|Gemeinschaftspraxis Prof. Dr.med. Christoph Salat und Dr.med. Oliver J. Stötzer, München, Germany|MVZ Nordhausen gGmbH, Praxis Dr. Grafe, Nordhausen, Germany|Sana Klinikum Offenbach GmbH; Klinik für Gynäkologie & Geburtshilfe, Offenbach, Germany|St. Vincenz-Krankenhaus Paderborn; Haus 3 Frauenklinik, Paderborn, Germany|Oncologianova GmbH - Gesellschaft für Innovationen in der Onkologie, Recklinghausen, Germany|Klinikum am Steinenberg Frauenklinik, Reutlingen, Germany|Universitätsfrauen- und Poliklinik am Klinikum Suedstadt, Rostock, Germany|gSUND Gynäkologie Kompetenzzentrum Stralsund; Frauenheilkunde & Geburtshilfe, Stralsund, Germany|Robert-Bosch-Krankenhaus; Brustzentrum, Stuttgart, Germany|Gemeinschaftspraxis Dr. Kronawitter und Dr. Jung, Traunstein, Germany|Universitätsklinik Tübingen; Frauenklinik, Tübingen, Germany|Universitätsklinikum Ulm Am Michelsberg; Frauenklinik, Ulm, Germany|HELIOS Dr. Horst Schmidt Kliniken Wiesbaden; Klinik für Gynäkologie und gynäkologische Onkologie, Wiesbaden, Germany|Marien-Hospital Witten; Frauenklinik Brustzentrum, Witten, Germany|Hämatologisch-Onkologische Schwerpunktpraxis; Dres. Schlag & Schöttker, Würzburg, Germany|Univ General Hosp Heraklion; Medical Oncology, Heraklion, Greece|Euromedical General Clinic of Thessaloniki; Oncology Department, Thessaloniki, Greece|Grupo Angeles, Guatemala City, Guatemala|Centro Oncológico Sixtino / Centro Oncológico SA, Guatemala, Guatemala|Queen Mary Hospital; Surgery, Hong Kong, Hong Kong|Pamela Youde Nethersole Eastern Hospital; Clinical Oncology, Hong Kong, Hong Kong|Tuen Mun Hospital; Clinical Oncology, Hong Kong, Hong Kong|Cork Uni Hospital; Oncology Dept, Cork, Ireland|St Vincent'S Uni Hospital; Medical Oncology, Dublin, Ireland|Mater Misericordiae Uni Hospital; Oncology, Dublin, Ireland|Beaumont Hospital; Cancer Clinical Trials Unit, Dublin, Ireland|Galway Uni Hospital; Oncology Dept, Galway, Ireland|University Hospital Limerick - Oncology, Limerick, Ireland|Soroka Medical Center, Beer Sheva, Israel|Shaare Zedek Medical Center; Oncology Dept, Jerusalem, Israel|Hadassah University Hospital - Ein Kerem, Jerusalem, Israel|Rabin MC; Davidof Center - Oncology Institute, Petach Tikva, Israel|Sheba Medical Center; Tel Hashomer, Ramat Gan, Israel|Kaplan Medical Center; Oncology Inst., Rehovot, Israel|Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Campania, Italy|Università degli Studi Federico II; Clinica di Oncologia Medica, Napoli, Campania, Italy|Policlinico S.Orsola-Malpighi; Istituto Oncologia R. Addarii, Bologna, Emilia-Romagna, Italy|Ausl Di Bologna-Ospedale Bellaria;U.O. Oncologia Medica, Bologna, Emilia-Romagna, Italy|Policlinico Universitario Campus Biomedico; Uoc Oncologia Medica, Roma, Lazio, Italy|Az. Osp. Sant'Andrea; Oncologia Medica, Roma, Lazio, Italy|IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A, Genova, Liguria, Italy|Asst Papa Giovanni XXIII; Oncologia Medica, Bergamo, Lombardia, Italy|ASST DI CREMONA; Unità di Patologia Mammaria Senologia e Breast Unit, Cremona, Lombardia, Italy|Irccs Ospedale San Raffaele;Oncologia Medica, Milano, Lombardia, Italy|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1, Milano, Lombardia, Italy|Istituto Europeo Di Oncologia, Milano, Lombardia, Italy|ASST DI MONZA; Oncologia Medica, Monza, Lombardia, Italy|Fondazione Del Piemonte Per L'oncologia IRCC Di Candiolo, Candiolo, Piemonte, Italy|Ospedale Antonio Perrino; Oncologia Medica, Brindisi, Puglia, Italy|Azlenda Ospendaliero-Universitaria Pisana; C.O. Oncologia 2, Pisa, Toscana, Italy|Azienda usl 5 Di Pisa-Ospedale Di Pontedera;U.O. Oncologia, Pontedera, Toscana, Italy|IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II, Padova, Veneto, Italy|A.O.U.I. VERONA-OSPEDALE BORGO TRENTO; ONCOLODIA MEDICA-d.O., Verona, Veneto, Italy|Hospital Angeles Metropolitano; Room 220, Mexico City, Mexico CITY (federal District), Mexico|Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico|Instituto Nacional de Cancerologia; Oncology, Distrito Federal, Mexico|Nstituto Nacional de Ciancias Medicas Y Nutricion, Salvador Zubir, Mexico City, Mexico|Oaxaca Site Management Organization, Oaxaca, Mexico|Centro Hemato Oncologico Panama, Panama, Panama|Centro Oncologico America, Panama, Panama|Centro Medico Monte Carmelo, Arequipa, Peru|Hospital Nacional Carlos Alberto Seguin Escobedo-Essalud; Oncology & Haemathology, Arequipa, Peru|Hospital IV Alberto Sabogal Sologuren; Unidad de Investigacion, Bellavista, Peru|Hospital Nacional Guillermo Almenara Irigoyen; Oncology, Lima, Peru|Clinica San Borja, Lima, Peru|Institute for Oncology and Radiology of Serbia; Medical Oncology, Belgrade, Serbia|Oncology Institute of Vojvodina, Sremska Kamenica, Serbia|Cape Town Oncology Trials, Cape Town, South Africa|Hopelands Cancer Centre, Hilton, South Africa|Medical Oncology Centre of Rosebank; Oncology, Johannesburg, South Africa|Wits Donald Gordon Clinical Trial Centre; Medical Oncology, Parktown, Johannesburg, South Africa|Cancercare, Port Elizabeth, South Africa|Private Oncology Centre, Pretoria, South Africa|Hospital de Donostia; Servicio de Oncologia Medica, San Sebastian, Guipuzcoa, Spain|Hospital Severo Ochoa; Servicio de Oncologia, Leganes, Madrid, Spain|Complexo Hospitalario de Vigo. Hospital Álvaro Cunqueiro; Servicio de Oncología, Vigo, Pontevedra, Spain|Hospital Universitari Sant Joan de Reus; Servicio de Oncologia, Reus, Tarragona, Spain|Hospital Clínic i Provincial; Servicio de Oncología, Barcelona, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia, Madrid, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Oncologia, Malaga, Spain|Hospital de Navarra; Servicio de Oncologia, Navarra, Spain|Hospital Clinico Universitario de Salamanca; Servicio de Oncologia, Salamanca, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Instituto Valenciano Oncologia; Oncologia Medica, Valencia, Spain|Hospital Universitario Dr. Peset; Servicio de Oncologia, Valencia, Spain|Gävle Sjukhus; Onkologiska Kliniken, Gävle, Sweden|Skånes University Hospital, Skånes Department of Onclology, Lund, Sweden|Karolinska Hospital; Oncology - Radiumhemmet, Stockholm, Sweden|Kantonsspital Aarau; Zentrum Für Onkologie, Hämatologie & Transfusionsmedizin, Aarau, Switzerland|Brustzentrum, Zürich, Switzerland|Taichung Veterans General Hospital; Dept of Surgery, Taichung, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology, Taipei City, Taiwan|VETERANS GENERAL HOSPITAL; Department of General Surgery, Taipei, Taiwan|National Taiwan Uni Hospital; General Surgery, Taipei, Taiwan|Chang Gung Medical Foundation-Taipei, Taoyuan, Taiwan|Uludag Uni Hospital; Oncology, Bursa, Turkey|Trakya University Medical Faculty Research And Practice Hospital Medical Oncology Department, Edirne, Turkey|Kartal Training and Research Hospital;Medical Oncology Department, Istanbul, Turkey|Ege Uni Medical Faculty Hospital; Oncology Dept, Izmir, Turkey|Inonu University Medical Faculty Turgut Ozal Medical Center Medical Oncology Department, Malatya, Turkey|University Hospital Birmingham The Cancer Centre, Queen Elizabeth Hospital, Birmingham, United Kingdom|Bradford Royal Infirmary; Dept of Medical Oncology C/O Ward15, Bradford, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, United Kingdom|Castle Hill Hospital; The Queens Centre for Oncology and Haematology, Cottingham, United Kingdom|North Devon District Hospital, Devon, United Kingdom|Ninewells Hospital; Cancer Medicine, Dundee, United Kingdom|Huddersfield Royal Infirmary, Huddersfield, United Kingdom|Leeds Teaching Hosp NHS Trust;St James's Institute of Onc, Leeds, United Kingdom|St Thomas Hospital; Medicine Div., London, United Kingdom|Charing Cross Hospital; Medical Oncology., London, United Kingdom|Christie Hospital Nhs Trust; Medical Oncology, Manchester, United Kingdom|Nottingham City Hospital; Oncology, Nottingham, United Kingdom|Weston Park Hospital, Sheffield, United Kingdom|Royal Cornwall Hospital; Dept of Clinical Oncology, Truro, United Kingdom",https://ClinicalTrials.gov/show/NCT01772472
86,"Massachusetts General Hospital|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Genentech, Inc.","Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer","Active, not recruiting",Has Results,Breast Cancer,Drug: cisplatin|Drug: bevacizumab|Drug: doxorubicin|Drug: cyclophosphamide|Drug: paclitaxel,Other|Industry,Interventional,"Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT00580333
87,Hoffmann-La Roche,"A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer","Active, not recruiting",Has Results,Early Breast Cancer,Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Docetaxel|Drug: Paclitaxel|Drug: Pertuzumab IV|Drug: FDC of Pertuzumab and Trastuzumab SC|Drug: Trastuzumab IV|Drug: Trastuzumab SC|Procedure: Surgery|Radiation: Post-operative Radiotherapy|Drug: Hormone Therapy,Industry,Interventional,"Maryland Oncology Hematology, Rockville, Maryland, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Northwest Medical Specialties, Lakewood, Washington, United States|Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina|COIBA, Provincia De Buenos Aires, Argentina|Institut Jules Bordet, Brussels, Belgium|GHdC Site Notre Dame, Charleroi, Belgium|UZ Antwerpen, Edegem, Belgium|Jessa Zkh (Campus Virga Jesse), Hasselt, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Clinique Ste-Elisabeth, Namur, Belgium|Hospital Araujo Jorge; Departamento de Ginecologia E Mama, Goiania, GO, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil|Hospital Perola Byington, Sao Paulo, SP, Brazil|Royal Victoria Hospital, Barrie, Ontario, Canada|Lakeridge Health Center; R. S. MacLaughlin Durham Regional Cancer Center, Oshawa, Ontario, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke - Hopital Fleurimont, Sherbrooke, Quebec, Canada|Masarykuv onkologicky ustav, Brno, Czechia|Multiscan s.r.o., Pardubice, Czechia|ICO Paul Papin; Oncologie Medicale., Angers, France|Institut Sainte Catherine, Avignon, France|CHRU Besançon, Besançon, France|Institut Bergonie; Oncologie, Bordeaux, France|Centre Léon Bérard, Lyon, France|Institut Curie; Oncologie Medicale, Paris, France|Hôpital Saint-Louis: Service Pharmacie - essaie Clinique, Paris, France|ICO - Site René Gauducheau, Saint Herblain, France|Klinikum Augsburg; Frauenklinik, Augsburg, Germany|Hochwaldkrankenhaus; Abt.Gynäkologie Geburtshilfe u.Senologie, Bad Nauheim, Germany|Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, Germany|St. Johannes-Hospital, Dortmund, Germany|Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH; Klinik für Senologie / Brustzentrum, Essen, Germany|Kooperatives Mammazentrum Hamburg Krankenhaus Jerusalem, Hamburg, Germany|Sana Klinikum Offenbach GmbH; Klinik für Gynäkologie & Geburtshilfe, Offenbach, Germany|gSUND Gynäkologie Kompetenzzentrum Stralsund; Frauenheilkunde & Geburtshilfe, Stralsund, Germany|Istituto Nazionale Tumori Irccs Fondazione g. PASCALE;U.O.C. Oncologia Medica Senologica, Napoli, Campania, Italy|Università degli Studi Federico II; Clinica di Oncologia Medica, Napoli, Campania, Italy|Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica, Aviano, Friuli-Venezia Giulia, Italy|Uni Degli Studi Di Genova ; Clinica Di Medicina Interna Ad Indirizzo Oncologico, Genova, Liguria, Italy|ASST DI LECCO; Oncologia Medica, Lecco, Lombardia, Italy|IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II, Padova, Veneto, Italy|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Gifu University Hospital, Gifu, Japan|Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan|Hiroshima University Hospital, Hiroshima, Japan|National Hospital Organization Hokkaido Cancer Center, Hokkaido, Japan|Hyogo College of Medicine Hospital, Hyogo, Japan|Sagara Hospital, Kagoshima, Japan|Kanagawa Cancer Center, Kanagawa, Japan|Tokai University Hospital, Kanagawa, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|Osaka International Cancer Institute, Osaka, Japan|Saitama Medical University International Medical Center, Saitama, Japan|St. Luke's International Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Ulsan University Hosiptal, Ulsan, Korea, Republic of|Centro Médico Zambrano Hellion, Monterrey, Nuevo LEON, Mexico|Oncologico Potosino, San Luis Potosí, SAN LUIS Potosi, Mexico|Iem-Fucam, D.f., Mexico|Bialostockie Centrum Onkologii im. Marii Sklodowskiej - Curie, Bialystok, Poland|Narodowy Inst.Onkol.im.Sklodowskiej-Curie Panstw.Inst.Bad Gliwice; Centr.Diagn.i Lecz.Chor.Piersi, Gliwice, Poland|Szpital Uniwersytecki w Krakowie, Kraków, Poland|Zachodniopomorskie Centrum Onkologii, Osrodek Innowacyjnosci, Rozwoju i Badan Klinicznych, Szczecin, Poland|Narodowy Inst.Onkologii im.Sklodowskiej-Curie Panstw.Inst.Bad; Klinika Nowtw.Piersi i Chir.Rekonstr, Warszawa, Poland|Dolnoslaskie Centrum Onkologii, Wroclaw, Poland|Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Russian Federation|Ivanovo Regional Oncology Dispensary, Ivanovo, Russian Federation|Clinical Oncology Dispensary of Ministry of Health of Tatarstan, Kazan, Russian Federation|Moscow city oncology hospital #62 of Moscow Healthcare Department, Moscow, Russian Federation|Omsk Region Clinical Oncology Dispensary; 1St Sergical Department, Omsk, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, Russian Federation|Hospital Universitario Reina Sofia; Servicio de Oncologia, Córdoba, Cordoba, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coruña, Spain|Hospital de Cruces; Servicio de Oncología Médica, Barakaldo, Vizcaya, Spain|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Institut Catala d Oncologia Hospital Duran i Reynals, Barcelona, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain|China Medical University Hospital; Surgery, Taichung, Taiwan|VETERANS GENERAL HOSPITAL; Department of General Surgery, Taipei, Taiwan|Chang Gung Medical Foundation - Linkou; Dept of Surgery, Taoyuan, Taiwan|Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Hospital; Department of Surgery/Head Neck and Breast Unit; Clinical Trial, Chiang Mai, Thailand|Songklanagarind Hospital; Department of Surgery, Songkla, Thailand|Municipal Noncommercial Institution Regional Center of Oncology, Kharkiv, Kharkiv Governorate, Ukraine|Chemotherapy SI Dnipropetrovsk MA of MOHU, Dnipropetrovsk, Ukraine|National Cancer Institute MOH of Ukraine, Kiev, Ukraine|Lviv State Oncology Regional Treatment and Diagnostic Centre, Lviv, Ukraine|RCI Sumy Regional Clinical Oncological Dispensary, Sumy, Ukraine|Brighton and Sussex Univ Hosp, Brighton, United Kingdom|Velindre Cancer Centre, Cardiff, United Kingdom|St Georges University Hospitals NHS Foundation Trust, London, United Kingdom|Christie Hospital NHS Trust, Manchester, United Kingdom|Freeman Hospital, Newcastle upon Tyne, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Peterborough City Hospital, Peterborough, United Kingdom",https://ClinicalTrials.gov/show/NCT03493854
88,Eli Lilly and Company,A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer,"Active, not recruiting",Has Results,Ovarian Cancer,Drug: Prexasertib,Industry,Interventional,"Arizona Oncology Associates, P.C., Tucson, Arizona, United States|Kaiser Permanente Medical Center, Vallejo, California, United States|University of Southern Florida School of Medicine, Gainesville, Florida, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Research Medical Center, Kansas City, Missouri, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cancer Care Associates, Tulsa, Oklahoma, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Sioux Valley Clinic, Sioux Falls, South Dakota, United States|University of Tennessee Medical Center, Knoxville, Tennessee, United States|Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Westmead Hospital, Wentworthville, New South Wales, Australia|Royal Brisbane and Womens Hospital, Herston, Queensland, Australia|Mater Adult Hospital Brisbane, South Brisbane, Queensland, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Burnside War Memorial Hospital, Toorak Gardens, South Australia, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Institut Jules Bordet, Brussel, Belgium|Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgium|GZA St Augustinus, Wilrijk, Belgium|Rambam Medical Center, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Sheba Medical Center, Ramat Gan, Israel|Policlinico Univ. Agostino Gemelli, Roma, Lazio, Italy|Istituto Europeo di Oncologia, Milano, Milan, Italy|Istituto Tumori Fondazione G. Pascale IRCCS, Napoli, Naples, Italy|Samsung Medical Center, Seoul, Korea, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, Korea, Republic of|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Reina Sofia, Cordoba, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|University College Hospital - London, London, Greater London, United Kingdom|Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom|Mount Vernon Hospital, Northwood, Middlesex, United Kingdom|Royal Surrey County Hospital, Guildford, Surrey, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, United Kingdom|Northampton General Hospital, Northampton, United Kingdom",https://ClinicalTrials.gov/show/NCT03414047
89,US Oncology Research|Bristol-Myers Squibb|Pfizer,PhII ICb With/Without Erbitux in MBC Pts,"Active, not recruiting",Has Results,Metastatic Breast Cancer,Drug: Irinotecan + Carboplatin|Drug: irinotecan + Carboplatin + erbitux,Industry,Interventional,"Birmingham Hematology and Oncology, Birmingham, Alabama, United States|Hematology Oncology Asscociates, Phoenix, Arizona, United States|Northern AZ Hematology & Oncology Assoc, Sedona, Arizona, United States|Rocky Mountain Cancer Center-Rose, Denver, Colorado, United States|Northwestern Connecticut Oncology Hematology Associates, Torrington, Connecticut, United States|Melbourne Internal Medicine Associates, Melbourne, Florida, United States|Florida Cancer Institute, New Port Richey, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Cancer Centers of Florida, P.A., Ocoee, Florida, United States|Hematology Oncology Associates of IL, Chicago, Illinois, United States|Central Indiana Cancer Center, Indianapolis, Indiana, United States|Kansas City Cancer-Southwest, Overland Park, Kansas, United States|Maryland Oncology Hematology, P.A., Columbia, Maryland, United States|Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States|Missouri Cancer Associates, Columbia, Missouri, United States|Arch Medical Services, Inc, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|NH Oncology-Hematology PA, Hooksett, New Hampshire, United States|Hematology-Oncology Associates of NNJ, P.A., Morristown, New Jersey, United States|Summit Medical Group, Summit, New Jersey, United States|New York Oncology Hematology, P.C., Albany, New York, United States|New York Oncology Hematology, PC, Rexford, New York, United States|Interlakes Oncology Hematology, PC, Rochester, New York, United States|Raleigh Hematology Oncology Clinic, Cary, North Carolina, United States|Greater Dayton Cancer Center, Kettering, Ohio, United States|Willamette Valley Cancer Center, Eugene, Oregon, United States|Cancer Center of the Carolinas, Seneca, Seneca, South Carolina, United States|Texas Cancer Center-Abilene(South), Abilene, Texas, United States|Texas Cancer Center, Arlington, Texas, United States|Texas Oncology Cancer Center, Austin, Texas, United States|Mamie McFaddin Ward Cancer Center, Beaumont, Texas, United States|Texas Oncology, P.A. - Bedford, Bedford, Texas, United States|Texas Cancer Center at Medical City, Dallas, Texas, United States|Texas Oncology, P.A., Dallas, Texas, United States|The Texas Cancer Center, Dallas, Texas, United States|Texas Oncology, P.A., Dallas, Texas, United States|Texas Oncology Center - Denton, Denton, Texas, United States|El Paso Cancer Treatment Ctr, El Paso, Texas, United States|Texas Oncology, P.A., Fort Worth, Texas, United States|San Antonio Tumor & Blood Clinic, Fredericksburg, Texas, United States|Texas Oncology, P.A., Houston, Texas, United States|Longview Cancer Center, Longview, Texas, United States|South Texas Cancer Center-McAllen, McAllen, Texas, United States|Texas Cancer Center of Mesquite, Mesquite, Texas, United States|Allison Cancer Center, Midland, Texas, United States|HOAST - New Braunfels, New Braunfels, Texas, United States|West Texas Cancer Center, Odessa, Texas, United States|Paris Regional Cancer Center, Paris, Texas, United States|Texas Cancer Center-Sherman, Sherman, Texas, United States|Texas Oncology Cancer Center-Sugar Land, Sugar Land, Texas, United States|Tyler Cancer Center, Tyler, Texas, United States|Waco Cancer Care and Research Center, Waco, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Onc and Hem Associates of SW VA, Inc., Salem, Virginia, United States|Puget Sound Cancer Center-Emonds, Edmonds, Washington, United States|Puget Sound Cancer Center-Seattle, Seattle, Washington, United States|Cancer Care Northwest-South, Spokane, Washington, United States|Northwest Cancer Specialists-Vancouver, Vancouver, Washington, United States|Yakima Valley Mem Hosp/North Star Lodge, Yakima, Washington, United States",https://ClinicalTrials.gov/show/NCT00248287
90,AstraZeneca,"Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer","Active, not recruiting",Has Results,Ovarian Cancer,Drug: olaparib|Drug: paclitaxel|Drug: carboplatin|Drug: Drug: carboplatin,Industry,Interventional,"Research Site, Los Angeles, California, United States|Research Site, Stanford, California, United States|Research Site, Orlando, Florida, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Portland, Oregon, United States|Research Site, Parkville, Australia|Research Site, Randwick, Australia|Research Site, Brussels, Belgium|Research Site, Leuven, Belgium|Research Site, Namur, Belgium|Research Site, Wilrijk, Belgium|Research Site, Vancouver, British Columbia, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Praha 2, Czechia|Research Site, Frankfurt, Germany|Research Site, Hamburg, Germany|Research Site, München, Germany|Research Site, Solingen, Germany|Research Site, Genova, Italy|Research Site, Milan, Italy|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Morioka-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Yamagata-shi, Japan|Research Site, Yonago-shi, Japan|Research Site, Amsterdam, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Ciudad de Panama, Panama|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Barcelona, Spain|Research Site, Valencia, Spain|Research Site, Birmingham, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Edinburgh, United Kingdom",https://ClinicalTrials.gov/show/NCT01081951
91,AstraZeneca,Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.,"Active, not recruiting",Has Results,Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV,Drug: Selumetinib 75 mg|Drug: Docetaxel 75 mg/m2|Drug: Docetaxel 60 mg/m2|Drug: Placebo,Industry,Interventional,"Research Site, Santa Monica, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Hollywood, Florida, United States|Research Site, Marrero, Louisiana, United States|Research Site, Boston, Massachusetts, United States|Research Site, Mineola, New York, United States|Research Site, New York, New York, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Barretos, Brazil|Research Site, Ijui, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, São Paulo, Brazil|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Vratza, Bulgaria|Research Site, Brest Cedex, France|Research Site, Caen, France|Research Site, Clermont Ferrand, France|Research Site, Lille, France|Research Site, Pierre Benite Cedex, France|Research Site, Villejuif, France|Research Site, Essen, Germany|Research Site, Esslingen, Germany|Research Site, Großhansdorf, Germany|Research Site, Karlsruhe, Germany|Research Site, Löwenstein, Germany|Research Site, Moers, Germany|Research Site, Wiesbaden, Germany|Research Site, Würzburg, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Edelény, Hungary|Research Site, Kaposvár, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Den Bosch, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Grudziądz, Poland|Research Site, Olsztyn, Poland",https://ClinicalTrials.gov/show/NCT01750281
92,Pfizer,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),"Active, not recruiting",Has Results,Ovarian Cancer,Biological: avelumab|Drug: PLD,Industry,Interventional,"Arizona Oncology Associates, PC - HAL, Chandler, Arizona, United States|Arizona Oncology Associates, PC - HAL, Phoenix, Arizona, United States|Arizona Oncology Associates, PC - HAL, Phoenix, Arizona, United States|Arizona Oncology Associates, PC - HAL, Scottsdale, Arizona, United States|Arizona Oncology Associates, PC-HAL, Tempe, Arizona, United States|Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States|Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|Highlands Oncology Group, Rogers, Arkansas, United States|University of California, Irvine/UC Irvine Health, Orange, California, United States|Sansum Clinic, Santa Barbara, California, United States|Sansum Clinic, Solvang, California, United States|Rocky Mountain Cancer Centers, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Boulder, Colorado, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, United States|Florida Cancer Specialists, Daytona Beach, Florida, United States|Florida Cancer Specialists, Wellington, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|Atlanta Gynecologic Oncology, Atlanta, Georgia, United States|Northside Hospital - Pharmacy, Atlanta, Georgia, United States|University Gynecologic Oncology, Atlanta, Georgia, United States|Northwest Georgia Oncology Centers, P.C., Austell, Georgia, United States|Northwest Georgia Oncology Centers, P.C., Carrollton, Georgia, United States|Northwest Georgia Oncology Centers, P.C., Cartersville, Georgia, United States|Northwest Georgia Oncology Centers, P.C., Douglasville, Georgia, United States|Northwest Georgia Oncology Centers, P.C., Marietta, Georgia, United States|The University of Kansas Clinical Research Center, Fairway, Kansas, United States|The University of Kansas Cancer Center and Medical Pavilion, Westwood, Kansas, United States|Norton Cancer Institute, Norton Healthcare Pavilion, Louisville, Kentucky, United States|Norton Healthcare Pharmacy, Attn: Marlon Baranda, Pharm D, Louisville, Kentucky, United States|Norton Hospital, Louisville, Kentucky, United States|Norton Cancer Institute, St. Matthews Campus, Louisville, Kentucky, United States|Norton Women's and Children's Hospital, Louisville, Kentucky, United States|Norton Brownsboro Hospital, Louisville, Kentucky, United States|Norton Cancer Institute, Brownsboro Hospital Campus, Louisville, Kentucky, United States|Maryland Oncology Hematology, P.A., Bethesda, Maryland, United States|Maryland Oncology Hematology, P.A., Columbia, Maryland, United States|Maryland Oncology Hematology P.A., Silver Spring, Maryland, United States|Maryland Oncology Hematology P.A., Silver Spring, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute/Pharmacy, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|The University of Kansas Cancer Center, CCP - North, Kansas City, Missouri, United States|Center of Hope at Renown Regional Medical Center, Reno, Nevada, United States|Southwest GYN Oncology Associates, Inc., Albuquerque, New Mexico, United States|University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States|Hope Women's Cancer Centers, Asheville, North Carolina, United States|Mission Hospital, Inc., Asheville, North Carolina, United States|Novant Health Oncology Specialists, Kernersville, North Carolina, United States|Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Fairview Hospital Moll Pavilion Cancer Center, Cleveland, Ohio, United States|Fairview Hospital Moll Pavilion Pharmacy, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Hillcrest Hospital Hirsch Cancer Center Pharmacy, Mayfield Heights, Ohio, United States|Hillcrest Hospital, Mayfield Heights, Ohio, United States|Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States|Investigational Drug Services, University of Pennsylvania, Philadelphia, Pennsylvania, United States|The University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Tennessee Oncology, PLLC, Dickson, Tennessee, United States|Tennessee Oncology, PLLC, Franklin, Tennessee, United States|Tennessee Oncology, PLLC, Gallatin, Tennessee, United States|Tennessee Oncology, PLLC, Hermitage, Tennessee, United States|Tennessee Oncology, PLLC, Lebanon, Tennessee, United States|Tennessee Oncology, PLLC, Murfreesboro, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|The Sarah Cannon Research Institute, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Shelbyville, Tennessee, United States|Tennessee Oncology, PLLC, Smyrna, Tennessee, United States|Texas Oncology-Austin Central, Austin, Texas, United States|Texas Oncology-South Austin, Austin, Texas, United States|Texas Oncology - Bedford, Bedford, Texas, United States|Texas Oncology -Fort Worth Cancer Center, Fort Worth, Texas, United States|US Oncology Investigational Products Center (IPC), Irving, Texas, United States|US Oncology Investigational Products Center, Irving, Texas, United States|Texas Oncology - San Antonio Medical Center, San Antonio, Texas, United States|Texas Oncology - The Woodlands, Gynecologic Oncology, The Woodlands, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Carilion Clinic Gynecologic Oncology, Roanoke, Virginia, United States|Carilion Clinic, Roanoke, Virginia, United States|Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Froedtert Hospital, Milwaukee, Wisconsin, United States|Epic Pharmacy,Newcastle Private Hospital, New Lambton Heights, New South Wales, Australia|Newcastle Private Hospital Pty Limited, Newcastle, New South Wales, Australia|Icon Cancer Care Wesley, Auchenflower, Queensland, Australia|Rivercity Pharmacy, Auchenflower, Queensland, Australia|Mater Pharmacy Services, Brisbane, Queensland, Australia|Icon Cancer Care Chermside, Chermside, Queensland, Australia|Clinical Research Unit, Herston, Queensland, Australia|Metro North Hospital and Health Service, Herston, Queensland, Australia|Oncology Pharmacy, Herston, Queensland, Australia|Icon Cancer Care, South Brisbane, Queensland, Australia|Icon Cancer Foundation, South Brisbane, Queensland, Australia|Mater Cancer Care Centre, South Brisbane, Queensland, Australia|Icon Cancer Care Southport, Southport, Queensland, Australia|Cabrini Health Limited, Brighton, Victoria, Australia|Cabrini Health Limited, Malvern, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Pharmacy Department, Parkville, Victoria, Australia|The Royal Women's Hospital, Parkville, Victoria, Australia|Medizinische Universitat Graz, LKH-Univ. Klinikum Graz, Graz, Austria|Medizinische Universitat Innsbruck, Innsbruck, Austria|University Hospital Gent, Gent, EAST Flanders, Belgium|Institut Jules Bordet, Brussels, Belgium|AZ Groeninge Hospital, Kortrijk, Belgium|Universitaire Ziekenhuizen Leuven, Leuven, Belgium|CHU de Liege - Sart Tilman, Liege, Belgium|Clinique et Maternite Sainte Elisabeth, Namur, Belgium|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency - Sindi Ahluwalia Hawkins Centre for the Southern Interior, Kelowna, British Columbia, Canada|British Columbia Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada|St. Boniface General Hospital, Winnipeg, Manitoba, Canada|Health Sciences Centre, Winnipeg, Manitoba, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Nova Scotia Health Authority, QEII Health Sciences Centre, Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada|Nova Scotia Health Authority, QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Sunnybrook Research Institute, Toronto, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|McGill University Health Centre - Glen Site, Montreal, Quebec, Canada|Oncology Pharmacy McGill University Health Centre, Montreal, Quebec, Canada|Vseobecna fakultni nemocnice v Praze, Fakultni poliklinika, Praha 2, Czech Republic, Czechia|Fakultni nemocnice Olomouc, Olomouc, Czechia|Fakultni nemocnice Ostrava, Ostrava-Poruba, Czechia|Vseobecna fakultni nemocnice v Praze, Nemocnicni lekarna,, Praha 2, Czechia|Vseobecna fakultni nemocnice v Praze, Neurologicka klinika, Praha 2, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|Fakultni nemocnice v Motole, Praha 5, Czechia|Krajska zdravotni a.s., Masarykova nemocnice v Usti nad Labem, o.z, Usti nad Labem, Czechia|Aalborg University Hospital, Aalborg, Denmark|Rigshospitalet, Copenhagen, Denmark|Centre Francois Baclesse, Caen Cedex 5, France|Centre Leon Berard, Lyon cedex 08, France|Service de Radiologie, LYON cedex 8, France|Centre Antoine Lacassagne, Nice cedex 2, France|Hôpital Européen Georges Pompidou, Paris cedex 15, France|Hôpital Européen Georges Pompidou, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite cedex, France|Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France|Gustave Roussy Cancer Campus, Villejuif cedex, France|General Oncology Hospital of Kifissia ""Agioi Anargiroi"", 2nd Department of Medical Oncology, Athens/New Kifissia, Greece|General Hospital of Athens Alexandra, Athens, Greece|Princess Margaret Hospital, Hong Kong, Hong Kong|University of Hong Kong, Hong Kong, Hong Kong|Orszagos Onkologiai Intezet, Gyogyszertar, Budapest, Hungary|Orszagos Onkologiai Intezet, Nogyogyaszati Osztaly, Budapest, Hungary|Debreceni Egyetem Klinikai Gyogyszertar, Debrecen, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet, Onkologiai Kozpont, Szolnok, Hungary|Mater Misericordiae University Hospital, Dublin 7, Dublin, Ireland|Mater Private Hospital, Dublin 7, Dublin, Ireland|Pharmacy Department, Dublin 4, Ireland|St Vincent's University Hospital, Dublin 4, Ireland|St James's Hospital, Dublin, Ireland|Mater Misericoridae University Hospital, Dublin, Ireland|Mater Private Hospital, Dublin, Ireland|University Hospital Waterford, Waterford, Ireland|Shaare Zedek Medical Center, Jerusalem, Israel|Poliambulatorio Specialistico Villa Salute, Manerbio, Brescia, Italy|Congregazione delle Suore Infermiere dell'Addolorata, Costa Masnaga, Lecco, Italy|ASST Fatebenefratelli Sacco, Miano, Milano, Italy|Servizio Sanitario Regionale Emilia-Romagna, Lugo, Ravenna, Italy|Fondazione del Piemonte per l'Oncologia, Candiolo, Torino, Italy|Habilita, San Marco Bergamo, Bergamo, Italy|Humanitas Cliniche Gavazzeni, Bergamo, Italy|Humanitas, Unita Operativa di Cardiologia 2, Bergamo, Italy|Fondazione Poliambulanza Istituto Ospedelario, Brescia, Italy|Congregazione delle Suore Infermiere dell'Addolorata, Como, Italy|Fondazione Teresa Camplani, Cremona, Italy|Regione Lombardia, A O Istituti Ospitalieri di Cremona, Cremona, Italy|Regione Lombardia, ASST Cremona, Cremona, Italy|Istituto Europeo di Oncologia, Milano, Italy|Ambulatorio dott. Francesco Cavanna, Medico Chirurgo, Piacenza, Italy|Azienda Unita Sanitaria Locale di Piacenza, Piacenza, Italy|Azienda USL 4 Prato, Prato, Italy|Azienda USL 4 Toscana Centro, Prato, Italy|Servizio Sanitario Regionale Emilia-Romagna, Rimini, Italy|C D C, Sede di Torino Centro, Torino, Italy|Shikoku Cancer Center, Matsuyama, Ehime, Japan|Ehime University Hospital, Toon, Ehime, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Hyogo Cancer Center, Akashi, Hyogo, Japan|University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan|Tokai University Hospital, Isehara, Kanagawa, Japan|Nippon Medical School Musashikosugi Hospital, Kawasaki, Kanagawa, Japan|Yokohama City University Hospital, Yokohama, Kanagawa, Japan|Tohoku University Hospital, Sendai, Miyagi, Japan|Saitama Medical University International Medical Center, Hidaka, Saitama, Japan|Saitama Cancer Center, Kita-adachi-gun, Saitama, Japan|National Defense Medical College Hospital, Tokorozawa, Saitama, Japan|Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan|Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan|The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|Kagoshima University Hospital, Kagoshima, Japan|Kagoshima City Hospital, Kagoshima, Japan|Niigata Cancer Center Hospital, Niigata, Japan|National Cancer Center, Goyangsi, Gyeonggi-do, Korea, Republic of|Clinical Trial Pharmacy, Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Clinical Trial Pharmacy, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center Clinical Trial Pharmacy, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Department of Pharamacy, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul, Korea, Republic of|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|LUMC, Leiden, Netherlands|Maastricht Universitair Medisch Centrum, Maastricht, Netherlands|Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway|Sykehusapoteket i Bergen, Bergen, Norway|Oslo Universitetssykehus, Oslo, Norway|Sykehusapoteket Oslo, Oslo, Norway|Centrum Onkologii, Instytut im. M. Sklodowskiej-Curie, Oddzial w Krakowie, Apteka Szpitalna, Krakow, Poland|Centrum Onkologii, Instytut im. M. Sklodowskiej-Curie, Oddzial w Krakowie, Krakow, Poland|Wojewodzki Szpital Specjalistyczny w Olsztynie, Apteka Szpitalna, Olsztyn, Poland|Wojewodzki Szpital Specjalistyczny w Olsztynie, Olsztyn, Poland|Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w, Poznan, Poland|Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego, Poznan, Poland|SPZOZ Wojewodzki Szpital Specjalistyczny nr 3 w Rybniku, Apteka Szpitalna, Rybnik, Poland|SPZOZ Wojewodzki Szpital Specjalistyczny nr 3 w Rybniku, Rybnik, Poland|State Budgetary Healthcare Institution ""Oncology Center #2"" of the Ministry of Healthcare, Sochi, Krasnodar Region, Russian Federation|State Budgetary Healthcare Institution Pyatigorsk Oncology Dispensary, Pyatigorsk, Stavropol Region, Russian Federation|Evimed Llc, Chelyabinsk, Russian Federation|State Budgetary Healthcare Institution, Chelyabinsk, Russian Federation|State Budgetary Healthcare Institution ""Clinical oncology dispensary #1"", Krasnodar, Russian Federation|Federal State Budgetary Institution ""Russian Cancer Research Center n.a. N.N. Blokhin"", Moscow, Russian Federation|State Budgetary Healthcare Institution of Nizhegorogsky region, Nizhniy Novgorod, Russian Federation|State Budgetary Healthcare Institution ""Orenburg Regional Clinical Oncological Dispensary"", Orenburg, Russian Federation|State Budget Institution of Healthcare Saint Petersburg Clinical Scientific - Practice Center, Saint Petersburg, Russian Federation|State Regional Budgetary Healthcare Institution ""Regional clinical oncology dispensary"", Velikiy Novgorod, Russian Federation|National University Hospital, Singapore, Singapore|National University Hospital, Singapore, Singapore|National Cancer Centre Singapore Pharmacy, Singapore, Singapore|National Cancer Centre Singapore, Singapore, Singapore|Raffles Hospital, Singapore, Singapore|Institut Catala d'Oncologia - Hospital Duran y Reynalds, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|lnstitut Catala d Oncologia de Girona. Hospital Universitario Dr. Josep Trueta, Girona, Spain|Hospital MD Anderson, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Centro Integral Oncologico Clara Campal, Madrid, Spain|Hospital Universitario Virgen de Valme, Sevilla, Spain|Universitatsspital Basel, Frauenklinik, Basel, Basel-stadt, Switzerland|Universitatsspital Basel, Basel, Basel-stadt, Switzerland|Luzerner Kantonsspital, Medizinische Onkologie, Studienzentrale Onkologie, Luzern 16, Luzern, Switzerland|Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Ticino, Switzerland|Kantonsapotheke Zurich, Zurich, Switzerland|Universitaetsspital Zurich, Klinik fuer Gynakologie, Zurich, Switzerland|Universitatsspital Zurich, Clinical Trials Center, Zurich, Switzerland|Universitatsspital Zurich, Institut fur diagnostische und interventionelle Radiologie, Zurich, Switzerland|Universitatsspital Zurich, Universitares Herzzentrum Zurich, Zurich, Switzerland|Clinical Trial Pharmacy, National Cheng Kung University Hospital, Tainan city, Taiwan|National Cheng Kung University Hospital, Tainan City, Taiwan|National Taiwan University Hospital, Taipei city, Taiwan|Clinical Trial Pharmacy, Mackay Memorial Hospital, Taipei City, Taiwan|Mackay Memorial Hospital, Taipei City, Taiwan|Clinical Trial Pharmacy, Koo Foundation Sun Yat-Sen Cancer Center, Taipei City, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center, Taipei City, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Clinical Trial Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital - Linkou Branch, Taoyuan City, Taiwan|Chemotherapy Pharmacy, Chang Gung Memorial Hospital - Linkou Branch, Taoyuan City, Taiwan|Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom|Ross Hall Hospital, Glasgow, CITY OF Glasgow, United Kingdom|The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, Merseyside, United Kingdom|The Clatterbridge Cancer Centre, Bebington, Wirral, Merseyside, United Kingdom|East and North Hertfordshire NHS Trust, Northwood, Middlesex, United Kingdom|Northampton General Hospital NHS Trust, Northampton, Northamptonshire, United Kingdom|Oxford University Hospitals NHS Foundation Trust, Headington, Oxford, United Kingdom|The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom|Spire Healthcare Limited (St. Anthony's Hospital), Sutton, Surrey, United Kingdom|NHS Greater Glasgow and Clyde, Glasgow, United Kingdom|University College London Hospital NHS Foundation Trust, London, United Kingdom|Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom|Guy's & St. Thomas' NHS Foundation Trust, London, United Kingdom|The Royal Marsden NHS Foundation Trust, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|University College London Hospital NHS Foundation Trust, London, United Kingdom|The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom|Nottingham University Hospital NHS Trust, Nottingham, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom",https://ClinicalTrials.gov/show/NCT02580058
93,Hoffmann-La Roche,A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy,"Active, not recruiting",Has Results,Breast Cancer,Drug: Taselisib|Drug: Placebo|Drug: Fulvestrant,Industry,Interventional,"Arizona Oncology, Tucson, Arizona, United States|Arizona Oncology Associates, P.C., Tucson, Arizona, United States|Georgia Cancer Specialists - Northside, Atlanta, Georgia, United States|Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital, Marietta, Georgia, United States|Ingalls Hospital, Harvey, Illinois, United States|Maryland Oncology Hematology, Rochville, Maryland, United States|Dana Farber Can Ins, Boston, Massachusetts, United States|Mercy Hospitals East Communities d/b/a Mercy Hospital St. Louis, Saint Louis, Missouri, United States|MSKCC at Basking Ridge, Basking Ridge, New Jersey, United States|John Theurer Cancer Ctr at Hackensack Univ Medical Ctr, Hackensack, New Jersey, United States|Memorial Sloan-Kettering; Cancer Center, Commack, New York, United States|Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering; at Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States|Oregon Health & Science University; Knight Cancer Institute, Community Hematology Oncology, Beaverton, Oregon, United States|Pinnacle Health, Harrisburg, Pennsylvania, United States|Liverpool Hospital; Cancer Therapy Centre, Liverpool, New South Wales, Australia|Macquarie University Hospital, Sydney, New South Wales, Australia|Newcastle Mater Misericordiae Hospital; Oncology, Waratah, New South Wales, Australia|Mater Hospital; Oncology, Brisbane, Queensland, Australia|Austin Hospital; Medical Oncology, Heidelberg, Victoria, Australia|Sunshine Hospital; Oncology Research, St Albans, Victoria, Australia|St John of God Murdoch Hospital; Oncology West, Murdoch, Western Australia, Australia|Lkh-Univ. Klinikum Graz; Klinik Für Innere Medizin I, Graz, Austria|Tiroler Landeskrankenanstalten Ges.M.B.H.; Abt. Für Gynäkologie, Innsbruck, Austria|Ordensklinikum Linz Barmherzige Schwestern; Abt. fur Innere Medizin 1, Linz, Austria|Medizinische Universität Wien; Univ.Klinik für Innere Medizin I, Wien, Austria|University Clinical Center of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina|Clinic of Oncology, University Clinical Center Sarajevo, Sarajevo, Bosnia and Herzegovina|Complex Oncological Center - Plovdiv, EOOD, Plovdiv, Bulgaria|MHAT Nadezhda, Sofia, Bulgaria|SHATO - Sofia, Sofia, Bulgaria|SHATOD Dr. Marko Antonov Markov-Varna, EOOD, Varna, Bulgaria|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency (Bcca) - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Grand River Hospital, Kitchener, Ontario, Canada|The Ottawa Hospital Cancer Centre; Oncology, Ottawa, Ontario, Canada|Sunnybrook Health Science Centre, Toronto, Ontario, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada|Hospital Du Saint-Sacrement, Quebec City, Quebec, Canada|the First Hospital of Jilin University, Changchun, China|Jilin Cancer Hospital, Changchun, China|Jiangsu Cancer Hospital, Nanjing, China|Fudan University Shanghai Cancer Center, Shanghai, China|Zhejiang Cancer Hospital, Zhejiang, China|Clinica del Country, Bogota, Colombia|Oncomedica S.A., Monteria, Colombia|University Hospital; Oncology and Radiotherapy, Hradec Kralove, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|KYS Sadesairaala; Syopatautien poliklinikka, Kuopio, Finland|Turku Uni Central Hospital; Oncology Clinics, Turku, Finland|Centre Jean Perrin; Hopital De Semaine, Clermont-Ferrand, France|Centre Georges François Leclerc; Service Pharmacie, Bp 77980, Dijon, France|Hopital Prive Drome Ardeche; Chir 2A 2B, Guilherand Granges, France|CHD Vendée, La Roche Sur Yon, France|Hopital Dupuytren; Oncologie Medicale, Limoges, France|Institut régional du Cancer Montpellier, Montpellier, France|Institut Curie; Oncologie Medicale, Paris, France|Ch Lyon Sud; Onco Secteur Jules Courmont, Pierre Benite, France|Pole de Cancerologie Prive Strasbourgeois, Strasbourg, France|Centre Alexis Vautrin; Oncologie Medicale, Vandoeuvre-les-nancy, France|Hochwaldkrankenhaus; Abt.Gynäkologie Geburtshilfe u.Senologie, Bad Nauheim, Germany|Praxisklinik Krebsheilkunde für Frauen / Brustzentrum (Dres. Kittel/Klare), Berlin, Germany|Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, Germany|Universitätsklinikum Essen; Zentrum Für Frauenheilkunde, Essen, Germany|Kooperatives Mammazentrum Hamburg Krankenhaus Jerusalem, Hamburg, Germany|Klinikum der Universität München; Frauenklinik - Onkologie II, München, Germany|Klinikum Mutterhaus der Borromäerinnen, Innere Medizin I, Trier, Germany|Alexandras General Hospital of Athens; Oncology Department, Athens, Greece|IASO General Hospital of Athens, Athens, Greece|Univ General Hosp Heraklion; Medical Oncology, Heraklion, Greece|University Hospital of Patras Medical Oncology, Patras, Greece|Euromedical General Clinic of Thessaloniki; Oncology Department, Thessaloniki, Greece|Papageorgiou General Hospital; Medical Oncology, Thessaloniki, Greece|Istituto Nazionale Tumori Irccs Fondazione g. PASCALE;U.O.C. Oncologia Medica Senologica, Napoli, Campania, Italy|ARCISPEDALE S. MARIA NUOVA - REGGIO EMILIA; Struttura Semplice Coordinamento Breast Unit Integrata, Reggio Emilia, Emilia-Romagna, Italy|A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia, Udine, Friuli-Venezia Giulia, Italy|IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A, Genova, Liguria, Italy|Istituto Europeo Di Oncologia, Milano, Lombardia, Italy|Centro Catanese Di Oncologia; Oncologia Medica, Catania, Sicilia, Italy|Azienda Ospedaliero-Universitaria Careggi; SOD Radioterapia, Firenze, Toscana, Italy|Azienda USL 9 Grosseto; Dipartimento Politiche del Farmaco, Grosseto, Toscana, Italy|Azienda usl 5 Di Pisa-Ospedale Di Pontedera;U.O. Oncologia, Pontedera, Toscana, Italy|AZ. Usll12 Veneziana-Ospedale Dell'angelo;Oncologia Medica, Mestre, Veneto, Italy|Inje university Haeundae Paik Hospital, Busan, Korea, Republic of|Chungbuk National University Hospital, Cheongju-si, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Ulsan University Hosiptal, Ulsan, Korea, Republic of|Iem-Fucam, D.f., Mexico|Instituto Nacional De Cancerologia; Oncology; Tumores Mamarios, Distrito Federal, Mexico|Consultorio de Medicina Especializada; Dentro de Condominio San Francisco, Mexico City, Mexico|Hospital San Jose Del Tec. de Monterrey; Oncology, Monterrey, Mexico|Oaxaca Site Management Organization, Oaxaca, Mexico|Medisch Centrum Alkmaar, Alkmaar, Netherlands|Ziekenhuis Rijnstate, Arnhem, Netherlands|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Clinica Internacional, Sede San Borja; Unidad de Investigacion de Clínica Internacional, Lima, Peru|Oncocenter Peru S.A.C.; Oncosalud, Lima, Peru|Instituto Regional de Enfermedades Neoplasicas - IREN Norte, Trujillo, Peru|Bialostockie Centrum Onkologii; Oddzial Onkologii Klinicznej, Bialystok, Poland|Centrum Onkologii w Bydgoszczy; Oddzial Kliniczny Onkologii, Bydgoszcz, Poland|Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii, Gdansk, Poland|Przychodnia Lekarska KOMED, Roman Karaszewski, Konin, Poland|Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Kliniki Onkologii, Kraków, Poland|Woj.Wielospecjalistyczne Centrum Onkologii i Traumatologii; Oddz.Hematologii Pododz.Chemioterapii, Lodz, Poland|Centrum Onkologii Ziemi LUBELSKIEJ im. Sw Jana z Dukli, I oddz. Chemioterapii, Lublin, Poland|Zachodniopomorskie Centrum Onkologii, Osrodek Innowacyjnosci, Rozwoju i Badan Klinicznych, Szczecin, Poland|Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie Klinika Nowotworów Piersi i Chirurgii, Warszawa, Poland|Wojewodzki Szpital Specjalistyczny; Osrodek Badawczo-Rozwojowy, Oddzial Chemioterapii, Wroclaw, Poland|Hospital Garcia de Orta; Servico de Oncologia Medica, Almada, Portugal|IPO de Lisboa; Servico de Oncologia Medica, Lisboa, Portugal|Hospital da Luz; Departamento de Oncologia Medica, Lisboa, Portugal|Hospital de Santa Maria; Servico de Oncologia Medica, Lisboa, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|Institut of Oncology Al. Trestioreanu Bucharest; Oncology Department, Bucuresti, Romania|Prof. Dr. I. Chiricuta Institute of Oncology, Cluj Napoca, Romania|Oncology Center Sf. Nectarie, Craiova, Romania|Euroclinic Center of Oncology SRL, Iasi, Romania|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, Russian Federation|Regional Clinical Oncology Dispensary; Surgery Dept, Thoracic, Arkhangelsk, Russian Federation|Ivanovo Regional Oncology Dispensary, Ivanovo, Russian Federation|Clinical Oncology Dispensary of Ministry of Health of Tatarstan, Kazan, Russian Federation|State Inst. Of Healthcare Orenburg Regional Clinical Oncology Dis, Orenburg, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, Russian Federation|Institute for Onc/Rad Serbia, Belgrade, Serbia|Clinical Center Bezanijska Kosa, Belgrade, Serbia|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coruña, Spain|Hospital Universitario Puerta de Hierro; Servicio de Oncologia, Majadahonda, Madrid, Spain|Hospital Universitario de Canarias;servicio de Oncologia, La Laguna, Tenerife, Spain|Hospital de Cruces; Servicio de Oncologia, Bilbao, Vizcaya, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain|Centro Oncologico MD Anderson Internacional; Servicio de Oncologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia, Madrid, Spain|Fundación IVO, Valencia, Spain|Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza, Spain|Uni Hospital Linkoeping; Dept. of Oncology, Linköping, Sweden|Sodersjukhuset; Onkologkliniken, Stockholm, Sweden|Akademiska sjukhuset, Onkologkliniken, Uppsala, Sweden|Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology, Taipei City, Taiwan|VETERANS GENERAL HOSPITAL; Department of General Surgery, Taipei, Taiwan|National Taiwan Uni Hospital; General Surgery, Taipei, Taiwan|Mackay Memorial Hospital; Dept of Surgery, Taipei, Taiwan|Department of Surgery, King Chulalongkorn Memorial Hospital, Bangkok, Thailand|Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Hospital; Department of Surgery/Head Neck and Breast Unit; Clinical Trial, Chiang Mai, Thailand|Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital; Medical Oncology, Adana, Turkey|Trakya University Medical Faculty Research And Practice Hospital Medical Oncology Department, Edirne, Turkey|Istanbul Uni Cerrahpasa Medical Faculty Hospital; Medical Oncology, Istanbul, Turkey|Ege Uni Medical Faculty; Oncology Dept, Izmir, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sihhiye/Ankara, Turkey",https://ClinicalTrials.gov/show/NCT02340221
94,"Genzyme, a Sanofi Company|Sanofi",An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer,"Active, not recruiting",Has Results,Thyroid Cancer,Drug: ZD6474 (Vandetanib),Industry,Interventional,"Investigational Site Number 3, Little Rock, Arkansas, United States|Investigational Site Number 8, San Francisco, California, United States|Investigational Site Number 9, Aurora, Colorado, United States|Investigational Site Number 11, New Haven, Connecticut, United States|Investigational Site Number 15, Jacksonville, Florida, United States|Investigational Site Number 18, Chicago, Illinois, United States|Investigational Site Number 17, Lexington, Kentucky, United States|Investigational Site Number 2, Boston, Massachusetts, United States|Investigational Site Number 7, Detroit, Michigan, United States|Investigational Site Number 14, Rochester, Minnesota, United States|Investigational Site Number 10, Saint Louis, Missouri, United States|Investigational Site Number 6, Cincinnati, Ohio, United States|Investigational Site Number 22, Portland, Oregon, United States|Investigational Site Number 19, Charleston, South Carolina, United States|Investigational Site Number 13, Houston, Texas, United States|Investigational Site Number 21, Burlington, Vermont, United States|Investigational Site Number 1001, St Leonards, Australia|Investigational Site Number 1901, Wien, Austria|Investigational Site Number 1101, Bruxelles, Belgium|Investigational Site Number 1102, Leuven, Belgium|Investigational Site Number 2301, Porto Alegre, Brazil|Investigational Site Number 2302, Ribeirão Preto, Brazil|Investigational Site Number 1203, Calgary, Canada|Investigational Site Number 1202, London, Canada|Investigational Site Number 1201, Moncton, Canada|Investigational Site Number 1204, Sherbrooke, Canada|Investigational Site Number 1205, Toronto, Canada|Investigational Site Number 3601, Praha 5, Czechia|Investigational Site Number 2701, Odense C, Denmark|Investigational Site Number 2802, BORDEAUX Cedex, France|Investigational Site Number 2803, LYON Cedex 8, France|Investigational Site Number 2801, Villejuif, France|Investigational Site Number 2002, Essen, Germany|Investigational Site Number 2001, Halle, Germany|Investigational Site Number 2005, Würzburg, Germany|Investigational Site Number 1601, Pécs, Hungary|Investigational Site Number 1401, Mumbai, India|Investigational Site Number 1402, Vellore, India|Investigational Site Number 2506, Catania, Italy|Investigational Site Number 2502, Milano, Italy|Investigational Site Number 2503, Napoli, Italy|Investigational Site Number 2501, Pisa, Italy|Investigational Site Number 2505, Roma, Italy|Investigational Site Number 2504, Siena, Italy|Investigational Site Number 1501, Seoul, Korea, Republic of|Investigational Site Number 2403, Cd. Madero, Mexico|Investigational Site Number 2402, Mexico City, Mexico|Investigational Site Number 2404, México, Mexico|Investigational Site Number 2902, Groningen, Netherlands|Investigational Site Number 2901, Utrecht, Netherlands|Investigational Site Number 1701, Gliwice, Poland|Investigational Site Number 1702, Poznan, Poland|Investigational Site Number 1703, Warszawa, Poland|Investigational Site Number 2602, Coimbra, Portugal|Investigational Site Number 2601, Lisboa, Portugal|Investigational Site Number 1801, Bucarest, Romania|Investigational Site Number 3301, Obninsk, Russian Federation|Investigational Site Number 3402, Belgrade, Serbia|Investigational Site Number 3401, Belgrad, Serbia|Investigational Site Number 3003, Madrid, Spain|Investigational Site Number 3001, Madrid, Spain|Investigational Site Number 3002, Pamplona, Spain|Investigational Site Number 3102, Stockholm, Sweden|Investigational Site Number 3101, Uppsala, Sweden|Investigational Site Number 2101, Basel, Switzerland|Investigational Site Number 2102, Bern, Switzerland",https://ClinicalTrials.gov/show/NCT00410761
95,AstraZeneca,A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer,"Active, not recruiting",Has Results,Non-Small Cell Lung Cancer,Drug: MEDI4736|Other: PLACEBO,Industry,Interventional,"Research Site, Chandler, Arizona, United States|Research Site, Goodyear, Arizona, United States|Research Site, Fayetteville, Arkansas, United States|Research Site, Jonesboro, Arkansas, United States|Research Site, Fullerton, California, United States|Research Site, Los Angeles, California, United States|Research Site, Oxnard, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Norwich, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Fort Myers, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Port Saint Lucie, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Augusta, Georgia, United States|Research Site, Lawrenceville, Georgia, United States|Research Site, Marietta, Georgia, United States|Research Site, Waterloo, Iowa, United States|Research Site, Topeka, Kansas, United States|Research Site, Hazard, Kentucky, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Rockville, Maryland, United States|Research Site, Salisbury, Maryland, United States|Research Site, Towson, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Lansing, Michigan, United States|Research Site, Saint Louis Park, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Hackensack, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, Lake Success, New York, United States|Research Site, Burlington, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Pinehurst, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Easley, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Fairfax, Virginia, United States|Research Site, Spokane, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Vancouver, Washington, United States|Research Site, Bedford Park, Australia|Research Site, Bendigo, Australia|Research Site, Box Hill, Australia|Research Site, Herston, Australia|Research Site, Kogarah, Australia|Research Site, Launceston, Australia|Research Site, Nedlands, Australia|Research Site, Port Macquarie, Australia|Research Site, Randwick, Australia|Research Site, Westmead, Australia|Research Site, Woolloongabba, Australia|Research Site, Aalst, Belgium|Research Site, Gilly, Belgium|Research Site, Leuven, Belgium|Research Site, Libramont-Chevigny, Belgium|Research Site, Liège, Belgium|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Barrie, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Canada|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Viña del Mar, Chile|Research Site, Avignon Cedex 9, France|Research Site, Bayonne, France|Research Site, Brest Cedex, France|Research Site, Lille, France|Research Site, Lyon, France|Research Site, Marseille Cedex 20, France|Research Site, Montpellier Cedex, France|Research Site, Nantes, France|Research Site, Nice, France|Research Site, Pau Cedex, France|Research Site, Rennes, France|Research Site, Saint Herblain, France|Research Site, Toulouse, France|Research Site, Villejuif Cedex, France|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Esslingen, Germany|Research Site, Grosshansdorf, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Lubeck, Germany|Research Site, Löwenstein, Germany|Research Site, Recklinghausen, Germany|Research Site, Regensburg, Germany|Research Site, Villingen-Schwenningen, Germany|Research Site, Athens, Greece|Research Site, Crete, Greece|Research Site, Patras, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Gyula, Hungary|Research Site, Miskolc, Hungary|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Aviano, Italy|Research Site, Catania, Italy|Research Site, Cremona, Italy|Research Site, Lecce, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Bunkyo-ku, Japan|Research Site, Bunkyo-ku, Japan|Research Site, Chuo-ku, Japan|Research Site, Fukuoka, Japan|Research Site, Habikino-shi, Japan|Research Site, Hidaka-shi, Japan|Research Site, Hirakata-shi, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Kanazawa, Japan|Research Site, Kashiwa, Japan|Research Site, Kitaadachi-gun, Japan|Research Site, Kurume-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Natori-shi, Japan|Research Site, Okayama-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osakasayama, Japan|Research Site, Ota-shi, Japan|Research Site, Sagamihara-shi, Japan|Research Site, Sakai-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Sunto-gun, Japan|Research Site, Takatsuki-shi, Japan|Research Site, Ube-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Busan, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Hwasun-gun, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon, Korea, Republic of|Research Site, Cuautitlan Izcalli, Mexico|Research Site, Monterrey, Mexico|Research Site, Oaxaca, Mexico|Research Site, Orizaba, Mexico|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Breda, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Lima, Peru|Research Site, Gdańsk, Poland|Research Site, Lublin, Poland|Research Site, Warszawa, Poland|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Bardejov, Slovakia|Research Site, Kosice, Slovakia|Research Site, Nove Zamky, Slovakia|Research Site, Trnava, Slovakia|Research Site, Cape Town, South Africa|Research Site, Pretoria, South Africa|Research Site, Vereeniging, South Africa|Research Site, Alicante, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Gerona, Spain|Research Site, Lérida, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, San Sebastian, Spain|Research Site, Sevilla, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Valencia, Spain|Research Site, Zaragoza, Spain|Research Site, Taichung, Taiwan|Research Site, Taipei City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Bangkok, Thailand|Research Site, Hat Yai, Thailand|Research Site, Muang, Thailand|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Konya, Turkey|Research Site, Malatya, Turkey|Research Site, Glasgow, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Truro, United Kingdom|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh, Vietnam",https://ClinicalTrials.gov/show/NCT02125461
96,"Genentech, Inc.",A Study of MTIG7192A in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer,"Active, not recruiting",Has Results,Non-small Cell Lung Cancer,Drug: Atezolizumab|Drug: MTIG7192A|Drug: Placebo,Industry,Interventional,"Arizona Oncology Associates, PC - HAL, Tempe, Arizona, United States|SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States|SCRI Florida Cancer Specialists North; Research Office North Region., Saint Petersburg, Florida, United States|Illinois Cancer Specialists, Arlington Heights, Illinois, United States|Illinois Cancer Care, Peoria, Illinois, United States|University of Kansas Medical Center, Westwood, Kansas, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|HCA Midwest Health, Kansas City, Missouri, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Northwest Cancer Specialists - Vancouver, Vancouver, Washington, United States|ICO Paul Papin; Oncologie Medicale., Angers, France|Institut Bergonié Centre Régional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest, Bordeaux, France|Centre Georges François Leclerc; Service Pharmacie, Bp 77980, Dijon, France|Hopital Nord AP-HM; Service Clinique des bronches allergies et sommeil, Marseille, France|Institut De Cancerologie De L'Ouest; Medical Oncology, Saint Herblain, France|Chungbuk National University Hospital, Cheongju-si, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Clinical Center of Serbia, Belgrade, Serbia|Institute for Oncology and Radiology of Serbia, Belgrade, Serbia|Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia|Institute of Lung Diseases Vojvodina, Sremska Kamenica, Serbia|Hospital Univ Germans Trias i Pujol, Badalona, Barcelona, Spain|Complejo Hospitalario Universitario Insular-Materno Infantil, Las Palmas de Gran Canaria, LAS Palmas, Spain|Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda, Madrid, Spain|Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitario Vall d'Hebron - PPDS, Barcelona, Spain|Clinica Universitaria Navarra (Madrid), Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Regional Universitario de Malaga - Hospital General; Servicio de Neurologia, Malaga, Spain|Centro Medico Quironsalud Sagrado Corazon, Sevilla, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Taipei Medical University -Shuang Ho Hospital, New Taipei City, Taiwan|National Cheng Kung University Hospital; Internal Medicine, North Dist., Taiwan|Taipei Veterans General Hospital, Taipei City, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital - Linkou, Taoyuan, Taiwan",https://ClinicalTrials.gov/show/NCT03563716
97,Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd,A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer,"Active, not recruiting",Has Results,Various Advanced Cancer,Drug: Nivolumab,Industry,Interventional,"Mayo Clinic, Phoenix, Arizona, United States|City Of Hope, Duarte, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|University Of Colorado, Aurora, Colorado, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Indiana University Health - University Hospital, Indianapolis, Indiana, United States|University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States|Crescent City Research Consortium, LLC, Marrero, Louisiana, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|GU Research Network, LLC, Omaha, Nebraska, United States|Mount Sinai Medical Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Providence Portland Medical Center, Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Erlanger Oncology & Hematology - Univ. of TN, Chattanooga, Tennessee, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Local Institution, Waratah, New South Wales, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Brussels, Belgium|Local Institution, Edegem, Belgium|Local Institution, Hasselt, Belgium|Local Institution, Brno, Czechia|Local Institution, Olomouc, Czechia|Local Institution, Praha 5, Czechia|Local Institution, Helsinki, Finland|Local Institution, Tampere, Finland|Local Institution, Erfurt, Germany|Local Institution, Erlangen, Germany|Local Institution, Hamburg, Germany|Local Institution, Heidelberg, Germany|Local Institution, Jena, Germany|Local Institution, Muenchen, Germany|Local Institution, Rostock, Germany|Local Institution, Tuebingen, Germany|Ospedale S. Donato - Usl 8, Arezzo, Italy|Iatituto Nazionale Per Lo Studio E La Cura Dei Tumori, Milano, Italy|Azienda Ospedaliera Di Rilievo Nazionale A. Cardarelli, Napoli, Italy|Local Institution, Pavia, Italy|U.O. Oncologia Medica Azienda, Roma, Italy|Local Institution, Akita-shi, Akita, Japan|Local Institution, Hirosaki-shi, Aomori, Japan|Local Institution, Morioka-shi, Iwate, Japan|Local Institution, Yokohama, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Osaka-Sayama-Shi, Osaka, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Tsukuba-shi, Japan|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Lodz, Poland|Local Institution, Szczecin, Poland|Local Institution, Wroclaw, Poland|Local Institution, Badalona-barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Hospitalet de Llobregat - Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Lund, Sweden",https://ClinicalTrials.gov/show/NCT02387996
98,AstraZeneca,Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer,"Active, not recruiting",Has Results,Ovarian Cancer,Drug: AZD2281|Drug: matching placebo,Industry,Interventional,"Research Site, Berkeley, California, United States|Research Site, Los Angeles, California, United States|Research Site, San Francisco, California, United States|Research Site, Sunrise, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, New York, New York, United States|Research Site, Providence, Rhode Island, United States|Research Site, East Bentleigh, Australia|Research Site, Heidelberg, Australia|Research Site, Melbourne, Australia|Research Site, Nambour, Australia|Research Site, North Terrace, Australia|Research Site, Randwick, Australia|Research Site, Toorak Gardens, Australia|Research Site, Brussels, Belgium|Research Site, Leuven, Belgium|Research Site, Vancouver, British Columbia, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Tallinn, Estonia|Research Site, Bordeaux, France|Research Site, Lyon Cedex 08, France|Research Site, Nantes, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Düsseldorf, Germany|Research Site, Essen, Germany|Research Site, Göttingen, Germany|Research Site, Hannover, Germany|Research Site, Kiel, Germany|Research Site, Marburg, Germany|Research Site, München, Germany|Research Site, Ulm, Germany|Research Site, Wiesbaden, Germany|Research Site, Haifa, Israel|Research Site, Holon, Israel|Research Site, Jerusalem, Israel|Research Site, Jerusalem, Israel|Research Site, Nahariya, Israel|Research Site, Ramat Gan, Israel|Research Site, Tel-Aviv, Israel|Research Site, Amsterdam, Netherlands|Research Site, Białystok, Poland|Research Site, Grzepnica, Poland|Research Site, Lublin, Poland|Research Site, Poznan, Poland|Research Site, Poznan, Poland|Research Site, Poznań, Poland|Research Site, Szczecin, Poland|Research Site, Baia Mare, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Iasi, Romania|Research Site, Suceava, Romania|Research Site, Barnaul, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Orenburg, Russian Federation|Research Site, Perm, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Barcelona, Spain|Research Site, Córdoba, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Valencia, Spain|Research Site, Donetsk, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Odesa, Ukraine|Research Site, Ternopil, Ukraine|Research Site, Uzhhorod, Ukraine|Research Site, Dundee, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Sutton, United Kingdom|Research Site, Wirral, United Kingdom",https://ClinicalTrials.gov/show/NCT00753545
99,Hoffmann-La Roche,A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants,"Active, not recruiting",Has Results,Non-Small Cell Lung Cancer,Drug: Alectinib|Drug: Crizotinib,Industry,Interventional,"Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Mayo Clinic Arizona, Phoenix, Arizona, United States|North Valley Hem Onc Med Grp; Thomas&Dorothy Leavey Can Ctr, Northridge, California, United States|Chao Family Comprehensive Cancer Center; UC Irvine Medical Center, Orange, California, United States|TMPN/ Cancer Care Associates, Redondo Beach, California, United States|UCSF Helen Diller Family CCC, San Francisco, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|St. Mary's Hospital Regional Cancer Center, Grand Junction, Colorado, United States|University of Miami-Deerfield Beach, Deerfield Beach, Florida, United States|Cancer Institute of Florida PA, Orlando, Florida, United States|Memorial Health Care System, Pembroke Pines, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital, Marietta, Georgia, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Beth Israel Deaconess Med Ctr; Hem/Onc, Boston, Massachusetts, United States|Dana Farber Can Ins, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Washington Uni School of Medicine, Saint Louis, Missouri, United States|Comprehensive Cancer Center - Peak, Las Vegas, Nevada, United States|Columbia University Medical Center, Bronx, New York, United States|Sarah Cannon Cancer Center - Tennessee Oncology, Pllc, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States|Kinghorn Cancer Centre; St Vincents Hospital, Darlinghurst, New South Wales, Australia|Royal North Shore Hospital; Oncology, St. Leonards, New South Wales, Australia|Calvary Mater Newcastle; Medical Oncology, Waratah, New South Wales, Australia|Queen Elizabeth Hospital; Medical Oncology, Woodville South, South Australia, Australia|Monash Health Translational Precinct; Clinical Trials Centre, Level 3, Victoria, Australia|University Clinical Centre of the Republic of Srpska; Clinic for Pulmonary Diseases, Banja Luka, Bosnia and Herzegovina|University Clinical Center Sarajevo;Clinic for Pulmonary disease, Sarajevo, Bosnia and Herzegovina|University Clinical Center Sarajevo;Institute of oncology, Sarajevo, Bosnia and Herzegovina|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Centro de Pesquisas Oncologicas - CEPON, Florianopolis, SC, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada|Mount Sinai Hospital; Oncology, Toronto, Ontario, Canada|Saskatoon Cancer Centre; Uni of Saskatoon Campus, Saskatoon, Saskatchewan, Canada|Centro Internacional de Estudios Clínicos (CIEC), Santiago, Chile|Sun Yet-sen University Cancer Center, Guangzhou, China|Shanghai Pulmonary Hospital, Shanghai, China|Clinica CIMCA, San Jose, Costa Rica|Kasr Eieny Uni Hospital; Oncology (Nemrock), Cairo, Egypt|CHU de Grenoble, Grenoble, France|CHRU de Lille, Lille, France|Centre Leon Berard; Departement Oncologie Medicale, Lyon, France|Hopital Haut Leveque, Pessac, France|Hopital Pontchaillou, Rennes, France|St. Vincentius Kliniken Karlsruhe; Abteilung Hämatologie / Onkologie, Karlsruhe, Germany|Klinik Löwenstein gGmbH Medizinische Klinik II, Löwenstein, Germany|Grupo Angeles, Guatemala City, Guatemala|Pamela Youde Nethersole Eastern Hospital; Clinical Oncology, Hong Kong, Hong Kong|Princess Margaret Hospital; Oncology, Hong Kong, Hong Kong|Queen Mary Hospital; Medicine & Respiratory, Hong Kong, Hong Kong|Tuen Mun Hospital; Clinical Oncology, Hong Kong, Hong Kong|Prince of Wales Hosp; Dept. Of Clinical Onc, Shatin, Hong Kong|Rambam Medical Center; Oncology, Haifa, Israel|Meir Medical Center; Oncology, Kfar-Saba, Israel|Seconda Universita' Degli Studi; Divsione Di Oncologia Medica, Napoli, Campania, Italy|A.O. Universitaria Di Parma; Oncologia Medica, Parma, Emilia-Romagna, Italy|Ospedale Provinciale Santa Maria Delle Croci; Oncologia Medica, Ravenna, Emilia-Romagna, Italy|Policlinico Umberto i di Roma; dip. Scienze Radiologiche, Oncologiche, Anatomopatologiche, Roma, Lazio, Italy|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1, Milano, Lombardia, Italy|Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica, Milano, Lombardia, Italy|Az. Osp. S. Luigi Gonzaga; Malattie Apparato Respiratorio 5 Ad Indirizzo Oncologico, Orbassano, Piemonte, Italy|Irccs Ist. Tumori Giovanni Paolo Ii; Dipartimento Oncologia Medica, Bari, Puglia, Italy|Az Ospedaliera Nuovo Garibaldi Quartiere Nesima; Oncologia Medica, Catania, Sicilia, Italy|Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica, Sant'Andrea Delle Fratte (PG), Umbria, Italy|National Cancer Center, Goyang-si, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Instituto Nacional De Enfermedades Respiratorias;Unidad de Investigación, Mexico City, Mexico|Uni of Auckland; Medical School, Auckland, New Zealand|Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii, Gdańsk, Poland|Ms Clinsearch Specjalistyczny Niepubliczny Zaklad Opieki Zdrowotnej, Lublin, Poland|Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc; Oddzial V Chemioterapii Nowotworow Pluc, Olsztyn, Poland|Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii, Otwock, Poland|Centrum Onkologii - Inst.Im. Marii Sklodowskiej-Curie; Oncology, Warszawa, Poland|CHUC - Unidade de Pneumologia Oncológica; Hospital de Dia de Oncologia Edificio Sao Jeronimo, Coimbra, Portugal|IPO de Lisboa; Servico de Pneumologia, Lisboa, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|N.N.Burdenko Main Military Clinical Hospital; Oncology Dept, Moscow, Russian Federation|Moscow city oncology hospital #62 of Moscow Healthcare Department, Moscow, Russian Federation|City Clinical Hospital No. 1, Novosibirsk, Russian Federation|Medical Radiological Research Centre Rams; Dept. of Radiotherapy & Chemotherapy of Hemoblastosis, Obninsk, Russian Federation|SPb City Clin Onc Dsp; Chemotherapy, St. Petersburg, Russian Federation|Scientific Research Oncology Institute named after N.N. Petrov; Oncology, St. Petersburg, Russian Federation|Clinical Center of Serbia, Belgrade, Serbia|Clinical Center Bezanijska Kosa; Oncology, Belgrade, Serbia|Institute for pulmonary diseases of Vojvodina, Sremska Kamenica, Serbia|National University Hospital; National University Cancer Institute, Singapore (NCIS), Singapore, Singapore|National Cancer Centre; Medical Oncology, Singapore, Singapore|Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Badalona, Barcelona, Spain|Hospital Universitario Puerta de Hierro; Servicio de Oncologia, Majadahonda, Madrid, Spain|Hospital General Univ. de Alicante; Servicio de Oncologia, Alicante, Spain|Hospital Universitario Quiron Dexeus, Barcelona, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Universitaetsspital Basel; Onkologie, Basel, Switzerland|Inselspital Bern; Universitätsklinik für medizinische Onkologie, Bern, Switzerland|CHUV; Departement d'Oncologie, Lausanne, Switzerland|UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie, Zürich, Switzerland|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung Univ Hosp, Tainan, Taiwan|Taipei Veterans General Hospital, Taipei City, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|National Cancer Inst., Bangkok, Thailand|Chiang Rai Prachanukroh Hospital; Department Of Medicine, Chiang Rai, Thailand|Khonkaen Hospital, Khonkaen, Thailand|King Chulalongkorn Memorial Hospital; Faculty of Medicine Chulalongkorn University, Patumwan, Thailand|Songklanagarind Hospital; Department of Internal Medicine, Division of Respiratory, Songkhla, Thailand|Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital; Medical Oncology, Adana, Turkey|Ankara University Medical Faculty; Medikal Onkoloji, Ankara, Turkey|Trakya University Medical Faculty Research And Practice Hospital Medical Oncology Department, Edirne, Turkey|Inonu University Medical Faculty Turgut Ozal Medical Center Medical Oncology Department, Malatya, Turkey|Dnipropetrovsk State Medical Academy; Chemotherapy Department, Dnipropetrovsk, Ukraine|Karkiv Regional Oncology Center, Kharkiv, Ukraine|Kyiv Regional Oncological Dispensary, Kyiv, Ukraine|Lviv State Oncology Regional Treatment and Diagnostic Centre; Department of hemotherapy, Lviv, Ukraine|Birmingham Heartlands Hospital; Dept of Oncology, Birmingham, United Kingdom|University College London Hospital, London, United Kingdom|Guys & St Thomas Hospital; Department of Oncology, London, United Kingdom",https://ClinicalTrials.gov/show/NCT02075840
100,"Dana-Farber Cancer Institute|Massachusetts General Hospital|SCRI Development Innovations, LLC|Texas Oncology Cancer Center|Genentech, Inc.","Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer","Active, not recruiting",Has Results,Esophageal Cancer|Gastric Cancer|Stomach Cancer,Drug: Bevacizumab|Drug: Cisplatin|Drug: Irinotecan|Device: Docetaxel,Other|Industry,Interventional,"Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Texas Oncology Research, Dallas, Texas, United States",https://ClinicalTrials.gov/show/NCT00911820
101,AstraZeneca,Study of Tremelimumab in Patients With Advanced Solid Tumors,"Active, not recruiting",Has Results,Urothelial Bladder Cancer|Triple-negative Breast Cancer|Pancreatic Ductal Adenocarcinoma,Biological: Tremelimumab monotherapy|Biological: MEDI4736 monotherapy|Biological: MEDI4736 + tremelimumab combination therapy,Industry,Interventional,"Research Site, San Francisco, California, United States|Research Site, Memphis, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Brussels, Belgium|Research Site, Charleroi, Belgium|Research Site, Wilrijk, Belgium|Research Site, Daejeon, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Groningen, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Gdańsk, Poland|Research Site, Łódź, Poland",https://ClinicalTrials.gov/show/NCT02527434
102,Hoffmann-La Roche,A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132),"Active, not recruiting",Has Results,Non-Small Cell Lung Cancer,Drug: Atezolizumab|Drug: Carboplatin|Drug: Cisplatin|Drug: Pemetrexed,Industry,Interventional,"Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States|St. Joseph Heritage Healthcare, Sebastopol, California, United States|Stamford Hospital; BCC, MOHR, Stamford, Connecticut, United States|Orlando Health Inc., Orlando, Florida, United States|Tallahassee Memorial Hospital, Tallahassee, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Illinois Cancer Care, Peoria, Illinois, United States|HealthCare Research Network II, LLC - PPDS, Tinley Park, Illinois, United States|Fort Wayne Med Oncology & Hematology Inc, Fort Wayne, Indiana, United States|Goshen Health System, Goshen, Indiana, United States|University of Kentucky; Markey Cancer Center, Lexington, Kentucky, United States|University of Michigan, Ann Arbor, Michigan, United States|CHI Health St. Francis, Grand Island, Nebraska, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Montefiore Medical Center, Bronx, New York, United States|Swedish Cancer Institute, Cary, North Carolina, United States|Providence Portland Medical Center, Portland, Oregon, United States|Gettysburg Cancer Center, Gettysburg, Pennsylvania, United States|Allegheny Cancer Center, Pittsburgh, Pennsylvania, United States|Oncology Consultants PA, Houston, Texas, United States|Virginia Cancer Specialists (Fairfax) - USOR, Fairfax, Virginia, United States|Peninsula Cancer Institute, Newport News, Virginia, United States|Blue Ridge Cancer Care, Roanoke, Virginia, United States|University of Washington, Seattle, Washington, United States|St. Vincent Hospital, Green Bay, Wisconsin, United States|Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, Buenos Aires, Argentina|Fundacion Clinica Colombo, Cordoba, Argentina|Centro de Investigacion; Clinica - Clinica Viedma S.A., Viedma, Argentina|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Sydney Adventist Hospital; Clinical Trial Unit, Sydney, New South Wales, Australia|St George Hospital; Medical Oncology, Sydney, New South Wales, Australia|Redcliffe Hospital, Redcliffe, Queensland, Australia|Mater Adult Hospital, South Brisbane, Queensland, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Ballarat Health Services, Ballarat, Victoria, Australia|Peninsula and South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia|Barwon Health, Geelong, Victoria, Australia|Klinikum Wels-Grieskirchen GmbH, Wels, Austria|AZ Maria Middelares, Gent, Belgium|Clinique André Renard; Pneumologie, Herstal, Belgium|AZ Delta (Campus Rumbeke), Apotheek, Roeselare, Belgium|Multiprofile Hospital for Active Treatment Serdika EOOD, Sofia, Bulgaria|Health & Care SPA, Santiago, Chile|Sociedad de Investigaciones Medicas Ltda (SIM), Temuco, Chile|Hospital Clinico Vina del Mar, Viña del Mar, Chile|Beijing Friendship Hospital Affiliated of Capital University of Medical Science, Beijing Shi, China|Beijing Cancer Hospital, Beijing, China|Hunan Cancer Hospital, Changsha City, China|Changzhou First People's Hospital, Changzhou, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou City, China|Sir Run Run Shaw Hospital Zhejiang University, Hangzhou City, China|Anhui Provincial Hospital; 2F,Tumor chemotherapy Department, Hefei, China|First Affliated Hospital of Anhui Medical University, Hefei, China|Anhui Provincial Hospital; Respiratory Department, Hefei, China|Qilu Hospital, Jinan City, China|Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University), Nanjing City, China|Shanghai Chest Hospital, Shanghai, China|Zhongshan Hospital Fudan University, Shanghai, China|Fudan University Shanghai Cancer Center, Shanghai, China|First Hospital of China Medical University, Shenyang, China|Tianjin Medical University Cancer Institute & Hospital, Tianjing, China|Tianjin Medical University General Hospital, Tianjin, China|Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, China|Tumor Center,Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China|Zhejiang Cancer Hospital, Zhejiang, China|Institut Sainte Catherine, Avignon, France|Hopital Louis Pradel; Pneumologie, Bron, France|Centre Jean Perrin Centre Regional de Lutte Contre Le Cancer D auvergne, Clermont-ferrand, France|Centre Hospitalier Intercommunal; Service de Pneumologie, Creteil, France|Polyclinique de Limoges - Site Chenieux; Oncologie Medicale, Limoges, France|Hopital Nord AP-HM, Marseille, France|Centre Regional de Lutte contre le Cancer Val d Aurelle - Paul Lamarque; Service d oncologie, Montpellier, France|Centre Hospitalier de Mulhouse - Hopital Emile Muller, Mulhouse, France|Hopital d'Instruction des Armees de Begin, Saint-Mande, France|Hopital d Instruction des Armees de Sainte Anne, Toulon, France|Veszprem Megyei Tudogyogyintezet, Farkasgyepu, Hungary|Petz Aladar Megyei Oktato Korhaz, Gyor, Hungary|Markusovszky Hospital, Szombathely, Hungary|Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz, Székesfehérvár, Hungary|Tudogyogyintezet Torokbalint, Torokbalint, Hungary|Mater Misecordiae University Hospital, Dublin, Ireland|St James's Hospital, Dublin, Ireland|Barzilai Medical Center, Ashkelon, Israel|Edith Wolfson Medical Center, Holon, Israel|Rabin Medical Center, Petach Tiqwa, Israel|Azienda Ospedaliero Universitaria di Parma, Parma, Emilia-Romagna, Italy|Ospedale Santa Maria Delle Croci, Ravenna, Emilia-Romagna, Italy|Istituto Nazionale Tumori Regina Elena, Roma, Lazio, Italy|Azienda Policlinico Umberto I, Roma, Lazio, Italy|Azienda Sanitaria Ospedaliera S Luigi Gonzaga; S.C.D.U. di Oncologia Toracica, Orbassano (TO), Piemonte, Italy|Presidio Ospedaliero Vito Fazzi; Unita Operativa Di Oncologia Medica, Lecce, Puglia, Italy|Ospedale Casa Sollievo Della Sofferenza IRCCS, San Giovanni Rotondo, Puglia, Italy|Ospedale San Vincenzo Taormina :Divisione di Oncologia Medica, Taormina, Sicilia, Italy|Ospedale San Luca - USL2 Lucca, Lucca, Toscana, Italy|National Hospital Organization Nagoya Medical Center, Aichi, Japan|National Cancer Center Hospital East, Chiba, Japan|Hiroshima University Hospital, Hiroshima, Japan|National Hospital Organization Asahikawa Medical Center, Hokkaido, Japan|National Hospital Organization Himeji Medical Center, Hyogo, Japan|Kanazawa University Hospital, Ishikawa, Japan|Kagoshima University Hospital, Kagoshima, Japan|Kanagawa Cancer Center, Kanagawa, Japan|Tohoku University Hospital, Miyagi, Japan|Niigata University Medical & Dental Hospital, Niigata, Japan|Osaka University Hospital, Osaka, Japan|Osaka Medical College Hospital, Osaka, Japan|Saga University Hospital, Saga, Japan|Tokushima University Hospital, Tokushima, Japan|Juntendo University Hospital, Tokyo, Japan|Nippon Medical School Hospital, Tokyo, Japan|Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|NTT Medical Center Tokyo, Tokyo, Japan|National Hospital Organization Yamaguchi - Ube Medical Center, Yamaguchi, Japan|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Riga East Clinical University Hospital Latvian Oncology Centre, Riga, Latvia|Panevezys Hospital, Panevezys, Lithuania|Advanced Medical and Dental Institute; Kompleks Klinikal, Kepala Batas, Penang, Malaysia|Hospital Kuala Lumpur, Kuala Lumpur, Malaysia|Amphia Ziekenhuis, Breda, Netherlands|Haga Ziekenhuis, Den Haag, Netherlands|Ziekenhuis Gelderse Vallei, EDE, Netherlands|Ziekenhuis St. Jansdal, Harderwijk, Netherlands|Zuyderland Medisch Centrum - Sittard Geleen, Sittard-Geleen, Netherlands|ETZ TweeSteden, Tilburg, Netherlands|Hospital Nacional Cayetano Heredia, Lima, Peru|Hospital Beatriz Angelo, Loures, Portugal|Unidade Local de Saude de Matosinhos SA, Matosinhos, Portugal|Hospital CUF Porto; Servico de Imunoalergologia, Senhora Da Hora - Porto, Portugal|Medisprof SRL, Cluj-Napoca, Romania|Spitalul Clinic Judetean de Urgenta Sf. Apostol Andrei Constanta, Constanta, Romania|Euroclinic Center of Oncology SRL, Iasi, Romania|Chelyabinsk Regional Clinical Oncology Dispensary, Chelyabinsk, Moskovskaja Oblast, Russian Federation|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, Russian Federation|Regional Clinical Oncology Hospital, Yaroslavl, Russian Federation|Hospital General Universitario de Elche; Servicio de Oncologia, Elche, Alicante, Spain|Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain|ICO L'Hospitalet; Servicio de oncologia medica, L Hospitalet De Llobregat, Barcelona, Spain|Corporacio Sanitaria Parc Tauli; Servicio de Oncologia, Sabadell, Barcelona, Spain|Hospital de Mataro, Mataro, Cantabria, Spain|Onkologikoa; Ensayos Clinicos, Donostia, Guipuzcoa, Spain|Centro Oncologico de Galicia COG; Medical Oncology, A Coruna, LA Coruña, Spain|Hospital Universitario Virgen de La Arrixaca; Servicio De Oncologia, El Palmar, Murcia, Spain|Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain|Complejo Hospitalario de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain|Complejo Hospitalario Nuestra Senora de Valme, Seville, Sevilla, Spain|Hospital General Univ. de Alicante, Alicante, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Dexeus - Grupo Quironsalud; Servicio de Oncologia Medica, Barcelona, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|C.A.U de Burgos- Hospital Universitario de Burgos; Servicio de Oncologia, Burgos, Spain|Hospital Universitari de Girona Dr Josep Trueta; Departamento de Oncologia Medica, Girona, Spain|Hospital Lucus Augusti; Servicio de Oncologia, Lugo, Spain|MD Anderson Cancer Center, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|HM Sanchinarro - CIOCC, Madrid, Spain|Hospital Regional Universitario de Malaga - Hospital General; Servicio de Neurologia, Malaga, Spain|Instituto Valenciano Oncologia; Oncologia Medica, Valencia, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Buddhist Dalin Tzuchi General Hospital, Dalin, Chiayi, Taiwan|E-DA Hospital; Chest, Kaohsiung, Taiwan|Chi Mei Medical Center Liou Ying Campus, Liuying Township, Taiwan|Taipei Veterans General Hospital, Taipei City, Taiwan|National Taiwan Uni Hospital; Internal Medicine, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|MI Dnipropetrovsk City Multifield Clinical Hospital 4 of Dnipropetrovsk Regional Council, Dnipropetrovsk, Katerynoslav Governorate, Ukraine|Kyiv Railway Clinical Hospital #3 of Branch Health Center of PJSC Ukrainian Railway; Surgery Dept, Kyiv, Kharkiv Governorate, Ukraine|MICR Oncology Dispensary of Cherkasy Regional Council; Regional Center of Clinical Oncology, Cherkasy, Ukraine|Private Enterprise Private Manufacturing Company Acinus, Kirovograd, Ukraine|Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary; Oncothoracic department, Sumy, Ukraine|MI Zaporizhzhia Regional Clinical Oncological Dispensary Zaporizhzhia SMU Ch of Oncology, Zaporizhzhya, Ukraine|Bristol Haematology and Oncology Centre, Bristol, United Kingdom|Velindre Hospital, Cardiff, United Kingdom|Gartnavel General Hospital; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Raigmore Hospital, Inverness, United Kingdom|St George's Hospital, London, United Kingdom|Charing Cross Hospital, London, United Kingdom|Churchill Hospital, Oxford, United Kingdom|Derriford Hospital; Plymouth Oncology Centre, Plymouth, United Kingdom|Queen's Hospital, Romford, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom",https://ClinicalTrials.gov/show/NCT02657434
103,Hoffmann-La Roche,A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131],"Active, not recruiting",Has Results,Squamous Non-Small Cell Lung Cancer,"Drug: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody|Drug: Carboplatin|Drug: Nab-Paclitaxel|Drug: Paclitaxel",Industry,Interventional,"Ironwood Cancer & Research Centers, Chandler, Arizona, United States|Highlands Oncology Group, Rogers, Arkansas, United States|Southern CA Permanente Med Grp, Bellflower, California, United States|Kaiser Permanente Oakland Medical Center, Oakland, California, United States|Kaiser Permanente - Sacramento Medical Center and Medical Offices, Sacramento, California, United States|Kaiser Permanente - San Leandro Medical Center, San Leandro, California, United States|Kaiser Permanente - Santa Clara, Santa Clara, California, United States|Kaiser Permanente; Oncology Clinical Trials, Vallejo, California, United States|Kaiser Permanente - Walnut Creek, Walnut Creek, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|Danbury Hospital, Danbury, Connecticut, United States|Holy Cross Hospital Inc, Fort Lauderdale, Florida, United States|SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States|Florida Cancer Specialists, Palm Beach Gardens, Florida, United States|Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida, United States|Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building), Saint Petersburg, Florida, United States|University Cancer & Blood Center, LLC; Research, Athens, Georgia, United States|Northwest Georgia Oncology Centers P.C., Carrollton, Georgia, United States|Central Georgia Cancer Care PC, Macon, Georgia, United States|Southeastern Regional Medical Center, Inc., Newnan, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Joliet Oncology-Hematology; Associates, Ltd., Joliet, Illinois, United States|Quincy Medical Group, Quincy, Illinois, United States|Fort Wayne Med Oncology & Hematology Inc, Fort Wayne, Indiana, United States|Hematology-Oncology; Associates of the Quad Cities, Bettendorf, Iowa, United States|Siouxland Hematology/Oncology, Sioux City, Iowa, United States|Lahey Clinic Med Ctr, Lexington, Kentucky, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|New England Cancer Specialists, Scarborough, Maine, United States|Southcoast Health System; Southcoast Centers For Cancer Care, Fairhaven, Massachusetts, United States|St. Joseph Mercy Health System, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|St. Luke's Regional Cancer Center, Duluth, Minnesota, United States|Hematology and Oncology Associates at Bridgepoint, Tupelo, Mississippi, United States|Billings Clinic, Billings, Montana, United States|Va Sierra Nevada Health Care System, Reno, Nevada, United States|Valley Hospital; Oncology Research, Paramus, New Jersey, United States|Regional Cancer Care Associates LLC, Sewell, New Jersey, United States|Clinical Research Alliance, New Hyde Park, New York, United States|W.G. Bill Hefner VA Medical Center, Salisbury, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Mark H. Zangmeister Center, Columbus, Ohio, United States|Oncology Hematology Care, Inc., Hamilton, Ohio, United States|St. Charles Medical Center Bend; Cancer Care Of The Cascades, Bend, Oregon, United States|Oregon Health & Science Uni, Portland, Oregon, United States|St. Luke's Cancer Care Associates, Bethlehem, Pennsylvania, United States|Maryland Oncology Hematology (Lanham) - USOR, Gettysburg, Pennsylvania, United States|Allegheny Cancer Center, Pittsburgh, Pennsylvania, United States|Univ of Pittsburgh Medical Ctr, Pittsburgh, Pennsylvania, United States|SCRI Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States|Tennessee Cancer Specialists, Knoxville, Tennessee, United States|SCRI The Center For Cancer and Blood Disorders, Denton, Texas, United States|Longview Cancer Center, Longview, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Blue Ridge Cancer Care, Roanoke, Virginia, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Medical Oncology Associates, Spokane, Washington, United States|Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Argentina|Sanatorio Allende, Cordoba, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina|Clínica Pergamino, Pergamino, Argentina|Fundacion Koriza, Santa Rosa, Argentina|Centro de Investigacion; Clinica - Clinica Viedma S.A., Viedma, Argentina|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|Calvary Mater Newcastle; Medical Oncology, Waratah, New South Wales, Australia|Prince Charles Hospital, Chermside, Queensland, Australia|Townsville Hospital, Townsville, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Austin Health, Heidelberg, Victoria, Australia|Cabrini Hospital Malvern, Malvern, Victoria, Australia|Sunshine Hospital, St Albans, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Paracelsus Medizinische Privatuniversität, Salzburg, Austria|Cliniques Universitaires St-Luc, Bruxelles, Belgium|CHU Sart-Tilman, Liège, Belgium|Clinique Ste-Elisabeth, Namur, Belgium|Werken Glorieux VZW, Ronse, Belgium|GasthuisZusters Antwerpen, Wilrijk, Belgium|Cenantron - Centro Avancado de Tratamento Oncologico, Belo Horizonte, MG, Brazil|Instituto Do Cancer Delondrina_X; Unidade De Pesquisa Clinica, Londrina, PR, Brazil|Liga Norte Riograndense Contra O Câncer, Natal, RN, Brazil|IPCEM; Instituto de Pesquisa de Estudos Multicêntricos, Caxias do Sul, RS, Brazil|Hospital Bruno Born, Lajeado, RS, Brazil|Hospital Mae de Deus, Porto Alegre, RS, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|*X*Fundação Pio XII Hospital de Câncer de Barretos, Barretos, SP, Brazil|Hospital de Base de Sao Jose do Rio Preto, Sao Jose do Rio Preto, SP, Brazil|Hospital Do Cancer A C Camargo, Sao Paulo, SP, Brazil|Multiprofile Hospital for Active Treatment Central Onco Hospital OOD, Plovdiv, Bulgaria|Multiprofile Hospital for Active Treatment Serdika EOOD, Sofia, Bulgaria|Royal Victoria Regional Health Centre, Barrie, Ontario, Canada|William Osler Health Centre, Etobicoke, Ontario, Canada|Lakeridge Health Center, Oshawa, Ontario, Canada|Cite de La Sante de Laval; Hemato-Oncologie, Laval, Quebec, Canada|Hôpital du Sacré-Coeur de Montreal, Montreal, Quebec, Canada|St. Jerome Medical Research, St. Jerome, Quebec, Canada|Health & Care SPA, Santiago, Chile|Sociedad de Investigaciones Medicas Ltda (SIM), Temuco, Chile|CHU de Grenoble, Grenoble, France|Ctr Jean Bernard Clin V. Hugo; Service d'Oncologie Méd, Le Mans, France|Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes, Lyon, France|Clinique Clémentville, Montpellier, France|Hopital de La Source, Orleans, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|Hopital de Pontchaillou; Service de Pneumologie, Rennes, France|Centre Hospitalier Regional Sud Reunion; Service de Pneumologie, Saint Pierre, France|CH de Saint Quentin, Saint Quentin, France|Hôpital d'Instruction des Armées de Sainte Anne; Service Pharmacie Essais Cliniques, Toulon Cedex 9, France|Charite - Universitätsmedizin Berlin, Berlin, Germany|Ev.Krankenhaus Bielefeld gGmbH; Klinik für Innere Medizin und Geriatrie, Bielefeld, Germany|Augusta Kranken-Anstalt gGmbH, Bochum, Germany|Universitätsklinikum ""Carl Gustav Carus"" der Technischen Universität Dresden, Dresden, Germany|St. Elisabethen Krankenhaus, Frankfurt am Main, Germany|Robert Bosch Krankenhaus; Pneumologie und pneumologische Onkologie, Gerlingen, Germany|LungenClinic Großhansdorf GmbH, Großhansdorf, Germany|Krankenhaus Martha-Maria; Halle-Dolau gGmbH, Halle, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Asklepios Klinik Harburg, Hamburg, Germany|Lungenklinik Hemer, Hemer, Germany|Universität Des Saarlandes; Klinik für Innere Medizin V, Homburg, Germany|Fachklinik für Lungenerkrankungen, Immenhausen, Germany|Kliniken der Stadt Koln gGmbH, Koln, Germany|Johannes Wesling Klinikum Minden, Minden, Germany|Klinikum Bogenhausen; Klinik für Pneumologie und Pneumologische Onkologie, München, Germany|Krankenhaus Barmherzige Bruder Regensburg, Regensburg, Germany|Klinikum der Universität Regensburg, Regensburg, Germany|Stiftung Mathias-Spital Rheine, Rheine, Germany|Schwarzwald-Baar Klinikum/VS GmbH; Onkologie/Hämatologie/Infektologie, Villingen-Schwenningen, Germany|Soroka Medical Center, Beer Sheva, Israel|Hadassah University Hospital - Ein Kerem, Jerusalem, Israel|Meir Medical Center; Oncology, Kfar-Saba, Israel|Rabin Medical Center, Petach Tiqwa, Israel|Chaim Sheba Medical Center; Oncology Dept, Ramat Gan, Israel|Rambam Health Corporation; Oncology Institute, Rambam, Israel|Tel Aviv Sourasky Medical Ctr; Oncology, Tel Aviv, Israel|Azienda Ospedaliera di Rilievo Nazionale e di Alta Specialita San Giuseppe Moscati, Avellino, Campania, Italy|AORN A Cardarelli, Napoli, Campania, Italy|Azienda Ospedaliero Universitaria Seconda Università degli Studi di Napoli; Farmacia Centralizzata, Napoli, Campania, Italy|Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale, Napoli, Campania, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Lazio, Italy|ASL 3 Genovese; DSM, Genova, Liguria, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Lombardia, Italy|IRCCS Giovanni Paolo II Istituto Oncologico, Bari, Puglia, Italy|Policlinico Vittorio Emanuele, Catania, Sicilia, Italy|Ospedale Civile - Livorno, Livorno, Toscana, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Toscana, Italy|Ospedale Silvestrini, Perugia, Umbria, Italy|Aichi Cancer Center Hospital; Respiratory Medicine, Aichi, Japan|Nagoya University Hospital; Respiratory Medicine, Aichi, Japan|National Cancer Center Hospital East; Thoracic Oncology, Chiba, Japan|National Hospital Organization Shikoku Cancer Center; Internal Medicine, Ehime, Japan|National Hospital Organization Kyushu Medical Center; Respiratory Internal Medicine, Fukuoka, Japan|Kyushu University Hospital; Respiratory, Fukuoka, Japan|Kobe City Medical Center General Hospital; Respiratory Medicine, Hyogo, Japan|National Hospital Organization Himeji Medical Center, Hyogo, Japan|Hyogo Cancer Center; Thoracic Oncology, Hyogo, Japan|Ibaraki Prefectural Central Hospital; Division of respiratory, Ibaraki, Japan|Kanagawa Cancer Center;Thoracic Oncology, Kanagawa, Japan|Kyoto University Hospital, Respiratory Medicine, Kyoto, Japan|Sendai Kousei Hospital; Pulmonary Medicine, Miyagi, Japan|Niigata University Medical & Dental Hospital; Respiratory Medicine and Infectious Disease, Niigata, Japan|Okayama University Hospital; Respiratory and Allergy Medicine, Okayama, Japan|Osaka International Cancer Institute; Thoracic Oncology, Osaka, Japan|Osaka City Uni Hospital; Respiratory Medicine, Osaka, Japan|Kansai Medical university Hospital; Thoracic Oncology, Osaka, Japan|Osaka Habikino Medical Center, Osaka, Japan|Saitama Cancer Center; Thoracic Oncology, Saitama, Japan|National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai-shi, Japan|Shizuoka Cancer Center; Thoracic Oncology, Shizuoka, Japan|National Cancer Center Hospital; Thoracic Medical Oncology, Tokyo, Japan|Tokyo Medical University Hospital; Dept of Surgery, Tokyo, Japan|Riga East Clinical University Hospital Latvian Oncology Centre, Riga, Latvia|Pauls Stradins Clinical University Hospital, Rīga, Latvia|National Cancer Institute, Vilnius, Lithuania|Centro Universitario Contra El Cancer, Monterrey, Mexico|Cancerología, Queretaro, Mexico|VU Medisch Centrum; VU University Medical Center, Amsterdam, Netherlands|Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands|Ziekenhuis Gelderse Vallei, EDE, Netherlands|Catharina Hospital; Afdeling Longgeneeskunde en Tuberculose, Eindhoven, Netherlands|St. Antonius Ziekenhuis; R&D Long, Nieuwegein, Netherlands|Centro Medico Monte Carmelo, Arequipa, Peru|Hospital Nacional Guillermo Almenara Irigoyen ESSALUD, Lima, Peru|Instituto Regional de Enfermedades Neoplásicas Del Norte, Trujillo, Peru|IPO de Lisboa; Servico de Pneumologia, Lisboa, Portugal|Hospital Pulido Valente; Servico de Pneumologia, Lisboa, Portugal|Centro Hospitalar do Porto - Hospital de Santo António, Porto, Portugal|Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe, Porto, Portugal|Hospital de Sao Joao; Servico de Pneumologia, Porto, Portugal|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, Russian Federation|Russian Oncology Research Center n.a. N.N. Blokhin, Moscow, Russian Federation|Clinical Oncology Dispensary, Omsk, Russian Federation|City Clinical Oncology Dispensary, Saint-Petersburg, Russian Federation|Volgograd Regional Clinical Oncology Dispensary, Volgograd, Russian Federation|National University Hospital, Singapore, Singapore|National Cancer Centre, Singapore, Singapore|Univerzitna nemocnica Bratislava, Bratislava, Slovakia|Narodny onkologicky ustav, Bratislava, Slovakia|POKO Poprad s.r.o., Poprad, Slovakia|Instituto Catalan de Oncologia de Hospitalet (ICO); Servicio de Farmacia, L'Hospitalet de Llobregat, Barcelona, Spain|Corporacio Sanitaria Parc Tauli; Servicio de Oncologia, Sabadell, Barcelona, Spain|Hospital Universitario Marques de Valdecilla; Servicio de Oncologia, Santander, Cantabria, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Islas Baleares, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, LA Coruña, Spain|Complejo Hospitalario Universitario Insular-Materno Infantil, Las Palmas de Gran Canaria, LAS Palmas, Spain|Hospital Nuestra Senora de Valme, Seville, Sevilla, Spain|Hospital Universitario de Canarias, S. Cristobal De La Laguna, Tenerife, Spain|Hospital del Mar, Barcelona, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital Lucus Augusti; Servicio de Oncologia, Lugo, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Fundación Jimenez Díaz, Madrid, Spain|Hospital Clinico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia, Madrid, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Changhua Christian Hospital; Hematology-Oncology, Changhua, Taiwan|Kaohsiung Medical University Hospital; Department of Urology, Kaohsiung City, Taiwan|Chi Mei Medical Center Liou Ying Campus, Liuying Township, Taiwan|Chang Gung Memorial Hospital Chiayi, Putzu, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan Uni Hospital, Taipei City, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|Municipal Institution City Clinical Hospital #4 of Dnipro City Council - PPDS; Dept of Chemotherapy, Dnipropetrovsk, Katerynoslav Governorate, Ukraine|Uzhgorod Central City Clinical Hospital, Uzhhorod, Katerynoslav Governorate, Ukraine|MNPE Zaporizhzhia Regional Antitumor Center ZRC, Zaporizhzhia, Katerynoslav Governorate, Ukraine|Communal Non profit Enterprise Regional Center of Oncology; Oncosurgical dept of thoracic organs, Kharkiv, Kharkiv Governorate, Ukraine|Communal Nonprofit Enterprise Podilsky Regional Center Of Oncology OfTheVinnytsia Regional Council, Vinnytsia, KIEV Governorate, Ukraine|MI of the Lviv Regional Council Lviv Oncology Regional Treatment and Diagnostic Centre; Chemotherapy, Lviv, Volhynian Governorate, Ukraine|Municipal Institution Chernivtsi Regional Clinical Oncology Dispensary; Surgery Department #1, Chernivtsi, Ukraine|SI Institute of Medical Radiology n.a. S.P. Hryhoriev of NAMS of Ukraine, Kharkiv, Ukraine|ME Kryviy Rih Oncology Dispensary of Dnipropetrovs'k Regional Council; Chemotherapy Department, Kryvyi Rih, Ukraine|Poltava Regional Clinical Oncology Dispensary of Poltava Regional Council; Thoracic department, Poltava, Ukraine|Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary, Sumy, Ukraine|Transcarpathian Regional Clinical Oncology Dispensary; Chemotherapy Department, Uzhhorod, Ukraine",https://ClinicalTrials.gov/show/NCT02367794
104,Roswell Park Cancer Institute|National Cancer Institute (NCI)|Boehringer Ingelheim|National Comprehensive Cancer Network,Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer,"Active, not recruiting",Has Results,Colon Adenocarcinoma|Rectal Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer,Drug: Capecitabine|Other: Laboratory Biomarker Analysis|Drug: Nintedanib|Other: Pharmacological Study,Other|NIH|Industry,Interventional,"City of Hope Comprehensive Cancer Center, Duarte, California, United States|Roswell Park Cancer Institute, Buffalo, New York, United States",https://ClinicalTrials.gov/show/NCT02393755
105,Bristol-Myers Squibb,Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens,"Active, not recruiting",Has Results,Squamous Cell Non-small Cell Lung Cancer,Drug: Nivolumab,Industry,Interventional,"University Of California Davis Medical Center, Sacramento, California, United States|Va San Diego Healthcare System, San Diego, California, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Local Institution, Metairie, Louisiana, United States|Tufts Medical Center, Boston, Massachusetts, United States|Providence Cancer Institute, Southfield, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Beth Israel Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University Of North Carolina At Chapel Hill, Chapel Hill, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Providence Oncology And Hematology, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Network Office of Research and Innovation, Allentown, Pennsylvania, United States|University Of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Henry-Joyce Cancer Center, Nashville, Tennessee, United States|Oncology Consultants, Pa, Houston, Texas, United States|Local Institution, Caen, France|Local Institution, Creteil, France|Local Institution, Pierre Benite, France|Local Institution, Rennes, France|Local Institution, Strasbourg, France|Local Institution, Toulouse, France|Local Institution, Villejuif, France|Local Institution, Berlin, Germany|Local Institution, Koeln, Germany|Local Institution, Muenchen, Germany|Local Institution, Livorno, Italy|Local Institution, Lucca, Italy|Local Institution, Terni, Italy",https://ClinicalTrials.gov/show/NCT01721759
106,Bristol-Myers Squibb,Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017),"Active, not recruiting",Has Results,Squamous Cell Non-small Cell Lung Cancer,Biological: Nivolumab|Drug: Docetaxel,Industry,Interventional,"Mayo Clinic Arizona, Scottsdale, Arizona, United States|City Of Hope, Duarte, California, United States|Yale University, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Northwest Georgia Oncology Ctr, Marietta, Georgia, United States|University Of Chicago Medical Center, Chicago, Illinois, United States|The Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Winthrop University Hospital, Mineola, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Nassau, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|St Mary Medical Center, Langhorne, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Guthrie Medical Group, P.C., Sayre, Pennsylvania, United States|South Carolina Oncology Associates, Columbia, South Carolina, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|University Of Texas Southwestern Medical Center, Dallas, Texas, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|U of Washington / Seattle Cancer Care Alliance, Seattle, Washington, United States|West Virginia University-Mbrcc, Morgantown, West Virginia, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Local Institution, San Miguel De Tucuman, Tucuman, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Wollongong, New South Wales, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Kurralta Park, South Australia, Australia|Local Institution, Clayton, Victoria, Australia|Local Institution, Linz, Austria|Local Institution, Salzburg, Austria|Local Institution, Vienna, Austria|Local Institution, Wels, Austria|Cancercare Manitoba, Winnipeg, Manitoba, Canada|Jewish General Hospital, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Recoleta, Santiago DE Chile, Chile|Local Institution, Vi?a Del Mar, Valparaiso, Chile|Local Institution, Antofagasta, Chile|Local Institution, Santiago, Chile|Local Institution, Praha 8, Czechia|Local Institution, Avignon Cedes 9, France|Local Institution, Caen, France|Local Institution, Dijon, France|Local Institution, La Roche Sur Yon Cedex 9, France|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 20, France|Local Institution, Pierre Benite, France|Local Institution, Rennes Cedex 9, France|Local Institution, Strasbourg, France|Local Institution, Toulouse, France|Local Institution, Bad Berka, Germany|Local Institution, Essen, Germany|Local Institution, Gerlingen, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Heidelberg, Germany|Local Institution, Koeln, Germany|Local Institution, Krefeld, Germany|Local Institution, Budapest, Hungary|Local Institution, Dublin 8, Dublin, Ireland|Local Institution, Dublin 9, Dublin, Ireland|Local Institution, Bologna, Italy|Local Institution, Meldola (fc), Italy|Local Institution, Milano, Italy|Local Institution, Padova, Italy|Local Institution, Perugia, Italy|Local Institution, Ravenna, Italy|Local Institution, Siena, Italy|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Leon, Guanajato, Guanajuato, Mexico|Local Institution, Hermosillo, Sonora, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Arequipa, Peru|Local Institution, Lima, Peru|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Olsztyn, Poland|Local Institution, Szczecin, Poland|Local Institution, Warszawa, Poland|Local Institution, Bucuresti, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Constanta, Romania|Local Institution, Craiova, Romania|Local Institution, Iasi, Romania|Local Institution, Timisoara, Romania|Local Institution, Moscow, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Barakaldo, Vizcaya, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Cottingham, EAST Yorkshire, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Withington, Manchester, United Kingdom|Local Institution, Sheffield, Yorkshire, United Kingdom",https://ClinicalTrials.gov/show/NCT01642004
107,Pfizer,A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations,"Active, not recruiting",Has Results,ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC,Drug: PF-06463922|Drug: Crizotinib,Industry,Interventional,"Highlands Oncology Group/Research, Fayetteville, Arkansas, United States|Highlands Oncology Group, Rogers, Arkansas, United States|Chao Family Comprehensive Cancer Center, Orange, California, United States|UC Irvine Medical Center, Orange, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|MDZ: Yale-New Haven Hospital, New Haven, Connecticut, United States|Smilow Cancer Hospital at Yale-New Haven, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Karmanos Center Institute, Detroit, Michigan, United States|Karmanos Cancer Institute, Farmington Hills, Michigan, United States|Siteman Cancer Center-West County, Creve Coeur, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Washington University Infusion Center Pharmacy, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, United States|Rockefeller Patient Pavilion - Memorial Sloan Kettering, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Rochester Regional Health System, Rochester, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|The Ohio State University, Columbus, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute (Pharmacy), Nashville, Tennessee, United States|Chris O'Brien Lifehouse, Sydney Local Health District [rpa], New South Wales, Australia|Chris O'Brien Lifehouse, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|University Hospital Antwerp, Edegem, Belgium|British Columbia Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CHU Grenoble/ Hôpital Albert Michallon, Grenoble Cedex 9, France|CHU Grenoble/Hopital Albert Michallon, Grenoble Cedex 9, France|CHU de Rennes - Hôpital Pontchaillou - CIC Inserm, Rennes Cedex 9, France|CHU de Rennes - Hôpital Pontchaillou, Rennes Cedex 9, France|Institut Universitaire du Cancer de Toulouse (IUCT-O), Toulouse Cedex 9, France|Institut Gustave Roussy (comite poumon-pneumologie), Villejuif Cedex, France|Institut Gustave Roussy- Pharmacie-Unite Essais Cliniques, Villejuif, France|Universitaetsklinik Koeln, Cologne, NRW, Germany|Department of Clinical Oncology, Prince of Wales Hospital, Shatin, Hong Kong|Struttura Operativa Complessa Oncologia, Aviano (PN), Italy|Dipartimento di Oncologia Medica, UO Medicina 1Q A, Unita' Nuovi Farmaci e Terapie Innovative, Milano, Italy|Unita di Farmacologia Clinica e Nuovi Farmaci, Milano, Italy|Oncologia Medica, Perugia, Italy|Aichi Cancer Center Hospital, Nagoya, Aichi, Japan|Nagoya University Hospital, Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Hyogo Cancer Center, Akashi, Hyogo, Japan|Kindai University Hospital, Osakasayama, Osaka, Japan|Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|Seoul National University Hospital / Department of Internal Medicine, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|National University Hospital, Singapore, Singapore|National University Hospital Medical Centre, Singapore, Singapore|National Cancer Center, Singapore, Singapore|Hospital Universitario Quiron Madrid, Pozuelo de Alarcón, Madrid, Spain|Clinica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Universitario Quiron Dexeus, Barcelona, Spain|Hospital Universitari de la Vall D'Hebron Edificio General. Planta Baja. UITM. Servicio de Oncologia, Barcelona, Spain|Hospital of Lausanne (CHUV), Lausanne, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|National Taiwan University Hospital, Taipei, Taiwan",https://ClinicalTrials.gov/show/NCT01970865
108,AstraZeneca,"A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer","Active, not recruiting",Has Results,Non - Small Cell Lung Cancer NSCLC,Drug: MEDI4736 (durvalumab)|Drug: Vinorelbine|Drug: Gemcitabine|Drug: Erlotinib|Drug: MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4)|Drug: tremelimumab (anti-CTLA4),Industry,Interventional,"Research Site, Chandler, Arizona, United States|Research Site, Anaheim, California, United States|Research Site, Duarte, California, United States|Research Site, La Jolla, California, United States|Research Site, San Diego, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Fort Myers, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Port Saint Lucie, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Athens, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Lawrenceville, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Waterloo, Iowa, United States|Research Site, Ashland, Kentucky, United States|Research Site, Rockville, Maryland, United States|Research Site, Battle Creek, Michigan, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Bronx, New York, United States|Research Site, Mineola, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, West Chester, Ohio, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Germantown, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Spokane, Washington, United States|Research Site, Murdoch, Australia|Research Site, Port Macquarie, Australia|Research Site, Charleroi, Belgium|Research Site, Gent, Belgium|Research Site, Libramont-Chevigny, Belgium|Research Site, Mons, Belgium|Research Site, Roeselare, Belgium|Research Site, Yvoir, Belgium|Research Site, Pleven, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Moncton, New Brunswick, Canada|Research Site, Saint John, New Brunswick, Canada|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Temuco, Chile|Research Site, Nova Ves pod Plesi, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 5, Czechia|Research Site, Avignon Cedex 9, France|Research Site, Bayonne, France|Research Site, Brest Cedex, France|Research Site, Creteil, France|Research Site, Le Mans, France|Research Site, Marseille Cedex 20, France|Research Site, Montpellier Cedex, France|Research Site, Nice, France|Research Site, Pau Cedex, France|Research Site, Saint Herblain, France|Research Site, Toulon, France|Research Site, Villejuif, France|Research Site, Villingen-Schwenningen, France|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Gauting, Germany|Research Site, Halle, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Homburg, Germany|Research Site, Köln, Germany|Research Site, Löwenstein, Germany|Research Site, Regensburg, Germany|Research Site, Trier, Germany|Research Site, Ulm, Germany|Research Site, Athens, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Hong Kong, Hong Kong|Research Site, Budapest, Hungary|Research Site, Miskolc, Hungary|Research Site, Törökbálint, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Tel Hashomer, Israel|Research Site, Aviano, Italy|Research Site, Candiolo, Italy|Research Site, Catania, Italy|Research Site, Cremona, Italy|Research Site, Genova, Italy|Research Site, Lucca, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Monza, Italy|Research Site, Napoli, Italy|Research Site, Orbassano, Italy|Research Site, Parma, Italy|Research Site, Pisa, Italy|Research Site, Rimini, Italy|Research Site, Terni, Italy|Research Site, Fukuoka, Japan|Research Site, Habikino-shi, Japan|Research Site, Hidaka-shi, Japan|Research Site, Hirakata-shi, Japan|Research Site, Hirosaki-shi, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Kanazawa, Japan|Research Site, Kobe-shi, Japan|Research Site, Kurume-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Natori-shi, Japan|Research Site, Okayama-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osakasayama, Japan|Research Site, Sakai-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Sunto-gun, Japan|Research Site, Takatsuki-shi, Japan|Research Site, Wakayama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Busan, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Jeonnam, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Amsterdam, Netherlands|Research Site, Lublin, Poland|Research Site, Poznań, Poland|Research Site, Warszawa, Poland|Research Site, Alba Iulia, Romania|Research Site, Baia Mare, Romania|Research Site, Cluj Napoca, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Onesti, Romania|Research Site, Oradea, Romania|Research Site, Timisoara, Romania|Research Site, Arkhangelsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Belgrade, Serbia|Research Site, Belgrad, Serbia|Research Site, Gornji Matejevac, Serbia|Research Site, Kragujevac, Serbia|Research Site, Sremska Kamenica, Serbia|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, A Coruña, Spain|Research Site, Alicante, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Girona, Spain|Research Site, Jaén, Spain|Research Site, Lleida, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, San Sebastian, Spain|Research Site, Sevilla, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Valencia, Spain|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Bangkok, Thailand|Research Site, Muang, Thailand|Research Site, Phitsanulok, Thailand|Research Site, Songkla, Thailand|Research Site, Birmingham, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Southampton, United Kingdom|Research Site, Stevenage, United Kingdom|Research Site, Truro, United Kingdom|Research Site, Wolverhampton, United Kingdom",https://ClinicalTrials.gov/show/NCT02352948
109,UNC Lineberger Comprehensive Cancer Center|Bayer,Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer,"Active, not recruiting",Has Results,Colorectal Cancer Metastatic,Drug: Regorafenib (BAY 73-4506)|Drug: FOLFIRI|Drug: Placebo,Other|Industry,Interventional,"Rocky Mountain Cancer Centers, Denver, Colorado, United States|Mount Sinai Medical Center-Miami, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Georgia Cancer Specialists, Atlanta, Georgia, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|University of Louisville James Brown Cancer Center, Louisville, Kentucky, United States|North Shore Long Island Jewish Health System, Manhasset, New York, United States|New York University Langone Medical Center, New York, New York, United States|Seby B. Jones Cancer Center, Boone, North Carolina, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Carolinas HealthCare System, Charlotte, North Carolina, United States|Southeast Medical Oncology Center, Goldsboro, North Carolina, United States|The Moses Cone Regional Cancer Center, Greensboro, North Carolina, United States|Leo W. Jenkins Cancer Center at ECU Medical School, Greenville, North Carolina, United States|First Health of the Carolinas, Moore Regional Hospital, Pinehurst, North Carolina, United States|Rex Cancer Center at Rex Hospital, Raleigh, North Carolina, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|University of Virginia, Charlottesville, Virginia, United States|Portsmouth Naval Medical Center, Portsmouth, Virginia, United States|Multicare Regional Cancer Center, Tacoma, Washington, United States|Ireland Cooperative Clinical Research Group, Dublin, Ireland",https://ClinicalTrials.gov/show/NCT01298570
110,Celgene,A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors,"Active, not recruiting",Has Results,Central Nervous System Neoplasms|Medulloblastoma,Drug: Pomalidomide,Industry,Interventional,"Stanford University Cancer Center, Stanford, California, United States|University of Florida, Gainesville, Florida, United States|Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States|National Cancer Institute, Bethesda, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Baylor College of Medicine, Houston, Texas, United States|Centre Oscar Lambret, Lille, France|Centre Leon Berard, Lyon, France|Hopital d'Enfants de la Timone, Marseille Cedex 01, France|Institut Curie, Paris, France|Hopital des Enfants, Toulouse, France|CHU Nancy Hematology, Vandoeuvre les Nancy, France|Institut Gustave Roussy Faculte de Medecine Paris Sud Service de pneumologie, Villejuif Cedex, France|Istituto G. Gaslini Ospedale Pediatrico IRCCS, Genova, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy|Ospedale Bambin Gesu, Roma, Italy|Hospital Universitario Vall D Hebron, Barcelona, Spain|Hospital Infantil Universitario Nino Jesus, Madrid, Spain|Hospital Universitario La Fe, Valencia, Spain|Leeds General Infirmary, Leeds, United Kingdom|Great Ormond Street Hospital, London, United Kingdom|The Royal Marsden Hospital, Sutton-Surrey, United Kingdom",https://ClinicalTrials.gov/show/NCT03257631
111,Seagen Inc.,A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer,"Active, not recruiting",Has Results,HER2 Positive Breast Cancer,Drug: tucatinib|Drug: capecitabine|Drug: trastuzumab|Drug: placebo,Industry,Interventional,"University of Alabama at Birmingham, Birmingham, Alabama, United States|University of South Alabama - Mitchell Cancer Institute, Mobile, Alabama, United States|Cancer Treatment Centers of America - Phoenix, Goodyear, Arizona, United States|Arizona Oncology Associates, PC - HAL, Phoenix, Arizona, United States|City of Hope National Medical Center, Duarte, California, United States|TRIO - Central Regulatory Office, Los Angeles, California, United States|UCLA Medical Center / David Geffen School of Medicine, Los Angeles, California, United States|Torrance Memorial Physician Network - TRIO, Redondo Beach, California, United States|University of California at San Francisco, San Francisco, California, United States|Kaiser Permanente San Marcos Medical Offices, San Marcos, California, United States|Central Coast Medical Oncology Corporation TRIO, Santa Maria, California, United States|Kaiser Permanente Medical Center Northern California, Vallejo, California, United States|University of Colorado Hospital / University of Colorado, Aurora, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Lombardi Cancer Center / Georgetown University Medical Center, Washington, District of Columbia, United States|Florida Cancer Specialists - South Region, Fort Myers, Florida, United States|Memorial Regional Hospital TRIO, Hollywood, Florida, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Mount Sinai Medical Center / Florida, Miami Beach, Florida, United States|University of Miami, Miami, Florida, United States|Orlando Health, Inc. TRIO, Orlando, Florida, United States|Florida Cancer Specialists - North Region, Saint Petersburg, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Florida Cancer Specialists - East West Palm Beach, FL (SCRI), West Palm Beach, Florida, United States|Winship Cancer Institute / Emory University School of Medicine, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|Augusta University, Augusta, Georgia, United States|Cancer Treatment Centers of America, Newnan, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Illinois Cancer Specialists / Advocate Lutheran General Hospital, Niles, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|University of Maryland, Baltimore, Maryland, United States|Maryland Oncology Hematology, P.A., Rockville, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Saint Luke's Cancer Institute LLC, Kansas City, Missouri, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|Dartmouth-Hitchcock Medical Center/ Norris Cotton Cancer Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Mount Sinai Beth Israel, New York, New York, United States|New York University (NYU) Cancer Institute, New York, New York, United States|Stony Brook University Cancer Center, Stony Brook, New York, United States|UNC Lineberger Comprehensive Cancer Center / University of North Carolina, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Leo W. Jenkins Cancer Services / Brody School of Medicine East Carolina University, Greenville, North Carolina, United States|James Cancer Hospital / Ohio State University, Columbus, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Northwest Cancer Specialists, P.C., Tualatin, Oregon, United States|University of Pennsylvania / Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States|Cancer Treatment Centers of America / Eastern Regional Medical Center, Philadelphia, Pennsylvania, United States|Roper St. Francis Healthcare, Charleston, South Carolina, United States|Medical University of South Carolina/Hollings Cancer Center, Charleston, South Carolina, United States|Wellmont Cancer Institute, Kingsport, Tennessee, United States|Tennessee Oncology - Nashville, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Oncology - Austin Midtown, Austin, Texas, United States|Texas Oncology Methodist, Dallas, Texas, United States|Texas Oncology - Denton South, Denton, Texas, United States|The Center for Cancer and Blood Disorders: Fortworth, Fort Worth, Texas, United States|Texas Oncology - Houston Memorial City, Houston, Texas, United States|MD Anderson Cancer Center / University of Texas, Houston, Texas, United States|Baylor Clinic, Houston, Texas, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States|Paris Regional Medical Center / US Oncology, Paris, Texas, United States|Texas Oncology - Plano East, Plano, Texas, United States|Texas Oncology - San Antonio Medical Center Northeast, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|US Oncology Central Regulatory, The Woodlands, Texas, United States|Texas Oncology - Deke Slayton Cancer Center, Webster, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Shenandoah Oncology P.C., Winchester, Virginia, United States|Swedish Cancer Institute, Seattle, Washington, United States|Seattle Cancer Care Alliance / University of Washington, Seattle, Washington, United States|Carbone Cancer Center / University of Wisconsin, Madison, Wisconsin, United States|Austin Hospital, Heidelberg, Australia|Cabrini Education and Research Precinct, Malvern, Australia|Peter MacCallum Cancer Centre, Melbourne, Australia|Breast Cancer Research Centre, Nedlands, Australia|Mater Hospital, North Sydney, Australia|Icon Cancer Care South Brisbane, South Brisbane, Australia|Mater Health Services, South Brisbane, Australia|Sunshine Hospital, St Albans, Australia|Westmead Hospital, Westmead, Australia|LKH- Universitat Klinikum Graz, Graz, Austria|Medizinische Universitat Innsbruck, Innsbruck, Austria|KH d. Barmherzigen Schwestern Linz, Linz, Austria|LKH Salzburg, Universitatsklinikum der PMU, Salzburg, Austria|AZ Klina, Brasschaat, Belgium|Cliniques Universitaires Saint Luc, Brussels, Belgium|Grand Hopital de Charleroi, Charleroi, Belgium|Centre Hospitalier de l'Ardenne, Libramont, Belgium|CHU UCL Namur-Site de Saint Elisabeth, Namur, Belgium|Tom Baker Cancer Centre, Calgary, Canada|University of Alberta / Cross Cancer Institute, Edmonton, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Canada|Jewish General Hospital, Montreal, Canada|Hopital du Saint-Sacrement, CHU de Quebec-Universite Laval, Quebec, Canada|Allan Blair Cancer Centre, Regina, Canada|Saskatoon Cancer Centre, Saskatoon, Canada|H. Bliss Murphy Cancer Centre, St John's, Canada|Sunnybrook Health Sciences Centre, Toronto, Canada|University Health Network, Princess Margaret Hospital, Toronto, Canada|British Columbia Cancer Agency - Vancouver Centre, Vancouver, Canada|Fakultni nemocnice Hradec Kralove-oddeleni klinicke hematologie, Hradec Kralove, Czechia|Fakultni Nemocnice Olomouc (Fnol) - Onkologicka Klinika, Olomouc, Czechia|Aalborg Universitetshospital, Aalborg, Denmark|Rigs Hospiltalet, Copenhagen, Denmark|Herlev Hospital, Herlev, Denmark|Odense University Hospital, Odense C, Denmark|Sygehus Lillebaelt - Vejle Sygehus, Vejle, Denmark|University Hospital of Besancon, Besancon cedex, France|Clinique Victor Hugo, Le Mans, France|Centre Leon Berard - Centre regional de lutte contre le cancer Rhone-Alpes, Lyon, France|Institut Paoli Calmettes, Marseille, France|Institute Curie - Centre de Lutte Contre Le Cancer CLCC de Paris, Paris, France|Centre Hospitalier Lyon Sud, Pierre Bénite Cedex, France|Institut Jean Godinot, REIMS Cedex, France|Centre Eugene Marquis, Rennes Cedex, France|Hopitaux Universitaires de Strasbourg, Strasbourg, France|Institut Claudius Regaud, Toulouse Cedex 9, France|CHU Tours - Hopital Bretonneau, TOURS Cedex 09, France|Charite Universitatsmedizin Berlin, Berlin, Germany|Kliniken Essen-Mitte - Evang. Huyssens-Stiftung, Essen, Germany|Universitaetsklinikum Hamburg-Eppendorf (UKE) - Onkologisches Zentrum - Interdisziplinaere Klinik und Poliklinik fuer Stammzelltransplantation, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitatsklinikum Schleswig-Holstein, Kiel, Germany|InVO- Institut fUr Versorgungsforschung in der onkologie GbR, Koblenz, Germany|Universitatsklinikum Koln, Köln, Germany|HOPE- Onkologisches Zentrum Rotkreuzklinikum, Munchen, Germany|Sana Klinikum Offenbach GmbH, Offenbach am Main, Germany|Rambam Health Corp., Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|Rabin Medical Center, Petach Tikva, Israel|Kaplan Medical Center, Rehovot, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Sheba Medical Center, Tel Hashomer, Israel|Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi, Bologna, Italy|Ospedale di Bolzano, Bolzano, Italy|Presido Ospedaliero- Senatore Antonio Perrino, Brindisi, Italy|Ospedale Ramazzini di Carpi, Carpi, Italy|Ospedale Policlinico San Martino, Genova, Italy|Istituto Europeo di Oncologia, Milano, Italy|IRCSS Policlinico San Matteo, Pavia, Italy|Azienda Ospedaliera S. Maria di Terni, Terni, Italy|A.O.U. - Ospedali Riuniti di Ancona, Torrette, Italy|Hospital Cuf Descobertas R. Mario Botas Parque das Nacoes, Lisboa, Portugal|Centro Hospitalar do Porto - Hospital Santo Antonio, Porto, Portugal|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital San Pedro de Alcantara, Caceres, Spain|Complejo Asistencial Universitario de Leon, Leon, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Son Espases, Palma de Mallorca, Spain|Hospital Clinico Univ De Santiago De Compostela, Santiago de Compostela, Spain|Hospital Arnau De Vilanova, Valencia, Spain|Hospital Clinico Universitario Lozano Blesa de Zaragoza, Zaragoza, Spain|Institute of Oncology of Southern Switzerland, Bellinzona, Switzerland|Colchester Hospital University NHS Foundation Trust, Colchester, United Kingdom|The Royal Marsden Hospital, London, United Kingdom|Sarah Cannon Research Institute UK, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Mount Vernon Hospital, UK, Northwood, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Peterborough City Hospital, Peterborough, United Kingdom|Weston Park Hospital- UK, Sheffield, United Kingdom|The Royal Marsden Hospital (Surrey), Sutton, United Kingdom|Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom",https://ClinicalTrials.gov/show/NCT02614794
112,Novartis Pharmaceuticals|North Central Cancer Treatment Group|National Cancer Institute (NCI)|Breast International Group|Canadian Cancer Trials Group|Novartis,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Active, not recruiting",Has Results,"Neoplasms, Breast",Drug: Lapatinib|Biological: Trastuzumab,Industry|Other|NIH,Interventional,"Novartis Investigative Site, Mobile, Alabama, United States|Novartis Investigative Site, Anchorage, Alaska, United States|Novartis Investigative Site, Fairbanks, Alaska, United States|Novartis Investigative Site, Phoenix, Arizona, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Jonesboro, Arkansas, United States|Novartis Investigative Site, Berkeley, California, United States|Novartis Investigative Site, Burlingame, California, United States|Novartis Investigative Site, Castro Valley, California, United States|Novartis Investigative Site, Duarte, California, United States|Novartis Investigative Site, Fairfield, California, United States|Novartis Investigative Site, Fremont, California, United States|Novartis Investigative Site, Fresno, California, United States|Novartis Investigative Site, Glendale, California, United States|Novartis Investigative Site, Greenbrae, California, United States|Novartis Investigative Site, La Jolla, California, United States|Novartis Investigative Site, La Jolla, California, United States|Novartis Investigative Site, Loma Linda, California, United States|Novartis Investigative Site, Martinez, California, United States|Novartis Investigative Site, Marysville, California, United States|Novartis Investigative Site, Monterey, California, United States|Novartis Investigative Site, Mountain View, California, United States|Novartis Investigative Site, Murrieta, California, United States|Novartis Investigative Site, Oakland, California, United States|Novartis Investigative Site, Oakland, California, United States|Novartis Investigative Site, Orange, California, United States|Novartis Investigative Site, Palm Springs, California, United States|Novartis Investigative Site, Palo Alto, California, United States|Novartis Investigative Site, Pismo Beach, California, United States|Novartis Investigative Site, Pleasanton, California, United States|Novartis Investigative Site, Sacramento, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, San Leandro, California, United States|Novartis Investigative Site, Vallejo, California, United States|Novartis Investigative Site, Aurora, Colorado, United States|Novartis Investigative Site, Boulder, Colorado, United States|Novartis Investigative Site, Colorado Springs, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Edwards, Colorado, United States|Novartis Investigative Site, Englewood, Colorado, United States|Novartis Investigative Site, Fort Collins, Colorado, United States|Novartis Investigative Site, Fort Collins, Colorado, United States|Novartis Investigative Site, Glenwood Springs, Colorado, United States|Novartis Investigative Site, Grand Junction, Colorado, United States|Novartis Investigative Site, Greeley, Colorado, United States|Novartis Investigative Site, Lone Tree, Colorado, United States|Novartis Investigative Site, Longmont, Colorado, United States|Novartis Investigative Site, Loveland, Colorado, United States|Novartis Investigative Site, Montrose, Colorado, United States|Novartis Investigative Site, Pueblo, Colorado, United States|Novartis Investigative Site, Thornton, Colorado, United States|Novartis Investigative Site, Wheat Ridge, Colorado, United States|Novartis Investigative Site, Hartford, Connecticut, United States|Novartis Investigative Site, New Haven, Connecticut, United States|Novartis Investigative Site, Stamford, Connecticut, United States|Novartis Investigative Site, Torrington, Connecticut, United States|Novartis Investigative Site, Dover, Delaware, United States|Novartis Investigative Site, Milford, Delaware, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Boca Raton, Florida, United States|Novartis Investigative Site, Fort Lauderdale, Florida, United States|Novartis Investigative Site, Fort Myers, Florida, United States|Novartis Investigative Site, Hollywood, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Jupiter, Florida, United States|Novartis Investigative Site, Lakeland, Florida, United States|Novartis Investigative Site, Miami Beach, Florida, United States|Novartis Investigative Site, New Port Richey, Florida, United States|Novartis Investigative Site, Ocala, Florida, United States|Novartis Investigative Site, Orange Park, Florida, United States|Novartis Investigative Site, Orlando, Florida, United States|Novartis Investigative Site, Orlando, Florida, United States|Novartis Investigative Site, Titusville, Florida, United States|Novartis Investigative Site, Weston, Florida, United States|Novartis Investigative Site, Athens, Georgia, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Augusta, Georgia, United States|Novartis Investigative Site, Augusta, Georgia, United States|Novartis Investigative Site, Austell, Georgia, United States|Novartis Investigative Site, Columbus, Georgia, United States|Novartis Investigative Site, Decatur, Georgia, United States|Novartis Investigative Site, Fort Gordon, Georgia, United States|Novartis Investigative Site, Gainesville, Georgia, United States|Novartis Investigative Site, Lawrenceville, Georgia, United States|Novartis Investigative Site, Marietta, Georgia, United States|Novartis Investigative Site, Riverdale, Georgia, United States|Novartis Investigative Site, Rome, Georgia, United States|Novartis Investigative Site, Savannah, Georgia, United States|Novartis Investigative Site, Valdosta, Georgia, United States|Novartis Investigative Site, 'Aiea, Hawaii, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis Investigative Site, Lihue, Hawaii, United States|Novartis Investigative Site, Wailuku, Hawaii, United States|Novartis Investigative Site, Boise, Idaho, United States|Novartis Investigative Site, Boise, Idaho, United States|Novartis Investigative Site, Alton, Illinois, United States|Novartis Investigative Site, Aurora, Illinois, United States|Novartis Investigative Site, Berwyn, Illinois, United States|Novartis Investigative Site, Bloomington, Illinois, United States|Novartis Investigative Site, Canton, Illinois, United States|Novartis Investigative Site, Carthage, Illinois, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Eureka, Illinois, United States|Novartis Investigative Site, Evanston, Illinois, United States|Novartis Investigative Site, Galesburg, Illinois, United States|Novartis Investigative Site, Harvey, Illinois, United States|Novartis Investigative Site, Havana, Illinois, United States|Novartis Investigative Site, Highland Park, Illinois, United States|Novartis Investigative Site, Hopedale, Illinois, United States|Novartis Investigative Site, Joliet, Illinois, United States|Novartis Investigative Site, Joliet, Illinois, United States|Novartis Investigative Site, Kankakee, Illinois, United States|Novartis Investigative Site, Kewanee, Illinois, United States|Novartis Investigative Site, La Grange, Illinois, United States|Novartis Investigative Site, Libertyville, Illinois, United States|Novartis Investigative Site, Macomb, Illinois, United States|Novartis Investigative Site, Maywood, Illinois, United States|Novartis Investigative Site, Moline, Illinois, United States|Novartis Investigative Site, Monmouth, Illinois, United States|Novartis Investigative Site, Mount Vernon, Illinois, United States|Novartis Investigative Site, Naperville, Illinois, United States|Novartis Investigative Site, Niles, Illinois, United States|Novartis Investigative Site, Normal, Illinois, United States|Novartis Investigative Site, Oak Lawn, Illinois, United States|Novartis Investigative Site, Ottawa, Illinois, United States|Novartis Investigative Site, Park Ridge, Illinois, United States|Novartis Investigative Site, Pekin, Illinois, United States|Novartis Investigative Site, Pekin, Illinois, United States|Novartis Investigative Site, Peoria, Illinois, United States|Novartis Investigative Site, Peoria, Illinois, United States|Novartis Investigative Site, Peoria, Illinois, United States|Novartis Investigative Site, Peoria, Illinois, United States|Novartis Investigative Site, Peoria, Illinois, United States|Novartis Investigative Site, Peru, Illinois, United States|Novartis Investigative Site, Princeton, Illinois, United States|Novartis Investigative Site, Rockford, Illinois, United States|Novartis Investigative Site, Skokie, Illinois, United States|Novartis Investigative Site, Spring Valley, Illinois, United States|Novartis Investigative Site, Springfield, Illinois, United States|Novartis Investigative Site, Urbana, Illinois, United States|Novartis Investigative Site, Warrenville, Illinois, United States|Novartis Investigative Site, Winfield, Illinois, United States|Novartis Investigative Site, Beech Grove, Indiana, United States|Novartis Investigative Site, Elkhart, Indiana, United States|Novartis Investigative Site, Fort Wayne, Indiana, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Kokomo, Indiana, United States|Novartis Investigative Site, La Porte, Indiana, United States|Novartis Investigative Site, Michigan City, Indiana, United States|Novartis Investigative Site, Mishawaka, Indiana, United States|Novartis Investigative Site, Muncie, Indiana, United States|Novartis Investigative Site, Richmond, Indiana, United States|Novartis Investigative Site, South Bend, Indiana, United States|Novartis Investigative Site, South Bend, Indiana, United States|Novartis Investigative Site, Ames, Iowa, United States|Novartis Investigative Site, Bettendorf, Iowa, United States|Novartis Investigative Site, Cedar Rapids, Iowa, United States|Novartis Investigative Site, Cedar Rapids, Iowa, United States|Novartis Investigative Site, Des Moines, Iowa, United States|Novartis Investigative Site, Des Moines, Iowa, United States|Novartis Investigative Site, Des Moines, Iowa, United States|Novartis Investigative Site, Des Moines, Iowa, United States|Novartis Investigative Site, Mason City, Iowa, United States|Novartis Investigative Site, Ottumwa, Iowa, United States|Novartis Investigative Site, Sioux City, Iowa, United States|Novartis Investigative Site, Sioux City, Iowa, United States|Novartis Investigative Site, Waterloo, Iowa, United States|Novartis Investigative Site, Waterloo, Iowa, United States|Novartis Investigative Site, Anthony, Kansas, United States|Novartis Investigative Site, Chanute, Kansas, United States|Novartis Investigative Site, Dodge City, Kansas, United States|Novartis Investigative Site, El Dorado, Kansas, United States|Novartis Investigative Site, Fort Scott, Kansas, United States|Novartis Investigative Site, Independence, Kansas, United States|Novartis Investigative Site, Kansas City, Kansas, United States|Novartis Investigative Site, Kingman, Kansas, United States|Novartis Investigative Site, Lawrence, Kansas, United States|Novartis Investigative Site, Liberal, Kansas, United States|Novartis Investigative Site, Newton, Kansas, United States|Novartis Investigative Site, Olathe, Kansas, United States|Novartis Investigative Site, Overland Park, Kansas, United States|Novartis Investigative Site, Overland Park, Kansas, United States|Novartis Investigative Site, Overland Park, Kansas, United States|Novartis Investigative Site, Parsons, Kansas, United States|Novartis Investigative Site, Prairie Village, Kansas, United States|Novartis Investigative Site, Pratt, Kansas, United States|Novartis Investigative Site, Salina, Kansas, United States|Novartis Investigative Site, Shawnee Mission, Kansas, United States|Novartis Investigative Site, Topeka, Kansas, United States|Novartis Investigative Site, Topeka, Kansas, United States|Novartis Investigative Site, Wellington, Kansas, United States|Novartis Investigative Site, Wichita, Kansas, United States|Novartis Investigative Site, Wichita, Kansas, United States|Novartis Investigative Site, Wichita, Kansas, United States|Novartis Investigative Site, Winfield, Kansas, United States|Novartis Investigative Site, Louisville, Kentucky, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Houma, Louisiana, United States|Novartis Investigative Site, New Orleans, Louisiana, United States|Novartis Investigative Site, New Orleans, Louisiana, United States|Novartis Investigative Site, Portland, Maine, United States|Novartis Investigative Site, Scarborough, Maine, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Bethesda, Maryland, United States|Novartis Investigative Site, Easton, Maryland, United States|Novartis Investigative Site, Frederick, Maryland, United States|Novartis Investigative Site, Hagerstown, Maryland, United States|Novartis Investigative Site, Silver Spring, Maryland, United States|Novartis Investigative Site, Towson, Maryland, United States|Novartis Investigative Site, Westminster, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Burlington, Massachusetts, United States|Novartis Investigative Site, Gloucester, Massachusetts, United States|Novartis Investigative Site, Hyannis, Massachusetts, United States|Novartis Investigative Site, Lowell, Massachusetts, United States|Novartis Investigative Site, Peabody, Massachusetts, United States|Novartis Investigative Site, Adrian, Michigan, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Battle Creek, Michigan, United States|Novartis Investigative Site, Big Rapids, Michigan, United States|Novartis Investigative Site, Byron Center, Michigan, United States|Novartis Investigative Site, Dearborn, Michigan, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Escanaba, Michigan, United States|Novartis Investigative Site, Flint, Michigan, United States|Novartis Investigative Site, Flint, Michigan, United States|Novartis Investigative Site, Grand Rapids, Michigan, United States|Novartis Investigative Site, Iron Mountain, Michigan, United States|Novartis Investigative Site, Jackson, Michigan, United States|Novartis Investigative Site, Kalamazoo, Michigan, United States|Novartis Investigative Site, Kalamazoo, Michigan, United States|Novartis Investigative Site, Lansing, Michigan, United States|Novartis Investigative Site, Livonia, Michigan, United States|Novartis Investigative Site, Monroe, Michigan, United States|Novartis Investigative Site, Muskegon, Michigan, United States|Novartis Investigative Site, Pontiac, Michigan, United States|Novartis Investigative Site, Port Huron, Michigan, United States|Novartis Investigative Site, Saginaw, Michigan, United States|Novartis Investigative Site, Saint Joseph, Michigan, United States|Novartis Investigative Site, Saint Joseph, Michigan, United States|Novartis Investigative Site, Southfield, Michigan, United States|Novartis Investigative Site, Traverse City, Michigan, United States|Novartis Investigative Site, Warren, Michigan, United States|Novartis Investigative Site, Albert Lea, Minnesota, United States|Novartis Investigative Site, Alexandria, Minnesota, United States|Novartis Investigative Site, Bemidji, Minnesota, United States|Novartis Investigative Site, Burnsville, Minnesota, United States|Novartis Investigative Site, Coon Rapids, Minnesota, United States|Novartis Investigative Site, Duluth, Minnesota, United States|Novartis Investigative Site, Edina, Minnesota, United States|Novartis Investigative Site, Fergus Falls, Minnesota, United States|Novartis Investigative Site, Fridley, Minnesota, United States|Novartis Investigative Site, Hutchinson, Minnesota, United States|Novartis Investigative Site, Litchfield, Minnesota, United States|Novartis Investigative Site, Mankato, Minnesota, United States|Novartis Investigative Site, Maplewood, Minnesota, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, Robbinsdale, Minnesota, United States|Novartis Investigative Site, Saint Cloud, Minnesota, United States|Novartis Investigative Site, Saint Louis Park, Minnesota, United States|Novartis Investigative Site, Saint Paul, Minnesota, United States|Novartis Investigative Site, Saint Paul, Minnesota, United States|Novartis Investigative Site, Shakopee, Minnesota, United States|Novartis Investigative Site, Waconia, Minnesota, United States|Novartis Investigative Site, Willmar, Minnesota, United States|Novartis Investigative Site, Woodbury, Minnesota, United States|Novartis Investigative Site, Jackson, Mississippi, United States|Novartis Investigative Site, Keesler Air Force Base, Mississippi, United States|Novartis Investigative Site, Pascagoula, Mississippi, United States|Novartis Investigative Site, Bolivar, Missouri, United States|Novartis Investigative Site, Cape Girardeau, Missouri, United States|Novartis Investigative Site, Cape Girardeau, Missouri, United States|Novartis Investigative Site, Independence, Missouri, United States|Novartis Investigative Site, Joplin, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Lee's Summit, Missouri, United States|Novartis Investigative Site, Liberty, Missouri, United States|Novartis Investigative Site, Saint Joseph, Missouri, United States|Novartis Investigative Site, Saint Joseph, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Springfield, Missouri, United States|Novartis Investigative Site, Springfield, Missouri, United States|Novartis Investigative Site, Springfield, Missouri, United States|Novartis Investigative Site, Billings, Montana, United States|Novartis Investigative Site, Bozeman, Montana, United States|Novartis Investigative Site, Butte, Montana, United States|Novartis Investigative Site, Great Falls, Montana, United States|Novartis Investigative Site, Havre, Montana, United States|Novartis Investigative Site, Helena, Montana, United States|Novartis Investigative Site, Kalispell, Montana, United States|Novartis Investigative Site, Missoula, Montana, United States|Novartis Investigative Site, Missoula, Montana, United States|Novartis Investigative Site, Missoula, Montana, United States|Novartis Investigative Site, Grand Island, Nebraska, United States|Novartis Investigative Site, Lincoln, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Las Vegas, Nevada, United States|Novartis Investigative Site, Concord, New Hampshire, United States|Novartis Investigative Site, Exeter, New Hampshire, United States|Novartis Investigative Site, Hooksett, New Hampshire, United States|Novartis Investigative Site, Keene, New Hampshire, United States|Novartis Investigative Site, Laconia, New Hampshire, United States|Novartis Investigative Site, Lebanon, New Hampshire, United States|Novartis Investigative Site, Manchester, New Hampshire, United States|Novartis Investigative Site, Portsmouth, New Hampshire, United States|Novartis Investigative Site, Hackensack, New Jersey, United States|Novartis Investigative Site, Hamilton, New Jersey, United States|Novartis Investigative Site, Livingston, New Jersey, United States|Novartis Investigative Site, Marlton, New Jersey, United States|Novartis Investigative Site, Morristown, New Jersey, United States|Novartis Investigative Site, Mount Holly, New Jersey, United States|Novartis Investigative Site, Neptune, New Jersey, United States|Novartis Investigative Site, New Brunswick, New Jersey, United States|Novartis Investigative Site, Pomona, New Jersey, United States|Novartis Investigative Site, Princeton, New Jersey, United States|Novartis Investigative Site, Ridgewood, New Jersey, United States|Novartis Investigative Site, Somerville, New Jersey, United States|Novartis Investigative Site, Sparta, New Jersey, United States|Novartis Investigative Site, Summit, New Jersey, United States|Novartis Investigative Site, Vineland, New Jersey, United States|Novartis Investigative Site, Voorhees, New Jersey, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Las Cruces, New Mexico, United States|Novartis Investigative Site, Bronx, New York, United States|Novartis Investigative Site, Bronx, New York, United States|Novartis Investigative Site, Bronx, New York, United States|Novartis Investigative Site, Buffalo, New York, United States|Novartis Investigative Site, Clifton Springs, New York, United States|Novartis Investigative Site, Cooperstown, New York, United States|Novartis Investigative Site, East Syracuse, New York, United States|Novartis Investigative Site, Elmhurst, New York, United States|Novartis Investigative Site, Jamaica, New York, United States|Novartis Investigative Site, Lake Success, New York, United States|Novartis Investigative Site, Manhasset, New York, United States|Novartis Investigative Site, Mineola, New York, United States|Novartis Investigative Site, New Hyde Park, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Rochester, New York, United States|Novartis Investigative Site, Rochester, New York, United States|Novartis Investigative Site, Rochester, New York, United States|Novartis Investigative Site, Stony Brook, New York, United States|Novartis Investigative Site, Syracuse, New York, United States|Novartis Investigative Site, Utica, New York, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Fayetteville, North Carolina, United States|Novartis Investigative Site, Gastonia, North Carolina, United States|Novartis Investigative Site, Goldsboro, North Carolina, United States|Novartis Investigative Site, Hendersonville, North Carolina, United States|Novartis Investigative Site, Kinston, North Carolina, United States|Novartis Investigative Site, Raleigh, North Carolina, United States|Novartis Investigative Site, Rutherfordton, North Carolina, United States|Novartis Investigative Site, Statesville, North Carolina, United States|Novartis Investigative Site, Washington, North Carolina, United States|Novartis Investigative Site, Winston-Salem, North Carolina, United States|Novartis Investigative Site, Bismarck, North Dakota, United States|Novartis Investigative Site, Fargo, North Dakota, United States|Novartis Investigative Site, Grand Forks, North Dakota, United States|Novartis Investigative Site, Minot, North Dakota, United States|Novartis Investigative Site, Beachwood, Ohio, United States|Novartis Investigative Site, Bellefontaine, Ohio, United States|Novartis Investigative Site, Bowling Green, Ohio, United States|Novartis Investigative Site, Canton, Ohio, United States|Novartis Investigative Site, Canton, Ohio, United States|Novartis Investigative Site, Chillicothe, Ohio, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Clyde, Ohio, United States|Novartis Investigative Site, Columbia, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Dayton, Ohio, United States|Novartis Investigative Site, Dayton, Ohio, United States|Novartis Investigative Site, Dayton, Ohio, United States|Novartis Investigative Site, Dayton, Ohio, United States|Novartis Investigative Site, Dayton, Ohio, United States|Novartis Investigative Site, Delaware, Ohio, United States|Novartis Investigative Site, Elyria, Ohio, United States|Novartis Investigative Site, Findlay, Ohio, United States|Novartis Investigative Site, Franklin, Ohio, United States|Novartis Investigative Site, Greenville, Ohio, United States|Novartis Investigative Site, Independence, Ohio, United States|Novartis Investigative Site, Kettering, Ohio, United States|Novartis Investigative Site, Lambertville, Ohio, United States|Novartis Investigative Site, Lima, Ohio, United States|Novartis Investigative Site, Marietta, Ohio, United States|Novartis Investigative Site, Maumee, Ohio, United States|Novartis Investigative Site, Maumee, Ohio, United States|Novartis Investigative Site, Mayfield Heights, Ohio, United States|Novartis Investigative Site, Newark, Ohio, United States|Novartis Investigative Site, Oregon, Ohio, United States|Novartis Investigative Site, Sandusky, Ohio, United States|Novartis Investigative Site, Springfield, Ohio, United States|Novartis Investigative Site, Springfield, Ohio, United States|Novartis Investigative Site, Sylvania, Ohio, United States|Novartis Investigative Site, Tiffin, Ohio, United States|Novartis Investigative Site, Toledo, Ohio, United States|Novartis Investigative Site, Toledo, Ohio, United States|Novartis Investigative Site, Toledo, Ohio, United States|Novartis Investigative Site, Toledo, Ohio, United States|Novartis Investigative Site, Toledo, Ohio, United States|Novartis Investigative Site, Troy, Ohio, United States|Novartis Investigative Site, Wauseon, Ohio, United States|Novartis Investigative Site, Westerville, Ohio, United States|Novartis Investigative Site, Wilmington, Ohio, United States|Novartis Investigative Site, Wooster, Ohio, United States|Novartis Investigative Site, Wright-Patterson Air Force Base, Ohio, United States|Novartis Investigative Site, Xenia, Ohio, United States|Novartis Investigative Site, Zanesville, Ohio, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Tulsa, Oklahoma, United States|Novartis Investigative Site, Coos Bay, Oregon, United States|Novartis Investigative Site, Eugene, Oregon, United States|Novartis Investigative Site, Gresham, Oregon, United States|Novartis Investigative Site, Hillsboro, Oregon, United States|Novartis Investigative Site, Klamath Falls, Oregon, United States|Novartis Investigative Site, Milwaukie, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Tualatin, Oregon, United States|Novartis Investigative Site, Abington, Pennsylvania, United States|Novartis Investigative Site, Bethlehem, Pennsylvania, United States|Novartis Investigative Site, Bryn Mawr, Pennsylvania, United States|Novartis Investigative Site, Butler, Pennsylvania, United States|Novartis Investigative Site, Danville, Pennsylvania, United States|Novartis Investigative Site, Ephrata, Pennsylvania, United States|Novartis Investigative Site, Hazleton, Pennsylvania, United States|Novartis Investigative Site, Hershey, Pennsylvania, United States|Novartis Investigative Site, Kingston, Pennsylvania, United States|Novartis Investigative Site, Lancaster, Pennsylvania, United States|Novartis Investigative Site, Langhorne, Pennsylvania, United States|Novartis Investigative Site, Lewistown, Pennsylvania, United States|Novartis Investigative Site, Media, Pennsylvania, United States|Novartis Investigative Site, Nashville, Pennsylvania, United States|Novartis Investigative Site, Paoli, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Phoenixville, Pennsylvania, United States|Novartis Investigative Site, Pottstown, Pennsylvania, United States|Novartis Investigative Site, Sayre, Pennsylvania, United States|Novartis Investigative Site, Scranton, Pennsylvania, United States|Novartis Investigative Site, Sellersville, Pennsylvania, United States|Novartis Investigative Site, State College, Pennsylvania, United States|Novartis Investigative Site, State College, Pennsylvania, United States|Novartis Investigative Site, West Reading, Pennsylvania, United States|Novartis Investigative Site, Wilkes-Barre, Pennsylvania, United States|Novartis Investigative Site, Wilkes-Barre, Pennsylvania, United States|Novartis Investigative Site, Wynnewood, Pennsylvania, United States|Novartis Investigative Site, Providence, Rhode Island, United States|Novartis Investigative Site, Providence, Rhode Island, United States|Novartis Investigative Site, Providence, Rhode Island, United States|Novartis Investigative Site, Warwick, Rhode Island, United States|Novartis Investigative Site, Anderson, South Carolina, United States|Novartis Investigative Site, Charleston, South Carolina, United States|Novartis Investigative Site, Columbia, South Carolina, United States|Novartis Inves",
113,"AstraZeneca|European Network of Gynaecological Oncological Trial Groups (ENGOT)|Myriad Genetic Laboratories, Inc.|Merck Sharp & Dohme Corp.",Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy,"Active, not recruiting",Has Results,Platinum Sensitive|BRCA Mutated|Relapsed Ovarian Cancer|Following Complete or Partial Response to Platinum Based Chemotherapy,Drug: Olaparib 300mg tablets|Drug: Placebo to match olaparib 300mg,Industry|Other,Interventional,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Palo Alto Foundation Medical Group, San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|Gynecologic Cancer Center, Orlando, Florida, United States|North Shore University, Evanston, Illinois, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Johns Hopkins, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|MD Anderson at Cooper Cancer Center, Voorhees, New Jersey, United States|Womens Cancer Care Associates, Albany, New York, United States|Winthrop Gynecologic Oncology Associates, Mineola, New York, United States|OSU JamesCare at Mill Run, Hilliard, Ohio, United States|Henry Joyce Cancer Clinic, Nashville, Tennessee, United States|Aurora St Lukes Medical Center, Milwaukee, Wisconsin, United States|Mercy Hospital for Women, Heidelberg, Australia|The Royal Womens Hospital, Parkville, Australia|Prince of Wales Hospital, Randwick, Australia|U.Z. Gent, Gent, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Centro Regional Integrado de Oncologia, Fortaleza, Brazil|Hospital Araujo Jorge, Goiânia, Brazil|Hospital de Caridade de Ijuí, Ijuí, Brazil|Centro de Novos Tratamentos Itajai, Itajai, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alagre, Porto Alegre, Brazil|Centro de Referencia da Saude da Mulher, São Paulo, Brazil|Instituto do Câncer de São Paulo, São Paulo, Brazil|Juravinski Cancer Centre, Hamilton, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Sunnybrook Health Sciences Center, Toronto, Ontario, Canada|CHUM - Hopital Norte-Dame, Montreal, Quebec, Canada|CHUS Site Fleurimont, Sherbrooke, Quebec, Canada|Hotel-Dieu de Quebec, Quebec, Canada|Beijing Cancer Hospital, Beijing, China|The Tumor Hospital affiliated to China Medical Science Insti, Beijing, China|1st Hospital of Jilin university, Changchun, China|Jilin Provincial Cancer Hospital, Changchun, China|Hunan Cancer Hospital, Changsha, China|West China Hospital Affiliated to Sichuan University, Chengdu, China|ChongQing Cancer Hospital, Chongqing, China|Research Site, Guangzhou, China|Women's Hospital, Zhejaing University School of Medicine, Hangzhou, China|The Tumour Hospital of Harbin Medical University, Harbin, China|Zhejiang Cancer Hospital, Huangzhou, Huangzhou, China|JINAN, Qi Lu Hosp. of SD Univ., Ji Nan, China|Shanghai Cancer Hospital of Fudan University, Shanghai, China|The First Affiliated Hospital of Soochow University, Suzhou, China|First affiliated hospital college of XianJiaotong University, Xian, China|Institut Bergonie, Bordeaux, France|CAC François Baclesse, Caen Cedex, France|69LYON, C Bérard, Onco, Lyon Cedex 08, France|Centre Catherine de Sienne, Nantes,, France|Institut Curie Paris Et Saint Cloud, Paris Cedex 5, France|75PARIS, H Tenon, Onco, Paris, France|Hopital Européen Georges Pompidou, Paris, France|69PIERREBE, CH Lyon Sud,, Pierre Benite Cedex, France|92STCLOUD, C Huguenin, Onco, Saint Cloud, France|Institut Claudius Regaud, Toulouse, France|Centre Alexis Vautrin, Vandoeuvre Les Nancy, France|Institut Gustave Roussy, Villejuif Cedex, France|Helios-Kliniken Berlin - Buch, Berlin, Germany|Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany|Klinikum Essen-Mitte,Evang. Huyssens-Stiftung/Knapps gGmbH, Essen, Germany|Johann-Wolfgang Goethe-Universität, Frankfurt, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Schleswig-Holstein, Lübeck, Germany|Klinikum rechts der Isar der Technischen Universität, München, Germany|Onkologie Ravensburg, Ravensburg, Germany|Universitätsklinikum Rostock, Rostock, Germany|Rambam Health Care Campus, Haifa, Israel|Sapir Medical Centre, Kfar Saba, Israel|Tel Hashomer, Ramat Gan, Israel|Istituto Europeo di Oncologia, Milano, Italy|Azienda Ospedaliera Policlinico Di Modena, Modena, Italy|Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy|Istituto Oncologico Veneto Irccs, Padova, Italy|Istituto Regina Elena-Polo Oncologico Ifo, Roma, Italy|Policlinico Universitario A. Gemelli, Roma, Italy|Hyogo Cancer Center, Akashi-shi, Japan|National Cancer Center Hospital, Chuo-ku, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Saitama Medical University International Medical Center, Hidaka-shi, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama-shi, Japan|Niigata University Medical and Dental Hospital, Niigata-shi, Japan|Kindai University Hospital, Osakasayama-shi, Japan|Hokkaido University Hospital, Sapporo-shi, Japan|Shizuoka Cancer Center, Sunto-gun, Japan|Asan Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands|Maastricht Universitair Medisch Centrum, Maastricht, Netherlands|Universitair Medisch Centrum St. Radboud, Nijmegen, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|Niepubliczny Zaklad Opieki Zdrowotnej Innowacyjna Medycyna, Grzepnica, Poland|SPZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii, Olsztyn, Poland|Wojewódzki Szpital Specjalistyczny w Olsztynie, Olsztyn, Poland|Centrum Onkologii Instytut im Marii Sklodowskiej-Curie, Warszawa, Poland|Szpital Specjalistyczny im. Swietej Rodziny SPZOZ, Warszawa, Poland|Chemotherapy Department, Russian Cancer Research Centre, Moscow, Russian Federation|St.Petersburg City Oncology Dispensary, Dept. Gynecology, Saint Petersburg, Russian Federation|Leningrad Regional Oncology Dispensary, St.Petersburg, Russian Federation|Barcelona,H.Clinic i Provincial,Oncología, Barcelona, Spain|Barcelona,H.de la Sta.Creu i S.Pau,Oncología, Barcelona, Spain|Córdoba,H.Reina Sofía,Oncología, Córdoba, Spain|Gerona,H.Josep Trueta,Oncología, Gerona, Spain|Madrid, H.C.S.Carlos,Oncología, Madrid, Spain|Madrid,H.12 de Octubre,Oncología, Madrid, Spain|Hospital Provincial de Navarra, Pamplona, Spain|Valencia, IVO, Oncología, Valencia, Spain|Valencia,H.C.U.Valencia,Oncología, Valencia, Spain|City Hospital Birmingham Cancer Trials Team, Birmingham, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|Arden Cancer Centre, Coventry, United Kingdom|Edinburgh Cancer Research UK Centre, Edinburgh, United Kingdom|Cancer Research UK and UCL Cancer Trials Centre, London, United Kingdom|Royal Marsden Hospital, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Royal Marsden Hospital and Institute of Cancer Research, Sutton, United Kingdom",https://ClinicalTrials.gov/show/NCT01874353
114,Novartis Pharmaceuticals|Novartis,"LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib","Active, not recruiting",Has Results,"Neoplasms, Gastrointestinal Tract",Drug: Lapatinib|Drug: Placebo|Drug: Capecitabine|Drug: Oxaliplatin,Industry,Interventional,"Novartis Investigative Site, Alhambra, California, United States|Novartis Investigative Site, Fullerton, California, United States|Novartis Investigative Site, La Verne, California, United States|Novartis Investigative Site, Northridge, California, United States|Novartis Investigative Site, Oxnard, California, United States|Novartis Investigative Site, Redondo Beach, California, United States|Novartis Investigative Site, Santa Maria, California, United States|Novartis Investigative Site, Santa Monica, California, United States|Novartis Investigative Site, Terre Haute, Indiana, United States|Novartis Investigative Site, Henderson, Nevada, United States|Novartis Investigative Site, Ciudad Aut6noma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Quilmes, Buenos Aires, Argentina|Novartis Investigative Site, Neuquen, Neuquén, Argentina|Novartis Investigative Site, Cipolletti, Río Negro, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Argentina|Novartis Investigative Site, La Rioja, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Tucuman, Argentina|Novartis Investigative Site, Belo Horizonte, Minas Gerais, Brazil|Novartis Investigative Site, Belo Horizonte, Minas Gerais, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Florianopolis, Santa Catarina, Brazil|Novartis Investigative Site, Barretos, São Paulo, Brazil|Novartis Investigative Site, Jau, São Paulo, Brazil|Novartis Investigative Site, Santo Andre, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Rio de Janeiro, Brazil|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Saint John, New Brunswick, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Temuco, Región De La Araucania, Chile|Novartis Investigative Site, Santiago, Región Metro De Santiago, Chile|Novartis Investigative Site, Vina del Mar, Valparaíso, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Hefei, Anhui, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Ha Er Bin, Heilongjiang, China|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Changchun, Jilin, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Fuzhou, China|Novartis Investigative Site, Hangzhou, China|Novartis Investigative Site, Qingdao, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Tianjin, China|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Tartu, Estonia|Novartis Investigative Site, Pokfulam, Hong Kong|Novartis Investigative Site, Tuen Mun, Hong Kong|Novartis Investigative Site, Gyor, Hungary|Novartis Investigative Site, Kaposvar, Hungary|Novartis Investigative Site, Kecskemet, Hungary|Novartis Investigative Site, Miskolc, Hungary|Novartis Investigative Site, Pecs, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Szolnok, Hungary|Novartis Investigative Site, Calcutta, India|Novartis Investigative Site, Coimbatore, India|Novartis Investigative Site, Kochi, India|Novartis Investigative Site, Kochi, India|Novartis Investigative Site, Kolkata, India|Novartis Investigative Site, Nagpur, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Parel, India|Novartis Investigative Site, Pune, India|Novartis Investigative Site, Trivandrum, India|Novartis Investigative Site, Beer-Sheva, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Petah-Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Rehovot, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Zrifin, Israel|Novartis Investigative Site, L'Aquila, Abruzzo, Italy|Novartis Investigative Site, Rionero In Vulture (PZ), Basilicata, Italy|Novartis Investigative Site, Cesena, Emilia-Romagna, Italy|Novartis Investigative Site, Meldola (FC), Emilia-Romagna, Italy|Novartis Investigative Site, Modena, Emilia-Romagna, Italy|Novartis Investigative Site, Parma, Emilia-Romagna, Italy|Novartis Investigative Site, Piacenza, Emilia-Romagna, Italy|Novartis Investigative Site, Rimini, Emilia-Romagna, Italy|Novartis Investigative Site, Udine, Friuli-Venezia-Giulia, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Genova, Liguria, Italy|Novartis Investigative Site, Bergamo, Lombardia, Italy|Novartis Investigative Site, Treviglio (BG), Lombardia, Italy|Novartis Investigative Site, Pesasro, Marche, Italy|Novartis Investigative Site, Bari, Puglia, Italy|Novartis Investigative Site, Firenze, Toscana, Italy|Novartis Investigative Site, Macerata, Italy|Novartis Investigative Site, Busan, Korea, Republic of|Novartis Investigative Site, Daegu, Korea, Republic of|Novartis Investigative Site, Hwasun, Korea, Republic of|Novartis Investigative Site, Seodaemun-gu, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Suwon, Kyonggi-do, Korea, Republic of|Novartis Investigative Site, Suwon, Korea, Republic of|Novartis Investigative Site, Acapulco, Guerrero, Mexico|Novartis Investigative Site, Mexico City, Mexico|Novartis Investigative Site, Oaxaca, Mexico|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Leeuwarden, Netherlands|Novartis Investigative Site, Nijmegen, Netherlands|Novartis Investigative Site, Callao, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Olsztyn, Poland|Novartis Investigative Site, Olsztyn, Poland|Novartis Investigative Site, Plock, Poland|Novartis Investigative Site, Poznan, Poland|Novartis Investigative Site, Rybnik, Poland|Novartis Investigative Site, Slupsk, Poland|Novartis Investigative Site, Szczecin, Poland|Novartis Investigative Site, Torun, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, San Juan, Puerto Rico|Novartis Investigative Site, Chelyabinsk, Russian Federation|Novartis Investigative Site, Kirov, Russian Federation|Novartis Investigative Site, Kursk, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Omsk, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, Saratov, Russian Federation|Novartis Investigative Site, Sochi, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Stavropol, Russian Federation|Novartis Investigative Site, Ufa,, Russian Federation|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taoyuan County, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Hatyai, Songkhla, Thailand|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Gaziantep, Turkey|Novartis Investigative Site, Trabzon, Turkey|Novartis Investigative Site, Cherkasy, Ukraine|Novartis Investigative Site, Chernivtsi, Ukraine|Novartis Investigative Site, Dnepropetrovsk, Ukraine|Novartis Investigative Site, Dnipropetrovsk, Ukraine|Novartis Investigative Site, Donetsk, Ukraine|Novartis Investigative Site, Ivano-Frankivsk, Ukraine|Novartis Investigative Site, Kharkiv, Ukraine|Novartis Investigative Site, Kryvyi Rih, Ukraine|Novartis Investigative Site, Kyiv, Ukraine|Novartis Investigative Site, Kyiv, Ukraine|Novartis Investigative Site, Kyiv, Ukraine|Novartis Investigative Site, Lutsk,, Ukraine|Novartis Investigative Site, Lviv, Ukraine|Novartis Investigative Site, Odessa, Ukraine|Novartis Investigative Site, Plyuty, Ukraine|Novartis Investigative Site, Simferopil, Ukraine|Novartis Investigative Site, Simferopol, Ukraine|Novartis Investigative Site, Sumy, Ukraine|Novartis Investigative Site, Ternopil, Ukraine|Novartis Investigative Site, Uzhgorod, Ukraine|Novartis Investigative Site, Vinnitsia, Ukraine|Novartis Investigative Site, Zaporizhzhia, Ukraine",https://ClinicalTrials.gov/show/NCT00680901
115,University of Alabama at Birmingham|National Cancer Institute (NCI)|Merck Sharp & Dohme Corp.,Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors,"Active, not recruiting",Has Results,Cancer Survivor|Prevention of Human Papillomavirus Infection,"Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58)|Other: laboratory biomarker analysis|Other: survey administration|Other: medical chart review",Other|NIH|Industry,Interventional,"University of Alabama at Birmingham, Birmingham, Alabama, United States|City of Hope Medical Center, Duarte, California, United States|Emory University School Of Medicine, Atlanta, Georgia, United States|University of Michigan, Ann Arbor, Michigan, United States|Saint Jude Children's Research Hospital, Memphis, Tennessee, United States",https://ClinicalTrials.gov/show/NCT01492582
116,"AstraZeneca|Myriad Genetic Laboratories, Inc.|Merck Sharp & Dohme Corp.",Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy,"Active, not recruiting",Has Results,Germline BRCA1/2 Mutations and|Metastatic Adenocarcinoma of the Pancreas,Drug: Olaparib|Drug: Placebo,Industry,Interventional,"Research Site, Gilbert, Arizona, United States|Research Site, Orange, California, United States|Research Site, Stanford, California, United States|Research Site, Aurora, Colorado, United States|Research Site, New Haven, Connecticut, United States|Research Site, Boca Raton, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Commack, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Columbus, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Houston, Texas, United States|Research Site, Seattle, Washington, United States|Research Site, Campbelltown, Australia|Research Site, Randwick, Australia|Research Site, St Leonards, Australia|Research Site, Antwerpen, Belgium|Research Site, Brussels (Anderlecht), Belgium|Research Site, Leuven, Belgium|Research Site, London, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Toronto, Canada|Research Site, Amiens, France|Research Site, Besançon, France|Research Site, Bordeaux, France|Research Site, Brest Cedex, France|Research Site, Clichy Cedex, France|Research Site, La Roche sur Yon, France|Research Site, Lille, France|Research Site, Lyon Cedex 03, France|Research Site, Nice, France|Research Site, Paris CEDEX 14, France|Research Site, Paris, France|Research Site, Poitiers, France|Research Site, STRASBOURG Cedex, France|Research Site, Toulouse, France|Research Site, Villejuif, France|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Bonn, Germany|Research Site, Dresden, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Leipzig, Germany|Research Site, München, Germany|Research Site, Schweinfurt, Germany|Research Site, Ulm, Germany|Research Site, Beer Sheva, Israel|Research Site, Haifa, Israel|Research Site, Holon, Israel|Research Site, Nahariya, Israel|Research Site, Petah Tikva, Israel|Research Site, Ramat Gan, Israel|Research Site, Rehovot, Israel|Research Site, Tel Aviv, Israel|Research Site, Zefir, Israel|Research Site, Bologna, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Padova, Italy|Research Site, Parma, Italy|Research Site, Pescara, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, San Giovanni Rotondo, Italy|Research Site, Verona, Italy|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Amsterdam, Netherlands|Research Site, Barcelona, Spain|Research Site, Girona, Spain|Research Site, L'Hospitalet de Llobregat, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Málaga, Spain|Research Site, Pamplona, Spain|Research Site, Sabadell, Spain|Research Site, Santiago de Compostela, Spain|Research Site, Valencia, Spain|Research Site, Zaragoza, Spain|Research Site, Edinburgh, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Surrey, United Kingdom",https://ClinicalTrials.gov/show/NCT02184195
117,"Janssen Biotech, Inc.",IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen,"Active, not recruiting",Has Results,Prostate Cancer|Prostatic Neoplasm,Drug: abiraterone acetate in combination with prednisone,Industry,Interventional,"Homewood, Alabama, United States|Huntsville, Alabama, United States|Tucson, Arizona, United States|Los Angeles, California, United States|San Diego, California, United States|San Francisco, California, United States|Aurora, Colorado, United States|Denver, Colorado, United States|Aventura, Florida, United States|Orange City, Florida, United States|Atlanta, Georgia, United States|Evanston, Illinois, United States|Galesburg, Illinois, United States|Glenview, Illinois, United States|Melrose Park, Illinois, United States|Fort Wayne, Indiana, United States|Jeffersonville, Indiana, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Rockville, Maryland, United States|Boston, Massachusetts, United States|Lansing, Michigan, United States|Omaha, Nebraska, United States|Lawrenceville, New Jersey, United States|Albany, New York, United States|Brooklyn, New York, United States|Buffalo, New York, United States|Garden City, New York, United States|New York, New York, United States|Poughkeepsie, New York, United States|Staten Island, New York, United States|Chapel Hill, North Carolina, United States|Raleigh, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Lancaster, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Greenville, South Carolina, United States|Myrtle Beach, South Carolina, United States|Nashville, Tennessee, United States|Arlington, Texas, United States|Houston, Texas, United States|Seattle, Washington, United States|Milwaukee, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT01314118
118,Eli Lilly and Company,Study of Participants With Advanced Non-Small Cell Lung Cancer,"Active, not recruiting",Has Results,Advanced Non-Small Cell Lung Cancer,Drug: Pemetrexed|Drug: Carboplatin|Drug: Paclitaxel|Biological: Bevacizumab,Industry,Interventional,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Scottsdale, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucson, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mission Hills, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aventura, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daytona Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Myers, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gainesville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jacksonville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Port Saint Lucie, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Augusta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Macon, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marietta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Post Falls, Idaho, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gurnee, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Joliet, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Goshen, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Albany, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sioux City, Iowa, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mount Sterling, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ann Arbor, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lansing, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Southfield, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rochester, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Branson, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Billings, Montana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Great Falls, Montana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albuquerque, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Burlington, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., High Point, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bismarck, North Dakota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fargo, North Dakota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cincinnati, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tulsa, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., DuBois, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbia, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chattanooga, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nashville, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Worth, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Richmond, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kennewick, Washington, United States",https://ClinicalTrials.gov/show/NCT00948675
119,AstraZeneca,Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC,"Active, not recruiting",Has Results,Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV,Drug: Selumetinib|Drug: Docetaxel|Drug: Placebo|Drug: Pegylated G-CSF,Industry,Interventional,"Research Site, Aurora, Colorado, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Metairie, Louisiana, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Danvers, Massachusetts, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Seattle, Washington, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Cordoba, Argentina|Research Site, Rosario, Argentina|Research Site, Camperdown, Australia|Research Site, Chermside, Australia|Research Site, Darlinghurst, Australia|Research Site, Fitzroy, Australia|Research Site, Kogarah, Australia|Research Site, Kurralta Park, Australia|Research Site, Malvern, Australia|Research Site, Wendouree, Australia|Research Site, Woodville South, Australia|Research Site, Innsbruck, Austria|Research Site, Linz, Austria|Research Site, Salzburg, Austria|Research Site, Vienna, Austria|Research Site, Wien, Austria|Research Site, Brussels, Belgium|Research Site, Bruxelles, Belgium|Research Site, Bruxelles, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Roeselare, Belgium|Research Site, Barretos, Brazil|Research Site, Ijui, Brazil|Research Site, Pelotas, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Vratza, Bulgaria|Research Site, Edmonton, Alberta, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Regina, Saskatchewan, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Quebec, Canada|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Brest Cedex, France|Research Site, Caen, France|Research Site, Clermont Ferrand, France|Research Site, Dijon, France|Research Site, Lille, France|Research Site, Marseille Cedex 20, France|Research Site, Paris, France|Research Site, Pierre Benite Cedex, France|Research Site, RENNES Cedex 9, France|Research Site, Toulouse, France|Research Site, Augsburg, Germany|Research Site, Bad Berka, Germany|Research Site, Dortmund, Germany|Research Site, Gerlingen, Germany|Research Site, Großhansdorf, Germany|Research Site, Halle, Germany|Research Site, Heidelberg, Germany|Research Site, Homburg, Germany|Research Site, Köln, Germany|Research Site, Löwenstein, Germany|Research Site, Moers, Germany|Research Site, München, Germany|Research Site, Ulm, Germany|Research Site, Wiesbaden, Germany|Research Site, Würzburg, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Edelény, Hungary|Research Site, Győr, Hungary|Research Site, Kaposvár, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Törökbálint, Hungary|Research Site, Beer Sheva, Israel|Research Site, Haifa, Israel|Research Site, Kfar Saba, Israel|Research Site, Petah Tikva, Israel|Research Site, Tel Hashomer, Israel|Research Site, Tel-Aviv, Israel|Research Site, Bari, Italy|Research Site, Genova, Italy|Research Site, Livorno, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Orbassano, Italy|Research Site, Parma, Italy|Research Site, Perugia, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Mexico, Mexico|Research Site, Monterrey, Mexico|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Bergen Op Zoom, Netherlands|Research Site, Den Bosch, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Miraflores, Peru|Research Site, Brzozow, Poland|Research Site, Bydgoszcz, Poland|Research Site, Gdańsk, Poland|Research Site, Gdańsk, Poland|Research Site, Grudziądz, Poland|Research Site, Kraków, Poland|Research Site, Lubin, Poland|Research Site, Olsztyn, Poland|Research Site, Opole, Poland|Research Site, Sucha Beskidzka, Poland|Research Site, Szczecin, Poland|Research Site, Warszawa, Poland|Research Site, Amadora, Portugal|Research Site, Coimbra, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Porto, Portugal|Research Site, Vila Nova de Gaia, Portugal|Research Site, Cluj Napoca, Romania|Research Site, Cluj Napoca, Romania|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Málaga, Spain|Research Site, Sevilla, Spain|Research Site, Vigo(Pontevedra), Spain|Research Site, Zaragoza, Spain|Research Site, Linköping, Sweden|Research Site, Uppsala, Sweden|Research Site, Örebro, Sweden|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, İstanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Izmir, Turkey|Research Site, Manisa, Turkey|Research Site, Chernivtsі, Ukraine|Research Site, Dnipro, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Kryvyi Rih, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Sumy, Ukraine|Research Site, Uzhhorod, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Aberdeen, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Sutton, United Kingdom|Research Site, Wolverhampton, United Kingdom",https://ClinicalTrials.gov/show/NCT01933932
120,Eli Lilly and Company,A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer,"Active, not recruiting",Has Results,Non Small Cell Lung Cancer,Drug: Abemaciclib|Drug: Erlotinib,Industry,Interventional,"Highlands Oncology Group, Fayetteville, Arkansas, United States|Clopton Clinic, Jonesboro, Arkansas, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|City of Hope National Medical Center, Duarte, California, United States|St Jude Medical Center, Fullerton, California, United States|University of California - San Diego, La Jolla, California, United States|Loma Linda University School of Medicine, Loma Linda, California, United States|SMO TRIO -Translational Research, Los Angeles, California, United States|UCLA Department of Medicine-Hematology/Oncology, Los Angeles, California, United States|Cancer Care Associates, Redondo Beach, California, United States|Dignity Health Care Institute, Sacramento, California, United States|Central Coast Medical Oncology Corporation, Santa Monica, California, United States|SMO Catholic Health Initiatives, Englewood, Colorado, United States|Medical Oncology Hematology Consultants, Newark, Delaware, United States|Lynn Cancer Institute Ctr for Hem-Onc, Boca Raton, Florida, United States|Halifax Medical Center, Daytona Beach, Florida, United States|Memorial Cancer Institute, Pembroke Pines, Florida, United States|H Lee Moffitt Cancer Center, Tampa, Florida, United States|Northeast Georgia Cancer Care, LLC, Athens, Georgia, United States|Harbin Clinic, Rome, Georgia, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Fort Wayne Oncology & Hematology, Fort Wayne, Indiana, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Cancer Center of Kansas, P.A., Wichita, Kansas, United States|Central Baptist Hospital, Lexington, Kentucky, United States|St Joseph Cancer Center, Lexington, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|National Cancer Institute, Bethesda, Maryland, United States|Metro-West and Greater Boston CNS Research, Framingham, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Freeman Cancer Institute, Joplin, Missouri, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|Billings Clinic Research Center, Billings, Montana, United States|St. Francis Medical Center, Grand Island, Nebraska, United States|Alegent Immanuel Cancer Center, Omaha, Nebraska, United States|Oncology Hematology West, Omaha, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Broome Oncology, Johnson City, New York, United States|Weill Cornell Medical College, New York, New York, United States|Oncology Hematology Care Inc, Cincinnati, Ohio, United States|Oklahoma Cancer Specialists & Research Institute, LLC, Tulsa, Oklahoma, United States|Providence Cancer Center Oncology Hematology Care, Portland, Oregon, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Roper St. Francis Healthcare, Charleston, South Carolina, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|SMO Sarah Cannon Research Inst., Nashville, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Mary Crowley Cancer Research Center, Dallas, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Columbia Basin Hematology & Oncology, Kennewick, Washington, United States|Swedish Medical Center, Seattle, Washington, United States|Cancer Care Northwest, Valley, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Berazategui, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ciudad Autonoma Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ciudad Autonoma Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ciudad Autonoma Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rosario, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Rosario, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Viedma, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Graz, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Linz, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Linz, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salzburg, Austria|Associação Hospital de Caridade Ijuí, Ijui, Brazil|Hospital Bruno Born, Lajeados, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Porto Alegre, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rio De Janeiro, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salvador, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sao Jose Rio Preto, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, São Paulo, Brazil|Fundação Antonio Prudente - Hospital do Câncer A.C Camargo, São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Calgary, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Edmonton, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Montreal, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Toronto, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Vancouver, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Winnipeg, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Beijing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beijing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Beijing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Changchun, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Changzhou, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chengdu, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haikou, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hang Zhou, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hefei, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nanning, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shanghai, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shenyang, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bron, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Dijon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Grenoble, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marseille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poitiers, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Saint-Brieuc, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Priest en Jarez, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vantoux, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gera, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Großhansdorf, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Immenhausen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nürnberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Regensburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rosenheim, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tübingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulm, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heraklion, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Patras, Greece|Soroka Medical Center, Beer Sheva, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Holon, Israel|Hadassah Medical Center - Ein Karem, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Petah Tiqva, Israel|Sheba Medical Center, Tel Hashomer, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Catania, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Genova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Livorno, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Parma, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amagasaki, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Asahikawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bunkyo-ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bunkyo-Ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Habikino, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hirakata, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hiroshima, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanazawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kashiwa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kishiwada, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kitaadachi-Gun, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kobe, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Koto-ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kurashiki, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Matsuyama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nagasaki, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nagoya, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nagoya, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Natori, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Okayama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osakasayama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sakai, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sendai, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shinjuku-ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sunto-Gun, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ube, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Utsunomiya, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wakayama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yokohama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yonago, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yufu-shi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Goyang-Si, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Incheon, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seowon-Gu, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Suwon, Korea, Republic of|For additional i",
121,Neal Ready|Merck Sharp & Dohme Corp.|Duke University,Neoadjuvant Pembrolizumab,"Active, not recruiting",Has Results,Non-small Cell Lung Carcinoma,Drug: Pembrolizumab,Other|Industry,Interventional,"Mayo Clinic, Rochester, Minnesota, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Duke University Medical Center, Durham, North Carolina, United States",https://ClinicalTrials.gov/show/NCT02818920
122,"AstraZeneca|Gynecologic Oncology Group|Myriad Genetic Laboratories, Inc.|Merck Sharp & Dohme Corp.",Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.,"Active, not recruiting",Has Results,Newly Diagnosed|Advanced Ovarian Cancer|FIGO Stage III-IV|BRCA Mutation|Complete Response|Partial Response|First Line Platinum Chemotherapy,Drug: Olaparib 300mg tablets,Industry|Other,Interventional,"Clearview Cancer Institute, Huntsville, Alabama, United States|Providence Cancer Center, Anchorage, Alaska, United States|St. Joseph's Hospital & Medical Center, Phoenix, Arizona, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|Kaiser Permanente, Oakland, California, United States|Kaiser Permanente, Roseville, California, United States|Stanford Women's Cancer Center, Stanford, California, United States|Babak Edraki, Walnut Creek, California, United States|University of Colorado, Aurora, Colorado, United States|Univ of Connecticut Health Center, Farmington, Connecticut, United States|Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Gynecologic Cancer Center, Orlando, Florida, United States|H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Nancy N. & J.C. Lewis Cancer and Research Pavillion, Savannah, Georgia, United States|The Queen's Medical Center, Honolulu, Hawaii, United States|University of Hawaii, Honolulu, Hawaii, United States|Northwestern University, Chicago, Illinois, United States|Univ Chicago Medical Center, Chicago, Illinois, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|St. Vincent Hospital & Health Care Center, Indianapolis, Indiana, United States|Northern Indiana Cancer Research Consortium, Mishawaka, Indiana, United States|McFarland Clinic, P.C., Ames, Iowa, United States|Norton Cancer Institute Research, Louisville, Kentucky, United States|Maine Medical Partners, Scarborough, Maine, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Johns Hopkins, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Gynecologic Oncology of West MI, PLLC, Grand Rapids, Michigan, United States|Minnesota Oncology Hematology, PA, Edina, Minnesota, United States|Mayo Clinic - Rochester, MN, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Missouri Valley Cancer Consortium CCOP, Omaha, Nebraska, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Womens Cancer Center of Nevada, Las Vegas, Nevada, United States|MD Anderson at Cooper Cancer Center, Camden, New Jersey, United States|John Theurer Cancer Center, Hackensack, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|Women's Cancer Care Associates, Albany, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Mount Sinai Medical Center - New York, New York, New York, United States|Perlmutter Cancer Center, New York, New York, United States|Hope Women's Cancer Centers, Asheville, North Carolina, United States|UNC Chapel Hill, Chapel Hill, North Carolina, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Sanford Roger Maris Cancer Center, Fargo, North Dakota, United States|Aultman Hospital, Canton, Ohio, United States|Cleveland Clinic Cancer Center at Fairview Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University Hospital Case Medical Center, Cleveland, Ohio, United States|OSU James Care at Mill Run, Columbus, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio, United States|Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|St. Luke's University Health Network, Bethlehem, Pennsylvania, United States|The University of Pennsylvania, Philadelphia, Pennsylvania, United States|Women and Infants Hospital, Providence, Rhode Island, United States|South Carolina Oncology Associates, PA, Columbia, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Sanford Clinic Women's Health, Sioux Falls, South Dakota, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|University of Texas Health Science Center of Houston, Houston, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Carilion Clinic Gynecological Oncology, Roanoke, Virginia, United States|Aurora Baycare Medical Center, Green Bay, Wisconsin, United States|University of Wisconsin-Madison, Madison, Wisconsin, United States|Froedtert Memorial Hospital, Milwaukee, Wisconsin, United States|Mercy Hospital for Women, Heidelberg, Australia|The Royal Womens Hospital, Parkville, Australia|Prince of Wales Hospital, Randwick, Australia|Centro Diagnóstico Barretos, Barretos, Brazil|Hospital Araujo Jorge, Goiânia, Brazil|Centro de Novos Tratamentos Itajai, Itajai, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alagre, Porto Alegre, Brazil|Hospital de Base São José do Rio Preto, São José do Rio Preto, Brazil|Centro de Referencia da Saude da Mulher, São Paulo, Brazil|Instituto do Câncer de São Paulo, São Paulo, Brazil|Juravinski Cancer Centre, Hamilton, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Sunnybrook Health Sciences Center, Toronto, Ontario, Canada|CHUM - Hopital Norte-Dame, Montreal, Quebec, Canada|Royal Victoria Hospital, Montreal, Quebec, Canada|Hotel-Dieu de Quebec, Quebec, Canada|Beijing Cancer Hospital, Beijing, China|The Tumor Hospital affiliated to China Medical Science Insti, Beijing, China|1st Hospital of Jilin university, Changchun, China|Jilin Provincial Cancer Hospital, Changchun, China|Hunan Cancer Hospital, Changsha, China|West China Hospital Affiliated to Sichuan University, Chengdu, China|ChongQing Cancer Hospital, Chongqing, China|EC of Cancer Center of SunYet-, Guangzhou, China|Women's Hospital, Zhejaing University School of Medicine, Hangzhou, China|The Tumour Hospital of Harbin Medical University, Harbin, China|Zhejiang Cancer Hospital, Huangzhou, Huangzhou, China|JINAN, Qi Lu Hosp. of SD Univ., Ji Nan, China|Obstetris and Gynecology Hospital of Fudan University, Shanghai, China|Shanghai Cancer Hospital of Fudan University, Shanghai, China|The First Affiliated Hospital of Soochow Universit, Suzhou, China|First affiliated hospital college of XianJiaotong University, Xian, China|Institut Bergonie, Bordeaux, France|CAC François Baclesse, Caen Cedex, France|69LYON, C Bérard, Onco, Lyon Cedex 08, France|Centre Catherine de Sienne, Nantes,, France|75PARIS, H Tenon, Onco, Paris, France|Centre Alexis Vautrin, Vandoeuvre Les Nancy, France|Institut Gustave Roussy, Villejuif Cedex, France|Rambam Health Care Campus, Haifa, Israel|Sapir Medical Centre, Kfar Saba, Israel|Rabin MC, Petach Tikva, Israel|Chaim Sheba Medical Centre, Tel Hashomer, Israel|Tel-Aviv Sourkasy Medical Center, Tel-Aviv, Israel|Bari- Istituto Tumori Giovanni Paolo II, Bari, Italy|Azienda Ospedaliera ""Cannizzaro"", Catania, Italy|Istituto Europeo di Oncologia, Milano, Italy|Istituto Nazionale Per Cura Tumori - Milano, Milano, Italy|Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy|Istituto Oncologico Veneto Irccs, Padova, Italy|Istituto Regina Elena-Polo Oncologico Ifo, Roma, Italy|Policlinico Universitario A. Gemelli, Roma, Italy|Hyogo CC, Akashi-shi, Japan|National Cancer Center Hosp, Chuo-ku, Japan|NHO Kyushu CC, Fukuoka, Japan|Saitama Med. Univ. Int. Med. C, Hidaka-shi, Japan|NHO Shikoku Cancer Center, Matsuyama-shi, Japan|Niigata Univ. Med. Dent., Niigata-shi, Japan|Hokkaido University Hospital, Sapporo-shi, Japan|Shizuoka Cancer Center, Sunto-gun, Japan|National Cancer Center, Goyang-si, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Korea Cancer Center Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands|Maastricht Universitair Medisch Centrum, Maastricht, Netherlands|Niepubliczny Zaklad Opieki Zdrowotnej Innowacyjna Medycyna, Grzepnica, Poland|SPZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii, Olsztyn, Poland|Wojewódzki Szpital Specjalistyczny w Olsztynie, Olsztyn, Poland|Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie, Warszawa, Poland|Szpital Specjalistyczny im. Swietej Rodziny SPZOZ, Warszawa, Poland|Udmurtia Republic Clinical Oncology Center, Izhevsk, Russian Federation|Chemotherapy Department, Russian Cancer Research Centre, Moscow, Russian Federation|State Institution of Heath Omsk Regional Oncology Dispensary, Omsk, Russian Federation|Cancer Research Institute, Saint Petersburg, Russian Federation|St.Petersburg City Oncology Dispensary, Dept. Gynecology, Saint Petersburg, Russian Federation|Leningrad Regional Oncology Dispensary, St.Petersburg, Russian Federation|Research Institute of Oncology RAMS, Tomsk, Russian Federation|Barcelona,H.Vall d´Hebrón,Oncología, Barcelona, Spain|Córdoba,H.Reina Sofía,Oncología, Córdoba, Spain|H.Llobregat,ICO-Duran i Reynals,Oncología, Hospitalet deLlobregat(Barcelo, Spain|Madrid, MD Anderson, Oncología, Madrid, Spain|Madrid,H.U.La Paz,Oncología, Madrid, Spain|Valencia, IVO, Oncología, Valencia, Spain|Valencia,H.C.U.Valencia,Oncología, Valencia, Spain|City Hospital, Birmingham, Cancer Trials Team, Birmingham, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|Arden Cancer Centre, Coventry, United Kingdom|Edinburgh Cancer Research UK Centre, Edinburgh, United Kingdom|Cancer Research UK and UCL Cancer Trials Centre, London, United Kingdom|Royal Marsden Hospital, London, United Kingdom|Royal Marsden Hospital and Institute of Cancer Research, Sutton, United Kingdom",https://ClinicalTrials.gov/show/NCT01844986
123,"Daiichi Sankyo, Inc.",Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS),"Active, not recruiting",Has Results,Pigmented Villonodular Synovitis|Giant Cell Tumors of the Tendon Sheath|Tenosynovial Giant Cell Tumor,Drug: Pexidartinib|Drug: Placebo,Industry,Interventional,"Mayo Clinic, Scottsdale, Arizona, United States|University of Southern California, Los Angeles, California, United States|Stanford Cancer Center, Palo Alto, California, United States|UCLA Medical Center, Santa Monica, California, United States|Mayo Clinic Cancer Center, Jacksonville, Florida, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|: Dana Farber Cancer Institute, Boston, Massachusetts, United States|Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|MD Anderson Cancer Center at Cooper, Camden, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke Cancer Center, Durham, North Carolina, United States|OHSU Knight Cancer Institute, Portland, Oregon, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Chris O'Brien Lifehouse, Sydney, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia|Princess Margaret Hospital, Toronto, Ontario, Canada|McGill University Health Centre, Montreal, Quebec, Canada|Herlev Hospital, Herlev, Denmark|Centre Leon Bérard, Lyon, France|Institut Gustave Roussy, Villejuif, France|HELIOS Klinikum Berlin-Buch, Berlin, Germany|Universitätsklinikum Essen, Essen, Germany|Military Hospital-State Health Center, Budapest, Hungary|Istituto Ortopedico Rizzoli, Bologna, BO, Italy|Istituto Nazionale Tumori-Fondazione IRCCS, Milano, MI, Italy|Leiden University Medical Center, Leiden, Netherlands|Radboud Univ. Medical Center, Nijmegen, Netherlands|Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Warszawa, Poland|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|University College Hospital, London, United Kingdom|The Royal Marsden NHS Foundation Trust, London, United Kingdom",https://ClinicalTrials.gov/show/NCT02371369
124,Sanofi,Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies,"Active, not recruiting",Has Results,Hematological Malignancy,Drug: Isatuximab SAR650984|Drug: Dexamethasone,Industry,Interventional,"Investigational Site Number 840003, Scottsdale, Arizona, United States|Investigational Site Number 840005, San Francisco, California, United States|Investigational Site Number 840009, Atlanta, Georgia, United States|Investigational Site Number 840010, Chicago, Illinois, United States|Investigational Site Number 840022, Ann Arbor, Michigan, United States|Investigational Site Number 840027, Detroit, Michigan, United States|Investigational Site Number 840018, Rochester, Minnesota, United States|Investigational Site Number 840013, Saint Louis, Missouri, United States|Investigational Site Number 840011, Hackensack, New Jersey, United States|Investigational Site Number 840014, New York, New York, United States|Investigational Site Number 840016, Durham, North Carolina, United States|Investigational Site Number 840004, Cincinnati, Ohio, United States|Investigational Site Number 840001, Nashville, Tennessee, United States|Investigational Site Number 840002, Salt Lake City, Utah, United States|Investigational Site Number 840012, Seattle, Washington, United States|Investigational Site Number 840017, Milwaukee, Wisconsin, United States|Investigational Site Number 032002, Caba, Argentina|Investigational Site Number 032003, Capital Federal, Argentina|Investigational Site Number 032001, Ciudad De Buenos Aires, Argentina|Investigational Site Number 056001, Antwerpen, Belgium|Investigational Site Number 076001, Barretos, Brazil|Investigational Site Number 076003, Porto Alegre, Brazil|Investigational Site Number 076004, Rio De Janeiro, Brazil|Investigational Site Number 076002, Sao Paulo, Brazil|Investigational Site Number 152001, Temuco, Chile|Investigational Site Number 246001, Helsinki, Finland|Investigational Site Number 246002, Turku, Finland|Investigational Site Number 250003, Nantes Cedex 01, France|Investigational Site Number 250004, Pierre Benite, France|Investigational Site Number 250001, Toulouse Cedex 9, France|Investigational Site Number 300001, Athens, Greece|Investigational Site Number 376004, Jerusalem, Israel|Investigational Site Number 376002, Tel Hashomer, Israel|Investigational Site Number 380001, Bologna, Italy|Investigational Site Number 380002, Torino, Italy|Investigational Site Number 484001, Monterrey, Mexico|Investigational Site Number 484003, San Luis Potosi, Mexico|Investigational Site Number 604001, Arequipa, Peru|Investigational Site Number 604002, Lima, Peru|Investigational Site Number 643002, Moscow, Russian Federation|Investigational Site Number 643003, Novosibirsk, Russian Federation|Investigational Site Number 643001, Petrozavodsk, Russian Federation|Investigational Site Number 643004, Saint-Petersburg, Russian Federation|Investigational Site Number 724007, Badalona, Spain|Investigational Site Number 724005, Barcelona, Spain|Investigational Site Number 724004, Madrid, Spain|Investigational Site Number 724002, Pamplona, Spain|Investigational Site Number 724001, Salamanca, Spain|Investigational Site Number 724008, Sevilla, Spain|Investigational Site Number 724006, Valencia, Spain|Investigational Site Number 792002, Ankara, Turkey|Investigational Site Number 792005, Ankara, Turkey|Investigational Site Number 792001, İstanbul, Turkey|Investigational Site Number 792004, Samsun, Turkey|Investigational Site Number 804001, Kyiv, Ukraine|Investigational Site Number 804004, Vinnitsya, Ukraine|Investigational Site Number 804002, Zaporizhzhya, Ukraine|Investigational Site Number 826001, Nottingham, United Kingdom|Investigational Site Number 826002, Southampton, United Kingdom",https://ClinicalTrials.gov/show/NCT01084252
125,AstraZeneca,Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours,"Active, not recruiting",Has Results,Non Small Cell Lung Cancer,Drug: AZD9291,Industry,Interventional,"Research Site, La Jolla, California, United States|Research Site, Orange, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Norwalk, Connecticut, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Boston, Massachusetts, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, New York, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Edmonton, Alberta, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Hong Kong, Hong Kong|Research Site, Shatin, Hong Kong|Research Site, Milano, Italy|Research Site, Milan, Italy|Research Site, Napoli, Italy|Research Site, Perugia, Italy|Research Site, Verona, Italy|Research Site, Akashi-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Kitaadachi-gun, Japan|Research Site, Kitakyushu-shi, Japan|Research Site, Koto-ku, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Niigata-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osakasayama, Japan|Research Site, Sakai-shi, Japan|Research Site, Wakayama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Goyang-si, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Málaga, Spain|Research Site, Valencia, Spain|Research Site, Taichung, Taiwan|Research Site, Taipei, Taiwan",https://ClinicalTrials.gov/show/NCT02094261
126,H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)|Lymphoma Research Foundation|Novartis,Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma,"Active, not recruiting",Has Results,Lymphoma,Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Dexamethasone|Biological: Autologous Tumor Cell-Based Vaccine|Drug: IL-2,Other|NIH|Industry,Interventional,"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",https://ClinicalTrials.gov/show/NCT00101101
127,Incyte Corporation,A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723),"Active, not recruiting",Has Results,Solid Tumor,Drug: Epacadostat|Drug: Pembrolizumab|Drug: Oxaliplatin|Drug: Leucovorin|Drug: 5-Fluorouracil|Drug: Gemcitabine|Drug: nab-Paclitaxel|Drug: Carboplatin|Drug: Paclitaxel|Drug: Pemetrexed|Drug: Cyclophosphamide|Drug: Cisplatin|Drug: Investigator's choice of platinum agent,Industry,Interventional,"Mayo Clinic Arizona, Phoenix, Arizona, United States|University of California San Diego Medical Center, Moores Cancer Center, La Jolla, California, United States|The Angeles Clinic and Research Institute, Los Angeles, California, United States|Mayo Clinic, Jacksonville, Florida, United States|University of Chicago, Chicago, Illinois, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Carolina Bio-Oncology Institute, PLLC, Huntersville, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Tennessee Oncology - Nashville; The Sarah Cannon Research Institute, Nashville, Tennessee, United States|Vanderbilt University; Henry Joyce Cancer Clinic, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States",https://ClinicalTrials.gov/show/NCT03085914
128,Novartis Pharmaceuticals|Novartis,LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib,"Active, not recruiting",Has Results,Non-Small Cell Lung Cancer,Drug: Ceritinib|Drug: pemetrexed|Drug: docetaxel,Industry,Interventional,"Highlands Oncology Group, Fayetteville, Arkansas, United States|Memorial Cancer Institute SC, Hollywood, Florida, United States|Cancer Specialists of North Florida, Jacksonville, Florida, United States|University of Miami SC, Miami, Florida, United States|Loyola University Medical Center /Cardinal Bernardin Cancer SC, Maywood, Illinois, United States|University of Iowa Hospitals and Clinics Comprehensive Cancer Center, Iowa City, Iowa, United States|Massachusetts General Hospital SC-8, Boston, Massachusetts, United States|Oklahoma Cancer Specialists and Research Institute SC-2, Tulsa, Oklahoma, United States|Sarah Cannon Research Institute SC-5, Nashville, Tennessee, United States|Texas Oncology-Sugarland, Sugar Land, Texas, United States|Texas Oncology Cancer Care and Research Center, Waco, Texas, United States|Virginia Cancer Specialists SC Virginia Cancer Specialists, Fairfax, Virginia, United States|Swedish Cancer Institute SC-1, Seattle, Washington, United States|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Edegem, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Marseille cedex 20, Bouches Du Rhone, France|Novartis Investigative Site, Le Mans, Cedex 09, France|Novartis Investigative Site, Besancon cedex, France|Novartis Investigative Site, Brest, France|Novartis Investigative Site, Caen Cedex, France|Novartis Investigative Site, Mulhouse cedex, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Suresnes, France|Novartis Investigative Site, Bad Berka, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Esslingen, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Limerick, Co Limerick, Ireland|Novartis Investigative Site, Dublin 4, Ireland|Novartis Investigative Site, Kfar Saba, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Avellino, AV, Italy|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Perugia, PG, Italy|Novartis Investigative Site, Pisa, PI, Italy|Novartis Investigative Site, Aviano, PN, Italy|Novartis Investigative Site, Reggio Emilia, RE, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Orbassano, TO, Italy|Novartis Investigative Site, Verona, VR, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Kashiwa, Chiba, Japan|Novartis Investigative Site, Fukuoka city, Fukuoka, Japan|Novartis Investigative Site, Fukuoka-city, Fukuoka, Japan|Novartis Investigative Site, Akashi, Hyogo, Japan|Novartis Investigative Site, Okayama-city, Okayama, Japan|Novartis Investigative Site, Hirakata-city, Osaka, Japan|Novartis Investigative Site, Osaka Sayama, Osaka, Japan|Novartis Investigative Site, Osaka-city, Osaka, Japan|Novartis Investigative Site, Takatsuki-city, Osaka, Japan|Novartis Investigative Site, Koto ku, Tokyo, Japan|Novartis Investigative Site, Niigata, Japan|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Seocho Gu, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Ashrafieh, Lebanon|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, La Coruna, Galicia, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Luzern, Switzerland|Novartis Investigative Site, St. Gallen, Switzerland|Novartis Investigative Site, Istanbul, TUR, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Pendik / Istanbul, Turkey|Novartis Investigative Site, Cheltenham, Gloucestershire, United Kingdom|Novartis Investigative Site, Hants, Southampton, United Kingdom|Novartis Investigative Site, Aberdeen, United Kingdom|Novartis Investigative Site, Leicester, United Kingdom|Novartis Investigative Site, London, United Kingdom",https://ClinicalTrials.gov/show/NCT01828112
129,Ultragenyx Pharmaceutical Inc,Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS),"Active, not recruiting",Has Results,Tumor Induced Osteomalacia (TIO)|Epidermal Nevus Syndrome (ENS),Biological: Burosumab,Industry,Interventional,"Colorado Center for Bone Research at Panorama Orthopedics and Spine Center, Golden, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Indiana University Hospital, Indianapolis, Indiana, United States|Johns Hopkins University, Baltimore, Maryland, United States|Mayo Clinic, Rochester, Minnesota, United States|Duke University, Durham, North Carolina, United States|Houston Methodist Research Institute, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT02304367
130,"Aragon Pharmaceuticals, Inc.","Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)","Active, not recruiting",Has Results,Prostate Cancer,Drug: ARN-509 (Phase 1)|Drug: ARN-509 (Phase 2),Industry,Interventional,"San Diego, California, United States|San Francisco, California, United States|Atlanta, Georgia, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Omaha, Nebraska, United States|New York, New York, United States|Raleigh, North Carolina, United States|Portland, Oregon, United States|Lancaster, Pennsylvania, United States|Myrtle Beach, South Carolina, United States|Dallas, Texas, United States|Seattle, Washington, United States|Madison, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT01171898
131,Bristol-Myers Squibb,A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC,"Active, not recruiting",Has Results,Non-Small Cell Lung Cancer,Biological: Ipilimumab|Biological: Nivolumab|Drug: Carboplatin|Drug: Paclitaxel|Drug: Pemetrexed|Drug: Cisplatin,Industry,Interventional,"Memorial Health Systems, Colorado Springs, Colorado, United States|Cancer Center Of Central Connecticut, Plainville, Connecticut, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Northwest Georgia Oncology Center, P.C., Marietta, Georgia, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Henry Ford Health System, Detroit, Michigan, United States|Broome Oncology, Johnson City, New York, United States|Winthrop University Hospital, Mineola, New York, United States|The Ohio State University, Columbus, Ohio, United States|West Penn Hospital, Jefferson Hills, Pennsylvania, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Southwest Regional Cancer Clinic, Saint George, Utah, United States|University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States|Instituto Alexander Fleming, Caba, Buenos Aires, Argentina|Instituto Medico Rio Cuarto S.A., Rio Cuarto, Cordoba, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Sanatorio Parque, Rosario, Santa FE, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Gosford, New South Wales, Australia|Local Institution, Bedford Park, South Australia, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Heidelberg, Victoria, Australia|St John of God Murdoch Hospital, Murdoch, Western Australia, Australia|Local Institution, Charleroi, Belgium|Local Institution, Leuven, Belgium|Local Institution, Roeselare, Belgium|Local Institution, Natal, RIO Grande DO Norte, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Blumenau, Santa Catarina, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Jose De Rio Preto, SAO Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Mcgill University Health Center - Royal Victoria Hospital, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Centro de Investigacion Clinica Bradford Hill, Santiago de Chile, Metropolitana, Chile|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Hospital Clinico Vina Del Mar, Vina Del Mar, Valparaiso, Chile|Local Institution, Beijing, Beijing, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Changsha, Hunan, China|Local Institution, Changchun, Jilin, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Beijing, China|Local Institution, Haikou, China|Local Institution, Caen, France|Local Institution, Lille Cedex, France|Centre Leon Berard, Lyon Cedex 08, France|Local Institution, Montpellier Cedex, France|Local Institution, Nantes, France|Local Institution, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|Centre Hospitalier De Saint-Brieuc Hopital Yves Le Foll, Saint-Brieuc, France|Local Institution, Berlin, Germany|Asklepios Fachkliniken Muenchen-Gauting, Gauting, Germany|Klinik Schillerhoehe GmbH, Gerlingen, Germany|LungenClinic Grosshansdorf GmbH, Grosshansdorf, Germany|Lungenklinik Hemer, Hemer, Germany|Lungenfachklinik Immenhausen, Immenhausen, Germany|Universitaetsklinikum Magdeburg, Magdeburg, Germany|Muenchen Klinik - Bogenhausen, Muenchen, Germany|Local Institution, Dublin, Ireland|Local Institution, Limerick, Ireland|Ospedale San Luca, Lucca, Italy|Irccs Ospedale S. Raffaele, Milano, Italy|Azienda Ospedaliera Monaldi, Napol, Italy|Local Institution, Fukushima-shi, Fukushima, Japan|Local Institution, Maebashi-shi, Gunma, Japan|Local Institution, Ota-shi, Gunma, Japan|Local Institution, Hiroshima-shi, Hiroshima, Japan|Local Institution, Hiroshima-shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Akashi-shi, Hyogo, Japan|Local Institution, Himeji-shi, Hyogo, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Shiwa-gun, Iwate, Japan|Local Institution, Yokohama-Shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Habikino-shi, Osaka, Japan|Local Institution, Osaka-sayama-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Ube-shi, Yamaguchi, Japan|Oncotech, La Paz, BAJA Californa SUR, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Faicic S. de Rl. de Cv, Veracruz, Veracruz, Mexico|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Oddzial Onkologii, Bytom, Poland|Local Institution, Gdansk, Poland|Local Institution, Bucharest, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Local Institution, Moscow, Russian Federation|Local Institution, St.petersburg, Russian Federation|Comp. Hosp. Univ. A Coruna, A Coru?a, Spain|H. Univ. Vall dHebron, Barcelona, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|Hospital Carlos Haya De Malaga, Malaga, Spain|Hospital Universitario La Fe, Valencia, Spain|Local Institution, London, Greater London, United Kingdom|Local Institution, Guildford, United Kingdom|Local Institution, Tauton, United Kingdom",https://ClinicalTrials.gov/show/NCT03215706
132,"Ludwig Institute for Cancer Research|MedImmune LLC|Celgene|Cancer Research Institute, New York City","Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer","Active, not recruiting",Has Results,Ovarian Cancer,Drug: Durvalumab|Drug: Pegylated Liposomal Doxorubicin|Drug: Motolimod,Other|Industry,Interventional,"Research Facitlity, Phoenix, Arizona, United States|Research Facility, New York, New York, United States|Research Facility, Hilliard, Ohio, United States|Research Facility, Providence, Rhode Island, United States|Research Facility, Lausanne, Switzerland",https://ClinicalTrials.gov/show/NCT02431559
133,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Translational Breast Cancer Research Consortium|Genentech, Inc.",Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer,"Active, not recruiting",Has Results,Breast Cancer,Procedure: Positron emission tomography (PET)|Drug: Trastuzumab|Drug: Pertuzumab,Other|Industry,Interventional,"University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States|Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital, Washington, District of Columbia, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Mayo Clinic, Rochester, Minnesota, United States|Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Vanderbilt University, Nashville, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Fred Hutchinson Cancer Research Center - University of Washington, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT01937117
134,"Tesaro, Inc.|European Organisation for Research and Treatment of Cancer - EORTC|Breast International Group|Myriad Genetic Laboratories, Inc.|US Oncology Research|Sarah Cannon|Facing Our Risk of Cancer Empowered","A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients","Active, not recruiting",Has Results,"Neoplasms, Breast|Carcinoma of Breast|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|BRCA1 Gene Mutation|BRCA2 Gene Mutation|Ovarian Neoplasms",Drug: niraparib|Drug: Physician's choice,Industry|Other,Interventional,"GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Fort Myers, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Henderson, Nevada, United States|GSK Investigational Site, Clifton Park, New York, United States|GSK Investigational Site, Lake Success, New York, United States|GSK Investigational Site, Stony Brook, New York, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Eugene, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Fort Worth, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Webster, Texas, United States|GSK Investigational Site, Weslaco, Texas, United States|GSK Investigational Site, Low Moor, Virginia, United States|GSK Investigational Site, Everett, Washington, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Green Bay, Wisconsin, United States|GSK Investigational Site, Aalst, Belgium|GSK Investigational Site, Brussels, Belgium|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Edegem, Belgium|GSK Investigational Site, Liège, Belgium|GSK Investigational Site, Namur, Belgium|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Kelowna, British Columbia, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Bordeaux, France|GSK Investigational Site, Dijon Cedex, France|GSK Investigational Site, Lille Cedex, France|GSK Investigational Site, Lyon Cedex 08, France|GSK Investigational Site, Montpellier, France|GSK Investigational Site, Nantes cedex, France|GSK Investigational Site, Paris Cedex 5, France|GSK Investigational Site, Saint-Cloud, France|GSK Investigational Site, Heraklion,Crete, Greece|GSK Investigational Site, Maroussi, Greece|GSK Investigational Site, Nea Kifissia, Greece|GSK Investigational Site, Neo Faliro, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Debrecen, Hungary|GSK Investigational Site, Miskolc, Hungary|GSK Investigational Site, Nyiregyhaza, Hungary|GSK Investigational Site, Pécs, Hungary|GSK Investigational Site, Szeged, Hungary|GSK Investigational Site, Reykjavik, Iceland|GSK Investigational Site, Haifa, Israel|GSK Investigational Site, Holon, Israel|GSK Investigational Site, Kfar-Saba, Israel|GSK Investigational Site, Rehovot, Israel|GSK Investigational Site, Tel Aviv, Israel|GSK Investigational Site, Tel Hashomer, Israel|GSK Investigational Site, Meldola (FC), Emilia-Romagna, Italy|GSK Investigational Site, Parma, Emilia-Romagna, Italy|GSK Investigational Site, Rimini, Emilia-Romagna, Italy|GSK Investigational Site, Viterbo, Lazio, Italy|GSK Investigational Site, Genova, Liguria, Italy|GSK Investigational Site, Cremona, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Ancona, Marche, Italy|GSK Investigational Site, Lecce, Puglia, Italy|GSK Investigational Site, Prato, Toscana, Italy|GSK Investigational Site, Legnago (VR), Veneto, Italy|GSK Investigational Site, Leiden, RC, Netherlands|GSK Investigational Site, Limburg, Netherlands|GSK Investigational Site, Zwolle, Netherlands|GSK Investigational Site, Lodz, Poland|GSK Investigational Site, Raciborz, Poland|GSK Investigational Site, Coimbra, Portugal|GSK Investigational Site, Lisbon, Portugal|GSK Investigational Site, Porto, Portugal|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Burgos, Spain|GSK Investigational Site, Cáceres, Spain|GSK Investigational Site, L'Hospitalet de Llobregat, Spain|GSK Investigational Site, Lerida, Spain|GSK Investigational Site, Lugo, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Pamplona, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Vigo, Spain|GSK Investigational Site, Southampton, Hampshire, United Kingdom|GSK Investigational Site, Northwood, Middlesex, United Kingdom|GSK Investigational Site, Headington, Oxford, Oxfordshire, United Kingdom|GSK Investigational Site, Sutton, Surrey, United Kingdom|GSK Investigational Site, Bebington, Wirral, United Kingdom|GSK Investigational Site, Belfast, United Kingdom|GSK Investigational Site, Edinburgh, United Kingdom|GSK Investigational Site, Glasgow, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Nottingham, United Kingdom|GSK Investigational Site, Whitchurch, Cardiff, United Kingdom",https://ClinicalTrials.gov/show/NCT01905592
135,Eli Lilly and Company,A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY),"Active, not recruiting",Has Results,Metastatic Non-Small Cell Lung Cancer,Drug: Ramucirumab|Drug: Placebo|Drug: Erlotinib|Drug: Gefitinib|Drug: Osimertinib,Industry,Interventional,"TRIO - Translational Research in Oncology-US, Inc., Los Angeles, California, United States|UCLA Medical Center, Los Angeles, California, United States|Pharmatech Oncology Inc, Denver, Colorado, United States|The Queen's Medical Center, Honolulu, Hawaii, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Queens Medical Associates, Fresh Meadows, New York, United States|Levine Cancer Institute- Carolinas Medical Center, Charlotte, North Carolina, United States|St. Charles Health System, Bend, Oregon, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Cross Cancer Institute, Edmonton, Alberta, Canada|CHU Albert Michallon, Grenoble, Cedex 9, France|CHRU de Lille-Hôpital Albert Calmette, Lille, France|Centre hospitalier universitaire Lapeyronie, Montpellier Cedex 5, France|APHP-Hôpital Européen Georges Pompidou, Paris, France|CHU la Miletrie, Poitiers, France|Klinik Schillerhöhe, Gerlingen, Baden-Württemberg, Germany|Thoraxklinik Heidelberg gGmbH, Heidelberg, Baden-Württemberg, Germany|Kliniken der Stadt Köln gGmbH Klinikum Köln-Merheim, Köln, Nordrhein-Westfalen, Germany|Städtisches Krankenhaus Martha-Maria Halle-Dölau gGmbH, Halle (Saale), Sachsen-Anhalt, Germany|Klinikum Chemnitz GmbH, Chemnitz, Sachsen, Germany|LungenClinic Grosshansdorf, Großhansdorf, Schleswig-Holstein, Germany|HELIOS Klinikum Emil von Behring, Berlin, Germany|University General Hospital of Patras, Patras, Achaia, Greece|SOTIRIA General Hospital, Athens, Greece|Queen Mary Hospital, Hong Kong, Hong Kong|Queen Elizabeth Hospital, Kowloon, Hong Kong|Azienda per l'Assistenza Sanitaria n°5 ""Friuli Occidentale"", Pordenone, PD, Italy|Azienda Ospedaliero - Universitaria S. Luigi Gonzaga, Orbassano, Torino, Italy|IRCCS Ospedale Oncologico di Bari, Bari, Italy|Policlinico S. Orsola Malpighi - Universita di Bologna, Bologna, Italy|IRCCS Ospedale San Raffaele, Milano, Italy|Istituto Oncologico Veneto, Padova, Italy|Nagoya Medical Center, Nagoya, Aichi, Japan|Aichi Cancer Center Hospital, Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|National Hospital Organization Asahikawa Medical Center, Asahikawa, Hokkaido, Japan|Hyogo Cancer Center, Akashi, Hyogo, Japan|Hyogo Prefectual Amagasaki General Medical Center, Amagashiki City, Hyogo, Japan|National Hospital Organization Himeji Medical Center, Himeji, Hyogo, Japan|Foundation for Biomedical Research and innovation, Kobe, Hyogo, Japan|Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Kanagawa Cardiovascular and Respiratory Center, Yokohama, Kanagawa, Japan|Kanagawa Cancer Center, Yokohama, Kanagawa, Japan|Sendai Kousei Hospital, Sendai, Miyagi, Japan|Osaka Habikino Medical Center, Habikino, Osaka, Japan|Kansai Medical University Hospital, Hirakata, Osaka, Japan|Kishiwada City Hospital, Kishiwada, Osaka, Japan|Kindai University Hospital, Osaka Sayama-shi, Osaka, Japan|National Hospital Organization Kinki-Chuo Chest Medical Cent, Sakai, Osaka, Japan|Saitama Cancer Center, Kita-Adachi, Saitama, Japan|Shizuoka Cancer Center, Sunto-Gun, Shizuoka, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan|Nippon Medical School Hospital, Bunkyo-Ku, Tokyo, Japan|Tokyo Met Cancer & Infectious Diseases Center Komagome Hp, Bunkyo-ku, Tokyo, Japan|National Cancer Center Hospital, Chuo-Ku, Tokyo, Japan|St. Lukes International Hospital, Chuo-Ku, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|Yamaguchi-Ube Medical Center, Ube, Yamaguchi, Japan|Chiba University Hospital, Chiba, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka, Japan|Kyushu Cancer Center, Fukuoka, Japan|Kyushu University Hospital, Fukuoka, Japan|Kyoto University Hospital, Kyoto, Japan|Nagasaki University Hospital, Nagasaki, Japan|Niigata University Medical & Dental Hospital, Niigata, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|Osaka City General Hospital, Osaka, Japan|Osaka International Cancer Institute, Osaka, Japan|Osaka City University Hospital, Osaka, Japan|Wakayama MedicaL University Hospital, Wakayama, Japan|Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of|Saint Vincent Hospital, Suwon, Gyeonggi-do, Korea, Republic of|Ajou University Hospital, Suwon, Gyeonggi-do, Korea, Republic of|Gyeong-Sang National University Hospital, Jin-ju-si, Gyeongsangnam-do, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Korea, Republic of|Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Seoul Municipal Boramae Hospital, Seoul, Korea, Republic of|S.C. MedisProf SRL, Cluj-Napoca, Cluj, Romania|Institutul Oncologic Dr Trestioreanu Bucuresti, Bucuresti, Sector 2, Romania|Hospital Fundacion Son Llatzer, Palma de Mallorca, Baleares, Spain|Institut Catala d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Quiron Madrid, Pozuelo de Alarcon, Madrid, Spain|Clinica Universitaria De Navarra, Pamplona, Navarra, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitario Nuestra Señora de Valme, Sevilla, Spain|Hospital Universitario La Fe de Valencia, Valencia, Spain|Chang Gung Memorial Hospital - Kaohsiung, Kaohsiung City, Taiwan|E-DA Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung City, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|MacKay Memorial Hospital, Taipei City, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Baskent Adana Educational Hospital, Adana, Turkey|Trakya University Faculty of Medicine, Edirne, Turkey|Ege University Faculty of Medicine, Izmir, Turkey|Inonu University Medical Faculty, Malatya, Turkey|Royal Marsden NHS Trust, London, Greater London, United Kingdom|Charing Cross Hospital, Chelsea, London, United Kingdom|Nottingham City Hospital, Nottingham, Nottinghamshire, United Kingdom",https://ClinicalTrials.gov/show/NCT02411448
136,Bristol-Myers Squibb,Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC,"Active, not recruiting",Has Results,Non-Squamous Cell Non-small Cell Lung Cancer,Biological: Nivolumab|Drug: Docetaxel,Industry,Interventional,"Mayo Clinic Arizona, Scottsdale, Arizona, United States|City Of Hope, Duarte, California, United States|Sharp Clinical Oncology Research, San Diego, California, United States|San Francisco Oncology Associates, San Francisco, California, United States|Yale University, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Northwest Georgia Oncology Center, P.C., Marietta, Georgia, United States|University Of Chicago Medical Center, Chicago, Illinois, United States|The Johns Hopkins University, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Winthrop University Hospital Oncology/Hematology, Mineola, New York, United States|Memorial Sloan Kettering Nassau, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|St. Mary Medical Center, Langhorne, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Guthrie Medical Group, P.C., Sayre, Pennsylvania, United States|South Carolina Oncology Associates, Columbia, South Carolina, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Henry-Joyce Cancer Center, Nashville, Tennessee, United States|University Of Texas Southwestern Medical Center, Dallas, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Kadlec Clinical Hematology and Oncology, Kennewick, Washington, United States|Swedish Cancer Institute, Seattle, Washington, United States|University of Washington - Seattle Cancer Care Alliance, Seattle, Washington, United States|West Virginia University-Mbrcc, Morgantown, West Virginia, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Ciudad De Buenos Aires, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, La Rioja, Argentina|Local Institution, Tweed Heads, New South Wales, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Kurralta Park, South Australia, Australia|Local Institution, Frankston, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Linz, Austria|Local Institution, Salzburg, Austria|Local Institution, Vienna, Austria|Local Institution, Wels, Austria|Local Institution, Salvador, Bahia, Brazil|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|Local Institution, London, Ontario, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Recoleta, Santiago DE Chile, Chile|Local Institution, Vi?a Del Mar, Valparaiso, Chile|Local Institution, Praha 8, Czechia|Local Institution, Creteil, France|Local Institution, Dijon Cedex, France|Local Institution, La Roche Sur Yon Cedex 9, France|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 20, France|Local Institution, Poitiers, France|Local Institution, Rennes Cedex 9, France|Local Institution, Toulouse, France|Local Institution, Bad Berka, Germany|Local Institution, Gerlingen, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Heidelberg, Germany|Local Institution, Koeln, Germany|Local Institution, Mainz, Germany|Local Institution, Recklinghausen, Germany|Local Institution, Ulm, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution, Budapest, Hungary|Local Institution, Bergamo, Italy|Local Institution, Bologna, Italy|Local Institution, Meldola (fc), Italy|Local Institution, Milano, Italy|Local Institution, Padova, Italy|Local Institution, Parma, Italy|Local Institution, Perugia, Italy|Local Institution, Ravenna, Italy|Local Institution, Siena, Italy|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Hermosillo, Sonora, Mexico|Local Institution, Oslo, Norway|Local Institution, Miraflores, Lima, Peru|Local Institution, Arequipa, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Olsztyn, Poland|Local Institution, Szczecin, Poland|Local Institution, Warszawa, Poland|Local Institution, Bucuresti, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Local Institution, Iasi, Romania|Local Institution, Timisoara, Romania|Local Institution, Moscow, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Vizcaya, Spain|Local Institution, Basel, Switzerland|Local Institution, Chur, Switzerland",https://ClinicalTrials.gov/show/NCT01673867
137,AstraZeneca,AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer,"Active, not recruiting",Has Results,Anticancer Treatment,Drug: Chemotherapy|Drug: Cross-over to Osimertinib,Industry,Interventional,"Research Site, Anaheim, California, United States|Research Site, Orange, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Norwalk, Connecticut, United States|Research Site, Gainesville, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Park Ridge, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Marrero, Louisiana, United States|Research Site, Chevy Chase, Maryland, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Brick, New Jersey, United States|Research Site, New York, New York, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Houston, Texas, United States|Research Site, Lacey, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Darlinghurst, Australia|Research Site, Heidelberg, Australia|Research Site, Kogarah, Australia|Research Site, Nedlands, Australia|Research Site, Woolloongabba, Australia|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Chongqing, China|Research Site, Chongqin, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Harbin, China|Research Site, Nanchang, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Tianjin, China|Research Site, Zhengzhou, China|Research Site, Ürümqi, China|Research Site, Clermont Ferrand, France|Research Site, Dijon, France|Research Site, Lille, France|Research Site, Marseille Cedex 20, France|Research Site, Paris, France|Research Site, Strasbourg Cedex, France|Research Site, Toulouse, France|Research Site, Villejuif, France|Research Site, Essen, Germany|Research Site, Frankfurt, Germany|Research Site, Gerlingen, Germany|Research Site, Oldenburg, Germany|Research Site, Regensburg, Germany|Research Site, Würzburg, Germany|Research Site, Hong Kong, Hong Kong|Research Site, Shatin, Hong Kong|Research Site, Budapest, Hungary|Research Site, Avellino, Italy|Research Site, Meldola, Italy|Research Site, Milano, Italy|Research Site, Orbassano, Italy|Research Site, Roma, Italy|Research Site, Akashi-shi, Japan|Research Site, Bunkyo-ku, Japan|Research Site, Fukuoka, Japan|Research Site, Hirakata-shi, Japan|Research Site, Kanazawa, Japan|Research Site, Kitaadachi-gun, Japan|Research Site, Kobe-shi, Japan|Research Site, Kurashiki-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Natori-shi, Japan|Research Site, Niigata-shi, Japan|Research Site, Okayama-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osakasayama, Japan|Research Site, Sakai-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Sunto-gun, Japan|Research Site, Takatsuki-shi, Japan|Research Site, Wakayama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Busan, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Jinju-si, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Ulsan, Korea, Republic of|Research Site, Mexico, Mexico|Research Site, Oaxaca, Mexico|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Groningen, Netherlands|Research Site, Ekaterinburg, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Saint Petersburg,, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Málaga, Spain|Research Site, Sevilla, Spain|Research Site, Zaragoza, Spain|Research Site, Göteborg, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden|Research Site, Changhua, Taiwan|Research Site, Hsinchu, Taiwan|Research Site, Kaohsiung City, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Tao-Yuan, Taiwan|Research Site, Aberdeen, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Huddersfield, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newcastle-Upon-Tyne, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Wolverhampton, United Kingdom",https://ClinicalTrials.gov/show/NCT02151981
138,Gynecologic Oncology Group|Novartis Pharmaceuticals,Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer,"Active, not recruiting",Has Results,"Advanced, Persistent, or Recurrent Endometrial Cancer",Drug: Everolimus|Drug: Tamoxifen|Drug: Letrozole|Drug: Medroxyprogesterone Acetate,Other|Industry,Interventional,"University of Colorado - Anschutz Cancer Pavilion, Aurora, Colorado, United States|University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States|John B. Amos Cancer Center, Columbus, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|Maine Medical Center, Scarborough, Maine, United States|Johns Hopkins, Baltimore, Maryland, United States|University of Massachusetts Memorial Center, Worcester, Massachusetts, United States|Sanford Clinic North - Bemidji, Bemidji, Minnesota, United States|St. Dominic-Jackson Memorial Hospital, Jackson, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Women's Cancer Center of Nevada, Las Vegas, Nevada, United States|New Mexico Cancer Alliance, Albuquerque, New Mexico, United States|Memorial Medical Center-Cancer Center, Albuquerque, New Mexico, United States|Women's Cancer Care Associates, Albany, New York, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Sanford Roger Maris Cancer Center, Fargo, North Dakota, United States|University Hospital Case Medical Center, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|The University of Pennsylvania, Philadelphia, Pennsylvania, United States|Magee Women's Hospital of UPMC, Pittsburgh, Pennsylvania, United States|Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|Sanford Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States",https://ClinicalTrials.gov/show/NCT02228681
139,Bristol-Myers Squibb,A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors,"Active, not recruiting",Has Results,Advanced or Metastatic Solid Tumors,Biological: Nivolumab|Biological: Ipilimumab|Drug: Cobimetinib,Industry,Interventional,"Northwest Alabama Cancer Center, Pc, Muscle Shoals, Alabama, United States|University Of Colorado, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|University Of Florida, Gainesville, Florida, United States|H. Lee Moffitt Cancer Center & Research Inst, Inc, Tampa, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Dana Farber/Partners Cancercare, Inc., Boston, Massachusetts, United States|Dana-Farber/ Partners Cancer Care, Inc., Boston, Massachusetts, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|Winthrop University Hospital, Mineola, New York, United States|Memorial Sloan Kettering Nassau, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke Cancer Institute, Durham, North Carolina, United States|Oregon Health & Science University, Portland, Oregon, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Ctr, Nashville, Tennessee, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Local Institution, Copenhagen, Denmark|Local Institution, Helsinki, Finland|Local Institution, Tampere, Finland|Local Institution, Bonn, Germany|Local Institution, Frankfurt, Germany|Local Institution, Heidelberg, Germany|Local Institution, Kassel, Germany|Azienda Ospedaliera S.Orsola-Malpighi, Bologna, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Istituto Oncologico Veneto IOV, Padova, Italy|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, London, Greater London, United Kingdom|Local Institution, Glasgow, Lanarkshire, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom",https://ClinicalTrials.gov/show/NCT01928394
140,"Jeffrey Zwicker, MD|Quercegen Pharmaceuticals|National Heart, Lung, and Blood Institute (NHLBI)|Dana-Farber Cancer Institute",Cancer Associated Thrombosis and Isoquercetin (CATIQ),"Active, not recruiting",Has Results,Thromboembolism of Vein VTE in Colorectal Cancer|Thromboembolism of Vein in Pancreatic Cancer|Thromboembolism of Vein in Non-small Cell Lung Cancer,Drug: Isoquercetin,Other|Industry|NIH,Interventional,"USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|VA Northern California Health Care System, Sacramento, California, United States|VA Connecticut Healthcare System, West Haven, Connecticut, United States|Veterans Affair Medical Center, Washington, District of Columbia, United States|York Hospital-Oncology Treatment Center, York, Maine, United States|Boston VA Healthcare System, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Mount Auburn Hospital, Waltham, Massachusetts, United States|Washington University in St. Louis, Saint Louis, Missouri, United States|Providence VA Medical Center, Providence, Rhode Island, United States|White River Junction VA Medical Center, White River Junction, Vermont, United States",https://ClinicalTrials.gov/show/NCT02195232
141,"Genzyme, a Sanofi Company|Sanofi",Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients,"Active, not recruiting",Has Results,Non Small Cell Lung Cancer|Lung Cancer,Drug: Vandetanib|Drug: Pemetrexed,Industry,Interventional,"Research Site, Casa Grande, Arizona, United States|Research Site, Chandler, Arizona, United States|Research Site, Farmington, Connecticut, United States|Research Site, Stamford, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Orlando, Florida, United States|Research Site, Gainesville, Georgia, United States|Research Site, Skokie, Illinois, United States|Research Site, Sioux City, Iowa, United States|Research Site, Mount Sterling, Kentucky, United States|Research Site, Portland, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Rockville, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Mineola, New York, United States|Research Site, Rochester, New York, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Middletown, Ohio, United States|Research Site, Hilton Head Island, South Carolina, United States|Research Site, Austin, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Avellaneda, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Córdoba, Argentina|Research Site, La Plata, Argentina|Research Site, Ramos Mejía, Argentina|Research Site, Salta, Argentina|Research Site, Santa Fe, Argentina|Research Site, Chermside, Australia|Research Site, Fitzroy, Australia|Research Site, Footscray, Australia|Research Site, Heidelberg, Australia|Research Site, Randwick, Australia|Research Site, St. Leonards, Australia|Research Site, Wodonga, Australia|Research Site, Brussels (Woluwé-St-Lambert), Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Bogota, Colombia|Research Site, Medellín, Colombia|Research Site, Pereira, Colombia|Research Site, Valledupar, Colombia|Research Site, Avignon Cedex 09, France|Research Site, Lyon Cedex 04, France|Research Site, Paris Cedex 15, France|Research Site, Pontoise Cedex, France|Research Site, Strasbourg Cedex, France|Research Site, Hannover, Germany|Research Site, Karlsruhe, Germany|Research Site, Kassel, Germany|Research Site, Köln, Germany|Research Site, Leipzig, Germany|Research Site, N. Faliro, Greece|Research Site, Patras, Greece|Research Site, Thessaloniki, Greece|Research Site, Hong Kong, Hong Kong|Research Site, Ahmedabad, India|Research Site, Vellore, India|Research Site, Beer-Sheeva, Israel|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Kfar Saba, Israel|Research Site, Petach-Tikva, Israel|Research Site, Safed, Israel|Research Site, Tel-Hashomer, Israel|Research Site, Zerifin, Israel|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Orbassano, Italy|Research Site, Roma, Italy|Research Site, S.Andrea Delle Fratte, Italy|Research Site, Aguascalientes, Mexico|Research Site, Mexico, Mexico|Research Site, Puebla, Mexico|Research Site, Cebu City, Philippines|Research Site, Manila, Philippines|Research Site, Pasay City, Philippines|Research Site, Quezon City, Philippines|Research Site, Lisboa, Portugal|Research Site, Santa Maria da Feira, Portugal|Research Site, Setúbal, Portugal|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Johannesburg, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Pretoria, South Africa|Research Site, A Coruña, Spain|Research Site, Lugo, Spain|Research Site, Majadahonda, Spain|Research Site, Mataró(Barcelona), Spain|Research Site, Málaga, Spain|Research Site, Orense, Spain|Research Site, Santiago De Compostela(A Coru, Spain|Research Site, Vigo(Pontevedra), Spain|Research Site, Lund, Sweden|Research Site, Sundsvall, Sweden|Research Site, Umeå, Sweden|Research Site, Uppsala, Sweden|Research Site, Västerås, Sweden|Research Site, Taipei, Taiwan|Research Site, Birmingham, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Wolverhampton, United Kingdom|Research Site, Caracas, Venezuela|Research Site, Valencia, Venezuela",https://ClinicalTrials.gov/show/NCT00418886
142,Southwest Oncology Group|National Cancer Institute (NCI)|Roche-Genentech,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,"Active, not recruiting",Has Results,Colorectal Cancer,Biological: cetuximab|Drug: irinotecan hydrochloride|Drug: vemurafenib,Other|NIH|Industry,Interventional,"Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Regional Hospital, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Fairbanks Memorial Hospital, Fairbanks, Alaska, United States|University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona, United States|University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States|The University of Arizona Medical Center-University Campus, Tucson, Arizona, United States|Mercy Cancer Center-Hot Springs, Hot Springs, Arkansas, United States|Fowler Family Center for Cancer Care, Jonesboro, Arkansas, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Veteran's Administration Medical Center, Little Rock, Arkansas, United States|Kaiser Permanente-Anaheim, Anaheim, California, United States|Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States|Sutter Auburn Faith Hospital, Auburn, California, United States|Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States|Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States|Kaiser Permanente-Bellflower, Bellflower, California, United States|Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Mills - Peninsula Hospitals, Burlingame, California, United States|Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, United States|Eden Hospital Medical Center, Castro Valley, California, United States|Sutter Davis Hospital, Davis, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|Epic Care-Dublin, Dublin, California, United States|Bay Area Breast Surgeons Inc, Emeryville, California, United States|Epic Care Partners in Cancer Care, Emeryville, California, United States|Kaiser Permanente Hospital, Fontana, California, United States|Kaiser Permanente-Fremont, Fremont, California, United States|Kaiser Permanente, Fresno, California, United States|Marin Cancer Care Inc, Greenbrae, California, United States|Marin General Hospital, Greenbrae, California, United States|Kaiser Permanente - Harbor City, Harbor City, California, United States|Kaiser Permanente-Irvine, Irvine, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Kaiser Permanente-Cadillac, Los Angeles, California, United States|Contra Costa Regional Medical Center, Martinez, California, United States|Fremont - Rideout Cancer Center, Marysville, California, United States|Memorial Medical Center, Modesto, California, United States|Kaiser Permanente-Modesto, Modesto, California, United States|Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States|Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States|Sutter Cancer Research Consortium, Novato, California, United States|Alta Bates Summit Medical Center - Summit Campus, Oakland, California, United States|Bay Area Tumor Institute, Oakland, California, United States|Hematology and Oncology Associates-Oakland, Oakland, California, United States|Kaiser Permanente Oakland-Broadway, Oakland, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States|Palo Alto Medical Foundation Health Care, Palo Alto, California, United States|Kaiser Permanente - Panorama City, Panorama City, California, United States|Keck Medical Center of USC Pasadena, Pasadena, California, United States|PCR Oncology, Pismo Beach, California, United States|Kaiser Permanente-Rancho Cordova Cancer Center, Rancho Cordova, California, United States|Kaiser Permanente-Redwood City, Redwood City, California, United States|Kaiser Permanente-Richmond, Richmond, California, United States|Kaiser Permanente-Riverside, Riverside, California, United States|Rohnert Park Cancer Center, Rohnert Park, California, United States|Kaiser Permanente-Roseville, Roseville, California, United States|Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California, United States|Sutter Roseville Medical Center, Roseville, California, United States|The Permanente Medical Group-Roseville Radiation Oncology, Roseville, California, United States|Sutter General Hospital, Sacramento, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Kaiser Permanente-South Sacramento, Sacramento, California, United States|South Sacramento Cancer Center, Sacramento, California, United States|Kaiser Permanente - Sacramento, Sacramento, California, United States|Salinas Valley Memorial, Salinas, California, United States|Kaiser Permanente-San Diego Mission, San Diego, California, United States|Kaiser Permanente-San Diego Zion, San Diego, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|Kaiser Permanente-San Francisco, San Francisco, California, United States|UCSF Medical Center-Mount Zion, San Francisco, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, United States|Kaiser Permanente San Leandro, San Leandro, California, United States|Kaiser Permanente-San Marcos, San Marcos, California, United States|Kaiser Permanente-San Rafael, San Rafael, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|Palo Alto Medical Foundation-Santa Cruz, Santa Cruz, California, United States|Kaiser Permanente-Santa Rosa, Santa Rosa, California, United States|Sutter Pacific Medical Foundation, Santa Rosa, California, United States|Kaiser Permanente Cancer Treatment Center, South San Francisco, California, United States|Kaiser Permanente-South San Francisco, South San Francisco, California, United States|Kaiser Permanente-Stockton, Stockton, California, United States|Palo Alto Medical Foundation-Sunnyvale, Sunnyvale, California, United States|Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee, California, United States|Sutter Cancer Centers Radiation Oncology Services-Vacaville, Vacaville, California, United States|Kaiser Permanente Medical Center-Vacaville, Vacaville, California, United States|Kaiser Permanente-Vallejo, Vallejo, California, United States|Sutter Solano Medical Center/Cancer Center, Vallejo, California, United States|Kaiser Permanente-Walnut Creek, Walnut Creek, California, United States|Kaiser Permanente, Woodland Hills, California, United States|Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States|The Medical Center of Aurora, Aurora, Colorado, United States|University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Rocky Mountain Cancer Centers-Boulder, Boulder, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|Memorial Hospital Colorado Springs, Colorado Springs, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Midtown, Denver, Colorado, United States|SCL Health Saint Joseph Hospital, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Rose, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Colorado Cancer Research Program NCORP, Denver, Colorado, United States|Mercy Medical Center, Durango, Colorado, United States|Southwest Oncology PC, Durango, Colorado, United States|Comprehensive Cancer Care and Research Institute of Colorado LLC, Englewood, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Mountain Blue Cancer Care Center, Golden, Colorado, United States|National Jewish Health-Western Hematology Oncology, Golden, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Rocky Mountain Cancer Centers-Greenwood Village, Greenwood Village, Colorado, United States|Rocky Mountain Cancer Centers-Lakewood, Lakewood, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers-Littleton, Littleton, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Rocky Mountain Cancer Centers-Sky Ridge, Lone Tree, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Rocky Mountain Cancer Centers-Parker, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers - Pueblo, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers-Thornton, Thornton, Colorado, United States|SCL Health Lutheran Medical Center, Wheat Ridge, Colorado, United States|Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut, United States|Smilow Cancer Hospital Care Center-Fairfield, Fairfield, Connecticut, United States|Greenwich Hospital, Greenwich, Connecticut, United States|Medical Oncology and Hematology Group PC-Guilford, Guilford, Connecticut, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|Middlesex Hospital, Middletown, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Yale-New Haven Hospital North Haven Medical Center, North Haven, Connecticut, United States|Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut, United States|Smilow Cancer Hospital-Orange Care Center, Orange, Connecticut, United States|Charlotte Hungerford Hospital Center for Cancer Care, Torrington, Connecticut, United States|Smilow Cancer Hospital Care Center-Trumbull, Trumbull, Connecticut, United States|Smilow Cancer Hospital-Waterbury Care Center, Waterbury, Connecticut, United States|Beebe Medical Center, Lewes, Delaware, United States|Christiana Gynecologic Oncology LLC, Newark, Delaware, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|Regional Hematology and Oncology PA, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Beebe Health Campus, Rehoboth Beach, Delaware, United States|Nanticoke Memorial Hospital, Seaford, Delaware, United States|Christiana Care Health System-Wilmington Hospital, Wilmington, Delaware, United States|Florida Hospital Cancer Institute Altamonte, Altamonte Springs, Florida, United States|University of Florida, Gainesville, Florida, United States|Florida Hospital Kissimmee, Kissimmee, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Florida Hospital Orlando, Orlando, Florida, United States|Florida Urology Associates-Orlando, Orlando, Florida, United States|UF Cancer Center at Orlando Health, Orlando, Florida, United States|Florida Hospital East Orlando, Orlando, Florida, United States|Florida Hospital Cancer Institute Winter Park, Winter Park, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|John B Amos Cancer Center, Columbus, Georgia, United States|Memorial University Medical Center, Savannah, Georgia, United States|Summit Cancer Care-Memorial, Savannah, Georgia, United States|Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States|Low Country Cancer Care Associates PC, Savannah, Georgia, United States|Hawaii Oncology Inc-Pali Momi, 'Aiea, Hawaii, United States|Pali Momi Medical Center, 'Aiea, Hawaii, United States|The Cancer Center of Hawaii-Leeward, 'Ewa Beach, Hawaii, United States|Hawaii Cancer Care Inc-POB II, Honolulu, Hawaii, United States|Queen's Medical Center, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Hawaii Cancer Care Inc-Liliha, Honolulu, Hawaii, United States|Hawaii Oncology Inc-Kuakini, Honolulu, Hawaii, United States|Kuakini Medical Center, Honolulu, Hawaii, United States|The Cancer Center of Hawaii-Liliha, Honolulu, Hawaii, United States|Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Fruitland, Fruitland, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States|Saint Luke's Mountain States Tumor Institute-Twin Falls, Twin Falls, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Saint Joseph Medical Center, Bloomington, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Northwestern University, Chicago, Illinois, United States|John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Center of Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, United States|NorthShore University HealthSystem-Highland Park Hospital, Highland Park, Illinois, United States|Joliet Oncology-Hematology Associates Limited, Joliet, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|Edward Hospital/Cancer Center, Naperville, Illinois, United States|UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Radiation Oncology of Northern Illinois, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center, Pekin, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|OSF Saint Francis Radiation Oncology at Peoria Cancer Center, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Edward Hospital/Cancer Center?Plainfield, Plainfield, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|North Shore Medical Center, Skokie, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Cancer Care Specialists of Illinois-Swansea, Swansea, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|Franciscan Saint Anthony Health-Michigan City, Michigan City, Indiana, United States|Woodland Cancer Care Center, Michigan City, Indiana, United States|Memorial Regional Cancer Center Day Road, Mishawaka, Indiana, United States|Reid Health, Richmond, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|Porter Memorial Hospital, Valparaiso, Indiana, United States|Mary Greeley Medical Center, Ames, Iowa, United States|McFarland Clinic PC-William R Bliss Cancer Center, Ames, Iowa, United States|McFarland Clinic PC-Boone, Boone, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States|Greater Regional Medical Center, Creston, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|McFarland Clinic PC-Trinity Cancer Center, Fort Dodge, Iowa, United States|McFarland Clinic PC-Jefferson, Jefferson, Iowa, United States|McFarland Clinic PC-Marshalltown, Marshalltown, Iowa, United States|Mercy Medical Center - North Iowa, Mason City, Iowa, United States|Story County Medical Center-South Campus, Nevada, Iowa, United States|Siouxland Regional Cancer Center, Sioux City, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Cancer Center of Kansas - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas - El Dorado, El Dorado, Kansas, United States|Newman Regional Health, Emporia, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Saint Catherine Hospital, Garden City, Kansas, United States|Saint Rose Ambulatory and Surgery Center, Great Bend, Kansas, United States|Hays Medical Center, Hays, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|University of Kansas Cancer Center-West, Kansas City, Kansas, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|Cancer Center of Kansas-Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Cancer Center of Kansas-Liberal, Liberal, Kansas, United States|Cancer Center of Kansas - Newton, Newton, Kansas, United States|Olathe Medical Center, Olathe, Kansas, United States|University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States|Cancer Center of Kansas - Parsons, Parsons, Kansas, United States|Via Christi Hospital-Pittsburg, Pittsburg, Kansas, United States|Cancer Center of Kansas - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas - Salina, Salina, Kansas, United States|Salina Regional Health Center, Salina, Kansas, United States|Saint Francis Hospital and Medical Center - Topeka, Topeka, Kansas, United States|Cancer Center of Kansas - Wellington, Wellington, Kansas, United States|Associates In Womens Health, Wichita, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Via Christi Regional Medical Center, Wichita, Kansas, United States|Wichita NCI Community Oncology Research Program, Wichita, Kansas, United States|Cancer Center of Kansas - Winfield, Winfield, Kansas, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States|Oncology Hematology Care Inc-Crestview, Crestview Hills, Kentucky, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, United States|Jewish Hospital Medical Center Northeast, Louisville, Kentucky, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, United States|Christus Saint Frances Cabrini Hospital, Alexandria, Louisiana, United States|LSU Health Baton Rouge-North Clinic, Baton Rouge, Louisiana, United States|Louisiana Hematology Oncology Associates LLC, Baton Rouge, Louisiana, United States|Medical Oncology LLC, Baton Rouge, Louisiana, United States|Mary Bird Cancer Center/Saint Tammany Parish, Covington, Louisiana, United States|Mary Bird Perkins Cancer Center/Terrebonne General Medical Center, Houma, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Harold Alfond Center for Cancer Care, Augusta, Maine, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Lafayette Family Cancer Center-EMMC, Brewer, Maine, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Union Hospital of Cecil County, Elkton, Maryland, United States|Northwest Hospital Center, Randallstown, Maryland, United States|Peninsula Regional Medical Center, Salisbury, Maryland, United States|Beverly Hospital, Beverly, Massachusetts, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|Addison Gilbert Hospital, Gloucester, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Hickman Cancer Center, Adrian, Michigan, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|McLaren-Bay Region, Bay City, Michigan, United States|Henry Ford Cancer Institute¿Downriver, Brownstown, Michigan, United States|Great Lakes Cancer Institute, Clarkston, Michigan, United States|Henry Ford Macomb Hospital-Clinton Township, Clinton Township, Michigan, United States|Beaumont Hospital-Dearborn, Dearborn, Michigan, United States|Henry Ford Medical Center-Fairlane, Dearborn, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Saint John Hospital and Medical Center, Detroit, Michigan, United States|Green Bay Oncology - Escanaba, Escanaba, Michigan, United States|Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Singh and Arora Hematology Oncology PC, Flint, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|McLaren-Greater Lansing, Lansing, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|McLaren Cancer Institute-Lapeer Region, Lapeer, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Monroe Cancer Center, Monroe, Michigan, United States|Toledo Clinic Cancer Centers-Monroe, Monroe, Michigan, United States|McLaren Cancer Institute-Macomb, Mount Clemens, Michigan, United States|McLaren Cancer Institute-Central Michigan, Mount Pleasant, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Lakeland Community Hospital, Niles, Michigan, United States|Assarian Cancer Center, Novi, Michigan, United States|Henry Ford Medical Center-Columbus, Novi, Michigan, United States|McLaren Cancer Institute-Northern Michigan, Petoskey, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Lake Huron Medical Center, Port Huron, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|Saint Mary's of Michigan, Saginaw, Michigan, United States|Lakeland Hospital, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Providence Hospital-Southfield Cancer Center, Southfield, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan, United States|Sanford Clinic North-Bemidgi, Bemidji, Minnesota, United States|Essentia Health Saint Joseph's Medical Center, Brainerd, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Essentia Health Saint Mary's Medical Center, Duluth, Minnesota, United States|Miller-Dwan Hospital, Duluth, Minnesota, United States|Saint Luke's Hospital of Duluth, Duluth, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Lake Region Healthcare Corporation-Cancer Care, Fergus Falls, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Hattiesburg Clinic - Hematology/Oncology Clinic, Hattiesburg, Mississippi, United States|Forrest General Hospital / Cancer Center, Hattiesburg, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Singing River Hospital, Pascagoula, Mississippi, United States|Central Care Cancer Center-Carrie J Babb Cancer Center, Bolivar, Missouri, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|CoxHealth Cancer Center, Branson, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Saint Luke's Hospital, Chesterfield, Missouri, United States|Barnes-Jewish West County Hospital, Creve Coeur, Missouri, United States|Capital Region Medical Center-Goldschmidt Cancer Center, Jefferson City, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|Mercy Hospital-Joplin, Joplin, Missouri, United States|Truman Medical Center, Kansas City, Missouri, United States|The University of Kansas Cancer Center-South, Kansas City, Missouri, United States|The University of Kansas Cancer Center-North, Kansas City, Missouri, United States|The University of Kansas Cancer Center-Lee's Summit, Lee's Summit, Missouri, United States|Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, United States|Saint John's Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Siteman Cancer Center - Saint Peters, Saint Peters, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|Heartland Hematology and Oncology, Kearney, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Nebraska Hematology and Oncology, Lincoln, Nebraska, United States|Nebraska Cancer Research Center, Lincoln, Nebraska, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Southeast Nebraska Cancer Center, Lincoln, Nebraska, United States|Faith Regional Medical Offices West, Norfolk, Nebraska, United States|Great Plains Regional Medical Center, North Platte, Nebraska, United States|Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Hemotology and Oncology Consultants PC, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Oncology Hematology West, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Oncology Hematology West PC, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Midlands Community Hospital, Papillion, Nebraska, United States|Regional West Medical Center, Scottsbluff, Nebraska, United States|Cancer and Blood Specialists-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada, United States|Las Vegas Cancer Center-Henderson, Henderson, Nevada, United States|21st Century Oncology - Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Southeast Henderson, Henderson, Nevada, United States|Cancer and Blood Specialists-Shadow, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Central, Las Vegas, Nevada, United States|21st Century Oncology, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-San Martin, Las Vegas, Neva",
143,"University of Florida|Taiho Oncology, Inc.",TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003),"Active, not recruiting",Has Results,Squamous Cell Lung Carcinoma,Drug: TAS-102,Other|Industry,Interventional,"UF Health Cancer Center, Gainesville, Florida, United States",https://ClinicalTrials.gov/show/NCT02920476
144,Memorial Sloan Kettering Cancer Center|Merck Sharp & Dohme Corp.|Cedars-Sinai Medical Center,Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients,"Active, not recruiting",Has Results,Breast Cancer|Metastatic Triple Negative,Drug: Pembrolizumab|Radiation: Radiotherapy,Other|Industry,Interventional,"Cedars-Sinai Medical Center, Los Angeles, California, United States|Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States",https://ClinicalTrials.gov/show/NCT02730130
145,Celgene,"Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer","Active, not recruiting",Has Results,"Carcinoma, Non-Small-Cell Lung",Drug: nab-paclitaxel IV|Drug: CC-486|Drug: Duravalumab,Industry,Interventional,"University of California San Francisco, San Francisco, California, United States|Hospital of Central Connecticut Gynecologic Oncology, New Britain, Connecticut, United States|University Cancer and Blood Center, LLC, Athens, Georgia, United States|Washington University, Saint Louis, Missouri, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Weill Cornell Medical College - New York - Presbyterian Hospital, New York, New York, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|Associates in Oncology and Hematology, Chattanooga, Tennessee, United States|Millennium Oncology, Houston, Texas, United States|Ottawa Hospital Riverside Campus, Ottawa, Ontario, Canada|Royal Victoria Hospital McGill Department of Oncology(RVH), Montreal, Quebec, Canada|Hopital Calmette, Lille, France|Centre Rene Gauducheau Centre de Lutte Contre Le Cancer Nantes Atlantique, Saint Herblain, France|Hopital Paul Brousse, Villejuif, France|Universitatsklinikum Essen, Essen, Germany|LungenClinic Grosshansdorf GmbH, Grosshansdorf, Germany|Klinik Loewenstein gGmbH, Loewenstein, Germany|Azienda Ospedaliero Universitaria Di Bologna - Policlinico S.Orsola Malpighi, Bologna, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Azienda Ospedaliero-Universitaria Santa Maria della Misericordia die Udine, Udine, Italy|Hospital Universitario Germans Trias i Pujol, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital General Carlos Haya, Malaga, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Liverpool Heart and Chest Hospital, Bebington, Wirral, United Kingdom|Heart of England NHS Foundation Trust, Birmingham, United Kingdom|Sarah Cannon Research Institute UK, London, United Kingdom|Charing Cross Hospital, London, United Kingdom|University Hospital of South Manchester NHS Foundation Trust -Wythenshawe Hospital - North West Lung, Manchester, United Kingdom|Newcastle Hospital, Newcastle Upon Tyne, United Kingdom|Churchhill Hospital, Oxford, United Kingdom",https://ClinicalTrials.gov/show/NCT02250326
146,Celgene,Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer,"Active, not recruiting",Has Results,"Carcinoma, Non-Small-Cell Lung",Drug: CC-486|Drug: Pembrolizumab|Drug: Placebo,Industry,Interventional,"Palo Verde Hematology Oncology, Glendale, Arizona, United States|UCLA Hematology Oncology, Los Angeles, California, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|University Cancer and Blood Center, LLC, Athens, Georgia, United States|Research Medical Center, Kansas City, Missouri, United States|Washington Univ School of Medicine, Saint Louis, Missouri, United States|North Shore Hematology Oncology Associates, East Setauket, New York, United States|Beth Israel Comprehensive Cancer Center, New York, New York, United States|NYU Langone Medical Center, New York, New York, United States|Vanderbilt Univ Medical Center, Nashville, Tennessee, United States|Centre Leon Berard, Lyon, France|CHU Amiens Picardie- Hôpital Nord, Marseille, France|Centre Hospitalier Universitaire de Toulouse, Toulouse, France|Institut Gustave Roussy IGR Centre de Lutte Contre le Canc, Villejuif, France|Evangelische Lungenklinik Berlin, Berlin, Germany|Klinikum Esslingen GmbH, Esslingen Am Neckar, Germany|Universitatsklinikum Koln, Koeln, Germany|Klinik Lowenstein gGmbH, Löwenstein, Germany|IASO General, Athens, Greece|Centro Di Riferimento Oncologico, Aviano, Italy|Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele, Catania, Italy|Ospedale San Raffaele S.r.l., Milano, Italy|Istituto Nazionale Dei Tumori, Milano, Italy|Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale, Napoli, Campania, Italy|A.O.U. Maggiore della Carità, Novara, Italy|Policlinico Universitario Campus Biomedico Di Roma, Roma, Italy|Hospital De Cruces, Baracaldo, Spain|Hospital Universitario Vall D hebron, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Fundacion Jimenez Daaz, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital General Universitario de Valencia, Valencia, Spain",https://ClinicalTrials.gov/show/NCT02546986
147,"Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Daiichi Sankyo, Inc.",Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer,"Active, not recruiting",Has Results,Anaplastic Thyroid Cancer|Recurrent Thyroid Cancer,Drug: efatutazone|Drug: paclitaxel,Other|NIH|Industry,Interventional,"Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Regional Hospital, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Mayo Clinic Hospital, Phoenix, Arizona, United States|Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Beebe Medical Center, Lewes, Delaware, United States|Christiana Gynecologic Oncology LLC, Newark, Delaware, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|Regional Hematology and Oncology PA, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Beebe Health Campus, Rehoboth Beach, Delaware, United States|Nanticoke Memorial Hospital, Seaford, Delaware, United States|Christiana Care Health System-Wilmington Hospital, Wilmington, Delaware, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Hawaii Oncology Inc-Pali Momi, 'Aiea, Hawaii, United States|Pali Momi Medical Center, 'Aiea, Hawaii, United States|The Cancer Center of Hawaii-Pali Momi, 'Aiea, Hawaii, United States|Hawaii Cancer Care Inc-POB II, Honolulu, Hawaii, United States|Queen's Medical Center, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Hawaii Cancer Care Inc-Liliha, Honolulu, Hawaii, United States|Hawaii Oncology Inc-Kuakini, Honolulu, Hawaii, United States|Kuakini Medical Center, Honolulu, Hawaii, United States|The Cancer Center of Hawaii-Liliha, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Walter Knox Memorial Hospital, Emmett, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Fruitland, Fruitland, Idaho, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Mountain States Tumor Institute-Twin Falls, Twin Falls, Idaho, United States|Northwestern University, Chicago, Illinois, United States|Cancer Center of Kansas - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Central Care Cancer Center - Garden City, Garden City, Kansas, United States|Central Care Cancer Center - Great Bend, Great Bend, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Cancer Center of Kansas-Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Kansas Institute of Medicine Cancer and Blood Center, Lenexa, Kansas, United States|Minimally Invasive Surgery Hospital, Lenexa, Kansas, United States|Cancer Center of Kansas-Liberal, Liberal, Kansas, United States|Cancer Center of Kansas-Manhattan, Manhattan, Kansas, United States|Cancer Center of Kansas - McPherson, McPherson, Kansas, United States|Cancer Center of Kansas - Newton, Newton, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Cancer Center of Kansas - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas - Salina, Salina, Kansas, United States|Cancer Center of Kansas - Wellington, Wellington, Kansas, United States|Associates In Womens Health, Wichita, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Via Christi Regional Medical Center, Wichita, Kansas, United States|Cancer Center of Kansas - Winfield, Winfield, Kansas, United States|Mercy Medical Center, Springfield, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|IHA Hematology Oncology Consultants-Brighton, Brighton, Michigan, United States|Saint Joseph Mercy Brighton, Brighton, Michigan, United States|IHA Hematology Oncology Consultants-Canton, Canton, Michigan, United States|Saint Joseph Mercy Canton, Canton, Michigan, United States|Caro Cancer Center, Caro, Michigan, United States|IHA Hematology Oncology Consultants-Chelsea, Chelsea, Michigan, United States|Saint Joseph Mercy Chelsea, Chelsea, Michigan, United States|Hematology Oncology Consultants-Clarkston, Clarkston, Michigan, United States|Newland Medical Associates-Clarkston, Clarkston, Michigan, United States|Beaumont Hospital-Dearborn, Dearborn, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Great Lakes Cancer Management Specialists-Doctors Park, East China Township, Michigan, United States|Genesee Cancer and Blood Disease Treatment Center, Flint, Michigan, United States|Genesee Hematology Oncology PC, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center, Grosse Pointe Woods, Michigan, United States|Lymphoma Clinic of Michigan, Grosse Pointe Woods, Michigan, United States|Michigan Breast Specialists-Grosse Pointe Woods, Grosse Pointe Woods, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Hope Cancer Clinic, Livonia, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Medical Campus, Macomb, Michigan, United States|Michigan Breast Specialists-Macomb Township, Macomb, Michigan, United States|Saint Mary's Oncology/Hematology Associates of Marlette, Marlette, Michigan, United States|21st Century Oncology-Pontiac, Pontiac, Michigan, United States|Hope Cancer Center, Pontiac, Michigan, United States|Newland Medical Associates-Pontiac, Pontiac, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Lake Huron Medical Center, Port Huron, Michigan, United States|Great Lakes Cancer Management Specialists-Rochester Hills, Rochester Hills, Michigan, United States|Saint Mary's of Michigan, Saginaw, Michigan, United States|Oncology Hematology Associates of Saginaw Valley PC, Saginaw, Michigan, United States|Bhadresh Nayak MD PC-Sterling Heights, Sterling Heights, Michigan, United States|Saint Joseph Health System-Tawas City, Tawas City, Michigan, United States|Advanced Breast Care Center PLLC, Warren, Michigan, United States|Bhadresh Nayak MD PC-Warren, Warren, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Professional Building, Warren, Michigan, United States|Macomb Hematology Oncology PC, Warren, Michigan, United States|Michigan Breast Specialists-Warren, Warren, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Saint Mary's Oncology/Hematology Associates of West Branch, West Branch, Michigan, United States|Huron Gastroenterology PC, Ypsilanti, Michigan, United States|IHA Hematology Oncology Consultants-Ann Arbor, Ypsilanti, Michigan, United States|Sanford Joe Lueken Cancer Center, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Fairview Maple Grove Medical Center, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, United States|Central Care Cancer Center - Bolivar, Bolivar, Missouri, United States|Centerpoint Medical Center LLC, Independence, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Heartland Hematology and Oncology Associates Incorporated, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Liberty Radiation Oncology Center, Liberty, Missouri, United States|Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Roger Maris Cancer Center, Fargo, North Dakota, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|University of Cincinnati/Barrett Cancer Center, Cincinnati, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|University Pointe, West Chester, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States|Saint Alphonsus Medical Center-Baker City, Baker City, Oregon, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Oncology and Hematology Care Southeast, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Saint Alphonsus Medical Center-Ontario, Ontario, Oregon, United States|Providence Willamette Falls Medical Center, Oregon City, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Saint Charles Health System-Redmond, Redmond, Oregon, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Pocono Medical Center, East Stroudsburg, Pennsylvania, United States|Geisinger Medical Center-Cancer Center Hazleton, Hazleton, Pennsylvania, United States|Lehigh Valley Hospital-Hazleton, Hazleton, Pennsylvania, United States|Geisinger Medical Oncology-Lewisburg, Lewisburg, Pennsylvania, United States|Lewistown Hospital, Lewistown, Pennsylvania, United States|Geisinger Cancer Services-Pottsville, Pottsville, Pennsylvania, United States|Community Medical Center, Scranton, Pennsylvania, United States|Geisinger Medical Oncology-Selinsgrove, Selinsgrove, Pennsylvania, United States|Geisinger Medical Group, State College, Pennsylvania, United States|Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States|Greenville Health System Cancer Institute-Easley, Easley, South Carolina, United States|Greenville Health System Cancer Institute-Andrews, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Butternut, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Faris, Greenville, South Carolina, United States|Greenville Memorial Hospital, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Eastside, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Greer, Greer, South Carolina, United States|Greenville Health System Cancer Institute-Seneca, Seneca, South Carolina, United States|Greenville Health System Cancer Institute-Spartanburg, Spartanburg, South Carolina, United States|Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|Cancer Care Center at Island Hospital, Anacortes, Washington, United States|Swedish Cancer Institute-Eastside Oncology Hematology, Bellevue, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Medical Center-Edmonds, Edmonds, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Jefferson Healthcare, Port Townsend, Washington, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, United States|Minor and James Medical PLLC, Seattle, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Kaiser Permanente Washington, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Cherry Hill, Seattle, Washington, United States|PeaceHealth United General Medical Center, Sedro-Woolley, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|Rockwood Clinic Cancer Treatment Center-Valley, Spokane Valley, Washington, United States|Rockwood Cancer Treatment Center-DHEC-Downtown, Spokane, Washington, United States|Evergreen Hematology and Oncology PS, Spokane, Washington, United States|Rockwood North Cancer Treatment Center, Spokane, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital, Yakima, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States",https://ClinicalTrials.gov/show/NCT02152137
148,Baylor Breast Care Center|Translational Breast Cancer Research Consortium|GlaxoSmithKline,Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy,"Active, not recruiting",Has Results,Breast Cancer,Drug: Lapatinib|Drug: Letrozole|Drug: Trastuzumab,Other|Industry,Interventional,"University of Alabama - Birmingham, Birmingham, Alabama, United States|University of Chicago, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Johns Hopkins, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Duke University, Durham, North Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor College of Medicine Lester and Sue Smith Breast Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT00999804
149,"Weill Medical College of Cornell University|Onyx Therapeutics, Inc.","Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma","Active, not recruiting",Has Results,Multiple Myeloma,Drug: carfilzomib|Drug: Dexamethasone|Drug: Clarithromycin|Drug: Lenalidomide,Other|Industry,Interventional,"Weill Cornell Medical College, New York, New York, United States",https://ClinicalTrials.gov/show/NCT01559935
150,AstraZeneca,AZD9291 First Time In Patients Ascending Dose Study,"Active, not recruiting",Has Results,Advanced Non Small Cell Lung Cancer|Advanced (Inoperable) Non Small Cell Lung Cancer,Drug: AZD9291,Industry,Interventional,"Research Site, Aurora, Colorado, United States|Research Site, Atlanta, Georgia, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Heidelberg, Australia|Research Site, Kogarah, Australia|Research Site, Perth, Australia|Research Site, Pierre Benite CEDEX, France|Research Site, Saint Herblain Cedex, France|Research Site, Villejuif, France|Research Site, Essen, Germany|Research Site, Köln, Germany|Research Site, Würzburg, Germany|Research Site, Genova, Italy|Research Site, Orbassano, Italy|Research Site, Roma, Italy|Research Site, Chiba-shi, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Fukuoka, Japan|Research Site, Habikino-shi, Japan|Research Site, Hirakata-shi, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Kanazawa, Japan|Research Site, Kashiwa, Japan|Research Site, Kobe-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Okayama-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Sunto-gun, Japan|Research Site, Takatsuki-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Sevilla, Spain|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Manchester, United Kingdom|Research Site, Newcastle upon Tyne, United Kingdom",https://ClinicalTrials.gov/show/NCT01802632
151,Weill Medical College of Cornell University|Celgene,"Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma","Active, not recruiting",Has Results,Multiple Myeloma,Drug: thalomid|Drug: lenalidomide|Drug: clarithromycin|Drug: dexamethasone,Other|Industry,Interventional,"Weill Medical College of Cornell University, New York, New York, United States",https://ClinicalTrials.gov/show/NCT00538733
152,University of Michigan Rogel Cancer Center|GlaxoSmithKline,Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma,"Active, not recruiting",Has Results,Multiple Myeloma,Drug: Iodine I 131 Tositumomab,Other|Industry,Interventional,"University of Michigan, Ann Arbor, Michigan, United States",https://ClinicalTrials.gov/show/NCT00135200
153,"Tesaro, Inc.|Merck Sharp & Dohme Corp.",Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer,"Active, not recruiting",Has Results,Triple Negative Breast Cancer|Ovarian Cancer|Breast Cancer|Metastatic Breast Cancer|Advanced Breast Cancer|Stage IV Breast Cancer|Fallopian Tube Cancer|Peritoneal Cancer,Drug: niraparib|Biological: pembrolizumab,Industry,Interventional,"Birmingham, Alabama, United States|Scottsdale, Arizona, United States|Scottsdale, Arizona, United States|Los Angeles, California, United States|San Francisco, California, United States|Stanford, California, United States|Washington, District of Columbia, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Covington, Louisiana, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Burlington, Massachusetts, United States|Detroit, Michigan, United States|Rochester, Minnesota, United States|Morristown, New Jersey, United States|Lake Success, New York, United States|New York, New York, United States|Chapel Hill, North Carolina, United States|Charlotte, North Carolina, United States|Cleveland, Ohio, United States|Oklahoma City, Oklahoma, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|San Antonio, Texas, United States|Charlottesville, Virginia, United States|Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT02657889
154,"Eli Lilly and Company|Quintiles, Inc.|Parexel|PPD|Medidata Solutions|Laboratory Corporation of America|University of Colorado, Denver|Thermo Fisher Scientific|Pacific Biomarkers|Intertek|Sysmex Inostics GmbH",First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin,"Active, not recruiting",Has Results,Non Small Cell Lung Cancer,Drug: Pemetrexed|Drug: Cisplatin|Biological: Necitumumab,Industry|Other,Interventional,"ImClone Investigational Site, Nyack, New York, United States|ImClone Investigational Site, Kogarah, New South Wales, Australia|ImClone Investigational Site, Hobart, Tasmania, Australia|ImClone Investigational Site, East Bentleigh, Victoria, Australia|ImClone Investigational Site, Rankweil, Austria|ImClone Investigational Site, Wien, Austria|ImClone Investigational Site, Wien, Austria|ImClone Investigational Site, Duffel, Belgium|ImClone Investigational Site, Liège, Belgium|ImClone Investigational Site, Namur, Belgium|ImClone Investigational Site, Barretos - SP, Brazil|ImClone Investigational Site, Brasilia, Distrito Federal, Brazil|ImClone Investigational Site, Goiania - GO, Brazil|ImClone Investigational Site, Ijui, Brazil|ImClone Investigational Site, Itajai, Brazil|ImClone Investigational Site, Lajeado, Brazil|ImClone Investigational Site, Porto Alegre/RS, Brazil|ImClone Investigational Site, Ribeirão Preto - SP, Brazil|ImClone Investigational Site, Salvador, Brazil|ImClone Investigational Site, Santo Andre - SP, Brazil|ImClone Investigational Site, São Paulo - SP, Brazil|ImClone Investigational Site, Montreal, Quebec, Canada|ImClone Investigational Site, Pula, Croatia|ImClone Investigational Site, Caen, France|ImClone Investigational Site, Paris, France|ImClone Investigational Site, Berlin, Germany|ImClone Investigational Site, Essen, Germany|ImClone Investigational Site, Frankfurt, Germany|ImClone Investigational Site, Gauting, Germany|ImClone Investigational Site, Großhansdorf, Germany|ImClone Investigational Site, Halle, Germany|ImClone Investigational Site, Hamburg, Germany|ImClone Investigational Site, Heidelberg, Germany|ImClone Investigational Site, Hemer, Germany|ImClone Investigational Site, Hofheim, Germany|ImClone Investigational Site, Karlsruhe, Germany|ImClone Investigational Site, Lostau, Germany|ImClone Investigational Site, Löwenstein, Germany|ImClone Investigational Site, Mainz, Germany|ImClone Investigational Site, München, Germany|ImClone Investigational Site, Münster, Germany|ImClone Investigational Site, Regensburg, Germany|ImClone Investigational Site, Ulm, Germany|ImClone Investigational Site, Athens, Greece|ImClone Investigational Site, Heraklion, Crete, Greece|ImClone Investigational Site, Patras, Greece|ImClone Investigational Site, Budapest, Hungary|ImClone Investigational Site, Budapest, Hungary|ImClone Investigational Site, Deszk, Hungary|ImClone Investigational Site, Mosonmagyaróvár, Hungary|ImClone Investigational Site, Szombathely, Hungary|ImClone Investigational Site, Székesfehérvár, Hungary|ImClone Investigational Site, Törökbálint, Hungary|ImClone Investigational Site, Lido di Camaiore, Lucca, Italy|ImClone Investigational Site, Aviano, Pordenone, Italy|ImClone Investigational Site, Frosinone, Italy|ImClone Investigational Site, Genova, Italy|ImClone Investigational Site, Milano, Italy|ImClone Investigational Site, Parma, Italy|ImClone Investigational Site, Perugia, Italy|ImClone Investigational Site, Olsztyn, Poland|ImClone Investigational Site, Otwock, Poland|ImClone Investigational Site, Poznan, Poland|ImClone Investigational Site, Radom, Poland|ImClone Investigational Site, Szczecin, Poland|ImClone Investigational Site, Wroclaw, Poland|ImClone Investigational Site, Coimbra, Portugal|ImClone Investigational Site, Lisboa, Portugal|ImClone Investigational Site, Brasov, Romania|ImClone Investigational Site, Bucharest, Romania|ImClone Investigational Site, Bucharest, Romania|ImClone Investigational Site, Cluj-Napoca, Romania|ImClone Investigational Site, Craiova, Dolj, Romania|ImClone Investigational Site, Iasi, Romania|ImClone Investigational Site, Sibiu, Romania|ImClone Investigational Site, Ivanovo, Russian Federation|ImClone Investigational Site, Kirov, Russian Federation|ImClone Investigational Site, Omsk, Russian Federation|ImClone Investigational Site, St. Petersburg, Russian Federation|ImClone Investigational Site, St. Petersburg, Russian Federation|ImClone Investigational Site, St. Petersburg, Russian Federation|ImClone Investigational Site, Ufa, Russian Federation|ImClone Investigational Site, Yaroslavi, Russian Federation|ImClone Investigational Site, Bratislava, Slovakia|ImClone Investigational Site, Nitra, Slovakia|ImClone Investigational Site, Bloemfontein, Free State, South Africa|ImClone Investigational Site, Pretoria, Gauteng, South Africa|Imclone Investigational Site, Sevilla, Andalucia, Spain|ImClone Investigational Site, Barcelona, Cataluña, Spain|ImClone Investigational Site, Barcelona, Cataluña, Spain|ImClone Investigational Site, Terrassa, Cataluña, Spain|ImClone Investigational Site, Madrid, Communidad De Madrid, Spain|ImClone Investigational Site, Madrid, Communidad De Madrid, Spain|ImClone Investigational Site, Majadahonda, Communidad De Madrid, Spain|ImClone Investigational Site, L'Hospitalet de Llobregat, Spain|ImClone Investigational Site, Aberdeen, United Kingdom|ImClone Investigational Site, Bournemouth, United Kingdom|ImClone Investigational Site, Edinburgh, United Kingdom|ImClone Investigational Site, Guildford, United Kingdom|ImClone Investigational Site, Leeds, United Kingdom|ImClone Investigational Site, Preston, United Kingdom",https://ClinicalTrials.gov/show/NCT00982111
155,Incyte Corporation|Merck Sharp & Dohme Corp.,"Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers","Active, not recruiting",Has Results,Microsatellite-instability (MSI) High Colorectal Cancer (CRC)|Endometrial Cancer|Head and Neck Cancer|Hepatocellular Carcinoma (HCC)|Gastric Cancer|Lung Cancer|Lymphoma|Renal Cell Carcinoma (RCC)|Ovarian Cancer|Solid Tumors|UC (Urothelial Cancer)|Melanoma|Bladder Cancer|Triple Negative Breast Cancer (TNBC),Drug: MK-3475|Drug: INCB024360,Industry,Interventional,"UC San Diego Moores Cancer Center, La Jolla, California, United States|The Angeles Clinic and Research Institute, Los Angeles, California, United States|US Davis Cancer Center, Sacramento, California, United States|University Of Colorado Cancer Center, Aurora, Colorado, United States|University of Connecticut Health Center Carole And Ray Neag Comprehensive Cancer Center, Farmington, Connecticut, United States|Miami Cancer Institute at Baptist Health, Inc, Miami, Florida, United States|Georgia Cancer Specialists affiliated with Northside Hospital Cancer Institute, Atlanta, Georgia, United States|The University of Chicago Medicine, Chicago, Illinois, United States|St. Francis Cancer Center, Topeka, Kansas, United States|Greater Baltimore Cancer Center, Baltimore, Maryland, United States|St. Agnes Hospital Cancer Institute, Baltimore, Maryland, United States|The Center for Cancer and Blood Disorders (RCCA MD LLC- Maryland Division), Bethesda, Maryland, United States|University of Michigan Hospital and Health Systems, Ann Arbor, Michigan, United States|Health Partners Institute, Saint Louis Park, Minnesota, United States|Hackensack University Medical Center - John Theurer Cancer Center, Hackensack, New Jersey, United States|The Christ Hospital Hematology Oncology, Lindner Research Center, Cincinnati, Ohio, United States|University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Greenville Health System Cancer Institute, Greenville, South Carolina, United States|West Cancer Center, Germantown, Tennessee, United States|Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee, United States|University Of Texas Southwestern Medical Center At Dallas, Dallas, Texas, United States|Virginia Cancer Specialists, Arlington, Virginia, United States",https://ClinicalTrials.gov/show/NCT02178722
156,"National Cancer Institute (NCI)|Celgene|Onyx Therapeutics, Inc.|National Institutes of Health Clinical Center (CC)","Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients","Active, not recruiting",Has Results,Multiple Myeloma,Drug: Carfilzomib|Drug: Lenalidomide|Drug: Dexamethasone,NIH|Industry,Interventional,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT01402284
157,"Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Astellas Pharma US, Inc.",Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers,"Active, not recruiting",Has Results,Salivary Cancer,Drug: enzalutamide,Other|NIH|Industry,Interventional,"Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Kaiser Permanente-Anaheim, Anaheim, California, United States|Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States|Kaiser Permanente-Bellflower, Bellflower, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Kaiser Permanente-Fontana, Fontana, California, United States|Kaiser Permanente-Irvine, Irvine, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente-Cadillac, Los Angeles, California, United States|Kaiser Permanente-Ontario, Ontario, California, United States|Kaiser Permanente - Panorama City, Panorama City, California, United States|Kaiser Permanente-Riverside, Riverside, California, United States|Kaiser Permanente-San Diego Mission, San Diego, California, United States|Kaiser Permanente-San Diego Zion, San Diego, California, United States|Kaiser Permanente-San Marcos, San Marcos, California, United States|Kaiser Permanente-Woodland Hills, Woodland Hills, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Smilow Cancer Hospital Care Center-Fairfield, Fairfield, Connecticut, United States|Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Smilow Cancer Hospital Care Center-Trumbull, Trumbull, Connecticut, United States|Beebe Medical Center, Lewes, Delaware, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|Regional Hematology and Oncology PA, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Beebe Health Campus, Rehoboth Beach, Delaware, United States|Nanticoke Memorial Hospital, Seaford, Delaware, United States|Christiana Care Health System-Wilmington Hospital, Wilmington, Delaware, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Fruitland, Fruitland, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Mountain States Tumor Institute-Twin Falls, Twin Falls, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Saint Joseph Medical Center, Bloomington, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|SIH Cancer Institute, Carterville, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Radiation Oncology of Northern Illinois, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|OSF Saint Francis Radiation Oncology at Peoria Cancer Center, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Cancer Care Specialists of Illinois-Swansea, Swansea, Illinois, United States|Southwest Illinois Health Services LLP, Swansea, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|Deaconess Clinic Downtown, Evansville, Indiana, United States|Franciscan Saint Anthony Health-Michigan City, Michigan City, Indiana, United States|Woodland Cancer Care Center, Michigan City, Indiana, United States|Chancellor Center for Oncology, Newburgh, Indiana, United States|Reid Health, Richmond, Indiana, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Broadlawns Medical Center, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Methodist West Hospital, West Des Moines, Iowa, United States|Oncology Hematology Care Inc-Crestview, Crestview Hills, Kentucky, United States|LSU Health Baton Rouge-North Clinic, Baton Rouge, Louisiana, United States|Louisiana Hematology Oncology Associates LLC, Baton Rouge, Louisiana, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Our Lady of the Lake Physicians Group - Medical Oncology, Baton Rouge, Louisiana, United States|Northshore Oncology Associates-Covington, Covington, Louisiana, United States|Oncology Center of The South Incorporated, Houma, Louisiana, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Henry Ford Cancer Institute?Downriver, Brownstown, Michigan, United States|Henry Ford Macomb Hospital-Clinton Township, Clinton Township, Michigan, United States|Henry Ford Medical Center-Fairlane, Dearborn, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Henry Ford Medical Center-Columbus, Novi, Michigan, United States|Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan, United States|Sanford Joe Lueken Cancer Center, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Fairview Maple Grove Medical Center, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Northwell Health/Center for Advanced Medicine, Lake Success, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Roger Maris Cancer Center, Fargo, North Dakota, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|Indu and Raj Soin Medical Center, Beavercreek, Ohio, United States|Dayton Physicians LLC-Miami Valley South, Centerville, Ohio, United States|Miami Valley Hospital South, Centerville, Ohio, United States|Oncology Hematology Care Inc-Eden Park, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Mercy West, Cincinnati, Ohio, United States|Oncology Hematology Care Inc - Anderson, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Blue Ash, Cincinnati, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Dayton Physicians LLC-Samaritan North, Dayton, Ohio, United States|Miami Valley Hospital North, Dayton, Ohio, United States|Oncology Hematology Care Inc-Healthplex, Fairfield, Ohio, United States|Armes Family Cancer Center, Findlay, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Orion Cancer Care, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Dayton Physicians LLC-Atrium, Franklin, Ohio, United States|Dayton Physicians LLC-Wayne, Greenville, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Greater Dayton Cancer Center, Kettering, Ohio, United States|First Dayton Cancer Care, Kettering, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Dayton Physicians LLC-Signal Point, Middletown, Ohio, United States|Dayton Physicians LLC-Wilson, Sidney, Ohio, United States|Springfield Regional Cancer Center, Springfield, Ohio, United States|Springfield Regional Medical Center, Springfield, Ohio, United States|Dayton Physicians LLC-Upper Valley, Troy, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|Cancer Centers of Southwest Oklahoma Research, Lawton, Oklahoma, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Oncology and Hematology Care Southeast, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Providence Willamette Falls Medical Center, Oregon City, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Saint Charles Health System-Redmond, Redmond, Oregon, United States|UPMC-Heritage Valley Health System Beaver, Beaver, Pennsylvania, United States|Christiana Care Health System-Concord Health Center, Chadds Ford, Pennsylvania, United States|UPMC Cancer Centers - Arnold Palmer Pavilion, Greensburg, Pennsylvania, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|UPMC-Johnstown/John P. Murtha Regional Cancer Center, Johnstown, Pennsylvania, United States|UPMC Cancer Center at UPMC McKeesport, McKeesport, Pennsylvania, United States|UPMC-Coraopolis/Heritage Valley Radiation Oncology, Moon, Pennsylvania, United States|UPMC-Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|UPMC-Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|UPMC-Saint Margaret, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|UPMC-Shadyside Hospital, Pittsburgh, Pennsylvania, United States|UPMC-Passavant Hospital, Pittsburgh, Pennsylvania, United States|UPMC-Saint Clair Hospital Cancer Center, Pittsburgh, Pennsylvania, United States|UPMC Cancer Center at UPMC Northwest, Seneca, Pennsylvania, United States|UPMC Uniontown Hospital Radiation Oncology, Uniontown, Pennsylvania, United States|UPMC Washington Hospital Radiation Oncology, Washington, Pennsylvania, United States|UPMC Susquehanna, Williamsport, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Greenville Health System Cancer Institute-Laurens, Clinton, South Carolina, United States|Greenville Health System Cancer Institute-Easley, Easley, South Carolina, United States|Greenville Health System Cancer Institute-Butternut, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Faris, Greenville, South Carolina, United States|Greenville Memorial Hospital, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Eastside, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Greer, Greer, South Carolina, United States|Greenville Health System Cancer Institute-Seneca, Seneca, South Carolina, United States|Greenville Health System Cancer Institute-Spartanburg, Spartanburg, South Carolina, United States|Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|Inova Fairfax Hospital-Woodburn Infusion Clinic, Annandale, Virginia, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|Cancer Care Center at Island Hospital, Anacortes, Washington, United States|Swedish Cancer Institute-Eastside Oncology Hematology, Bellevue, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Medical Center-Edmonds, Edmonds, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Minor and James Medical PLLC, Seattle, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Kaiser Permanente Washington, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Cherry Hill, Seattle, Washington, United States|PeaceHealth United General Medical Center, Sedro-Woolley, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|Rockwood Clinic Cancer Treatment Center-Valley, Spokane Valley, Washington, United States|Rockwood Cancer Treatment Center-DHEC-Downtown, Spokane, Washington, United States|Rockwood North Cancer Treatment Center, Spokane, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital, Yakima, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|Marshfield Clinic-Chippewa Center, Chippewa Falls, Wisconsin, United States|Marshfield Clinic Cancer Center - Eau Claire, Eau Claire, Wisconsin, United States|Marshfield Clinic Cancer Center at Sacred Heart, Eau Claire, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|Marshfield Clinic - Ladysmith Center, Ladysmith, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|Marshfield Clinic-Rice Lake Center, Rice Lake, Wisconsin, United States|Marshfield Clinic Stevens Point Center, Stevens Point, Wisconsin, United States|Marshfield Clinic-Wausau Center, Wausau, Wisconsin, United States|Marshfield Clinic - Weston Center, Weston, Wisconsin, United States|Marshfield Clinic - Wisconsin Rapids Center, Wisconsin Rapids, Wisconsin, United States|Big Horn Basin Cancer Center, Cody, Wyoming, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States",https://ClinicalTrials.gov/show/NCT02749903
158,Novartis Pharmaceuticals|Novartis,"A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies","Active, not recruiting",Has Results,Advanced Non-small Cell Lung Cancer,Drug: EGF816,Industry,Interventional,"Massachusetts General Hospital Mass General, Boston, Massachusetts, United States|Memorial Sloan Kettering Oncology Department, New York, New York, United States|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Fukuoka-city, Fukuoka, Japan|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Taipei, Taiwan ROC, Taiwan",https://ClinicalTrials.gov/show/NCT02108964
159,Incyte Corporation|Merck Sharp & Dohme Corp.,"Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)","Active, not recruiting",Has Results,Head and Neck Cancer,Drug: Pembrolizumab|Drug: Epacadostat|Drug: Cetuximab|Drug: Cisplatin|Drug: Carboplatin|Drug: 5-Fluorouracil,Industry,Interventional,"UCLA Hematology & Oncology, Los Angeles, California, United States|Sansum Clinic Research, Santa Barbara, California, United States|Providence Saint John's Health Center, Santa Monica, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Lynn Cancer Institute, Boca Raton, Florida, United States|Florida Cancer Specialists (South Region) - Research Office, Fort Myers, Florida, United States|Florida Cancer Specialists (North Region) Research Office, Saint Petersburg, Florida, United States|Illinois Cancer Care, PC, Peoria, Illinois, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Weinberg Cancer Institute at Franklin Square, Baltimore, Maryland, United States|Maryland Oncology Hematology, P.A., Rockville, Maryland, United States|Dana Farber Cancer Hospital, Boston, Massachusetts, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Michigan, Ann Arbor, Michigan, United States|Minnesota Oncology Specialist, PA, Fridley, Minnesota, United States|MMCORC, Saint Louis Park, Minnesota, United States|Southeast Nebraska Hematology & Oncology Consultants, P.C., Lincoln, Nebraska, United States|New York Oncology Hematology P.C, Albany, New York, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Tennessee Erlanger Oncology & Hematology, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC/The Sarah Cannon Research Institute, Chattanooga, Tennessee, United States|SCRI/Tennessee Oncology-Nashville, Nashville, Tennessee, United States|Tennessee Oncology, PLLC/The Sarah Cannon Research Institute, Nashville, Tennessee, United States|Texas Oncology-South Austin, Austin, Texas, United States|Texas Oncology-Baylor Sammons Cancer Center, Dallas, Texas, United States|Oncology & Hematology Assoc. SW Virginia, Inc., DBA Blue Ridge Cancer Care, Blacksburg, Virginia, United States|Inova Medical Oncology, Fairfax, Virginia, United States|Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Roanoke, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Blacktown Hospital Western Sydney Local Health District, Blacktown, New South Wales, Australia|Chris OBrien Lifehouse, Camperdown, New South Wales, Australia|Macquarie University Hospital, North Ryde, New South Wales, Australia|MNCCI Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Southern Medical Day Care Centre, Wollongong, New South Wales, Australia|Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia|Cairns and Hinterland Hospital and Health Service, Cairns, Queensland, Australia|Greenslopes Private Hospital, Greenslopes, Queensland, Australia|Royal Brisbane & Women s Hospital, Herston, Queensland, Australia|Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia|Austin Health-Austin Hospital, Heidelberg, Victoria, Australia|Cabrini Health, Malvern, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|St John of God Murdoch Medical Clinic, Murdoch, Western Australia, Australia|Adelaide Cancer Centre, Kurralta Park, Australia|The Crown Princess Mary Cancer Centre Westmead, Westmead, Australia|Landeskrankenhaus Salzburg, Salzburg, Austria|Allgemeines Krankenhaus der Stadt Wien, Wien, Austria|Cross Cancer Institute, Edmonton, Alberta, Canada|BCCA-Cancer Centre of the Southern Interior, Kelowna, British Columbia, Canada|Lions Gate Hospital, North Vancouver, British Columbia, Canada|Moncton Hospital - Horizon Health Network, Moncton, New Brunswick, Canada|William Osler Health System, Brampton, Ontario, Canada|Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Ontario, Canada|Kingston Health Sciences Centre, Kingston, Ontario, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Sault Area Hospital, Sault Ste Marie, Ontario, Canada|Sunnybrook Research Institute, Toronto, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CISSS de la Monteregie-Centre, Greenfield Park, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|CIUSSS Ouest de l'Ile - St-Mary's Hospital, Montreal, Quebec, Canada|McGill University Health Centre, Montréal, Quebec, Canada|CIUSSS du Nord-de-l ILe-de-Montreal Hopital du Sacre-Coeur de Montreal, Montréal, Quebec, Canada|CIUSSS de la Mauricie et du Centre du Quebec, Trois-Rivieres, Quebec, Canada|C H U Q - Pavillion l'Hotel Dieu de Quebec, Quebec, Canada|CHU de Quebec-Universite Laval-Hotel Dieu de Quebec, Quebec, Canada|Orszagos Onkologiai Intezet, Budapest, Pest, Hungary|Orszagos Koranyi TBC es Pulmonologiai Intezet, Budapest, Hungary|University of Debrecen Medical Center Clinic of Oncology, Debrecen, Hungary|Veszprem Megyei Tudogyogyintezet, Farkasgyepu, Hungary|Bekes Megyei Pandy Kalman Korhaz., Gyula, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz, Miskolc, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi OktatoKorhaz, Miskolc, Hungary|CRU Hungary KFT, Miskolc, Hungary|Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet, Szolnok, Hungary|Zala Megyei Korhaz Pozvai Telephely, Zalaegerszeg, Hungary|Azienda Ospedaliera San Giuseppe Moscati, Avellino, Italy|ASST Papa Giovanni XXIII, Bergamo, Italy|A.O.U. Policlinico Vittorio Emanuele - Presidio Gaspare Rodolico, Catania, Italy|IRCCS A.O.U. San Martino - IST, Genova, Italy|IRCCS Ospedale Policlinico San Martino, Genova, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy|Istituto Europeo di Oncologia, Milano, Italy|Istituto Nazionale dei Tumori, Milan, Italy|Ospedale San Gerardo - ASST Monza, Monza, Italy|Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy|Istituto Oncologico Veneto, Padova, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Azienda Ospedaliero Universitaria Senese, Siena, Italy|National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan|Nagoya University Hospital, Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|Asahikawa Medical University Hospital, Asahikawa, Hokkaido, Japan|University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Kanagawa Cancer Center, Yokohama, Kanagawa, Japan|Miyagi Cancer Center, Natori, Miyagi, Japan|Sendai Kousei Hospital, Sendai, Miyagi, Japan|Tohoku University Hospital, Sendai, Miyagi, Japan|Kindai University Hospital, Osakasayama, Osaka, Japan|Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan|Yamaguchi University Hospital, Ube, Yamaguchi, Japan|Kyushu University Hospital, Fukuoka, Japan|Hiroshima University Hospital, Hiroshima, Japan|Kyoto University Hospital, Kyoto, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|Osaka International Cancer Institute, Osaka, Japan|Shizuoka Cancer Center Hospital and Research Institute, Shizuoka, Japan|National Cancer Center Hospital, Tokyo, Japan|Nippon Medical School Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Keio University Hospital, Tokyo, Japan|Wakayama Medical University Hospital, Wakayama, Japan|Chungbuk National University Hospital, Cheongju si, Chungcheongbuk Do, Korea, Republic of|Chungnam National University Hospital, Daejeon, Chungnam, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun Gun, Jeollanam Do, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Mazowiecki Szpital Onkologiczny, Wieliszew, Mazowieckie, Poland|Beskidzkie Centrum Onkologii im. Jana Pawla II, Bielsko-Biala, Poland|Powiatowe Centrum Zdrowia w Brzezinach, Brzeziny, Poland|Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny, Brzozow, Poland|Centrum Onkologii im. Prof. Franciszka Lukaszczyka, Bydgoszcz, Poland|Centrum Onkologii. Instytut im. Marii Sklodowskiej-Curie, Gliwice, Poland|Wojewodzkie Centrum Szpitalne Kotliny Jeleniogorskiej, Jelenia Gora, Poland|Uniwersyteckie Centrum Kliniczne Slaskiego Uniwersytetu Medycznego, Katowice, Poland|Osrodek Badan Klinicznych Gyncentrum, Katowice, Poland|Swietokrzyskie Centrum Onkologii SPZOZ, Kielce, Poland|Przychodnia Lekarska Komed, Konin, Poland|Centrum Onkologii-Instytut im. Marii Sklodowskiej, Krakow, Poland|Szpital Powiatowy im. Edmunda Biernackiego w Mielcu, Mielec, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 7. Szpital w Ochojcu, Ochojec, Poland|Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc, Olsztyn, Poland|SP ZOZ Opolskie Centrum Onkologii im. prof. T. Koszarowskiego w Opolu, Opole, Poland|Europejskie Centrum Zdrowia Otwock, Otwock, Poland|Szpital Kliniczny, Poznan, Poland|Urologica Praktyka Lekarska Adam Marcheluk, Siedlce, Poland|Lubelskie Centrum Diagnostyczne Tomasz Blicharski, Swidnik, Poland|Pomorski Uniwersytet Medyczny, Szczecin, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 2 PUM w Szczecinie, Szczecin, Poland|Wojewodzki Szpital im. Zofii z Zamoyskich Tarnowskiej w Tarnobrzegu, Tarnobrzeg, Poland|Specjalistyczny Szpital Miejski Mikolaja Kopernika w Toruniu, Torun, Poland|Wojskowy Instytut Medyczny, Warszawa, Poland|Magodent Szpital Elblaska, Warszawa, Poland|Szpital Sw. Elzbiety Mokotowskie Centrum Medyczne, Warszawa, Poland|Centrum Onkologii. Instytut im. Marii Sklodowskiej-Curie, Warszawa, Poland|Wojewodzki Szpital Specjalistyczny we Wroclawiu, Wroclaw, Poland|Inst. Portugues de Oncologia de Coimbra Frencisco Gentil EPE, Coimbra, Portugal|Inst. Portugues de Oncologia de Lisboa Francisco Gentil EPE, Lisboa, Portugal|Centro Hospitalar Lisboa Norte EPE - Hospital de Santa Maria, Lisboa, Portugal|Inst. Portugues de Oncologia de Porto Francisco Gentil EPE, Porto, Portugal|Hospital Parc Tauli, Sabadell, Barcelona, Spain|Complejo Hospitalario Universitario A Coruna. CHUAC, A Coruna, Galicia, Spain|Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Gran Canaria, Spain|Onkologikoa - Instituto Oncologico de San Sebastian, Donostia, Guipuzcoa, Spain|Hospital Alvaro Cunqueiro, Vigo, Pontevedra, Spain|Hospital General de Alicante, Alicante, Spain|Hospital Infanta Cristina, Badajoz, Spain|Hospital Germans Trias i Pujol. ICO de Badalona, Badalona, Spain|Hospital del Mar, Barcelona, Spain|Hospital General Universitari Vall d Hebron, Barcelona, Spain|Hospital Clinic i Provincial, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Juan Ramón Jimenez, Huelva, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen de la Victoria, Malaga, Spain|Xarxa Assistencial Universitaria Manresa, Manresa, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Hospital Universitario Virgen de la Macarena, Sevilla, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital de Nuestra Senora de Valme, Sevilla, Spain|Instituto Valenciano de Oncologia, Valencia, Spain|Hospital Clinico de Valencia, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital Universitario La Fe, Valencia, Spain|Hospital Clinico Lozano Blesa, Zaragoza, Spain|Taipei Veterans General Hospital, Taipei, Beitou, Taiwan|Chang Gung Medical Foundation. Kaohsiung Branch, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Chang Gung Medical Foundation. Linkou, Taoyuan, Taiwan|Baskent Universitesi Adana Uygulama ve Arastirma Hastanesi, Adana, Turkey|Basken Adana Dr.Turgut Noyan Uygulama ve Arastirma Merkezi, Adana, Turkey|Cukurova Universitesi Tıp Fakultesi Balcalı Hastanesi, Adana, Turkey|Adana Sehir Hastanesi, Adana, Turkey|Ankara University Medical Faculty, Ankara, Turkey|Hacettepe Universitesi Tip Fakultesi Hastanesi, Ankara, Turkey|Akdeniz Universitesi Tip Fakultesi, Antalya, Turkey|Trakya Universitesi Tip Fakultesi, Edirne, Turkey|Istanbul Universitesi Onkoloji Enstitusu, Istanbul, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi, Istanbul, Turkey|Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi, Istanbul, Turkey|Ege Universitesi Tip Fakultesi Hastanesi, Izmir, Turkey|Dokuz Eylul University Faculty of Medicine, Izmir, Turkey|Necmettin Erbakan Universitesi Meram Tip Fakultesi Hastanesi, Konya, Turkey|Inonu Universitesi Turgut Ozal Tip Merkezi, Malatya, Turkey|Samsun Medical Park Hastanesi, Samsun, Turkey|Namık Kemal University Medical Faculty, Tekirdag, Turkey|Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom|Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|Leeds Teaching Hospital NHS Trust. St. James University Hospital, Leeds, United Kingdom|North Middlesex Hospital, London, United Kingdom|The Royal Free London NHS Foundation Trust, London, United Kingdom|The Royal Marsden Foundation Trust, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Freeman Hospital Newcastle upon Tyne Foundation NHS Trust, Newcastle upon Tyne, United Kingdom",https://ClinicalTrials.gov/show/NCT03358472
160,Mayo Clinic|National Cancer Institute (NCI)|Novartis Pharmaceuticals,Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma,"Active, not recruiting",Has Results,Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma,Other: Laboratory Biomarker Analysis|Drug: Lenalidomide|Drug: Sonidegib,Other|NIH|Industry,Interventional,"Mayo Clinic, Rochester, Minnesota, United States",https://ClinicalTrials.gov/show/NCT02086552
161,Cristina Gasparetto|Celgene|Duke University,Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma,"Active, not recruiting",Has Results,Multiple Myeloma,Drug: Bendamustine|Drug: Pomalidomide|Drug: Dexamethasone,Other|Industry,Interventional,"Duke University Medical Center, Durham, North Carolina, United States",https://ClinicalTrials.gov/show/NCT01754402
162,H. Lee Moffitt Cancer Center and Research Institute|Karyopharm Therapeutics Inc,Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma,"Active, not recruiting",Has Results,Multiple Myeloma,Drug: Selinexor|Drug: Liposomal doxorubicin|Drug: Dexamethasone,Other|Industry,Interventional,"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States",https://ClinicalTrials.gov/show/NCT02186834
163,H. Lee Moffitt Cancer Center and Research Institute|Pfizer,Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS),"Active, not recruiting",Has Results,Myelodysplastic Syndrome (MDS)|Chronic Myelomonocytic Leukemia (CMML),Drug: PF-04449913,Other|Industry,Interventional,"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",https://ClinicalTrials.gov/show/NCT01842646
164,National Cancer Institute (NCI)|GlaxoSmithKline|Novartis Pharmaceuticals,"Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer","Active, not recruiting",Has Results,Hematopoietic and Lymphoid Cell Neoplasm|Locally Advanced Malignant Solid Neoplasm|Locally Advanced Melanoma|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7|Unresectable Malignant Solid Neoplasm|Unresectable Melanoma,Drug: Dabrafenib Mesylate|Drug: Trametinib Dimethyl Sulfoxide|Drug: Uprosertib,NIH|Industry,Interventional,"USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|UCSF Medical Center-Mount Zion, San Francisco, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Milwaukie Hospital, Milwaukie, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Providence Willamette Falls Medical Center, Oregon City, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States",https://ClinicalTrials.gov/show/NCT01902173
165,Hoffmann-La Roche,A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC),"Active, not recruiting",Has Results,Small Cell Lung Carcinoma,"Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Drug: Carboplatin|Drug: Etoposide|Drug: Placebo",Industry,Interventional,"Florida Cancer Specialists - Fort Myers (Broadway), Fort Myers, Florida, United States|Florida Hospital, Orlando, Florida, United States|Florida Cancer Specialists., Saint Petersburg, Florida, United States|Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Illinois Cancer Care, Peoria, Illinois, United States|Cancer Treatment Centers of America - Midwestern Regional Medical Center, Zion, Illinois, United States|Louisville Oncology, Louisville, Kentucky, United States|New England Cancer Specialists, Scarborough, Maine, United States|Weinberg CA Inst Franklin Sq, Baltimore, Maryland, United States|Mayo Clinic, Rochester, Minnesota, United States|Comprehensive Cancer Centers of Nevada - Eastern Avenue, Las Vegas, Nevada, United States|The Valley Hospital, Paramus, New Jersey, United States|Broome Oncology - Binghamton, Binghamton, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Chattanooga Oncology and Hematology Associates, PC, Chattanooga, Tennessee, United States|Tennessee Oncology PLLC - Nashville (20th Ave), Nashville, Tennessee, United States|Vanderbilt Medical Center, Nashville, Tennessee, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Blue Ridge Cancer Care, Roanoke, Virginia, United States|Northwest Medical Specialties, Tacoma, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|The Prince Charles Hospital; Oncology Dept., Chermside, Queensland, Australia|Royal Melbourne Hospital; Hematology and Medical Oncology, Parkville, Victoria, Australia|Kepler Universitätskliniken GmbH - Med Campus III; Abt. für Lungenkrankheiten, Linz, Austria|Salzburger Landeskliniken; Universitätsklinik für Pneumologie/ Lungenheilkunde, Salzburg, Austria|SMZ - Baumgartner Hohe, Otto-Wagner-Spital; 2.Interne Lungenabteilung, Wien, Austria|Krankenhaus Nord - Klinik Floridsdorf; Abteilung Pulmologie, Wien, Austria|Santa Casa de Misericordia de Salvador, Salvador, BA, Brazil|Hospital Bruno Born, Lajeado, RS, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, Brazil|Bradford Hill Centro de Investigaciones Clinicas; Bradford Hill Centro de Investigaciones Clinicas, Recoleta, Chile|OrlandiOncología, Santiago, Chile|Beijing Cancer Hospital, Beijing, China|Jilin Cancer Hospital, Changchun, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Jiangsu Cancer Hospital, Nanjing, China|Zhongshan Hospital Fudan University, Shanghai, China|Fudan University Shanghai Cancer Center, Shanghai, China|Zhejiang Cancer Hospital, Zhejiang, China|Henan Cancer Hospital, Zhengzhou, China|Fakultni nemocnice Olomouc, Olomouc, Czechia|Thomayerova nemocnice, Praha 4 - Krc, Czechia|Fakultni nemocnice Na Bulovce, Praha 8, Czechia|Institut Bergonie; Oncologie, Bordeaux, France|Centre Francois Baclesse; Oncologie, Caen, France|Hopital Calmette; Pneumologie Oncologie Ouest, Lille, France|Hôpital Nord - AP-HM Marseille#, Marseille, France|Asklepios-Fachklinik Muenchen-Gauting; Klinik Für Pneumologie, Gauting, Germany|LungenClinic Großhansdorf GmbH, Großhansdorf, Germany|Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin II, Halle, Germany|Thoraxklinik Heidelberg gGmbH, Heidelberg, Germany|Fachklinik für Lungenerkrankungen, Immenhausen, Germany|Sotiria Chest Hospital of Athens, Athens, Greece|Agioi Anargyroi; 3Rd Dept. of Medical Oncology, Athens, Greece|University Hospital of Patras Medical Oncology, Patras, Greece|Semmelweis Egyetem, AOK, Pulmonologiai Klinika, Budapest, Hungary|Orszagos Koranyi TBC es Pulmonologiai Intezet, Budapest, Hungary|Debreceni Egyetem, Klinikai Kozpont, Tudogyogyaszati Klinika, Debrecen, Hungary|Tudogyogyintezet Torokbalint, Torokbalint, Hungary|A.O. Universitaria Di Parma, Parma, Emilia-Romagna, Italy|Policlinico Universitario Campus Biomedico; Uoc Oncologia Medica, Roma, Lazio, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy|Irccs Istituto Europeo di Oncologia (IEO); Divisione di Oncologia, Milano, Lombardia, Italy|IRCCS Ospedale Casa Sollievo Della Sofferenza; Oncologia, San Giovanni Rotondo, Puglia, Italy|Azienda Ospedaliera Universitaria Pisana - Ospedale Cisanello; Dipartimento Cardio Toraco Vascolare, Pisa, Toscana, Italy|Kyushu University Hospital; Respiratory, Fukuoka, Japan|National Hospital Organization Himeji Medical Center, Hyogo, Japan|Kanagawa Cancer Center;Thoracic Oncology, Kanagawa, Japan|University Hospital Kyoto Prefectural University of Medicine, Pulmonary Medicine, Kyoto, Japan|Sendai Kousei Hospital; Pulmonary Medicine, Miyagi, Japan|Kurashiki Central Hospital; Respiratory Medicine, Okayama, Japan|Kindai University Hospital; Medical Oncology, Osaka, Japan|National Hospital Organization Kinki-Chuo Chest Medical Center; Internal Medicine, Osaka, Japan|Saitama Cancer Center; Thoracic Oncology, Saitama, Japan|Shizuoka Cancer Center; Thoracic Oncology, Shizuoka, Japan|Tokyo Metropolitan Komagome Hospital; Thoracic Oncology and Respiratory Medicine, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Respiratory Medicine, Tokyo, Japan|Wakayama Medical University Hospital; Respiratory Medicine and Medical Oncology, Wakayama, Japan|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Health Pharma Professional Research, Cdmx, Mexico CITY (federal District), Mexico|Medical University of Gdansk, Gdansk, Poland|Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi, Lodz, Poland|Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc; Oddzial V Chemioterapii Nowotworow Pluc, Olsztyn, Poland|Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy, Otwock, Poland|Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu, Poznan, Poland|Centrum Onkologii - Inst.Im. Marii Sklodowskiej-Curie; Oncology, Warszawa, Poland|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, Russian Federation|N.N.Burdenko Main Military Clinical Hospital; Oncology Dept, Moscow, Russian Federation|Russian Oncology Research Center n.a. N.N. Blokhin, Moscow, Russian Federation|City Clinical Hospital No. 1, Novosibirsk, Russian Federation|City Clinical Onc., Saint-Petersburg, Russian Federation|Scientific Research Oncology Institute named after N.N. Petrov; Oncology, St. Petersburg, Russian Federation|Clinical Center of Serbia, Belgrade, Serbia|Clinical Center Bezanijska Kosa, Belgrade, Serbia|Clinical Center Nis; Clinic for pulmonary diseases, Nis, Serbia|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Hosp Clinico Univ Lozano Blesa; División De Oncología Médica, Zaragoza, Spain|National Taiwan Uni Hospital; Internal Medicine, Taipei, Taiwan|Taipei Veterans General Hospital; Chest Dept , Section of Thoracic Oncology, Taipei, Taiwan|Chang Gung Medical Foundation - Linkou; Chest Dept, Taoyuan, Taiwan|Royal Devon & Exeter Hospital; Oncology Centre, Exeter, United Kingdom|Barts and the London NHS Trust., London, United Kingdom|Guys and St Thomas NHS Foundation Trust, Guys Hospital, London, United Kingdom|Christie Hospital Nhs Trust; Medical Oncology, Manchester, United Kingdom",https://ClinicalTrials.gov/show/NCT02763579
166,AstraZeneca,Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).,"Active, not recruiting",Has Results,Non-Small-Cell Lung Carcinoma NSCLC,Biological: MEDI4736 (Durvalumab)|Biological: MEDI4736 (Durvalumab)+Tremelimumab|Drug: Paclitaxel + Carboplatin|Drug: Gemcitabine + Cisplatin|Drug: Gemcitabine + Carboplatin|Drug: Pemetrexed + Cisplatin|Drug: Pemetrexed + Carboplatin|Biological: Tremelimumab,Industry,Interventional,"Research Site, Scottsdale, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Yuma, Arizona, United States|Research Site, Bakersfield, California, United States|Research Site, Fullerton, California, United States|Research Site, La Jolla, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Redondo Beach, California, United States|Research Site, Sacramento, California, United States|Research Site, San Luis Obispo, California, United States|Research Site, Santa Maria, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Jacksonville, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Athens, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Baltimore, Maryland, United States|Research Site, Edina, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, Summit, New Jersey, United States|Research Site, Mineola, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Charleston, South Carolina, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Richmond, Virginia, United States|Research Site, Madison, Wisconsin, United States|Research Site, Box Hill, Australia|Research Site, Gosford, Australia|Research Site, Kogarah, Australia|Research Site, Melbourne, Australia|Research Site, Port Macquarie, Australia|Research Site, Southport, Australia|Research Site, St Leonards, Australia|Research Site, Brussels, Belgium|Research Site, Charleroi, Belgium|Research Site, Duffel, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Kingston, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Sault Ste. Marie, Ontario, Canada|Research Site, St. Catharines, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Regina, Saskatchewan, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Bordeaux Cedex, France|Research Site, Brest Cedex, France|Research Site, Creteil, France|Research Site, Lille, France|Research Site, Lyon Cedex 08, France|Research Site, Marseille cedex, France|Research Site, Aachen, Germany|Research Site, Bad Berka, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Freiburg, Germany|Research Site, Gauting, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research Site, Hemer, Germany|Research Site, Homburg/Saar, Germany|Research Site, Immenhausen, Germany|Research Site, Lubeck, Germany|Research Site, Löwenstein, Germany|Research Site, Mainz, Germany|Research Site, Münster, Germany|Research Site, Oldenburg, Germany|Research Site, Ulm, Germany|Research Site, Velbert, Germany|Research Site, Würzburg, Germany|Research Site, Budapest, Hungary|Research Site, Deszk, Hungary|Research Site, Edelény, Hungary|Research Site, Kaposvár, Hungary|Research Site, Kecskemét, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Pécs, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Genova, Italy|Research Site, Meldola, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, San Giovanni Rotondo, Italy|Research Site, Siena, Italy|Research Site, Fukushima-shi, Japan|Research Site, Himeji-shi, Japan|Research Site, Hirakata-shi, Japan|Research Site, Hirosaki-shi, Japan|Research Site, Iizuka-shi, Japan|Research Site, Iwakuni-shi, Japan|Research Site, Izumi-shi, Japan|Research Site, Kanazawa, Japan|Research Site, Kishiwada-shi, Japan|Research Site, Kobe-shi, Japan|Research Site, Koga-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Mitaka-shi, Japan|Research Site, Nagaoka-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Okayama-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osakasayama, Japan|Research Site, Saga-shi, Japan|Research Site, Saitama-shi, Japan|Research Site, Sakai-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Tokushima-shi, Japan|Research Site, Ube-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokosuka-shi, Japan|Research Site, Busan, Korea, Republic of|Research Site, Changwon-si, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Jinju-si, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Ulsan, Korea, Republic of|Research Site, Amsterdam, Netherlands|Research Site, Arnhem, Netherlands|Research Site, Breda, Netherlands|Research Site, Den Bosch, Netherlands|Research Site, Groningen, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, A Coruña, Spain|Research Site, Alicante, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Gerona, Spain|Research Site, Jaén, Spain|Research Site, León, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Majadahonda, Spain|Research Site, Málaga, Spain|Research Site, Sevilla, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Bellinzona, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Tao-Yuan, Taiwan|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Hat Yai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Hanoi City, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh city, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Ho Chi Minh, Vietnam",https://ClinicalTrials.gov/show/NCT02453282
167,"Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Astellas Pharma US, Inc.|Medivation, Inc.|Biologics, Inc.",Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,"Active, not recruiting",Has Results,Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer,Drug: enzalutamide|Drug: abiraterone|Drug: prednisone,Other|NIH|Industry,Interventional,"University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|Southern Cancer Center PC-Providence, Mobile, Alabama, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Mayo Clinic in Arizona, Scottsdale, Arizona, United States|University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona, United States|University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States|The University of Arizona Medical Center-University Campus, Tucson, Arizona, United States|Fowler Family Center for Cancer Care, Jonesboro, Arkansas, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Veteran's Administration Medical Center, Little Rock, Arkansas, United States|Kaiser Permanente-Anaheim, Anaheim, California, United States|Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States|Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States|Kaiser Permanente-Bellflower, Bellflower, California, United States|Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|Kaiser Permanente Hospital, Fontana, California, United States|Kaiser Permanente-Fremont, Fremont, California, United States|University Oncology Associates, Fresno, California, United States|California Cancer Center - North Fresno, Fresno, California, United States|Kaiser Permanente, Fresno, California, United States|Marin Cancer Care Inc, Greenbrae, California, United States|Kaiser Permanente - Harbor City, Harbor City, California, United States|Kaiser Permanente-Irvine, Irvine, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Kaiser Permanente-Cadillac, Los Angeles, California, United States|Fremont - Rideout Cancer Center, Marysville, California, United States|Memorial Medical Center, Modesto, California, United States|Kaiser Permanente-Modesto, Modesto, California, United States|USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States|Palo Alto Medical Foundation Health Care, Palo Alto, California, United States|Kaiser Permanente - Panorama City, Panorama City, California, United States|Feather River Cancer Center, Paradise, California, United States|Kaiser Permanente-Redwood City, Redwood City, California, United States|Kaiser Permanente-Richmond, Richmond, California, United States|Kaiser Permanente-Riverside, Riverside, California, United States|Kaiser Permanente-Roseville, Roseville, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Kaiser Permanente-South Sacramento, Sacramento, California, United States|Kaiser Permanente - Sacramento, Sacramento, California, United States|Saint Helena Hospital, Saint Helena, California, United States|Kaiser Permanente-San Diego Zion, San Diego, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Naval Medical Center -San Diego, San Diego, California, United States|Veterans Administration-San Diego Medical Center, San Diego, California, United States|Kaiser Permanente-San Francisco, San Francisco, California, United States|UCSF Medical Center-Mount Zion, San Francisco, California, United States|Veterans Affairs Medical Center - San Francisco, San Francisco, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, United States|Kaiser Permanente San Leandro, San Leandro, California, United States|Kaiser Permanente-San Marcos, San Marcos, California, United States|Kaiser Permanente-San Rafael, San Rafael, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|Palo Alto Medical Foundation-Santa Cruz, Santa Cruz, California, United States|Kaiser Permanente-Santa Rosa, Santa Rosa, California, United States|Kaiser Permanente-South San Francisco, South San Francisco, California, United States|Saint Joseph's Medical Center, Stockton, California, United States|Kaiser Permanente-Stockton, Stockton, California, United States|Palo Alto Medical Foundation-Sunnyvale, Sunnyvale, California, United States|Kaiser Permanente Medical Center-Vacaville, Vacaville, California, United States|Kaiser Permanente-Vallejo, Vallejo, California, United States|Kaiser Permanente-Walnut Creek, Walnut Creek, California, United States|Kaiser Permanente, Woodland Hills, California, United States|Rocky Mountain Cancer Centers-Boulder, Boulder, Colorado, United States|Memorial Hospital Colorado Springs, Colorado Springs, Colorado, United States|Kaiser Permanente-Franklin, Denver, Colorado, United States|Southwest Oncology PC, Durango, Colorado, United States|The Shaw Regional Cancer Center, Edwards, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Rocky Mountain Cancer Centers-Lakewood, Lakewood, Colorado, United States|Greenwich Hospital, Greenwich, Connecticut, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|Middlesex Hospital, Middletown, Connecticut, United States|Norwalk Hospital, Norwalk, Connecticut, United States|Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut, United States|Stamford Hospital/Bennett Cancer Center, Stamford, Connecticut, United States|Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven, Connecticut, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Sibley Memorial Hospital, Washington, District of Columbia, United States|Veterans Affairs Medical Center -Washington DC, Washington, District of Columbia, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Lakeland Regional Cancer Center, Lakeland, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Florida Hospital Orlando, Orlando, Florida, United States|UF Cancer Center at Orlando Health, Orlando, Florida, United States|Sacred Heart Hospital, Pensacola, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|John B Amos Cancer Center, Columbus, Georgia, United States|Atlanta VA Medical Center, Decatur, Georgia, United States|Medical Center of Central Georgia, Macon, Georgia, United States|Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States|South Georgia Medical Center/Pearlman Cancer Center, Valdosta, Georgia, United States|Hawaii Oncology Inc-Pali Momi, 'Aiea, Hawaii, United States|Pali Momi Medical Center, 'Aiea, Hawaii, United States|Hawaii Cancer Care Inc-POB II, Honolulu, Hawaii, United States|Hawaii Oncology Inc-POB I, Honolulu, Hawaii, United States|Island Urology, Honolulu, Hawaii, United States|Queen's Medical Center, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Hawaii Cancer Care Inc-Liliha, Honolulu, Hawaii, United States|Hawaii Oncology Inc-Kuakini, Honolulu, Hawaii, United States|Kuakini Medical Center, Honolulu, Hawaii, United States|Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii, United States|Tripler Army Medical Center, Honolulu, Hawaii, United States|Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Mount Sinai Hospital Medical Center, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Weiss Memorial Hospital, Chicago, Illinois, United States|Advocate Illinois Masonic Medical Center, Chicago, Illinois, United States|Cancer Care Center of Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Northwestern Medicine Cancer Center Delnor, Geneva, Illinois, United States|NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|NorthShore University HealthSystem-Highland Park Hospital, Highland Park, Illinois, United States|Hines Veterans Administration Hospital, Hines, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Quincy Medical Group-Clinic, Quincy, Illinois, United States|West Suburban Medical Center, River Forest, Illinois, United States|OSF Saint Anthony Medical Center, Rockford, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States|Fort Wayne Medical Oncology and Hematology Inc - Jefferson Boulevard, Fort Wayne, Indiana, United States|Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne, Indiana, United States|Michiana Hematology Oncology PC-Mishawaka, Mishawaka, Indiana, United States|The Community Hospital, Munster, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Michiana Hematology Oncology PC-Westville, Westville, Indiana, United States|McFarland Clinic PC-William R Bliss Cancer Center, Ames, Iowa, United States|Hematology Oncology Associates-Quad Cities, Bettendorf, Iowa, United States|Oncology Associates at Mercy Medical Center, Cedar Rapids, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Genesis Medical Center - East Campus, Davenport, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Iowa City VA Healthcare System, Iowa City, Iowa, United States|Mercy Medical Center - North Iowa, Mason City, Iowa, United States|Siouxland Regional Cancer Center, Sioux City, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Cancer Center of Kansas - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas - El Dorado, El Dorado, Kansas, United States|Newman Regional Health, Emporia, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Saint Catherine Hospital, Garden City, Kansas, United States|Saint Rose Ambulatory and Surgery Center, Great Bend, Kansas, United States|Hays Medical Center, Hays, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|University of Kansas Cancer Center-West, Kansas City, Kansas, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|Cancer Center of Kansas-Kingman, Kingman, Kansas, United States|Cancer Center of Kansas-Liberal, Liberal, Kansas, United States|Cancer Center of Kansas - Newton, Newton, Kansas, United States|Olathe Medical Center, Olathe, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Cancer Center of Kansas - Parsons, Parsons, Kansas, United States|Via Christi Hospital-Pittsburg, Pittsburg, Kansas, United States|Cancer Center of Kansas - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas - Salina, Salina, Kansas, United States|Salina Regional Health Center, Salina, Kansas, United States|Saint Francis Hospital and Medical Center - Topeka, Topeka, Kansas, United States|Cancer Center of Kansas - Wellington, Wellington, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Cancer Center of Kansas - Winfield, Winfield, Kansas, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|Christus Saint Frances Cabrini Hospital, Alexandria, Louisiana, United States|Hematology/Oncology Clinic LLP, Baton Rouge, Louisiana, United States|Ochsner Health Center-Summa, Baton Rouge, Louisiana, United States|Ochsner Medical Center Kenner, Kenner, Louisiana, United States|East Jefferson General Hospital, Metairie, Louisiana, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Harold Alfond Center for Cancer Care, Augusta, Maine, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Lafayette Family Cancer Center-EMMC, Brewer, Maine, United States|Penobscot Bay Medical Center, Rockport, Maine, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Frederick Memorial Hospital, Frederick, Maryland, United States|Montgomery General Hospital-Olney, Olney, Maryland, United States|William E Kahlert Regional Cancer Center/Sinai Hospital, Westminster, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Simonds-Sinon Regional Cancer Center, Fitchburg, Massachusetts, United States|Newton-Wellesley Hospital, Newton, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Green Bay Oncology - Escanaba, Escanaba, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Green Bay Oncology - Iron Mountain, Iron Mountain, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|Saint Mary's of Michigan, Saginaw, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Sanford Clinic North-Bemidgi, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Saint Luke's Hospital of Duluth, Duluth, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Lake Region Healthcare Corporation-Cancer Care, Fergus Falls, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Mayo Clinic Health Systems-Mankato, Mankato, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Minneapolis Veterans Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|The West Clinic - Corinth, Corinth, Mississippi, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Saint Luke's Hospital, Chesterfield, Missouri, United States|University of Missouri - Ellis Fischel, Columbia, Missouri, United States|Barnes-Jewish West County Hospital, Creve Coeur, Missouri, United States|Capital Region Medical Center-Goldschmidt Cancer Center, Jefferson City, Missouri, United States|Truman Medical Center, Kansas City, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Kansas City Veterans Affairs Medical Center, Kansas City, Missouri, United States|The University of Kansas Cancer Center-South, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|The University of Kansas Cancer Center-North, Kansas City, Missouri, United States|The University of Kansas Cancer Center-Lee's Summit, Lee's Summit, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Nebraska Hematology and Oncology, Lincoln, Nebraska, United States|Southeast Nebraska Cancer Center, Lincoln, Nebraska, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|HealthCare Partners Medical Group Oncology/Hematology-San Martin, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Tenaya, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada, United States|New Hampshire Oncology Hematology PA-Concord, Concord, New Hampshire, United States|Wentworth-Douglass Hospital, Dover, New Hampshire, United States|New Hampshire Oncology Hematology PA-Hooksett, Hooksett, New Hampshire, United States|LRGHealthcare-Lakes Region General Hospital, Laconia, New Hampshire, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Norris Cotton Cancer Center-Manchester, Manchester, New Hampshire, United States|Saint Joseph Hospital, Nashua, New Hampshire, United States|Norris Cotton Cancer Center-Nashua, Nashua, New Hampshire, United States|Portsmouth Regional Hospital, Portsmouth, New Hampshire, United States|Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States|Veterans Adminstration New Jersey Health Care System, East Orange, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Virtua Memorial, Mount Holly, New Jersey, United States|The Valley Hospital-Luckow Pavilion, Paramus, New Jersey, United States|Virtua Voorhees, Voorhees, New Jersey, United States|Valley Health System-Hematology/Oncology, Westwood, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Memorial Medical Center - Las Cruces, Las Cruces, New Mexico, United States|Christus Saint Vincent Regional Cancer Center, Santa Fe, New Mexico, United States|Montefiore Medical Center-Einstein Campus, Bronx, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Bronx Veterans Administration Medical Center, Bronx, New York, United States|Kings County Hospital, Brooklyn, New York, United States|Maimonides Medical Center, Brooklyn, New York, United States|Veterans Affairs Western New York Health Care System-Buffalo, Buffalo, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center Commack, Commack, New York, United States|Arnot Ogden Medical Center/Falck Cancer Center, Elmira, New York, United States|Memorial Sloan-Kettering Cancer Center West Harrison, Harrison, New York, United States|North Shore-LIJ Health System/Center for Advanced Medicine, New Hyde Park, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|Columbia University/Herbert Irving Cancer Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Weill Medical College of Cornell University, New York, New York, United States|University of Rochester, Rochester, New York, United States|Memorial Sloan Kettering Cancer Center Rockville Centre, Rockville Centre, New York, United States|Memorial Sloan Kettering Cancer Center Sleepy Hollow, Sleepy Hollow, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|Syracuse Veterans Administration Medical Center, Syracuse, New York, United States|Randolph Hospital, Asheboro, North Carolina, United States|Cone Health Cancer Center at Alamance Regional, Burlington, North Carolina, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|Oncology Specialists of Charlotte, Charlotte, North Carolina, United States|Southern Oncology Specialists-Charlotte, Charlotte, North Carolina, United States|Durham Veterans Affairs Medical Center, Durham, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wayne Memorial Hospital, Goldsboro, North Carolina, United States|Cone Health Cancer Center, Greensboro, North Carolina, United States|Lake Norman Hematology Oncology Specialists-Huntersville, Huntersville, North Carolina, United States|Southern Oncology Specialists-Huntersville, Huntersville, North Carolina, United States|Novant Health Oncology Specialists-Kernersville, Kernersville, North Carolina, United States|Kinston Medical Specialists PA, Kinston, North Carolina, United States|Novant Health Cancer Specialists-Matthews, Matthews, North Carolina, United States|Lake Norman Hematology Oncology Specialists-Mooresville, Mooresville, North Carolina, United States|Novant Health Oncology Specialists-Mount Airy, Mount Airy, North Carolina, United States|Annie Penn Memorial Hospital, Reidsville, North Carolina, United States|Carolina Oncology Associates PA, Salisbury, North Carolina, United States|Veterans Administration Medical Center, Salisbury, North Carolina, United States|Novant Health Oncology Specialists-Statesville, Statesville, North Carolina, United States|Novant Health Oncology Specialists-Davidson County, Thomasville, North Carolina, United States|Marion L Shepard Cancer Center at Vidant Beaufort Hospital, Washington, North Carolina, United States|Novant Health Oncology Specialists-Wilkesboro, Wilkesboro, North Carolina, United States|Novant Health Forsyth Medical Center, Winston-Salem, North Carolina, United States|Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States|Winston-Salem Health Care, Winston-Salem, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Sanford Clinic North-Fargo, Fargo, North Dakota, United States|Sanford Medical Center-Fargo, Fargo, North Dakota, United States|Altru Cancer Center, Grand Forks, North Dakota, United States|Trinity Cancer Care Center, Minot, North Dakota, United States|Summa Akron City Hospital/Cooper Cancer Center, Akron, Ohio, United States|Summa Barberton Hospital, Barberton, Ohio, United States|UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio, United States|Mercy Medical Center, Canton, Ohio, United States|Dayton Physicians LLC-Miami Valley South, Centerville, Ohio, United States|Geaugra Hospital, Chardon, Ohio, United States|University of Cincinnati/Barrett Cancer Center, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Health Center, Dayton, Ohio, United States|Hematology Oncology Center Incorporated, Elyria, Ohio, United States|Mercy Cancer Center-Elyria, Elyria, Ohio, United States|Armes Family Cancer Center, Findlay, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Orion Cancer Care, Findlay, Ohio, United States|Cleveland Clinic Cancer Center Independence, Independence, Ohio, United States|Greater Dayton Cancer Center, Kettering, Ohio, United States|Cleveland Clinic Cancer Center Mansfield, Mansfield, Ohio, United States|Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio, United States|Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio, United States|Ireland Cancer Center Landerbrook Health Center, Mayfield Heights, Ohio, United States|Summa Health Center at Lake Medina, Medina, Ohio, United States|Lake University Ireland Cancer Center, Mentor, Ohio, United States|Southwest General Health Center Ireland Cancer Center, Middleburg Heights, Ohio, United States|University Hospitals Parma Medical Center, Parma, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|Ireland Cancer Center at Firelands Regional Medical Center, Sandusky, Ohio, United States|North Coast Cancer Care, Sandusky, Ohio, United States|Cleveland Clinic Cancer Center Strongsville, Strongsville, Ohio, United States|University of Toledo, Toledo, Ohio, United States|Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio, United States|University Hospitals Sharon Health Center, Wadsworth, Ohio, United States|South Pointe Hospital, Warrensville Heights, Ohio, United States|University Pointe, West Chester, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|UH-Seidman Cancer Center at Saint John Medical Center, Westlake, Ohio, United States|UHHS-Westlake Medical Center, Westlake, Ohio, United States|Cleveland Clinic Wooster Family Health and Surgery Center, Wooster, Ohio, United States|Wright-Patterson Medical Center, Wright-Patterson Air Force Base, Ohio, United States|Cancer Centers of Southwest Oklahoma Research, Lawton, Oklahoma, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Mercy Hospital Oklahoma City, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States|Good Samaritan Hospital, Corvallis, Oregon, United States|Providence Milwaukie Hospital, Milwaukie, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Providence Willamette Falls Medical Center, Oregon City, Oregon, United States|Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Kaiser Permanente Northwest, Portland, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Adams Cancer Center, Gettysburg, Pennsylvania, United States|Saint Mary Medical and Regional Cancer Center, Langhorne, Pennsylvania, United States|Allegheny Valley Hospital, Natrona Heights, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|WellSpan Health-York Hospital, York, Pennsylvania, United States|Roger Williams Medical Center, Providence, Rhode Island, United States|Roper Hospital, Charleston, South Carolina, United States|Charleston Hematology Oncology Associates-Roper, Charleston, South Carolina, United States|Lowcountry Hematology Oncology PA-North Charleston, Charleston, South Carolina, United States|Bon Secours Saint Francis Hospital, Charleston, South Carolina, United States|Charleston Hematology Oncology Associates PA-St. Francis, Charleston, South Carolina, United States|Lowcountry Hematology Oncology PA-West Ashley, Charleston, South Carolina, United States|Greenville Health System Cancer Institute-Easley, Easley, South Carolina, United States|Saint Francis Hospital, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Butternut, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Faris, Greenville, South Carolina, United States|Saint Francis Cancer Center, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Eastside, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Greer, Greer, South Carolina, United States|Carolina Blood and Cancer Care Associates PA-Lancaster, Lancaster, South Carolina, United States|Lowcountry Hematology Oncology PA-Mount Pleasant, Mount Pleasant, South Carolina, United States|Greenville Health System Cancer Institute-Seneca, Seneca, South Carolina, United States|Greenville Health System Cancer Institute-Spartanburg, Spartanburg, South Carolina, United States|Avera Cancer Institute-Aberdeen, Aberdeen, South Dakota, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Sanford Cancer Center-Oncology Clinic, Sioux Falls, South Dakota, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|The West Clinic - Wolf River, Germantown, Tennessee, United States|University of Tennessee Health Science Center, Memphis, Tennessee, United States|Parkland Memorial Hospital, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth, Texas, United St",
168,Celgene,"Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the ""Apact"" Study)","Active, not recruiting",Has Results,"Pancreatic Neoplasms|Digestive System Neoplasms|Neoplasms by Site|Neoplasms|Endocrine Gland Neoplasms|Pancreatic Diseases|Digestive System Diseases|Endocrine System Diseases|Gemcitabine|Antimetabolites, Antineoplastic",Drug: nab-Paclitaxel|Drug: Gemcitabine,Industry,Interventional,"Mayo Clinic - Arizona, Scottsdale, Arizona, United States|UCSD Moores Cancer Center, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|UC Davis Cancer Center, Sacramento, California, United States|University of California, San Francisco Cutaneous Oncology and Melanoma Center, San Francisco, California, United States|University of California Los Angeles, Santa Monica, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, LLP [Denver-Midtown], Denver, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Lynn Cancer Institute, Boca Raton, Florida, United States|Florida Cancer Institute Cancer Spec, Fort Myers, Florida, United States|Gainesville Heme Oncology Associates, Gainesville, Florida, United States|University of Florida, Gainesville, Florida, United States|University of Miami and Sylvester Cancer Center, Miami, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|H Lee Moffitt Cancer Center, Tampa, Florida, United States|Georgia Cancer Specialist, Atlanta, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Northshore University Healthsystem Research Institute, Evanston, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|University of Louisville, Louisville, Kentucky, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel-Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Karmanos Cancer Center Wayne State University, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|MSKCC Basking Ridge, Basking Ridge, New Jersey, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan-Kettering Cancer Center, Commack, New York, United States|Memorial Sloan Kettering Cancer Center West Harrison, Harrison, New York, United States|NYU Langone Medical Center, Lake Success, New York, United States|Memorial Sloan-Kettering Cancer Center - NYC, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|University of Rochester Cancer Center, James P. Wilmot Cancer Center, Rochester, New York, United States|MSKCC at Mercy Medical Center Mercy RockvilleCenter, Rockville Center, New York, United States|MSKCC at Phelps Memorial Hospital Center. Phelps Sleepy Hollow, Sleepy Hollow, New York, United States|State University of New York Upstate Medical Center, Syracuse, New York, United States|Wake Forest Univ. Health Sciences Outpatient Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|University of Cincinnati Medical CenterDivsion of Hematology OncologyThe Barrett Center, Cincinnati, Ohio, United States|Case Western Reserve Center, Cleveland, Ohio, United States|Cleveland Clinic - Taussig Cancer Institute, Cleveland, Ohio, United States|Cleveland Clinic Foundation IRB, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Oregon Health and Science University OHSU, Portland, Oregon, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|UPMC Cancer Pavillion, Pittsburgh, Pennsylvania, United States|Chattanooga Oncology Hematology Care, Chattanooga, Tennessee, United States|Sarah Cannon Research Inst, Nashville, Tennessee, United States|Vanderbilt- Ingram Cancer Center, Nashville, Tennessee, United States|Texas Oncology, Dallas, Texas, United States|Baylor Sammons Cancer Center, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|The Center for Cancer and Blood Disorders - Fort Worth, Fort Worth, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Texas Oncology, P.A. - Tyler, Tyler, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Seattle Cancer Care Alliance - Seattle, Seattle, Washington, United States|Virginia Mason Cancer Center, Seattle, Washington, United States|University of Wisconsin - Madison Cancer Center, Madison, Wisconsin, United States|Canberra Hospital, Garran, Australian Capital Territory, Australia|Northern Cancer Institute, St Leonards, New South Wales, Australia|ICON Cancer Center, Milton, Queensland, Australia|St John of God Subiaco Hospital, Subiaco, Western Australia, Australia|Monash Medical Centre Moorabbin Campus, Bentleigh East, Australia|Saint Vincent's Hospital, Darlinghurst, Australia|Austin Hospital, Heidelberg, Australia|Royal Brisbane and Women's Hospital, Herston, Australia|Cabrini Hospital, Malvern, Australia|Prince of Wales Hospital, Randwick, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|Medical University of Graz, Graz, Austria|Medical University Innsbruck, Innsbruck, Austria|Hospital of Elisabethinen Linz, Linz, Austria|Salzburger Landkliniken St. Johanns-Spital, Salzburg, Austria|Klinikum Wels-Grieskirchen GmbH, Wels, Austria|Hospital Wiener Neustadt, Wiener Neustadt, Austria|Medizinische Universitat Wien, Wien, Austria|Kaiser-Franz-Josef Spital, Wien, Austria|Hopital Erasme, Brussels, Belgium|UZ Antwerpen, Edegem, Belgium|UZ Gent, Gent, Belgium|UZ Leuven, Leuven, Belgium|Tom Baker Cancer Center, Calgary, Alberta, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Centre Hospitalier de L'Universite de Montreal St-Luc, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Krajska nemocnice Liberec, a.s., Liberec, Czechia|Krajska nemocnice T. Bati a.s., Zlin, Czechia|Hæmatologisk afd. B Aalborg Sygehus Syd, Aalborg, Denmark|Herlev Hospital, Herlev, Denmark|Onk.Dep., Odense Universitets hospital, Odense C, Denmark|Helsingin yliopistollinen keskussairaala, Helsinki, Finland|Tampereen yliopistollinen sairaala, Tampere, Finland|Turku University Hospital, Turku, Finland|Center Hospitalier Universitaire d' Angers, Angers cedex 09, France|Hopital Henri Mondor, Creteil, France|CHRU de Lille France, Lille, France|Hopital Edouard Herriot - Hepato-gastroenterologie, Lyon Cedex 3, France|Hopital prive Jean Mermoz, Lyon, France|Hopital Europeen Georges Pompidou, Paris, France|Hopital Saint Antoine, Paris, France|Hopital Pitie Salpetriere, Paris, France|CHU La Miletrie, Poitiers Cedex, France|Pole Des Specialites Medicales, Hopital Purpan, Toulose, France|Klinikum Weiden, Bayern, Germany|Charite - Universitätsmedizin Berlin, Berlin, Germany|Universitatsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Germany|Kliniken Essen-Mitte, Essen, Germany|Universitatsklinkum Frankfurt, Frankfurt, Germany|Praxis Internistischer Onkologie und Hamatologie Frechen, Frechen, Germany|Praxis für Innere Medizin, Dr.Oettle Helmut, Friedrichshafen, Germany|Ernst-Moritz-Arndt-Universität Greifswald, Greifswald, Germany|Universitaetsklinik Hamburg - Eppendorf, Hamburg, Germany|Praxis Internistischer Onkologie und Hamatologie Koln, Köln, Germany|Universitatsklinik Magdeburg, Magdeburg, Germany|Klinikum der Johannes Gutenberg Uniervsitaet ,Haematologie, Mainz, Germany|Klinikum der Universitat Munchen-Grosshadern, München, Germany|Klinikum Neuperlach, München, Germany|University of Tubingen, Tübingen, Germany|Universitatsklinikum Würzburg, Würzburg, Germany|Queen Mary Hospital, Hong Kong, Hong Kong|Tuen Mun Hospital, Hong Kong, Hong Kong|Prince of Wales Hospital the Chinese University of Hong Kong, Sha Tin, Hong Kong|Fovarosi Szent Istvan es Szent Laszlo Korhaz es Rendelointezet, Budapest, Hungary|Uzsoki Utcai Korhaz, Budapest, Hungary|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Petz Aladar Megyei Oktato Korhaz,II. Belgyogyaszat, Gyor, Hungary|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont Szent-Gyorgyi Albert TE AOK Borgyogy, Szeged, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet, Szolnok, Hungary|Cork University Hospital, Cork, Ireland|St Vincent's University Hospital, Dublin 4, Ireland|Ospedali Riuniti Umberto I GM Lancisi, Ancona, Italy|Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi, Bologna, Italy|Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy|Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori (I.R.S.T.), Meldola, Italy|Ospedale San Raffaele S.r.l., Milano, Italy|Azienda Ospedaliera Niguarda Ca Granda, Milano, Italy|Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy|Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Istituto Nazionale Tumori Regina Elena, Roma, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy|Azienda Ospedaliera S Maria di Terni, Terni, Italy|Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Academisch Medisch Centrum Amsterdam, Amsterdam, Netherlands|Catharina Hospital, Eindhoven, Netherlands|Isala Klinieken, Zwolle, Netherlands|Centro Hospitalar de Lisboa Central - Hospital de Santo António dos Capuchos, Lisboa, Portugal|Hospital Da Luz, Lisboa, Portugal|Hospital de Sao Joao, Porto, Portugal|National University Hospital, Singapore, Singapore|National Cancer Center, Singapore, Singapore|Clinic Barcelona Hospital Universitari, Barcelona, Spain|Instituto Catalan de Oncologia-Hospital Duran, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital General Gregorio Maranon, Madrid, Spain|Ramon y Cajal Univeresity Hospital, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Centro Integral, Madrid, Spain|Hospital General Carlos Haya, Malaga, Spain|Complejo Hospitalario de Navarra, Pamplona/ Navarra, Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Hospital Clinico Universitario De Santiago De Compostela, Santiago De Compostela, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiana, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Chang Gung Medical Foundation-Linkou Branch, Taoyuan, Taiwan|National Taiwan University Hospital, Tapei, Taiwan|Addenbrookes Hospital, Cambridge, United Kingdom|Glasgow Royal Infirmary, Glasgow, United Kingdom|Weston Park Hospital, Sheffield South Yorkshire, United Kingdom",https://ClinicalTrials.gov/show/NCT01964430
169,Eli Lilly and Company,A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer,"Active, not recruiting",Has Results,Metastatic Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma,Drug: Ramucirumab|Drug: Capecitabine|Drug: Cisplatin|Drug: Placebo|Drug: Fluorouracil,Industry,Interventional,"Highlands Oncology Group, Fayetteville, Arkansas, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|St Jude Medical Center, Fullerton, California, United States|SMO TRIO -Translational Research, Los Angeles, California, United States|UCLA Medical Center, Los Angeles, California, United States|Cancer Care Associates Medical Group, Redondo Beach, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Medical Oncology Corporation, Santa Monica, California, United States|University of Colorado School of Medicine, Aurora, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists and Research Institute, Saint Petersburg, Florida, United States|Emory University, Atlanta, Georgia, United States|Illinois CancerCare, Peoria, Illinois, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Weill Cornell Medical College, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Oncology Hematology Care Inc, Cincinnati, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|SMO Sarah Cannon Research Inst., Nashville, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|UT Southwestern Med Ctr, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Viedma, Rio Negro, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rosario, Santa Fe, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ciudad Autonoma Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Rioja, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rosario, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salta, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussels, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleroi, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gent, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven, Belgium|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Montreal, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Montreal, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Ottawa, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Toronto, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Toronto, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Toronto, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Toronto, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Vancouver, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brno, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hradec Kralove, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Olomouc, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Praha 2, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Praha 5, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aalborg, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aarhus C, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Odense C, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Helsinki, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oulu, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Turku, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Avignon Cedex 9, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Clermont-Ferrand, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Etienne, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Herblain Cedex, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Villejuif, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dresden, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt am Main, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mannheim, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., München, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Budapest, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Debrecen, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gyula, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kaposvar, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Szolnok, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haifa, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jerusalem, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Petach Tikva, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Hashomer, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel-Aviv Jaffa, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Firenze, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Napoli, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Padova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pisa, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roma, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Torrette Di Ancona, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Udine, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiba, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Higashinari-Ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kashiwa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kitaadachi-Gun, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kobe, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Koto-ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nagoya, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Suita-shi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sunto-Gun, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Utsunomiya, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, DF, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guadalajara, Jalisco, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Bernardino, Toluca, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Juchitan, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Merida, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oaxaca, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Breda, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nieuwegein, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sittard - Geleen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gdansk, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lodz, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poznan, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warszawa, Poland|Ad-Vance Medical Research, Ponce, Puerto Rico|Hospital Espanol Auxilio Mutuo, San Juan, Puerto Rico|VA Caribbean Healthcare System, San Juan, Puerto Rico|Hospital Municipal de San Juan, San Juan, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Arkhangelsk, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Elche, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aberdeen, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cambridge, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Merseyside, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nottingham, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sheffield, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sutton, United Kingdom",https://ClinicalTrials.gov/show/NCT02314117
170,Eisai Limited|Eisai Inc.,Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma,"Active, not recruiting",Has Results,Tumors|Solid Malignant Tumors|Osteosarcoma|Differentiated Thyroid Cancer (DTC),Drug: Lenvatinib|Drug: Ifosfamide|Drug: Etoposide,Industry,Interventional,"Texas Children's Hospital, Houston, Texas, United States|CHU Strasbourg - Hopital Hautepierre, Strasbourg, Bas Rhin, France|Centre Oscar Lambret Lille, Lille, Rhone, France|Centre Leon Berard, Lyon, Rhone, France|CHU Nantes - Hopital Mere-Enfant, Nantes, France|Institut Curie - Centre de Lutte Contre le Cancer (CLCC) de Paris, Paris, France|Institut Gustave Roussy, Paris, France|CHU de Toulouse - Hopital des Enfants, Toulouse, France|Universitaetsklinikum Muenster, Muenster, Germany|Kinderklinik des Olga hospitals, Stuttgart, Germany|Istituto Ortopedico Rizzoli, Bologna, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy|Ospedale Pediatrico Bambino Gesu, Roma, Italy|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Infantil Universitario Nino Jesus, Madrid, Spain|Hospital Universitario y Politecnico La Fe Hospital La Fe Valencia, Valencia, Spain|Birmingham Children's Hospital, Birmingham, United Kingdom|University College London Hospital, London, United Kingdom|Royal Victoria Infirmary, Newcastle, United Kingdom",https://ClinicalTrials.gov/show/NCT02432274
171,AstraZeneca,Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer,"Active, not recruiting",Has Results,Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN,Drug: MEDI4736|Drug: MEDI4736 + Tremelimumab|Drug: Standard of Care,Industry,Interventional,"Research Site, Tucson, Arizona, United States|Research Site, Fullerton, California, United States|Research Site, Los Angeles, California, United States|Research Site, Redondo Beach, California, United States|Research Site, Stanford, California, United States|Research Site, Denver, Colorado, United States|Research Site, Newark, Delaware, United States|Research Site, Miami Beach, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Evanston, Illinois, United States|Research Site, Lexington, Kentucky, United States|Research Site, Boston, Massachusetts, United States|Research Site, Rochester, New York, United States|Research Site, Rochester, New York, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Germantown, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, McAllen, Texas, United States|Research Site, Norfolk, Virginia, United States|Research Site, Caba, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, Adelaide, Australia|Research Site, Heidelberg, Australia|Research Site, Melbourne, Australia|Research Site, St Leonards, Australia|Research Site, Woolloongabba, Australia|Research Site, Brussels, Belgium|Research Site, Bruxelles, Belgium|Research Site, Charleroi, Belgium|Research Site, Kortrijk, Belgium|Research Site, Leuven, Belgium|Research Site, Namur, Belgium|Research Site, Barretos, Brazil|Research Site, Curitiba, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Santo Andre, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, São Paulo, Brazil|Research Site, Shumen, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Temuco, Chile|Research Site, Osijek, Croatia|Research Site, Zagreb, Croatia|Research Site, Olomouc, Czechia|Research Site, Zlin, Czechia|Research Site, Angers, France|Research Site, Bordeaux, France|Research Site, Dijon, France|Research Site, Le Mans, France|Research Site, Lyon Cedex 08, France|Research Site, Montpellier Cedex 5, France|Research Site, Paris Cedex 5, France|Research Site, Plerin SUR MER, France|Research Site, Rouen, France|Research Site, St Grégoire, France|Research Site, Strasbourg Cedex, France|Research Site, Villejuif Cedex, France|Research Site, Lorient Cedex, Georgia|Research Site, Berlin, Germany|Research Site, Essen, Germany|Research Site, Halle, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Leipzig, Germany|Research Site, München, Germany|Research Site, Potsdam, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Gyor, Hungary|Research Site, Kecskemét, Hungary|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Petach-Tikva, Israel|Research Site, Tel Aviv, Israel|Research Site, Tel Hashomer, Israel|Research Site, Aosta, Italy|Research Site, Bologna, Italy|Research Site, Gallarate, Italy|Research Site, Legnago, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Pavia, Italy|Research Site, Roma, Italy|Research Site, Siena, Italy|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Hirakata-shi, Japan|Research Site, Isehara-shi, Japan|Research Site, Kashiwa, Japan|Research Site, Kitaadachi-gun, Japan|Research Site, Kobe-shi, Japan|Research Site, Koto-ku, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Nagoya, Japan|Research Site, Natori-shi, Japan|Research Site, Okayama, Japan|Research Site, Osakasayama, Japan|Research Site, Osaka, Japan|Research Site, Sapporo, Japan|Research Site, Sapporo, Japan|Research Site, Shimotsuke-shi, Japan|Research Site, Sunto-gun, Japan|Research Site, Takatsuki-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama, Japan|Research Site, Daegu, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon, Korea, Republic of|Research Site, Kraków, Poland|Research Site, Poznań, Poland|Research Site, Łódź, Poland|Research Site, Baia Mare, Romania|Research Site, Brasov, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Cluj, Romania|Research Site, Craiova, Romania|Research Site, Arkhangelsk, Russian Federation|Research Site, Chelyabinsk, Russian Federation|Research Site, Kursk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Pyatigorsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Sankt-Peterburg, Russian Federation|Research Site, Sochi, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Vladimir, Russian Federation|Research Site, Belgrade, Serbia|Research Site, Belgrad, Serbia|Research Site, Kragujevac, Serbia|Research Site, Nis, Serbia|Research Site, Sremska Kamenica, Serbia|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, L'Hospitalet de Llobregat, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Malaga, Spain|Research Site, Marbella, Spain|Research Site, Pamplona, Spain|Research Site, Valencia, Spain|Research Site, Valencia, Spain|Research Site, Zaragoza, Spain|Research Site, Kaohsiung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoynan, Taiwan|Research Site, Dnipro, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Sumy, Ukraine|Research Site, Uzhhorod, Ukraine|Research Site, Zaporizhzhia, Ukraine",https://ClinicalTrials.gov/show/NCT02369874
172,Pfizer,Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer,"Active, not recruiting",Has Results,Squamous Cell Carcinoma of the Head and Neck (SCCHN),Drug: palbociclib|Drug: Cetuximab|Drug: Placebo,Industry,Interventional,"UC San Diego Medical Center - La Jolla (Thornton Hospital), La Jolla, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|UC San Diego Medical Center- Hillcrest, San Diego, California, United States|University Medical Center, lnc.:DBA University of Louisville Hospital, Louisville, Kentucky, United States|Mayo Clinic, Rochester, Minnesota, United States|Siteman Cancer Center - West County, Creve Coeur, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Washington University School of Medicine, Siteman Cancer Center, Saint Louis, Missouri, United States|Siteman Cancer Center - South County, Saint Louis, Missouri, United States|Siteman Cancer Center, Saint Peters, Missouri, United States|University of Cincinnati Investigational Pharmacy, Cincinnati, Ohio, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|UC Health Physicians Office South, West Chester, Ohio, United States|Henry Joyce Cancer Clinic, Nashville, Tennessee, United States|Fakultni nemocnice Olomouc, Olomouc, Czechia|Fakultni nemocnice Olomouc, Lekarna, Olomouc, Czechia|Nemocnice Na Bulovce, Centralni laboratore Pavilon c. 8, Praha 8, Czechia|Nemocnice Na Bulovce, Lekarna, Oddeleni Centralni pripravy, Praha 8, Czechia|Nemocnice Na Bulovce, Ustav radiacni onkologie, Praha 8, Czechia|Debreceni Egyetem klinikai Koezpont Onkologiai Intezet, Debrecen, Hungary|Neuro CT Kft, Pecs, Hungary|Pecsi Tudomanyegyetem, Klinikai Kozpont, Laboratoriumi, Pecs, Hungary|Pecsi Tudomanyegyetem, Klinikai Kozpont,, Pecs, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet,Onkologiai Kozpont, Szolnok, Hungary|Istituto Nazionale Tumori Napoli, Napoli, Italy|Aichi cancer center Central hospital, Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|Hokkaido University Hospital/Otolaryngology, Sapporo, Hokkaido, Japan|Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Instituto Nacional de Cancerologia, Mexico, Distrito Federal, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo LEON, Mexico|Cirugia y Ginecobstetricia de Oaxaca S.A de C.V Hospital Reforma, Oaxaca, Oaxaca DE Juarez, Mexico|Diaz San Juan Noe, Imagenologia Siglo XXI San Felipe, Oaxaca, Oaxaca DE Juarez, Mexico|Daniel Javier Mendez Lopez Imagen y Diagnostico Medico IDM, Oaxaca, Oaxaca DE Juarez, Mexico|Oaxaca Site Management Organization S C, Oaxaca, Mexico|Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im. ks. B. Markiewicza, Brzozow, Poland|Uniwersyteckie Centrum Kliniczne Klinika Onkologii i Radioterapii, Gdansk, Poland|Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi Oddzial Chemioterapii, Lodz, Poland|SPZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie Oddzial Kliniczny Onkologii, Olsztyn, Poland|SC Medisprof SRL, Cluj-Napoca, Cluj, Romania|Centrul de Oncologie Sf. Nectarie SRL, Craiova, Dolj, Romania|SC Oncolab SRL, Craiova, Dolj, Romania|S.C. ONCOCENTER Oncologie Clinica S.R.L., Timisoara, Timis, Romania|Spitalul Clinic Judetean de Urgenta Sibiu, Clinica Oncologie Medicala, Sibiu, Romania|State Budgetary Healthcare Institution of Arkhangelsk Region, Arkhangelsk, Arkhangelsk Region, Russian Federation|State Budgetary Healthcare Institution ""Oncology Center #2"" of the Ministry of, Sochi, Krasnodar Region, Russian Federation|State Autonomous Healthcare Institution Republican Clinical Oncology Dispensary of the Ministry, Kazan, Tatarstan Republic, Russian Federation|FSBI ""National Medical Scientific Centre of Oncology n.a.N.N.Petrov"" of the MOH of Russia, Saint-Petersburg, Russian Federation|Institute for Oncology and Radiology of Serbia, Belgrade, Serbia|Military Medical Academy, Belgrade, Serbia|Narodny onkologicky ustav, Bratislava, Slovakia|POKO Poprad, s.r.o., Poprad, Slovakia|Servicio de Oncologia, Pamplona, Navarra, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Taichung Veterans General Hospital, Taichung City, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Cheng Kung University Hospital Department of Pathology, Tainan, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Communal Institution of Kherson Regional Council Kherson Regional Oncological Dispensary, Antonivka, Kherson Region, Ukraine|Communal Institution ""Chernivtsi Regional clinical oncology dispensary"",, Chernivtsy, Ukraine|SI Dnipropetrovsk Medical Academy of MoH of Ukraine, Chair of Oncology and Medical Radiology, Dnipropetrovsk, Ukraine|CI Dnipropetrovsk City Multifunctional Clinical Hospital #4 of Dnipropetrovsk Regional Council, Dnipropetrovsk, Ukraine|Regional Clinical Hospital, Department of microsurgery of otolaryngology organs, Ivano-Frankivsk, Ukraine|Communal Institution ""Krivorizhskiy Oncology Dispensary"" of Dnipropetrovsk Regional Council,, Kriviy Rig, Ukraine|Clinic of SI ""Institute of Otolaryngology n.a. Prof. O.S. Kolomyichenka of NAMSU"", Kyiv, Ukraine|Podilskiy Regional Center of Oncology, Chemotherapy Department, Vinnytsia, Ukraine",https://ClinicalTrials.gov/show/NCT02499120
173,"Andrew J. Wagner, MD, PhD|Brigham and Women's Hospital|Massachusetts General Hospital|Novartis|Dana-Farber Cancer Institute",Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor,"Active, not recruiting",Has Results,Pigmented Villonodular Synovitis|Diffuse-type Giant Cell Tumor|Tenosynovial Giant Cell Tumor,Drug: nilotinib,Other|Industry,Interventional,"Sarcoma Oncology Center, Santa Monica, California, United States|Stanford University Medical Center, Stanford, California, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|UT MD Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT01207492
174,Eli Lilly and Company,A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer,"Active, not recruiting",Has Results,Urothelial Carcinoma,Drug: Ramucirumab|Drug: Docetaxel|Drug: Placebo,Industry,Interventional,"Highlands Oncology Group, Fayetteville, Arkansas, United States|St. Jude Medical Center, Fullerton, California, United States|UCLA Medical Center, Los Angeles, California, United States|USC Norris Cancer Hospital, Los Angeles, California, United States|SMO TRIO -Translational Research, Los Angeles, California, United States|Cancer Care Associates Medical Group, Redondo Beach, California, United States|University of California, Davis - Health Systems, Sacramento, California, United States|Central Coast Medical Oncology Corporation, Santa Monica, California, United States|University of Colorado, Aurora, Colorado, United States|Pharmatech Oncology Inc, Denver, Colorado, United States|St Mary's Hospital Regional Cancer Center, Grand Junction, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Southeast Florida Hematology/Oncology, Fort Lauderdale, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Lakeland Regional Cancer Center, Lakeland, Florida, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Southeastern Regional Medical Center, Newnan, Georgia, United States|The Queen's Medical Center, Honolulu, Hawaii, United States|Fort Wayne Oncology & Hematology, Fort Wayne, Indiana, United States|Alton Ochsner Medical Center, New Orleans, Louisiana, United States|University of Maryland- Biological Sciences, Baltimore, Maryland, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Cornell University Medical College, New York, New York, United States|SUNY at Stony Brook, Stony Brook, New York, United States|Oncology Hematology Care Inc., Cincinnati, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|SMO Sarah Cannon Research Inst., Nashville, Tennessee, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States|Inova Comprehensive Cancer Care & Research Institute, Fairfax, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Adelaide, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Footscray, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Randwick, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Subiaco, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussels, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wilrijk, Belgium|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Toronto, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Vancouver, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Herlev, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Odense, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Caen, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lyon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montpellier, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dusseldorf, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Freiburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Homburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jena, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tubingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heraklion, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Patras, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Thessaloniki, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Budapest, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miskolc, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haifa, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kfar Saba, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Petach Tikva, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Hashomer, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Tel-Aviv, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zerifin, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Arezzo, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bologna, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orbassano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Verona, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bunkyo-ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiba, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hidaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hirosaki, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kashiwa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kita-gun, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kobe, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Matsuyama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Morioka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Niigata, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sapporo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sendai, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Suita-shi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tsukuba, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daejeon, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Seongnam-si, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seongnam, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aguascalientes, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Culiacan, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Morelia, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Arnhem, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Maastricht, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rotterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sittard, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gdansk, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poznan, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warszawa, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wieliszew, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baia Mare, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cluj-Napoca, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Craiova, Romania|Ivanovo regional clinical oncology dispensary, Ivanovo, Russian Federation|Republic Oncology Dispensary of MoH of Republic Tatarstan, Kazan, Russian Federation|Scientific research oncology institute n.a. P. A. Herzen, Moscow, Russian Federation|Saint-Petersburg city clinical oncology dispensary, Saint Petersburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saratov, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Badajoz, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kaohsiung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tainan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ankara, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Antalya, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edirne, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Istanbul, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malatya, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dnipropetrovsk, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyiv, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lutsk, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bebington, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Chelsea, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nottingham, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Southampton, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sutton, United Kingdom",https://ClinicalTrials.gov/show/NCT02426125
175,Northwestern University|Robert H. Lurie Cancer Center|National Comprehensive Cancer Network|GlaxoSmithKline,Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery,"Active, not recruiting",Has Results,Pancreatic Alpha Cell Carcinoma|Pancreatic Beta Islet Cell Carcinoma|Pancreatic Delta Cell Carcinoma|Pancreatic G-cell Carcinoma|Recurrent Islet Cell Carcinoma,Drug: temozolomide|Drug: pazopanib hydrochloride,Other|Industry,Interventional,"Northwestern University, Chicago, Illinois, United States|University of Michigan, Ann Arbor, Michigan, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|University of Washington Seattle Cancer Care Alliance, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT01465659
176,Centus Biotherapeutics Limited,Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer,"Active, not recruiting",Has Results,"Carcinoma, Non-Small-Cell Lung",Drug: FKB238 (bevacizumab)|Drug: Avastin (bevacizumab)|Drug: Paclitaxel|Drug: Carboplatin,Industry,Interventional,"Research Site 7814 - Compassionate Care Research Group, Fountain Valley, California, United States|Research Site 7811 - Innovative Clinical Research Institute, Whittier, California, United States|Research Site 7803 - 21st Century Oncology, Jacksonville, Florida, United States|Research Site 7812 - Joliet Oncology-Hematology Associates, Ltd., Joliet, Illinois, United States|Research Site 7810 - Edward H. Kaplan, MD and Associates, Skokie, Illinois, United States|Research Site 7813 - Trinity Cancer Care Center, Minot, North Dakota, United States|Research Site 7805 - Hematology & Oncology Associates, Inc., Canton, Ohio, United States|Research Site 7801 - Gabrail Cancer Center, Canton, Ohio, United States|Research Site 7804 - Tri-County Hematology & Oncology Associates, Inc., Massillon, Ohio, United States|Research Site 7809 - Millennium Oncology, Houston, Texas, United States|Research Site 7806 - Vista Oncology Inc. PS, Olympia, Washington, United States|Research Site 8507, Brest, Brestskaya Voblasts, Belarus|Research Site 8505, Grodno, Hrodzenskaya Voblasts, Belarus|Research Site 8502, Mogilev, Mahilyowskaya Voblasts, Belarus|Research Site 8501, Lesnoy, Minskaya Voblasts, Belarus|Research Site 8504, Minsk, Minskaya Voblasts, Belarus|Research Site 8506, Vitebsk, Vitsyebskaya Voblasts, Belarus|Research Site 8605, Tuzla, Tuzlanski Kanton, Bosnia and Herzegovina|Research Site 8606, Banja Luka, Bosnia and Herzegovina|Research Site 8602, Mostar, Bosnia and Herzegovina|Research Site 8601, Sarajevo, Bosnia and Herzegovina|Research Site 8603, Sarajevo, Bosnia and Herzegovina|Research Site 8604, Zenica, Bosnia and Herzegovina|Research Site 0905, Sofia, Dobrich, Bulgaria|Research Site 0904, Varna, Bulgaria|Research Site 1802, Zagreb, Grad Zagreb, Croatia|Research Site 1803, Zagreb, Grad Zagreb, Croatia|Research Site 1801, Osijek, Osjecko-baranjska Županija, Croatia|Research Site 2504, Bat'umi, Ajaria, Georgia|Research Site 2507, Kutaisi, Imereti, Georgia|Research Site 2503, Tbilisi, Georgia|Research Site 2505, Tbilisi, Georgia|Research Site 2508, Tbilisi, Georgia|Research Site 2605, Würselen, Nordrhein-Westfalen, Germany|Research Site 2603, Kiel, Schleswig-Holstein, Germany|Research Site 2604, Hamburg, Germany|Research Site 3004, Athens, Greece|Research Site 3003, Thessaloniki, Greece|Research Site 3005, Thessaloníki, Greece|Research Site 3303, Gyula, Békés, Hungary|Research Site 3302, Deszk, Csongrád, Hungary|Research Site 3301, Mátraháza, Heves, Hungary|Research Site 3305, Budapest, Hungary|Research Site 3304, Budapest, Hungary|Research Site 3306, Zalaegerszeg, Hungary|Research Site 4107, Catania, Italy|Research Site 4106, Piacenza, Italy|Research Site 4301, Fukuyama-shi, Hiroshima, Japan|Research Site 4304, Kumamoto-shi, Kumamoto, Japan|Research Site 4303, Sasebo-shi, Nagasaki, Japan|Research Site 6005, Busan, Busan Gwang'yeogsi, Korea, Republic of|Research Site 6004, Suwon-si, Gyeonggido, Korea, Republic of|Research Site 6002, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Research Site 6003, Ulsan, Ulsan Gwang'yeogsi, Korea, Republic of|Research Site 5402, Arequipa, Peru|Research Site 5404, Arequipa, Peru|Research Site 5401, Lima, Peru|Research Site 5405, Lima, Peru|Research Site 5505, Cebu City, Cebu, Philippines|Research Site 5504, Makati City, National Capital Region, Philippines|Research Site 5501, Manila, National Capital Region, Philippines|Research Site 5502, Manila, National Capital Region, Philippines|Research Site 5506, Manila, National Capital Region, Philippines|Research Site 5503, Quezon, Philippines|Research Site 5705, Toruniak, Kujawsko-pomorskie, Poland|Research Site 5708, Lodz, Lódzkie, Poland|Research Site 5701, Krakow, Malopolskie, Poland|Research Site 5702, Elblag, Warminsko-mazurskie, Poland|Research Site 5706, Olsztyn, Warminsko-mazurskie, Poland|Research Site 5711, Brzozów, Poland|Research Site 5703, Nowy Sacz, Poland|Research Site 6105, Cluj-Napoca, Cluj, Romania|Research Site 6106, Cluj-Napoca, Cluj, Romania|Research Site 6108, Floreşti, Cluj, Romania|Research Site 6101, Baia Mare, Romania|Research Site 6102, Constanta, Romania|Research Site 6103, Craiova, Romania|Research Site 6107, Iasi, Romania|Research Site 6209, Arkhangelsk, Arkhangel'skaya Oblast', Russian Federation|Research Site 6220, Ufa, Bashkortostan, Respublika, Russian Federation|Research Site 6221, Belgorod, Belgorodskaya Oblast', Russian Federation|Research Site 6211, Chelyabinsk, Chelyabinskaya Oblast', Russian Federation|Research Site 6217, Kuzmolovskiy, Leningradskaya Oblast', Russian Federation|Research Site 6219, Saransk, Mordoviya, Respublika, Russian Federation|Research Site 6225, Moscow, Moskva, Russian Federation|Research Site 6203, Moscow, Moskva, Russian Federation|Research Site 6230, Novgorod, Nizhegorodskaya Oblast', Russian Federation|Research Site 6214, Novosibirsk, Novosibirskaya Oblast', Russian Federation|Research Site 6213, Novosibirsk, Novosibirskaya Oblast', Russian Federation|Research Site 6215, Omsk, Omskaya Oblast', Russian Federation|Research Site 6224, Omsk, Omskaya Oblast', Russian Federation|Research Site 6208, Orenburg, Orenburgskaya Oblast', Russian Federation|Research Site 6223, Rostov-on-Don, Rostovskaya Oblast', Russian Federation|Research Site 6205, Ryazan', Ryazanskaya Oblast', Russian Federation|Research Site 6234, Samara, Samarskaya Oblast', Russian Federation|Research Site 6235, Saint Petersburg, Sankt-Peterburg, Russian Federation|Research Site 6212, Saint Petersburg, Sankt-Peterburg, Russian Federation|Research Site 6216, Saint Petersburg, Sankt-Peterburg, Russian Federation|Research Site 6201, Saint Petersburg, Sankt-Peterburg, Russian Federation|Research Site 6202, Sankt Petersburg, Sankt-Peterburg, Russian Federation|Research Site 6210, Sankt Petersburg, Sankt-Peterburg, Russian Federation|Research Site 6229, Izhevsk, Udmurtskaya Respublika, Russian Federation|Research Site 6228, Kursk, Russian Federation|Research Site 6207, Magnitogorsk, Russian Federation|Research Site 6222, Saint Petersburg, Russian Federation|Research Site 6401, Sremska Kamenica, Vojvodina, Serbia|Research Site 6402, Belgrade, Serbia|Research Site 6403, Belgrade, Serbia|Research Site 6404, Belgrade, Serbia|Research Site 6405, Belgrade, Serbia|Research Site 6406, Kragujevac, Šumadijski Okrug, Serbia|Research Site 7004, A Coruna, A Coruña, Spain|Research Site 7002, Castellón De La Plana, Castellon, Spain|Research Site 7005, Cordoba, Córdoba, Spain|Research Site 7009, Jaen, Jaén, Spain|Research Site 7001, Burgos, Spain|Research Site 7007, Madrid, Spain|Research Site 7008, Murcia, Spain|Research Site 7003, Murcia, Spain|Research Site 7402, New Taipei City, Taipei, Taiwan|Research Site 7404, Douliu, Yunlin, Taiwan|Research Site 7403, Changhua, Taiwan|Research Site 7401, Taipei, Taiwan|Research Site 7506, Bangkok, Krung Thep Maha Nakhon, Thailand|Research Site 7501, Hat Yai, Songkhla, Thailand|Research Site 7504, Bangkok, Thailand|Research Site 7507, Chiang Mai, Thailand|Research Site 7505, Chiang Rai, Thailand|Research Site 7503, Khon Kaen, Thailand|Research Site 7502, Udon Thani, Thailand|Research Site 7607, Ankara, Turkey|Research Site 7605, İzmir, Turkey|Research Site 7601, Izmir, Turkey|Research Site 7606, Malatya, Turkey|Research Site 7702, Chernivtsi, Chernivets'ka Oblast', Ukraine|Research Site 7705, Kharkiv, Kharkivs'ka Oblast', Ukraine|Research Site 7706, Odesa, Odes'ka Oblast', Ukraine|Research Site 7713, Lutsk, Volyns'ka Oblast', Ukraine|Research Site 7707, Uzhgorod, Zakarpats'ka Oblast', Ukraine|Research Site 7709, Dnipropetrovs'k, Ukraine|Research Site 7701, Ivano-Frankivs'k, Ukraine|Research Site 7708, Kryvyi Rih, Ukraine|Research Site 7704, Kyiv, Ukraine|Research Site 7710, Sumy, Ukraine|Research Site 8401, Hanoi, Ha Noi, Thu Do, Vietnam|Research Site 8402, Hanoi, Ha Noi, Thu Do, Vietnam|Research Site 8405, Hanoi, Ha Noi, Thu Do, Vietnam",https://ClinicalTrials.gov/show/NCT02810457
177,AstraZeneca|Hutchinson MediPharma (HMP),Savolitinib vs. Sunitinib in MET-driven PRCC.,"Active, not recruiting",Has Results,"Carcinoma|Carcinoma, Renal Cell|Kidney Neoplasms|Urologic Neoplasms|Kidney Diseases|Neoplasms by Site|Enzyme Inhibitors|Protein Kinase Inhibitors",Drug: Savolitinib|Drug: Sunitinib,Industry|Other,Interventional,"Research Site, La Jolla, California, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Iowa City, Iowa, United States|Research Site, Boston, Massachusetts, United States|Research Site, Kansas City, Missouri, United States|Research Site, New York, New York, United States|Research Site, Nashville, Tennessee, United States|Research Site, Barretos, Brazil|Research Site, Curitiba, Brazil|Research Site, Passo Fundo, Brazil|Research Site, Pelotas, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, Bordeaux Cedex, France|Research Site, Vandoeuvre les Nancy, France|Research Site, Villejuif, France|Research Site, Arezzo, Italy|Research Site, Meldola, Italy|Research Site, Milano, Italy|Research Site, Modena, Italy|Research Site, Orbassano, Italy|Research Site, Pavia, Italy|Research Site, Roma, Italy|Research Site, Daejeon, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Hwasun-gun, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Krasnoyarsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Murmansk, Russian Federation|Research Site, Nizhnii Novgorod, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Dnipro, Ukraine|Research Site, Dnipro, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Odesa, Ukraine|Research Site, Sumy, Ukraine",https://ClinicalTrials.gov/show/NCT03091192
178,"Massachusetts General Hospital|Stanford University|Yale University|University of Maryland, College Park|Genentech, Inc.",Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations,"Active, not recruiting",Has Results,Non-small Cell Lung Cancer,Drug: Erlotinib|Drug: Hydroxychloroquine,Other|Industry,Interventional,"Stanford Cancer Institute, Stanford, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|University of Maryland, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT00977470
179,AstraZeneca,Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats,"Active, not recruiting",Has Results,Ovarian|Breast|Prostate|Pancreatic|Advanced Tumours,Drug: olaparib,Industry,Interventional,"Research Site, Los Angeles, California, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Melbourne, Australia|Research Site, Randwick, Australia|Research Site, Köln, Germany|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Petah Tikva, Israel|Research Site, Barcelona, Spain|Research Site, Lund, Sweden",https://ClinicalTrials.gov/show/NCT01078662
180,"Brigham and Women's Hospital|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI)|Office of Dietary Supplements (ODS)|National Institute of Neurological Disorders and Stroke (NINDS)|National Center for Complementary and Integrative Health (NCCIH)|Pharmavite LLC|Pronova BioPharma|BASF",Vitamin D and Omega-3 Trial (VITAL),"Active, not recruiting",Has Results,Cancer|Cardiovascular Disease,Dietary Supplement: vitamin D3|Drug: omega-3 fatty acids (fish oil)|Dietary Supplement: Vitamin D3 placebo|Dietary Supplement: Fish oil placebo,Other|NIH|Industry,Interventional,"Brigham and Women's Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT01169259
181,University of Iowa|Amgen,TVEC and Preop Radiation for Sarcoma (4 ml Dose),"Active, not recruiting",Has Results,Soft Tissue Sarcoma,Drug: Talimogene Laherparepvec|Radiation: Radiotherapy,Other|Industry,Interventional,"University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",https://ClinicalTrials.gov/show/NCT02453191
182,Massachusetts General Hospital|Dana-Farber Cancer Institute|PharmaMar,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,"Active, not recruiting",Has Results,Metastatic Sarcoma,Drug: PM01183|Drug: Doxorubicin|Drug: Gemcitabine,Other|Industry,Interventional,"Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT02448537
183,Bristol-Myers Squibb|AbbVie,"Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma","Active, not recruiting",Has Results,Multiple Myeloma,Drug: Lenalidomide|Drug: Dexamethasone|Biological: Elotuzumab (BMS-901608; HuLuc63),Industry,Interventional,"Alabama Oncology, Birmingham, Alabama, United States|University Of South Alabama / Mitchell Cancer Institute, Mobile, Alabama, United States|Southern Cancer Center, Inc., Mobile, Alabama, United States|Ironwood Cancer And Research Centers, Pc, Chandler, Arizona, United States|Acrc/Arizona Clinical Research Center, Inc., Tucson, Arizona, United States|Comprehensive Blood And Cancer Center, Bakersfield, California, United States|Alta Bates Summit Comprehensive Cancer Center, Berkeley, California, United States|Compassionate Cancer Care Medical Group, Inc., Corona, California, United States|Compassionate Cancer Res Grp, Corona, California, United States|Marin Cancer Care, Inc, Greenbrae, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|Ucla-Division Of Hematology/Oncology, Los Angeles, California, United States|Medical Oncology Care Associates, Orange, California, United States|Sharp Clinical Oncology Research, San Diego, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Washington Cancer Inst at MedStar Washington Hospital Ctr, Washington, District of Columbia, United States|Lynn Cancer Institute Center For Hematology-Oncology, Boca Raton, Florida, United States|Local Institution, Brooksville, Florida, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|Memorial Cancer Institute, Hollywood, Florida, United States|Cancer Specialists, LLC, Jacksonville, Florida, United States|Local Institution, New Port Richey, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Palm Beach Cancer Institute, West Palm Beach, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Kaiser Permanente Hawaii, Honolulu, Hawaii, United States|The University Of Chicago, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Loyola University Chicago, Maywood, Illinois, United States|Illinois Cancercare, PC, Peoria, Illinois, United States|Orchard Healthcare Research Inc., Skokie, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Premier Healthcare, Llc, Bloomington, Indiana, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|Investigative Clinical Research Of Indiana, Llc, Indianapolis, Indiana, United States|Local Institution, Mishawaka, Indiana, United States|University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Cancer Center Of Acadiana At Lafayette General, Lafayette, Louisiana, United States|Crescent City Research Consortium, LLC, Marrero, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Willis Knighton Cancer Center, Shreveport, Louisiana, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Harry & Jeanette Weinberg Cancer Institute, Baltimore, Maryland, United States|Dana Farber Cancer Institute., Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University Of Michigan, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Columbia Comprehensive Cancer Care Clinic, Jefferson City, Missouri, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|Local Institution, Lincoln, Nebraska, United States|University Of Nebraska Medical Center, Omaha, Nebraska, United States|Winthrop University Hospital, Mineola, New York, United States|Local Institution, New York, New York, United States|St. Luke'S Roosevelt Hospital Center, New York, New York, United States|St. Luke'S-Roosevelt Hosp. Ctr., New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Southeastern Medical Oncology Center, Goldsboro, North Carolina, United States|Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Benson, Md, Don, Columbus, Ohio, United States|Mid Ohio Onc/Hema, Inc., Dba, Columbus, Ohio, United States|Signal Point Clinical Research Center, Llc, Middletown, Ohio, United States|Oklahoma Cancer Specialists and Research Institute, LLC-Clinical Research, Tulsa, Oklahoma, United States|Cancer Care Associates, Bethlehem, Pennsylvania, United States|Alliance Cancer Specialists, Langhorne, Pennsylvania, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Va Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|Donald Guthrie Foundation, Sayre, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Musc Hollings Cancer Center, Charleston, South Carolina, United States|GHS Cancer Institute, Greenville, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Tennessee Cancer Specialists, Knoxville, Tennessee, United States|Baptist Cancer Center, Memphis, Tennessee, United States|Tennessee Oncology, Pc, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Cancer Specialists Of South Texas, Pa, Corpus Christi, Texas, United States|Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Baylor College Of Medicine, Houston, Texas, United States|Michael E Debakey VA Medical Center, Houston, Texas, United States|Northwest Cancer Center, Houston, Texas, United States|Community Cancer Trials of Utah, Ogden, Utah, United States|Hematology-Oncology Associates Of Fredricksburg, Inc, Fredericksburg, Virginia, United States|Va Puget Sound Health Care System, Seattle, Washington, United States|Fred Hutchinson Cancer Research Ctr, Seattle, Washington, United States|Edwards Comprehensive Cancer Center, Huntington, West Virginia, United States|Gundersen Clinic, Ltd, La Crosse, Wisconsin, United States|Dean Clinic-Hematology And Oncology, Madison, Wisconsin, United States|University Of Wisconsin Hospital And Clinics, Madison, Wisconsin, United States|Local Institution, Garran, Australian Capital Territory, Australia|Local Institution, Waratah, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Herston, Queensland, Australia|Local Institution, Milton, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Woodville South, South Australia, Australia|Local Institution, Fitzroy, Victoria, Australia|Local Institution, Frankston, Victoria, Australia|Local Institution, Heidelberg Melbourne, Victoria, Australia|Local Institution, Wodonga, Victoria, Australia|Local Institution, Murdoch, Australia|Local Institution, Nedlands, Australia|Local Institution, Fadingerstra?e 1, Austria|Local Institution, Innsbruck, Austria|Local Institution, Rankweil, Austria|Local Institution, Wels, Austria|Local Institution, Brussels, Belgium|Local Institution, Brussels, Belgium|Local Institution, Brussels, Belgium|Local Institution, Brussles, Belgium|Local Institution, Charleroi, Belgium|Local Institution, Edegem-antwerp, Belgium|Local Institution, Gent, Belgium|Local Institution, Haine St Paul, Belgium|Local Institution, Leuven, Belgium|Local Institution, Liege, Belgium|Local Institution, Roeselare, Belgium|Local Institution, Yvoir, Belgium|Local Institution, Calgary, Alberta, Canada|Local Institution, Edmonton, Alberta, Canada|Local Institution, Winnipeg, Manitoba, Canada|Local Institution, Saint John, New Brunswick, Canada|Local Institution, Halifax, Nova Scotia, Canada|Local Institution, London, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Greenfield Park, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Saskatoon, Saskatchewan, Canada|Local Institution, Hradec Kralove, Czechia|Local Institution, Praha 10, Czechia|Local Institution, Praha 2, Czechia|Local Institution, Aschaffenburg, Germany|Local Institution, Berlin, Germany|Local Institution, Chemnitz, Germany|Local Institution, Dresden, Germany|Local Institution, Hamm, Germany|Local Institution, Heidelberg, Germany|Local Institution, Jena, Germany|Local Institution, Koln, Germany|Local Institution, Mainz, Germany|Local Institution, Munchen, Germany|Local Institution, Munster, Germany|Local Institution, Offenbach, Germany|Local Institution, Stuttgart, Germany|Local Institution, Tuebingen, Germany|Local Institution, Ulm, Germany|Local Institution, Athens, Greece|Local Institution, Athens, Greece|Local Institution, Ioannina, Greece|Local Institution, Larissa, Greece|Local Institution, Patras, Greece|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Debrecen, Hungary|Local Institution, Gyor, Hungary|Local Institution, Szeged, Hungary|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Afula, Israel|Local Institution, Ashkelon, Israel|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Jerusalem, Israel|Local Institution, Kfar Saba, Israel|Local Institution, Nahariya, Israel|Local Institution, Petah Tikva, Israel|Local Institution, Rehovot, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Zerifin, Israel|Local Institution, Ancona, Italy|Local Institution, Bari, Italy|Local Institution, Bergamo, Italy|Local Institution, Bologna, Italy|Local Institution, Firenze, Italy|Local Institution, Genova, Italy|Local Institution, Meldola, Italy|Local Institution, Milano, Italy|Local Institution, Milan, Italy|Local Institution, Monza, Italy|Local Institution, Napoli, Italy|Local Institution, Palermo, Italy|Local Institution, Ravenna, Italy|Local Institution, Reggio Nell Emilia (RE), Italy|Local Institution, Rimini, Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, Rome, Italy|Local Institution, Terni, Italy|Local Institution, Torino, Italy|Local Institution, Bialystok, Poland|Local Institution, Chorzow, Poland|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Lodz, Poland|Local Institution, Lublin, Poland|Local Institution, Poznan, Poland|Local Institution, Szczecin, Poland|Local Institution, Warszawa, Poland|Local Institution, Warszawa, Poland|Local Institution, Warszawa, Poland|Local Institution, Wroclaw, Poland|Local Institution, Ponce, Puerto Rico|Local Institution, San Juan, Puerto Rico|Local Institution, Brasov, Romania|Local Institution, Bucaresti, Romania|Local Institution, Bucuresti, Romania|Local Institution, Bucuresti, Romania|Local Institution, Bucuresti, Romania|Local Institution, Lasi, Romania|Local Institution, Samara, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Badalona-barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, La Laguna- Tenerife, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain|Local Institution, Salamanca, Spain|Local Institution, San Sebastian, Spain|Local Institution, Toledo, Spain|Local Institution, Bern, Switzerland|Local Institution, St Gallen, Switzerland|Local Institution, Zurich, Switzerland|Local Institution, Zurich, Switzerland|Local Institution, Izmir, Bornova, Turkey|Local Institution, Ankara, Dikimevi, Turkey|Local Institution, Izmir, Inciralti, Turkey|Local Institution, Gaziantep, Turkey|Local Institution, Belfast, Antrim, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, London, United Kingdom",https://ClinicalTrials.gov/show/NCT01335399
184,Bristol-Myers Squibb|Celgene|AbbVie,An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3),"Active, not recruiting",Has Results,Multiple Myeloma,Drug: Elotuzumab|Drug: Pomalidomide|Drug: Dexamethasone,Industry,Interventional,"Winship Cancer Institute, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Investigative Clinical Research Of Indiana, Llc, Indianapolis, Indiana, United States|Beth Israel Comprehensive Cancer Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute., Boston, Massachusetts, United States|Rochester General Hospital, Rochester, New York, United States|Carolinas Healthcare System, Charlotte, North Carolina, United States|Va Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|St Francis Hospital, Greenville, South Carolina, United States|Tennessee Cancer Specialists, Knoxville, Tennessee, United States|Northern Utah Associates, Ogden, Utah, United States|University Of Washington, Seattle, Washington, United States|Local Institution, South Brisbane, Queensland, Australia|Local Institution, London, Ontario, Canada|CISSS de l'Outaouais, Gatineau, Quebec, Canada|CIUSSS de l'Est-de-L'Ile-de-Montreal - Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Local Institution, Nantes Cedex 1, France|Local Institution, Paris Cedex 12, France|Local Institution, Pessac, France|Local Institution, Poitiers Cedex, France|Local Institution, Saint Pierre Cedex, France|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|Universitaetsklinikum Freiburg, Freiburg, Germany|St. Barbara-Klinik, Hamm, Germany|Universitasklinikum Heidelberg, Heidelberg, Germany|Universitasklinikum Schleswig-Holstein, Kiel, Germany|Klinikum Der Johannes Gutenberg Universitaet Mainz, Mainz, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Laiko University Hospital, Athens, Greece|Alexandra General Hospital Of Athens, Athens, Greece|Azienda Ospedaliero Universitaria Ospedali Riuniti Di Ancona, Ancona, Italy|A. O. U. Di Bologna, Policlinico S. Orsola Malpighi, Bologna, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Local Institution, Roma, Italy|Universita' La Sapienza, Roma, Italy|Azienda Ospedaliera Citta' Della Salute E Della Scienza Di Torino, Torino, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Morioka-shi, Iwate, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Shibuya-ku, Tokyo, Japan|Local Institution, Tachikawa-shi, Tokyo, Japan|Local Institution, Kasama-shi, Japan|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Maastrict, Netherlands|Local Institution, Utrecht, Netherlands|Oddzial Kliniczny Hematologii i Profilaktyki Chorob Nowotworowych, Chorzow, Poland|Local Institution, Lublin, Poland|Oddzial Hematologii i Transplantacji Szpiku, Poznan, Poland|Local Institution, Pamplona, Navarra, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Valencia, Spain",https://ClinicalTrials.gov/show/NCT02654132
185,MedImmune LLC,"Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma","Active, not recruiting",Has Results,Unresectable Pleural or Peritoneal Malignant Mesothelioma,Drug: Tremelimumab|Drug: Placebo,Industry,Interventional,"Research Site, Scottsdale, Arizona, United States|Research Site, La Jolla, California, United States|Research Site, Los Angeles, California, United States|Research Site, San Francisco, California, United States|Research Site, Santa Monica, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Newark, Delaware, United States|Research Site, Tampa, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Canton, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Adelaide, Australia|Research Site, Auchenflower, Australia|Research Site, Box Hill, Australia|Research Site, Chermside, Australia|Research Site, East Bentleigh, Australia|Research Site, Gosford, Australia|Research Site, Heidelberg, Australia|Research Site, Nedlands, Australia|Research Site, Saint Leonards, Australia|Research Site, Waratah, Australia|Research Site, Antwerp, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Toronto, Ontario, Canada|Research Site, Sainte Foy, Quebec, Canada|Research Site, Copenhagen, Denmark|Research Site, Caen Cedex, France|Research Site, Le Mans Cedex, France|Research Site, Lille Cedex, France|Research Site, Nice, France|Research Site, Rennes Cedex 9, France|Research Site, Toulouse, France|Research Site, Villejuif Cedex, France|Research Site, Berlin, Germany|Research Site, Esslingen a.N., Germany|Research Site, Freiburg, Germany|Research Site, Gauting, Germany|Research Site, Grosshansdorf, Germany|Research Site, Hamburg, Germany|Research Site, Hemer, Germany|Research Site, Karlsruhe, Germany|Research Site, Lubeck, Germany|Research Site, Löwenstein, Germany|Research Site, Mátraháza, Hungary|Research Site, Törökbálint, Hungary|Research Site, Beer Sheva, Israel|Research Site, Alessandria, Italy|Research Site, Aviano, Italy|Research Site, Bergamo, Italy|Research Site, Bologna, Italy|Research Site, Candiolo, Italy|Research Site, Genova, Italy|Research Site, Meldola, Italy|Research Site, Milano, Italy|Research Site, Orbassano, Italy|Research Site, Padova, Italy|Research Site, Rozzano, Italy|Research Site, Siena, Italy|Research Site, Jeonnam, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Breda, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Gdansk, Poland|Research Site, Poznan, Poland|Research Site, Szczecin, Poland|Research Site, Warszawa, Poland|Research Site, Craiova, Romania|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Kraaifontein, South Africa|Research Site, Pretoria, South Africa|Research Site, Pretoria, South Africa|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Sabadell (Barcelona), Spain|Research Site, San Sebastian, Spain|Research Site, Sevilla, Spain|Research Site, Linkoping, Sweden|Research Site, Lund, Sweden|Research Site, Umea, Sweden|Research Site, Leeds, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Maidstone, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Southampton, United Kingdom|Research Site, Wirral, United Kingdom",https://ClinicalTrials.gov/show/NCT01843374
186,"Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)|Translational Breast Cancer Research Consortium|Conquer Cancer Foundation|Genentech, Inc.",Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer,"Active, not recruiting",Has Results,Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|Progesterone Receptor Negative|Progesterone Receptor Positive|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma,Other: Biomarker Analysis|Drug: Enzalutamide|Other: Pharmacological Study|Drug: Taselisib,Other|NIH|Industry,Interventional,"University of Alabama, Birmingham, Birmingham, Alabama, United States|Georgetown University, Washington, District of Columbia, United States|University of Chicago, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Baylor Breast Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT02457910
187,GlaxoSmithKline,A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody,"Active, not recruiting",Has Results,Multiple Myeloma,Drug: GSK2857916 frozen liquid|Drug: GSK2857916 lyophilized powder,Industry,Interventional,"GSK Investigational Site, New Haven, Connecticut, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Fairway, Kansas, United States|GSK Investigational Site, New Orleans, Louisiana, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Rochester, Minnesota, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Madison, Wisconsin, United States|GSK Investigational Site, Woodville, South Australia, Australia|GSK Investigational Site, Fitzroy, Victoria, Australia|GSK Investigational Site, Melbourne, Victoria, Australia|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Winnipeg, Manitoba, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Lille Cedex, France|GSK Investigational Site, Nantes cedex 1, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Pessac, France|GSK Investigational Site, Pierre-Bénite cedex, France|GSK Investigational Site, Toulouse cedex 9, France|GSK Investigational Site, Tuebingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Wuerzburg, Bayern, Germany|GSK Investigational Site, Schwerin, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Koblenz, Rheinland-Pfalz, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Rionero In Vulture (Pz), Basilicata, Italy|GSK Investigational Site, Parma, Emilia-Romagna, Italy|GSK Investigational Site, Aviano (PN), Friuli-Venezia-Giulia, Italy|GSK Investigational Site, Torino, Piemonte, Italy|GSK Investigational Site, Badalona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Granada, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Murcia, Spain|GSK Investigational Site, Pamplona, Spain|GSK Investigational Site, Pozuelo De Alarcón/Madrid, Spain|GSK Investigational Site, Salamanca, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Stoke-on-Trent, Staffordshire, United Kingdom|GSK Investigational Site, Sutton, Surrey, United Kingdom|GSK Investigational Site, Birmingham, United Kingdom|GSK Investigational Site, Bournemouth, United Kingdom|GSK Investigational Site, Headington, Oxford, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Nottingham, United Kingdom",https://ClinicalTrials.gov/show/NCT03525678
188,Amgen,"Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.","Active, not recruiting",Has Results,Relapsed Multiple Myeloma|Refractory Multiple Myeloma,Drug: Dexamethasone|Drug: Daratumumab|Drug: Carfilzomib,Industry,Interventional,"Research Site, Boca Raton, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Hattiesburg, Mississippi, United States|Research Site, Hackensack, New Jersey, United States|Research Site, New York, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Canton, Ohio, United States|Research Site, Charleston, South Carolina, United States|Research Site, Dallas, Texas, United States|Research Site, Liverpool, New South Wales, Australia|Research Site, St Leonards, New South Wales, Australia|Research Site, Westmead, New South Wales, Australia|Research Site, Herston, Queensland, Australia|Research Site, Woolloongabba, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, East Melbourne, Victoria, Australia|Research Site, Fitzroy, VIC, Victoria, Australia|Research Site, Geelong, Victoria, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Graz, Austria|Research Site, Salzburg, Austria|Research Site, Antwerpen, Belgium|Research Site, Brussel, Belgium|Research Site, Charleroi, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Ostrava-Poruba, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 2, Czechia|Research Site, La Roche Sur Yon Cedex 9, France|Research Site, Le Chesnay cedex, France|Research Site, Lille Cedex, France|Research Site, Nantes Cedex 1, France|Research Site, Pessac Cedex, France|Research Site, Pierre-Benite cedex, France|Research Site, Poitiers Cedex, France|Research Site, Vandoeuvre les Nancy, France|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyula, Hungary|Research Site, Szeged, Hungary|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Toyohashi-shi, Aichi, Japan|Research Site, Kamogawa-shi, Chiba, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Ogaki-shi, Gifu, Japan|Research Site, Maebashi-shi, Gunma, Japan|Research Site, Shibukawa-city, Gunma, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Niigata-shi, Niigata, Japan|Research Site, Okayama-shi, Okayama, Japan|Research Site, Suita-shi, Osaka, Japan|Research Site, Kawagoe-shi, Saitama, Japan|Research Site, Utsunomiya-shi, Tochigi, Japan|Research Site, Tokushima-shi, Tokushima, Japan|Research Site, Koto-ku, Tokyo, Japan|Research Site, Shibuya-ku, Tokyo, Japan|Research Site, Goyang-si, Gyeonggi-do, Korea, Republic of|Research Site, Hwasun, Jeollanam-do, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Bialystok, Poland|Research Site, Chorzow, Poland|Research Site, Lublin, Poland|Research Site, Poznan, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Craiova, Romania|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Petrozavodsk, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Salamanca, Castilla León, Spain|Research Site, Badalona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Pamplona, Navarra, Spain|Research Site, Madrid, Spain|Research Site, Changhua, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Izmir, Turkey|Research Site, Samsun, Turkey|Research Site, Leeds, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom",https://ClinicalTrials.gov/show/NCT03158688
189,"Janssen Research & Development, LLC","Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma","Active, not recruiting",Has Results,Multiple Myeloma,Drug: Lenalidomide|Drug: Bortezomib|Drug: Dexamethasone|Drug: Daratumumab,Industry,Interventional,"Birmingham, Alabama, United States|Duarte, California, United States|La Jolla, California, United States|Los Angeles, California, United States|San Francisco, California, United States|Aurora, Colorado, United States|Washington, District of Columbia, United States|Orlando, Florida, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Westwood, Kansas, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Worcester, Massachusetts, United States|Detroit, Michigan, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|Buffalo, New York, United States|New York, New York, United States|Chapel Hill, North Carolina, United States|Charlotte, North Carolina, United States|Durham, North Carolina, United States|Winston-Salem, North Carolina, United States|Columbus, Ohio, United States|Portland, Oregon, United States|Abington, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Seattle, Washington, United States|Spokane, Washington, United States|Milwaukee, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT02874742
190,"Millennium Pharmaceuticals, Inc.|Takeda",A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT),"Active, not recruiting",Has Results,Multiple Myeloma,Drug: Placebo|Drug: Ixazomib,Industry,Interventional,"Robert A Moss MD FACP Inc, Fountain Valley, California, United States|UCLA Medical Hematology and Oncology, Los Angeles, California, United States|North County Oncology Medical Clinic Inc, Oceanside, California, United States|Ventura County Hematology Oncology Specialists, Oxnard, California, United States|Emad Ibrahim, MD, Inc, Redlands, California, United States|Global Cancer Research Institute (GCRI), Inc., San Jose, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States|Siouxland Hematology - Oncology Associates LLP, Sioux City, Iowa, United States|Appalachian Regional Healthcare, Hazard, Kentucky, United States|New England Cancer Specialists, Scarborough, Maine, United States|Saint Agnes Hospital, Baltimore, Maryland, United States|Center For Cancer and Blood Disorders, Bethesda, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Herbert-Herman Cancer Center, Lansing, Michigan, United States|Clinical Research Alliance Inc, New York, New York, United States|New York Presbyterian Hospital - Weill-Cornell, New York, New York, United States|Cancer Care of WNC PA, Asheville, North Carolina, United States|UPMC Cancer Pavillion, Pittsburgh, Pennsylvania, United States|HOPE Cancer Center of East Texas, Tyler, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|W VA University Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States|Hospital Universitario Austral, Buenos Aires, Ciudad Autonoma De BuenosAires, Argentina|Hospital Italiano de Buenos Aires, Buenos Aires, Ciudad Autonoma De BuenosAires, Argentina|Centro de Educacion Medica e Investigaciones Clinicas ""Norberto Quirno"" (CEMIC), Buenos Aires, Ciudad Autonoma De BuenosAires, Argentina|Sanatorio Allende, Cordoba, Argentina|Hospital Iturraspe, Santa Fe, Argentina|St Vincents Hospital Melbourne, Fitzroy, Victoria, Australia|Frankston Hospital, Frankston, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Universitatsklinikum Innsbruck, Innsbruck, Tirol, Austria|Paracelsus Medizinische Privatuniversitat, Salzburg, Austria|Klinikum Wels-Grieskirchen GmbH, Wels, Austria|Medizinische Universitat Wien, Wien, Austria|UZ Brussel, Brussel, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Brussels, Belgium|CEHON - Centro de Hematologia e Oncologia da Bahia Ltda, Salvador, Bahia, Brazil|Hospital Das Clinicas Da Universidade Federal de Goias, Goiania, Goias, Brazil|Hospital Das Clinicas Da UFMG, Belo Horizonte, Minas Gerais, Brazil|Liga Paranaense de Combate Ao Cancer, Curitiba, Parana, Brazil|Liga Norte Riograndense Contra O Cancer, Natal, Rio Grande Do Norte, Brazil|Universidade de Caxias do Sul, Caxias Do Sul, Rio Grande Do Sul, Brazil|Associacao Hospital de Caridade Ijui, Ijui, Rio Grande Do Sul, Brazil|Hospital Da Cidade de Passo Fundo, Passo Fundo, Rio Grande Do Sul, Brazil|Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Mae de Deus Center Hospital Giovanni Battista, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Sao Lucas da PUCRS, Porto Alegre, Rio Grande Do Sul, Brazil|Instituto Joinvilense de Hematologia E Oncologia, Joinville, Santa Catarina, Brazil|Fundacao PIO XII, Barretos, Sao Paulo, Brazil|Universidade Estadual de Campinas, Campinas, Sao Paulo, Brazil|Hospital Amaral Carvalho, Jau, Sao Paulo, Brazil|Faculdade de Medicina Do ABC, Santo Andre, Sao Paulo, Brazil|HEMORIO - Unidade de Pesquisa Clinica, Rio De Janeiro, Brazil|Instituto Nacional de Cancer, Rio de Janeiro, Brazil|Universidade Federal do Rio de Janeiro - UFRJ, Rio De Janeiro, Brazil|Hospital de Base Da Faculdade de Medicina de Sao Jose Do Rio Preto, Sao Jose Do Rio Preto, Brazil|Instituto de Ensino E Pesquisa Sao Lucas, Sao Paulo, Brazil|Hospital Sirio Libanes, Sao Paulo, Brazil|Hospital Do Cancer A C Camargo, Sao Paulo, Brazil|Clinica Sao Germano, Sao Paulo, Brazil|Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil|Hospital Israelita Albert Einstein, Sao Paulo, Brazil|Hospital Santa Marcelina, Sao Paulo, Brazil|Royal Victoria Regional Health Centre, Barrie, Ontario, Canada|William Osler Health Centre, Brampton, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|McGill University Health Center, Montreal, Quebec, Canada|Instituto Nacional Del Cancer, Santiago, Chile|Centro Internacional de Estudios Clinicos, Santiago, Chile|Instituto Clinico Oncologico del Sur (ICOS), Temuco, Chile|Centro de Investigaciones Clinicas Vina del Mar, Vina Del Mar, Chile|Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China|1st Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China|Beijing Chaoyang Hospital Capital Medical University, Beijing, China|Peking University Third Hospital, Beijing, China|Jiangsu Province Hospital, Beijing, China|Peking Union Medical College Hospital, Beijing, China|West China Hospital Sichuan University, Chengdu, China|The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China|Renji Hospital Medical School of Shanghai Jiaotong University, Shanghai, China|Renji Hospital Medical School of Shanghai Jiaotong University, Shanghai, China|Shanghai Chang Zheng Hospital, Shanghai, China|Shanxi Medical University - Second Hospital, Taiyuan Shi, China|Hospital Pablo Tobon Uribe, Medellin, Antioquia, Colombia|Instituto Nacional de Cancerologia Colombia, Bogota, Cundinamarca, Colombia|Hospital Universitario San Ignacio, Bogota, Distrito Capital De Bogota, Colombia|Clinical Hospital Dubrava, Zagreb, Grad Zagreb, Croatia|Clinical Hospital Center Rijeka, Rijeka, Croatia|University Klinichki Bolnicki Centar Zagreb, Zagreb, Croatia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Kralovehradeck Kraj, Czechia|Fakultni nemocnice Kralovske Vinohrady, Prague, Praha, Hlavni Mesto, Czechia|Fakultni nemocnice Brno, Brno, Czechia|Fakultni nemocnice Olomouc, Olomouc, Czechia|Fakultni nemocnice Ostrava, Ostrava, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|Arhus Universitetshospital Arhus Sygehus, Aarhus, Denmark|Herlev Hospital, Herlev, Denmark|Regionshospitalet Holstebro, Holstebro, Denmark|Odense Universitetshospital, Odense, Denmark|Hopital Antoine Beclere, Clamart, Hauts-de-Seine, France|Hotel Dieu, Nantes, Loire-Atlantique, France|CHRU Nancy, Vandoeuvre-les-nancy, Meurthe-et-Moselle, France|CHRU Dijon Complexe Du Bocage, Dijon, France|Hopital Saint Vincent de Paul GHICL, Lille, France|CHRU Lille, Lille, France|Hopital de la Pitie Salpetriere, Paris, France|Groupe Hospitalier Necker Enfants Malades, Paris, France|Hopital Haut Leveque, Pessac, France|Hopital Jean Bernard, Poitiers, France|CHRU Rennes, Rennes, France|Universitatsklinikum Ulm, Ulm, Baden-Wurttemberg, Germany|Schwarzwald Baar Klinkum Villingen-Schwenningen GmbH, Villingen-Schwenningen, Baden-Wurttemberg, Germany|Hamatologische Onkologische Gemeinschaftspraxis Dr. Brudler, Dr. Heinrich, Dr. Bangerter, Augsburg, Bayern, Germany|Internistisch Hamatologische und Internistische Praxis, Herrsching am Ammersee, Bayern, Germany|LMU Klinikum der Universitat Munchen, Munchen, Bayern, Germany|Pius Hospital Oldenburg, Oldenburg, Niedersachsen, Germany|Universitatsklinikum Essen, Essen, Nordrhein-Westfalen, Germany|Gemeinschaftspraxis fur Hamatologie und Onkologie, Munster, Nordrhein-Westfalen, Germany|Universitatsmedizin der Johannes Gutenberg-Universitat Mainz, Mainz, Rheinland-Pfalz, Germany|Universitat Des Saarlandes, Homburg, Saarland, Germany|Onkologie Aschaffenburg, Aschaffenburg, Germany|Charite - Universitatsmedizin Berlin, Berlin, Germany|Medizinisches Versorgungszentrum Onkologischer Schwerpunkt, Berlin, Germany|Klinikum Landshut, Landshut, Germany|Klinikum rechts der Isar der Technischen Universitat Munchen, Munchen, Germany|Praxis Pihusch Medizinisches Versorgungszentrum GbR, Rosenheim, Germany|Gemeinschaftspraxis Dr. med. R. Schlag & Dr. med. B. Schottker & Dr. med. J. Haas, Wurzburg, Germany|University of Athens Medical School - Regional General Hospital Alexandra, Athens, Attiki, Greece|Evangelismos General Hospital of Athens, Athens, Greece|University General Hospital of Ioannina, Ioannina, Greece|University General Hospital of Larissa, Larissa, Greece|Theageneio Anticancer Oncology Hospital of Thessaloniki, Thessaloniki, Greece|Georgios Papanikolaou General Hospital of Thessaloniki, Thessaloniki, Greece|Semmelweis Egyetem, Budapest, Hungary|Egyesitett Szent Istvan es Szent Laszlo Korhaz - Rendelointezet, Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont, Szeged, Hungary|Soroka University Medical Centre, Beer Sheva, Israel|Bnai Zion Medical Center, Haifa, Israel|Hadassah University Hospital Ein Kerem, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|Rabin Medical Center - PPDS, Petah Tikva, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Assuta Medical Centers, Tel Aviv, Israel|Baruch Padeh Poriya Medical Center, Tiberias, Israel|Assaf Harofe Medical Center, Zerfin, Israel|AORN A Cardarelli, Napoli, Campania, Italy|Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi, Bologna, Emilia-Romagna, Italy|Ospedale Infermi di Rimini, Rimini, Emilia-Romagna, Italy|IRCCS Azienda Ospedaliera Universitaria San Martino Istituto Nazionale Per La Ricerca Sul Cancro, Genova, Liguria, Italy|ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia, Brescia, Lombardia, Italy|ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda Ca' Granda, Milano, Lombardia, Italy|AO Ospedale Policlinico Consorziale Di Bari, Bari, Puglia, Italy|Ospedale Casa Sollievo Della Sofferenza IRCCS, San Giovanni Rotondo, Puglia, Italy|Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele, Catania, Sicilia, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Toscana, Italy|Azienda Ospedaliera S Maria Di Terni, Terni, Umbria, Italy|Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona-Umberto I G.M. Lancisi G. Salesi, Ancona, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Ospedale Santa Maria Delle Croci, Ravenna, Italy|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Italy|Ogaki Municipal Hospital, Ogaki, Gihu, Japan|Kobe City Medical Center General Hospital, Kobe-City, Hyogo, Japan|Hitachi General Hospital, Hitachi, Ibaraki, Japan|Nara Hospital Kinki University Faculty of Medicine, Ikoma-City, Nara, Japan|National Hospital Organization Okayama Medical Center, Okayama-city, Okayama, Japan|Juntendo University Hospital, Bunkyo, Tokyo, Japan|Japanese Red Cross Medical Center, Shibuya-ku, Tokyo, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka, Japan|Fukushima Medical University Hospital, Fukushima-City, Japan|National Hospital Organization Mito Medical Center, Higashiibaraki-gun, Japan|Kurume University Hospital, Kurume, Japan|Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan|Nagoya City University Hospital, Nagoya, Japan|Japanese Red Cross Narita Hospital, Narita-shi, Japan|Niigata Cancer Center Hospital, Niigata-city, Japan|Osaka Saiseikai Nakatsu Hospital, Osaka, Japan|Shizuoka Cancer Center, Suntou-gun, Japan|National Hospital Organization Disaster Medical Center, Tachikawa, Japan|Toyohashi Municipal Hospital, Toyohashi, Aichi, Japan|Yamanashi Prefectural Central Hospital, Yamanashi, Japan|National Cancer Center, Goyang-si, Gyeonggido, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital Yonsei University Health System - PPDS, Seoul, Korea, Republic of|Samsung Medical Center - PPDS, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Centro de Investigacion Farmaceutica Especializada de Occidente, SC, Guadalajara, Jalisco, Mexico|Hospital Y Clinica OCA Sociedad Anonima de Capital Variable, Monterrey, Nuevo Leon, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo Leon, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico|Oaxaca Site management Organization (OSMO), Oaxaca, Mexico|MTZ Clinical Research Sp z o o, Warszawa, Mazowieckie, Poland|Szpital Uniwersytecki Nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich, Chorzow, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wroclawiu, Wroclaw, Poland|Instituto Portugues de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon, Lisboa, Portugal|Hospital Garcia de Orta, Almada, Portugal|Hospital de Braga, Braga, Portugal|Champalimaud Cancer Center, Lisboa, Portugal|Centro Hospitalar do Porto - Hospital de Santo Antonio, Porto, Portugal|Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe, Porto, Portugal|Centro Hospitalar de Sao Joao EPE, Porto, Portugal|State Medical and Preventive Treatment Institution Kirov Regional Clinical Oncology Dispensary, Kirov, Russian Federation|Stavropol Regional Clinical Oncology Centre Pyatigorsk Affiliate, Pyatigorsk, Russian Federation|Ryazan Regional Clinical Hospital, Ryazan, Russian Federation|Russian Research Institute of Hematology and Blood Transfusion, St. Petersburg, Russian Federation|City Center of MS Treatment based on Saint-Petersburg City Clinical Hospital #31, St. Petersburg, Russian Federation|Clinical Center of Serbia, Belgrade, Serbia|Clinical Hospital Center ''Bezanijska Kosa'', Belgrade, Serbia|Clinical Center Kragujevac, Kragujevac, Serbia|Clinical Center Nis, Nis, Serbia|National University Hospital, Singapore, Singapore|Singapore General Hospital (SGH), Singapore, Singapore|Medical Oncology Centre of Rosebank, Johannesburg, Gauteng, South Africa|Albert Alberts Stem Cell Transplant Centre, Pretoria, Gauteng, South Africa|Mary Potter Oncology Centre, Pretoria, Gauteng, South Africa|Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitario Quironsalud Madrid, Pozuelo De Alarcon, Madrid, Communidad Delaware, Spain|Clinica Universidad Navarra, Pamplona, Navarra, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital de La Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario HM Sanchinarro CIOCC, Madrid, Spain|Hospital General Universitario Morales Meseguer, Murcia, Spain|Complejo Asistencial Universitario de Salamanca H. Clinico, Salamanca, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Karolinska Universitetssjukhuset Huddinge, Stockholm, Sodermanlands Lan, Sweden|Karolinska Universitetssjukhuset Solna, Stockholm, Sodermanlands Lan, Sweden|Sahlgrenska Universitetssjukhuset, Goteborg, Vastra Gotalands Lan, Sweden|Skanes Universitetssjukhus Lund, Lund, Sweden|Spital STS AG, Thun, Switzerland|Kaohsiung Medical University Hospital, Kaohsiung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Ramathibodi Hospital, Bangkok, Krung Thep Maha Nakhon, Thailand|Chulalongkorn University, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Chiang Mai University, Chiangmai, Thailand|Hacettepe Universitesi Tip Fakultesi Hastanesi, Ankara, Turkey|Ankara University Medical Faculty Cebeci Hospital, Ankara, Turkey|Istanbul Universitesi Istanbul Tip Fakultesi Hastanesi, Istanbul, Turkey|Dokuz Eylul University Medical Faculty, Izmir, Turkey|Belfast City Hospital, Belfast, Antrim, United Kingdom|Birmingham Heartlands Hospital, West Midlands, Birmingham, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, Bristol, City Of, United Kingdom|Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom|Queen Alexandra Hospital, Portsmouth, Hampshire, United Kingdom|Kent and Canterbury Hospital, Canterbury, Kent, United Kingdom|Barts Health NHS Trust, London, London, City Of, United Kingdom|University College London, London, London, City Of, United Kingdom|Kings College Hospital, London, London, City Of, United Kingdom|Hammersmith Hospital, London, London, City Of, United Kingdom|Hillingdon Hospital, Uxbridge, London, City Of, United Kingdom|James Paget University Hospitals NHS Foundation Trust, Great Yarmouth, Norfolk, United Kingdom|Churchill Hospital, Oxford, Oxfordshire, United Kingdom|New Cross Hospital, Wolverhampton, Staffordshire, United Kingdom|Royal Marsden Hospital - Surrey, Sutton, Surrey, United Kingdom|Royal United Hospital, Bath, United Kingdom|Ulster Hospital, Belfast, United Kingdom|Southmead Hospital, Bristol, United Kingdom|Broomfield Hospital, Broomfield, United Kingdom|Cardiff University School of Medicine, Cardiff, United Kingdom|West Middlesex University Hospital, Isleworth, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Chelsea and Westminster NHS Trust, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|Northwick Park Hospital, Middlesex, United Kingdom|Royal Oldham Hospital, Oldham, United Kingdom|Ealing Hospital, Southall, United Kingdom|Ealing Hospital, Southall, United Kingdom|Singleton Hospital, Swansea, United Kingdom",https://ClinicalTrials.gov/show/NCT02312258
191,"Janssen Research & Development, LLC","Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma","Active, not recruiting",Has Results,Multiple Myeloma,Drug: Daratumumab IV|Drug: Lenalidomide|Drug: Dexamethasone|Drug: Daratumumab SC,Industry,Interventional,"Birmingham, Alabama, United States|Mobile, Alabama, United States|Glendale, Arizona, United States|Berkeley, California, United States|Beverly Hills, California, United States|El Cajon, California, United States|Greenbrae, California, United States|Los Angeles, California, United States|Oceanside, California, United States|San Diego, California, United States|West Hills, California, United States|Whittier, California, United States|Denver, Colorado, United States|Fort Collins, Colorado, United States|Glenwood Springs, Colorado, United States|New Haven, Connecticut, United States|Norwalk, Connecticut, United States|Washington, District of Columbia, United States|Boca Raton, Florida, United States|Boynton Beach, Florida, United States|Fort Lauderdale, Florida, United States|Fort Myers, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Lake City, Florida, United States|Saint Petersburg, Florida, United States|Weston, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Macon, Georgia, United States|Marietta, Georgia, United States|Chicago, Illinois, United States|Niles, Illinois, United States|Fort Wayne, Indiana, United States|Iowa City, Iowa, United States|Louisville, Kentucky, United States|Lafayette, Louisiana, United States|Marrero, Louisiana, United States|Shreveport, Louisiana, United States|Annapolis, Maryland, United States|Baltimore, Maryland, United States|Frederick, Maryland, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Duluth, Minnesota, United States|Rochester, Minnesota, United States|Kansas City, Missouri, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|Hooksett, New Hampshire, United States|Brick, New Jersey, United States|Hackensack, New Jersey, United States|Livingston, New Jersey, United States|Plainfield, New Jersey, United States|Somerville, New Jersey, United States|Summit, New Jersey, United States|Mineola, New York, United States|New York, New York, United States|Rochester, New York, United States|Asheboro, North Carolina, United States|Charlotte, North Carolina, United States|Pinehurst, North Carolina, United States|Winston-Salem, North Carolina, United States|Canton, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Bend, Oregon, United States|Bethlehem, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Spartanburg, South Carolina, United States|Sioux Falls, South Dakota, United States|Chattanooga, Tennessee, United States|Nashville, Tennessee, United States|Arlington, Texas, United States|Edinburg, Texas, United States|Fort Sam Houston, Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Plano, Texas, United States|San Antonio, Texas, United States|Ogden, Utah, United States|Seattle, Washington, United States|Spokane, Washington, United States|Tacoma, Washington, United States|Box Hill, Australia|Fitzroy, Australia|Footscray, Australia|Kogarah, Australia|Kurralta Park, Australia|Nedlands, Australia|New South Wales, Australia|Woodville, Australia|Woolloongabba N/a, Australia|Innsbruck, Austria|Linz, Austria|Salzburg, Austria|Wien N/a, Austria|Wien Wien, Austria|Brugge, Belgium|Brussels, Belgium|Brussel, Belgium|Haine-saint-paul, LA Louviere, Belgium|Leuven, Belgium|Liege, Belgium|Calgary, Alberta, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Montréal, Quebec, Canada|Greenfield Park, Canada|N/a N/a, Canada|Nova Scotia, Canada|Quebec, Canada|Vancouver, Canada|Aarhus C, Denmark|Odense, Denmark|Vejle, Denmark|Amiens N/a Picardie, France|Angers, France|Bayonne Cedex, France|Bretagne, France|Caen, France|Cergy Pontoise, France|Chalons Sur Saone, France|Clermont-Ferrand, France|Creteil, France|Dijon, France|Dunkerque Cedex 1, France|Grenoble Cedex 9, France|La Roche sur Yon Cedex 9, France|Le Chesnay Cedex, France|Le Coudray, France|Le Mans, France|Lille Cedex, France|Lille, France|Limoges, France|Lyon, Pierre-Benite, France|Marseille Cedex 9, France|Metz-Tessy, France|Montivilliers, France|Montpellier, France|Mulhouse, France|Nantes, France|Nice N/a, France|Paris Cedex 12, France|Paris, 75, France|Paris, France|PERIGUEUX cedex, France|Perpignan, France|Pessac, France|Poitiers, France|Reims, France|Rennes, France|Rouen Cedex, France|Saint Brieuc Cedex 1, France|Saint Priest en Jarez, France|St Malo Cedex, France|St Quentin Cedex, France|Strasbourg, France|Toulouse Cedex 9, France|TOURS Cedex 9, France|Vandoeuvre Les Nancy, France|Aschaffenburg, Germany|Bad Berka, Germany|Bonn, Germany|Braunschweig, Germany|Dresden, Germany|Essen, Germany|Frankfurt, Germany|Hannover, Germany|Heidelberg, Germany|Kiel, Germany|Koblenz, Germany|Mainz, Germany|Mannheim, Germany|Rostock, Germany|Schwerin, Germany|Stuttgart, Germany|Tuebingen, Germany|Ulm, Germany|Villingen-Schwenningen, Germany|Dublin, Ireland|Galway, Ireland|Hadera, Israel|Haifa, Israel|Jerusalem, Israel|Nahariya, Israel|Petah Tikva, Israel|Ramat Gan, Israel|Tel-Aviv, Israel|Hilversum, Netherlands|Hoofddorp, Netherlands|Rotterdam, Netherlands|Tilburg, Netherlands|Falun, Sweden|Göteborg, Sweden|Halmstad, Sweden|Helsingborg, Sweden|Huddinge, Sweden|Lulea, Sweden|Lund, Sweden|Stockholm, Sweden|Örebro, Sweden|Aberdeen, United Kingdom|Canterbury, United Kingdom|Dundee, United Kingdom|Leeds, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Nottingham, United Kingdom|Oxford, United Kingdom|Plymouth, Devon, United Kingdom|Southampton, United Kingdom|Truro, United Kingdom|Wf, United Kingdom|Wolverhampton, United Kingdom",https://ClinicalTrials.gov/show/NCT02252172
192,"Janssen Research & Development, LLC",A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma,"Active, not recruiting",Has Results,Multiple Myeloma,Drug: Velcade|Drug: Melphalan|Drug: Prednisone|Drug: Daratumumab IV|Drug: Dexamethasone|Drug: Daratumumab SC,Industry,Interventional,"California City, California, United States|Corona, California, United States|Fountain Valley, California, United States|Los Angeles, California, United States|Hialeah, Florida, United States|Orange Park, Florida, United States|Chicago, Illinois, United States|Springfield, Missouri, United States|Cleveland, Ohio, United States|Fredericksburg, Virginia, United States|Buenos Aires, Argentina|Ciudad Autonoma Buenos Aires, Argentina|Córdoba, Argentina|Santa Fe, Argentina|Adelaide, Australia|Bendigo, Australia|Camperdown N/a, Australia|Geelong, Australia|Gosford, Australia|Greenslopes, Australia|Hobart, Australia|North Adelaide, Australia|Parkville, Australia|Antwerpen, Belgium|Antwerp, Belgium|Brussel, Belgium|Charleroi, Belgium|Gent, Belgium|Kortrijk, Belgium|Roeselare, Belgium|Turnhout, Belgium|Yvoir, Belgium|Barretos, Brazil|Cuiaba - Mount, Brazil|Fortaleza Ceara, Brazil|Fortaleza, Brazil|Goiânia, Brazil|Natal, Brazil|Niteroi N/a, Brazil|Porto Alegre, Brazil|Riberao Preto, Brazil|Sao Paulo, Brazil|Pleven, Bulgaria|Plovdiv, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Vratsa, Bulgaria|Zadar, Croatia|Zagreb, Croatia|Brno, Czechia|Hradec Kralove, Czechia|Olomouc, Czechia|Ostrava-Poruba, Czechia|Praha 10, Czechia|Praha 2, Czechia|Tbilisi, Georgia|Berlin, Germany|Dortmund, Germany|Karlsruhe, Germany|Potsdam, Germany|Saarbrücken, Germany|Stuttgart, Germany|Würzburg, Germany|Athens Attica, Greece|Athens, Greece|Patra, Greece|Thessaloniki, Greece|Budapest, Hungary|Debrecen, Hungary|Kaposvar, Hungary|Pecs N/a, Hungary|Chiba, Japan|Hitachi, Japan|Kanazawa, Japan|Kawasaki, Japan|Kobe, Japan|Kurume, Japan|Matsuyama, Japan|Nagoya, Japan|Narita, Japan|Ohgaki, Japan|Okayama, Japan|Osaka, Japan|Sendai, Japan|Shibukawa, Japan|Tachikawa, Japan|Tokyo, Japan|Toyohashi, Japan|Busan, Korea, Republic of|Gyeonggi-do, Korea, Republic of|Incheon, Korea, Republic of|Jeonnam, Korea, Republic of|Seongnam, Korea, Republic of|Seoul, Korea, Republic of|Skopje, North Macedonia|Bialystok, Poland|Bydgoszcz, Poland|Chorzow, Poland|Gdansk, Poland|Legnica, Poland|Lublin, Poland|Opole, Poland|Slupsk, Poland|Warszawa Ul, Poland|Warszawa, Poland|Wroclaw, Poland|Lisboa, Portugal|Lisbon, Portugal|Porto, Portugal|Brasov, Romania|Bucharest, Romania|Iasi, Romania|Arkhangelsk, Russian Federation|Dzerzhinsk, Russian Federation|Ekaterinbourg, Russian Federation|Nizhny Novgorod, Russian Federation|Ryazan, Russian Federation|Saint-Petersburg, Russian Federation|Saratov, Russian Federation|Sochi, Russian Federation|St Petersburg, Russian Federation|Volgograd, Russian Federation|Belgrade, Serbia|Nis, Serbia|Novi Sad, Serbia|Sremska Kamenica, Serbia|Zemun, Serbia|Andalucía, Spain|Badalona, Spain|Barcelona, Spain|Córdoba, Spain|Girona, Spain|La Laguna, Spain|Madrid, Spain|Maranon, Spain|Murcia N/a, Spain|Ourense, Spain|Pamplona, Spain|Salamanca, Spain|Sevilla, Spain|Toledo, Spain|Valencia, Spain|Zaragoza, Spain|Altindag, Turkey|Ankara, Turkey|Aydin, Turkey|Izmir, Turkey|Kayseri, Turkey|Samsun, Turkey|Tekirdag, Turkey|Cherkassy, Ukraine|Dnepropetrovsk, Ukraine|Ivano-Frankivsk, Ukraine|Kharkov, Ukraine|Khmelnitskiy, Ukraine|Lviv, Ukraine|Zaporizhzhia, Ukraine|Birmingham, United Kingdom|Cambridge, United Kingdom|Colchester, United Kingdom|Harlow, United Kingdom|Leicester, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Woolwich, United Kingdom",https://ClinicalTrials.gov/show/NCT02195479
193,"Janssen Research & Development, LLC",Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma,"Active, not recruiting",Has Results,Multiple Myeloma,Drug: Daratumumab|Drug: VELCADE (Bortezomib)|Drug: Dexamethasone,Industry,Interventional,"Birmingham, Alabama, United States|Los Angeles, California, United States|Stamford, Connecticut, United States|Jacksonville, Florida, United States|Atlanta, Georgia, United States|Niles, Illinois, United States|Topeka, Kansas, United States|Westwood, Kansas, United States|Marrero, Louisiana, United States|Boston, Massachusetts, United States|Lansing, Michigan, United States|New York, New York, United States|Chapel Hill, North Carolina, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Providence, Rhode Island, United States|Seattle, Washington, United States|Adelaide, Australia|Concord, Australia|Fitzroy, Australia|Hobart, Australia|Melbourne, Australia|Nedlands, Australia|Woodville South, Australia|Barretos, Brazil|Porto Alegre, Brazil|Salvador, Brazil|Sao Paulo, Brazil|São Paulo, Brazil|Brno, Czechia|Hradec Kralove, Czechia|Ostrava-Poruba, Czechia|Praha 10, Czechia|Praha 2, Czechia|Bamberg, Germany|Berlin, Germany|Duesseldorf, Germany|Freiburg, Germany|Göttingen, Germany|Hamburg, Germany|Mainz, Germany|München, Germany|Stuttgart, Germany|Tübingen, Germany|Ulm, Germany|Würzburg, Germany|Budapest, Hungary|Debrecen, Hungary|Győr, Hungary|Pécs N/a, Hungary|Veszprém, Hungary|Busan, Korea, Republic of|Jeonnam, Korea, Republic of|Seoul, Korea, Republic of|Suwon, Korea, Republic of|Ulsan, Korea, Republic of|Huixquilucan, Mexico|Monterrey, Mexico|Alkmaar, Netherlands|Amersfoort, Netherlands|Den Haag, Netherlands|Dordrecht, Netherlands|Groningen, Netherlands|Leiden, Netherlands|Maastricht, Netherlands|Nijmegen, Netherlands|Chorzów, Poland|Katowice, Poland|Krakow, Poland|Poznan, Poland|Warszawa, Poland|Krasnodar, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Penza, Russian Federation|Pyatigorsk, Russian Federation|Ryazan, Russian Federation|Samara, Russian Federation|Sochi, Russian Federation|Syktyvkar, Russian Federation|Madrid, Spain|Salamanca, Spain|San Sebastian de los Reyes, Spain|Toledo, Spain|Valencia, Spain|Linkoping, Sweden|Lulea, Sweden|Lund, Sweden|Orebro, Sweden|Sundsvall, Sweden|Umea, Sweden|Uppsala, Sweden|Västerås, Sweden|Ankara, Turkey|Istanbul, Turkey|Izmir, Turkey|Kayseri, Turkey|Kocaeli, Turkey|Malatya, Turkey|Cherkasy, Ukraine|Dnepropetrovsk, Ukraine|Ivano-Frankivsk, Ukraine|Kiev, Ukraine|Lviv, Ukraine|Poltava, Ukraine|Vinnitsa, Ukraine|Zaporizhzhya, Ukraine",https://ClinicalTrials.gov/show/NCT02136134
194,"Janssen Research & Development, LLC","A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma","Active, not recruiting",Has Results,Multiple Myeloma,Drug: Daratumumab|Drug: Lenalidomide|Drug: Dexamethasone,Industry,Interventional,"Little Rock, Arkansas, United States|Gainesville, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Iowa City, Iowa, United States|Louisville, Kentucky, United States|Baton Rouge, Louisiana, United States|New Orleans, Louisiana, United States|Bethesda, Maryland, United States|Columbia, Maryland, United States|Boston, Massachusetts, United States|Rochester, Minnesota, United States|Omaha, Nebraska, United States|New Brunswick, New Jersey, United States|New York, New York, United States|Charlotte, North Carolina, United States|Eugene, Oregon, United States|Spartanburg, South Carolina, United States|Austin, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Fairfax, Virginia, United States|Camperdown, Australia|Geelong, Australia|Heidelberg, Australia|Malvern, Australia|South Brisbane, Australia|Southport, Australia|Antwerpen, Belgium|Brussel, Belgium|Edegem, Belgium|Gent, Belgium|Kortrijk, Belgium|Leuven, Belgium|Liege, Belgium|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Halifax, Nova Scotia, Canada|Hamilton, Ontario, Canada|London, Ontario, Canada|Montreal, Quebec, Canada|Quebec City, Quebec, Canada|Surrey N/a, Canada|Toronto N/a, Canada|Copenhagen, Denmark|Odense, Denmark|Vejle, Denmark|Argenteuil, France|Caen, France|Lille, France|Limoges, France|Nantes Cedex 1, France|Paris, France|Pessac, France|Pierre Benite, France|Rennes, France|Toulouse Cedex 9, France|Tours Cedex 9, France|Vandoeuvre les Nancy, France|Berlin, Germany|Bonn, Germany|Hamburg, Germany|Hamm, Germany|Heidelberg, Germany|Jena, Germany|Karlsruhe, Germany|Koblenz, Germany|Köln, Germany|Saarbrücken, Germany|Villingen-Schwenningen, Germany|Athens Attica, Greece|Haifa, Israel|Jerusalem, Israel|Nahariya, Israel|Netanya, Israel|Petah Tikva, Israel|Ramat Gan, Israel|Tel Aviv, Israel|Hitachi, Japan|Kanazawa, Japan|Kobe, Japan|Kurume, Japan|Matsuyama, Japan|Nagoya, Japan|Narita, Japan|Ohgaki, Japan|Okayama, Japan|Osaka, Japan|Sendai, Japan|Shibukawa, Japan|Shibuya, Japan|Tachikawa, Japan|Tokyo, Japan|Gyeonggi-do, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Amsterdam, Netherlands|Rotterdam, Netherlands|Utrecht, Netherlands|Zwolle, Netherlands|Brzozow, Poland|Chorzów, Poland|Gdansk, Poland|Legnica, Poland|Lublin, Poland|Poznan, Poland|Slupsk, Poland|Wroclawa, Poland|Dzerzhinsk, Russian Federation|Ekaterinburg, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Petrozavodsk, Russian Federation|Ryazan, Russian Federation|Samara, Russian Federation|St-Petersburg, Russian Federation|St. Petersburg, Russian Federation|Syktyvkar, Russian Federation|Badalona, Spain|Barcelona, Spain|La Laguna (Santa Cruz De Tenerife), Spain|Madrid, Spain|Pamplona, Spain|Salamanca N/a, Spain|Sevilla, Spain|Falun, Sweden|Göteborg, Sweden|Helsingborg, Sweden|Huddinge, Sweden|Lund, Sweden|Stockholm, Sweden|Uppsala, Sweden|Changhua, Taiwan|Taichung City, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Birmingham, United Kingdom|Leeds, United Kingdom|London, United Kingdom|Oxford, United Kingdom|Southampton, United Kingdom|Surrey, United Kingdom|Wolverhampton, United Kingdom",https://ClinicalTrials.gov/show/NCT02076009
195,"Millennium Pharmaceuticals, Inc.|Takeda",A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma,"Active, not recruiting",Has Results,Relapsed Multiple Myeloma|Refractory Multiple Myeloma,Drug: Ixazomib|Drug: Lenalidomide|Drug: Dexamethasone|Drug: Placebo,Industry,Interventional,"University of Arkansas Medical Sciences, Little Rock, Arkansas, United States|Pacific Cancer Medical Center Inc, Anaheim, California, United States|West Contra Costa Healthcare District, Berkeley, California, United States|University of Florida, Gainesville, Florida, United States|Cancer & Blood Disease Center, Lecanto, Florida, United States|Northwest Georgia Oncology Center, Marietta, Georgia, United States|John H. Stroger, Jr. Hospital of Cook County, Chicago, Illinois, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Columbia University Medical Center, New York, New York, United States|Blood and Cancer Clinic, Fayetteville, North Carolina, United States|Scranton Hematology Oncology, Scranton, Pennsylvania, United States|MUSC Hollings Cancer Center, Charleston, South Carolina, United States|Fred Hutchinson Cancer Research, Seattle, Washington, United States|West Virginia University Hospitals and Clinic, Morgantown, West Virginia, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Saint John Regional Hospital, Saint John, New Brunswick, Canada|CHUM Notre-Dame Hospital, Montreal, Quebec, Canada|MUHC Glen Site Cedars Cancer Centre, Montreal, Quebec, Canada",https://ClinicalTrials.gov/show/NCT01564537
196,"Millennium Pharmaceuticals, Inc.|Takeda",A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant,"Active, not recruiting",Has Results,Multiple Myeloma|Autologous Stem Cell Transplant,Drug: Ixazomib Citrate|Drug: Placebo,Industry,Interventional,"Rochester, Minnesota, United States|Bronx, New York, United States|Dallas, Texas, United States|Morgantown, West Virginia, United States|La Plata, Buenos Aires, Argentina|Rosario, Santa Fe, Argentina|Ciudad Autonoma de Buenos Aires, Argentina|Santa Fe, Argentina|Kogarah, New South Wales, Australia|Waratah, New South Wales, Australia|Westmead, New South Wales, Australia|Milton, Queensland, Australia|Southport, Queensland, Australia|Adelaide, South Australia, Australia|Woodville South, South Australia, Australia|Heidelberg, Victoria, Australia|Melbourne, Victoria, Australia|Linz, Austria|Salzburg, Austria|Wien, Austria|La Louviere, Hainaut, Belgium|Mons, Hainaut, Belgium|Gent, Oost-Vlaanderen, Belgium|Brugge, West-Vlaanderen, Belgium|Antwerpen, Belgium|Belo Horizonte, Minas Gerais, Brazil|Curitiba, Parana, Brazil|Passo Fundo, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Florian0polis, Santa Catarina, Brazil|Joinville, Santa Catarina, Brazil|Jau, Sao Paulo, Brazil|Sao Jose Do Rio Preto, Sao Paulo, Brazil|Sao Paulo, Brazil|Toronto, Ontario, Canada|Bogota, Cundinamarca, Colombia|Cali, Valle Del Cauca, Colombia|Medellin, Colombia|Hradec Kralove, Kralovehradecky Kraj, Czechia|Brno, Czechia|Olomouc, Czechia|Ostrava, Czechia|Praha 2, Czechia|Praha, Czechia|Alborg, Nordjylland, Denmark|Roskilde, Sjalland, Denmark|Arhus, Denmark|Copenhagen, Denmark|Herlev, Denmark|Odense, Denmark|Vejle, Denmark|Clamart, Hauts-de-Seine, France|Nantes, Loire-Atlantique, France|Lille, Nord, France|Limoges, France|Paris, France|Heidelberg, Baden-Wurttemberg, Germany|Mannheim, Baden-Wurttemberg, Germany|Munchen, Bayern, Germany|Wurzburg, Bayern, Germany|Darmstadt, Hessen, Germany|Frankfurt am Main, Hessen, Germany|Oldenburg, Niedersachsen, Germany|Bonn, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Hagen, Nordrhein-Westfalen, Germany|Koln, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Dresden, Sachsen, Germany|Berlin, Germany|Hamburg, Germany|Hannover, Germany|Ludwigshafen, Germany|Tubingen, Germany|Athens, Attiki, Greece|Athens, Greece|Thessaloniki, Greece|Budapest, Hungary|Debrecen, Hungary|Kaposvar, Hungary|Szeged, Hungary|Ashkelon, Israel|Haifa, Israel|Jerusalem, Israel|Nahariya, Israel|Petach Tikva, Israel|Ramat-Gan, Israel|Rehovot, Israel|Safed, Israel|Tel Aviv, Israel|Tzrifin, Israel|Pescara, Abruzzo, Italy|Roma, Lazio, Italy|Pavia, Lombardia, Italy|Ancona, Marche, Italy|Torino, Piemonte, Italy|Rionero In Vulture, Potenza, Italy|Terni, Umbria, Italy|Bologna, Italy|Brescia, Italy|Firenze, Italy|Genova, Italy|Meldola, Italy|Milano, Italy|Rimini, Italy|Shibukawa-city, Gunma, Japan|Kobe-City, Hyogo, Japan|Okayama-City, Okayama, Japan|Chiba, Tokyo, Japan|Shibuya-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Fukuoka, Japan|Nagoya-City, Japan|Nagoya, Japan|Tachikawa, Japan|Goyang, Gyeonggido, Korea, Republic of|Daejeon, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Guadalajara, Jalisco, Mexico|Monterrey, Nuevo Le0n, Mexico|Amsterdam, Noord-Holland, Netherlands|Dordrecht, Zuid-Holland, Netherlands|Groningen, Netherlands|Rotterdam, Netherlands|Utrecht, Netherlands|Gjettum, Oppland, Norway|Trondheim, Sor-Trondelag, Norway|Oslo, Norway|Stavanger, Norway|Warszawa, Mazowieckie, Poland|Brzozow, Podkarpackie, Poland|Chorzow, Poland|Lodz, Poland|Braga, Portugal|Coimbra, Portugal|Porto, Portugal|Singapore, Singapore|Groenkloof, Pretoria, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Badalona, Barcelona, Spain|Madrid, Madrid, Communidad Delaware, Spain|Pamplona, Navarra, Spain|Barcelona, Spain|C0rdoba, Spain|Girona, Spain|Madrid, Spain|Murcia, Spain|Salamanca, Spain|Sevilla, Spain|Helsingborg, Skane Lan, Sweden|Lund, Skane Lan, Sweden|Stockholm, Sodermanlands Lan, Sweden|Uppsala, Uppsala Lan, Sweden|Goteborg, Vastra Gotalands Lan, Sweden|Basel, Basel-Stadt (de), Switzerland|Zurich, Zurich (de), Switzerland|Kaohsiung, Taiwan|Kaoshiung, Taiwan|Putzu, Taiwan|Taipei, Taiwan|Taoyuan City, Taiwan|Bangkok, Krung Thep Maha Nakhon-Bangkok, Thailand|Ankara, Turkey|Denizli, Turkey|Istanbul, Turkey|Kayseri, Turkey|Trabzon, Turkey|Kyiv, Ukraine|Southampton, Hampshire, United Kingdom|London, London, City Of, United Kingdom|Oxford, Oxfordshire, United Kingdom|Sutton, Surrey, United Kingdom|Leeds, Yorkshire, United Kingdom|Sheffield, Yorkshire, United Kingdom|Leicester, United Kingdom|Swansea, United Kingdom",https://ClinicalTrials.gov/show/NCT02181413
197,"Molecular Insight Pharmaceuticals, Inc.",A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma,"Active, not recruiting",Has Results,Pheochromocytoma|Paraganglioma,Radiation: Ultratrace® Iobenguane I131,Industry,Interventional,"University of California-San Francisco, San Francisco, California, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|University of Iowa, Iowa City, Iowa, United States|Johns Hopkins University, Baltimore, Maryland, United States|Washington University School of Medicine, Alvin J. Siteman Cancer Center, Saint Louis, Missouri, United States|Mount Sinai School of Medicine, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|MD Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT00874614
198,Eli Lilly and Company,A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein,Recruiting,Has Results,Hepatocellular Carcinoma,Drug: Ramucirumab|Drug: Placebo,Industry,Interventional,"Pacific Hematology and Oncology Associates, Daly City, California, United States|UCLA Medical Center, Los Angeles, California, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|University of Iowa Hospital, Iowa City, Iowa, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Mount Sinai Medical Center, New York, New York, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|OREGON HEALTH and SCIENCE UNIVERSITY, Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kurralta Park, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Woodville, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Linz, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wien, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussels, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liege, Belgium|Fundação PIO XII, Barretos, Brazil|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Barretos, Brazil|Cenantron - Centro Avançado de Tratamento Oncológico, Belo Horizonte, Brazil|Associação Hospital de Caridade Ijuí, Ijui, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Porto Alegre, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Montreal, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Toronto, Canada|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Beijing, China|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Beijing, China|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Beijing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beijing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Changsha, China|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Changsha, China|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Chongqing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guangdong, China|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Guangzhou, China|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Hangzhou, China|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Hangzhou, China|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Hangzhou, China|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Hebei, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hefei, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heilongjiang, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Henan, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hubei, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nanjing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nanjing, China|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Nanning, China|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Qingdao, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shanghai, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Shanghai, China|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Shanghai, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shanghai, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shenyang, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wu Han, China|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Xi'an, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brno, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Praha 5, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amiens, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Avignon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Besancon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Caen, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Clermont-Ferrand, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lyon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montpellier, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nantes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pessac, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Etienne, France|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Bayern, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Essen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leipzig, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Magdeburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., München, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tubingen, Germany|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Hong Kong, Hong Kong|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hong Kong, Hong Kong|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Kowloon, Hong Kong|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., ShaTin, Hong Kong|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tuen Mun, Hong Kong|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haifa, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Aviv, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Benevento, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bologna, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cremona, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Padova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Chuo Ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Fukuoka, Japan|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Iizuka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanazawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kashiwa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Matsuyama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shimotsuke, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Suita-shi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sunto-Gun, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yokohama, Japan|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Ōsaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Incheon, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulsan, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gdansk, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poznan, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warszawa, Poland|Hospital Universitari de Girona Dr. Josep Trueta, Girona, Spain|Hospital Clínico San Carlos, Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santander, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bern, Switzerland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kaohsiung city, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Puzi City, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tainan, Taiwan|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Tainan, Taiwan|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Tainan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei city, Taiwan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Taipei city, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taoyuan City, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Acton, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Acton, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bebington, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom",https://ClinicalTrials.gov/show/NCT02435433
199,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Agenus Inc.,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,"Active, not recruiting",Has Results,Recurrent Glioblastoma|Recurrent Adult Brain Tumor|Gliosarcoma,Biological: HSPPC-96|Drug: bevacizumab,Other|NIH|Industry,Interventional,"Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Regional Hospital, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Mercy Cancer Center-Hot Springs, Hot Springs, Arkansas, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States|Sutter Auburn Faith Hospital, Auburn, California, United States|Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States|Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Mills - Peninsula Hospitals, Burlingame, California, United States|Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, United States|Eden Hospital Medical Center, Castro Valley, California, United States|Sutter Davis Hospital, Davis, California, United States|Epic Care-Dublin, Dublin, California, United States|Bay Area Breast Surgeons Inc, Emeryville, California, United States|Epic Care Partners in Cancer Care, Emeryville, California, United States|Kaiser Permanente-Fremont, Fremont, California, United States|Fresno Cancer Center, Fresno, California, United States|Kaiser Permanente, Fresno, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Contra Costa Regional Medical Center, Martinez, California, United States|Memorial Medical Center, Modesto, California, United States|Kaiser Permanente-Modesto, Modesto, California, United States|Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States|Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States|Alta Bates Summit Medical Center - Summit Campus, Oakland, California, United States|Bay Area Tumor Institute, Oakland, California, United States|Kaiser Permanente Oakland-Broadway, Oakland, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Palo Alto Medical Foundation Health Care, Palo Alto, California, United States|Stanford Cancer Institute, Palo Alto, California, United States|Kaiser Permanente-Rancho Cordova Cancer Center, Rancho Cordova, California, United States|Kaiser Permanente-Redwood City, Redwood City, California, United States|Kaiser Permanente-Richmond, Richmond, California, United States|Rohnert Park Cancer Center, Rohnert Park, California, United States|Kaiser Permanente-Roseville, Roseville, California, United States|Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California, United States|Sutter Roseville Medical Center, Roseville, California, United States|The Permanente Medical Group-Roseville Radiation Oncology, Roseville, California, United States|Sutter General Hospital, Sacramento, California, United States|Kaiser Permanente-South Sacramento, Sacramento, California, United States|South Sacramento Cancer Center, Sacramento, California, United States|Kaiser Permanente - Sacramento, Sacramento, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|Kaiser Permanente-San Francisco, San Francisco, California, United States|UCSF Medical Center-Mount Zion, San Francisco, California, United States|UCSF Medical Center-Parnassus, San Francisco, California, United States|Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, United States|Kaiser Permanente San Leandro, San Leandro, California, United States|Kaiser Permanente-San Rafael, San Rafael, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|Palo Alto Medical Foundation-Santa Cruz, Santa Cruz, California, United States|Kaiser Permanente-Santa Rosa, Santa Rosa, California, United States|Sutter Pacific Medical Foundation, Santa Rosa, California, United States|Kaiser Permanente Cancer Treatment Center, South San Francisco, California, United States|Kaiser Permanente-South San Francisco, South San Francisco, California, United States|Kaiser Permanente-Stockton, Stockton, California, United States|Palo Alto Medical Foundation-Sunnyvale, Sunnyvale, California, United States|Sutter Cancer Centers Radiation Oncology Services-Vacaville, Vacaville, California, United States|Kaiser Permanente Medical Center-Vacaville, Vacaville, California, United States|Kaiser Permanente-Vallejo, Vallejo, California, United States|Sutter Solano Medical Center/Cancer Center, Vallejo, California, United States|Kaiser Permanente-Walnut Creek, Walnut Creek, California, United States|Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States|The Medical Center of Aurora, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Rocky Mountain Cancer Centers-Boulder, Boulder, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Midtown, Denver, Colorado, United States|SCL Health Saint Joseph Hospital, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Rose, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Colorado Cancer Research Program NCORP, Denver, Colorado, United States|Mercy Medical Center, Durango, Colorado, United States|Southwest Oncology PC, Durango, Colorado, United States|Comprehensive Cancer Care and Research Institute of Colorado LLC, Englewood, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Mountain Blue Cancer Care Center, Golden, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Rocky Mountain Cancer Centers-Greenwood Village, Greenwood Village, Colorado, United States|Rocky Mountain Cancer Centers-Lakewood, Lakewood, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers-Littleton, Littleton, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Rocky Mountain Cancer Centers-Sky Ridge, Lone Tree, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Rocky Mountain Cancer Centers-Parker, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers - Pueblo, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers-Thornton, Thornton, Colorado, United States|SCL Health Lutheran Medical Center, Wheat Ridge, Colorado, United States|Saint Vincent's Medical Center, Bridgeport, Connecticut, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|Boca Raton Regional Hospital, Boca Raton, Florida, United States|Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|Memorial Hospital West, Pembroke Pines, Florida, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Piedmont Hospital, Atlanta, Georgia, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Fruitland, Fruitland, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Mountain States Tumor Institute-Twin Falls, Twin Falls, Idaho, United States|Saint Joseph Medical Center, Bloomington, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Cancer Care Center of Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Northwestern Medicine Cancer Center Delnor, Geneva, Illinois, United States|NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, United States|NorthShore University HealthSystem-Highland Park Hospital, Highland Park, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Radiation Oncology of Northern Illinois, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center, Pekin, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|OSF Saint Francis Radiation Oncology at Peoria Cancer Center, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Cancer Care Specialists of Illinois-Swansea, Swansea, Illinois, United States|Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States|Elkhart Clinic, Elkhart, Indiana, United States|Michiana Hematology Oncology PC-Elkhart, Elkhart, Indiana, United States|Elkhart General Hospital, Elkhart, Indiana, United States|Radiation Oncology Associates PC, Fort Wayne, Indiana, United States|Parkview Hospital Randallia, Fort Wayne, Indiana, United States|Franciscan Health Indianapolis, Indianapolis, Indiana, United States|Community Howard Regional Health, Kokomo, Indiana, United States|IU Health La Porte Hospital, La Porte, Indiana, United States|Memorial Regional Cancer Center Day Road, Mishawaka, Indiana, United States|Michiana Hematology Oncology PC-Mishawaka, Mishawaka, Indiana, United States|Saint Joseph Regional Medical Center-Mishawaka, Mishawaka, Indiana, United States|Michiana Hematology Oncology PC-Plymouth, Plymouth, Indiana, United States|Reid Health, Richmond, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Michiana Hematology Oncology PC-South Bend, South Bend, Indiana, United States|South Bend Clinic, South Bend, Indiana, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|Michiana Hematology Oncology PC-Westville, Westville, Indiana, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States|Greater Regional Medical Center, Creston, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Kansas Institute of Medicine Cancer and Blood Center, Lenexa, Kansas, United States|Minimally Invasive Surgery Hospital, Lenexa, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Kansas City NCI Community Oncology Research Program, Prairie Village, Kansas, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|Norton Hospital Pavilion and Medical Campus, Louisville, Kentucky, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, United States|Jewish Hospital Medical Center Northeast, Louisville, Kentucky, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, United States|Maine Medical Center- Scarborough Campus, Scarborough, Maine, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Northwest Hospital Center, Randallstown, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Bixby Medical Center, Adrian, Michigan, United States|Hickman Cancer Center, Adrian, Michigan, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Michigan Cancer Research Consortium NCORP, Ann Arbor, Michigan, United States|Beaumont Hospital-Dearborn, Dearborn, Michigan, United States|Saint John Hospital and Medical Center, Detroit, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Marquette General Hematology Oncology, Marquette, Michigan, United States|Marquette General Hospital, Marquette, Michigan, United States|Mercy Memorial Hospital, Monroe, Michigan, United States|Toledo Clinic Cancer Centers-Monroe, Monroe, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Saint Mary's of Michigan, Saginaw, Michigan, United States|Lakeland Hospital, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Essentia Health Saint Mary's Medical Center, Duluth, Minnesota, United States|Miller-Dwan Hospital, Duluth, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Fairview Maple Grove Medical Center, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Centerpoint Medical Center LLC, Independence, Missouri, United States|Capital Region Medical Center-Goldschmidt Cancer Center, Jefferson City, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|North Kansas City Hospital, Kansas City, Missouri, United States|Heartland Hematology and Oncology Associates Incorporated, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Liberty Radiation Oncology Center, Liberty, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Joseph Oncology Inc, Saint Joseph, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Montana Cancer Consortium NCORP, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Frontier Cancer Center and Blood Institute-Billings, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Montana Cancer Specialists, Missoula, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|Heartland Hematology and Oncology, Kearney, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Nebraska Cancer Research Center, Lincoln, Nebraska, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Hemotology and Oncology Consultants PC, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Midlands Community Hospital, Papillion, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|The Valley Hospital-Luckow Pavilion, Paramus, New Jersey, United States|Neurosurgeons of New Jersey-Ridgewood, Ridgewood, New Jersey, United States|Valley Hospital, Ridgewood, New Jersey, United States|Valley Health System-Hematology/Oncology, Westwood, New Jersey, United States|Columbia University/Herbert Irving Cancer Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Altru Cancer Center, Grand Forks, North Dakota, United States|Toledo Clinic Cancer Centers-Bowling Green, Bowling Green, Ohio, United States|University of Cincinnati/Barrett Cancer Center, Cincinnati, Ohio, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Health Center, Dayton, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Lima Memorial Hospital, Lima, Ohio, United States|Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio, United States|Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio, United States|Saint Charles Hospital, Oregon, Ohio, United States|Toledo Clinic Cancer Centers-Oregon, Oregon, Ohio, United States|Flower Hospital, Sylvania, Ohio, United States|Mercy Hospital of Tiffin, Tiffin, Ohio, United States|The Toledo Hospital/Toledo Children's Hospital, Toledo, Ohio, United States|Saint Vincent Mercy Medical Center, Toledo, Ohio, United States|University of Toledo, Toledo, Ohio, United States|Mercy Saint Anne Hospital, Toledo, Ohio, United States|Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|Fulton County Health Center, Wauseon, Ohio, United States|University Pointe, West Chester, Ohio, United States|Greene Memorial Hospital, Xenia, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Oncology and Hematology Care Southeast, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Legacy Mount Hood Medical Center, Gresham, Oregon, United States|Providence Milwaukie Hospital, Milwaukie, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Providence Willamette Falls Medical Center, Oregon City, Oregon, United States|Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Legacy Meridian Park Hospital, Tualatin, Oregon, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Memorial Hospital, Chattanooga, Tennessee, United States|Pulmonary Medicine Center of Chattanooga-Hixson, Hixson, Tennessee, United States|Memorial GYN Plus, Ooltewah, Tennessee, United States|Saint Joseph Regional Cancer Center, Bryan, Texas, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Fredericksburg Oncology Inc, Fredericksburg, Virginia, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|Cancer Care Center at Island Hospital, Anacortes, Washington, United States|Swedish Cancer Institute-Eastside Oncology Hematology, Bellevue, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States|Harrison Medical Center, Bremerton, Washington, United States|Highline Medical Center-Main Campus, Burien, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Medical Center-Edmonds, Edmonds, Washington, United States|Saint Elizabeth Hospital, Enumclaw, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Saint Francis Hospital, Federal Way, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|Saint Clare Hospital, Lakewood, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, United States|Minor and James Medical PLLC, Seattle, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Group Health Cooperative-Seattle, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|Rockwood Clinic Cancer Treatment Center-Valley, Spokane Valley, Washington, United States|Rockwood Cancer Treatment Center-DHEC-Downtown, Spokane, Washington, United States|Evergreen Hematology and Oncology PS, Spokane, Washington, United States|Franciscan Research Center-Northwest Medical Plaza, Tacoma, Washington, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Compass Oncology Vancouver, Vancouver, Washington, United States|Legacy Salmon Creek Hospital, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital, Yakima, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|Aurora Cancer Care-Racine, Racine, Wisconsin, United States|Cheyenne Regional Medical Center-West, Cheyenne, Wyoming, United States|Big Horn Basin Cancer Center, Cody, Wyoming, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States",https://ClinicalTrials.gov/show/NCT01814813
200,"Janssen Research & Development, LLC",A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma,"Active, not recruiting",Has Results,Multiple Myeloma,Drug: Dara SC|Drug: Dara IV,Industry,Interventional,"Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Royal Prince Alfred Hospital, Camperdown, Australia|St. Vincent's Hospital Melbourne, Fitzroy, Australia|Alfred Health, Melbourne, Australia|Fiona Stanley Hospital, Murdoch, Australia|Sir Charles Gairdner Hospital, Nedlands, Australia|Calvary Mater Newcastle Hospital, Waratah, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|Hospital Do Cancer De Barretos - Fundacao Pio Xii, Barretos, Brazil|Centro de Pesquisas Oncológicas - CEPON, Florianópolis, Brazil|Hospital Amaral Carvalho - Centro de Ensino e Pesquisa, Jaú, Brazil|Instituto Joinvilensse de Hematologia e Oncologia, Joinville, Brazil|Centro de Pesquisa do Instituto do Câncer- Hospital São Vicente de Paulo, Passo Fundo, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil|Instituto COI de Pesquisa, Educacao e Gestao, Rio de Janeiro, Brazil|CEHON, Salvador, Brazil|Hospital de Base de São José do Rio Preto, São José do Rio Preto, Brazil|Clinica Sao Germano, São Paulo, Brazil|HCFMUSP, São Paulo, Brazil|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|The Gordon & Leslie Diamond Health Care Center, Vancouver, British Columbia, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Victoria Hospital, London, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|CHU de Québec -L'Hôtel-Dieu de Québec, Québec, Quebec, Canada|Fakultni nemocnice Brno, Brno, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Fakultní nemocnice Olomouc, Olomouc, Czechia|Fakultni nemocnice Ostrava, Ostrava, Czechia|Fakultni nemocnice Plzen, Hemato-onkologicke oddeleni, Plzen, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha 10, Czechia|Vseobecna fakultni nemocnice v Praze - I. interni klinika - klinika hematologie, Praha 2, Czechia|CHU Caen - Côte de Nacre, Caen, France|Hopital Claude Huriez, Lille Cedex, France|CHU de Nantes hôtel-Dieu, Nantes Cedex 1, France|CHU de Boreaux, Pessac, France|Centre hospitalier Lyon-Sud, Pierre-Bénite, France|CHU Poitiers - Hôpital la Milétrie, Poitiers, France|CHU Nancy Brabois, Vandoeuvre Les Nancy, France|Alexandra General Hospital of Athens, Athens Attica, Greece|Hillel Yaffe Medical Center - Oncology, Hadera, Israel|Rambam Med.Center - Hematology Institute, Haifa, Israel|Carmel Medical Center, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel|Sheba Medical Center Tel Hashomer, Ramat Gan, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Policlinico Sant'Orsola Malpighi, Bologna, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|Ospedale Villa Sofia-Cervello, Palermo, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Azienda USL di Piacenza, Piacenza, Italy|Università di Roma La Sapienza, Roma, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|A.O.U. Città della Salute e della Scienza, Torino, Italy|Fukuoka University Hospital, Fukuoka, Japan|Chugoku Central Hospital, Fukuyama, Japan|Ogaki Municipal Hospital, Gifu, Japan|Gunma University Hospital, Gunma, Japan|Iwate Medical University Hospital, Iwate, Japan|Kobe City Medical Center General Hospital, Kobe-City,, Japan|University Hospital Kyoto Perfectural University of Medicine, Kyoto, Japan|Matsuyama Red Cross Hospital, Matsuyama, Japan|Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan|Nagoya City University Hospital, Nagoya, Japan|Niigata Cancer Center Hospital, Niigata, Japan|National Hospital Organization Okayama Medical Center, Okayama, Japan|Osaka University Hospital, Osaka, Japan|National Hospital Organization Sendai Medical Center, Sendai, Japan|National Hospital Organization Shibukawa Medical Center, Shibukawa, Japan|Japanese Red Cross Medical Center, Shibuya, Japan|Pusan National University Hospital, Busan, Korea, Republic of|National Cancer Center, Goyang-Si, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Republic of|Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im. Ks. B. Markiewicza, Brzozow, Poland|Szpital Uniwersytecki nr 2 im. Jana Biziela w Bydgoszczy, Bydgoszcz, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich, Chorzów, Poland|Szpitale Pomorskie Sp. z o.o., Gdynia, Poland|Szpital Uniwersytecki w Krakowie, Krakow, Poland|Wojewodzki Szpital Specjalistyczny w Legnicy, Legnica, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie, Lublin, Poland|Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego, Poznan, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Warszawa, Poland|Emergency Hospital of Dzerzhinsk, Dzerzhinsk, Russian Federation|Ekaterinburg City Clinical Hospital # 7, Ekaterinburg, Russian Federation|S.P. Botkin Moscow City Clinical Hospital, Moscow, Russian Federation|City Clinical Hospital # 40, Moscow, Russian Federation|Nizhniy Novgorod Region Clinical Hospital, Nizny Novgorod, Russian Federation|Penza Regional Oncology Dispensary, Penza, Russian Federation|Ryazan Regional Clinical Hospital, Ryazan, Russian Federation|Saint Petersburg City Hospital #15, Saint-Petersburg, Russian Federation|Samara Region Clinical Hospital, Samara, Russian Federation|Clinical Research Institute of Hematology and Transfusiology, St-Petersburg, Russian Federation|St.-Petersburg City Clinical Hospital nr 31, St. Petersburg, Russian Federation|Oncology Dispensary of Komi Republic, Syktyvkar, Russian Federation|Hosp. Univ. Germans Trias I Pujol, Badalona, Spain|Hosp. Clinic I Provincial de Barcelona, Barcelona, Spain|Hosp. Univ. Dr. Josep Trueta, Girona, Spain|Hosp. Univ. Virgen de Las Nieves, Granada, Spain|Hosp. Univ. de Canarias, La Laguna, Spain|Hosp. de Leon, Leon, Spain|Hosp. Gral. Univ. Gregorio Marañon, Madrid, Spain|Hosp. Univ. Infanta Leonor, Madrid, Spain|Hosp. Univ. 12 de Octubre, Madrid, Spain|Clinica Univ. de Navarra, Pamplona, Spain|Hosp. Quiron Madrid Pozuelo, Pozuelo de Alarcon, Spain|Hosp. Clinico Univ. de Salamanca, Salamanca, Spain|Hosp. Univ. Dr. Peset, Valencia, Spain|Falu Lasarett, Falun, Sweden|Helsingborgs lasarett, Helsingborg, Sweden|Karolinska University Hospital, Huddinge, Huddinge, Sweden|Skanes universitetssjukhus, Lund, Sweden|Norrlands University Hospital, Umea, Sweden|Akademiska Sjukhuset, Uppsala, Sweden|Chang-Hua Christian Hospital, Changhua, Taiwan|China Medical University Hospital, Taichung City, Taiwan|Taichung Veterans General Hospital, Taichung,, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital, Taoyuan, Taiwan|Communal Nonprofit Enterprise 'Cherkasy Regional Oncology Dispensary Of Cherkasy Regional Council', Cherkasy, Ukraine|Dnepropetrovsk City Clinical Hospital #4, Regional Hematology Center, Dnepropetrovsk, Ukraine|Ivano-Frankivsk Regional Clinical Hospital, Ivano-Frankivsk, Ukraine|SI Grigoriev Institute for Medical Radiology National Academy of Medical Science of Ukraine, Kharkiv, Ukraine|National Cancer Institute, Dept. of chemotherapy of hemoblastosis, Kiev, Ukraine|Kiev Marrow Transplantation Center, Bone Marrow Transplantation Department, Kiev, Ukraine|State Institution ''Scientific Center for Radiation Medicine Academy of Medical Sciences of Ukraine'', Kiev, Ukraine|Institute of Blood Pathology and Transfusion Medicine of AMS of Ukraine, Lviv, Ukraine|Mykolaiv Regional Clinical Hospital, Mykolaiv, Ukraine|Ukrainian Medical Stomatological Academy, Poltava Regional Clinical Hospital, Poltava, Ukraine|Blackpool Victoria Hospital, Blackpool, United Kingdom|Royal Bournemouth Hospital, Bournemouth, United Kingdom|Leicester Royal Infirmary - Haematology, Leicester, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|Guy's & St Thomas Hospital, London, United Kingdom|Christie Hospital NHS Trust, Manchester, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Royal Marsden Hospital, Surrey, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom",https://ClinicalTrials.gov/show/NCT03277105
201,Sanofi,"Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients","Active, not recruiting",Has Results,Plasma Cell Myeloma,Drug: Isatuximab|Drug: Pomalidomide|Drug: Dexamethasone,Industry,Interventional,"Investigational Site Number 8400002, Plantation, Florida, United States|Investigational Site Number 8400006, Boston, Massachusetts, United States|Investigational Site Number 0360005, Melbourne, Australia|Investigational Site Number 0360002, Prahran, Australia|Investigational Site Number 0360006, Richmond, Australia|Investigational Site Number 0360004, St Leonards, Australia|Investigational Site Number 0360001, Waratah, Australia|Investigational Site Number 0560003, Antwerpen, Belgium|Investigational Site Number 0560002, Brussel, Belgium|Investigational Site Number 0560004, Gent, Belgium|Investigational Site Number 0560001, Leuven, Belgium|Investigational Site Number 1240001, Montreal, Canada|Investigational Site Number 1240004, Montreal, Canada|Investigational Site Number 1240005, Sherbrooke, Canada|Investigational Site Number 2030005, Brno, Czechia|Investigational Site Number 2030004, Hradec Kralove, Czechia|Investigational Site Number 2030001, Olomouc, Czechia|Investigational Site Number 2030002, Ostrava - Poruba, Czechia|Investigational Site Number 2030003, Praha 2, Czechia|Investigational Site Number 2080002, Ålborg, Denmark|Investigational Site Number 2500021, Bayonne, France|Investigational Site Number 2500008, Caen, France|Investigational Site Number 2500009, Dijon, France|Investigational Site Number 2500017, Grenoble, France|Investigational Site Number 2500013, La Roche Sur Yon, France|Investigational Site Number 2500003, Lille, France|Investigational Site Number 2500023, Limoges, France|Investigational Site Number 2500019, Montpellier Cedex, France|Investigational Site Number 2500002, Nantes, France|Investigational Site Number 2500015, Paris, France|Investigational Site Number 2500016, Paris, France|Investigational Site Number 2500005, Pessac, France|Investigational Site Number 2500004, Pierre Benite Cedex, France|Investigational Site Number 2500007, Poitiers Cedex, France|Investigational Site Number 2500025, Reims, France|Investigational Site Number 2500014, Rennes, France|Investigational Site Number 2500001, Toulouse Cedex 9, France|Investigational Site Number 2500012, Tours, France|Investigational Site Number 2500018, Vandoeuvre-Les-Nancy Cedex, France|Investigational Site Number 2760001, Leipzig, Germany|Investigational Site Number 3000002, Athens, Greece|Investigational Site Number 3000005, Athens, Greece|Investigational Site Number 3000001, Athens, Greece|Investigational Site Number 3000004, Patra, Greece|Investigational Site Number 3000003, Thessaloniki, Greece|Investigational Site Number 3480001, Budapest, Hungary|Investigational Site Number 3480003, Budapest, Hungary|Investigational Site Number 3480002, Debrecen, Hungary|Investigational Site Number 3800001, Bologna, Italy|Investigational Site Number 3800010, Catania, Italy|Investigational Site Number 3800009, Firenze, Italy|Investigational Site Number 3800008, Genova, Italy|Investigational Site Number 3800007, Milano, Italy|Investigational Site Number 3800002, Milano, Italy|Investigational Site Number 3800006, Padova, Italy|Investigational Site Number 3800004, Terni, Italy|Investigational Site Number 3800003, Torino, Italy|Investigational Site Number 3920006, Kyoto-Shi, Japan|Investigational Site Number 3920001, Nagoya-Shi, Japan|Investigational Site Number 3920003, Okayama-Shi, Japan|Investigational Site Number 3920004, Sapporo-Shi, Japan|Investigational Site Number 3920005, Shibukawa-Shi, Japan|Investigational Site Number 3920002, Shibuya-Ku, Japan|Investigational Site Number 3920007, Sunto-Gun, Japan|Investigational Site Number 3920008, Suwa-Shi, Japan|Investigational Site Number 4100007, Hwasun-Gun, Korea, Republic of|Investigational Site Number 4100006, Incheon, Korea, Republic of|Investigational Site Number 4100001, Seoul, Korea, Republic of|Investigational Site Number 4100002, Seoul, Korea, Republic of|Investigational Site Number 4100005, Seoul, Korea, Republic of|Investigational Site Number 5540002, Auckland, New Zealand|Investigational Site Number 5540004, Dunedin, New Zealand|Investigational Site Number 5540003, Hamilton, New Zealand|Investigational Site Number 5540001, Takapuna, New Zealand|Investigational Site Number 5780001, Oslo, Norway|Investigational Site Number 6160002, Chorzow, Poland|Investigational Site Number 6160005, Krakow, Poland|Investigational Site Number 6160003, Lublin, Poland|Investigational Site Number 6160001, Warszawa, Poland|Investigational Site Number 6200004, Coimbra, Portugal|Investigational Site Number 6200002, Lisboa, Portugal|Investigational Site Number 6200001, Porto, Portugal|Investigational Site Number 6430004, Moscow, Russian Federation|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430002, Moscow, Russian Federation|Investigational Site Number 7030001, Bratislava, Slovakia|Investigational Site Number 7240001, Barcelona, Spain|Investigational Site Number 7240003, Madrid, Spain|Investigational Site Number 7240002, Pamplona, Spain|Investigational Site Number 7240004, Salamanca, Spain|Investigational Site Number 7240006, Santander, Spain|Investigational Site Number 7240005, Santiago De Compostela, Spain|Investigational Site Number 7520004, Luleå, Sweden|Investigational Site Number 7520005, Uddevalla, Sweden|Investigational Site Number 1580004, Kaohsiung, Taiwan|Investigational Site Number 1580002, Taichung, Taiwan|Investigational Site Number 1580001, Taipei, Taiwan|Investigational Site Number 1580003, Taoyuan, Taiwan|Investigational Site Number 7920001, Ankara, Turkey|Investigational Site Number 7920002, Antalya, Turkey|Investigational Site Number 7920005, Istanbul, Turkey|Investigational Site Number 7920003, Istanbul, Turkey|Investigational Site Number 7920004, Istanbul, Turkey|Investigational Site Number 7920006, İstanbul, Turkey|Investigational Site Number 7920008, Izmir, Turkey|Investigational Site Number 7920010, Izmir, Turkey|Investigational Site Number 7920009, Kayseri, Turkey|Investigational Site Number 7920007, Kocaeli, Turkey|Investigational Site Number 8260002, London, United Kingdom|Investigational Site Number 8260003, London, United Kingdom|Investigational Site Number 8260001, London, United Kingdom",https://ClinicalTrials.gov/show/NCT02990338
202,Southwest Oncology Group|National Cancer Institute (NCI)|Halozyme Therapeutics,"S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer","Active, not recruiting",Has Results,Metastatic Pancreatic Adenocarcinoma,Drug: PEGPH20|Drug: Oxaliplatin|Drug: Leucovorin|Drug: Irinotecan|Drug: 5-fluorouracil,Other|NIH|Industry,Interventional,"Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States|The University of Arizona Medical Center-University Campus, Tucson, Arizona, United States|Sutter Auburn Faith Hospital, Auburn, California, United States|Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States|Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Mills - Peninsula Hospitals, Burlingame, California, United States|Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, United States|Eden Hospital Medical Center, Castro Valley, California, United States|City of Hope Corona, Corona, California, United States|UC Irvine Health Cancer Center-Newport, Costa Mesa, California, United States|Sutter Davis Hospital, Davis, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Fremont - Rideout Cancer Center, Marysville, California, United States|Memorial Medical Center, Modesto, California, United States|Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States|Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States|Sutter Cancer Research Consortium, Novato, California, United States|UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States|Palo Alto Medical Foundation Health Care, Palo Alto, California, United States|Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California, United States|Sutter Roseville Medical Center, Roseville, California, United States|Sutter General Hospital, Sacramento, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|Palo Alto Medical Foundation-Santa Cruz, Santa Cruz, California, United States|Sutter Pacific Medical Foundation, Santa Rosa, California, United States|Palo Alto Medical Foundation-Sunnyvale, Sunnyvale, California, United States|Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee, California, United States|Sutter Cancer Centers Radiation Oncology Services-Vacaville, Vacaville, California, United States|Sutter Solano Medical Center/Cancer Center, Vallejo, California, United States|City of Hope West Covina, West Covina, California, United States|Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut, United States|Smilow Cancer Hospital Care Center-Fairfield, Fairfield, Connecticut, United States|Medical Oncology and Hematology Group PC-Guilford, Guilford, Connecticut, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Yale-New Haven Hospital North Haven Medical Center, North Haven, Connecticut, United States|Smilow Cancer Hospital-Orange Care Center, Orange, Connecticut, United States|Charlotte Hungerford Hospital Center for Cancer Care, Torrington, Connecticut, United States|Smilow Cancer Hospital Care Center-Trumbull, Trumbull, Connecticut, United States|Smilow Cancer Hospital-Waterbury Care Center, Waterbury, Connecticut, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Fruitland, Fruitland, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States|Saint Luke's Mountain States Tumor Institute-Twin Falls, Twin Falls, Idaho, United States|Saint Joseph Medical Center, Bloomington, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Cancer Care Center of Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Radiation Oncology of Northern Illinois, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center, Pekin, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|OSF Saint Francis Radiation Oncology at Peoria Cancer Center, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Cancer Care Specialists of Illinois-Swansea, Swansea, Illinois, United States|Kansas Institute of Medicine Cancer and Blood Center, Lenexa, Kansas, United States|Minimally Invasive Surgery Hospital, Lenexa, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Kansas City NCI Community Oncology Research Program, Prairie Village, Kansas, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Centerpoint Medical Center LLC, Independence, Missouri, United States|Capital Region Medical Center-Goldschmidt Cancer Center, Jefferson City, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Heartland Hematology and Oncology Associates Incorporated, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Liberty Radiation Oncology Center, Liberty, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Randolph Hospital, Asheboro, North Carolina, United States|Cone Health Cancer Center at Alamance Regional, Burlington, North Carolina, United States|Southeastern Medical Oncology Center-Clinton, Clinton, North Carolina, United States|Southeastern Medical Oncology Center-Goldsboro, Goldsboro, North Carolina, United States|Wayne Memorial Hospital, Goldsboro, North Carolina, United States|Cone Health Cancer Center, Greensboro, North Carolina, United States|Hendersonville Hematology and Oncology at Pardee, Hendersonville, North Carolina, United States|Margaret R Pardee Memorial Hospital, Hendersonville, North Carolina, United States|Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States|Cone Heath Cancer Center at Mebane, Mebane, North Carolina, United States|Annie Penn Memorial Hospital, Reidsville, North Carolina, United States|Southeastern Medical Oncology Center-Wilson, Wilson, North Carolina, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Oncology and Hematology Care Southeast, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Providence Willamette Falls Medical Center, Oregon City, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|Cancer Care Center at Island Hospital, Anacortes, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Medical Center-Edmonds, Edmonds, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Seattle Cancer Care Alliance at EvergreenHealth, Kirkland, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Minor and James Medical PLLC, Seattle, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Group Health Cooperative-Seattle, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|Rockwood Clinic Cancer Treatment Center-Valley, Spokane Valley, Washington, United States|Rockwood Cancer Treatment Center-DHEC-Downtown, Spokane, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States",https://ClinicalTrials.gov/show/NCT01959139
203,Eisai Limited|Eisai Inc.,"A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma","Active, not recruiting",Has Results,Hepatocellular Carcinoma (HCC),Drug: Lenvatinib|Drug: Sorafenib,Industry,Interventional,"Facility # 1, Los Angeles, California, United States|Facility # 1, Sacramento, California, United States|Facility # 1, San Francisco, California, United States|Facility # 1, Washington, District of Columbia, United States|Facility # 1, Tampa, Florida, United States|Facility # 1, Duluth, Georgia, United States|Facility # 1, Lawrenceville, Georgia, United States|Facility # 1, Baltimore, Maryland, United States|Facility # 1, Detroit, Michigan, United States|Facility # 1, Kansas City, Missouri, United States|Facility # 1, Saint Louis, Missouri, United States|Facility # 1, East Orange, New Jersey, United States|Facility # 1, Brooklyn, New York, United States|Facility # 1, Lake Success, New York, United States|Facility # 1, New York, New York, United States|Facility # 1, Charlotte, North Carolina, United States|Facility # 1, Durham, North Carolina, United States|Facility # 1, Portland, Oregon, United States|Facility # 1, Austin, Texas, United States|Facility # 1, Lubbock, Texas, United States|Facility # 1, Seattle, Washington, United States|Facility # 1, Camperdown, New South Wales, Australia|Facility # 1, Wentworthville, New South Wales, Australia|Facility # 1, Woolloongabba, Queensland, Australia|Facility # 1, Fitzroy, Victoria, Australia|Facility # 1, Melbourne, Victoria, Australia|Facility # 2, Melbourne, Victoria, Australia|Facility # 1, Nedlands, Western Australia, Australia|Facility # 1, Bruxelles, Belgium|Facility # 1, Edegem, Belgium|Facility # 1, Liege, Belgium|Facility # 1, Ottawa, Ontario, Canada|Facility # 1, Hefei, Anhui, China|Facility # 1, Beijing, Beijing, China|Facility # 2, Beijing, Beijing, China|Facility # 3, Beijing, Beijing, China|Facility # 1, Chongqing, Chongqing, China|Facility # 1, Fuzhou, Fujian, China|Facility # 2, Fuzhou, Fujian, China|Facility # 1, Guangzhou, Guangdong, China|Facility # 1, Harbin, Heilongjiang, China|Facility # 1, Changsha, Hunan, China|Facility # 1, Nanjing, Jiangsu, China|Facility # 1, Suzhou, Jiangsu, China|Facility # 1, Changchun, Jilin, China|Facility # 1, Dalian, Liaoning, China|Facility # 1, Jinan, Shandong, China|Facility # 1, Shanghai, Shanghai, China|Facility # 3, Shanghai, Shanghai, China|Facility # 1, Xi'an, Shanxi, China|Facility # 2, Xi'an, Shanxi, China|Facility # 1, Hangzhou, Zhejiang, China|Facility # 1, Tianjin, Zhejiang, China|Facility # 1, Nice Cedex 3, Alpes Maritimes, France|Facility # 1, Pessac Cedex, Gironde, France|Facility # 1, Pessac, Gironde, France|Facility # 1, Toulouse, Haute Garonne, France|Facility # 1, Montpellier cedex 5, Herault, France|Facility # 1, Rennes cedex, Ille Et Vilaine, France|Facility # 1, Vandoeuvre les Nancy, Meurthe Et Moselle, France|Facility # 1, Amiens cedex 1, Somme, France|Facility # 1, Creteil Cedex, Val De Marne, France|Facility # 1, Bordeaux, France|Facility # 1, Lille cedex, France|Facility # 1, Lyon, France|Facility # 1, Nord, France|Facility # 1, Paris cedex 12, France|Facility # 1, Paris, France|Facility # 1, Rhone, France|Facility # 1, Heidelberg, Baden Wuerttemberg, Germany|Facility # 1, Tuebingen, Baden Wuerttemberg, Germany|Facility # 1, Marburg, Hessen, Germany|Facility # 1, Hannover, Niedersachsen, Germany|Facility # 1, Essen, Nordrhein Westfalen, Germany|Facility # 1, Koeln, Nordrhein Westfalen, Germany|Facility # 1, Mainz, Rheinland Pfalz, Germany|Facility # 1, Hong Kong, Hong Kong|Facility # 2, Hong Kong, Hong Kong|Facility # 3, Hong Kong, Hong Kong|Facility # 1, Kowloon, Hong Kong|Facility # 1, Petach Tikva, Israel|Facility # 1, Petah Tiqwa, Israel|Facility # 1, Torrette, Ancona, Italy|Facility # 1, Bari, Italy|Facility # 1, Benevento, Italy|Facility # 1, Bologna, Italy|Facility # 1, Napoli, Italy|Facility # 2, Napoli, Italy|Facility # 1, Palermo, Italy|Facility # 1, Roma, Italy|Facility # 1, Nagoya, Aichi, Japan|Facility # 1, Kashiwa, Chiba, Japan|Facility # 1, Matsuyama, Ehime, Japan|Facility # 1, Kurume, Fukuoka, Japan|Facility # 1, Sapporo, Hokkaido, Japan|Facility # 2, Sapporo, Hokkaido, Japan|Facility # 1, Nishinomiya, Hyogo, Japan|Facility # 1, Kanazawa, Ishikawa, Japan|Facility # 1, Kawasaki, Kanagawa, Japan|Facility # 1, Yokohama, Kanagawa, Japan|Facility # 1, Tsu, Mie, Japan|Facility # 1, Omura, Nagasaki, Japan|Facility # 1, Osaka-Sayama, Osaka, Japan|Facility # 1, Bunkyo-Ku, Tokyo, Japan|Facility # 1, Chuo-ku, Tokyo, Japan|Facility # 1, Koto-ku, Tokyo, Japan|Facility # 1, Minato-ku, Tokyo, Japan|Facility # 1, Musashino, Tokyo, Japan|Facility # 1, Shimonoseki, Yamaguchi, Japan|Facility # 1, Fukuoka, Japan|Facility # 1, Hiroshima, Japan|Facility # 1, Okayama, Japan|Facility # 2, Osaka, Japan|Facility # 1, Saga, Japan|Facility # 2, Saga, Japan|Facility # 1, Goyang-si, Gyeonggi-do, Korea, Republic of|Facility # 1, Seongnam-Si, Gyeonggi-do, Korea, Republic of|Facility # 2, Seongnam-Si, Gyeonggi-do, Korea, Republic of|Facility # 1, Suwon, Gyeonggi-do, Korea, Republic of|Facility # 1, Daegu, Gyeongsangbuk-do, Korea, Republic of|Facility # 1, Hwasun, Jeollanam-do, Korea, Republic of|Facility # 1, Busan, Korea, Republic of|Facility # 2, Busan, Korea, Republic of|Facility # 3, Busan, Korea, Republic of|Facility # 1, Incheon, Korea, Republic of|Facility # 1, Seoul, Korea, Republic of|Facility # 2, Seoul, Korea, Republic of|Facility # 3, Seoul, Korea, Republic of|Facility # 4, Seoul, Korea, Republic of|Facility # 5, Seoul, Korea, Republic of|Facility # 6, Seoul, Korea, Republic of|Facility # 7, Seoul, Korea, Republic of|Facility # 8, Seoul, Korea, Republic of|Facility # 1, Kuantan, Pahang, Malaysia|Facility # 1, Penang, Pulau Pinang, Malaysia|Facility # 1, Miri, Sarawak, Malaysia|Facility # 1, Batu Caves, Selangor, Malaysia|Facility # 1, Kuala Lumpur, Malaysia|Facility # 1, Cebu City, Philippines|Facility # 2, Cebu City, Philippines|Facility # 1, Davao City, Philippines|Facility # 1, Quezon City, Philippines|Facility # 2, Quezon City, Philippines|Facility # 1, Gdansk, Poland|Facility # 1, Warszawa, Poland|Facility # 1, Wroclaw, Poland|Facility # 1, Arkhangelsk, Russian Federation|Facility # 1, Moscow, Russian Federation|Facility # 2, Moscow, Russian Federation|Facility # 3, Saint Petersburg, Russian Federation|Facility # 4, Saint Petersburg, Russian Federation|Facility # 1, Ufa, Russian Federation|Facility # 1, Singapore, Singapore|Facility # 2, Singapore, Singapore|Facility # 3, Singapore, Singapore|Facility # 4, Singapore, Singapore|Facility # 1, L'Hospitalet de Llobregat, Barcelona, Spain|Facility # 1, Santander, Cantabria, Spain|Facility # 1, Badajoz, Spain|Facility # 1, Girona, Spain|Facility # 1, Madrid, Spain|Facility # 2, Madrid, Spain|Facility # 3, Madrid, Spain|Facility # 4, Madrid, Spain|Facility # 1, Kaohsiung, Taiwan|Facility # 2, Kaohsiung, Taiwan|Facility # 1, Taichung, Taiwan|Facility # 2, Taichung, Taiwan|Facility # 1, Tainan, Taiwan|Facility # 2, Tainan, Taiwan|Facility # 1, Taipei, Taiwan|Facility # 2, Taipei, Taiwan|Facility # 3, Taipei, Taiwan|Facility # 4, Taipei, Taiwan|Facility # 5, Taipei, Taiwan|Facility # 1, Taoyuan City, Taiwan|Facility # 1, Bangkoknoi, Bangkok, Thailand|Facility # 1, Pathum Wan, Bangkok, Thailand|Facility # 1, Ratchathewi, Bangkok, Thailand|Facility # 1, Muang, Chiang Mai, Thailand|Facility # 1, Muang, Chiang Rai, Thailand|Facility # 2, London, Greater London, United Kingdom|Facility # 1, London, Greater London, United Kingdom|Facility # 3, London, Greater London, United Kingdom|Facility # 1, Manchester, Greater Manchester, United Kingdom|Facility # 1, Liverpool, Merseyside, United Kingdom|Facility # 1, Glasgow, Strathclyde, United Kingdom|Facility # 1, Birmingham, West Midlands, United Kingdom",https://ClinicalTrials.gov/show/NCT01761266
204,Celgene,A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma,"Active, not recruiting",Has Results,Multiple Myeloma,Drug: Durvalumab|Drug: Lenalidomide|Drug: Dexamethasone,Industry,Interventional,"University of Alabama Birmingham, Birmingham, Alabama, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Weill Medical College of Cornell University, New York, New York, United States|Carolinas Healthcare System, Charleston, South Carolina, United States|Swedish Medical Center, Seattle, Washington, United States|Tom Baker Cancer Center, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada|Rigshospitalet University Hospital, Copenhagen, Denmark|Odense Universitetshospital, Odense, Denmark|Vejle Hospital, Vejle, Denmark|Helsinki UniversityCentral Hospital, Helsinki, Finland|Universitatsklinikum Essen, Essen, Germany|Praxis fuer Haematologie und Onkologie Koblenz, Koblenz, Germany|University of Tubingen, Tübingen, Germany|Policlinico S. Orsola, Bologna, Italy|I.R.C.C.S. Policlinico San Matteo - Universita di Pavia, Pavia, Italy|Servizio di Ematologia, A.O. - Arcispedale S.Maria Nuova, Reggio Emilia, Italy|Policlinico Agostino Gemelli, Rome, Italy|Azienda Ospedaliera San Giovanni Battista - Ospedale Molinette, Torino, Italy|VU Medical Center, Amsterdam, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|Hopsital Germans Trias I Pujol, Badalona, Spain|Hospital 12 de Octobre, Madrid, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Doctor Peset, Valencia, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain",https://ClinicalTrials.gov/show/NCT02685826
205,OHSU Knight Cancer Institute|Bayer|National Cancer Institute (NCI),"Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma","Active, not recruiting",Has Results,Pleomorphic Rhabdomyosarcoma|Stage IIB Adult Soft Tissue Sarcoma AJCC v7|Stage III Adult Soft Tissue Sarcoma AJCC v7|Stage IV Adult Soft Tissue Sarcoma AJCC v7,Drug: Epirubicin Hydrochloride|Radiation: External Beam Radiation Therapy|Drug: Ifosfamide|Other: Laboratory Biomarker Analysis|Drug: Sorafenib Tosylate|Procedure: Therapeutic Conventional Surgery,Other|Industry|NIH,Interventional,"OHSU Knight Cancer Institute, Portland, Oregon, United States",https://ClinicalTrials.gov/show/NCT02050919
206,AbbVie,A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy,"Active, not recruiting",Has Results,Acute Myeloid Leukemia (AML),Drug: Placebo|Drug: Venetoclax|Drug: Cytarabine,Industry,Interventional,"H. Lee Moffit Cancer Center /ID# 164273, Tampa, Florida, United States|Norton Cancer Institute /ID# 158998, Louisville, Kentucky, United States|Univ of Pittsburgh Med Ctr /ID# 158997, Pittsburgh, Pennsylvania, United States|Univ TX, MD Anderson /ID# 159678, Houston, Texas, United States|Swedish Medical Center /ID# 161280, Seattle, Washington, United States|Gundersen Health System /ID# 164272, La Crosse, Wisconsin, United States|Cemic /Id# 159676, Buenos Aires, Argentina|Sanatorio Allende /ID# 159675, Cordoba, Argentina|Calvary Mater Newcastle /ID# 160123, Waratah, New South Wales, Australia|Westmead Hospital /ID# 160121, Westmead, New South Wales, Australia|Alfred Hospital /ID# 160125, Melbourne, Victoria, Australia|Box Hill Hospital /ID# 162920, Melbourne, Victoria, Australia|Universitair Ziekenhuis Antwerpen /ID# 159566, Edegem, Antwerpen, Belgium|Cliniques Universitaires Saint Luc /ID# 159567, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|Centro de Pesquisas Oncologicas /ID# 163567, Florianopolis, Santa Catarina, Brazil|Hospital de Cancer de Barretos /ID# 163568, Barretos, Sao Paulo, Brazil|Hospital do Cancer Mae de Deus /ID# 163416, Porto Alegre, Brazil|Casa de Saúde Santa Marcelina /ID# 163413, Sao Paulo, Brazil|University of Alberta Hospital /ID# 159646, Edmonton, Alberta, Canada|CISSS de la Monteregie /ID# 159782, Greenfield Park, Quebec, Canada|Hospital Maisonneuve-Rosemont /ID# 159780, Montreal, Quebec, Canada|Hopital Sacre Coeur Montreal /ID# 160982, Montreal, Quebec, Canada|Fujian Medical Univ Union Hosp /ID# 167321, Fuzhou, Fujian, China|Nanfang Hospital of Southern Medical University /ID# 170147, Guangzhou, Guangdong, China|Jiangsu Province People's Hospital /ID# 167511, Nanjing, Jiangsu, China|The First Hosp of Jilin Univ /ID# 167512, Changchun, Jilin, China|Ruijin Hospital, Shanghai Jiaotong /ID# 167325, Shanghai, Shanghai, China|West China Hospital /ID# 167514, Chengdu, Sichuan, China|Blood disease hosp of Chinese Academy of Med Sciences(Institute of Hematology) /ID# 167509, Tianjin, Tianjin, China|The First Affiliated Hospital,College of Medicine, Zhejiang University /ID# 167324, Hangzhou, Zhejiang, China|Qilu Hospital of Shandong Univ /ID# 167507, Jinan, China|Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 167515, Wuhan, China|Henan Cancer Hospital /ID# 167327, Zhengzhou, Henan, China|Fakultni Nemocnice Brno /ID# 159247, Brno, Czechia|Univ Hosp Ostrava-Poruba /ID# 159246, Ostrava, Czechia|Fakult Nem Kralovske Vinohrady /ID# 159248, Prague, Czechia|Centre Hospitalier Lyon Sud /ID# 159705, Pierre Benite CEDEX, Rhone, France|Centre Hospitalier Le Mans /ID# 159702, Le Mans CEDEX 9, Sarthe, France|Centre Hospitalier de la Cote /ID# 159697, Bayonne, France|CHU Bordeaux /ID# 159704, Pessac, France|CHU De Nancy /ID# 159700, Vandoeuvre Les Nancy Cedex, France|Schwarzwald-Baar-Klinikum /ID# 159571, Villingen-Schwenningen, Baden-Wuerttemberg, Germany|Vivantes Klinikum Am Urban /ID# 159569, Berlin, Germany|Universitaetsklinikum Hamburg /ID# 161760, Hamburg, Germany|General Hospital of Athens Laiko /ID# 157870, Athens, Attiki, Greece|Gen Univ Hosp Alexandroupolis /ID# 157868, Alexandroupolis, Greece|General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 157869, Athens, Greece|University Gen Hosp of Patra /ID# 157871, Patras, Greece|General Hospital of Thessaloniki George Papanikolaou /ID# 157867, Thessaloniki, Greece|Dél-pesti Centrumkórház- Országos Hematológiai és Infektológiai Intézet /ID# 159127, Budapest IX, Budapest, Hungary|Pecsi Tudomanyegyetem /ID# 163161, Pécs, Pecs, Hungary|Semmelweis Egyetem I. Belklini /ID# 158180, Budapest, Hungary|Debreceni Egyetem Klinikai Koz /ID# 158178, Debrecen, Hungary|Petz Aladar Megyei Oktato Korh /ID# 161739, Gyor, Hungary|Kaposi Mor Oktato Korhaz /ID# 158175, Kaposvar, Hungary|Bacs-Kiskun Megyei Korhaz /ID# 160973, Kecskemét, Hungary|St. James's Hospital /ID# 162730, Dublin 8, Dublin, Ireland|Beaumont Hospital /ID# 162733, Dublin, Ireland|University Hospital Galway /ID# 162734, Galway, Ireland|University Hospital Limerick /ID# 162735, Limerick, Ireland|University of Fukui Hospital /ID# 159770, Yoshida-gun, Fukui, Japan|Kyushu University Hospital /ID# 159688, Fukuoka-shi, Fukuoka, Japan|Gunmaken Saiseikai Maebashi Hospital /ID# 160597, Maebashi-shi, Gunma, Japan|National Hospital Organization Mito Medical Center /ID# 162988, Higashi Ibaraki-gun, Ibaraki, Japan|Kyoto Prefect Univ Med /ID# 160101, Kyoto-shi, Kyoto, Japan|Tohoku University Hospital /ID# 161151, Sendai-shi, Miyagi, Japan|Nagasaki University Hospital /ID# 160233, Nagasaki-shi, Nagasaki, Japan|Osaka City University Hospital /ID# 159722, Osaka-shi, Osaka, Japan|Kinki University -Osakasayama Campus /ID# 160777, Osakasayama-shi, Osaka, Japan|Tokyo Metropolitan Komagome Hospital /ID# 160759, Bunkyo-ku, Tokyo, Japan|Tokyo Jikei Daisan Hospital /ID# 159769, Komae-shi, Tokyo, Japan|NTT Medical Center Tokyo /ID# 160678, Shinagawa-ku, Tokyo, Japan|Yamagata University Hospital /ID# 161223, Yamagata-shi, Yamagata, Japan|Akita University Hospital /ID# 160602, Akita, Japan|Saitama Med Univ Int Med Ctr /ID# 161308, Hidaka, Japan|NHO Nagoya Medical Center /ID# 159768, Nagoya, Japan|Dokkyo Medical University Hosp /ID# 159650, Shimotsuga, Japan|Juntendo University Hospital /ID# 159781, Tokyo, Japan|Pusan National University Hosp /ID# 158725, Busan, Busan Gwang Yeogsi, Korea, Republic of|Chungnam National University Hospital /ID# 158726, Jung-gu, Daejeon Gwang Yeogsi, Korea, Republic of|Cath Univ Seoul St Mary's Hosp /ID# 158724, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul National University Hospital /ID# 162253, Seoul, Korea, Republic of|Instituto Nacional de Cancerol /ID# 159269, Ciudad de México, Ciudad De Mexico, Mexico|Centro de Invest Clin Chapulte /ID# 162625, Morelia, Michoacan, Mexico|Hosp. Univ. Dr. Jose E. Gonz /ID# 159268, Monterrey, Nuevo Leon, Mexico|North Shore Hospital /ID# 160132, Auckland, New Zealand|Middlemore Clinical Trials /ID# 160131, Auckland, New Zealand|Haukeland University Hospital /ID# 165630, Bergen, Hordaland, Norway|Sykehuset Ostfold Kalnes /ID# 165632, Gralum, Norway|VA Caribbean Healthcare System /ID# 158999, San Juan, Puerto Rico|Kemerovo Regional Clinical Hospital n.a. S.V. Belyaev /ID# 162991, Kemerovo, Kemerovskaya Oblast, Russian Federation|Nizhniy Novgorod regional clinical hospital named N. A. Semashko /ID# 163186, Nizhnij Novgorod, Nizhegorodskaya Oblast, Russian Federation|State Institution of Health of the Ryazan Regional Clinical Hospital /ID# 163126, Ryazan, Ryazanskaya Oblast, Russian Federation|City Clinical Hospital Botkina /ID# 164086, Moscow, Russian Federation|Samara State Medical Universit /ID# 164173, Samara, Russian Federation|Almazov North-West Federal Med /ID# 162170, Sankt-peterburg, Russian Federation|saratov state medical /ID# 163130, Saratov, Russian Federation|Saint Petersburg State Institu /ID# 162171, St. Petersburg, Russian Federation|Yaroslavl Regional Clinic Hosp /ID# 162172, Yaroslavl, Russian Federation|Netcare Pretoria East Hospital /ID# 157373, Pretoria, Gauteng, South Africa|Tshwane District Hospital /ID# 157361, Pretoria, Gauteng, South Africa|Hospital Universitario y Politecnico La Fe /ID# 161181, Valencia, Valenciana, Spain|Hospital Infanta Leonor /ID# 161180, Madrid, Spain|National Taiwan Univ Hosp /ID# 162781, Taipei City, Taipei, Taiwan|Tri-Service General Hospital /ID# 161683, Taipei City, Taipei, Taiwan|Kaohsiung Medical University /ID# 161693, Kaohsiung, Taiwan|Heartlands Hospital /ID# 163534, Birmingham, United Kingdom|University Hospital of Wales /ID# 162726, Cardiff, United Kingdom|Northwick Park Hospital /ID# 162727, Harrow, United Kingdom",https://ClinicalTrials.gov/show/NCT03069352
207,"Astellas Pharma Global Development, Inc.|Astellas Pharma Inc",A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,"Active, not recruiting",Has Results,"Leukemia, Acute Myeloid (AML)","Drug: gilteritinib|Drug: LoDAC (Low Dose Cytarabine)|Drug: Azacitidine|Drug: MEC (Mitoxantrone, Etoposide, Cytarabine)|Drug: FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)",Industry,Interventional,"Site US10011, Birmingham, Alabama, United States|Site US10012, Los Angeles, California, United States|Site US10076, Orange, California, United States|Site US10073, San Francisco, California, United States|Site US10067, New Haven, Connecticut, United States|Site US10045, Gainesville, Florida, United States|Site US10081, Atlanta, Georgia, United States|Site US10006, Chicago, Illinois, United States|Site US10075, Westwood, Kansas, United States|Site US10074, Louisville, Kentucky, United States|Site US10048, New Orleans, Louisiana, United States|Site US10005, Baltimore, Maryland, United States|Site US10034, Boston, Massachusetts, United States|Site US10022, Boston, Massachusetts, United States|Site US10085, Boston, Massachusetts, United States|Site US10087, Detroit, Michigan, United States|Site US10057, Minneapolis, Minnesota, United States|Site US10023, Lebanon, New Hampshire, United States|Site US10027, Hackensack, New Jersey, United States|Site US10077, New Brunswick, New Jersey, United States|Site US10001, Buffalo, New York, United States|Site US10037, New York, New York, United States|Site US10008, New York, New York, United States|Site US10013, New York, New York, United States|Site US10072, New York, New York, United States|Site US10046, Syracuse, New York, United States|Site US10024, Durham, North Carolina, United States|Site US10078, Winston-Salem, North Carolina, United States|Site US10044, Cleveland, Ohio, United States|Site US10084, Columbus, Ohio, United States|Site US10058, Oklahoma City, Oklahoma, United States|Site US10041, Hershey, Pennsylvania, United States|Site US10010, Philadelphia, Pennsylvania, United States|Site US10080, Philadelphia, Pennsylvania, United States|Site US10014, Charleston, South Carolina, United States|Site US10063, Nashville, Tennessee, United States|Site US10035, Milwaukee, Wisconsin, United States|Site BE32002, Yvoir, Belgium|Site CA15004, Edmonton, Alberta, Canada|Site CA15001, Hamilton, Ontario, Canada|Site CA15015, Toronto, Ontario, Canada|Site CA15003, Montreal, Quebec, Canada|Site FR33013, Brest, France|Site FR33002, Le Chesnay Cedex, France|Site FR33010, Lille, France|Site FR33009, Pessac, France|Site FR33014, Rennes, France|Site FR33008, Toulouse, France|Site DE49009, Dresden, Germany|Site DE49011, Leipzig, Germany|Site DE49003, Marburg, Germany|Site DE49002, Munchen, Germany|Site DE49010, Tubingen, Germany|Site IL97201, Ashkelon, Israel|Site IL97209, Haifa, Israel|Site IL97203, Jerusalem, Israel|Site IL97210, Jerusalem, Israel|Site IL97206, Petah Tikva, Israel|Site IL97208, Rehovot, Israel|Site IT39005, Bologna, Italy|Site IT39010, Brescia, Italy|Site IT39001, Milan, Italy|Site IT39004, Palermo, Italy|Site IT39011, Pavia, Italy|Site IT39007, Roma, Italy|Site IT39002, Varese, Italy|Site JP81002, Nagoya, Aichi, Japan|Site JP81010, Narita, Chiba, Japan|Site JP81026, Yoshida-gun, Fukui, Japan|Site JP81016, Sapporo, Hokkaido, Japan|Site JP81018, Kobe, Hyogo, Japan|Site JP81017, Tsukuba, Ibaraki, Japan|Site JP81009, Isehara, Kanagawa, Japan|Site JP81006, Yokohama, Kanagawa, Japan|Site JP81012, Sendai, Miyagi, Japan|Site JP81007, Kurashiki, Okayama, Japan|Site JP81014, Osakasayama, Osaka, Japan|Site JP81020, Kawagoe, Saitama, Japan|Site JP81027, Shimotsuke, Tochigi, Japan|Site JP81005, Chuo-ku, Tokyo, Japan|Site JP81004, Shinagawa-ku, Tokyo, Japan|Site JP81022, Shinjuku-ku, Tokyo, Japan|Site JP81023, Akita, Japan|Site JP81021, Aomori, Japan|Site JP81013, Kumamoto, Japan|Site JP81025, Kyoto, Japan|Site JP81008, Nagasaki, Japan|Site JP81024, Okayama, Japan|Site JP81011, Osaka, Japan|Site KR82005, Suwon-si, Gyeonggi-do, Korea, Republic of|Site KR82010, Busan, Korea, Republic of|Site KR82009, Goyang, Korea, Republic of|Site KR82003, Jeollanam-do, Korea, Republic of|Site KR82007, Seoul, Korea, Republic of|Site KR82004, Seoul, Korea, Republic of|Site KR82001, Seoul, Korea, Republic of|Site KR82002, Seoul, Korea, Republic of|Site KR82008, Seoul, Korea, Republic of|Site KR82011, Seoul, Korea, Republic of|Site PL48002, Gdansk, Poland|Site PL48005, Opole, Poland|Site PL48003, Slupsk, Poland|Site PL48004, Wroclaw, Poland|Site ES34009, Badalona, Spain|Site ES34011, Barcelona, Spain|Site ES34012, Barcelona, Spain|Site ES34010, Barcelona, Spain|Site ES34016, Girona, Spain|Site ES34005, L'Hospitalet de Llobregat, Spain|Site ES34014, Salamanca, Spain|Site ES34017, Valencia, Spain|Site TW88606, Kaohsiung, Taiwan|Site TW88604, Kaohsiung, Taiwan|Site TW88609, Taichung City, Taiwan|Site TW88608, Taichung, Taiwan|Site TW88601, Tainan, Taiwan|Site TW88603, Taipei, Taiwan|Site TW88610, Taipei, Taiwan|Site TW88611, Taipei, Taiwan|Site TW88602, Taipei, Taiwan|Site TW88605, Taoyuan, Taiwan|Site TR90001, Ankara, Turkey|Site TR90004, Ankara, Turkey|Site GB44014, Bournemouth, United Kingdom|Site GB44013, Harrow, United Kingdom|Site GB44003, Manchester, United Kingdom|Site GB44015, Plymouth, United Kingdom",https://ClinicalTrials.gov/show/NCT02421939
208,"Daiichi Sankyo, Inc.",(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive,"Active, not recruiting",Has Results,AML,Drug: Quizartinib|Drug: Salvage Chemotherapy,Industry,Interventional,"City of Hope National Medical Center, Duarte, California, United States|University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States|UCLA Medical Center, Los Angeles, California, United States|UC Davis Cancer Center, Sacramento, California, United States|Stanford University Medical Center Stanford Comprehensive Cancer Center, Stanford, California, United States|Yale University, New Haven, Connecticut, United States|Emory Winship Cancer Institute, Atlanta, Georgia, United States|University of Illinois at Chicago, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Franciscan Alliance, Indianapolis, Indiana, United States|University of Kansas Medical Center Research Institute Inc, Westwood, Kansas, United States|LSU Health Sciences Center Feist Weiller Cancer Center, Shreveport, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Columbia University Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|NY Medical College, Valhalla, New York, United States|UNC Linebreger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Duke Cancer Institute at Duke University Health System, Durham, North Carolina, United States|Wake Forest University Baptist Health, Winston-Salem, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Oregon Health and Science University Knight Cancer Institute, Portland, Oregon, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|MD Anderson Center, The University of Texas, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|The Canbera Hospital, Garran, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|The Princess Alexandra Hospital, Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|The Queen Elizabeth Hospital, Woodville, South Australia, Australia|Alfred Hospital, Melbourne, Victoria, Australia|ZNA Stuivenberg, Antwerpen, BE, Belgium|UCL St Luc, Brussels, BE, Belgium|Leuven UZ Gasthuisberg, Leuven, BE, Belgium|University of Alberta Hospital, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre Princess Margaret Hospital, Toronto, Ontario, Canada|Klinička Bolinca Merkur, Zagreb, Croatia|Kliničko Bolnički Centar Zagreb, Zagreb, Croatia|Fakultni nemocnice Brno, Brno, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Králové, Czechia|Fakultni nemocnice Olomouc, Olomouc, Czechia|CHU de Caen, Caen, France|Centre Hospitalier Universitaire Grenoble Hopital Michalon, Grenoble, France|Centre Hospitalier de Versailles, Le Chesnay, France|Hopital de la Conception, Marseille, France|Centre Hospitalier Universitaire Nantes, Nantes, France|Hôpital Saint Louis, Paris, France|Hopital Saint-Antoine, Paris, France|Hopital Haut Leveque Centre Francois Magendie, Pessac, France|Centre Henri-Becquerel, Rouen, France|Centre Hospitalier Universitaire Purpan, Toulouse, France|Charité Universitätsmedizin Berlin, Berlin, Germany|Charité Campus Virchow Klinikum, Berlin, Germany|Klinikum Braunschweig, Braunschweig, Germany|Universitatsklinikum Dresden, Dresden, Germany|Klinikum der Johann Wolfgang-Goethe-Universität, Frankfurt, Germany|Universitätsklinikum Halle, Halle, Germany|Medizinische Hochschule Hannover, Hanover, Germany|Uniklinik Heidelberg Medizinische Klinik und Poliklinik V, Heidelberg, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|University Mainz, Mainz, Germany|Universitätsklinikum Giessen und Marburg GmbH, Marburg, Germany|LMU München Klinikum Großhadern, Munchen, Germany|Medizinische Klinik A Hämatologie Hämostaseologie Internistische Onkologie und Pneumologie, Münster, Germany|The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, Hong Kong|The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong|Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar Szent Gyorgyi Albert Klinikai Kozpont, Szeged, Csongrad, Hungary|Debreceni Egyetem Klinikai Kozpont, Belgyogyaszati Intezet, Debrecen, Hajdu Bihar, Hungary|Semmelweis Egyetem Altalanos Orvostudomanyi Kar I. Belgyogyaszati Klinika, Budapest, Pest, Hungary|AOU Policlinico Consorziale di Bari, Bari, Italy|Università di Bologna, Bologna, Italy|Unità Operativa di Ematologia e Unità Operativa CTMO, Cagliari, Italy|Arcispedale S Anna, Ferrara, Italy|AOU Careggi, Firenze, Italy|IRCCS Azienda Ospedaliera Universitaria San Martino, Genova, Italy|Opsedale San Martino di Genova, Genova, Italy|Ospedale San Raffaele, Milan, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Italy|Azienda Ospedaliero Universitaria San Luigi Gonzaga, Orbassano, Italy|L'UOC di Ematologia del Policlinico Tor Vergata, Rome, Italy|Policlinico Universitario Agostino Gemelli, Rome, Italy|Azienda Ospedaliero Universitaria Senese, Policlinico S. Maria alle Scotte, Siena, Italy|Ospedale di Circolo-a Fondazione Macchi, Varese, Italy|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|VU Medisch Centrum, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|Uniwersytecki Szpital Kliniczny w Biatymstoku, Klinika Hematologii z Pododzialem Chorob Naczyn, Bialystok, Poland|Samodzielny Publiczny Szpital Kliniczny im. Andrzeja Mieleckiego Slaskiego Uniwersytetu Medycznego w Katowicach Oddzial Hematologii i Transplantacji Szpiku, Katowice, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1, Klinika Hematoonkologii i Transplantacji Szpiku, Lublin, Poland|Klinicki Centar Srbije, Belgrade, Serbia|Klinicki Centar Vojvodine, Novi Sad, Serbia|National University of Singapore, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|Hospital Son Espases, Palma, De Mallorca, Spain|Hospital La Fe, Valencia, SP, Spain|Hospital Clinic I Provincial de Barcelona, Barcelona, Spain|Hospital Universitari Germans Trias i Pujol, Barcelona, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom|Saint James University Hospital, Leeds, England, United Kingdom|King's College Hospital, London, England, United Kingdom|Nottingham City Hospital NHS Trust, Nottingham, England, United Kingdom|Royal Marsden Hospital Sutton, Sutton, England, United Kingdom|Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom|University Hospital of Wales, Cardiff, South Glamorgan, United Kingdom",https://ClinicalTrials.gov/show/NCT02039726
209,"Dana-Farber Cancer Institute|Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Celgene Corporation|Millennium Pharmaceuticals, Inc.","Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma","Active, not recruiting",Has Results,Multiple Myeloma,Drug: Bortezomib|Drug: Lenalidomide|Drug: dexamethasone,Other|Industry,Interventional,"Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT00378105
210,Celgene,Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission,"Active, not recruiting",Has Results,"Leukemia, Myeloid, Acute",Drug: 300 mg Oral Azacitidine|Drug: Placebo,Industry,Interventional,"Arizona Oncology Associates, P.C., Phoenix, Arizona, United States|Providence St Joseph Medical Center Cancer Center, Burbank, California, United States|City of Hope, Duarte, California, United States|University of California San Francisco Fresno Campus, Fresno, California, United States|University of Southern California Norris Cancer Center, Los Angeles, California, United States|UCLA, Los Angeles, California, United States|UC Irvine, Orange, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Stanford Cancer Center, Stanford, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|The Hospital of Central Connecticut, Southington, Connecticut, United States|George Washington University Cancer Center, Washington, District of Columbia, United States|University of Florida, Gainesville, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|University of Florida Health Cancer Center at Orlando Health, Orlando, Florida, United States|Northwestern University Medical Center Division of Hematology Oncology, Chicago, Illinois, United States|Loyola University Chicago, Maywood, Illinois, United States|Cancer Care and Hematology Specialists of Chicagoland, P.C. - Niles, IL, Niles, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|Kansas University Medical Center, Westwood, Kansas, United States|University of Louisville, Louisville, Kentucky, United States|Norton Cancer Institute Louisville Oncology, Louisville, Kentucky, United States|Tulane University Medical Center, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Massachusetts, Worcester, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Kansas City VA Medical Center University of Kansas Medical Center, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Winthrop University Hospital, Mineola, New York, United States|Mt. Sinai Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|New York Medical College, Valhalla, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Kaiser Permanente Northwest Oncology Hematology, Portland, Oregon, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|UPMC Cancer Pavillion, Pittsburgh, Pennsylvania, United States|Greenville Hospital System, Greenville, South Carolina, United States|Sarah Cannon Research Inst, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Brooke-Army Medical Center, Fort Sam Houston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Cancer Care Centers of South Texas - Loop, San Antonio, Texas, United States|Methodist Hospital, San Antonio, Texas, United States|VA Commonwealth University Massey Cancer Center, Richmond, Virginia, United States|Swedish Cancer Inst, Seattle, Washington, United States|Yakima Valley Memorial Hospital/ North Star Lodge, Yakima, Washington, United States|Froedtert Hospital BMT Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Mater Private Medical Centre Haematology and Oncology Clinics of Australasia Research Centre, South Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Flinders Medical Centre, Dept Of Oncology, Bedford Park, South Australia, Australia|Austin Hospital, Heidelberg, Australia|Royal Hobart Hospital, Hobart, Australia|Liverpool Hospital, Liverpool, Australia|The Alfred Hospital, Melbourne, Australia|Royal Perth Hospital, Perth, Australia|Royal North Shore Hospital, St Leonards, Australia|Wollongong Hospital, Wollongong, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|Medical University of Graz, Graz, Austria|University Hospital of Salzburg, Salzburg, Austria|KH Hietzing, Vienna, Austria|Medical University of Vienna, Vienna, Austria|Hanusch Krankenhaus, Wien, Austria|AZ St-Jan Brugge Oostende AV, Brugge, Belgium|Grand Hopital de Charleroi, Charleroi, Belgium|Center Hospitalier Universitaire Ambroise Pare, Mons, Belgium|Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Erasto Gaertner, Curitiba, Brazil|Instituto Nacional de Cancer - INCA, Rio de Janeiro, Brazil|Saint Petersburg Medical State Institution Municipal n.a. I.P. Pavlov, Saint Petersburg, Brazil|Hospital Albert Einstein Sociedade Beneficente Israelita Brasileira, Sao Paulo, Brazil|Sociedade Beneficente de Senhoras Hospital Sirio Libanes, São Paulo, Brazil|University of Alberta, Edmonton, Alberta, Canada|Cancer Care Manitoba, Winnipeg, Manitoba, Canada|Regional Health Authority B-Saint John Regional Hospital, Saint John, New Brunswick, Canada|Health Sciences Center, St John's, Newfoundland and Labrador, Canada|Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|McGill University, Dept. Oncology Clinical Research Program, Montreal, Quebec, Canada|Hopital du Sacre-Coeur de Montreal, Montreal, Quebec, Canada|Fakultni nemocnice Brno, Brno, Czechia|Vseobecna Fakultni Nemocnice v Praze, Praha, Czechia|Ustav hematologie a krevni transfuze, Praha, Czechia|Helsinki University Central Hospital, Helsinki, Finland|University HospitaClinik of internal medicin, Tampere, Finland|Turku University Hospital, Turku, Finland|Hopital Sud, CHU d'Amiens, Amiens, France|CH Argenteuil Victor Dupouy, Argenteuil, France|Hopital Avicenne, Bobigny Cedex, France|Centre hospitalier de Boulognes - Duchenne, Boulognes Sur Mer, France|Hopital dinstruction des armees Percy, Clamart Cedex, France|Hopital Henri Mondor, Creteil, France|Centre Hospitalier de Versailles Hopital Andre Mignot, Le Chesnay Cedex, France|CHRU de Lille-Hopital Claude Huriez Service des Maladies du Sang, Lille, France|CHU Limoges, Limoges Cedex, France|CHU Hopital Edouard Herriot, Lyon cedex, France|Hopital Saint Louis, Paris Cedex 10, France|Hospital of Necker, Paris, France|Hopital Saint Louis, Paris, France|Centre Hospitalier Pontoise Rene Dubos, Pontoise, France|Centre Henri Becquerel, Rouen, France|Institut Curie, Saint-Cloud, France|Institut Gustave Roussy, Villejuif Cedex, France|Charite - Universitätsmedizin Berlin, Berlin, Germany|Universitaetsklinikum Bonn, Bonn, Germany|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|University Duesseldorf, Düsseldorf, Germany|Universitaetsklinikum Erlangen, Erlangen, Germany|Staedtische Kliniken Frankfurt am Main Hochst, Frankfurt am Main, Germany|Wilhelm-Anton-Hospital Goch gGmbH Hämatologie und Internistische Onkologie, Goch, Germany|Medizinische Hochschule Hannover, Hannover, Germany|SLK Kliniken Heilbronn GmbH - Klinikum am Gesundbrunnen, Heilbronn, Germany|Universitatsklinikum Jena, Jena, Germany|Universitatsklinikum Schleswig-Holstein, Keil, Germany|Universitaetsklinikum Mannheim, Mannheim, Germany|Staedtisches Klinikum Muenchen Schwabing, Muenchen, Germany|TU München - Klinikum rechts der Isar, München, Germany|Klinikum Oldenburg gGmbH, Oldenburg, Germany|St. Antonius-Hospital, Schweiler, Germany|University of Ulm, Ulm, Germany|Tallaght Adelaide and Meath Hospital, Dublin, Ireland|University College Hospital Galway, Galway, Ireland|Soroka University Medical Center, Beer Sheva, Israel|Rambam Medical Center, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Rabin Medical Center, Petach Tikva, Israel|Az. Osp. SS.Antonio e Biagio - SC Ematologia, Alessandria, Italy|Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari, Italy|Policlinico Sant'Orsola-Malpighi, Bologna, Italy|Ospedale Bingaghi, Cagliari, Italy|Istituti Ospitalieri di Cremona, Cremona, Italy|Azienda Ospedaliero Universitaria Careggi, Firenze, Italy|IRCCS AziendaOspedaliera Universitaria San Martino, Genova, Italy|Ematologia ed Immunologia, Azienda Ospedaliera Vito Fazzi di Lecce, Lecce, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Milano, Italy|Fondazione Ca Granda IRCCS Ospedale Maggiore, Milan, Italy|Ospedale S. Gerardo di Monza, Monza, Italy|Azienda ospedeliera della 2 Universita di Napoli, Naples, Italy|Ospedale Cardarelli, Naples, Italy|AOU San Luigi Gonzaga, Orbassano (TO), Italy|Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy|Casa di Cura La Maddalena, Divisione di Ematologia, Palermo, Italy|Azienda Ospedaliera Ospedali Riuniti Marche Nord AORMN, Pesaro, Italy|Azienda Ospedaliera ""Bianchi-Melacrino-Morelli"", Reggio Calabria, Italy|Universita degli Studi di Roma La Sapienza - Azienda Policlinico Umberto I, Roma, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Azienda Ospedaliera S. Andrea - Università La Sapienza, Roma, Italy|University Hospital Tor Vergata, Rome, Italy|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Italy|Azienda Ospedaliero-Universitaria Santa Maria della Misericordia die Udine, Udine, Italy|A.O. Universitaria Fondazione Macchi, Varese, Italy|Pusan National University Hospital, Busan, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea Seoul - Saint Mary's Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Klaipeda seaman hospital, Klaipeda, Lithuania|Hospital Angeles Lomas - Consultorio 830, Huixquilucan de Degollado, Mexico|Instituto Nacional de Cancerología, Mexico, Mexico|Hospital Universitario Eleuterio Gomez, Monterrey, Mexico|Szpital Uniwersytecki nr 2 im dr. Jana Biziela, Bydgoszcz, Poland|Institute of Internal Diseases University of Medicine, Gdansk, Poland|Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi, Lodz, Poland|Institute of Hematology and Transfusion Medicine, Warsaw, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wroclawiu, Wroclaw, Poland|Centro Hospital e Universitario de Coimbra, Coimbra, Portugal|Instituto Portugues de Oncologia de Lisboa, Lisboa, Portugal|Centro Hospitalar de Lisboa Central - Hospital de Santo António dos Capuchos, Lisboa, Portugal|Instituto Portugues de Oncologia do Porto, Francisco Gentil, Porto, Portugal|Hospital de Sao Joao, Porto, Portugal|Moscow State Medical Institution Municipal Clinical Hospital n.a. S.P. Botkin, Moscow, Russian Federation|Nizhniy Novgorod State Medical Academy of Roszdrav, Nizhniy Novgorod, Russian Federation|Federal Centre of Heart, Blood and Endocrinology of Rosmed technlologies V.A. Almazov, St Petersburg, Russian Federation|Hospital Universitari Germans Trias i Pujol, Badalona (Barcelona), Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital de San Pedro de Alcantara, Caceres, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Complejo Universitario La Coruna, La Coruna, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Universitario Gregorio Maranon, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llatzer, Palma de Mallorca, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Taipei Veterans General Hospital, Beitou District, Taipei City, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Niaosong District Kaohsiung City, Taiwan|China Medical University Hospital, Taichung, Northern Dist., Taiwan|National Cheng Kung University Hospital, Tainan, Taiana, Taiwan|National Taiwan University Hospital, Taipei, Zhongzheng Dist., Taiwan|Hacettepe Universitesi, Ankara, Turkey|Dr. Abdurrahman Yurtaslan Ankara Onkoloji hospital, Ankara, Turkey|Marmara School of Medicine, Istanbul, Turkey|Ondokuz Mayis University Medical Faculty, Samsun, Turkey|United Lincolnshire Hospitals NHS Trust, Boston, United Kingdom|Royal Sussex County Hospital, Brighton East Sussex, United Kingdom|Kent and Canterbury Hospital, Canterbury Kent, United Kingdom|University College London Hospitals, London, United Kingdom|Kings College Hospital, London, United Kingdom|Imperial College Hammersmith Hospital, London, United Kingdom|Maidstone Hospital, Maidstone Kent, United Kingdom|Christie NHS Trust Hospital, Manchester, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Queen's Hospital, Barking, Havering and Redbridge University Hospitals NHS Trust, Romford, Essex, United Kingdom",https://ClinicalTrials.gov/show/NCT01757535
211,NYU Langone Health|Bristol-Myers Squibb,Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma,"Active, not recruiting",Has Results,Melanoma,Biological: Nivolumab|Biological: Ipilimumab,Other|Industry,Interventional,"Laura and Isaac Perlmutter Cancer Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT02970981
212,Memorial Sloan Kettering Cancer Center|Merck Sharp & Dohme Corp.,Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma,"Active, not recruiting",Has Results,Adrenocortical Carcinoma,Drug: Pembrolizumab,Other|Industry,Interventional,"Memorial Sloan Kettering Cancer Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT02673333
213,Novartis Pharmaceuticals|Novartis,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),"Active, not recruiting",Has Results,Secondary Progressive Multiple Sclerosis,Drug: BAF312|Drug: Placebo,Industry,Interventional,"Novartis Investigative Site, Phoenix, Arizona, United States|Novartis Investigative Site, Berkeley, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Oceanside, California, United States|Novartis Investigative Site, Sacramento, California, United States|Novartis Investigative Site, Aurora, Colorado, United States|Novartis Investigative Site, Basalt, Colorado, United States|Novartis Investigative Site, Boulder, Colorado, United States|Novartis Investigative Site, Colorado Springs, Colorado, United States|Novartis Investigative Site, Englewood, Colorado, United States|Novartis Investigative Site, Fairfield, Connecticut, United States|Novartis Investigative Site, Delray Beach, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Maitland, Florida, United States|Novartis Investigative Site, Ormond Beach, Florida, United States|Novartis Investigative Site, Port Charlotte, Florida, United States|Novartis Investigative Site, Sunrise, Florida, United States|Novartis Investigative Site, Tampa, Florida, United States|Novartis Investigative Site, Tampa, Florida, United States|Novartis Investigative Site, Vero Beach, Florida, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Evanston, Illinois, United States|Novartis Investigative Site, Flossmoor, Illinois, United States|Novartis Investigative Site, Lenexa, Kansas, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Golden Valley, Minnesota, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Las Vegas, Nevada, United States|Novartis Investigative Site, Lebanon, New Hampshire, United States|Novartis Investigative Site, Freehold, New Jersey, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Patchogue, New York, United States|Novartis Investigative Site, Stony Brook, New York, United States|Novartis Investigative Site, Charlotte, North Carolina, United States|Novartis Investigative Site, Akron, Ohio, United States|Novartis Investigative Site, Dayton, Ohio, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Springfield, Oregon, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Providence, Rhode Island, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Lubbock, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, Burlington, Vermont, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Milwaukee, Wisconsin, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Capital Federal, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Camperdown, New South Wales, Australia|Novartis Investigative Site, Kogarah, New South Wales, Australia|Novartis Investigative Site, Liverpool, New South Wales, Australia|Novartis Investigative Site, Heidelberg, Victoria, Australia|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Klagenfurt, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Edegem, Antwerpen, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Fraiture En Condroz, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Pelt, Belgium|Novartis Investigative Site, Sijsele, Belgium|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Burnaby, British Columbia, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Kingston, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Greenfield Park, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Changchun, Jilin, China|Novartis Investigative Site, Taiyuan, Shanxi, China|Novartis Investigative Site, Xi'an, Shanxi, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Brno, Czech Rep., Czechia|Novartis Investigative Site, Teplice, Czech Republic, Czechia|Novartis Investigative Site, JIhlava, Czechia|Novartis Investigative Site, Prague 5, Czechia|Novartis Investigative Site, Praha, Czechia|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Nancy, Cedex, France|Novartis Investigative Site, Bordeaux Cedex, France|Novartis Investigative Site, CAEN Cedex, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Montpellier, France|Novartis Investigative Site, Nimes, France|Novartis Investigative Site, Paris Cedex 13, France|Novartis Investigative Site, Rennes, France|Novartis Investigative Site, St Herblain, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Regensburg, Bavaria, Germany|Novartis Investigative Site, Aschaffenburg, Germany|Novartis Investigative Site, Bad Mergentheim, Germany|Novartis Investigative Site, Bayreuth, Germany|Novartis Investigative Site, Berg, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bielefeld, Germany|Novartis Investigative Site, Boblingen, Germany|Novartis Investigative Site, Bochum, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Erbach, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Homburg, Germany|Novartis Investigative Site, Itzehoe, Germany|Novartis Investigative Site, Jena, Germany|Novartis Investigative Site, Kassel, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Münster, Germany|Novartis Investigative Site, Neuburg an der Donau, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Potsdam, Germany|Novartis Investigative Site, Prien, Germany|Novartis Investigative Site, Rostock, Germany|Novartis Investigative Site, Schwendi, Germany|Novartis Investigative Site, Siegen, Germany|Novartis Investigative Site, Stade, Germany|Novartis Investigative Site, Stadtroda, Germany|Novartis Investigative Site, Teupitz, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Unterhaching, Germany|Novartis Investigative Site, Wiesbaden, Germany|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Heraklion Crete, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Budapest, HUN, Hungary|Novartis Investigative Site, Budapest, HUN, Hungary|Novartis Investigative Site, Budapest, HUN, Hungary|Novartis Investigative Site, Esztergom, HUN, Hungary|Novartis Investigative Site, Balassagyarmat, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Eger, Hungary|Novartis Investigative Site, Miskolc, Hungary|Novartis Investigative Site, Nyiregyhaza, Hungary|Novartis Investigative Site, Veszprem, Hungary|Novartis Investigative Site, Dublin 9, D9, Ireland|Novartis Investigative Site, Dublin 4, Ireland|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Cefalu, PA, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Toon-city, Ehime, Japan|Novartis Investigative Site, Asahikawa-city, Hokkaido, Japan|Novartis Investigative Site, Morioka, Iwate, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, Japan|Novartis Investigative Site, Suita city, Osaka, Japan|Novartis Investigative Site, Kawagoe, Saitama, Japan|Novartis Investigative Site, Tokorozawa city, Saitama, Japan|Novartis Investigative Site, Kodaira, Tokyo, Japan|Novartis Investigative Site, Ota-ku, Tokyo, Japan|Novartis Investigative Site, Shinjuku ku, Tokyo, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan|Novartis Investigative Site, Aomori, Japan|Novartis Investigative Site, Chiba, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Riga, LV, Latvia|Novartis Investigative Site, Riga, Latvia|Novartis Investigative Site, Riga, Latvia|Novartis Investigative Site, Kaunas, LTU, Lithuania|Novartis Investigative Site, Klaipeda, Lithuania|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, Breda, CK, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Eindhoven, Netherlands|Novartis Investigative Site, Hoorn, Netherlands|Novartis Investigative Site, Sittard-Geleen, Netherlands|Novartis Investigative Site, Tilburg, Netherlands|Novartis Investigative Site, Grudziadz, Poland|Novartis Investigative Site, Katowice, Poland|Novartis Investigative Site, Kielce, Poland|Novartis Investigative Site, Konskie, Poland|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Lodz, Poland|Novartis Investigative Site, Poznan, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Amadora, Portugal|Novartis Investigative Site, Braga, Portugal|Novartis Investigative Site, Coimbra, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Constanta, Jud. Constanta, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Suceava, Romania|Novartis Investigative Site, Targu Mures, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Kazan, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Novosibirsk, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Ufa, Russian Federation|Novartis Investigative Site, Banska Bystrica, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Martin, Slovakia|Novartis Investigative Site, Nitra, Slovakia|Novartis Investigative Site, Presov, Slovakia|Novartis Investigative Site, Trencin, Slovakia|Novartis Investigative Site, Trnava, Slovakia|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Barcelona, Cataluna, Spain|Novartis Investigative Site, Barcelona, Cataluna, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, L Hospitalet De Llobregat, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, El Palmar, Murcia, Spain|Novartis Investigative Site, Bilbao, Pais Vasco, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Goeteborg, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Aarau, CH, Switzerland|Novartis Investigative Site, Basel, Switzerland|Novartis Investigative Site, Lausanne, Switzerland|Novartis Investigative Site, Lugano, Switzerland|Novartis Investigative Site, Luzern, Switzerland|Novartis Investigative Site, St Gallen, Switzerland|Novartis Investigative Site, Zuerich, Switzerland|Novartis Investigative Site, Istanbul, TUR, Turkey|Novartis Investigative Site, Altunizade, Turkey|Novartis Investigative Site, Haseki / Istanbul, Turkey|Novartis Investigative Site, Kocaeli, Turkey|Novartis Investigative Site, Mecidiyekoy/Istanbul, Turkey|Novartis Investigative Site, Samsun, Turkey|Novartis Investigative Site, Trabzon, Turkey|Novartis Investigative Site, Salford, Manchester, United Kingdom|Novartis Investigative Site, Headington, Oxfordshire, United Kingdom|Novartis Investigative Site, Sheffield, South Yorkshire, United Kingdom|Novartis Investigative Site, Bristol, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, Leicester, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Newcastle Upon Tyne, United Kingdom",https://ClinicalTrials.gov/show/NCT01665144
214,Eli Lilly and Company,A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma,"Active, not recruiting",Has Results,Soft Tissue Sarcoma,Drug: Olaratumab|Drug: Doxorubicin|Drug: Placebo,Industry,Interventional,"City of Hope National Medical Center, Duarte, California, United States|University of California-San Diego, La Jolla, California, United States|UCLA Medical Center, Los Angeles, California, United States|Stanford University, Stanford, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|University of Florida School of Medicine, Gainesville, Florida, United States|Mayo Clinic of Jacksonville, Jacksonville, Florida, United States|Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Georgia Cancer Specialists PC, Atlanta, Georgia, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Kaiser Foundation Hospitals, Honolulu, Hawaii, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|University of Louisville, Louisville, Kentucky, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University Medical Center, Saint Louis, Missouri, United States|Nebraska Methodist Cancer Center, Omaha, Nebraska, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Columbia University, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Carolinas Healthcare System, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Oncology Hematology Care Inc, Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Gibbs Cancer Center, Spartanburg, South Carolina, United States|The West Clinic, Germantown, Tennessee, United States|SMO Sarah Cannon Research Inst., Nashville, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|University of Utah School of Medicine, Salt Lake City, Utah, United States|Fairfax Northern Virginia Hematology Oncology, PC, Fairfax, Virginia, United States|University of Wisconsin-Madison Hospital and Health Clinic, Madison, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rosario, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Camperdown, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wien, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussels, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gent, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rio de Janeiro, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sao Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Calgary, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Edmonton, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Montreal, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Toronto, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Vancouver, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aarhus, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Herlev, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampere, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Turku, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bordeaux, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dijon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lyon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marseille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Villejuif, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Essen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mannheim, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munchen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tubingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Budapest, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jerusalem, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Aviv Jaffa, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Hashomer, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Catania, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Terni, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Torino, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chuo-Ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hidaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kashiwa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Koto-ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nagoya, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Okayama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sapporo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Suita-shi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Gangnam-gu, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ilsandong-gu, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Seodaemun-gu, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Songpa-gu, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guadalajara, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Merida, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Luis Potosi, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tijuana, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Groningen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leiden, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Maastricht, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nijmegen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rotterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warszawa, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kazan, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St. Petersburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lund, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bern, Switzerland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Gallen, Switzerland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taoyuan Hsien, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bebington, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sheffield, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sutton, United Kingdom",https://ClinicalTrials.gov/show/NCT02451943
215,"Duke University|Genentech, Inc.|GlaxoSmithKline",Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma,"Active, not recruiting",Has Results,Malignant Glioma|Glioblastoma|Gliosarcoma,Drug: Bevacizumab|Drug: Temozolomide|Radiation: Radiation Therapy (XRT)|Drug: Topotecan,Other|Industry,Interventional,"The Preston Robert Tisch Brain Tumor Center at Duke, Durham, North Carolina, United States",https://ClinicalTrials.gov/show/NCT01004874
216,"University of California, San Diego|Celgene Corporation",Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL),"Active, not recruiting",Has Results,Chronic Lymphocytic Leukemia|CLL,Drug: Revlimid|Drug: Rituximab,Other|Industry,Interventional,"University of California, San Diego, La Jolla, California, United States",https://ClinicalTrials.gov/show/NCT01199575
217,Weill Medical College of Cornell University|Celgene,Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL,"Active, not recruiting",Has Results,Chronic Lymphocytic Leukemia,Drug: thalidomide|Drug: lenalidomide|Biological: rituximab,Other|Industry,Interventional,"Weill Cornell Medical College, New York, New York, United States",https://ClinicalTrials.gov/show/NCT01125176
218,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Novartis Pharmaceuticals,"Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","Active, not recruiting",Has Results,Leukemia,Drug: cytarabine|Drug: daunorubicin|Drug: midostaurin|Other: placebo|Drug: dexamethasone acetate,Other|NIH|Industry,Interventional,"UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|University of California Davis Cancer Center, Sacramento, California, United States|Aurora Presbyterian Hospital, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Penrose Cancer Center at Penrose Hospital, Colorado Springs, Colorado, United States|St. Anthony Central Hospital, Denver, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Presbyterian - St. Luke's Medical Center, Denver, Colorado, United States|St. Joseph Hospital, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|CCOP - Colorado Cancer Research Program, Denver, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Hope Cancer Care Center at Longmont United Hospital, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|North Suburban Medical Center, Thornton, Colorado, United States|Exempla Lutheran Medical Center, Wheat Ridge, Colorado, United States|Helen and Harry Gray Cancer Center at Hartford Hospital, Hartford, Connecticut, United States|Tunnell Cancer Center at Beebe Medical Center, Lewes, Delaware, United States|CCOP - Christiana Care Health Services, Newark, Delaware, United States|University of Florida Shands Cancer Center, Gainesville, Florida, United States|Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States|Baptist Cancer Institute - Jacksonville, Jacksonville, Florida, United States|Florida Hospital Cancer Institute at Florida Hospital Orlando, Orlando, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States|MBCCOP - Medical College of Georgia Cancer Center, Augusta, Georgia, United States|Charles B. Eberhart Cancer Center at DeKalb Medical Center, Decatur, Georgia, United States|Medical Center of Central Georgia, Macon, Georgia, United States|Nancy N. and J. C. Lewis Cancer and Research Pavilion at St. Joseph's/Candler, Savannah, Georgia, United States|Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|Queen's Cancer Institute at Queen's Medical Center, Honolulu, Hawaii, United States|Illinois CancerCare - Bloomington, Bloomington, Illinois, United States|Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States|University of Illinois Cancer Center, Chicago, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States|Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood, Illinois, United States|BroMenn Regional Medical Center, Normal, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States|McFarland Clinic, PC, Ames, Iowa, United States|Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Mercy Medical Center - Sioux City, Sioux City, Iowa, United States|St. Luke's Regional Medical Center, Sioux City, Iowa, United States|Lucille P. Markey Cancer Center at University of Kentucky, Lexington, Kentucky, United States|Tulane Cancer Center Office of Clinical Research, Alexandria, Louisiana, United States|Feist-Weiller Cancer Center at Louisiana State University Health Sciences, Shreveport, Louisiana, United States|Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Boston University Cancer Research Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Baystate Regional Cancer Program at D'Amour Center for Cancer Care, Springfield, Massachusetts, United States|Battle Creek Health System Cancer Care Center, Battle Creek, Michigan, United States|Mecosta County Medical Center, Big Rapids, Michigan, United States|Butterworth Hospital at Spectrum Health, Grand Rapids, Michigan, United States|CCOP - Grand Rapids, Grand Rapids, Michigan, United States|Lacks Cancer Center at Saint Mary's Health Care, Grand Rapids, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|Providence Cancer Institute at Providence Hospital - Southfield Campus, Southfield, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Mercy and Unity Cancer Center at Unity Hospital, Fridley, Minnesota, United States|HealthEast Cancer Care at St. John's Hospital, Maplewood, Minnesota, United States|Minnesota Oncology Hematology, PA - Maplewood, Maplewood, Minnesota, United States|Virginia Piper Cancer Institute at Abbott - Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center - Minneapolis, Minneapolis, Minnesota, United States|Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States|Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center, Robbinsdale, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|Park Nicollet Cancer Center, Saint Louis Park, Minnesota, United States|Regions Hospital Cancer Care Center, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Minnesota Oncology Hematology, PA - Woodbury, Woodbury, Minnesota, United States|University of Mississippi Cancer Clinic, Jackson, Mississippi, United States|Ellis Fischel Cancer Center at University of Missouri - Columbia, Columbia, Missouri, United States|Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, Saint Louis, Missouri, United States|UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|CCOP - Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, United States|Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Monter Cancer Center of the North Shore-LIJ Health System, Lake Success, New York, United States|CCOP - North Shore University Hospital, Manhasset, New York, United States|Don Monti Comprehensive Cancer Center at North Shore University Hospital, Manhasset, New York, United States|Tucker Center for Cancer Care at Orange Regional Medical Center, Middletown, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States|New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States|SUNY Upstate Medical University Hospital, Syracuse, New York, United States|Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Blumenthal Cancer Center at Carolinas Medical Center, Charlotte, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Leo W. Jenkins Cancer Center at ECU Medical School, Greenville, North Carolina, United States|Kinston Medical Specialists, Kinston, North Carolina, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Summa Center for Cancer Care at Akron City Hospital, Akron, Ohio, United States|Barberton Citizens Hospital, Barberton, Ohio, United States|Charles M. Barrett Cancer Center at University Hospital, Cincinnati, Ohio, United States|Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|St. Rita's Medical Center, Lima, Ohio, United States|Cleo Craig Cancer Research Clinic, Lawton, Oklahoma, United States|Oklahoma University Cancer Institute, Oklahoma City, Oklahoma, United States|Geisinger Cancer Institute at Geisinger Health, Danville, Pennsylvania, United States|Geisinger Hazleton Cancer Center, Hazleton, Pennsylvania, United States|Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States|Geisinger Medical Group - Scenery Park, State College, Pennsylvania, United States|Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States|Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States|Cancer Centers of the Carolinas - Easley, Easley, South Carolina, United States|Cancer Centers of the Carolinas - Faris Road, Greenville, South Carolina, United States|Cancer Centers of the Carolinas - Grove Commons, Greenville, South Carolina, United States|Greenville Hospital Cancer Center, Greenville, South Carolina, United States|CCOP - Greenville, Greenville, South Carolina, United States|Self Regional Cancer Center at Self Regional Medical Center, Greenwood, South Carolina, United States|Cancer Centers of the Carolinas - Greer Medical Oncology, Greer, South Carolina, United States|Cancer Centers of the Carolinas - Seneca, Seneca, South Carolina, United States|Cancer Centers of the Carolinas - Spartanburg, Spartanburg, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Sanford Cancer Center at Sanford USD Medical Center, Sioux Falls, South Dakota, United States|University of Tennessee Cancer Institute - Memphis, Memphis, Tennessee, United States|Tennessee Oncology, PLLC at Sarah Cannon Cancer Center, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Baylor University Medical Center - Houston, Houston, Texas, United States|Ben Taub General Hospital, Houston, Texas, United States|Veterans Affairs Medical Center - Houston, Houston, Texas, United States|Mountainview Medical, Berlin, Vermont, United States|Fletcher Allen Health Care - University Health Center Campus, Burlington, Vermont, United States|Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia, United States|West Virginia University Health Sciences Center - Charleston, Charleston, West Virginia, United States|Mary Babb Randolph Cancer Center at West Virginia University Hospitals, Morgantown, West Virginia, United States|Marshfield Clinic - Chippewa Center, Chippewa Falls, Wisconsin, United States|Center for Cancer Treatment & Prevention at Sacred Heart Hospital, Eau Claire, Wisconsin, United States|Marshfield Clinic Cancer Care at Regional Cancer Center, Eau Claire, Wisconsin, United States|Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Green Bay Oncology, Limited at St. Mary's Hospital, Green Bay, Wisconsin, United States|St. Mary's Hospital Medical Center - Green Bay, Green Bay, Wisconsin, United States|St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States|Holy Family Memorial Medical Center Cancer Care Center, Manitowoc, Wisconsin, United States|Bay Area Cancer Care Center at Bay Area Medical Center, Marinette, Wisconsin, United States|Marshfield Clinic - Marshfield Center, Marshfield, Wisconsin, United States|Saint Joseph's Hospital, Marshfield, Wisconsin, United States|Marshfield Clinic - Lakeland Center, Minocqua, Wisconsin, United States|D.N. Greenwald Center, Mukwonago, Wisconsin, United States|Regional Cancer Center at Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States|Ministry Medical Group at Saint Mary's Hospital, Rhinelander, Wisconsin, United States|Marshfield Clinic - Indianhead Center, Rice Lake, Wisconsin, United States|Marshfield Clinic at Saint Michael's Hospital, Stevens Point, Wisconsin, United States|Waukesha Memorial Hospital Regional Cancer Center, Waukesha, Wisconsin, United States|Marshfield Clinic - Weston Center, Weston, Wisconsin, United States|Ministry Saint Clare's Hospital, Weston, Wisconsin, United States|Marshfield Clinic - Wisconsin Rapids Center, Wisconsin Rapids, Wisconsin, United States|Tom Baker Cancer Centre - Calgary, Calgary, Alberta, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada|McGill Cancer Centre at McGill University, Montreal, Quebec, Canada",https://ClinicalTrials.gov/show/NCT00651261
219,"Janssen Research & Development, LLC",Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma,"Active, not recruiting",Has Results,Multiple Myeloma,Drug: Part 1 (Dose Escalation): Daratumumab|Drug: Part 2 (Dose Expansion): Daratumumab|Drug: Lenalidomide|Drug: Dexamethasone,Industry,Interventional,"Boston, Massachusetts, United States|Copenhagen Ø, Denmark|Vejle, Denmark|Lille Cedex, France|Nantes N/a, France|Vandoeuvre les Nancy, France|Utrecht, Netherlands|London, United Kingdom",https://ClinicalTrials.gov/show/NCT01615029
220,H. Lee Moffitt Cancer Center and Research Institute|Novartis|Celgene Corporation,Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL),"Active, not recruiting",Has Results,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Drug: High Dose Methylprednisolone (HDMP)|Drug: Ofatumumab|Drug: Lenalidomide,Other|Industry,Interventional,"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",https://ClinicalTrials.gov/show/NCT01497496
221,St. Jude Children's Research Hospital|Schering-Plough,Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma,"Active, not recruiting",Has Results,Malignant Melanoma,Drug: Peginterferon alfa-2b|Drug: Temozolomide|Drug: Recombinant interferon alfa-2b,Other|Industry,Interventional,"Rady Children's Hospital, San Diego, California, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|The Children's Cancer Hospital at UT M.D. Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT00539591
222,Acerta Pharma BV,"An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma","Active, not recruiting",Has Results,Mantle Cell Lymphoma (MCL),Drug: ACP-196 (acalabrutinib),Industry,Interventional,"New York, New York, United States|Plymouth, United Kingdom",https://ClinicalTrials.gov/show/NCT02213926
223,Sidney Kimmel Cancer Center at Thomas Jefferson University|GlaxoSmithKline|Novartis|Thomas Jefferson University,"Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-Cell Lymphomas","Active, not recruiting",Has Results,Non-Hodgkin's Lymphoma,Drug: Bendamustine|Drug: Ofatumumab|Drug: Carboplatin|Drug: Etoposide|Procedure: CT Scan|Procedure: PET Scan|Genetic: Stem Cell Transplant (STC),Other|Industry,Interventional,"Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT01458366
224,"C. Babis Andreadis|University of California, San Francisco|GlaxoSmithKline",Study of Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma,"Active, not recruiting",Has Results,Diffuse Large Cell Lymphoma Relapsed/Refractory,Drug: Ofatumumab|Drug: Etoposide|Drug: Cytarabine,Other|Industry,Interventional,"University of California, San Francisco, San Francisco, California, United States",https://ClinicalTrials.gov/show/NCT01555541
225,"National Heart, Lung, and Blood Institute (NHLBI)|University of Virginia|GlaxoSmithKline|National Institutes of Health Clinical Center (CC)",Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL,"Active, not recruiting",Has Results,Small Lymphocytic Lymphoma|CLL (Chronic Lymphocytic Leukemia),Drug: Fludarabine Phosphate|Biological: Ofatumumab|Drug: Cyclophosphamide,NIH|Other|Industry,Interventional,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT01145209
226,Novartis Pharmaceuticals|Novartis,Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).,"Active, not recruiting",Has Results,Melanoma,Drug: Dabrafenib|Drug: Trametinib|Drug: Placebos,Industry,Interventional,"Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Aurora, Colorado, United States|Novartis Investigative Site, Farmington, Connecticut, United States|Novartis Investigative Site, Fort Myers, Florida, United States|Novartis Investigative Site, Lake Worth, Florida, United States|Novartis Investigative Site, Orlando, Florida, United States|Novartis Investigative Site, Saint Petersburg, Florida, United States|Novartis Investigative Site, Stuart, Florida, United States|Novartis Investigative Site, Tampa, Florida, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Lutherville-Timonium, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Morristown, New Jersey, United States|Novartis Investigative Site, Winston-Salem, North Carolina, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Murray, Utah, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Capital Federal, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Viedma, Río Negro, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Gateshead, New South Wales, Australia|Novartis Investigative Site, North Sydney, New South Wales, Australia|Novartis Investigative Site, Tweed Heads, New South Wales, Australia|Novartis Investigative Site, Westmead, New South Wales, Australia|Novartis Investigative Site, Greenslopes, Queensland, Australia|Novartis Investigative Site, Milton, Queensland, Australia|Novartis Investigative Site, Woolloongabba, Queensland, Australia|Novartis Investigative Site, Adelaide, South Australia, Australia|Novartis Investigative Site, Box Hill, Victoria, Australia|Novartis Investigative Site, Heidelberg, Victoria, Australia|Novartis Investigative Site, Melbourne, Victoria, Australia|Novartis Investigative Site, Nedlands, Western Australia, Australia|Novartis Investigative Site, Graz, Austria|Novartis Investigative Site, Innsbruck, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Wels, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Goiania, Goiás, Brazil|Novartis Investigative Site, Curitiba, Paraná, Brazil|Novartis Investigative Site, Ijui, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Rio De Janeiro, Brazil|Novartis Investigative Site, São Paulo, Brazil|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Hamilton, Ontario, Canada|Novartis Investigative Site, Oshawa, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, Hradec Kralove, Czechia|Novartis Investigative Site, Olomouc, Czechia|Novartis Investigative Site, Praha 10, Czechia|Novartis Investigative Site, Praha 2, Czechia|Novartis Investigative Site, Zlin, Czechia|Novartis Investigative Site, Arhus C, Denmark|Novartis Investigative Site, Herlev, Denmark|Novartis Investigative Site, Odense, Denmark|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Boulogne-Billancourt, France|Novartis Investigative Site, Brest cedex, France|Novartis Investigative Site, Dijon, France|Novartis Investigative Site, Grenoble, France|Novartis Investigative Site, Lille, France|Novartis Investigative Site, Marseille cedex 5, France|Novartis Investigative Site, Montpellier cedex 5, France|Novartis Investigative Site, Nice, France|Novartis Investigative Site, Paris Cedex 10, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Pierre-Benite cedex, France|Novartis Investigative Site, Reims Cedex, France|Novartis Investigative Site, Rennes Cedex, France|Novartis Investigative Site, Toulouse cedex 9, France|Novartis Investigative Site, Tours Cedex 9, France|Novartis Investigative Site, Villejuif cedex, France|Novartis Investigative Site, Freiburg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Heidelberg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Heilbronn, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Mannheim, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Tuebingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Ulm, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Nuernberg, Bayern, Germany|Novartis Investigative Site, Regensburg, Bayern, Germany|Novartis Investigative Site, Wuerzburg, Bayern, Germany|Novartis Investigative Site, Darmstadt, Hessen, Germany|Novartis Investigative Site, Kassel, Hessen, Germany|Novartis Investigative Site, Marburg, Hessen, Germany|Novartis Investigative Site, Wiesbaden, Hessen, Germany|Novartis Investigative Site, Schwerin, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Buxtehude, Niedersachsen, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Aachen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Bochum, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Bonn, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Muenster, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Mainz, Rheinland-Pfalz, Germany|Novartis Investigative Site, Homburg, Saarland, Germany|Novartis Investigative Site, Magdeburg, Sachsen-Anhalt, Germany|Novartis Investigative Site, Quedlinburg, Sachsen-Anhalt, Germany|Novartis Investigative Site, Kiel, Schleswig-Holstein, Germany|Novartis Investigative Site, Luebeck, Schleswig-Holstein, Germany|Novartis Investigative Site, Erfurt, Thueringen, Germany|Novartis Investigative Site, Gera, Thueringen, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Genova, Liguria, Italy|Novartis Investigative Site, Bergamo, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Candiolo, Piemonte, Italy|Novartis Investigative Site, Pisa, Toscana, Italy|Novartis Investigative Site, Padova, Veneto, Italy|Novartis Investigative Site, Shizuoka, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Leeuwarden, Netherlands|Novartis Investigative Site, Maastricht, Netherlands|Novartis Investigative Site, Nijmegen, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Auckland, New Zealand|Novartis Investigative Site, Alesund, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Konin, Poland|Novartis Investigative Site, Poznan, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Chelyabinsk, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Volgograd, Russian Federation|Novartis Investigative Site, Badalona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Cartagena, Spain|Novartis Investigative Site, Las Palmas De Gran Canaria, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Malaga, Spain|Novartis Investigative Site, Palma de Mallorca, Spain|Novartis Investigative Site, Pamplona, Spain|Novartis Investigative Site, San Sebastian, Spain|Novartis Investigative Site, Santander, Spain|Novartis Investigative Site, Sevilla, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Goteborg, Sweden|Novartis Investigative Site, Lund, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Basel, Switzerland|Novartis Investigative Site, Chur, Switzerland|Novartis Investigative Site, Zurich, Switzerland|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taoyuan, Taiwan|Novartis Investigative Site, Northwood, Middlesex, United Kingdom|Novartis Investigative Site, Exeter, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, Guildford, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom|Novartis Investigative Site, Newcastle upon Tyne, United Kingdom|Novartis Investigative Site, Norwich, United Kingdom|Novartis Investigative Site, Preston, United Kingdom|Novartis Investigative Site, Southampton, United Kingdom",https://ClinicalTrials.gov/show/NCT01682083
227,"Dana-Farber Cancer Institute|Verastem, Inc.","A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL","Active, not recruiting",Has Results,Chronic Lymphocytic Leukemia,Drug: IPI-145|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Rituximab,Other|Industry,Interventional,"Beth Isreal Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT02158091
228,H. Lee Moffitt Cancer Center and Research Institute|Celgene,"Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)","Active, not recruiting",Has Results,Myelodysplastic Syndrome|Acute Myeloid Leukemia,Drug: Idarubicin|Drug: Cytarabine|Drug: Lenalidomide (Revlimid®),Other|Industry,Interventional,"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Cleveland Clinic - Taussig Cancer Institute, Cleveland, Ohio, United States",https://ClinicalTrials.gov/show/NCT00831766
229,AbbVie,A Study to Evaluate the Efficacy of Venetoclax in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) Including Those With 17p Deletion or TP53 Mutation or Those Who Have Received a Prior B-cell Receptor Inhibitor,"Active, not recruiting",Has Results,Chronic Lymphocytic Leukemia,Drug: Venetoclax,Industry,Interventional,"Norton Cancer Institute /ID# 149788, Louisville, Kentucky, United States|St. Agnes Cancer Center /ID# 149782, Baltimore, Maryland, United States|Hackensack Univ Med Ctr /ID# 151574, Hackensack, New Jersey, United States|Utah Cancer Specialists /ID# 151604, Salt Lake City, Utah, United States|Cancer Care Northwest /ID# 151605, Spokane, Washington, United States|West Virginia Univ School Med /ID# 151602, Morgantown, West Virginia, United States|LKH-Univ. Klinikum Graz /ID# 147547, Graz, Austria|LKH Salzburg and Paracelsus /ID# 147549, Salzburg, Austria|Hanusch Krankenhaus der WGKK /ID# 147548, Wien, Austria|Cliniques Universitaires Saint Luc /ID# 147388, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|UZ Leuven /ID# 147387, Leuven, Belgium|BC Cancer Agency /ID# 153091, Vancouver, British Columbia, Canada|Qe Ii Hsc /Id# 147460, Halifax, Nova Scotia, Canada|Juravinski Cancer Clinic /ID# 149152, Hamilton, Ontario, Canada|Sunnybrook Health Sciences Ctr /ID# 147462, Toronto, Ontario, Canada|CHU de Quebec-Universite Laval /ID# 150299, Quebec City, Quebec, Canada|Herlev Hospital /ID# 150183, Herlev, Hovedstaden, Denmark|Aarhus University Hospital /ID# 147409, Aarhus N, Midtjylland, Denmark|Turku University Hospital /ID# 147551, Turku, Finland|CHU Dupuytren /ID# 147552, Limoges CEDEX 1, Franche-Comte, France|CHU de la miletrie /ID# 147484, Poitiers, Poitou-Charentes, France|Institut Bergonie /ID# 147482, Bordeaux, France|CHRU de Brest - Hopital Morvan /ID# 147485, Brest, France|clinique Sainte Anne /ID# 147556, Strasbourg, France|Onkologische Schwerpunktpraxis /ID# 147516, Berlin, Germany|Cent fuer Haematologie und Onk /ID# 147511, Frankfurt, Germany|OncoResearch Lerchenfeld GmbH /ID# 164044, Hamburg, Germany|Mannheimer Onkologiepraxis /ID# 147512, Mannheim, Germany|Staedt. Klinikum Schwabing /ID# 147510, Munich, Germany|General Hospital of Athens Laiko /ID# 147517, Athens, Attiki, Greece|G. Papanikolaou Hospital /ID# 147518, Thessaloniki, Greece|St. James's Hospital /ID# 147519, Dublin 8, Dublin, Ireland|Beaumont Hospital /ID# 147522, Dublin, Ireland|Tel Aviv Sourasky Medical Ctr /ID# 151624, Tel Aviv-Yafo, Tel-Aviv, Israel|Galilee Medical Center /ID# 159971, Nahariya, Israel|Sheba Medical Center /ID# 147509, Ramat Gan, Israel|A.O.U. Policlinico S.Orsola-Malpighi /ID# 147505, Bologna, Emilia-Romagna, Italy|AP Romano Umberto I /ID# 147500, Rome, Lazio, Italy|ASST Grande Ospedale Metropolitano Niguarda /ID# 147503, Milano, Lombardia, Italy|Ospedale San Raffaele IRCCS /ID# 147504, Milan, Italy|AO Maggiore della Carita /ID# 147499, Novara, Italy|Academisch Medisch Centrum /ID# 147494, Amsterdam, Noord-Holland, Netherlands|Albert Schweitzer Ziekenhuis /ID# 147495, Dordrecht, Zuid-Holland, Netherlands|Haukeland University Hospital /ID# 147382, Bergen, Hordaland, Norway|Rikshospitalet OUS HF /ID# 201812, Oslo, Norway|IPO Lisboa FG, EPE /ID# 147385, Lisboa, Portugal|IPO Porto FG, EPE /ID# 147389, Porto, Portugal|Puerto Rico Hematology Oncolog /ID# 150003, San Juan, Puerto Rico|Hospital Santa Creu i Sant Pau /ID# 151230, Barcelona, Spain|Fundacion Jimenez Diaz /ID# 151231, Madrid, Spain|Hosp Univ Puerta de Hierro /ID# 147391, Majadahonda, Spain|Hospital Clinico Univ de Salamanca /ID# 147392, Salamanca, Spain|Hosp Clin Univ de Valencia /ID# 147396, València, Spain|Skanes Universitetssjukhus Lund /ID# 147439, Lund, Skane Lan, Sweden|Akademiska Sjukhuset /ID# 150184, Uppsala, Uppsala Lan, Sweden|Hopitaux Universitaires de Geneve /ID# 147930, Genève, Geneve, Switzerland|University Hospital Zurich /ID# 157910, Zurich, Zuerich, Switzerland|Ospedale Regional Bellinzona e /ID# 151232, Bellinzona, Switzerland|Ankara Univ Medical Faculty /ID# 147443, Ankara, Turkey|Istanbul University Istanbul Medical Faculty /ID# 156040, Istanbul, Turkey|Vehbi Koc vakfi Amerikan Hasta /ID# 147325, Istanbul, Turkey|Dokuz Eylul University /ID# 147442, Izmir, Turkey|Ondokuz mayis University Facul /ID# 147326, Samsun, Turkey|Blackpool Teaching Hosp NHS /ID# 149581, Blackpool, United Kingdom|Univ Hosp Bristol NHS Foundati /ID# 147647, Bristol, United Kingdom|Southampton General Hospital /ID# 147646, Southampton, United Kingdom|The Royal Wolverhampton NHS Tr /ID# 147945, Wolverhampton, United Kingdom",https://ClinicalTrials.gov/show/NCT02756611
230,Exelixis,Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib,"Active, not recruiting",Has Results,Hepatocellular Carcinoma,Drug: Cabozantinib tablets|Drug: Placebo tablets,Industry,Interventional,"Corona, California, United States|Los Angeles, California, United States|San Diego, California, United States|San Francisco, California, United States|Gainesville, Florida, United States|Atlanta, Georgia, United States|Honolulu, Hawaii, United States|Chicago, Illinois, United States|Burlington, Massachusetts, United States|Rochester, Minnesota, United States|Kansas City, Missouri, United States|Saint Louis, Missouri, United States|Las Vegas, Nevada, United States|East Orange, New Jersey, United States|New York, New York, United States|New York, New York, United States|Valhalla, New York, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Seattle, Washington, United States|Seattle, Washington, United States|Spokane, Washington, United States|Camperdown, New South Wales, Australia|Concord, New South Wales, Australia|Darlinghurst, New South Wales, Australia|Kogarah, New South Wales, Australia|Westmead, New South Wales, Australia|Kurralta Park, South Australia, Australia|Melbourne, Victoria, Australia|Perth, Western Australia, Australia|Edegem, Antwerpen, Belgium|La Louvière, Hainaut, Belgium|Gent, Oost-Vlaanderen, Belgium|Liege, Belgium|Calgary, Alberta, Canada|Toronto, Ontario, Canada|Saskatoon, Saskatchewan, Canada|Nice, Alpes-Maritimes, France|Amiens, Somme, France|Creteil, Val-de-Marne, France|Besançon, France|Bordeaux, France|Clermont-Ferrand, France|Lille, France|Lyon, France|Esslingen am Neckar, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|München, Bayern, Germany|Frankfurt am Main, Hessen, Germany|Magdeburg, Sachsen-Anhalt, Germany|Berlin, Germany|Freiburg, Germany|Hong Kong, Hong Kong|Dublin, Ireland|Bologna, Emilia-Romagna, Italy|Faenza, Emilia-Romagna, Italy|Meldola, Emilia-Romagna, Italy|Rimini, Emilia-Romagna, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Genova, Liguria, Italy|Milan, Lombardia, Italy|Rozzano, Lombardia, Italy|Palermo, Sicilia, Italy|Padova, Veneto, Italy|Goyang, Gyeonggido, Korea, Republic of|Busan, Korea, Republic of|Seongnam, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Suwon-si, Korea, Republic of|Maastricht, Limburg, Netherlands|Amsterdam, Noord-Holland, Netherlands|Amsterdam, Noord-Holland, Netherlands|Leiden, Zuid-Holland, Netherlands|Auckland, North Island, New Zealand|Olsztyn, Warminsko-Mazurskie, Poland|Myslowice, Poland|Poznan, Poland|Cluj-Napoca, Cluj, Romania|Brasov, Romania|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Elche, Alicante, Spain|Majadahonda, Madrid, Spain|Torrejon de Ardoz, Madrid, Spain|Madrid, Spain|Madrid, Spain|Zaragoza, Spain|Liuying Township, Tainan, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Edirne, Turkey|Gaziantep, Turkey|Wirral, England, United Kingdom|Birmingham, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom",https://ClinicalTrials.gov/show/NCT01908426
231,Weill Medical College of Cornell University|Celgene,Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma,"Active, not recruiting",Has Results,Mantle Cell Lymphoma,Drug: lenalidomide|Biological: rituximab,Other|Industry,Interventional,"Moffitt Cancer Center, Tampa, Florida, United States|University of Chicago, Chicago, Illinois, United States|Weill Cornell Medical College, New York, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT01472562
232,Northwestern University|Bayer|National Cancer Institute (NCI),"Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma","Active, not recruiting",Has Results,Adult Angiosarcoma|Recurrent Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma,Drug: regorafenib,Other|Industry|NIH,Interventional,"Sarcoma Oncology Center, Santa Monica, California, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Northwestern University, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University-St. Louis, Saint Louis, Missouri, United States",https://ClinicalTrials.gov/show/NCT02048722
233,NewLink Genetics Corporation|Lumos Pharma,Immunotherapy Study for Patients With Stage IV Melanoma,"Active, not recruiting",Has Results,Stage IV Melanoma|Metastatic Melanoma,Drug: HyperAcute®-Melanoma (HAM) Immunotherapy|Drug: Ipilimumab|Drug: Pembrolizumab|Drug: Nivolumab,Industry,Interventional,"Oncology Specialists, Niles, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|University of Tennessee Medical Center, Knoxville, Tennessee, United States",https://ClinicalTrials.gov/show/NCT02054520
234,Northwestern University|National Cancer Institute (NCI)|Merck Sharp & Dohme Corp.,PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma,"Active, not recruiting",Has Results,Classical Hodgkin Lymphoma|Lymphocyte-Depleted Classical Hodgkin Lymphoma|Lymphocyte-Rich Classical Hodgkin Lymphoma|Mixed Cellularity Classical Hodgkin Lymphoma|Nodular Sclerosis Classical Hodgkin Lymphoma,Procedure: Computed Tomography|Drug: Dacarbazine|Drug: Doxorubicin Hydrochloride|Radiation: Fludeoxyglucose F-18|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab|Procedure: Positron Emission Tomography|Drug: Vinblastine Sulfate,Other|NIH|Industry,Interventional,"Stanford Cancer Institute, Stanford, California, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rutgers Cancer Institute, New Brunswick, New Jersey, United States",https://ClinicalTrials.gov/show/NCT03226249
235,Bristol-Myers Squibb|ICON plc|PPD|Molecular MD|European Organisation for Research and Treatment of Cancer - EORTC|MultiPharma|Steering Committee,Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response,"Active, not recruiting",Has Results,Chronic Phase Chronic Myeloid Leukemia,Drug: Dasatinib,Industry|Other,Interventional,"City of Hope National Medical Center, Duarte, California, United States|David Geffen School of Medicine at UCLA, Los Angeles, California, United States|Ucsf-Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States|John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States|Herbert Irving Comprehensive Cancer Center-Columbia University Medical Center, New York, New York, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|MD Anderson Cancer Center Clinic, Houston, Texas, United States|Local Institution, Toronto, Ontario, Canada|Local Institution, Paris, France|Local Institution, Pessac, France|Local Institution, Pierre Benite Cedex, France|Local Institution, Vandoeuvre-les-Nancy Cedex, France|Local Institution, Aachen, Germany|Local Institution, Berlin, Germany|Local Institution, Mannheim, Germany|Local Institution, Rostock, Germany|Local Institution, Ulm, Germany|Local Institution, Catania, Italy|Local Institution, Firenze, Italy|Local Institution, Napoli, Italy|Local Institution, Orbassano, Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, Las Palmas de Gran Canaria, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Oviedo, Spain",https://ClinicalTrials.gov/show/NCT01850004
236,"Bristol-Myers Squibb|ICON Clinical Research|PPD|Molecular MD|MultiPharma|Q2 Solutions|Donald E. Morisky|MD Anderson Symptom Inventory (MDASI-CML)|OBiS, Inc|Steering Committee",Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib,"Active, not recruiting",Has Results,Chronic Phase Chronic Myeloid Leukemia,Drug: Imatinib|Drug: Dasatinib,Industry|Other,Interventional,"Pacific Cancer Medical Center, Inc., Anaheim, California, United States|Kaiser Permanente Medical Center_Fontana, Fontana, California, United States|University Of Southern California University Hospital, Los Angeles, California, United States|Kaiser Permanente Medical Center, Oakland, California, United States|Kaiser Permanente Oncology Clinical Trials, Vallejo, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Cancer Center of Central Connecticut, Southington, Connecticut, United States|Northwestern University, Evanston, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|University Of Iowa, Iowa City, Iowa, United States|Mayo Clinic, Rochester, Minnesota, United States|USOR - Oncology Hematology Care, Cincinnati, Ohio, United States|Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Tennesssee Oncology - Centennial Clinic Location, Nashville, Tennessee, United States|Michael E Debakey VAMC, Houston, Texas, United States|Institute of Oncology Hematology Biomedical Research, Laredo, Texas, United States|Edwards Comprehensive Cancer Center, Huntington, West Virginia, United States|Froedtert & Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Local Institution, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Local Institution, La Plata, Buenos Aires, Argentina|Local Institution, Ramos Mejia, Buenos Aires, Argentina|Local Institution, Corrientas, Provincia DE Corientas, Argentina|Local Institution, San Miguel de Tucuman, Tucuman, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Furstenfeld, Austria|Local Institution, Graz, Austria|Local Institution, Innsbruck, Austria|Local Institution, Linz, Austria|Local Institution, Wels, Austria|Local Institution, Wien, Austria|Local Institution, Brugge, Belgium|Local Institution, Merksem, Belgium|Local Institution, Yvoir, Belgium|Local Institution, Goiania, Goias, Brazil|Local Institution, Curitiba, Parana, Brazil|Local Institution, Campinas, SAO Paulo, Brazil|Local Institution, Ribeir?o Preto, SAO Paulo, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Saint John, New Brunswick, Canada|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Haerbin, Heilongjiang, China|Local Institution, Wuhan, Hubei, China|Local Institution, Wuhan, Hubei, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Suzhou, Jiangsu, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Xian, Shan3xi, China|Local Institution, Xian, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Tianjin, Tianjin, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Jinan, China|Local Institution, Shenzhen, China|Local Institution, Brno, Czechia|Local Institution, Hradec Kralove, Czechia|Local Institution, Olomouc, Czechia|Local Institution, Prague 10, Czechia|Local Institution, Prague 2, Czechia|Local Institution, Le Chesnay Cedex, France|Local Institution, Lille cedex, France|Local Institution, Nantes, France|Local Institution, Pierre Benite cedex, France|Local Institution, Vandoeuvre-les-Nancy Cedex, France|Local Institution, Budapest, Hungary|Local Institution, Szeged, Hungary|Local Institution, Bari, Italy|Local Institution, Bologna, Italy|Local Institution, Brescia, Italy|Local Institution, Catania, Italy|Local Institution, Firenze, Italy|Local Institution, Monza, Italy|Local Institution, Napoli, Italy|Local Institution, Orbassano, Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Gdansk, Poland|Local Institution, Katowice, Poland|Local Institution, Krakow, Poland|Local Institution, Warszawa, Poland|Local Institution, L'Hospitalet Del Llobregat, Spain|Local Institution, Las Palmas de Gran Canaria, Spain|Local Institution, Madrid, Spain|Local Institution, Salamanca, Spain|Local Institution, Santiago de Compostela, Spain|Local Institution, Toledo, Spain|Local Institution, Bangkok, Thailand|Local Institution, Khon Kaen, Thailand|Local Institution, Muang, Thailand",https://ClinicalTrials.gov/show/NCT01593254
237,"Dartmouth-Hitchcock Medical Center|Cephalon|Spectrum Pharmaceuticals, Inc",Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma,"Active, not recruiting",Has Results,"Lymphoma, Follicular",Drug: Bendamustine|Drug: Rituximab|Radiation: Y-90 ibritumomab,Other|Industry,Interventional,"Maine Center for Cancer Medicine, Scarborough, Maine, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Duke University Medical Center, Durham, North Carolina, United States|Rhode Island Hospital, Providence, Rhode Island, United States",https://ClinicalTrials.gov/show/NCT01234766
238,Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd,Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141),"Active, not recruiting",Has Results,Squamous Cell Carcinoma of the Head and Neck,Drug: Nivolumab|Drug: Cetuximab|Drug: Methotrexate|Drug: Docetaxel,Industry,Interventional,"Stanford University Medical Center, Stanford, California, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|University Of Chicago, Chicago, Illinois, United States|Crescent City Research Consortium, LLC, Metairie, Louisiana, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University Of Michigan, Ann Arbor, Michigan, United States|Dumc, Durham, North Carolina, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Upmc Cancer Center, Pittsburgh, Pennsylvania, United States|Vanderbilt Cancer Clinic, Nashville, Tennessee, United States|Univ Of Tx. Md Anderson, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Medical College Of Wisconsin, Milwaukee, Wisconsin, United States|COIBA, Berazategui, Buenos Aires, Argentina|Centro Para La Atencion Integral Del Paciente Oncologico, San Miguel De Tucuman, Tucuman, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Sao Paulo, Brazil|British Columbia Cancer Agency-Vancouver Ctr, Vancouver, British Columbia, Canada|London Regional Cancer Program, London, Ontario, Canada|Local Institution, Lyon Cedex 08, France|Local Institution, Nice Cedex 2, France|Local Institution, Villejuif Cedex, France|Local Institution, Berlin, Germany|Universitaetsklinikum Bonn, Bonn, Germany|Universitaetsklinikum Essen, Essen, Germany|Uniklinikum Hamburg-Eppendorf, Hamburg, Germany|Med Hochschule Hannover, Hannover, Germany|Klinikum Der Universitaet, Wuerzburg, Germany|Local Institution, Hong Kong, Hong Kong|Ist.Scient. Romagnolo Per Lo Studio E Cura Tumori, Meldola, FC, Italy|Local Institution, Milano, MI, Italy|Local Institution, Torino, TO, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Nagoya, Aichi, Japan|Local Institution, Kashiwa, Chiba, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Takatsuki, Osaka, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Akashi, Hyogo, Japan|Local Institution, Tokyo, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Leiden, Netherlands|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Valencia, Spain|Universitatsspital Zurich, Zuerich, Switzerland|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Wirral, Merseyside, United Kingdom|Local Institution, Surrey, United Kingdom",https://ClinicalTrials.gov/show/NCT02105636
239,Acerta Pharma BV,"An Open-label, Phase 2 Study of Acalabrutinib in Subjects With Waldenström Macroglobulinemia","Active, not recruiting",Has Results,Waldenström Macroglobulinemia (WM),Drug: Acalabrutinib,Industry,Interventional,"Washington, District of Columbia, United States|New York, New York, United States|Houston, Texas, United States|Amsterdam, Netherlands|Leicester, United Kingdom",https://ClinicalTrials.gov/show/NCT02180724
240,"Kite, A Gilead Company|Genentech, Inc.|Gilead Sciences",Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL),"Active, not recruiting",Has Results,Refractory Diffuse Large B Cell Lymphoma,Biological: KTE-C19|Biological: Atezolizumab|Drug: Cyclophosphamide|Drug: Fludarabine,Industry,Interventional,"City of Hope, Duarte, California, United States|Stanford Cancer Center, Palo Alto, California, United States|H Lee Moffitt Cancer Center, Tampa, Florida, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT02926833
241,Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd,A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL),"Active, not recruiting",Has Results,Lymphoma,Drug: Nivolumab,Industry,Interventional,"University of Alabama at Birmingham, Birmingham, Alabama, United States|City Of Hope Medical Center, Duarte, California, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|H. Lee Moffitt Cancer Center & Research Inst, Inc, Tampa, Florida, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University, New York, New York, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Baylor Research Institute, Dallas, Texas, United States|Swedish Medical Center, Seattle, Washington, United States|Instituto Do Cancer Mae De Deus / Cor Hospital Mae De Deus, Porto Alegre, RIO Grande DO SUL, Brazil|Fundacao Pio Xii Hosp Cancer De Barretos, Barretos, SAO Paulo, Brazil|Hospital Das Clinicas - Fmusp, Sao Paulo, Brazil|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CHU de Quebec, Quebec, Canada|I. interni klinika - klinika hematologie 1. LF UK a VFN v Praze, Praha 2, Czechia|Local Institution, Bordeaux, France|Local Institution, Caen, France|Local Institution, La Tronche, France|Local Institution, Lille Cedex, France|Local Institution, Paris cedex 13, France|Centre Hospitalier Lyon Sud - UPCO, Pierre Benite, France|Local Institution, Rennes Cedex 9, France|Local Institution, St. Cloud, France|Local Institution, Tours Cedex 9, France|Klinikum Stuttgart, Stuttgart, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution, Budapest, Hungary|Belgyogyaszati Onkologia OOI, Budapest, Hungary|Local Institution, Debrecen, Hungary|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Petah Tikva, Israel|Local Institution, Tel Aviv, Israel|Irccs Ospedale S. Raffaele, Milano, Italy|Fondazione Policlinico Universitario A. Gemelli, Roma, Italy|Istituto Clinico Humanitas, Rozzano (milano), Italy|Local Institution, Nagoya, Aichi, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Kotoku, Tokyo, Japan|Local Institution, Mitaka-shi, Tokyo, Japan|Local Institution, Yamagata, Japan|Local Institution, Moscow, Russian Federation|Local Institution, Singapore, Singapore",https://ClinicalTrials.gov/show/NCT02857426
242,"Millennium Pharmaceuticals, Inc.|Seagen Inc.|Takeda",A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,"Active, not recruiting",Has Results,Hodgkin Lymphoma,Drug: brentuximab vedotin|Drug: doxorubicin|Drug: bleomycin|Drug: vinblastine|Drug: dacarbazine,Industry,Interventional,"Birmingham, Alabama, United States|Gilbert, Arizona, United States|Tucson, Arizona, United States|Burbank, California, United States|Duarte, California, United States|Fresno, California, United States|Fullerton, California, United States|La Jolla, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Sacramento, California, United States|San Luis Obispo, California, United States|Santa Barbara, California, United States|Santa Monica, California, United States|Stanford, California, United States|Colorado Springs, Colorado, United States|Denver, Colorado, United States|Lonetree, Colorado, United States|Washington, District of Columbia, United States|Fort Myers, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Lawrenceville, Georgia, United States|Chicago, Illinois, United States|Maywood, Illinois, United States|Niles, Illinois, United States|Zion, Illinois, United States|Fort Wayne, Indiana, United States|Goshen, Indiana, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|Fairway, Kansas, United States|Baltimore, Maryland, United States|Bethesda, Maryland, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Detroit, Michigan, United States|Minneapolis, Minnesota, United States|Rochester, Minnesota, United States|Saint Louis, Missouri, United States|Springfield, Missouri, United States|Lincoln, Nebraska, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Basking Ridge, New Jersey, United States|Hackensack, New Jersey, United States|Morristown, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Bronx, New York, United States|Commack, New York, United States|New York, New York, United States|Rochester, New York, United States|Rockville Centre, New York, United States|Charlotte, North Carolina, United States|Raleigh, North Carolina, United States|Bismarck, North Dakota, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Oklahoma City, Oklahoma, United States|Eugene, Oregon, United States|Hershey, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Charleston, South Carolina, United States|Greenville, South Carolina, United States|Chattanooga, Tennessee, United States|Knoxville, Tennessee, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Tyler, Texas, United States|Salt Lake City, Utah, United States|Fairfax, Virginia, United States|Richmond, Virginia, United States|Kennewick, Washington, United States|Seattle, Washington, United States|Vancouver, Washington, United States|Yakima, Washington, United States|Morgantown, West Virginia, United States|Milwaukee, Wisconsin, United States|Kingswood, New South Wales, Australia|St Leonards, New South Wales, Australia|Westmead, New South Wales, Australia|South Brisbane, Queensland, Australia|Bedford Park, South Australia, Australia|Hobart, Tasmania, Australia|East Melbourne, Victoria, Australia|Geelong, Victoria, Australia|Heidelberg, Victoria, Australia|Parkville, Victoria, Australia|Perth, Western Australia, Australia|Antwerpen, Belgium|Brugge, Belgium|Gent, Belgium|Salvador, Bahia, Brazil|Curitiba, Parana, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Santo Andre, Sao Paulo, Brazil|Rio De Janeiro, Brazil|Sao paulo, Brazil|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Winnipeg, Mb, Manitoba, Canada|Halifax, Nova Scotia, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Saskatoon, Saskatchewan, Canada|Hradec Kralove, Czechia|Prague, Czechia|Praha 10, Czechia|Aalborg, Denmark|Aarhus C, Denmark|Copenhagen, Denmark|Odense C, Denmark|Roskilde, Denmark|Argenteuil, Cedex, France|La Tronche, France|Limoges, France|Paris, France|Lai Chi Kok, Kowloon, Hong Kong|Hong Kong, Hong Kong|Tuen Mun, New Territories, Hong Kong|Budapest, Hungary|Debrecen, Hungary|Gyor, Hungary|Pecs, Hungary|Szeged, Hungary|Modena, Emilia-Romagna, Italy|Roma, Lazio, Italy|Alessandria, Italy|Bologna, Italy|Cagliari, Italy|Cuneo, Italy|Genova, Italy|Milano, Italy|Napoli, Italy|Rionero In Volture, Italy|Rome, Italy|Rozzano, Milano, Italy|Torrette Di Ancona, Italy|Minami-ku, Fukuoka-city, Japan|Higashi-ku, Fukuoka, Japan|Minami-ku, Hiroshima-city, Japan|Showamachi, Maebashi-city, Japan|Chikusa-ku, Nagoya, Japan|Suita, Osaka Prefecture, Japan|Aoba-ku, Sendai-city, Japan|Chuo-ku, Japan|Isehara-shi, Japan|Koto-ku, Japan|Goyang, Gyeonggi, Korea, Republic of|Hwasun-gun, Jeollanam-do, Korea, Republic of|Seocho-gu, Seoul, Korea, Republic of|Busan, Korea, Republic of|Daegu, Korea, Republic of|Incheon, Korea, Republic of|Jeonju, Korea, Republic of|Seoul, Korea, Republic of|Bergen, Norway|Oslo, Norway|Gdansk, Poland|Katowice, Poland|Krakow, Poland|L0dz, Poland|Olsztyn, Poland|Warszawa, Poland|Wroclaw, Poland|Saint-Petersburg, Poselok Pesochny, Russian Federation|Ufa, Republic Of Bashkortostan, Russian Federation|Kazan, Republic Tatrstan, Russian Federation|Moscow, Russian Federation|Moskva, Russian Federation|St.Petersburg, Russian Federation|Johannesburg, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Amanzimtoti, Kwa Zulu Natal, South Africa|Bloemfontein, South Africa|Cape Town, South Africa|Badalona, Spain|Barcelona, Spain|Marbella, Spain|Pamplona, Spain|Salamanca, Spain|Santiago de Compostela, Spain|Valencia, Spain|Changhua City, Taiwan|Chiayi County 613, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taoyuan County, Taiwan|Ankara, Turkey|Istanbul, Turkey|Samsun, Turkey|Truro, Cornwall, United Kingdom|Aberdeen, Scotland, United Kingdom|Glasgow, Scotland, United Kingdom|Sutton, Surrey, United Kingdom|Cardiff, Wales, United Kingdom|Birmingham, United Kingdom|Canterbury, United Kingdom|Exeter, United Kingdom|Inverness, United Kingdom|Leicester, United Kingdom|Lincoln, United Kingdom|Liverpool, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Norfolk, United Kingdom|Northwood, Middx, United Kingdom|Nottingham, United Kingdom|Oxford, United Kingdom|Romford, United Kingdom|Southampton, United Kingdom",https://ClinicalTrials.gov/show/NCT01712490
243,"Massachusetts General Hospital|Dana-Farber Cancer Institute|Brigham and Women's Hospital|Genzyme, a Sanofi Company",Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma,"Active, not recruiting",Has Results,"Follicular Lymphoma|Marginal Zone Lymphoma|Mantle Cell Lymphoma|Small Lymphocytic Lymphoma|Lymphoplasmacytic Lymphoma|Low Grade B-cell Lymphoma, Not Otherwise Specified|Diffuse Large B-cell Lymphoma|Peripheral T-cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Anaplastic Large-cell Lymphoma",Drug: Clofarabine,Other|Industry,Interventional,"Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT00644189
244,Incyte Corporation|Merck Sharp & Dohme Corp.,Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302),"Active, not recruiting",Has Results,Renal Cell Carcinoma (RCC),Drug: Pembrolizumab|Drug: Epacadostat|Drug: Sunitinib|Drug: Pazopanib,Industry,Interventional,"Pinnacle Oncology Hematology, Scottsdale, Arizona, United States|Scottsdale Healthcare, Scottsdale, Arizona, United States|Arizona Oncology Associates PC- HOPE, Tucson, Arizona, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|UC Irvine Comprehensive Cancer Center/Chao Family Comprehensive Cancer Center, Orange, California, United States|UC Davis Comprehensive Cancer Center, Sacramento, California, United States|Woodlands Medical Specialists, PA, Pensacola, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|Atlanta Cancer Care - Conyers, Conyers, Georgia, United States|Northwest Georgia Oncology Centers Pc, Marietta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Southeast Nebraska Hematology & Oncology Consultants, P.C., Lincoln, Nebraska, United States|New York Oncology Hematology P.C, Albany, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States|University of Tennessee Erlanger Oncology & Hematology, Chattanooga, Tennessee, United States|The West Clinic, P.C., Germantown, Tennessee, United States|US Oncology and Research, The Woodlands, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Roanoke, Virginia, United States|Shenandoah Oncology, P.C., Winchester, Virginia, United States|Canberra Hospital, Garran, Australian Capital Territory, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Cabrini Health, Malvern, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Australia|Centro de pesquisa Porto Alegre, Porto Alegre, Florianopolis, Brazil|Fundacao Pio XII - Hospital de Cancer de Barretos, Barretos, Sao Paulo, Brazil|Instituto do Cancer de Sao Paulo - ICESP, São Paulo, Sao Paulo, Brazil|Hospital Sao Jose, São Paulo, Sao Paulo, Brazil|Centro Avancado de Tratamento Oncologico - CENANTRON -, Belo Horizonte, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Kingston Health Sciences Centre - KGH Site, Kingston, Ontario, Canada|Sunnybrook Health Sciences, Odette Cancer Centre, Toronto, Ontario, Canada|Jewish General Hospital, Montréal, Quebec, Canada|CIUSSS de la Mauricie-et-du-Centre-du-Quebec, Trois-Rivières, Quebec, Canada|CHU de Quebec-Universite Laval-Hotel Dieu de Quebec, Quebec, Canada|Clinica Alemana de Osorno, Osorno, Region De Los Lagos, Chile|Fundacion Arturo Lopez Perez FALP, Santiago, Chile|Pontificia Universidad Catolica de Chile, Santiago, Chile|Hospital Clinico Vina del Mar, Vina del Mar, Chile|Centre Antoine Lacassagne, Nice, Cedex 2, France|CHU Besancon - Hopital Jean Minjoz, Besançon, France|Hopital Saint Andre, Bordeaux, France|Centre Francois Baclesse, Caen, France|Hopital Prive Toulon Hyeres Sainte Marguerite, Hyeres, France|Hopital Europeen Georges Pompidou, Paris, France|Hospices Civils de Lyon Centre Hospitalier Lyon Sud, Pierre Benite, France|Clinique Sainte Anne, Strasbourg, France|CHU de Strasbourg - Nouvel Hopital Civil, Strasbourg, France|Institut Gustave Roussy, Villejuif, France|Helios Klinikum Berlin Buch, Berlin, Germany|Universitaetsklinikum der Technischen Universitaet Dresden, Dresden, Germany|Universitaetsklinikum Essen. Klinik und Poliklinik fuer Urologie, Essen, Germany|Universitaetsklinikum Essen, Essen, Germany|Universitaetsklinikum Frankfurt, Frankfurt am Main, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitaetsklinikum Jena, Jena, Germany|Universitaetsklinikum Magdeburg. Klinik fuer Urologie, Magdeburg, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Orszagos Onkologiai Intezet, Budapest, Pest, Hungary|Zala Megyei Szent Rafael Korhaz, Zalaegerszeg, Pozva, Hungary|Somogy Megyei Kaposi Mor Oktato Korhaz, Kaposvar, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz, Miskolc, Hungary|Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet, Szolnok, Hungary|Markusovszky Egyetemi Oktatokorhaz, Szombathely, Hungary|Adelaide & Meath Hospital, Dublin, Ireland|University Hospital Waterford, Waterford, Ireland|Medical Oncology Ospedale San Donato, Arezzo, Italy|Azienda Ospedaliera-Spedali Civili, Brescia, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|A.O. Cardarelli, Napoli, Italy|Policlinico San Matteo, Pavia, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Italy|Nagoya University Hospital, Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Nara Medical University Hospital, Kashihara, Nara, Japan|Kindai University Hospital, Osakasayama, Osaka, Japan|Saitama Medical University International Medical Center, Hidaka, Saitama, Japan|Yamaguchi University Hospital, Ube, Yamaguchi, Japan|Akita University Hospital, Akita, Japan|Kyushu University Hospital, Fukuoka, Japan|Niigata University Medical & Dental Hospital, Niigata, Japan|Toranomon Hospital, Tokyo, Japan|Nippon Medical School Hospital, Tokyo, Japan|Keio University Hospital, Tokyo, Japan|Chonnam National University Hwasun Hospital, Hwasun, Jeollanam Do, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Auckland City Hospital, Auckland, Grafton, New Zealand|Helse Bergen HF Haukeland sykehus, Bergen, Norway|Sykehuset Oestfold, Gralum, Norway|Sorlandet sykehus HF, Kristiansand, Norway|Akershus University Hospital, Lørenskog, Norway|Oslo universitetssykehus, Oslo, Norway|Universitetssykehuset i Nord Norge. Kreftavdelingen, Tromsø, Norway|St Olavs Hospital, Trondheim, Norway|Leningrad Regional Oncology Dispensary, Saint Petersburg, Leningrad Region, Vsevolozhsky District, Russian Federation|Ivanovo regional oncology dispensary, Ivanovo, Russian Federation|Russian Scientific Center of Roentgenoradiology, Moscow, Russian Federation|Central Clinical Hospital with outpatient Clinic, Moscow, Russian Federation|National Medical Research Radiology Centre, Moscow, Russian Federation|Republican Clinical Oncology Dispensary of Republic of Bashkortostan, Ufa, Russian Federation|Hospital Parc Tauli, Sabadell, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Germans Trias i Pujol, Barcelona, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario HM Sanchinarro, Madrid, Spain|Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain|Instituto Valenciano de Oncologia, Valencia, Spain|Chang Gung Med Foundation. Kaohsiung Branch, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Baskent Universitesi Adana Dr. Turgut Noyan Uygulama ve Arastirma Merkezi, Adana, Turkey|Ankara Numune Education and Research Hospital, Ankara, Turkey|Hacettepe University Medical Faculty, Ankara, Turkey|Istanbul Universitesi Onkoloji Enstitusu, Istanbul, Turkey|Istanbul Medeniyet Universitesi Goztepe EAH, Istanbul, Turkey|Ege Universitesi Tıp Fakultesi, Izmir, Turkey|Namik Kemal Universitesi Tip Fakultesi, Tekirdag, Turkey|MI Kryviy Rih Center of Dnipropetrovsk Regional Council, Kryvyi Rih, Dnipropetrovsk Region, Ukraine|Dnipropetrovsk Regional Hospital n.a. I.I. Mechnikov, Dnipropetrovs'k, Ukraine|Dnipropetrovsk City Multidiscipline Clinical Hosp. 4 of DRC, Dnipropetrovs'k, Ukraine|MI Precarpathian Clinical Oncology Center, Ivano-Frankivs'k, Ukraine|RMI Sumy Regional Clinical Oncology Dispensary, Sumy, Ukraine|The Royal Marsden NHS Foundation Trust., Sutton, Surrey, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|Beatson Institute of Cancer Research, Glasgow, United Kingdom|Barts Health NHS Trust - St Bartholomew s Hospital, London, United Kingdom|The Royal Marsden Foundation Trust, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom",https://ClinicalTrials.gov/show/NCT03260894
245,Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd,An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma,"Active, not recruiting",Has Results,Hepatocellular Carcinoma,Drug: Nivolumab|Drug: Sorafenib,Industry,Interventional,"University Of Alabama At Birmingham, Birmingham, Alabama, United States|Ucla-Division Of Hematology/Oncology, Los Angeles, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|University Of California San Francisco, San Francisco, California, United States|University Of Chicago, Chicago, Illinois, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Icahn School Of Medicine At Mount Sinai, New York, New York, United States|Memorial Sloan Kettering Nassau, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|The University Of Texas Health Science Center, San Antonio, Texas, United States|Scott & White Memorial Hospital And Clinic, Temple, Texas, United States|Virginia Mason Medical Center, Seattle, Washington, United States|University of Washington - Seattle Cancer Care Alliance, Seattle, Washington, United States|University Of Wisconsin, Madison, Wisconsin, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Monash Medical Centre Clayton, Clayton, Victoria, Australia|Austin Hospital, Heidelberg, Victoria, Australia|The Alfred Hospital, Prahran, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Universitaetsklinikum Graz, Graz, Austria|AKH Wien, Wien, Austria|Local Institution, Bruxelles, Belgium|Local Institution, Leuven, Belgium|Local Institution, Liege, Belgium|Tom Baker Cancer Centre, Calgary, Alberta, Canada|British Columbia Cancer Agency-Vancouver Ctr, Vancouver, British Columbia, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Local Institution, Hefei, Anhui, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Nanning, Guangxi, China|Local Institution, Harbin, Heilongjiang, China|Local Institution, Changsha, Hunan, China|Local Institution, Changzhou, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Changchun, Jilin, China|Local Institution, Dalian, Liaoning, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Tianjin, Tianjin, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, China|Klinika komplexni onkologicke pece, Brno, Czechia|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Onkologicka klinika, Olomouc, Czechia|Local Institution, La Tronche, France|Local Institution, Lille Cedex, France|Local Institution, Lyon, France|Local Institution, Montpellier Cedex, France|Local Institution, Paris Cedex 13, France|Local Institution, Pessac, France|Local Institution, Rennes Cedex, France|Local Institution, Toulouse Cedex 9, France|Charite Campus Virchow Klinikum, Berlin, Germany|Kliniken Essen-Mitte/Huyssens-Stift, Essen, Germany|Klinikum Der Johann Wolfgang Goethe-Universitat, Frankfurt, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitaetsklinikum Leipzig, Leipzig, Germany|Johannes -Gutenberg Universitat, Mainz, Germany|Klinikum Grosshadern, Munich, Germany|Universitaetsklinikum Regensburg, Regensburg, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Petah-tikva, Israel|Local Institution, Tel Aviv, Israel|Ospedale G.Rummo, Benevento, Italy|Azienda Ospedaliera Papa Giovanni Xxiii, Bergamo, Italy|Istituto Nazionale Per Lo Studio E La Cura, Milano, Italy|Local Institution, Orbassano, Italy|AOUS - Policlinico S.Maria Alle Scotte, Siena, Italy|Local Institution, Chiba City, Chiba, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Kurume-shi, Fukuoka, Japan|Local Institution, Ogaki-shi, Gifu, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Kawasaki-shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Osaka-Sayama-Shi, Osaka, Japan|Local Institution, Saga-shi, Saga, Japan|Local Institution, Chiyoda-ku, Tokyo, Japan|Local Institution, Mitaka-shi, Tokyo, Japan|Local Institution, Musashino-shi, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Suita, Japan|Local Institution, Seoul, Seocho-gu, Korea, Republic of|Local Institution, Daegu, Korea, Republic of|Local Institution, Gyeonggi-do, Korea, Republic of|Local Institution, Jeollanam-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Uniwersyteckie Centrum Kliniczne Klinika Onkologii I Radiote, Gdansk, Poland|Klinika Gastroenterologii Onkologicznej, Warszawa, Poland|Oddzial Onkologii, Wroclaw, Poland|Local Institution, Moscow, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Alicante, Spain|Local Institution, Majadahonda - Madrid, Spain|Local Institution, Pamplona, Spain|Local Institution, Santiago Compostela, Spain|Local Institution, Goteborg, Sweden|Local Institution, Stockholm, Sweden|Universitaetsspital Basel, Basel, Switzerland|Inselspital Bern, Bern, Switzerland|Local Institution, Kaohsiung County, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Glasgow, Lanarkshire, United Kingdom|Local Institution, Liverpool, United Kingdom",https://ClinicalTrials.gov/show/NCT02576509
246,Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd,Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214),"Active, not recruiting",Has Results,Advanced Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma,Biological: Nivolumab|Biological: Ipilimumab|Drug: Sunitinib,Industry,Interventional,"City Of Hope, Duarte, California, United States|UCSD Moores Cancer Center, La Jolla, California, United States|Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Stanford Cancer Center, Stanford, California, United States|Smilow Cancer Hospital. At Yale New Haven, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Indiana University Health Melvin And Bren Simon Cancer Center, Indianapolis, Indiana, United States|University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States|University Of Kansas Cancer Center, Fairway, Kansas, United States|Uof Md,Greenebaum Cancer Ctr., Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Beth Isr. Deacon. Med Cnt, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University Of Michigan Health System, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Nassau, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute Cancer Services, Pittsburgh, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Erlanger Oncology & Hematology - Univ. of TN, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Texas Oncology, P.A., Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|University of Washington - Seattle Cancer Care Alliance, Seattle, Washington, United States|COIBA, Berazategui, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Centro Medico San Roque, San Miguel de Tucuman, Tucuman, Argentina|Centro Para La Atencion Integral Del Paciente Oncologico, San Miguel De Tucuman, Tucuman, Argentina|Instituto Medico Especialazado Alexander Fleming, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Kogarah, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Herston, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Clayton, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Murdoch, Australia|Local Institution, Linz, Austria|Local Institution, Vienna, Austria|Local Institution, Wels, Austria|Local Institution, Gent, Belgium|Local Institution, Leuven, Belgium|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Calgary, Alberta, Canada|Local Institution, Edmonton, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Moncton, New Brunswick, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Centro de Investigacion Clinica Bradford Hill, Santiago, Metropolitana, Chile|Centro De Cancer, Pontificia Universidad Catolica, Santiago, Metropolitana, Chile|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Instituto Oncologico, Vina del Mar, Chile|Local Institution, Bogota, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|Instituto de Cancerologia SA, Medellin, Colombia|Local Institution, Brno, Czechia|Local Institution, Hradec Kralove, Czechia|Local Institution, Liberec, Czechia|Local Institution, Olomouc, Czechia|Aarhus Universitetshospital, Aarhus N, Denmark|Herlev University Hospital, Herlev, Denmark|Local Institution, Odense, Denmark|Helsinki University Hospital, Helsinki, Finland|Tampere University Hospital, Tampere, Finland|CHU Hopital Jean Minjoz, Besancon, France|Local Institution, Bordeaux, France|Local Institution, La Roche sur Yon, France|Institut Paoli-Calmettes, Marseille Cedex 9, France|Local Institution, Paris, France|Local Institution, Saint Herblain, France|Local Institution, Strasbourg, France|Institut Claudius Regaud, Toulouse Cedex 9, France|Local Institution, Villejuif, France|Local Institution, Aachen, Germany|Local Institution, Erlangen, Germany|Local Institution, Frankfurt, Germany|Local Institution, Hamburg, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Local Institution, Homburg, Germany|Local Institution, Jena, Germany|Local Institution, Magdeburg, Germany|Local Institution, Muenchen, Germany|Local Institution, Muenster, Germany|Local Institution, Ulm, Germany|Local Institution, Budapest, Hungary|Local Institution, Debrecen, Hungary|Local Institution, Gyula, Hungary|Local Institution, Pecs, Hungary|Local Institution, Wilton, Cork, Ireland|Local Institution, Dublin 7, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Beer Jacob, Israel|Local Institution, Haifa, Israel|Local Institution, Kfar Saba, Israel|Local Institution, Petach Tikva, Israel|Local Institution, Ramat-gan, Israel|Ospedal S. Donato Usl 8, Arezzo, Italy|Ist.Scient. Romagnolo Per Lo Studio E Cura Tumori, Meldola (fc), Italy|Local Institution, Milano, Italy|Azienda Ospedaliera Di Rilievo Nazionale A. Cardarelli, Napoli, Italy|Istituto Oncologico Veneto IOV, Padova, Italy|Local Institution, Pavia, Italy|Local Institution, Roma, Italy|Local Institution, Akita-shi, Akita, Japan|Local Institution, Hirosaki-shi, Aomori, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Sapporo-shi, Hokai-do, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe, Hyogo, Japan|Local Institution, Morioka-shi, Iwate, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Osaka-sayama, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Hamamatsu-shi, Shizuoka, Japan|Local Institution, Tokushima-shi, Tokushima, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Shinjuku-Ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Yamagata-shi, Yamagata, Japan|Local Institution, Bunkyo-ku, Japan|Local Institution, Tsukuba-shi, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Mexico D.f., Distrito Federal, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Santiago de Queretaro, Queretaro, Mexico|Local Institution, Oaxaca, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Krakow, Poland|Local Institution, Poznan, Poland|Local Institution, Wroclaw, Poland|Hospital De La Santa Creu I Sant Pau, Barcelona, Spain|H. Univ. Vall dHebron, Barcelona, Spain|Hospital Ramon Y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|Hospital General De Asturias, Oviedo, Spain|Hosp. Univ. Virgen Del Rocio, Sevilla, Spain|Karolinska University Hospital, Solna, Sweden|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Ankara, Turkey|Local Institution, Antalya, Turkey|Local Institution, Istanbul, Turkey|Local Institution, London, Greater London, United Kingdom|Local Institution, Glasgow, Lanarkshire, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Northwood, United Kingdom|Local Institution, Swansea, United Kingdom",https://ClinicalTrials.gov/show/NCT02231749
247,"Astellas Pharma Global Development, Inc.|Pfizer|Astellas Pharma Inc",A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma,"Active, not recruiting",Has Results,Advanced Hepatocellular Carcinoma,Drug: enzalutamide|Drug: placebo,Industry,Interventional,"Site US10003, San Francisco, California, United States|Site US10009, Skokie, Illinois, United States|Site US10017, Minneapolis, Minnesota, United States|Site US10021, Lebanon, New Hampshire, United States|Site US10008, Portland, Oregon, United States|Site US10014, Philadelphia, Pennsylvania, United States|Site US10019, Philadelphia, Pennsylvania, United States|Site US10016, Milwaukee, Wisconsin, United States|Site CA15001, Toronto, Ontario, Canada|Site CA15002, Montreal, Quebec, Canada|Site CA15003, Montreal, Canada|Site HK85202, Kowloon, Hong Kong|Site HK85204, Shatin, Hong Kong|Site IT39008, Rozzano, Milan, Italy|Site IT39005, Benevento, Italy|Site IT39006, Milano, Italy|Site IT39002, Milan, Italy|Site IT39011, Padova, Italy|Site IT39004, Pavia, Italy|Site KR82002, Seongnam-Si, Gyeonggi-do, Korea, Republic of|Site KR82005, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Site KR82006, Seoul, Korea, Republic of|Site KR82007, Seoul, Korea, Republic of|Site KR82004, Seoul, Korea, Republic of|Site KR82001, Seoul, Korea, Republic of|Site US10001, San Juan, Puerto Rico|Site ES34003, Barcelona, Spain|Site ES34006, Cordoba, Spain|Site ES34004, Madrid, Spain|Site TW88603, Douliu, Taiwan|Site TW88606, Tainan, Taiwan|Site TW88605, Tainan, Taiwan|Site TW88604, Taipei City, Taiwan|Site GB44007, Birmingham, United Kingdom|Site GB44004, London, United Kingdom|Site GB44008, London, United Kingdom|Site GB44005, Manchester, United Kingdom|Site GB44002, Wirral, United Kingdom",https://ClinicalTrials.gov/show/NCT02528643
248,Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd,Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025),"Active, not recruiting",Has Results,Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma,Biological: Nivolumab|Drug: Everolimus,Industry,Interventional,"Highland Oncology Group, Fayetteville, Arkansas, United States|UCSD Moores Cancer Center, La Jolla, California, United States|University Of Southern California, Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Ucsf Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Stanford Cancer Institute, Stanford, California, United States|University Of Colorado, Aurora, Colorado, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Loyola University Chicago, Maywood, Illinois, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University Of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Nassau, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|St Francis Hospital, Greenville, South Carolina, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|CTRC at UTHSC San Antonio, San Antonio, Texas, United States|Virginia Cancer Institute, Richmond, Virginia, United States|University Of Washington, Seattle, Washington, United States|COIBA, Berazategui, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Centro Para La Atencion Integral Del Paciente Oncologico, San Miguel De Tucuman, Tucuman, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Westmead, New South Wales, Australia|Local Institution, Woodville South, South Australia, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Clayton, Victoria, Australia|Local Institution, Melbourne, Australia|Local Institution, Linz, Austria|Local Institution, Vienna, Austria|Local Institution, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Local Institution, Leuven, Belgium|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|Centre D'Oncologie Dr-Leon-Richard, Moncton, New Brunswick, Canada|QEII Health Sciences Centre, Halfax, Nova Scotia, Canada|Lakeridge Health Oshawa-Durham Regional Cancer Centre, Oshawa, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Chum, Hopital Notre-Dame, Montreal, Quebec, Canada|Smbd Jewish General Hospital, Montreal, Canada|Local Institution, Hradec Kralove, Czechia|Local Institution, Olomouc, Czechia|Local Institution, Prague 5, Czechia|Local Institution, Aarhus N, Denmark|Local Institution, Herlev, Denmark|Local Institution, Odense, Denmark|Local Institution, Helsinki, Finland|Local Institution, Bordeaux, France|Local Institution, Lyon Cedex, France|Local Institution, Marseille Cedex 9, France|Local Institution, Paris, France|Local Institution, Poitiers, France|Local Institution, Saint Herblain Cedex, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Vandoeuvre Les Nancy, France|Local Institution, Villejuif Cedex, France|Local Institution, Aachen, Germany|Local Institution, Dresden, Germany|Local Institution, Erlangen, Germany|Local Institution, Essen, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Local Institution, Munich, Germany|Local Institution, Tuebingen, Germany|Alexandra Hospital, Athens, Greece|Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece|Local Institution, Tallaght, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Haifa, Israel|Local Institution, Petah Tikva, Israel|Local Institution, Ramat-gan, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Arezzo, Italy|Local Institution, Meldola (fc), Italy|Local Institution, Milano, Italy|Local Institution, Rimini, Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, Rozzano, Italy|Local Institution, Siena, Italy|Local Institution, Terni, Italy|Local Institution, Akita-shi, Akita, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Higashi-ku, Fukuoka, Japan|Local Institution, Sapporo-city, Hokkaido, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Morioka-shi, Iwate, Japan|Local Institution, Yokohama, Kangawa, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Osaka-sayama-shi, Osaka, Japan|Local Institution, Suita, Osaka, Japan|Local Institution, Hamamatsu-shi, Shizuoka, Japan|Local Institution, Tokushima-shi, Tokushima, Japan|Local Institution, Yamagata-shi, Yamagata, Japan|Local Institution, Kobe-city, Hyogo, Japan|Local Institution, Kumamoto, Japan|Local Institution, Tokyo, Japan|Local Institution, Tokyo, Japan|Local Institution, Tokyo, Japan|Local Institution, Tokyo, Japan|Local Institution, Tokyo, Japan|Local Institution, Tokyo, Japan|Local Institution, Bergen, Norway|Local Institution, Lorenskog, Norway|Local Institution, Gdansk, Poland|Local Institution, Lodz, Poland|Local Institution, Poznan, Poland|Local Institution, Rybnik, Poland|Local Institution, Warszawa, Poland|Local Institution, Wroclaw, Poland|Local Institution, Bucharest, Romania|Local Institution, Craiova, Romania|Local Institution, Iasi, Romania|Local Institution, Timisoara, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, Hospitalet De Llobregat, Barcelona, Spain|Local Institution, Pamplona, Navarra, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Gothenberg, Sweden|Local Institution, Solna, Sweden|Local Institution, Cambridge, Cambridgeshire, United Kingdom|Local Institution, Swansea, Carmarthenshire, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom",https://ClinicalTrials.gov/show/NCT01668784
249,Bristol-Myers Squibb|Ono Pharma USA Inc,BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC),"Active, not recruiting",Has Results,Renal Cell Carcinoma,Biological: nivolumab,Industry,Interventional,"UCSD Moores Cancer Center, La Jolla, California, United States|Ucla, Los Angeles, California, United States|Samuel Oschin Comprehensive Cancer Inst., Los Angeles, California, United States|Stanford Cancer Center, Stanford, California, United States|University Of Colorado, Aurora, Colorado, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Northwestern University Feinberg School Of Medicine, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Indiana University Health Melvin And Bren Simon Cancer Center, Indianapolis, Indiana, United States|University Of Kansas Medical Center, Kansas City, Kansas, United States|University Of Maryland, Baltimore, Maryland, United States|The Bunting-Blaustein Cancer Research Building, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Ctr., Boston, Massachusetts, United States|University Of Michigan Medical Center, Ann Arbor, Michigan, United States|Wayne State University, Detroit, Michigan, United States|Masonic Cancer Ctr, University Of Minnesota, Minneapolis, Minnesota, United States|North Mississippi Hematology And Oncology Associates, Ltd, Tupelo, Mississippi, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|St. Luke'S Roosevelt Hospital Center, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Memorial Sloan Kettering Nassau, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Blumenthal Cancer Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Ctr, Nashville, Tennessee, United States|University of Washington - Seattle Cancer Care Alliance, Seattle, Washington, United States|Wheaton Franciscan Health Care, Wauwatosa, Wisconsin, United States|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Centre D'Oncologie Dr-Leon-Richard, Moncton, New Brunswick, Canada|Local Institution, Halifax, Nova Scotia, Canada|London Regional Cancer Program, London, Ontario, Canada|Centre Hospitalier Universitaire De Montreal-Notre-Dame Hosp, Montreal, Quebec, Canada|Local Institution, Helsinki, Finland|Local Institution, Siena, Italy",https://ClinicalTrials.gov/show/NCT01354431
250,Celgene,"A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia","Active, not recruiting",Has Results,"Lymphoma|Leukemia, Lymphocytic, Chronic, B-Cell",Drug: Durvalumab|Drug: Lenalidomide|Drug: Rituximab|Drug: Ibrutinib|Drug: Bendamustine,Industry,Interventional,"Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Pinnacle Oncology Hematology, Scottsdale, Arizona, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Shands Cancer Center University of Florida, Gainesville, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Weill Cornell Medical College, New York, New York, United States|University of Rochester, Rochester, New York, United States|The Ohio State University, Columbus, Ohio, United States|University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Jefferson Medical Oncology Associates, Philadelphia, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|Houston Methodist Cancer Center, Houston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Centre Hospitalier Universitaire d'Avicennes, Bobigny Cedex, France|Hopital Henri Mondor, Creteil, France|Centre Hospitalier, Dijon Cedex, France|Institut Paoli Calmettes, Marseille Cedex 9, France|CHU Montpellier, Montpellier Cedex 5, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|Hopital Haut Leveque, Pessac Cedex, France|Centre Hospitalier Lyon-Sud, Pierre-Benite CEDEX, France|CHRU Rennes, Rennes, France|Centre Henri Becquerel, Rouen Cedex, France|Universitatsklinikum Essen, Essen, Germany|UKG Universitatsklinikum Gottingen, GÃ¶ttingen, Germany|Universitatsklinikum des Saarlandes, Homburg-Saar, Germany|Universitatsklinik Koln, KÃ¶ln, Germany|Medizinische Klinik III Klinikum der UniversitÃ¤t MÃ¼nchen-GroÃŸhadern, MÃ¼nchen, Germany|University of Bologna, Bologna, Italy|Spedali Civili Di Brescia, Brescia, Italy|IEO- Istituto Europeo di Oncologia, Milano, Italy|A.O. Ospedale Ca Granda - Niguarda, Milano, Italy|Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale, Napoli, Campania, Italy|I.R.C.C.S. Policlinico San Matteo, Pavia, Italy|IRCCS Humanitas Clinical Institute, Rozzano (milano), Italy|National Cancer Center Hospital, Chuo-ku, Japan|Tokai University Hospital, Isehara City, Kanagawa, Japan|Aichi Cancer Center, Nagoya, Japan|VU Academic Medical Center, Amsterdam, Amsterdam, Netherlands|UMC Groningen, Groningen, Netherlands|Leids Universitair Medisch Centrum, Leiden, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|St James University Hospital, Leeds, United Kingdom|UCL Cancer Institute, London, United Kingdom|Christie Hospital NHS Trust, Manchester, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Oxford University Hospitals NHS Trust- Churchill Hospital-Oxford Centre for Respiratory Medicine, Oxford, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Southampton University Hospitals NHS Trust, Southampton, United Kingdom",https://ClinicalTrials.gov/show/NCT02733042
251,"Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Daiichi Sankyo, Inc.",Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery,"Active, not recruiting",Has Results,Liposarcoma,Drug: efatutazone,Other|NIH|Industry,Interventional,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|University of Colorado Hospital, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|MedStar Washington Hospital Center, Washington, District of Columbia, United States|Northside Hospital, Atlanta, Georgia, United States|Northside Hospital-Forsyth, Cumming, Georgia, United States|Hawaii Oncology Inc-Pali Momi, 'Aiea, Hawaii, United States|Pali Momi Medical Center, 'Aiea, Hawaii, United States|The Cancer Center of Hawaii-Pali Momi, 'Aiea, Hawaii, United States|Hawaii Cancer Care Inc-POB II, Honolulu, Hawaii, United States|Hawaii Oncology Inc-POB I, Honolulu, Hawaii, United States|Island Urology, Honolulu, Hawaii, United States|Queen's Medical Center, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Hawaii Cancer Care Inc-Liliha, Honolulu, Hawaii, United States|Hawaii Oncology Inc-Kuakini, Honolulu, Hawaii, United States|Kuakini Medical Center, Honolulu, Hawaii, United States|The Cancer Center of Hawaii-Liliha, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Saint Joseph Medical Center, Bloomington, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|SIH Cancer Institute, Carterville, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Radiation Oncology of Northern Illinois, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|OSF Saint Francis Radiation Oncology at Peoria Cancer Center, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Cancer Care Specialists of Illinois-Swansea, Swansea, Illinois, United States|Memorial and Saint Elizabeth's Health Care Services LLP, Swansea, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|Deaconess Clinic Downtown, Evansville, Indiana, United States|Franciscan Saint Anthony Health-Michigan City, Michigan City, Indiana, United States|Woodland Cancer Care Center, Michigan City, Indiana, United States|Chancellor Center for Oncology, Newburgh, Indiana, United States|Kansas Institute of Medicine Cancer and Blood Center, Lenexa, Kansas, United States|Minimally Invasive Surgery Hospital, Lenexa, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Saint Louis Cancer and Breast Institute-Ballwin, Ballwin, Missouri, United States|Central Care Cancer Center - Bolivar, Bolivar, Missouri, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|Cox Cancer Center Branson, Branson, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States|Centerpoint Medical Center LLC, Independence, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|Mercy Hospital Joplin, Joplin, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, United States|Mercy Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Mercy Hospital Washington, Washington, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Norris Cotton Cancer Center-Manchester, Manchester, New Hampshire, United States|Norris Cotton Cancer Center-Nashua, Nashua, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Columbia University/Herbert Irving Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|Integris Southwest Medical Center, Oklahoma City, Oklahoma, United States|Mercy Hospital Oklahoma City, Oklahoma City, Oklahoma, United States|Integris Cancer Institute of Oklahoma, Oklahoma City, Oklahoma, United States|Greenville Health System Cancer Institute-Easley, Easley, South Carolina, United States|Greenville Health System Cancer Institute-Andrews, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Butternut, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Faris, Greenville, South Carolina, United States|Greenville Memorial Hospital, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Eastside, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Greer, Greer, South Carolina, United States|Greenville Health System Cancer Institute-Seneca, Seneca, South Carolina, United States|Greenville Health System Cancer Institute-Spartanburg, Spartanburg, South Carolina, United States|Norris Cotton Cancer Center-North, Saint Johnsbury, Vermont, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT02249949
252,Celgene,Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma),"Active, not recruiting",Has Results,"Lymphoma, Non-Hodgkin",Drug: Rituximab|Drug: Lenalidomide|Drug: Placebo,Industry,Interventional,"Mitchell Cancer Center, University of South Alabama, Mobile, Alabama, United States|Arizona Center for Cancer Care, Glendale, Arizona, United States|Southwest Cancer Care Medical Group, Escondido, California, United States|Marin Oncology Associates, Greenbrae, California, United States|Wilshire Oncology Medical Group, Inc, La Verne, California, United States|North County Hematology Oncology (NCHO) - TRM, LLC., Oceanside, California, United States|Hematology-Oncology Medical Group of Orange County, Inc., Orange, California, United States|UC Davis Medical Center, Sacramento, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|Wellness Hematology Oncology, West Hills, California, United States|Cancer Center of Central Connecticut, Southington, Connecticut, United States|Florida Cancer Specialists North Region Sarah Cannon Research, Saint Petersburg, Florida, United States|Illinois Cancer Care, P.C., Peoria, Illinois, United States|LRG Healthcare Oncology Clinic, Laconia, Indiana, United States|Iowa Oncology Research Association, Des Moines, Iowa, United States|University of Louisville, J.G. Brown Cancer Center, Louisville, Kentucky, United States|Providence Cancer Institute, Southfield, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Coborn Cancer Center at the St. Cloud Hospital, Saint Cloud, Minnesota, United States|NH Oncology - Hematology, PA, Hooksett, New Hampshire, United States|The Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Hematology-Oncology Associates of Northern NJ, Morristown, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|Weill Cornell Medical College, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Oncology Hematology Care Sarah Cannon Research, Cincinnati, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|St Francis Hospital, Greenville, South Carolina, United States|Spartanburg Regional Healthcare System - Gibbs Cancer Center & Research Institute, Spartanburg, South Carolina, United States|Sarah Cannon Research Inst, Nashville, Tennessee, United States|Arlington Cancer Center, Arlington, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, United States|AZ St-Jan Brugge Oostende AV, Brugge, Belgium|UZ Gent, Gent, Belgium|AZ Groeninge, Kortrijk, Belgium|CHU Mont -Godinne, Yvoir, Belgium|Associacao Hospitalar Moinhos de Vento Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS, Porto Alegre, Rio Grande Do Sul, Brazil|Associacao Educudora Sao Carlos AESC Hospital Giovanni Battista HGB Hospital Mae de Deus Center, Porto Alegre, Rio Grande Do Sul, Brazil|Fundacao Pio XII - Hospital de Cancer de Barretos, Barretos, São Paulo, Brazil|Hospital Dr. Amaral Carvalho/ Hospital Amaral Carvalho Jaú, Jau/SP, São Paulo, Brazil|MS INCA HC I Hospital do Cancer I, Rio De Janeiro, Brazil|Sociedade Beneficente de Senhoras Hospital Sirio Libanes, São Paulo, Brazil|Real e Benemerita Associacao Portuguesa de Beneficencia, São Paulo, Brazil|Fundação Antonio Prudente - AC Camargo Câncer center, São Paulo, Brazil|Beijing Cancer Hospital, Beijing, PR, China|Peking University People's Hospital, Beijing, China|307 Hospital of PLA, Beijing, China|Peking Union Medical College Hospital, Beijing, China|The Third Xiangya hospital of central south university, Changsha, China|West China Hospital of Sichuan University, Chengdu, China|Fujian Medical University Union Hospital, Fuzhou, China|Sun Yat-sen University Cancer Center, Guangzhou, China|Guangdong General Hospital, Guangzhou, China|The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou City, China|Jiangsu Province Hospital The First Hospital affiliated with Nanjing Medical University, Nanjing, China|Cancer Hospital, Fudan University, Shanghai, China|Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China|The First Affiliated Hospital of Soochow University, Suzhou, China|Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, China|Xijing Hospital, Xi'an, China|Interni hematoonkologicka klinika, Brno, Czechia|Fakultni nemocnice Hradec Kralove, IV.interni hematologicka klinika, Hradec Kralove, Czechia|Fakultni Nemocnice Ostrava, Klinika hematoonkologie,, Ostrava, Czechia|Fakultni nemocnice Kralovske Vinohrady, Interni hematologicka klinika, Prague 10, Czechia|Vseobecna Fakultni Nemocnice v Praze, Praha, Czechia|CHU d'Angers, Angers, France|Centre Hospitalier Universitaire d'Avicennes, Bobigny Cedex, France|CHRU de Brest - Hopital Morvan, Brest Cedex, France|Hopital Saint-Louis, Paris, France|CH Perpignan - Hopital Saint-Jean, Perpignan, France|CHU de Poitiers, Poitiers, France|Centre Hospitalier de Valence, Valence, France|Charite - Universitaetsmedizin Berlin Charité - Campus Benjamin Franklin, Berlin, Germany|Charite - Universitaetsmedizin Berlin Campus Virchow Klinikum, Berlin, Germany|Krankenhaus Nordwest, Frankfurt, Germany|Onkologische Schwerpunktpraxis Leer - Emden, Leer, Germany|Kliniken Maria Hilf GmbH, Mönchengladbach, Germany|Klinkum der Stadt Villingen-Schwenningen GmbH, Villingen-Schwenningen, Germany|Soroka University Medical Center, Beer Sheva, Israel|Hadassah University Hospital, Jerusalem, Israel|Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel|Centro di Riferimento Oncologico - IRCCS, Aviano (PN), Italy|U.O.C. Ematologia, Barletta, Italy|A.O.U. di Bologna Policlinico S.Orsola-Malpighi, Bologna, Italy|Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi - Nesima, Catania, Italy|Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori (I.R.S.T.), Meldola, Italy|Istituto Europeo di Oncologia - IEO, Milano, Italy|Ospedale Niguarda Ca Granda, Milano, Italy|IRCCS- Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione ""G. Pascale"", Napoli, Italy|Az. Osp. Vincenzo Cervello, Palermo, Italy|Casa di Cura La Maddalena, Palermo, Italy|Azienda Ospedaliero-Universitaria di Parma, Parma, Italy|Ospedale di Ravenna, Ravenna, Italy|Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy|Ospedale degli Infermi di Rimini, Rimini, Italy|Azienda Ospedaliera S. Andrea - Università La Sapienza, Roma, Italy|National Cancer Center Hospital, Chuo-ku, Japan|Chugoku Central Hospital, Hiroshima, Japan|National Cancer Center Hospital East, Kashiwa, Japan|Kobe City Medical Center General Hospital, Kobe-city, Japan|The Cancer Institute Hospital of Japanese Foundation For Cancer Research, Koto-ku, Japan|University Hospital, Kyoto Prefectural University of Medicine, Kyoto-city, Japan|Toranomon Hospital, Minato-ku, Japan|The Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan|Nagoya Medical Center,Division of Hematology/Oncology, Nagoya, Japan|National University Corporation Tohoku University, Tohoku University Hospital, Sendai-shi, Japan|Malopolskie Centrum Medyczne S.C., Kraków, Poland|Instytut Hematologii i Transfuzjologii w Warszawie, Warszawa, Poland|Centrum Onkologii, Instytut im. Marii Sklodowskiej-Curie, Warszawa, Poland|Instituto Portugues de Oncologia de Lisboa, Francisco Gentil, Lisboa, Portugal|Instituto Portugues de Oncologia do Porto, Francisco Gentil, Porto, Portugal|Hospital Auxilio Muto Centro de Cancer, San Juan, Puerto Rico|Krasnoyarsk Regional Clinical Hospital, Krasnoyarsk, Russian Federation|Russian Academy of Medical Sciences Institution, Moscow, Russian Federation|Moscow State Medical Institution Municipal Clinical Hospital n.a. S.P. Botkin, Moscow, Russian Federation|Federal Centre of Heart, Blood and Endocrinology of Rosmed technlologies V.A. Almazov, St Petersburg, Russian Federation|St. Petersburg Pavlov State Medical University, St.Petersburg, Russian Federation|The Ministry of Health and Social Development of the Tula region state institution Health Tula regio, Tula, Russian Federation|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital Costa del Sol, Marbella, Spain|Hospital Morales Meseguer, Murcia, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|Cukurova University Medical Faculty Balcali Hospital, Adana, Turkey|Hacettepe Universitesi, Ankara, Turkey|Pamukkale University Medical Faculty, Denizli, Turkey|Gaziantep University, Gaziantep, Turkey|Marmara University, Istanbul, Turkey|Dokuz Eylul University Izmir, Izmir, Turkey|19 Mayis Medical Faculty - Samsun, Samsun, Turkey|Kocaeli Derince Training and Research Hospital, Umuttepe Kocaeli, Turkey|Eastbourne District General Hospital, Eastbourne, United Kingdom|Royal Liverpool University Hospital, Prescot Street, Liverpool, United Kingdom|Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, United Kingdom|Southend University Hospital NHS Foundation Trust, Prittlewell Chase, Westcliff on Sea, United Kingdom",https://ClinicalTrials.gov/show/NCT01938001
253,"Verastem, Inc.",A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO),"Active, not recruiting",Has Results,Indolent Non-Hodgkin Lymphoma,Drug: Duvelisib,Industry,Interventional,"Los Angeles, California, United States|Whittier, California, United States|Denver, Colorado, United States|Fort Myers, Florida, United States|Saint Petersburg, Florida, United States|Tallahassee, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Louisville, Kentucky, United States|Baltimore, Maryland, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Saint Louis, Missouri, United States|Morristown, New Jersey, United States|Rockville Centre, New York, United States|Canton, Ohio, United States|Lawton, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Philadelphia, Pennsylvania, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Lynchburg, Virginia, United States|Lesnoy, Minsk Region, Belarus|Brest, Belarus|Minsk, Belarus|Vitebsk, Belarus|Gent, Belgium|Kortrijk, Belgium|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Toronto, Ontario, Canada|Gatineau, Quebec, Canada|Montreal, Quebec, Canada|Brno, Czechia|Ostrava-Poruba, Czechia|Angers Cedex 09, France|Bordeaux, France|Clermont-Ferrand, France|Marseille, France|Pierre Benite, France|Tbilisi, Georgia|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Bologna, Italy|Brescia, Italy|Busto Arsizio, Italy|Genova, Italy|Meldola, Italy|Milano, Italy|Modena, Italy|Orbassano, Italy|Parma, Italy|Ravenna, Italy|Rimini, Italy|Varese, Italy|Barcelona, Spain|Madrid, Spain|Salamanca, Spain|Cardiff, United Kingdom|Chelsea, United Kingdom|Liverpool, United Kingdom|London, United Kingdom|London, United Kingdom|Sutton, United Kingdom",https://ClinicalTrials.gov/show/NCT01882803
254,Bayer,"Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas","Active, not recruiting",Has Results,"Lymphoma, Non-Hodgkin","Drug: Copanlisib (Aliqopa, BAY80-6946)",Industry,Interventional,"Birmingham, Alabama, United States|Gilbert, Arizona, United States|Anaheim, California, United States|Aurora, Colorado, United States|Englewood, Colorado, United States|Fort Collins, Colorado, United States|Port Saint Lucie, Florida, United States|Louisville, Kentucky, United States|Detroit, Michigan, United States|Saint Louis Park, Minnesota, United States|Lake Success, New York, United States|Goldsboro, North Carolina, United States|Canton, Ohio, United States|San Antonio, Texas, United States|Spokane, Washington, United States|Garran, Australian Capital Territory, Australia|Linz, Austria|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Gent, Belgium|Leuven, Belgium|Turnhout, Belgium|Wilrijk, Belgium|Sofia, Bulgaria|Saint John, New Brunswick, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Helsinki, Finland|Oulu, Finland|Tampere, Finland|Turku, Finland|Brest, France|Creteil, France|La Roche Sur Yon, France|Lille, France|PARIS cedex, France|Pessac, France|Pierre Benite, France|Poitiers, France|Rouen, France|Vandoeuvre-les-nancy, France|München, Bayern, Germany|Potsdam, Berlin, Germany|Münster, Nordrhein-Westfalen, Germany|Recklinghausen, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Dresden, Sachsen, Germany|Berlin, Germany|Berlin, Germany|Athens, Greece|Hong Kong, Hong Kong|Shatin, Hong Kong|Budapest, Hungary|Budapest, Hungary|Kaposvar, Hungary|Galway, Ireland|Petah Tikva, Israel|Ramat Gan, Israel|Zerifin, Israel|Napoli, Campania, Italy|Bologna, Emilia-Romagna, Italy|Roma, Lazio, Italy|Brescia, Lombardia, Italy|Milano, Lombardia, Italy|Torino, Piemonte, Italy|Busan, Busan Gwang''yeogsi, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Christchurch, New Zealand|Gdynia, Poland|Krakow, Poland|Lisboa, Portugal|Kemerovo, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Omsk, Russian Federation|Saratov, Russian Federation|St. Petersburg, Russian Federation|Singapore, Singapore|Singapore, Singapore|Majadahonda, Madrid, Spain|Marbella, Málaga, Spain|Barcelona, Spain|Madrid, Spain|Sevilla, Spain|Valencia, Spain|Uddevalla, Sweden|Ankara, Turkey|Istanbul, Turkey|Izmir, Turkey|Izmir, Turkey|Cambridge, Cambridgeshire, United Kingdom|Plymouth, Devon, United Kingdom|Southampton, Hampshire, United Kingdom|Harrow, London, United Kingdom|Liverpool, Merseyside, United Kingdom|Sutton, Surrey, United Kingdom|Birmingham, West Midlands, United Kingdom|Leeds, United Kingdom|Manchester, United Kingdom|Romford, United Kingdom",https://ClinicalTrials.gov/show/NCT01660451
255,Bristol-Myers Squibb|Children's Oncology Group|EsPhALL,Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia,"Active, not recruiting",Has Results,"Leukemia, Pediatric",Drug: Dasatinib,Industry|Other,Interventional,"University Of Alabama At Birmingham, Birmingham, Alabama, United States|Phoenix Children'S Hospital/Ctr. For Cancer & Blood Ctr., Phoenix, Arizona, United States|University Of Arkansas For Medical Sciences, Little Rock, Arkansas, United States|Antranik Agop Bedros, Loma Linda, California, United States|Miller Children's and Women Hospital, Long Beach, California, United States|Children'S Hospital Of L.A., Los Angeles, California, United States|Southern California Permanente Medical Group, Los Angeles, California, United States|Valley Children's Hospital, Madera, California, United States|Children's Hospital of Orange County, Orange, California, United States|Lpch & Sumc, Palo Alto, California, United States|Kaiser Medical Center, Roseville, California, United States|Ucsf - Hematology/Oncology, San Francisco, California, United States|Children'S Hospital Colorado, Aurora, Colorado, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|A. I. Dupont Hospital For Children, Wilmington, Delaware, United States|Children'S National Medical Center, Washington, District of Columbia, United States|Lee Memorial Health System, Fort Myers, Florida, United States|University Of Florida, Gainesville, Florida, United States|Nemours Children'S Clinic, Jacksonville, Florida, United States|Md Anderson Cancer Center Orlando, Orlando, Florida, United States|Nemours Childrens Hospital, Orlando, Florida, United States|All Children'S Hospital, Saint Petersburg, Florida, United States|St. Joseph's Children's Hospital, Tampa, Florida, United States|St. Mary'S, West Palm Beach, Florida, United States|Children's Healthcare Of Atlanta, Atlanta, Georgia, United States|Kapiolani Medical Center For Women & Children, Honolulu, Hawaii, United States|Mountain States Tumor Institute, Boise, Idaho, United States|Ann & Robert H Lurie Children's Hospital Of Chicago, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Southern Illinois University School Of Medicine, Springfield, Illinois, United States|James Whitcomb Riley Hospital For Children, Indianapolis, Indiana, United States|Children'S Center For Cancer And Blood Diseases, Indianapolis, Indiana, United States|University Of Kentucky, Lexington, Kentucky, United States|Norton Children's Hospital, Louisville, Kentucky, United States|Sinai Hospital Of Baltimore, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|Children'S Hospital Of Michigan, Detroit, Michigan, United States|Helen Devos Children'S Hospital, Grand Rapids, Michigan, United States|Michigan State University, Lansing, Michigan, United States|Childrens Hospitals And Clinics Of Minnesota, Minneapolis, Minnesota, United States|Univ Of Mississippi Med Ctr, Jackson, Mississippi, United States|University Of Missouri Health Care, Columbia, Missouri, United States|Children'S Mercy Hospital And Clinics, Kansas City, Missouri, United States|Washington University Medical Center, Saint Louis, Missouri, United States|Children'S Specialty Center Of Nevada, Las Vegas, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Goryeb Children'S Hospital, Morristown, New Jersey, United States|The Cancer Institute Of New Jersey, New Brunswick, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|St. Joseph's Regional Medical Center, Paterson, New Jersey, United States|University Of New Mexico, Albuquerque, New Mexico, United States|New York University, New York, New York, United States|The Herbert Irving Pavilion, New York, New York, United States|New York Presbyterian/Weill Cornell, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|New York Medical College, Valhalla, New York, United States|Levine Children's Hospital, Charlotte, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Cincinnati Children'S Hospital Medical Center, Cincinnati, Ohio, United States|Nationwide Children'S Hospital, Columbus, Ohio, United States|The Children'S Medical Center Of Dayton, Dayton, Ohio, United States|The Toledo Children'S Hospital, Toledo, Ohio, United States|Mercy Children's Hospital, Toledo, Ohio, United States|University Of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Legacy Emanuel Hospital & Health Center, Portland, Oregon, United States|Oregon Health & Sci Univ, Portland, Oregon, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Children'S Hospital Of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital Of Pittsburgh Of UPMC, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|East Tennessee Children'S Hosp, Knoxville, Tennessee, United States|Vanderbilt University, Nashville, Tennessee, United States|Dell Children'S Medical Center Of Central Texas, Austin, Texas, United States|Driscoll Children'S Hospital, Corpus Christi, Texas, United States|Ut Southwestern, Dallas, Texas, United States|Cook Children'S Hem/Onc Center, Fort Worth, Texas, United States|Texas Children'S Cancer Center, Houston, Texas, United States|Scott & White - McLane Children's Specialty Clinic, Temple, Texas, United States|Primary Children's Medical Center, Salt Lake City, Utah, United States|Inova Pediatric Specialty Center Ii, Fairfax, Virginia, United States|Children'S Hosp-Kings Daughter, Norfolk, Virginia, United States|Seattle Children'S, Seattle, Washington, United States|St Vincent Hospital, Green Bay, Wisconsin, United States|Kenneth Desantes, Md, Madison, Wisconsin, United States|Medical College Of Wisconsin, Milwaukee, Wisconsin, United States|Local Institution, Sth Brisbane, Queensland, Australia|Local Institution, Parkville, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Alberta Children'S Hospital, Calgary, Alberta, Canada|Stollery Children'S Hospital, Edmonton, Alberta, Canada|Local Institution, London, Ontario, Canada|Children'S Hospital Of Eastern Ontario, Ottawa, Ontario, Canada|Chu Ste-Justine, Montreal, Quebec, Canada|The Montreal Children's Hospital of the MUHC, Montreal, Quebec, Canada|Local Institution, Saskatoon, Saskatchewan, Canada|Local Institution, Bologna, Italy|Local Institution, Cagliari, Italy|Local Institution, Catania, Italy|Local Institution, Firenze, Italy|Local Institution, Genova, Italy|Local Institution, Monza, Italy|Local Institution, Napoli, Italy|Local Institution, Palermo, Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, Torino, Italy|Local Institution, Trieste, Italy|Local Institution, San Juan, Puerto Rico|Local Institution, Bristol, Avon, United Kingdom|Local Institution, Cardiff, Glamorgan, United Kingdom|Local Institution, Aberdeen, Grampian, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Glasgow, Lanarkshire, United Kingdom|Local Institution, Edinburgh, Lothian, United Kingdom|Local Institution, Liverpool, Merseyside, United Kingdom|Local Institution, Leeds, North Yorkshire, United Kingdom|Local Institution, Nottingham, Nottinghamshire, United Kingdom|Local Institution, Oxford, Oxfordshire, United Kingdom|Local Institution, Sheffield, South Yorkshire, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom|Local Institution, Newcastle-upon-tyne, Tyne and Wear, United Kingdom|Local Institution, Birmingham, WEST Midlands, United Kingdom|Local Institution, Cambridge, United Kingdom",https://ClinicalTrials.gov/show/NCT01460160
256,"Hoffmann-La Roche|German Low Grade Lymphoma Study Group|Institute of Cancer Research, United Kingdom",A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),"Active, not recruiting",Has Results,Non-Hodgkin's Lymphoma,Drug: Obinutuzumab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Bendamustine|Drug: Rituximab,Industry|Other,Interventional,"Highlands Oncology Group, Rogers, Arkansas, United States|The Regents of the University of California; Office of Research, Irvine, California, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Illinois Cancer Care, P.C. - Galesburg, Galesburg, Illinois, United States|Siouxland Hematology/Oncology, Sioux City, Iowa, United States|University of Kansas; Medical Center & Medical pavilion, Westwood, Kansas, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|MT Cancer Inst Fndtn; MT Can Spec, Missoula, Montana, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Northwest Medical Specialties, Tacoma, Washington, United States|Concord Repatriation General Hospital; Haematology, Sydney, New South Wales, Australia|Westmead Hospital; Haematology, Sydney, New South Wales, Australia|Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology, Woolloongabba, Queensland, Australia|St Vincent'S Hospital; Haematology, Fitzroy, Victoria, Australia|Peter MacCallum Cancer Centre; Department of Haematology, Melbourne, Victoria, Australia|Austin and Repatriation Medical Centre; Cancer Services, Melbourne, Victoria, Australia|Monash Medical Centre; Haematology, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|UZ Gent, Gent, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Tom Baker Cancer Centre-Calgary, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Dr. Léon-Richard Oncology Centre, Moncton, New Brunswick, Canada|Ottawa General Hospital, Ottawa, Ontario, Canada|North York General Hospital, Toronto, Ontario, Canada|Humber River Hospital, Toronto, Ontario, Canada|Toronto East General Hospital; Haematology/Oncology, Toronto, Ontario, Canada|Hopital Charles Lemoyne; Centre Integre de Lutte Contre Le Cancer de La Monteregie, Greenfield Park, Quebec, Canada|Peking University First Hospital, Beijing City, China|Cancer Hospital Chinese Academy of Medical Sciences., Beijing, China|Beijing Cancer Hospital, Beijing, China|General Hospital of Chinese PLA; Department of Hematology, Beijing, China|the First Hospital of Jilin University, Changchun, China|Fujian Medical University Union Hospital, Fujian, China|Sun Yet-sen University Cancer Center, Guangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Jiangsu Cancer Hospital, Nanjing, China|Jiangsu Province Hospital, Nanjing, China|Shanghai Jiao Tong University School of Medicine (SJTUSM) - Ruijin Hospital (GuangCi Hospital), Shanghai, China|Fudan University Shanghai Cancer Center, Shanghai, China|Union Hospital of Tongji Medical College, Dept. of Cancer Center; Cancer Center, Wuhan, China|Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika, Brno, Czechia|Fn Hr. Kralove; IV. Interni Hematologicka Klinika, Hradec Kralove, Czechia|Vseobecna Fakultni Nemocnice v Praze, I. Interni Klinika - Klinika Hematoonkologie VFN a 1. LF UK, Praha 2, Czechia|Helsinki University Central Hospital; Dept of Oncology, Helsinki, Finland|Hotel Dieu; Medecine D, Angers, France|Hopital Augustin Morvan; Hematologie, Brest, France|Chu Estaing; Hematologie Clinique Adultes, Clermont Ferrand, France|Clinique Victor Hugo, LeMans, France|Hopital De La Conception; Hematologie Clinique, Marseille, France|Hopital Saint Eloi; Hematologie Oncologie Medicale, Montpellier, France|Hopital Saint Jean; Hematologie, Perpignan, France|Onkologischer Schwerpunkt am Oskar-Helene-Heim; Dres. Herrenberger, Keitel-Wittig u. Kirsch, Berlin, Germany|Klinikum Chemnitz gGmbH Krankenhaus Küchwald Klinik f.Innere Medizin III, Chemnitz, Germany|Städtisches Klinikum Dessau, Dessau-Roßlau, Germany|BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie-Onkologie, Dresden, Germany|Gemeinschaftspraxis Dr. med. J. Mohm und Dr. med. G. Prange-Krex; Fachaerzte fuer Innere Medizin, Dresden, Germany|HELIOS Klinikum Erfurt I.Medizinische Klinik, Erfurt, Germany|St Antonius Hospital; Haematologie/Onkologie, Eschweiler, Germany|Universitätsklinikum Essen; Innere Klinik und Poliklinik für Tumorforschung, Essen, Germany|Klinik Johann Wolfgang von Goethe Uni; Medizinische Klinik II, Frankfurt, Germany|Universitätsklinikum Freiburg; Klinik für Innere Medizin I; Hämatologie/Onkologie, Freiburg, Germany|Universitätsklinikum Greifswald Klinik für Innere Medizin C und Poliklinik, Greifswald, Germany|Uni Göttingen, Georg-August-Universität; Klinik für Hämatologie und Medizinische Onkologie, Göttingen, Germany|Kath. Krankenhaus Hagen gem. GmbH, St.-Josefs-Hospital; Klinik für Hämatologie und Onkologie, Hagen, Germany|Onkologische Schwerpunktpraxis Dres. Bernd Gaede, Hans-Ulrich Ehlers, Ulrike Rodewig u.w., Hannover, Germany|Dres.Andreas Karcher und Stefan Fuxius, Heidelberg, Germany|Uniklinik Heidelberg, Medizinische Klinik & Poliklinik V, Heidelberg, Germany|Universitaetsklinikum des Saarlandes; medizinische Klinik und Poliklinik; Innere Medizin I, Homburg/Saar, Germany|Universitätsklinikum Jena; Klinik für Innere Medizin II, Jena, Germany|UKSH Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie, Kiel, Germany|Institut für Versorgungsforschung in der Onkologie GbR Koblenz, Koblenz, Germany|Klinik der Uni zu Köln; Klinik für Innere Medizin, Köln, Germany|Tagesklinik Landshut; Hämatologie/Onkologie, Landshut, Germany|Caritas Krankenhaus; Haematologie/Intern. Onkologie, Lebach, Germany|Klinikum St.Georg gGmbH Klinik für Internistische Onkologie und Hämotologie, Leipzig, Germany|Klinikum der Stadt Ludwigshafen; Medizinische Klinik A, Ludwigshafen, Germany|Onkologische Gemeinschaftspraxis, Magdeburg, Germany|Otto von Guericke Uni Magdeburg Uniklinik; Hämatologie/Onkologie, Magdeburg, Germany|Uni. der Johannes Gutenberg-Universitaet Mainz; III. Medizinische Klinik und Poliklinik, Mainz, Germany|Mannheimer Onkologie Praxis Dres. Jürgen Brust Dieter Schuster, Mannheim, Germany|Klinikum Mannheim III. Medizinische Klinik, Mannheim, Germany|Kliniken Ostalb, Stauferklinikum Schwäbisch-Gmünd; Zentrum für Innere Medizin, Mutlangen, Germany|St. Frankziskus Krankenhaus, Med. Klinik I; Klinik für Hämatologie,Onkologie u. Gastroenterologie, Mönchengladbach, Germany|Klinikum der Universität München, Campus Großhadern; Medizinische Klinik und Poliklinik III, München, Germany|Klinikum rechts der Isar der TU München; III. Medizinischen Klinik (Hämatologie/Onkologie), München, Germany|Gemeinschaftspraxis Dr. med. Holger Klaproth / Dr. med. Anca Astrid Cura, Neunkirchen/Saar, Germany|Pius-Hospital; Klinik fuer Haematologie und Onkologie, Oldenburg, Germany|Brüderkrankenhaus St. Josef, Paderborn, Germany|Prosper-Hospital, Medizinische Klinik I, Recklinghausen, Germany|Krankenhaus Barmherziger Brüder; Klinik für Internistische Onkologie / Hämatologie, Regensburg, Germany|Praxis für Hämatologie & Onkologie, Saarbruecken, Germany|Krankenhaus der Barmherzigen Brüder Trier; Innere Medizin I, Hämatologie / Internistische Onkologie, Trier, Germany|Universität Tübingen; Med. Klinik; Innere Medizin I, Tübingen, Germany|Universtitätsklinikum Ulm; Klinik für Innere Medizin III, Ulm, Germany|Helios Dr. Horst Schmidt Kliniken; Klinik Innere MED III: Hämatologie, Onkologie, Palliativmedizin, Wiesbaden, Germany|Hämatologisch-Onkologische Schwerpunktpraxis; Dres. Schlag & Schöttker, Würzburg, Germany|Semmelweis University, First Dept of Medicine, Budapest, Hungary|National Institute of Oncology, A Dept of Internal Medicine, Budapest, Hungary|University of Debrecen Medical and Health Science Center, Institute of Internal Medicine, Hematology, Debrecen, Hungary|Petz Aladar Megyei Korhaz; Hematologia, Gyor, Hungary|University of Szeged, II Dept of Internal Medicine, Szeged, Hungary|Rambam Medical Center; Heamatology & Bone Marrow Transplantation, Haifa, Israel|Beilinson Medical Center; Haematology, Petach Tikva, Israel|Chaim Sheba Medical Center; Hematology BMT & CBB, Ramat-Gan, Israel|Azienda Ospedaliera Universitaria di Modena, Modena, Emilia-Romagna, Italy|Az. Osp. S. Camillo Forlanini; Uo Ematologia E Trapianti Di Midollo Osseo, Roma, Lazio, Italy|ASST PAPA GIOVANNI XXIII; Ematologia, Bergamo, Lombardia, Italy|Ospedale Maggiore Di Milano; U.O. Ematologia I - Padiglione Marcora, Milano, Lombardia, Italy|Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia, Milano, Lombardia, Italy|Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia, Rozzano, Lombardia, Italy|A.O. Univ.Ospedali Riuniti Umerto I -G.M.Lancisi G.Salesi; U.O. Clinica Di Ematologia, Torrette DI Ancona, Marche, Italy|Ospedale V. Cervello; U.O. Ematologia E Trapianti, Palermo, Sicilia, Italy|Uni Degli Studi; Dip.Med.Clinica E Sperim. Ematologia, Padova, Veneto, Italy|Aichi Cancer Center Hospital; Hematology and Cell Therapy, Aichi, Japan|Nagoya Daini Red Cross Hospital; Hematology & Oncology, Aichi, Japan|Nagoya City University Hospital; Hematology and Oncology, Aichi, Japan|Aomori Prefectural Central Hospital; Hematology, Aomori, Japan|Chiba Cancer Center;Hematology and Oncology, Chiba, Japan|National Cancer Center Hospital East;Hematology, Chiba, Japan|Shikoku Cancer Center; Hematology and Oncology, Ehime, Japan|National Hospital Organization Kyushu Cancer Center; Hematology, Fukuoka, Japan|Gunma University Hospital;Hematology, Gunma, Japan|Hiroshima University Hospital; Hematology, Hiroshima, Japan|Kobe City Medical Center General Hospital; Hematology, Hyogo, Japan|Hyogo Cancer Center; Department of hematology, Hyogo, Japan|Tokai University Hospital; Hematology, Kanagawa, Japan|Kumamoto University Hospital; Hematology Rheumatology and Clinical Immunology, Kumamoto, Japan|University Hospital, Kyoto Prefectural University of Medicine; Hematology, Kyoto, Japan|Tohoku University Hospital; Hematology and Immunology, Miyagi, Japan|Shinshu University Hospital; Hematology, Nagano, Japan|Niigata Cancer Center Hospital; Internal Medicine, Niigata, Japan|Matsushita Memorial Hospital; hematology, Osaka, Japan|Jichi Medical University Hospital; Hematology, Tochigi, Japan|National Cancer Center Hospital; Hematology, Tokyo, Japan|Toranomon Hospital; Hematology, Tokyo, Japan|The Cancer Institute Hospital of JFCR; Hematology Oncology, Tokyo, Japan|The Jikei University Daisan Hospital; Department of Clinical Oncology and Hematology, Tokyo, Japan|FSBI Russian Oncology Research Center n.a. Blokhin of MOH RF, Moscow, Russian Federation|Regional Clinical Hospital N.A. Semashko; Hematology, Nizhny Novgorod, Russian Federation|Republican Clinical Hospital n.a. Baranov; Haematology, Petrozavodsk, Russian Federation|Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia, Badalona, Barcelona, Spain|Corporacio Sanitaria Parc Tauli; Servicio de Hematologia, Sabadell, Barcelona, Spain|Fundacion Hospital de Alcorcon; Servicio de Hematologia, Alcorcon, Madrid, Spain|Hospital de Basurto; Servicio de Hematologia, Bilbao, Vizcaya, Spain|Hospital Univ. 12 de Octubre; Servicio de Hematologia, Madrid, Spain|Hospital Universitario la Paz; Servicio de Hematologia, Madrid, Spain|Sahlgrenska Universitetssjukhuset; Sektionen för hematologi och koagulation, Göteborg, Sweden|Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology, Taipei City, Taiwan|National Taiwan Universtiy Hospital; Division of Hematology, Taipei, Taiwan|Chang Gung Medical Foundation - Linkou; Division of Hematology- Oncology, Taoyuan, Taiwan|Aberdeen Royal Infirmary; Haematology - Ward 16, Aberdeen, United Kingdom|Queen Elizabeth Hospital; Centre for Clinical Haematology, Birmingham, United Kingdom|Royal Bournemouth General Hospital; Haematology, Bournemouth, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, United Kingdom|Addenbrookes Hospital; Haematology, Cambridge, United Kingdom|Kent & Canterbury Hospital; Clinical Haematology, Canterbury, United Kingdom|Velindre NHS Trust; Haematology Department, Cardiff, United Kingdom|Castle Hill Hospital; The Queens Centre for Oncology and Haematology, Cottingham, United Kingdom|Western General Hospital; Department of Haematology, Edinburgh, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|James Paget Hospital; Haematology Department, Great Yarmouth, United Kingdom|Princess Alexandra Hospital; Department of Haematology, Harlow, United Kingdom|St James Uni Hospital; Icrf Cancer Medicine Research Unit, Leeds, United Kingdom|Leicester Royal Infirmary; Dept of Haematology, Leicester, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|King'S College Hospital; Haematology, London, United Kingdom|St. George'S Hospital; Haematology, London, United Kingdom|Hammersmith Hospital; Haematology, London, United Kingdom|University College Hospital; Macmillan Cancer Centre, London, United Kingdom|Christie Hospital; Breast Cancer Research Office, Manchester, United Kingdom|Norfolk & Norwich Hospital; Dept of Haematology, Norwich, United Kingdom|Nottingham City Hospital; Dept of Haematology, Nottingham, United Kingdom|Churchill Hospital; Oxford Cancer and Haematology Centre, Oxford, United Kingdom|Queen Alexandra Hospital; Haematology and Oncology Centre, Portsmouth, United Kingdom|Southampton General Hospital; Medical Oncology, Southampton, United Kingdom|Royal Marsden Hospital; Dept of Medical Oncology, Sutton, United Kingdom|Singleton Hospital; Pharmacy, Swansea, United Kingdom|Great Western;Department of Haematology, Swindon, United Kingdom|Royal Cornwall Hospital; Haematology Clinic, Truro, United Kingdom",https://ClinicalTrials.gov/show/NCT01332968
257,"Seagen Inc.|Millennium Pharmaceuticals, Inc.",ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,"Active, not recruiting",Has Results,Anaplastic Large-Cell Lymphoma|Non-Hodgkin Lymphoma|T-Cell Lymphoma,Drug: brentuximab vedotin|Drug: doxorubicin|Drug: prednisone|Drug: vincristine|Drug: cyclophosphamide,Industry,Interventional,"Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|City of Hope National Medical Center, Duarte, California, United States|Stanford Cancer Center, Stanford, California, United States|Shands Cancer Center / University of Florida, Gainesville, Florida, United States|Orlando Health, Inc., Orlando, Florida, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Cardinal Bernardin Cancer Center / Loyola University Medical Center, Maywood, Illinois, United States|Holden Comprehensive Cancer Center / University of Iowa, Iowa City, Iowa, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center - Basking Ridge, Basking Ridge, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Albert Einstein Cancer Center, Bronx, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Memorial Sloan Kettering Cancer Center - Commack, Commack, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|James P. Wilmot Cancer Center / University of Rochester Medical Center, Rochester, New York, United States|Jewish Hospital, The, Cincinnati, Ohio, United States|Cleveland Clinic, The, Cleveland, Ohio, United States|Mercy Clinic Oncology, Oklahoma City, Oklahoma, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Charles A. Sammons Cancer Center / Baylor University Medical Center, Dallas, Texas, United States|MD Anderson Cancer Center / University of Texas, Houston, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Virginia Commonwealth University Medical Center, Richmond, Virginia, United States|Benaroya Research Institute/Virginia Mason Medical Center, Seattle, Washington, United States|Seattle Cancer Care Alliance / University of Washington, Seattle, Washington, United States|Royal Adelaide Hospital, Adelaide, Australia|Moorabbin Hospital, Bentleigh East, Australia|Icon Cancer Care Chermside, Chermside, Australia|Icon Cancer Care South Brisbane, Chermside, Australia|Icon Cancer Care Southport, Chermside, Australia|Icon Cancer Care Wesley, Chermside, Australia|Monash Medical Centre, Clayton, Australia|Concord Repatriation General Hospital, Concord, Australia|St. Vincent's Hospital Sydney, Darlinghurst, Australia|St Vincent's Public Hospital Sydney - Fitzroy, Fitzroy, Australia|Western Hospital, Footscray, Australia|Austin Health, Heidelberg, Australia|Calvary Mater Newcastle, Waratah, Australia|McGill University Department of Oncology / McGill University Health Centre, Montreal, Canada|Jewish General Hospital, Montreal, Canada|Sunnybrook Health Sciences Centre, Toronto, Canada|British Columbia Cancer Agency - Vancouver Centre, Vancouver, Canada|Fakultni nemocnice Brno, Brno, Czechia|Fakultni nemocnice Hradec Kralove-oddeleni klinicke hematologie, Hradec Kralove, Czechia|Fakultni Nemocnice Ostrava, Ostrava - Poruba, Czechia|Fakultni Nemocnice Kralovske Vinohrady, Praha 10, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|Aarhus University Hospital, Aarhus C., Denmark|Rigs Hospiltalet, Copenhagen, Denmark|Odense University Hospital, Odense C, Denmark|Hôpital Henri Mondor, Créteil, France|CHD Vendée, Site de La Roche-sur-Yon, Les Oudairies, La Roche-sur-Yon Cedex 9, France|Centre Hospitalier Universitaire de Grenoble, La Tronche, France|Clinique Victor Hugo, Le Mans, France|CHRU de Lille, Lille cedex, France|Centre Hospitalier Universitaire (CHU) De Limoges - Hopital Dupuytren, Limoges Cedex, France|Centre Hospitalier Universitaire Nantes-Hotel Dieu, Nantes cedex 1, France|Hopital Saint-Louis / Service d'Hematologie, Paris Cedex 10, France|Groupe Hospitalier Pitié-Salpétrière, Paris, France|Groupe Hospitalier du Haut Leveque, Pessac, France|Centre Hospitalier Lyon Sud, Pierre Bénite Cedex, France|Centre Hospitalier Universitaire de Poitiers, Poitiers Cedex, France|Centre Hospitalier Universitaire de Rennes, Hopital Pontchaillou, Rennes Cedex 9, France|Centre Henri Becquerel / Centre Regional de Lutte Contre le Cancer, Rouen, France|Charite Universitatsmedizin Berlin, Berlin, Germany|Charite Campus Benjamin Franklin, Berlin, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Universitatsklinikum Essen, Essen, Germany|Krankenhaus Nordwest GmbH, Frankfurt am Main, Germany|Georg-August-Universität Göttingen, Göttingen, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum des Saarlandes, Homburg/Saar, Germany|Klinik für Innere Medizin II, Friedrich-Schiller-Universität, Jena, Germany|Universitatsklinikum Koln, Köln, Germany|Klinikum der Ludwig-Maximilians-Universität München, München, Germany|Klinikum Nürnberg, Nürnberg, Germany|Universitätsklinikum Ulm, Ulm, Germany|Semmelweis Egyetem, Budapest, Hungary|Debreceni Egyetem, Debrecen, Hungary|Somogy Megyei Kaposi Mór Oktató Kórház, Kaposvár, Hungary|Markusovszky Egyetemi Oktatokorhaz, Szombathely, Hungary|Soroka Medical Center, Dept. of Oncology, Beer Sheva, Israel|Rambam Health Corp., Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Rabin Medical Center, Petach Tikva, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Azienda Ospedaliera SS. Antonio E. Biagio E. Cesare Arrigo di Alessandria, Alessandria, Italy|Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy|Instituto di Ematologia ed Oncologia Medica, Bologna, Italy|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy|Azienda Ospedaliera-Universitaria Vittorio Emanuele-Ferrarotto-Santo Bambino, Catania, Italy|Azienda Ospedaliera Universitaria San Martino, Genova, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy|Ospedale Niguarda Ca' Granda, Milano, Italy|IRCSS Policlinico San Matteo, Pavia, Italy|Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, Italy|Università degli Studi di Roma ""La Sapienza, Policlinico Umberto I, Roma, Italy|Istituto Clinico Humanitas-Humanitas Cancer Center, Rozzano, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy|Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul Saint Mary's Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im. Ks. B. Markiewicza, Brzozow, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespól Szpitali Miejskich, Chorzów, Poland|Malopolskie Centrum Medyczne S.C., Krakow, Poland|Centrum Onkologii Institut im. Marii Sklodowskiej-Curie, Warsaw, Poland|Institutul Clinic Fundeni, Centrul de Hematologie si Transplant Medular Stefan Berceanu, Bucharest, Romania|Spitalul Clinic Coltea, Bucuresti, Romania|Institutul Oncologic ""Prof. Dr. I. Chiricuta"" Cluj-Napoca, Cluj-Napoca, Romania|Spitalul Clinic Judetean de Urgenta Targu Mures, Sectia Clinica Hematologie si Transplant Medular, Targu Mures, Romania|Hospital de la Santa Creu i Sant Paul, Barcelona, Spain|Institut Universitari Dexeus, Barcelona, Spain|Institut Català D'oncologia, L'Hospitalet de Llobregat, Spain|Hospital de León, León, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Puerta de Hierro Majadahonda, Majadahonda, Spain|Hospital Universitaro de Salamanca, Salamanca, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Chang Gung Memorial Hospital - Kaohsiung, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng-Kung University Hospital, Tainan, Taiwan|Chang Gung Memorial Hospital - Taoyuan, Taoyuan, Taiwan|Addenbrooke's Hospital, Cambridge, United Kingdom|University Hospitals of Leicester NHS Trust, Leicester, United Kingdom|Saint George's Hospital NHS Trust, London, United Kingdom|Christie Hospital NHS Foundation Trust, Manchester, United Kingdom|Freeman Hospital, Newcastle upon Tyne, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom",https://ClinicalTrials.gov/show/NCT01777152
258,Hoffmann-La Roche|AbbVie,A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL),"Active, not recruiting",Has Results,Chronic Lymphocytic Leukemia,Drug: Bendamustine|Drug: Venetoclax|Drug: Rituximab,Industry,Interventional,"University of California San Diego Medical Center, La Jolla, California, United States|Henry Ford Health System, Detroit, Michigan, United States|Memorial Sloan Kettering Cancer Center; Clinical Trials Office, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Huntsman Cancer Institute; University of Utah, Salt Lake City, Utah, United States|The Canberra Hospital, Garran, Australian Capital Territory, Australia|Concord Repatriation General Hospital, Concord, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Frankston Hospital, Frankston, Victoria, Australia|Peter MacCallum Cancer Center, Melbourne, Victoria, Australia|Monash Medical Centre; Haematology, Melbourne, Victoria, Australia|Slade Health Pharmacy, Mount Waverley, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|The Perth Blood Institute, Nedlands, Western Australia, Australia|Medizinische Universität Innsbruck, Innsbruck, Austria|LKH - Universitätsklinikum der PMU Salzburg, Salzburg, Austria|Medizinische Universität Wien, Wien, Austria|Wiener Gesundheitsverbund - Klinik Ottakring, Wien, Austria|ZNA Antwerpen; Department Hematology, Antwerpen, Belgium|Cliniques Universitaires Saint-Luc; Hematology, Bruxelles, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Leuven; Department Hematology, Leuven, Belgium|CHU UCL Mont-Godinne, Mont-godinne, Belgium|AZ Delta; Department Hematology, Roeselare, Belgium|Foothills Medical Centre; Centre Dept of Medical Clinical Neuroscience, Calgary, Alberta, Canada|Juravinski Cancer Clinic, Hamilton, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Saskatoon City Hospital;Saskatchewan Cancer Centre, Saskatoon, Saskatchewan, Canada|Fakultni nemocnice Brno, Brno, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Fakultní nemocnice Olomouc, Olomouc, Czechia|Fakultni nemocnice Ostrava, Ostrava - Poruba, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha, Czechia|Herlev Hospital, Herlev, Denmark|Rigshospitalet, København Ø, Denmark|Odense Universitetshospital, Odense C, Denmark|Sjællands Universitetshospital, Roskilde, Roskilde, Denmark|Sygehus Lillebælt, Vejle, Vejle, Denmark|Hôpital Morvan, Brest, France|Centre Hospitalier Départemental Les Oudairies, La Roche sur Yon, France|Hopital Claude Huriez - CHU Lille, Lille, France|Hopital Saint Eloi, Montpellier, France|CHU Nantes - Hôtel Dieu; Service Assistance Medicale à la Procreation, Nantes, France|Hopital Robert Debre, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|CHU Poitiers - Hopital La Miletrie, Poitiers, France|CHU de Rennes - Hopital de Pontchaillo, Rennes, France|Centre Henri Becquerel, Rouen, France|Institut Claudius Régaud, Toulouse, France|CHU Tours - Hôpital Bretonneau, Tours, France|Hôpital de Brabois Adultes, Vandoeuvre-les-nancy, France|Universitätsklinikum ""Carl Gustav Carus"" der Technischen Universität Dresden, Dresden, Germany|Universitaetsklinikum Freiburg, Freiburg, Germany|Universitätsklinikum Tübingen, Tuebingen, Germany|Semmelweis Egyetem, Budapest, Hungary|Orszagos Onkologiai Intezet, Budapest, Hungary|Debreceni Egyetem Klinikai Központ; Bőrgyógyászati Klinika, Debrecen, Hungary|Somogy Megyei Kaposi Mor Oktato Korhaz, Pecs, Hungary|Szegedi Tud.Egyetem Szent-Gyorgyi Albert Klin.Kozp., Szeged, Hungary|Azienda Ospedaliera Città della Salute e della Scienza di Torino; Radiology, Torino, Abruzzo, Italy|Azienda Ospedaliero Universitaria San Martino, Genova, Liguria, Italy|Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII), Bergamo, Lombardia, Italy|Ospedale San Raffaele, Milano, Lombardia, Italy|Asst Grande Ospedale Metropolitano Niguarda; SC Farmacia Ospedale, Milano, Lombardia, Italy|Azienda Ospedaliero Universitaria Ospedali Riuniti, Torrette Di Ancona, Marche, Italy|Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari, Bari, Puglia, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Toscana, Italy|Azienda Ospedaliera Di Padova, Padova, Veneto, Italy|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Amsterdam UMC, Locatie VUMC; Neurology, Amsterdam, Netherlands|Amsterdam UMC Location AMC, Amsterdam, Netherlands|Albert Schweitzer Ziekenhuis, Dordwijk; Internal Medicine, Hemato-Oncology, Dordrecht, Netherlands|Medisch Spectrum Twente, Enschede, Netherlands|Leids Universitair Medisch Centrum; Cardiology, Leiden, Netherlands|Erasmus Medisch Centrum Rotterdam; Lokatie Daniel den Hoed, Rotterdam, Netherlands|UMC Utrecht, Utrecht, Netherlands|North Shore Hospital; Haematolgy, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Baxter Healthcare, Aukland, New Zealand|Christchurch Hospital NZ, Christchurch, New Zealand|SP ZOZ Zespol Szpitali Miejskich w Chorzowie, Chorzow, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi, Lodz, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1, Lublin, Poland|Szpital Wojewodzki w Opolu, Opole, Poland|MTZ Clinical Research Sp. z o.o., Warszawa, Poland|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|FSBSI ""Russian Oncological Scientific Center n.a. N.N. Blokhin"", Moscow, Russian Federation|BHI of Omsk region Clinical Oncology Dispensary, Omsk, Russian Federation|SRI of Hematology and Transfusiology, St. Petersburg, Russian Federation|North-West Federal Medical Research Center n.a. V.A. Almazov, St. Petersburg, Russian Federation|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona; Hematology, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Clinico Universitario de Salamanca, Salamanca, Spain|Skånes Universitetssjukhus, Lund, Sweden|Akademiska Sjukhuset, Uppsala, Sweden|National Taiwan University Hospital, Taipei, Taiwan|Bristol Haematology and Oncology Centre, Bristol, United Kingdom|The Christie, Manchester, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|Singleton Hospital; Pharmacy Department, Swansea, United Kingdom",https://ClinicalTrials.gov/show/NCT02005471
259,Eisai Inc.,A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease,"Active, not recruiting",Has Results,Non Clear Cell Renal Cell Carcinoma (nccRCC),Drug: lenvatinib|Drug: everolimus,Industry,Interventional,"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|Weill Cornell Medical College, New York, New York, United States|Texas Oncology, Dallas, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States",https://ClinicalTrials.gov/show/NCT02915783
260,Hoffmann-La Roche,A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma,"Active, not recruiting",Has Results,Advanced BRAFV600 Wild-type Melanoma,Drug: Cobimetinib|Drug: Atezolizumab|Drug: Pembrolizumab,Industry,Interventional,"University of Arizona Cancer Center, Tucson, Arizona, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|USC Norris Cancer Center, Los Angeles, California, United States|USC Norris Cancer Center; USC Oncology Hematology Newport Beach, Newport Beach, California, United States|University of California at Irvine Medical Center; Department of Oncology, Orange, California, United States|Stanford Comprehensive Cancer Center, Stanford, California, United States|UF Health Cancer Center at Orlando Health, Orlando, Florida, United States|Florida Cancer Specialist, North Region, Saint Petersburg, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|Northwestern University, Chicago, Illinois, United States|Massachusetts General Hospital;Hematology/ Oncology, Boston, Massachusetts, United States|University of Michigan; Michigan Institute for Clinical and Health Research (MICHR), Ann Arbor, Michigan, United States|Dartmouth-Hitchcock Medical Center; Hematology/Oncology, Lebanon, New Hampshire, United States|Morristown Medical Center, Morristown, New Jersey, United States|Forsythe Memorial Hospital Inc., dba Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States|TriHealth Hatton Institute; Surgical Education, Cincinnati, Ohio, United States|St. Luke's University Health network, Bethlehem, Pennsylvania, United States|Thomas Jefferson University Hospital;Medical Oncology, Philadelphia, Pennsylvania, United States|SCRI Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|M.D Anderson Cancer Center; Uni of Texas At Houston, Houston, Texas, United States|West Virginia University Hospitals Inc, Morgantown, West Virginia, United States|Cairns Base Hospital, Cairns, Queensland, Australia|Townsville General Hospital, Douglas, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Cliniques Universitaires St-Luc, Bruxelles, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Instituto Nacional de Cancer - INCa; Oncologia, Rio de Janeiro, RJ, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Hopital Avicenne; Dermatologie, Bobigny, France|Hopital Saint Andre CHU De Bordeaux; Dermatologie, Bordeaux, France|Chu Site Du Bocage;Dermatologie, Dijon, France|CHU de Grenoble - Hôpital Nord, Grenoble, France|Centre Hospitalier Le Mans; Dermatologie, Le Mans, France|Hopital Claude Huriez; Sce Dermatologie, Lille, France|Hopital Timone Adultes; Dermatologie, Marseille, France|CHU de Nantes; Cancéro-dermatologie, Nantes, France|Hopital l Archet 2; Ginestriere, Service de; Dermatologie, Nice cedex 3, France|Groupe Hospitalier Bichat Claude Bernard, Paris, France|Hopital Saint Louis; Dermatologie 1, Paris, France|Hopital Robert Debre; DERMATOLOGIE, Reims, France|Centre Eugene Marquis; Service d'oncologie, Rennes, France|Hopital Charles Nicolle; Dermatologie Serv., Rouen, France|Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O), Toulouse, France|Institut Gustave Roussy; Dermatologie, Villejuif, France|Universitätsklinikum ""Carl Gustav Carus""; Klinik und Poliklinik für Dermatologie, Dresden, Germany|HELIOS Klinikum Erfurt; Klinik für Dermatologie & Allergologie, Erfurt, Germany|Universitatsklinikum Essen; Klinik für Dermatologie, Essen, Germany|Klinik Johann Wolfgang von Goethe Uni; Klinik für Dermatologie, Venerologie und Allergologie, Frankfurt, Germany|SRH Wald-Klinikum Gera; Klinik für Hautkrankheiten und Allergologie, Gera, Germany|Medizinische Hochschule Hannover; Klinik für Dermatologie, Allergologie und Venerologie, Hannover, Germany|UKSH Kiel; Klinik für Dermatologie, Venerologie und Allergologie, Kiel, Germany|Klinik und Poliklinik fur Dermatologie; Universitatsklinikum Mainz, Mainz, Germany|Klinikum Mannheim Klinik fuer Dermatologie, Venerologie und Allergologie, Mannheim, Germany|Johannes Wesling Klinikum Minden, Minden, Germany|Klinikum der Ludwigs-Maximilians-Universität München; Dermatologie, München, Germany|Fachklinik Hornheide; Dermatologie, Münster, Germany|Zentrum für Dermatoonkologie, Universitäts-Hautklinik Tübingen, Tübingen, Germany|Anticancer Hospital Ag. Savas ; 2Nd Dept. of Oncology - Internal Medicine, Athens, Greece|Laiko General Hospital Athen, Athens, Greece|Metropolitan Hospital; Dept. of Oncology, Pireaus, Greece|Bioclinic Thessaloniki, Thessaloniki, Greece|Orszagos Onkologiai Intezet; Borgyogyaszati Osztaly, Budapest, Hungary|Pecsi Tudomanyegyetem AOK; Borgyogyaszati Klinika, Pecs, Hungary|University of Szeged Szent-Györgyi Albert Clinical Center; Department of Dermatology and Allergology, Szeged, Hungary|Azienda Osp Uni Seconda Università Degli Studi Di Napoli; Unità Operativa Oncologia Medica, Napoli, Campania, Italy|IRCCS Istituto Nazionale Tumori Fondazione Pascale; Oncologia Medica B, Napoli, Campania, Italy|A.O. Universitaria Policlinico Di Modena; Ematologia, Modena, Emilia-Romagna, Italy|IFO - Istituto Regina Elena; Oncologia Medica, Roma, Lazio, Italy|IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A, Genova, Liguria, Italy|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, Milano, Lombardia, Italy|Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica, Milano, Lombardia, Italy|Fondazione Del Piemonte Per L'oncologia Ircc Di Candiolo; Dipartimento Oncologico, Candiolo, Piemonte, Italy|A.O.U. Cons. Policlinico Bari - Consorzlale Policlinico; Scienze Biomediche e Oncologia Umana, Bari, Puglia, Italy|Azienda Ospedaliero - Universitaria Pisana U.O. Oncologia Medica 2 Universitaria - Polo Oncologico, Pisa, Toscana, Italy|IOV - Istituto Oncologico Veneto IRCCS, Padova, Veneto, Italy|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Antoni Van Leeuwenhoek Ziekenhuis; Inwendige Geneeskunde, Amsterdam, Netherlands|Amphia Ziekenhuis, locatie Langendijk;Oncology, Breda, Netherlands|Erasmus Mc - Daniel Den Hoed Kliniek; Interne Oncologie, Rotterdam, Netherlands|Zuyderland ziekenhuis locatie Geleen, Sittard-Geleen, Netherlands|Copernicus Podmiot Medyczny Sp. z o.o. Wojewodzkie Centrum Onkologii, Gdansk, Poland|COZL Oddzial Onkologii Klinicznej z pododdzialem Chemioterapii Dziennej, Lublin, Poland|Szpital Kliniczny im. Heliodora Święcickiego UM w Poznaniu., Poznań, Poland|Zachodniopomorskie Centrum Onkologii, Osrodek Innowacyjnosci, Rozwoju i Badan Klinicznych, Szczecin, Poland|Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy, Warszawa, Poland|Dolnoslaskie Centrum Onkologii, Wrocław, Poland|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, Russian Federation|FSBSI ""Russian Oncological Scientific Center n.a. N.N. Blokhin"", Moscow, Russian Federation|FBI ""Scientific Research Institute of Oncology n. a. N. N. Petrov"", Saint-Petersburg, Russian Federation|St. Petersburg Oncology Hospital, St Petersburg, Russian Federation|Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Badalona, Barcelona, Spain|Hospital Universitario Son Espases; Servicio de Oncologia, Palma De Mallorca, Islas Baleares, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coruña, Spain|Hospital Universitario Materno Infantil de Gran Canaria; Servicio de Oncologia, Las Palmas de Gran Canaria, LAS Palmas, Spain|Clinica Universitaria de Navarra; Servicio de oncología, Pamplona, Navarra, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Clínic i Provincial; Servicio de Oncología, Barcelona, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Virgen Macarena; Servicio de Oncologia, Sevilla, Spain|Instituto Valenciano Oncologia; Oncologia Medica, Valencia, Spain|Hospital General Universitario de Valencia; Servicio de oncologia, Valencia, Spain|Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza, Spain|BRISTOL ONCOLOGY CENTRE; CLINICAL TRIALS UNIT; R & D department, Bristol, United Kingdom|Western General Hospital; Edinburgh Cancer Center, Edinburgh, United Kingdom|Leicester Royal Infirmary; Dept. of Medical Oncology, Leicester, United Kingdom|University College London Hospital, London, United Kingdom|Guys & St Thomas Hospital; Department of Oncology, London, United Kingdom|University Hospitals of North Midlands NHS Trust-Royal Stoke University Hospital, Stoke-On-Trent, United Kingdom|Singleton Hospital; Pharmacy, Swansea, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom",https://ClinicalTrials.gov/show/NCT03273153
261,"Astellas Pharma Global Development, Inc.|Astellas Pharma Inc",A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma,"Active, not recruiting",Has Results,Metastatic Renal Cell Carcinoma,Drug: AGS-16C3F|Drug: Axitinib,Industry,Interventional,"Site US01026, Tucson, Arizona, United States|Site US01008, La Jolla, California, United States|Site US01007, Los Angeles, California, United States|Site US01020, Los Angeles, California, United States|Site US01019, Palo Alto, California, United States|Site US01010, Atlanta, Georgia, United States|Site US01023, Baltimore, Maryland, United States|Site US01002, Boston, Massachusetts, United States|Site US01004, Ann Arbor, Michigan, United States|Site US01013, Detroit, Michigan, United States|Site US01012, Omaha, Nebraska, United States|Site US01006, Buffalo, New York, United States|Site US01022, Durham, North Carolina, United States|Site US01017, Portland, Oregon, United States|Site US01021, Pittsburgh, Pennsylvania, United States|Site US01011, Charleston, South Carolina, United States|Site US01003, Houston, Texas, United States|Site US01014, Temple, Texas, United States|Site US01001, Seattle, Washington, United States|Site US01009, Milwaukee, Wisconsin, United States|Site CA02006, Calgary, Alberta, Canada|Site CA02004, Edmonton, Alberta, Canada|Site CA02005, Kelowna, British Columbia, Canada|Site CA02001, Vancouver, British Columbia, Canada|Site CA02002, Hamilton, Ontario, Canada|Site CA02008, London, Ontario, Canada",https://ClinicalTrials.gov/show/NCT02639182
262,"AVEO Pharmaceuticals, Inc.",A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC,"Active, not recruiting",Has Results,"Carcinoma, Renal Cell",Drug: tivozanib hydrochloride|Drug: Sorafenib,Industry,Interventional,"University Of UA Cancer Center(UACC)/DH-SJHMC, Phoenix, Arizona, United States|Arizona Oncology Associates, PC - HAL, Phoenix, Arizona, United States|Arizona Oncology - Phoenix - Deer Valley Women's Center Loca, Phoenix, Arizona, United States|Arizona Oncology - Scottsdale, Scottsdale, Arizona, United States|City of Hope Comprehensive Breast Cancer Center, Duarte, California, United States|Long Beach Memorial Medical Center, Fountain Valley, California, United States|Marin Cancer Care, Greenbrae, California, United States|UCLA, Los Angeles, California, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Loyola University Medical Center, Maywood, Illinois, United States|Investigative Clinical Research of Indiana, Indianapolis, Indiana, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Midwest Cancer Center, Omaha, Nebraska, United States|Urology Cancer Center, PC, Omaha, Nebraska, United States|Comprehensive Cancer Center Of Nevada, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Comprehensive Cancer Center Of Nevada, Las Vegas, Nevada, United States|Comprehensive Cancer Center of Nevada, Las Vegas, Nevada, United States|Hackensack University Medical Center - John Theurer Cancer, Hackensack, New Jersey, United States|New York Oncology Hematology, P.C., Albany, New York, United States|New York Oncology Hematology, PC, Albany, New York, United States|Montefiore Medical Center, Bronx, New York, United States|New York Oncology Hematology, P.C., Clifton Park, New York, United States|New York Presbyterian Hospital, New York, New York, United States|Columbia University Medical Center - Herbert Irving Pavilion, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Wake Forest University Baptist Medical Center (WFUBMC), Winston-Salem, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio Cancer Specialists, Mansfield, Ohio, United States|North Coast Cancer Care, Inc, Sandusky, Ohio, United States|Wooster Specialty and Surgery Center, Wooster, Ohio, United States|St. Luke University Health Network, Easton, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States|Texas Oncology - Austin Midtown, Austin, Texas, United States|Texas Oncology-Central Austin Cancer Center, Austin, Texas, United States|Texas Oncology - South Austin Cancer Center, Austin, Texas, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology - Fort Worth 12th Ave, Fort Worth, Texas, United States|Texas Oncology SW Fort Worth Cancer Center, Fort Worth, Texas, United States|Arizona Oncology Associates, PC - HAL, Fort Worth, Texas, United States|Comprehensive Cancer Centers of Nevada (CCCN), Fort Worth, Texas, United States|Comprehensive Cancer Centers of Nevada, Fort Worth, Texas, United States|Nebraska Cancer Specialists (NCS) - Midwest Cancer Center, Fort Worth, Texas, United States|Texas Oncology - El Paso Cancer Treatment Center, Fort Worth, Texas, United States|Texas Oncology-El Paso Cancer Treatment Center, Fort Worth, Texas, United States|Texas Oncology-Garland, Garland, Texas, United States|Baylor College of Medicine - Baylor Clinic, Houston, Texas, United States|Texas Oncology - Longview Cancer Center, Longview, Texas, United States|Texas Oncology, P.A., Plano, Texas, United States|Texas Oncology - Tyler, Tyler, Texas, United States|UZ Antwerpen, Edegem, Antwerpen, Belgium|Institut Jules Bordet, Bruxelles, Brussels Capital Region, Belgium|Grand Hôpital de Charleroi - Site Notre-Dame, Charleroi, Hainaut, Belgium|CHU Ambroise Paré, Mons, Hainaut, Belgium|Jessa Ziekenhuis - Campus Virga Jesse, Hasselt, Limburg, Belgium|CHU Dinant Godinne UCL Namur, Yvoir, Namur, Belgium|UZ Gent, Gent, Oost-Vlaanderen, Belgium|AZ Sint-Jan Brugge - Oostende - Campus Sint-Jan, Brugge, West-Vlaanderen, Belgium|British Columbia Cancer Agency (BCCA), Vancouver, British Columbia, Canada|Dr. Leon Richard Oncology Centre, Moncton, New Brunswick, Canada|London Health Sciences Center, London, Ontario, Canada|Sunnybrook, Toronto, Ontario, Canada|Masarykuv onkologicky ustav, Brno, Brno-město, Czechia|FN Hradec Kralove, Hradec Kralove, Královéhradecký Kraj, Czechia|Fakultni nemocnice Olomouc, Olomouc, Olomoucký Kraj, Czechia|Fakultni nemocnice u sv. Anny v Brne, Brno, Czechia|Fakultni nemocnice v Motole, Praha 5, Czechia|Herlev Hospital, Herlev, Capital, Denmark|Aarhus Universitetshospital, Aarhus C, Central Jutland, Denmark|Odense Universitetshospital, Odense, South Denmark, Denmark|Hopital Saint-André, Bordeaux Cedex, Gironde, France|CHRU de Tours - Hopital Bretonneau TOURS, Tours CEDEX 1, Indre-et-Loire, France|Institut de Cancerologie de la Loire, Saint-Priest-en-Jarez, Loire, France|Institut de Cancérologie de l'Ouest Site Paul Papin, Angers, Maine-et-Loire, France|Institut de cancérologie de Lorraine, Vandoeuvre Les Nancy, Meurthe-et-Moselle, France|centre Oscar Lambret, Lille, Nord-Pas-de-Calais, France|Clinique Victor Hugo, Le Mans, Pays-de-la-Loire, France|Institut Paoli-Calmettes, Marseille Cedex 09, France|Chu De Poitiers, Poitiers, France|ICO, Saint Herblain CEDEX, France|Institut Gustave Roussy, Villejuif, France|Universitätsklinikum Freiburg, Freiburg, Baden-Württemberg, Germany|Univesitaetsklinik Heidelberg, Heidelberg, Baden-Württemberg, Germany|Kliniken Nordoberpfalz AG, Klinikum Weiden, Weiden, Bayern, Germany|Johann Wolfgang Goethe Universität, Frankfurt am Main, Hessen, Germany|Evangelisches Krankenhaus Bielefeld, Bielefeld, Nordrhein-Westfalen, Germany|SZB Study Center University Hospital Bonn, Bonn, Nordrhein-Westfalen, Germany|Uniklinik Köln Klinik und Poliklinik für Urologie, Köln, Nordrhein-Westfalen, Germany|Universitätsklinikum des Saarlandes, Homburg, Saarland, Germany|Universitätsklinikum Carl Gustav Carus, Dresden, Sachsen, Germany|Jena University Hospital, Jena, Thüringen, Germany|Universitätsklinikum Aachen, Aachen, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Universität Tübingen, Tübingen, Germany|Pécsi Tudományegyetem Klinikai Központ, Pécs, Baranya, Hungary|Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház, Miskolc, Borsod-Abaúj-Zemplén, Hungary|Békés Megyei Pándy Kálmán Kórház, Gyula, Békés, Hungary|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpo, Szeged, Csongrád, Hungary|Debreceni Egyetem Klinikai Központ, Debrecen, Hajdú-Bihar, Hungary|Szent Margit Kórház, Budapest, Hungary|Magyar Honvédség Egészségügyi Központ, Budapest, Hungary|Semmelweis Egyetem, Budapest, Hungary|Semmelweis Egyetem, Budapest, Hungary|Országos Onkológiai Intézet, Budapest, Hungary|Egyesített Szent István és Szent László Kórház-Rendelőintéze, Budapest, Hungary|Somogy Megyei Kaposi Mór Oktató Kórház, Kaposvár, Hungary|Markusovszky Egyetemi Oktatókórház, Szombathely, Hungary|Zala Megyei Korhaz, Zalaegerszeg, Hungary|Casa Sollievo della Sofferenza, IRCCS, San Giovanni Rotondo, Foggia, Italy|Irccs Irst, Meldola, Forli, Italy|Istituto Clinico Humanitas Rozzano, IRCCS, Rozzano, Milano, Italy|Usl 7 Siena - Ospedale Alta Valdelsa ASL TOSCANA SUD-EST, Poggibonsi, Siena, Italy|Istituto di Candiolo, IRCCS, Candiolo, Torino, Italy|Ospedale S.Donato, AUSL 8 di Arezzo, Arezzo, Italy|Centro di Riferimento Oncologico IRCCS, Aviano, Italy|AO Spedali Civili di Brescia, PO Spedali Civili, Brescia, Italy|P.O. Ss. Annunziata, Chieti, Italy|ASST-Istituti Ospitalieri di Cremona, AO di Cremona, Cremona, Italy|AOU Careggi, Firenze, Italy|IRCCS AOU San Martino-IST Istituto Nazionale per la Ricerca, Genova, Italy|Ospedale Vito Fazzi, ASL Lecce, Lecce, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|Ieo, Irccs, Milano, Italy|AOU Policlinico di Modena, Modena, Italy|IRCCS Fondazione ""Giovanni Pascale"", Napoli, Italy|Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy|IRCCS Policlinico San Matteo, Pavia, Italy|PU Campus Bio-medico di Roma, Roma, Italy|Regina Elena, Istituto Nazionale dei Tumori, IFO, IRCCS, Roma, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Italy|Azienda Ospedaliera S. Maria di Terni, Terni, Italy|Europejskie Centrum Zdrowia Otwock, Szpital im. F. Chopina, Otwock, Mazowieckie, Poland|Centrum Onkologii - Instytut im. Marii Sklodowskiej - Curie, Warszawa, Mazowieckie, Poland|MAGODENT Sp. z o.o. Szpital Onkologiczno-Kardiologiczny, Warszawa, Mazowieckie, Poland|Szpital Specjalist w Brzozowie Podkarpacki Ośrodek Onkologiczny, Brzozow, Poland|COPERNICUS Podmiot Leczn. Sp z o.o.,Wojew. Centrum Onkologii, Gdansk, Poland|NZOZ Vesalius Sp. z o.o., Krakow, Poland|Uniwersytecki Szpital Kliniczny im. J. Mikulicza-Radeckiego, Wroclaw, Poland|H.G.U. de Elche, Elche, Alicante, Spain|H.U.Son Espases, Palma, Baleares, Spain|Institut Català d'Oncologia-Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Institut Catalá d´Oncología (I.C.O.), L'Hospitalet De Llobregat, Barcelona, Spain|C.S. Parc Taulí, Sabadell, Barcelona, Spain|H.U.F. Alcorcón, Alcorcón, Madrid, Spain|H.U.P Hierro-Majadahonda, Majadahonda, Madrid, Spain|C.H. de Navarra, Pamplona, Navarra, Spain|H.del Mar, Barcelona, Spain|H.Sta.Creu i St.Pau, Barcelona, Spain|H.U.Vall d'Hebrón, Barcelona, Spain|H. Clinic de Barcelona, Barcelona, Spain|H.U. Reina Sofía, Córdoba, Spain|ICO-H.U.Dr.J.Trueta, Girona, Spain|C.H. de Jaén, Jaén, Spain|H.G.U. G. Marañón, Madrid, Spain|H.U. Infanta Leonor, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|H.C. S.Carlos, Madrid, Spain|H.U. F. Jiménez Díaz, Madrid, Spain|H.U. 12 de Octubre, Madrid, Spain|H.U. La Paz, Madrid, Spain|H. Madrid Norte Sanchinarro, Madrid, Spain|H.U. Virgen de la Victoria, Málaga, Spain|H.U.V. Macarena, Sevilla, Spain|F.I. Valenciano de Oncología, Valencia, Spain|H.U.P.La Fe, Valencia, Spain|H.U. Miguel Servet, Zaragoza, Spain|Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom|Beatson West Of Scotland Cancer Centre, Glasgow, Glasgow City, United Kingdom|Cheltenham General Hospital, Cheltenham, Gloucestershire, United Kingdom|Southampton University Hospitals Nhs Trust, Southampton, Hampshire, United Kingdom|East Lancashire Hospitals NHS Trust, Blackburn, Lancashire, United Kingdom|Lancashire Teaching Hospitals NHS Foundation Trust, Preston, Lancashire, United Kingdom|Royal Stroke Center, Stoke-on-Trent, Staffordshire, United Kingdom|The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom|St James's University Hospital / Leeds Teaching Hospitals, Leeds, United Kingdom|The Royal Marsden NHS Foundation Trust, London, United Kingdom|Charing Cross Hospital, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Mount Vernon Cancer Care, Middlesex, United Kingdom|Nottingham University Hospitals NHS Trust - City Hospital, Nottingham, United Kingdom|Churchill Hospital [Oncology], Oxford, United Kingdom|Singleton Hospital, Swansea, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom",https://ClinicalTrials.gov/show/NCT02627963
263,Hoffmann-La Roche,A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC),"Active, not recruiting",Has Results,Renal Cell Carcinoma,"Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Drug: Bevacizumab|Drug: Sunitinib",Industry,Interventional,"University of Arizona Cancer Center, Tucson, Arizona, United States|University of California at Irvine Medical Center; Department of Oncology, Orange, California, United States|University of California, San Francisco, California, United States|University of Colorado; Anschutz Cancer Pavilion, Aurora, Colorado, United States|Rocky Mountain Cancer Center; Medical Oncology, Denver, Colorado, United States|Georgetown U; Lombardi Comp Can, Washington, District of Columbia, United States|Lynn Cancer Institute/Boca Raton Regional Hospital, Boca Raton, Florida, United States|Florida Cancer Specialists - Port Charlotte, Port Charlotte, Florida, United States|Florida Cancer Specialist, North Region, Saint Petersburg, Florida, United States|Piedmont Cancer Institute, PC, Atlanta, Georgia, United States|The University of Chicago, Chicago, Illinois, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Inst., Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Comprehensive Cancer Centers of Nevada - Eastern Avenue, Las Vegas, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|New York Oncology Hematology,P.C.-Albany, Albany, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Oncology Hematology Care Inc, Cincinnati, Ohio, United States|Cleveland Clinic Foundation; Taussig Cancer Center, Cleveland, Ohio, United States|Northwest Cancer Specialists, P.C., Tigard, Oregon, United States|SCRI Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States|Sarah Cannon Cancer Center and Research Institute, Nashville, Tennessee, United States|Vanderbilt Univ Medical Ctr, Nashville, Tennessee, United States|Texas Oncology-Baylor Sammons Cancer Center, Dallas, Texas, United States|Oncology and Hematology Associates of SW Virginia-Raonoke, Roanoke, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Lifehouse, Camperdown, New South Wales, Australia|Macquarie University Hospital, Sydney, New South Wales, Australia|Calvary Mater Newcastle; Medical Oncology, Waratah, New South Wales, Australia|Icon Cancer Foundation, South Brisbane, Queensland, Australia|Ashford Cancer Center Research, Kurralta Park, South Australia, Australia|Austin Hospital; Medical Oncology, Heidelberg, Victoria, Australia|St John of God Hospital, Murdoch, Western Australia, Australia|University Clinical Centre of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina|Hospital de Caridade de Ijui; Oncologia, Ijui, RS, Brazil|Santa Casa de Misericordia de Porto Alegre, Porto Alegre, RS, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, Brazil|Queen Elizabeth II Health Sciences Centre; Oncology, Halifax, Nova Scotia, Canada|Royal Victoria Hospital, Barrie, Ontario, Canada|Hamilton Health Sciences - Juravinski Cancer Centre, Hamilton, Ontario, Canada|London Regional Cancer Centre, London, Ontario, Canada|Lakeridge Health Oshawa; Oncology, Oshawa, Ontario, Canada|The Ottawa Hospital Cancer Centre; Oncology, Ottawa, Ontario, Canada|Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada|Princess Margaret Cancer Center, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|CHU de Quebec Hotel-Dieu de Quebec, Quebec City, Quebec, Canada|Masarykuv onkologicky ustav, Brno, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|Fakultni Poliklinika Vseobecne Fakultni Niemocnice; Onkologicka Klinika, Praha 2, Czechia|Thomayerova nemocnice, Praha 4 - Krc, Czechia|Aarhus Universitetshospital; Kræftafdelingen, Aarhus N, Denmark|Herlev Hospital; Afdeling for Kræftbehandling, Herlev, Denmark|Odense Universitetshospital, Onkologisk Afdeling R, Odense C, Denmark|ICO Paul Papin; Oncologie Medicale., Angers, France|Hopital Saint Andre; Oncologie 2, Bordeaux, France|Centre Francois Baclesse; Urologie Gynecologie, Caen, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Institut Paoli Calmettes; Oncologie Medicale, Marseille, France|Centre D'Oncologie de Gentilly; Oncology, Nancy, France|APHP - Hospital Saint Louis, Paris, France|Hopital Europeen Georges Pompidou; Service D'Oncologie Medicale, Paris, France|ICO - Site René Gauducheau, Saint Herblain, France|Institut Gustave Roussy; Departement Oncologie Medicale, Villejuif, France|Universitätsklinikum ""Carl Gustav Carus""; Klinik und Poliklinik für Urologie, Dresden, Germany|Universitätsklinikum Essen; Innere Klinik und Poliklinik für Tumorforschung, Essen, Germany|Nationales Centrum für Tumorerkrankungen Heidelberg (NCT); Thoraxklinik Heidelberg, Heidelberg, Germany|Klinikum d.Universität München Campus Großhadern, München, Germany|Universitätsklinikum Tübingen; Klinik für Urologie, Tübingen, Germany|Az. Osp. Cardarelli; Divisione Di Oncologia, Napoli, Campania, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|A.O. Universitaria Policlinico Di Modena; Oncologia, Modena, Emilia-Romagna, Italy|Azienda Ospedaliera San Camillo Forlanini; Oncologia Medica, Roma, Lazio, Italy|Irccs Ospedale San Raffaele;Oncologia Medica, Milano, Lombardia, Italy|Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia, Milano, Lombardia, Italy|Fondazione IRCCS Policlinico San Matteo, Oncologia, Pavia, Lombardia, Italy|Azienda USL8 Arezzo-Presidio Ospedaliero 1 San Donato;U.O.C. Oncologia, Arezzo, Toscana, Italy|Nagoya University Hospital; Urology, Aichi, Japan|Chiba Cancer Center, Chiba, Japan|Kyushu University Hospital, Fukuoka, Japan|Gunma University Hospital, Gunma, Japan|Hokkaido University Hospital, Hokkaido, Japan|University of Tsukuba Hospital; Urology, Ibaraki, Japan|Iwate Medical University Hospital, Iwate, Japan|Yokohama City University Hospital, Kanagawa, Japan|Kitasato University Hospital, Kanagawa, Japan|Kumamoto University Hospital, Kumamoto, Japan|Niigata University Medical & Dental Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|Osaka International Cancer Institute; Urology, Osaka, Japan|Osaka City University Hospital, Osaka, Japan|Osaka University Hospital, Osaka, Japan|Kindai University Hospital, Osaka, Japan|Tokushima University Hospital, Tokushima, Japan|Toranomon Hospital, Tokyo, Japan|Tokyo Medical And Dental University, Medical Hospital, Tokyo, Japan|Nippon Medical School Hospital, Tokyo, Japan|The Cancer Institute Hospital, JFCR; Urology, Tokyo, Japan|Keio University Hospital, Tokyo, Japan|Tokyo Women's Medical University, Tokyo, Japan|Chungnam National University Hospital, Daejeon, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Cancerología, Queretaro, Mexico|Centro Oncologico Estatal ISSEMYM, Toluca, Mexico|Centrum Onkologii Ziemi Lubelskiej im. św. Jana z Dukli, Lublin, Poland|Szpital Kliniczny; Przemienienia Panskiego;Uniwersytetu Medyczny im.; Karola Marcinkowskiego w Pozna, Poznan, Poland|Saint Elizabeth's Hospital, Warsaw, Poland|MAGODENT Sp. z o.o., Warsaw, Poland|ALTAI REGIONAL ONCOLOGICAL CENTER; ""Nadezhda"" Clinic, Barnaul, Altaj, Russian Federation|GBUZ Nizhegorodskay Region: Clinical Diagnostic Center, Nizhni Novgorod, Niznij Novgorod, Russian Federation|P.A. Herzen Oncological Inst. ; Oncology, Moscow, Russian Federation|Moscow city oncology hospital #62 of Moscow Healthcare Department, Moscow, Russian Federation|National University Hospital, Singapore, Singapore|National Cancer Centre; Medical Oncology, Singapore, Singapore|Corporacio Sanitaria Parc Tauli; Servicio de Oncologia, Sabadell, Barcelona, Spain|Hospital Universitario Reina Sofia; Servicio de Oncologia, Córdoba, Cordoba, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Clínic i Provincial; Servicio de Oncología, Barcelona, Spain|Hospital Duran i Reynals; Oncologia, Barcelona, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Taichung Veterans General Hospital; Division of Urology, Taichung, Taiwan|National Taiwan Uni Hospital; Dept of Oncology, Taipei, Taiwan|Chang Gung Medical Foundation-Linkou, Urinary Oncology, Taoyuan, Taiwan|Chulalongkorn Hospital; Medical Oncology, Bangkok, Thailand|Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc, Bangkok, Thailand|Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, Thailand|Maharaj Nakorn Chiangmai Hospital; Department of Surgery/ Urology unit, Chiangmai, Thailand|Songklanagarind Hospital; Department of Oncology, Songkhla, Thailand|Hacettepe University Medical Faculty, Ankara, Turkey|Trakya University Medical Faculty Research And Practice Hospital Medical Oncology Department, Edirne, Turkey|Istanbul Uni Cerrahpasa Medical Faculty Hospital; Medical Oncology, Istanbul, Turkey|Clatterbridge Cancer Centre, Bebington, United Kingdom|Queen Elizabeth Hospital, Birmingham, United Kingdom|Royal Blackburn Hospital, Blackburn, United Kingdom|Addenbrookes Nhs Trust; Oncology Clinical Trials Unit, Cambridge, United Kingdom|Barts Health NHS Trust - St Bartholomew's Hospital, London, United Kingdom|Royal Free Hospital; Dept of Oncology, London, United Kingdom|Christie Hospital Nhs Trust; Medical Oncology, Manchester, United Kingdom|Churchill Hospital; Oxford Cancer and Haematology Centre, Oxford, United Kingdom|Southampton General Hospital; Medical Oncology, Southampton, United Kingdom|Royal Marsden Hospital; Dept of Medical Oncology, Sutton, United Kingdom|Singleton Hospital; Pharmacy Department, Swansea, United Kingdom",https://ClinicalTrials.gov/show/NCT02420821
264,Bristol-Myers Squibb,"A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma","Active, not recruiting",Has Results,Melanoma,Biological: Nivolumab 3 mg/kg IV|Biological: Ipilimumab 1 mg/kg IV|Biological: Nivolumab 1 mg/kg IV|Biological: Ipilimumab 3 mg/kg IV|Biological: Nivolumab 6 mg/kg IV,Industry,Interventional,"University Of Colorado Cancer Center, Aurora, Colorado, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Allina Health, Fridley, Minnesota, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|University Of Virginia Health System, Charlottesville, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Waratah, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Melbourne, Victoria, Australia|Cross Cancer Institute, Edmonton, Alberta, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Local Institution, Aarhus N, Denmark|Local Institution, Herlev, Denmark|Local Institution, Odense, Denmark|Hopital Saint Andre, Bordeaux, France|Chru De Lille, Lille, France|Hopital De La Timone, Marseille Cedex 5, France|Hopital Hotel Dieu, Nantes Cedex, France|Hopital Saint Louis, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|Institut Claudius Regaud, Toulouse Cedex 9, France|Institut Gustave Roussy, Villejuif, France|Universitaetsklinikum Essen, Essen, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|Ludwig-Maximilians-Universitaet, Muenchen, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Local Institution, Ramat Gan, Israel|ASST Papa Giovanni XXIII, Bergamo, Italy|Istituto Nazionale Tumori, Milano, Italy|Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy|Istituto Oncologico Veneto IOV, Padova, Italy|Azienda Ospedaleira Universitaria Senese S. Maria Alle Scott, Siena, Italy|Ospedale San Vincenzo, Taormina, Italy|Netherland Cancer Institute, Amsterdam, Netherlands|Local Institution, Amsterdam, Netherlands|University Medical Center Groningen (Umcg), Groningen, Netherlands|Uniwersyteckie Centrum Kliniczne Klinika Onkologii I Radiote, Gdansk, Poland|Klinika Nowotworow Ukladowych i Uogolnionych, Krakow, Poland|Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow, Warszawa, Poland|Local Institution, Moscow, Russian Federation|Local Institution, Badalona-barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, San Sabastian Gipuzkoa, Spain|Local Institution, Valencia, Spain|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Oxford, Oxfordshire, United Kingdom|Local Institution, Guildford, Surrey, United Kingdom|Local Institution, London, United Kingdom",https://ClinicalTrials.gov/show/NCT02714218
265,"EMD Serono Research & Development Institute, Inc.|EMD Serono",Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200),"Active, not recruiting",Has Results,"Carcinoma, Merkel Cell",Drug: Avelumab,Industry,Interventional,"UCLA Medical Center, Los Angeles, California, United States|The Angeles Clinic and Research Institute - West LA, Los Angeles, California, United States|University of Colorado, Aurora, Colorado, United States|H. Lee Moffitt Cancer Center and Research Institute, Inc, Tampa, Florida, United States|National Cancer Institute, Bethesda, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Mount Sinai, New York, New York, United States|Peggy & Charles Stephenson Oklahoma Cancer Center, Oklahoma City, Oklahoma, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Washington - Seattle Cancer Care Alliance, Seattle, Washington, United States|Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|Tasman Oncology Research Ltd, Southport, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia|St John of God Subiaco Hospital, Perth, Western Australia, Australia|CHU Nice - Hopital de l Archet 2, Nice cedex 3, Alpes Maritimes, France|Hôpital de la Timone, Marseille cedex 05, Bouches-du-Rhône, France|CHU Besançon - Hôpital Jean Minjoz, Besançon Cedex, Doubs, France|Hôpital Ambroise Paré - Boulogne-Billancourt, Boulogne Billancourt, Hauts De Seine, France|CHU Nantes - Hôtel Dieu, Nantes Cedex 1, Loire Atlantique, France|Hopital Claude Huriez - CHU Lille, Lille cedex, Nord, France|Hôpital Saint-Louis, Paris Cedex 10, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite cedex, Rhone, France|Institut Gustave Roussy, Villejuif cedex, Val De Marne, France|Groupe Hospitalier Saint André - Hôpital Saint André, Bordeaux, France|CHU Tours - Hôpital Trousseau, Chambray Les Tours, France|CHU de Dijon - Hopital du Bocage, Dijon, France|CHU de Grenoble - Hôpital A Michallon, Grenoble, France|CHU de Limoges - Hôpital Dupuytren, Limoges, France|Universitaetsklinikum Heidelberg, Heidelberg, Baden Wuerttemberg, Germany|Klinikum der Johann Wolfgang Goethe-Universitaet, Frankfurt, Hessen, Germany|St. Josef-Hospital Universitaetsklinikum, Bochum, Nordrhein Westfalen, Germany|Universitaetsklinikum Essen, Essen, Nordrhein Westfalen, Germany|Universitaetsklinikum Koeln, Koeln, Nordrhein Westfalen, Germany|Fachklinik Hornheide, Muenster, Nordrhein Westfalen, Germany|Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden, Sachsen, Germany|Universitaetsklinikum Schleswig-Holstein - Klinik fuer Allgemeine Innere Medizin, Kiel, Schleswig Holstein, Germany|Universitaetsklinikum Schleswig Holstein - Campus Luebeck, Luebeck, Schleswig Holstein, Germany|Helios Klinikum Erfurt, Erfurt, Thueringen, Germany|Charite Universitaetsmedizin Berlin - Campus Charite Mitte, Berlin, Germany|Fondazione del Piemonte per l'Oncologia IRCC Candiolo, Candiolo, Torino, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|IEO Istituto Europeo di Oncologia, Milano, Italy|Istituto Nazionale Tumori Fondazione G.Pascale, Napoli, Italy|IOV - Istituto Oncologico Veneto IRCCS, Padova, Italy|Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia, Perugia, Italy|Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Italy|Istituto Nazionale Tumori Regina Elena IRCCS, Roma, Italy|A.O.U. Senese Policlinico Santa Maria alle Scotte, Siena, Italy|Shizuoka Cancer Center, Shizuoka, Shizuoka-Ken, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo-To, Japan|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital General Universitario de Valencia, Valencia, Spain",https://ClinicalTrials.gov/show/NCT02155647
266,Amgen,Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma,"Active, not recruiting",Has Results,"Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma",Drug: Talimogene Laherparepvec|Procedure: Immediate surgical resection of melanoma lesion(s),Industry,Interventional,"Research Site, Birmingham, Alabama, United States|Research Site, Duarte, California, United States|Research Site, Orange, California, United States|Research Site, San Francisco, California, United States|Research Site, Santa Monica, California, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Louisville, Kentucky, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Omaha, Nebraska, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Columbus, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Memphis, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, North Sydney, New South Wales, Australia|Research Site, Woodville South, South Australia, Australia|Research Site, Heidelberg, Victoria, Australia|Research Site, Florianopolis, Santa Catarina, Brazil|Research Site, Barretos, São Paulo, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Dijon, France|Research Site, Marseille cedex 05, France|Research Site, Paris, France|Research Site, Pierre Benite Cedex, France|Research Site, Toulouse cedex 9, France|Research Site, Athens, Greece|Research Site, Heraklion - Crete, Greece|Research Site, Poznan, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Moscow, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Malaga, Andalucía, Spain|Research Site, Pamplona, Navarra, Spain|Research Site, Madrid, Spain|Research Site, Chur, Switzerland|Research Site, Zürich, Switzerland",https://ClinicalTrials.gov/show/NCT02211131
267,Bristol-Myers Squibb,"Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma","Active, not recruiting",Has Results,Unresectable Melanoma|Metastatic Melanoma,Drug: Nivolumab|Drug: Ipilimumab|Drug: Placebo,Industry,Interventional,"San Francisco Oncology Associates, San Francisco, California, United States|Orlando Health Inc, Orlando, Florida, United States|University Of Louisville Medical Center, Inc., Dba, Louisville, Kentucky, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Comprehensive Cancer Centers Of Nevada, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|University Of New Mexico Cancer Center, Albuquerque, New Mexico, United States|NYU Clinical Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|The Christ Hospital, Cincinnati, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|St. Luke's Hospital, Easton, Pennsylvania, United States|GHS Cancer Institute, Greenville, South Carolina, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University Of Wisconsin Paul P Carbone Comprehensive Ca Ctr, Madison, Wisconsin, United States|Local Institution, Toulouse, France|Institut Gustave Roussy, Villejuif, France",https://ClinicalTrials.gov/show/NCT01927419
268,Bristol-Myers Squibb,Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067),"Active, not recruiting",Has Results,Unresectable or Metastatic Melanoma,Biological: Nivolumab|Biological: Ipilimumab|Biological: Placebo for Nivolumab|Biological: Placebo for Ipilimumab,Industry,Interventional,"Banner-MD Anderson Cancer Center, Gilbert, Arizona, United States|University Of Arizona Cancer Center, Tucson, Arizona, United States|UC San Diego Moores Cancer Ctr, La Jolla, California, United States|The Angeles Clinic And Research Institute., Los Angeles, California, United States|University Of California - Los Angeles, Los Angeles, California, United States|Comprehensive Cancer Center At Desert Regional Medical Ctr, Palm Springs, California, United States|Desert Hematology Oncology Medical Group, Rancho Mirage, California, United States|California Pacific Medical Center Research Institute, San Francisco, California, United States|Ucsf Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|University Of Colorado Cancer Center, Aurora, Colorado, United States|Yale University Cancer Center, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Medstar Washington Hospital Center, Washington, District of Columbia, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Maine Center For Cancer Medicine, Scarborough, Maine, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Lutherville, Maryland, United States|Beth Israel Deaconness Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University Of Michigan Health System, Ann Arbor, Michigan, United States|Allina Health, Minneapolis, Minnesota, United States|University Of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Comprehensive Cancer Centers Of Nevada, Las Vegas, Nevada, United States|Atlantic Melanoma Center, Morristown, New Jersey, United States|University Of New Mexico Cancer Center, Albuquerque, New Mexico, United States|New York Oncology Hematology, Pc, Clifton Park, New York, United States|NYU Clinical Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke Cancer Institute, Durham, North Carolina, United States|University Hospitals, Cleveland, Ohio, United States|Providence Cancer Center Oncology and Hematology Care- Eastside, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|St. Luke's Cancer Center - Anderson Campus, Easton, Pennsylvania, United States|Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Greenville Health System, Greenville, South Carolina, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Texas Oncology, Dallas, Texas, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University of Washington, Seattle, Washington, United States|Local Institution, Camperdown, New South Wales, Australia|Local Institution, Coffs Harbour, New South Wales, Australia|Local Institution, Gateshead, New South Wales, Australia|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Kurralta Park, South Australia, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Melbourne, Australia|Local Institution, Salzburg, Austria|Local Institution, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Edegem, Belgium|Local Institution, Gent, Belgium|Local Institution, Leuven, Belgium|Cross Cancer Institute, Edmonton, Alberta, Canada|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|London Regional Cancer Program, London, Ontario, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CHUM, Montreal, Canada|CHU de Quebec, Quebec, Canada|Local Institution, Brno, Czechia|Local Institution, Hradec Kralove, Czechia|Local Institution, Praha 2, Czechia|Local Institution, Praha 8, Czechia|Aarhus University Hospital, Aarhus, Denmark|Herlev University Hospital, Herlev, Denmark|Odense University Hospital, Odense, Denmark|Local Institution, Helsinki, Finland|Local Institution, Tampere, Finland|Local Institution, Boulogne Billancourt, France|Local Institution, Marseille Cedex 5, France|Local Institution, Nantes Cedex, France|Local Institution, Paris Cedex 10, France|Local Institution, Pierre Benite, France|Local Institution, Rennes, France|Local Institution, Villejuif, France|Local Institution, Buxtehude, Germany|Local Institution, Erfurt, Germany|Local Institution, Erlangen, Germany|Local Institution, Essen, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Local Institution, Kiel, Germany|Local Institution, Leipzig, Germany|Local Institution, Munchen, Germany|Local Institution, Tuebingen, Germany|Local Institution, Cork, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Jerusalem, Israel|Local Institution, Tel Hashomer, Israel|Local Institution, Bergamo, Italy|Local Institution, Genova, Italy|Local Institution, Meldola (FC), Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Roma, Italy|Local Institution, Siena, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Leiden, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Auckland, New Zealand|Local Institution, Oslo, Norway|Local Institution, Bydgoszcz, Poland|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Lodz, Poland|Local Institution, Warsaw, Poland|Local Institution, Badalona-Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Pamplona, Spain|Local Institution, Gothenberg, Sweden|Local Institution, Stockholm, Sweden|Local Institution, Geneva, Switzerland|Local Institution, Lausanne, Switzerland|Local Institution, St. Gallen, Switzerland|Local Institution, Zurich, Switzerland|Local Institution, Cambridge, Cambridgeshire, United Kingdom|Local Institution, Swansea, Carmarthenshire, United Kingdom|Local Institution, Glasgow, Dumfries & Galloway, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Northwood, Middlesex, United Kingdom|Local Institution, Nottingham, Nottinghamshire, United Kingdom",https://ClinicalTrials.gov/show/NCT01844505
269,Hoffmann-La Roche|AbbVie|German CLL Study Group,A Study to Compare the Efficacy and Safety of Obinutuzumab + Venetoclax (GDC-0199) Versus Obinutuzumab + Chlorambucil in Participants With Chronic Lymphocytic Leukemia,"Active, not recruiting",Has Results,"Lymphocytic Leukemia, Chronic",Drug: Chlorambucil|Drug: Venetoclax|Drug: Obinutuzumab,Industry|Other,Interventional,"Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|City of Hope, Duarte, California, United States|San Diego Pacific Hematology Assocates, Encinitas, California, United States|UC San Diego Health System, La Jolla, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Henry Ford Hospital, Detroit, Michigan, United States|Joe Arrington Cancer Center, Lubbock, Texas, United States|Hospital Italiano, Buenos Aires, Argentina|The Northern Hospital, Epping, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|Tweed Hospital, Tweed Heads, New South Wales, Australia|The Townsville Hospital, Douglas, Queensland, Australia|Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital; Haematology Clinical Trials, Adelaide, South Australia, Australia|Ashford Cancer Centre Research; Internal Medicine/Medical Oncology, Ashford, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Monash Medical Centre; Haematology, Melbourne, Victoria, Australia|Tiroler Landeskrankenanstalten Ges.M.B.H.; Innere Medizin Abt. Für Hämatologie & Onkologie, Innsbruck, Austria|Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Hämatologie & Hämostaseologie, Wien, Austria|Hanusch-Krankenhaus; Iii. Medizinische Abt., Wien, Austria|Wilhelminenspital; I. Medizinische Abt., Wien, Austria|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Instituto de Ensino e Pesquisa Sao Lucas - IEP, Sao Paulo, SP, Brazil|Hospital Sírio-Libanês, Sao Paulo, SP, Brazil|Hospital das Clinicas - FMUSP, Sao Paulo, SP, Brazil|Hospital Santa Marcelina, Sao Paulo, SP, Brazil|UMHAT Dr Georgi Stranski; Hematology, Pleven, Bulgaria|UMHAT "" Sveti Georgi"" Plovdiv - Clinic of Oncology and Hematology, Plovdiv, Bulgaria|University Hospital Sv.Georgi Clnic of Hematology; Hematology, Plovdiv, Bulgaria|University Multiprofile Hospital For Active Treatment ""Sveti Ivan Rilski"" EAD; clinical hematology, Sofia, Bulgaria|MHAT Hristo Botev; First Internal Department, Vratsa, Bulgaria|Tom Baker Cancer Centre; Dept of Medicine, Calgary, Alberta, Canada|Queen Elizabeth II Health Sciences Centre; Oncology, Halifax, Nova Scotia, Canada|Jewish General Hospital, Montreal, Quebec, Canada|University Hospital Center Zagreb; Haematology Department, Zagreb, Croatia|University Hospital Merkur Clinic for Internal Medicine/ Hematology, Zagreb, Croatia|Herlev Hospital, Herlev, Denmark|Rigshospitalet, København Ø, Denmark|Sjællands Universitetshospital, Roskilde, Roskilde, Denmark|Sygehus Lillebælt, Vejle, Vejle, Denmark|North Estonia medical Centre; Hematology, Tallinn, Estonia|Tartu Uni Hospital; Hematology - Oncology Clinic, Tartu, Estonia|CHU Besançon - Hôpital Jean Minjoz, Besançon Cedex, France|Institut d'Hématologie de Basse Normandie, Caen, France|Chu Estaing; Hematologie Clinique Adultes, Clermont Ferrand, France|Hopital Henri Mondor, Creteil, France|CHU de Dijon - Hopital le Bocage, Dijon, France|CHU de Grenoble, Grenoble, France|Centre Jean Bernard, Le Mans, France|Centre Leon Berard; Departement Oncologie Medicale, Lyon, France|Hôpital Saint Eloi; Service d'Hématologie et Oncologie Clinique - Recherche Clinique, Montpellier, France|Hopital Hotel Dieu Et Hme;Hopital De Jour, Nantes, France|Hopital Saint Louis ; Service d Oncologie Medicale Fougere 6 (Pr Misset), Paris, France|Hopital Pontchaillou; Hematologie Clinique, Rennes, France|Centre Henri Becquerel; Hematologie, Rouen, France|CH de Toulon Hôpital Sainte Musse, Toulon, France|Institut Gustave Roussy - Hematologie, Villejuif, France|Uniklinik RWTH Aachen; Klinik IV; Klinik Hämatologie, Onkologie, Hämostaseologie und Stamm., Aachen, Germany|Gesundheitszentrum St. Marien GmbH; Med. II, Hämatologie/Onkologie, Amberg, Germany|Charite - Universitätsmedizin Berlin, Berlin, Germany|Charite - Campus Virchow-Klinikum, Berlin, Germany|BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie-Onkologie, Dresden, Germany|Universitätsklinikum ""Carl Gustav Carus""; Medizinische Klinik und Poliklinik I, Dresden, Germany|Universitätsklinikum Essen; Klinik für Hämatologie, Essen, Germany|Klinik Esslingen; Klinik für Allgemeine Innere Medizin, Onkologie/Haematologie, Esslingen, Germany|Klinikum Frankfurt/Oder, Frankfurt/Oder, Germany|Uniklinikum Freiburg, Freiburg, Germany|Uni Göttingen, Georg-August-Universität; Klinik für Hämatologie und Medizinische Onkologie, Göttingen, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Stiftung Kathol. Krankenhaus Marienhospital Herne Klinik Mitte, Herne, Germany|Praxisklinik für Hämatologie und Onkologie Koblenz, Koblenz, Germany|Uniklinik Köln, Köln, Germany|Tagesklinik Landshut; Hämatologie/Onkologie, Landshut, Germany|Klinikum rechts der Isar der Technischen Universität München, Munchen, Germany|Klinikum Schwäbisch Gmünd, Mutlangen, Germany|Kliniken Maria Hilf GmbH; Innere Medizin I; Hämatologie und internistische Onkologie, Mönchengladbach, Germany|München Klinik Schwabing; Klinik für Hämatologie, Onkologie, Immunologie, München, Germany|Klinikum der Universität München, Campus Großhadern; Medizinische Klinik und Poliklinik III, München, Germany|Gemeinschaftspraxis Dr. med. Holger Klaproth / Dr. med. Anca Astrid Cura, Neunkirchen/Saar, Germany|Brüderkrankenhaus St. Josef Paderborn, Paderborn, Germany|Krankenhaus Barmherzige Bruder Regensburg, Regensburg, Germany|Marienhospital, Stuttgart, Germany|Robert-Bosch-Krankenhaus, Stuttgart, Germany|Universitätsklinikum Tübingen, Tuebingen, Germany|Universtitätsklinikum Ulm; Klinik für Innere Medizin III, Ulm, Germany|Medizinisches Versorgungszentrum Nuklearmedizin-Strahlentherapie-Onkologie, Weiden, Germany|Arcispedale S. Anna; Sezione Di Ematologia, Ferrara, Emilia-Romagna, Italy|Ospedali Riuniti Papardo-Piemonte; Struttura Complessa Di Ematologia, Messina, Lazio, Italy|Uni Cattolica; Divisione Di Ematologia, Roma, Lazio, Italy|AOU Città della Salute e della Scienza di Torino - Presidio Le Molinette, Torino, Lazio, Italy|Ospedale San Raffaele, Milano, Lombardia, Italy|Az. Osp. S. Maria; Dept. Di Oncologia Medica, Terni, Umbria, Italy|Ospedale dell' Angelo; U.O. Ematologia, Venezia Mestre, Veneto, Italy|Hospital General de Culiacan, Culiacan, Mexico|Canterbury Health Laboratories; Haematology, Christchurch, New Zealand|Dunedin Hospital, Dunedin, New Zealand|Midcentral District Health Board, Palmerston North, New Zealand|Wellington Hospital, Wellington, New Zealand|Uniwersytecki Szpital Kliniczny w Białymstoku, Klinika Hematologii z Pododdziałem Chorob Naczyn, Bialystok, Poland|Samodzielny Public Zaklad, Chorzów, Poland|Wojewódzki Szpital Specjalistyczny im.MikołajaKopernika;KlinikaHematologiiUniwersytetuMedycznego, Lodz, Poland|Wojewodzki Szpital Specjalistyczny im. J. Korczaka; Oddział Chorób Wewnetrznych/Hematologiczny, Slupsk, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wrocławiu; Klinika Hematologii, Wroclaw, Poland|Fundeni Clinical Inst. ; Hematology Dept, Bucharest, Romania|Institutul Regional de Oncologie Iasi; Clinica de Hematologie, Iasi, Romania|Spitalul Clinic Judetean de Urgenta Targu-Mures; compartiment Hematologie, Targu-mures, Romania|Republican Clinical Oncologic Dispensary of Republic Of Tatarstan, Kazan, Russian Federation|Moscow State Budgetary Healthcare Institution, Moscow, Russian Federation|Regional Clinical Hospital N.A. Semashko; Hematology, Nizhny Novgorod, Russian Federation|Penza Regional Oncology Dispensary, Penza, Russian Federation|Clinical MSCh No1, Perm, Russian Federation|Rostov State Medical Uni ; Hematology, Rostov-na-donu, Russian Federation|SBEI of HPE ""Bashkir State Medical University"" of MoH RF, Ufa, Russian Federation|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Universitario de Canarias;servicio de Hematologia, La Laguna, Tenerife, Spain|Hospital del Mar; Servicio de Hematologia, Barcelona, Spain|Hospital Universitari Vall d'Hebron; Servicio de Hematologia, Barcelona, Spain|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain|Hospital Universitario de la Princesa; Servicio de Hematologia, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Univ. 12 de Octubre; Servicio de Hematologia, Madrid, Spain|Hospital Clinico Universitario de Salamanca;Servicio de Hematologia, Salamanca, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Complejo Hospitalario de Toledo- H. Virgen de la Salud; Servicio de Hematología, Toledo, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain|Hospital Arnau de Vilanova (Valencia) Servicio de Hematologia, Valencia, Spain|Inselspital Bern; Hämatologie und Hämatologisches Zentrallabor, Bern, Switzerland|Luzerner Kantonsspital, Hämatologie, Luzern, Switzerland|Universitätsspital Zürich; Klinik für Hämatologie, Zürich, Switzerland|Birmingham Heartlands Hospital, Birmingham, United Kingdom|Boston Pilgrim Hospital, Boston,Lincolnshire, United Kingdom|Western General Hospital; Department of Haematology, Edinburgh, United Kingdom|Lincoln County Hospital, Lincoln, United Kingdom|University Hospital Southampton NHS Foundation Trust, Southhampton, United Kingdom",https://ClinicalTrials.gov/show/NCT02242942
270,Bristol-Myers Squibb,A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037),"Active, not recruiting",Has Results,Unresectable or Metastatic Melanoma,Biological: BMS-936558|Drug: Dacarbazine|Drug: Carboplatin|Drug: Paclitaxel,Industry,Interventional,"Mayo Clinic, Phoenix, Arizona, United States|UCSD Moores Cancer Center, La Jolla, California, United States|The Angeles Clinic & Research Institute, Los Angeles, California, United States|University Of California - Los Angeles, Los Angeles, California, United States|San Francisco Oncology Associates, San Francisco, California, United States|UCSF Comprehensive Cancer Center, San Francisco, California, United States|University Of Colorado, Aurora, Colorado, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University Of Michigan Health System, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Allina Health, Minneapolis, Minnesota, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|NYU Clinical Cancer Center, New York, New York, United States|MSKCC Clinical Laboratory at Nassau, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals, Cleveland, Ohio, United States|Providence Oncology And Hematology, Portland, Oregon, United States|Network Office of Research and Innovation, Allentown, Pennsylvania, United States|St. Luke'S Health System, Easton, Pennsylvania, United States|Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Local Institution, Innsbruck, Austria|Local Institution, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Edegem, Belgium|Local Institution, Leuven, Belgium|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Sir Mortimer B Davis - Jewish General Hospital, Montreal, Quebec, Canada|CHUM, Montreal, Canada|Aarhus Universitetshospital, Aarhus, Denmark|Herlev Hospital, Herlev, Denmark|Odense University Hospital, Odense, Denmark|Local Institution, Clermont Ferrand, France|Local Institution, Lille Cedex, France|Hopital La Timone, Marseille, France|Local Institution, Nantes Cedex 01, France|Local Institution, Nice, France|Local Institution, Paris, France|Local Institution, Pierre Benite, France|Local Institution, Villejuif, France|Local Institution, Wuerzburg, Bayern, Germany|Local Institution, Buxtehude, Germany|Local Institution, Dresden, Germany|Local Institution, Essen, Germany|Local Institution, Frankfurt am Main, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Local Institution, Kiel, Germany|Local Institution, Luebeck, Germany|Local Institution, Magdeburg, Germany|Local Institution, Munich, Germany|Local Institution, Tubingen, Germany|Local Institution, Jerusalem, Israel|Local Institution, Ramat Gan, Israel|Local Institution, Bari, Italy|Local Institution, Bergamo, Italy|Local Institution, Genova, Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Roma, Italy|Local Institution, Siena, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Maastricht, Netherlands|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain|Local Institution, Valencia, Spain|Local Institution, Lausanne, Switzerland|Local Institution, Zurich, Switzerland|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Oxford, Oxfordshire, United Kingdom|Local Institution, London, Surrey, United Kingdom|Local Institution, Newcastle Upon Tyne, Tyne and Wear, United Kingdom",https://ClinicalTrials.gov/show/NCT01721746
271,Bristol-Myers Squibb,An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma,"Active, not recruiting",Has Results,Renal Cell Carcinoma,Biological: Opdivo|Biological: Yervoy,Industry,Interventional,"Cancer Specialists of North FL, Jacksonville, Florida, United States|University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Local Institution, Waratah, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Herston, Queensland, Australia|Local Institution, Malvern, Victoria, Australia|Local Institution, Elizabeth Vale, Australia|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile",https://ClinicalTrials.gov/show/NCT03029780
272,Novartis Pharmaceuticals|Novartis,Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma,"Active, not recruiting",Has Results,"Carcinoma, Renal Cell",Drug: Pazopanib|Drug: Sunitinib,Industry,Interventional,"Novartis Investigative Site, Huntsville, Alabama, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Little Rock, Arkansas, United States|Novartis Investigative Site, Beverly Hills, California, United States|Novartis Investigative Site, Escondido, California, United States|Novartis Investigative Site, Fresno, California, United States|Novartis Investigative Site, Greenbrae, California, United States|Novartis Investigative Site, Hayward, California, United States|Novartis Investigative Site, La Jolla, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Montebello, California, United States|Novartis Investigative Site, Oakland, California, United States|Novartis Investigative Site, Orange, California, United States|Novartis Investigative Site, Roseville, California, United States|Novartis Investigative Site, Sacramento, California, United States|Novartis Investigative Site, Sacramento, California, United States|Novartis Investigative Site, San Bernardino, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, San Jose, California, United States|Novartis Investigative Site, Santa Clara, California, United States|Novartis Investigative Site, South San Francisco, California, United States|Novartis Investigative Site, Vallejo, California, United States|Novartis Investigative Site, Walnut Creek, California, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Southington, Connecticut, United States|Novartis Investigative Site, Trumbull, Connecticut, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Fort Myers, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Orlando, Florida, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Elk Grove Village, Illinois, United States|Novartis Investigative Site, Maywood, Illinois, United States|Novartis Investigative Site, Peoria, Illinois, United States|Novartis Investigative Site, Carmel, Indiana, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Cedar Rapids, Iowa, United States|Novartis Investigative Site, Louisville, Kentucky, United States|Novartis Investigative Site, Paducah, Kentucky, United States|Novartis Investigative Site, Annapolis, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Worcester, Massachusetts, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Duluth, Minnesota, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, Tupelo, Mississippi, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Lincoln, Nebraska, United States|Novartis Investigative Site, Las Vegas, Nevada, United States|Novartis Investigative Site, Las Vegas, Nevada, United States|Novartis Investigative Site, Lebanon, New Hampshire, United States|Novartis Investigative Site, Hackensack, New Jersey, United States|Novartis Investigative Site, Buffalo, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Hickory, North Carolina, United States|Novartis Investigative Site, Raleigh, North Carolina, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Dayton, Ohio, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Tulsa, Oklahoma, United States|Novartis Investigative Site, Eugene, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Charleston, South Carolina, United States|Novartis Investigative Site, Charleston, South Carolina, United States|Novartis Investigative Site, Greenville, South Carolina, United States|Novartis Investigative Site, Mount Pleasant, South Carolina, United States|Novartis Investigative Site, Chattanooga, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Arlington, Texas, United States|Novartis Investigative Site, Bedford, Texas, United States|Novartis Investigative Site, Corpus Christi, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Fort Worth, Texas, United States|Novartis Investigative Site, Lubbock, Texas, United States|Novartis Investigative Site, Round Rock, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, Tyler, Texas, United States|Novartis Investigative Site, Webster, Texas, United States|Novartis Investigative Site, Wichita Falls, Texas, United States|Novartis Investigative Site, Charlottesville, Virginia, United States|Novartis Investigative Site, Hampton, Virginia, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Salem, Virginia, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Camperdown, New South Wales, Australia|Novartis Investigative Site, Kogarah, New South Wales, Australia|Novartis Investigative Site, Randwick, New South Wales, Australia|Novartis Investigative Site, Waratah, New South Wales, Australia|Novartis Investigative Site, Westmead, New South Wales, Australia|Novartis Investigative Site, Bedford Park, South Australia, Australia|Novartis Investigative Site, Hobart, Tasmania, Australia|Novartis Investigative Site, Heidelberg, Victoria, Australia|Novartis Investigative Site, Wodonga, Victoria, Australia|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Winnipeg, Manitoba, Canada|Novartis Investigative Site, Moncton, New Brunswick, Canada|Novartis Investigative Site, Hamilton, Ontario, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Oshawa, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Tianjin, China|Novartis Investigative Site, Kirchheim, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Sigmaringen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Stuttgart, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Planegg, Bayern, Germany|Novartis Investigative Site, Marburg, Hessen, Germany|Novartis Investigative Site, Offenbach, Hessen, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Aachen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Bonn, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Dortmund, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Duesseldorf, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Duisburg, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Homburg, Saarland, Germany|Novartis Investigative Site, Eisleben, Sachsen-Anhalt, Germany|Novartis Investigative Site, Magdeburg, Sachsen-Anhalt, Germany|Novartis Investigative Site, Dresden, Sachsen, Germany|Novartis Investigative Site, Leipzig, Sachsen, Germany|Novartis Investigative Site, Plauen, Sachsen, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Galway, Ireland|Novartis Investigative Site, Tallaght, Dublin, Ireland|Novartis Investigative Site, Napoli, Campania, Italy|Novartis Investigative Site, Meldola (FC), Emilia-Romagna, Italy|Novartis Investigative Site, Ravenna, Emilia-Romagna, Italy|Novartis Investigative Site, Pordenone, Friuli-Venezia-Giulia, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Arezzo, Toscana, Italy|Novartis Investigative Site, Ehime, Japan|Novartis Investigative Site, Fukuoka, Japan|Novartis Investigative Site, Fukuoka, Japan|Novartis Investigative Site, Hokkaido, Japan|Novartis Investigative Site, Hokkaido, Japan|Novartis Investigative Site, Ibaraki, Japan|Novartis Investigative Site, Iwate, Japan|Novartis Investigative Site, Kanagawa, Japan|Novartis Investigative Site, Kyoto, Japan|Novartis Investigative Site, Okayama, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Shizuoka, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Yamagata, Japan|Novartis Investigative Site, Daegu, Korea, Republic of|Novartis Investigative Site, Daejeon, Korea, Republic of|Novartis Investigative Site, Goyang-si, Gyeonggi-Do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Alkmaar, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Breda, Netherlands|Novartis Investigative Site, Den Haag, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Sittard-geleen, Netherlands|Novartis Investigative Site, Tilburg, Netherlands|Novartis Investigative Site, Utrecht, Netherlands|Novartis Investigative Site, Badalona, Spain|Novartis Investigative Site, Barakaldo (Vizcaya), Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Gerona, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Pamplona, Spain|Novartis Investigative Site, Lund, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Kaohsiung Hsien, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taoyuan, Taiwan|Novartis Investigative Site, Bristol, Gloucestershire, United Kingdom|Novartis Investigative Site, Northwood, Middlesex, United Kingdom|Novartis Investigative Site, Bebington, Wirral, United Kingdom|Novartis Investigative Site, Birmingham, United Kingdom|Novartis Investigative Site, Cambridge, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom|Novartis Investigative Site, Sheffield, United Kingdom|Novartis Investigative Site, Swansea, United Kingdom",https://ClinicalTrials.gov/show/NCT00720941
273,Seagen Inc.|Bristol-Myers Squibb,A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma,"Active, not recruiting",Has Results,Hodgkin Lymphoma,Drug: brentuximab vedotin|Drug: nivolumab,Industry,Interventional,"City of Hope National Medical Center, Duarte, California, United States|Stanford Cancer Center, Stanford, California, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute / Wayne State University, Detroit, Michigan, United States|Mayo Clinic Minnesota, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center - Commack, Commack, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|James Cancer Hospital / Ohio State University, Columbus, Ohio, United States|Charles A. Sammons Cancer Center / Baylor University Medical Center, Dallas, Texas, United States",https://ClinicalTrials.gov/show/NCT02572167
274,"University of Alabama at Birmingham|Genentech, Inc.",Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas,"Active, not recruiting",Has Results,Neurofibromatosis Type 2|Progressive Vestibular Schwannomas,Drug: Bevacizumab,Other|Industry,Interventional,"Children's Hospital Los Angeles, Los Angeles, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's HealthCare of Atlanta, Atlanta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Indiana Unversity, Indianapolis, Indiana, United States|National Cancer Institute (NCI), Bethesda, Maryland, United States|Children' Hospital Boston and Massachusetts General Hospital, Boston, Massachusetts, United States|Washington University - St. Louis, Saint Louis, Missouri, United States|New York University Medical Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Utah, Salt Lake City, Utah, United States",https://ClinicalTrials.gov/show/NCT01767792
275,"Celgene|Acceleron Pharma, Inc.","A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes","Active, not recruiting",Has Results,Myelodysplastic Syndromes,Drug: Luspatercept|Other: Placebo,Industry,Interventional,"Stanford Cancer Center, Stanford, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|Ochsner Medical Institutions, New Orleans, Louisiana, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Montefiore Medical Center Albert Einstein Cancer Center, Bronx, New York, United States|Columbia-Presbyterian Medical Center, New York, New York, United States|Gabrail Cancer Center, Canton, Ohio, United States|Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Algemeen Ziekenhuis Klina, Brasschaat, Belgium|AZ Sint-Jan AV Brugge, Brugge, Belgium|UZ Brussels, Brussel, Belgium|Grand Hopital de Charleroi, Charleroi, Belgium|UZ Gent, Gent, Belgium|UZ Leuven, Leuven, Belgium|Cliniques Universitaires UCL de Mont-Godine, Yvoir, Belgium|Tom Baker Cancer Center, Calgary, Alberta, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|CHU d'Angers, Angers, France|CHU Hotel, Grenoble Cedex 09, France|CHRU de Lille-Hopital Claude Huriez Service des Maladies du Sang, Lille, France|Institut Paoli Calmettes, Marseille cedex, France|CHU de Nice Archet I, Nice, France|Hopital Saint Louis, Paris, France|Hopital Haut Leveque, Pessac Cedex, France|Centre hospitalier Lyon Sud Hematologie, Pierre-Bénite cedex, France|Hopital civil, Strasbourg, France|Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse Cedex 9, France|Hopital Bretonneau, Tours, France|Universitatsklinikum Bonn, Bonn, Germany|Universitatsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Germany|Marien Hospital, Dusseldorf, Germany|Universitätsklinikum Düsseldorf, Düsseldorf, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Klinikum rechts der Isar der Technischen Universität München, München, Germany|Azienda Ospedaliera Santi Antonio Biagio E Cesare Arrigo, Allessandria, Italy|Azienda Ospedaliero Universitaria Di Bologna Policlinico Sorsola Malpighi, Bologna, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Azienda Sanitaria Locale Lecce, Lecce, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio, Calabria, Italy|Fondazione Policlinico Universitario A Gemelli, Roma, Italy|Fondazione PTV Policlinico Tor Vergata, Roma, Italy|VU Medisch Centrum, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Spaarne Ziekenhuis, Hoofddorp, Netherlands|Hospital Universitario Cruces, Barakaldo, Spain|Hospital Universitario Vall D hebron, Barcelona, Spain|Instituto Catalan de Oncologia-Hospital Duran i Reynals, Barcelona, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen del Rocio, Seville, Spain|Hospital Universitario La Fe, Valencia, Spain|Sahlgrenska Universitetssjukhus, Göteborg, Sweden|Skanes Universitetssjukhus Lund, Lund, Sweden|Karolinska University Hospital, Stockholm, Sweden|Akademiska Sjukhuset, Uppsala, Sweden|Cukurova University Medical Faculty Balcali Hospital, Adana, Turkey|Ankara University Medical Faculty Cebeci Hospital, Ankara, Turkey|Istanbul University Cerrahpasa Medical Faculty Hospital, Istanbul, Turkey|Ege Universitesi Tip Fakultesi Hastanesi, Izmir, Turkey|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|John Radcliffe Hospital, Headington, United Kingdom|St James University Hospital, Leeds, United Kingdom|Guys Hospital, London, United Kingdom|Kings College Hospital, London, United Kingdom|Kings Mill Hospital, Sutton in Ashfield, United Kingdom",https://ClinicalTrials.gov/show/NCT02631070
276,H. Lee Moffitt Cancer Center and Research Institute|Incyte Corporation,A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib,"Active, not recruiting",Has Results,Myelomonocytic Leukemia,Drug: Ruxolitinib,Other|Industry,Interventional,"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Weill Medical College of Cornell, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States",https://ClinicalTrials.gov/show/NCT01776723
277,Incyte Corporation,A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202),"Active, not recruiting",Has Results,Lymphoma,Drug: Parsaclisib,Industry,Interventional,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Sutter Gould Medical Foundation, Modesto, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Advanced Pharma CR, LLC, Miami, Florida, United States|Asclepes Research Centers, Weeki Wachee, Florida, United States|Oncology Specialists, S.C., Park Ridge, Illinois, United States|Indiana BMT, Beech Grove, Indiana, United States|Parkview Research Center, Fort Wayne, Indiana, United States|University of Kentucky Hospital, Lexington, Kentucky, United States|St. Agnes Hospital, Baltimore, Maryland, United States|St. John Hospital and Medical Center, Detroit, Michigan, United States|Karmanos Cancer Institute, Farmington Hills, Michigan, United States|CHI Health - St. Francis Medical Center, Grand Island, Nebraska, United States|Summit Medical Group, Morristown, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Clinical Research Alliance, Lake Success, New York, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Utah Cancer Specialists- Network, Salt Lake City, Utah, United States|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Ballarat Base Hospital, Ballarat, Victoria, Australia|Sunshine Hospital, St Albans, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|ZNA Stuivenberg, Antwerpen, Belgium|UZ Leuven, Leuven, Belgium|AZ Delta, Roeselare, Belgium|LHSC - Victoria Hospital, London, Ontario, Canada|Fakultni nemocnice Brno, Brno, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Fakultni nemocnice Ostrava, Ostrava - Poruba, Czechia|Fakultni nemocnice v Motole, Praha 5, Czechia|Centre Antoine Lacassagne, Nice cedex 02, Alpes Maritimes, France|Centre Francois Baclesse, Caen Cedex 05, Calvados, France|CHU Dijon - Hopital du Bocage, Dijon cedex, Cote dÝOr, France|Centre Hospitalier Libourne, Libourne Cedex, Gironde, France|CHU de Grenoble - Hôpital Albert Michallon, Grenoble, Isere, France|Centre Hospitalier d'Angers, Angers Cedex 01, Maine Et Loire, France|CHU de Nancy - Hôpital de Brabois Adultes, Vandoeuvre les Nancy, Meurthe Et Moselle, France|Hopital Claude Huriez - CHU Lille, Lille cedex, Nord, France|Hôpital Saint-Louis, Paris cedex 10, Paris, France|Centre Hospitalier Lyon Sud, Pierre Bénite, Rhone, France|Clinique Victor Hugo - Centre Jean Bernard, Le Mans Cedex 02, Sarthe, France|Hôpital Henri Mondor, Créteil Cedex, Val De Marne, France|Groupe Hospitalier Pitie-Salpetriere, Paris, France|IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy|Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari, Bari, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Szpital Specjalistyczny W Brzozowie, Podkarpacki Osrodek Onkologiczny Im.Ks.B.Markiewicza, Brzozów, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Malopolskie Centrum Medyczne s.c., Krakow, Poland|ICO l´Hospitalet - Hospital Duran i Reynals, L'Hospitalet de llobregat, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario Nuestra Señora de Valme, Sevilla, Spain|The Christie, Manchester, Greater Manchester, United Kingdom|Royal Marsden Hospital, Sutton, United Kingdom",https://ClinicalTrials.gov/show/NCT02998476
278,Celgene,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,"Active, not recruiting",Has Results,"Lymphoma, Large B-Cell, Diffuse",Drug: Durvalumab|Drug: Rituximab|Drug: Doxorubicin|Drug: Vincristine|Drug: Cyclophosphamide|Drug: Prednisone|Drug: Lenalidomide,Industry,Interventional,"Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Parkview Research Center, Fort Wayne, Indiana, United States|Mayo Clinic, Rochester, Minnesota, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Mid Ohio Oncology Hematology Inc, Columbus, Ohio, United States|Swedish Cancer Institute, Seattle, Washington, United States|Innsbruck Medical University Department of Internal Medicine, Innsbruck, Austria|Landeskrankenhaus Salzburg, Salzburg, Austria|Medical University of Vienna Internalmedicine 1, Hematology, Vienna, Austria|Hanusch Krankenhaus, Wien, Austria|Aarhus Sygehus, Arhus C, Denmark|Rigshospitalet, Kobenhavns Universitet - Centre for Clinical Intervention Research - The Copenhagen, Copenhagen, Denmark|Odense Universitetshospital, Odense C, Denmark|(North Estonia Medical Centre) - Onkoloogia-ja Hematoloogiakliinik, Tallinn, Estonia|Tartu University Hospital, Tartu, Estonia|University Hospital Birmingham, Birmingham, United Kingdom|Royal Marsden Hospital, London, United Kingdom|Oxford University Hospitals NHS Trust- Churchill Hospital-Oxford Centre for Respiratory Medicine, Oxford, United Kingdom",https://ClinicalTrials.gov/show/NCT03003520
279,"Kite, A Gilead Company|Gilead Sciences",Study to Evaluate the Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma,"Active, not recruiting",Has Results,Relapsed/Refractory Mantle Cell Lymphoma,Biological: brexucabtagene autoleucel|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Axicabtagene Ciloleucel,Industry,Interventional,"Banner MD Anderson, Gilbert, Arizona, United States|City of Hope, Duarte, California, United States|University California Los Angeles (UCLA), Santa Monica, California, United States|Stanford University, Stanford, California, United States|Sarah Cannon, Denver, Colorado, United States|University of Miami, Miami, Florida, United States|H Lee Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Loyola University Chicago, Maywood, Illinois, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|University of Rochester Medical Center, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Robert W. Franz Cancer Research Center, Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|Centre Hospitalier Universitaire (CHU), Bordeaux, France|Hospital Saint Louis, Paris, France|Hopital Haut-Leveque, Pessac, France|Universitätsklinik Dresden, Dresden, Germany|Universitaetsklinikum Wuerzburg, Wuerzburg, Germany|Academisch Medisch Centrum, Amsterdam, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands",https://ClinicalTrials.gov/show/NCT02601313
280,Northwestern University|GlaxoSmithKline|National Cancer Institute (NCI),Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas,"Active, not recruiting",Has Results,Adult Liposarcoma|Metastatic Liposarcoma|Metastatic Osteosarcoma|Recurrent Adult Soft Tissue Sarcoma|Recurrent Liposarcoma|Recurrent Osteosarcoma|Stage IV Adult Soft Tissue Sarcoma,Drug: Pazopanib Hydrochloride|Drug: Oral Topotecan Hydrochloride|Other: Laboratory Biomarker Analysis,Other|Industry|NIH,Interventional,"Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Northwestern University, Chicago, Illinois, United States|Northwestern University- Lake Forest Hospital, Lake Forest, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States",https://ClinicalTrials.gov/show/NCT02357810
281,MorphoSys AG,A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL,"Active, not recruiting",Has Results,Diffuse Large B-cell Lymphoma,Drug: MOR00208|Drug: Lenalidomide,Industry,Interventional,"MorphoSys Research Site, Bakersfield, California, United States|MorphoSys Research Site, Redondo Beach, California, United States|MorphoSys Research Site, Santa Maria, California, United States|MorphoSys Research Site, Grand Junction, Colorado, United States|MorphoSys Research Site, Norwalk, Connecticut, United States|MorphoSys Research Site, Michigan Center, Michigan, United States|MorphoSys Research Site, Columbus, Ohio, United States|MorphoSys Research Site, Charleston, South Carolina, United States|MorphoSys Research Site, Tyler, Texas, United States|MorphoSys Research Site, Antwerp, Belgium|MorphoSys Research Site, Kortrijk, Belgium|MorphoSys Research Site, Liege, Belgium|MorphoSys Research Site, Yvoir, Belgium|MorphoSys Research Site, Olomouc, Czechia|MorphoSys Research Site, Clermont-Ferrand, France|MorphoSys Research Site, Limoges, France|MorphoSys Research Site, Lyon, France|MorphoSys Research Site, Paris, France|MorphoSys Research Site, Essen, Germany|MorphoSys Research Site, Frankfurt, Germany|MorphoSys Research Site, Munich, Germany|MorphoSys Research Site, Nürnberg, Germany|MorphoSys Research Site, Würzburg, Germany|MorphoSys Research Site, Budapest, Hungary|MorphoSys Research Site, Budapest, Hungary|MorphoSys Research Site, Debrecen, Hungary|MorphoSys Research Site, Bari, Italy|MorphoSys Research Site, Bologna, Italy|MorphoSys Research Site, Firenze, Italy|MorphoSys Research Site, Modena, Italy|MorphoSys Research Site, Novara, Italy|MorphoSys Research Site, Perugia, Italy|MorphoSys Research Site, Roma, Italy|MorphoSys Research Site, Terni, Italy|MorphoSys Research Site, Krakow, Poland|MorphoSys Research Site, Olsztyn, Poland|MorphoSys Research Site, Opole, Poland|MorphoSys Research Site, Poznan, Poland|MorphoSys Research Site, Rzeszow, Poland|MorphoSys Research Site, Warszawa, Poland|MorphoSys Research Site, Warszawa, Poland|MorphoSys Research Site, Barcelona, Spain|MorphoSys Research Site, Barcelona, Spain|MorphoSys Research Site, Barcelona, Spain|MorphoSys Research Site, Madrid, Spain|MorphoSys Research Site, Madrid, Spain|MorphoSys Research Site, Madrid, Spain|MorphoSys Research Site, Pamplona, Spain|MorphoSys Research Site, Sevilla, Spain|MorphoSys Research Site, Bournemouth, United Kingdom|MorphoSys Research Site, Liverpool, United Kingdom|MorphoSys Research Site, London, United Kingdom|MorphoSys Research Site, Newcastle, United Kingdom",https://ClinicalTrials.gov/show/NCT02399085
282,Celgene,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,"Active, not recruiting",Has Results,"Lymphoma, Large B-Cell, Diffuse",Drug: lenalidomide|Drug: Placebo|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: prednisone|Drug: vincristine,Industry,Interventional,"Highlands Oncology Group, Fayetteville, Arkansas, United States|John Muir Health, Concord, California, United States|California Cancer Associates for Research and Excellence cCARE, Encinitas, California, United States|Moores UCSD Cancer Center MC-0987, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|University of Californai, Irvine, Orange, California, United States|UC Davis Cancer Center, Sacramento, California, United States|Memorial Hospital, Colorado Springs, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Memorial Healthcare System, Hollywood, Florida, United States|John B Amos Cancer Center, Columbus, Georgia, United States|Cancer Treatment Centers of America - Southeastern Regional Medical Center, Newnan, Georgia, United States|University of Illinois at Chicago, Chicago, Illinois, United States|McFarland Clinic, Ames, Iowa, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|University of Kansas Cancer Center, Fairway, Kansas, United States|Hematology-Oncology Clinic, Baton Rouge, Louisiana, United States|Cancer Center of Acadiana, Lafayette, Louisiana, United States|West Jefferson Medical Center, Marrero, Louisiana, United States|Willis Knighton Medical Center, Shreveport, Louisiana, United States|Center For Cancer and Blood Disorders, Bethesda, Maryland, United States|Maryland Oncology Hematology PA, Columbia, Maryland, United States|Associates of Oncology/Hematology, P.C., Rockville, Maryland, United States|Saint Joseph Medical Center, Westminster, Maryland, United States|St. Joseph Mercy Hosp, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|St. Louis Cancer Care LLP, Bridgeton, Missouri, United States|Saint Louis Univ Hospital - Saint Louis, Saint Louis, Missouri, United States|Regional Cancer Care Associates/Cherry Hill Division, LLC., Cherry Hill, New Jersey, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Carol G Simon Cancer Center, Morristown, New Jersey, United States|Regional Cancer Care Associates - Somerset Division, Somerville, New Jersey, United States|Queens Medical Associates PC, Fresh Meadows, New York, United States|Columbia University Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Firsthealth of The Carolinas, Pinehurst, North Carolina, United States|St. Luke's Hospital and Health Network, Bethlehem, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Bon Secours Saint Francis Health System, Greenville, South Carolina, United States|Texas Oncology-Arlington South, Arlington, Texas, United States|Parkland Health and Hospital Systems, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Houston Methodist Cancer Center, Houston, Texas, United States|Millennium Oncology, Houston, Texas, United States|Utah Cancer Specialist, Salt Lake City, Utah, United States|Virginia Cancer Institute, Richmond, Virginia, United States|VCU Massey Cancer Center, Richmond, Virginia, United States|Swedish Cancer Institute Edmonds Campus, Edmonds, Washington, United States|Swedish Medical Center, Issaquah, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Cancer Institute, Seattle, Washington, United States|Swedish Cancer Institute Ballard Campus, Seattle, Washington, United States|Medical Oncology Associates, Spokane, Washington, United States|Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, United States|Albury Wodonga Regional Cancer Centre, Albury, New South Wales, Australia|Shoalhaven Cancer Care Centre, Nowra, New South Wales, Australia|Bendigo Hosp, Bendigo, Victoria, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Geelong Hospital, Geelong, Victoria, Australia|St Vincents Hospital Melbourne, Fitzroy, Australia|Frankston Hospital, Frankston, Australia|Austin Hospital, Heidelberg, Australia|Royal Melbourne Hospital, Parkville, Australia|Wellington Hospital, Wellington, Australia|Westmead Hospital, Westmead, Australia|Wollongong Hospital, Wollongong, Australia|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Centre Hospitalier Universitaire de Liege, Liege, Belgium|H. Hartziekenhuis Roeselare-Menen vzw campus Wilgenstraat, Roeselare, Belgium|AZ Nikolaas, Sint-Niklaas, Belgium|Regionaal Ziekenhuis Jan Yperman VZW, West-Vlaanderen, Belgium|GZA St. Augustinus, Wilrijk, Belgium|Cliniques Universitaires UCL de Mont-Godine, Yvoir, Belgium|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Fraser Health Authority, Surrey, British Columbia, Canada|Saint John Regional Hospital, Saint John, New Brunswick, Canada|Ottawa Hospital, Ottawa, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Centre Hospitalier Universitaire de Sherbrooke CHUS, Greenfield Park, Quebec, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|Beijing Cancer Hospital, Beijing, PR, China|Peking University People's Hospital, Beijing, China|Peking University Third Hospital, Beijing, China|Peking Union Medical College Hospital, Beijing, China|First Hospital of Jilin University, Changchun, China|West China Medical School West China Hospital Sichuan University, Chengdu, China|Xinqiao Hospital, Third Military Medical University, Chongqing, China|Fujian Medical University Union Hospital, Fuzhou, China|Guangdong General Hospital, Guangzhou, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, China|Nanfang Hospital of Southern medicine university in Guangzhou, Guangzhou, China|First Affiliated Hospital, Hangzhou, China|Harbin Medical University Tumor Hospital, Harbin, Heilongjiang, China|Jiangsu Cancer Hospital, Nanjing, Jiangsu, China|Jiangsu Province Hospital, Nanjing, China|Fudan University Shanghai Cancer Center, Shanghai, China|First Affiliated Hospital of Soochow University, Suzhu, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, China|Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China|Fakultni Nemocnice Brno, Brno, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Fakultni nemocnice Olomouc, Olomouc, Czechia|Fakultni nemocnice Kralovske Vinohrady, Interni hematologicka klinika, Prague 10, Czechia|Vseobecna Fakultni Nemocnice v Praze, Praha, Czechia|Centre Hospitalier de la cote basque, Bayonne, France|Institut Bergonie Centre Regional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest, Bordeaux, France|CHRU de Brest - Hopital Morvan, Brest Cedex, France|Hopital Henri Mondor, Creteil, France|Centre Hospitalier Departemental de Vendee, La Roche -Sur-Yon - Cedex 9, France|CHU Hopital Saint Eloi, Montepellier Cedex 5, France|Hotel Dieu, Nantes, France|Hopital Necker, Paris Cedex 15, France|Hopital Saint Louis, Paris, France|Hopital Haut Leveque, Pessac Cedex, France|Centre Hospitalier D'annecy, Pringy, France|CHRU Rennes, Rennes, France|Centre Hospitalier de Saint Brieuc Hopital Yves le Foll, ST-Brieuc cedex 1, France|Centre Hospitalier Universitaire de Toulouse, Toulose, France|CHU de Nancy-Hopital Brabois Adulte, Vandoeuvre les Nancy, France|Institut Gustave Roussy, Villejuif CEDEX, France|Cork University Hospital, Wilton, Cork, Ireland|St Vincent's University Hospital, Dublin 4, Ireland|St James's Hospital, Dublin 8, Ireland|Mater Misericordiae University Hospital, Dublin, Ireland|Mater Private Hospital, Dublin, Ireland|University College Hospital Galway, Galway, Ireland|The Soroka University Medical Center, Beer-Sheva, Israel|Rambam Medical Center, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah Medical Center, Jerusalem, Israel|Meir Medical Center, Kfar-Saba, Israel|Rabin Medical Center, Petach Tikva, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Assuta Medical Centers, Tel Aviv, Israel|Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel|Assaf Harofeh Medical Center, Zerifin, Israel|Azienda Ospedaliera Santi Antonio Biagio E Cesare Arrigo, Allessandria, Italy|Azienda Ospedaliero Universitaria Ospedali, Ancona, Italy|Centro di Riferimento Oncologico, Aviano, Italy|Azienda Ospedaliera Poloclinico di Bari, Bari, Italy|Azienda Ospedaliero Universitaria Di Bologna Policlinico Sorsola Malpighi, Bologna, Italy|Spedali Civili Di Brescia, Brescia, Italy|Ospedale Ferrarotto, Catania, Italy|Azienda Sanitaria Ospedaliera S. Croce e Carle, Cuneo, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Azienda Ospedaliera Universitaria San Martino, Genova, Italy|Ospedale Civile di Ivrea, Ivrea, Italy|Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori (I.R.S.T.), Meldola, Italy|Ospedale San Raffaele S.r.l., Milano, Italy|Istituto Nazionale Dei Tumori, Milano, Italy|Azienda Ospedaliera Niguarda Ca Granda, Milano, Italy|Azienda Ospedaliero Universitaria Di Modena Policlinico, Modena, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Campania, Italy|Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale, Napoli, Campania, Italy|A.O.U. Maggiore della Carità, Novara, Italy|AOU San Luigi Gonzaga, Orbassano (TO), Italy|Hospital of Di Padova, Padova, Italy|Presidio Ospedaliero Andrea Tortora, Pagani, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Ospedale Civile Spirito Santo, Pescara, Italy|Azienda Sanitaria Locale di Ravenna, Ravenna, Italy|Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy|Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Ospedale degli Infermi di Rimini, Rimini, Italy|Policlinico Umberto I, Roma, Italy|Azienda Ospedaliera Sant Andrea, Roma, Italy|Policlinico Universitario Campus Biomedico Di Roma, Roma, Italy|Azienda Ospedaliera San Camillo Forlanini, Rome, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|Azienda Ospedaliera Universitaria Senese, Siena, Italy|Azienda Ospedaliera S Maria di Terni, Terni, Italy|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Italy|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Italy|Presidio Ospedaliero Di Treviso Ca' Foncello, Treviso, Italy|Azienda Ospedaliera Cardinale G Panico, Tricase, Italy|Azienda Ospedaliero-Universitaria Santa Maria della Misericordia die Udine, Udine, Italy|Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy|Azienda ULSS 6 Vicenza, Vicenza, Italy|Akita University Hospital, Akita-shi, Japan|National Cancer Center Hospital, Chuo-ku, Japan|Kyushu University Hospital, Fukuoka, Japan|Japan Mutual Aid Association of Public School Teachers Chugoku Central Hospital, Fukuyama, Japan|Tokai University School of Medicine, Isehara City, Kanagawa, Japan|National Cancer Center Hospital East, Kashiwa, Japan|The Cancer Institute Hospital of Japanese Foundation For Cancer Research, Koto-ku, Japan|University Hospital, Kyoto Prefectural University of Medicine, Kyoto-City, Japan|National Hospital Organization Kyushu Cancer Center, Minami-Ku, Fukuoka, Japan|Toranomon Hospital, Minato-ku, Japan|Aichi Cancer Center, Nagoya, Japan|Kochi Medical School Hospital, Nankoku-shi, Japan|Sendai Medical Center, Sendai-city, Japan|Ehime University Hospital, Toon, Japan|Yamagata University Hospital, Yamagata, Japan|National Cancer Center, Gyeonggi-do, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul St Marys Hospital College of Medicine The Catholic University of Korea, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands|VU University Medical Center VU Medisch Centrum, Amsterdam, Netherlands|Amphia Ziekenhuis Molengracht, Breda, Netherlands|HagaZiekenhuis, Den Haag, Netherlands|Spaarne Ziekenhuis, Hoofddorp, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|Maasstad Ziekenhuis, Rotterdam, Netherlands|Jeroen Bosch Ziekenhuis, s-Hertogenbosch, Netherlands|Vlietland Ziekenhuis, Schiedam, Netherlands|St. Elisabeth Ziekenhuis, Tilburg, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Auckland City Hospital, Auckland, New Zealand|Canterbury Health Laboratories, Christchurch, New Zealand|Palmerston North Hospital, Palmerston, New Zealand|Szpital Morski im. PCK, Gdynia, Poland|Malopolskie Centrum Medyczne S.C., Kraków, Poland|Zaklad Opieki Zdrowotnej MSW z Warminsko-Mazurskim Centrum Onkologii, Olsztyn, Poland|Samodz.Pub.Zaklad Opieki Zdrow-ej Min-wa Spraw Wewnetrznych w Poznaniu im Prof.Ludwika Bierkowskiego, Poznan, Poland|Wojskowy Instytut Medyczny, Warszawa, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wroclawiu, Wroclaw, Poland|Centro Hospitalar E Universitario de Coimbra EPE, Coimbra, Portugal|Hospital Distrital Da Figueira Da Foz, Figueira da Foz, Portugal|Instituto Portugues de Oncologia de Lisboa, Francisco Gentil, Lisboa, Portugal|Champalimaud Cancer Center, Lisboa, Portugal|Centro Hospitalar do Porto - Hospital de Santo António, Porto, Portugal|Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe, Porto, Portugal|Hospital Garcia de Orta, Pragal, Portugal|Auxilio Mutuo Cancer Center, San Juan, Puerto Rico|Tatarstan Republican Oncology Center, Kazan, Russian Federation|Russian Cancer Research Center n.a. Blokhin, Chemotherapy Department, Moscow, Russian Federation|Research Oncology Institute of Rosmed Technologies n.a. prof. N.N. Petrov, St. Petersburg, Russian Federation|Hospital del Mar, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Germans Trias i Pujol, Barcelona, Spain|Hospital de San Pedro de Alcantara, Caceres, Spain|Hospital Universitario de Canarias, La Laguna, Spain|Hospital Universitario de la Princessa, Madrid, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Hospital Costa del Sol, Marbella, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Hospital Son Llatzer, Palma de Mallorca, Spain|Complejo Hospitalario de Navarra, Pamplona/ Navarra, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Complejo Hospitalario Nuestra Senora de Valme, Sevilla, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Universitario Doctor Peset, Valencia, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Kantonsspital Aarau AG, Aarau, Switzerland|Ente Ospedaliero Cantonale, Bellinzona, Switzerland|Hopitaux Universitaire de Geneve, Geneva, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|Chang Gung Medical Foundation, Kaohsiung Memorial Hospital, Niao-Sung Hsiang Kaohsiung County, Taiwan|Chang Gung Memorial Hospital - Chiayi, Puzi City Chiayi County, Taiwan|China Medical University Hospital, Taichung City, Taiwan|National Taiwan University Hospital, Taipei, Zhongzheng Dist., Taiwan|Chang Gung Medical Foundation-Linkou Branch, Taoyuan, Taiwan|Cukurova Universitesi Tip Fakultesi Balcali Hastanesi, Adana, Turkey|Hacettepe Universitesi Tip Fakultesi Hastanesi, Ankara, Turkey|Ankara University Medical Faculty Cebeci Hospital, Ankara, Turkey|Akdeniz University Medical Faculty, Antalya, Turkey|Pamukkale University Medical Faculty, Denizli, Turkey|Dicle University Medical Faculty, Diyarbakir, Turkey|Trakya Universitesi Tip Fakultesi Hastanesi, Edirne, Turkey|Istanbul Universitesi Istanbul Tip Fakultesi Hastanesi, Istanbul, Turkey|Koc Universitesi Tip Fakultesi Amerikan Hastanesi, Istanbul, Turkey|Dokuz Eylul University Izmir, Izmir, Turkey|Erciyes University Kayseri, Kayseri, Turkey",https://ClinicalTrials.gov/show/NCT02285062
283,Bristol-Myers Squibb,Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140),"Active, not recruiting",Has Results,Lymphoma,Drug: Nivolumab,Industry,Interventional,"Mayo Clinic Arizona, Phoenix, Arizona, United States|Division Of Hematology & Oncology Ctr. For Health Sciences, Los Angeles, California, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Weill Cornell Medical College, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Local Institution, Woodville, South Australia, Australia|Local Institution, Parkville, Victoria, Australia|Local Institution, B-leuven, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Jewish General Hospital, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Local Institution, Creteil, France|Local Institution, Montpellier Cedex 05, France|Local Institution, Pierre Benite Cedex, France|Local Institution, Rennes, France|Universitaetsklinikum Essen, Essen, Germany|Universitaetsklinikum d. Saarlandes, Homburg, Germany|Universitaetsklinikum Des Saarlandes, Homburg, Germany|Local Institution, Regensburg, Germany|Universitaetsklinikum Ulm, Ulm, Germany|Local Institution, Bergamo, Italy|Local Institution, Bologna, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Roma, Italy|Local Institution, Oslo, Norway|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Hospital Duran I Reynals, Hospitalet Llobregat- Barcelona, Spain|Local Institution, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Local Institution, Salamanca, Spain|Local Institution, Gothenberg, Sweden|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Withington, Manchester, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom",https://ClinicalTrials.gov/show/NCT02038946
284,"Verastem, Inc.",A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO),"Active, not recruiting",Has Results,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Drug: Duvelisib|Drug: Ofatumumab,Industry,Interventional,"La Jolla, California, United States|Denver, Colorado, United States|Altamonte Springs, Florida, United States|Bonita Springs, Florida, United States|Bradenton, Florida, United States|Brandon, Florida, United States|Cape Coral, Florida, United States|Clearwater, Florida, United States|Englewood, Florida, United States|Fort Myers, Florida, United States|Gainesville, Florida, United States|Hudson, Florida, United States|Inverness, Florida, United States|Largo, Florida, United States|Naples, Florida, United States|New Port Richey, Florida, United States|Orange City, Florida, United States|Orlando, Florida, United States|Port Charlotte, Florida, United States|Saint Petersburg, Florida, United States|Sarasota, Florida, United States|Spring Hill, Florida, United States|Tampa, Florida, United States|Tavares, Florida, United States|Venice, Florida, United States|Crestview Hills, Kentucky, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Saint Louis, Missouri, United States|Hackensack, New Jersey, United States|New Brunswick, New Jersey, United States|New York, New York, United States|New York, New York, United States|Cincinnati, Ohio, United States|Fairfield, Ohio, United States|Nashville, Tennessee, United States|Charlottesville, Virginia, United States|Bedford Park, Australia|East Melbourne, Australia|Melbourne, Australia|Vienna, Austria|Wels, Austria|Wien, Austria|Bruxelles, Belgium|Bruxelles, Belgium|Gent, Belgium|Leuven, Belgium|Sint- Niklaas, Belgium|Argenteuil, France|Bobigny, France|Bordeaux, France|Caen, France|Clermont-Ferrand, France|La Roche Sur Yon, France|Limoges Cedex, France|Nantes, France|Rennes, France|Vendœuvres, France|Berlin, Germany|Köln, Germany|Leer, Germany|Rostock, Germany|Ulm, Germany|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Gyor, Hungary|Kaposvár, Hungary|Pecs, Hungary|Szeged, Hungary|Catania, Italy|Lecce, Italy|Meldola, Italy|Milano, Italy|Milano, Italy|Padova, Italy|Ravenna, Italy|Rimini, Italy|Roma, Italy|Auckland, New Zealand|Palmerston North, New Zealand|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Pamplona, Spain|Bournemouth, United Kingdom|Leeds, United Kingdom|Manchester, United Kingdom|Nottingham, United Kingdom|Oxford, United Kingdom",https://ClinicalTrials.gov/show/NCT02004522
285,"Kyowa Kirin Pharmaceutical Development, Inc.",Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL,"Active, not recruiting",Has Results,Cutaneous T-Cell Lymphoma,Biological: KW-0761|Drug: Vorinostat,Industry,Interventional,"University of Alabama - Birmingham, Birmingham, Alabama, United States|Banner MD Anderson, Gilbert, Arizona, United States|City of Hope National Medical Center, Duarte, California, United States|UCLA Medical Center, Los Angeles, California, United States|Stanford Medical Center, Stanford, California, United States|University of Colorado, Aurora, Colorado, United States|Yale University School of Medicine - Yale Cancer Center, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|The Winship Cancer Institute (Emory University), Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Tulane University Medical Center, New Orleans, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston Medical Center, Department of Medicine, Section of Hem/Onc, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Universal Dermatology, PLLC, Fairport, New York, United States|Columbia Presbyterian, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Rochester School of Medicine, Rochester, New York, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|M.D.Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University of Washington, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Westmead Hospital, Westmead, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Parkville Cancer Clinical Trials Unit, Melbourne, Victoria, Australia|Aarhus University Hospital, Aarhus, Denmark|CHU de Nantes, Nantes, France|Hôpital Saint Louis, Paris, France|CHU Bordeaux - Hopital Haut-Leveque, Pessac, France|Centre Hospitalier Lyon Sud, Pierre-Benite Cedex, France|University Medical Centre Mannheim, Mannheim, Germany|University Hospital Muenster, Muenster, Germany|Institute of Hematology and Oncology Lorenzo e Ariosto Seràgnoli, University of Bologna, Bologna, Italy|Universita degli Studi di Torino, Turin, Italy|Nagoya City University Hospital, Nagoya-shi, Aichi, Japan|Fukushima Medical University Hospital, Fukushima-shi, Fukushima, Japan|Gunma University Hospital, Maebashi-shi, Gunma, Japan|Hiroshima University Hospital, Hiroshima-shi, Hiroshima, Japan|Asahikawa Medical University Hospital, Asahikawa, Hokkaido, Japan|Imamura Bun-in Hospital, Kagoshima-shi, Kagoshima, Japan|Yokohama City University Hospital, Yokohama-shi, Kanagawa, Japan|Kochi Medical School Hospital, Nankoku-shi, Kochi, Japan|Mie University Hospital, Tsu-shi, Mie, Japan|Tohoku University Hospital, Sendai-shi, Miyagi, Japan|Shinshu University Hospital, Matsumoto-shi, Nagano, Japan|Okayama University Hospital, Okayama-shi, Okayama, Japan|Kansai Medical University Hospital, Hirakata-shi, Osaka, Japan|Osaka University Hospital, Suita-shi, Osaka, Japan|Hamamatsu University Hospital, Hamamatsu-shi, Shizuoka, Japan|The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|Tokyo Metropolitan Tama Medical Center, Fuchu-shi, Tokyo, Japan|Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan|Leiden University Medical Center - Leids Universitair Medisch Centrum (LUMC), Leiden, Netherlands|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|University Hospital Zurich, Zurich, Switzerland|The Christie Hospital Foundation NHS Trust, Manchester, Greater Manchester, United Kingdom|University Hospital Birmingham, Birmingham, United Kingdom|Guys & St. Thomas NHS Trust, London, United Kingdom",https://ClinicalTrials.gov/show/NCT01728805
286,Bristol-Myers Squibb,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),"Active, not recruiting",Has Results,Hodgkin Disease,Drug: Nivolumab|Drug: Doxorubicin|Drug: Vinblastine|Drug: Dacarbazine,Industry,Interventional,"Cedars Sinai Medical Center, Los Angeles, California, United States|Division Of Hematology & Oncology Ctr. For Health Sciences, Los Angeles, California, United States|Winship Cancer Center, Atlanta, Georgia, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|The Cancer Center At Hackensack University Medical Center, Hackensack, New Jersey, United States|Weill Cornell Med Coll/Ny Pres, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Md Anderson Can Cnt, Houston, Texas, United States|Universitaetsklinikum Innsbruck, Innsbruck, Austria|Department Fuer Haematologie, Wien, Austria|Local Institution, B-leuven, Belgium|Local Institution, Gent, Belgium|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Praha 2, Czechia|Local Institution, Berlin, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|Universitaetsklinikum Koeln, Koeln, Germany|University Hopistal ULM Dept of Internal Medizin, Ulm, Germany|Local Institution, Bologna, Italy|Local Institution, Napoli, Italy|Istituto Clinico Humanitas, Rozzano (milano), Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Utrecht, Netherlands|Hospital Costa Del Sol, Marbella, Malaga, Spain|Hospital Duran I Reynals, Hospitalet Llobregat- Barcelona, Spain|Hosp. Univ. Puerta De Hierro, Majadahonda - Madrid, Spain|Singleton Hospital, Swansea, Carmarthenshire, United Kingdom|The Christie NHS Foundation Trust, Withington, Manchester, United Kingdom|Churchill Hospital, Oxford, Oxfordshire, United Kingdom|The Royal Marsden Hospital, Sutton, United Kingdom",https://ClinicalTrials.gov/show/NCT02181738
287,Bristol-Myers Squibb,A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib,"Active, not recruiting",Has Results,Leukemia,Drug: Dasatinib,Industry,Interventional,"Phoenix Children'S Hospital, Phoenix, Arizona, United States|Jonathan Jaques Children'S Cancer Center, Long Beach, California, United States|Children'S Hospital Of Orange County, Orange, California, United States|Children'S Hospital, Aurora, Colorado, United States|Children's Healthcare Of Atlanta - Egleston, Atlanta, Georgia, United States|Children's Hospital of Chicago, Chicago, Illinois, United States|Dana Faber Cancer Institute, Boston, Massachusetts, United States|Stephen D. Hassenfeld Children'S Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Oregon Health & Sci Univ, Portland, Oregon, United States|Children'S Hospital Of Philadelphia, Philadelphia, Pennsylvania, United States|Children'S Hospital Of Pittsburgh, Pittsburgh, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|Texas Children'S Cancer Center, Houston, Texas, United States|Seattle Children'S, Seattle, Washington, United States|Local Institution, Bunos Aires, Buenos Aires, Argentina|Hospital Nacional Profesor Alejandro Posadas, El Palomar, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Randwick, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Sth Brisbane, Queensland, Australia|Local Institution, North Adelaide, South Australia, Australia|Local Institution, Parkville, Victoria, Australia|Local Institution, Curitiba, Parana, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Campinas, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Alberta Children'S Hospital, Calgary, Alberta, Canada|Stollery Children'S Hospital, Edmonton, Alberta, Canada|Bc Children'S Hospital, Vancouver, British Columbia, Canada|Iwk Health Centre, Halifax, Nova Scotia, Canada|Children'S Hospital Of Eastern Ontario, Ottawa, Ontario, Canada|The Hospital For Sick Children, Toronto, Ontario, Canada|Chu Ste-Justine, Montreal, Quebec, Canada|Local Institution, Lyon, France|Local Institution, Nantes, France|Local Institution, Paris Cedex 12, France|Local Institution, Paris, France|Local Institution, Poitiers, France|Local Institution, Frankfurt, Germany|Local Institution, Hannover, Germany|Local Institution, Navrangpura, Ahmedabad, Gujarat, India|Local Institution, Bangalore, Karnataka, India|Local Institution, Pune, Maharashtra, India|Local Institution, Madurai, Tamil NADU, India|Local Institution, Vellore, Tamilnadu, India|Local Institution, Kolkatta, India|Local Institution, Mumbai, India|Local Institution, Trivandrum, India|Local Institution, Bologna, Italy|Local Institution, Monza (MB), Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, Torino, Italy|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Mexico, D. F., Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Hospital Civil De Guadalajara - Nuevo Dr. Juan I. Menchaca, Guadalajara, Jalisco, Mexico|Local Institution, Monterrey, N.l., Nuevo LEON, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Rotterdam, Netherlands|Local Institution, Bucharest, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Saint-petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Bloemfontein, FREE State, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, Tygerberg, Western CAPE, South Africa|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Valencia, Spain|Local Institution, Glasgow, Central, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom|Local Institution, Birmingham, WEST Midlands, United Kingdom",https://ClinicalTrials.gov/show/NCT00777036
288,Celgene,An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML),"Active, not recruiting",Has Results,"Leukemia, Myeloid, Acute|Myelodysplastic Syndromes",Drug: Azacitidine|Biological: Durvalumab,Industry,Interventional,"Yale Cancer Center, New Haven, Connecticut, United States|Georgetown University Hospital, Washington, District of Columbia, United States|University of Florida, Gainesville, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|University of Chicago, Chicago, Illinois, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas- MD Anderson, Houston, Texas, United States|Medizinische Universitat Graz, Graz, Austria|Medizinische Universitat Innsbruck, Innsbruck, Austria|Elisabethinen Hospital Linz, Linz, Austria|Salzburger Landkliniken St. Johanns-Spital, Salzburg, Austria|AKH Wien, Wein, Austria|Hanusch Krankenhaus der Stadt Wien, Wien, Austria|Cliniques Universitaires St-Luc, Brussels, Belgium|Grand Hopital de Charleroi, Charleroi, Belgium|UH Gent, Gent, Belgium|UH Gasthuisberg, Leuven, Belgium|Cliniques Universitaires UCL de Mont-Godine, Yvoir, Belgium|University of Alberta, Edmonton, Alberta, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Saint John Regional Hospital, Saint John, New Brunswick, Canada|Ottawa General Hospital, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CHUM - Notre Dame, Montreal, Quebec, Canada|Centre Hospitalier Universitaire d' Angers, Angers, France|Hopital Avicenne, Bobigny Cedex, France|Hopital Henri Mondor, Creteil, France|Centre Hospitalier Universitaire de Grenoble Hopital Albert Michallon, La Tronche, France|Centre Leon Berard, Lyon, France|CHRU de Nantes - Hotel Dieu, Nantes, France|Hopital Saint Louis, Paris, France|CHU Bordeaux, Pessac, France|Centre Hospitalier Lyon Sud, Pierre-Bénite Cedex, France|IUCT Oncopole, Toulouse, France|Universitatsklinikum Carl Gustav Carus, Dresden, Germany|Marien Hospital, Dusseldorf, Germany|Universitatsklinikum Essen, Essen, Germany|Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt am Main, Germany|Universitatsklinikum Freiburg, Freiburg, Germany|Medizinische Hochschule HannoverZentrum Innere Medizin, Hannover, Germany|Universitatsklinikum Leipzig, Leipzig, Germany|Klinikum der LMU Campus Grosshadern, Munchen, Germany|Klinikum rechts der Isar der TU Munchen, Munchen, Germany|Universitatsklinikum Ulm, Ulm, Germany|AO Spedali Civili di Brescia, Brecia, Italy|Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy|Ospedale Niguarda Milano, Milano, Italy|Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy|I.R.C.C.S. Policlinico San Matteo - Universita di Pavia, Pavia, Italy|Azienda Ospedaliera Bianchi-Melacrino-Morelli, Roma, Italy|Policlinico Agostino Gemelli - Istituto di Ematologia, Roma, Italy|Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Rome, Italy|Azienda Ospedaliero-Universitaria Santa Maria della Misericordia die Udine, Udine, Italy|Universita degli Studi dell'Insubria - Ospedale di Circolo e Fondazione Macchi - Varese, Varese, Italy|VU University Medical Center, Amsterdam, Netherlands|Oddzial Hematologii Onkologicznej Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologicz, Brzozow, Poland|Katedra i Klinika Hematologii i Transplantologii Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1 Klinika Hematoonkologii i Transplantacji Szpiku, Lubin, Poland|Oddzial Hematologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej MSW, Olsztyn, Poland|Klinika Hematologii Nowotworow Krwi i Transplantacji Szpiku, Wroclaw, Poland|Hospitais da Universidade de Coimbra, Coimbra, Portugal|Instituto Portugues de Oncologia de Lisboa Francisco Gentil EPE, Lisbon, Portugal|Ipo Instituto Portugues De Oncologia Porto, Porto, Portugal|Hospital de Sao Joao, Porto, Portugal|Hospital Universitario Vall D hebron, Barcelona, Spain|Hospital Clinic I Provincial de Barcelona, Barcelona, Spain|Complejo Hospitalario San Pedro de Alcantara, Caceres, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Gregorio Maranon, Madrid, Spain|Hospital Universitario Virgen de la Victoria, Malaga, Spain|Hospital Son Llatzer, Palma de Mallorca, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Universitario La Fe, Valencia, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|University Hospital Birmingham, Birmingham, United Kingdom|St James University Hospital, Leeds, United Kingdom|University College London Hospital, London Bloomsbury, United Kingdom|St Bartholomews Hospital, London, United Kingdom|Kings College Hospital, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom",https://ClinicalTrials.gov/show/NCT02775903
289,"Millennium Pharmaceuticals, Inc.|Takeda","An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)","Active, not recruiting",Has Results,"Myelodysplastic Syndromes|Leukemia, Myelomonocytic, Chronic|Leukemia, Myeloid, Acute",Drug: Azacitidine|Drug: Pevonedistat,Industry,Interventional,"University of Alabama, Birmingham, Alabama, United States|Greenville Health System, Little Rock, Arkansas, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Compassionate Cancer Care Medical Group Incorporated, Riverside, California, United States|Rocky Mountain Cancer Centers, Aurora, Colorado, United States|Smilow Cancer Center at Yale New Haven Hospital, New Haven, Connecticut, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Johns Hopkins University, Baltimore, Maryland, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Monter Cancer Center, Lake Success, New York, United States|Weill Cornell Medical College, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Cancer Care Center of South Texas, New Braunfels, Texas, United States|Nebraska Cancer Specialists, The Woodlands, Texas, United States|Texas Oncology - Waco, TX, Tyler, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Medical Oncology Associates, Spokane, Washington, United States|Yakima Valley Memorial Hospital, Yakima, Washington, United States|AZ Sint-Jan AV, Brugge, West-Vlaanderen, Belgium|Grand Hopital de Charleroi asbl, Charleroi, Belgium|Cliniques Universitaires UCL de Mont-Godinne, Yvoir, Belgium|University Multiprofile Hospital for Active Treatment Sv Ivan Rilski EAD, Sofia, Bulgaria|Specialized Hospital for Active Treatment of Haematological Diseases - Sofia, Sofia, Bulgaria|University Multi-Profile Hospital for Active Treatment Dr Georgi Stranski, Sofia, Bulgaria|Sunnybrook Health Science Centre, Toronto, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Fakultni Nemocnice Brno, Brno, Czechia|Fakultni Nemocnice Kralovske Vinohrady, Praha 10, Czechia|CHU de GRENOBLE, Grenoble, France|CHRU Lille, Lille, France|Hopital Saint Louis, Paris, France|Marien Hospital Akademisches Lehrkrankenhaus, Dusseldorf, Germany|Universitatsklinikum Ulm, Ulm, Germany|Tallaght Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Shaare Zedek Medical Center, Jerusalem, Israel|ZIV Medical Center, Safed, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi, Bologna, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy|Azienda Ospedaliero Universitaria San Giovanni Battista Di Torino, Torino, Italy|Hospital Universitario Son Espases, Palma de Mallorca, Baleares, Spain|Hospital Universitario Quironsalud Madrid, Pozuelo De Alarcon, Madrid, Spain|Hospital Universitario Germans Trias i Pujol, Badalona, Spain|ICO I'Hospitalet Hospital Duran i Reynals Instituto Catalan de Oncologia de Hospitalet (ICO), Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de Malaga - Hospital Universitario Virgen de la Victoria, Malaga, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain",https://ClinicalTrials.gov/show/NCT02610777
290,MorphoSys AG,Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi,"Active, not recruiting",Has Results,"Leukemia, Lymphocytic, Chronic, B-Cell|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma",Biological: Tafasitamab|Drug: Idelalisib|Drug: Venetoclax,Industry,Interventional,"Clinical Study Site, Jacksonville, Florida, United States|Clinical Study Site, Rochester, Minnesota, United States|Clinical Study Site, Columbus, Ohio, United States|Clinical Study Site, Graz, Austria|Clinical Study Site, Salzburg, Austria|Clinical Study Site, Wien, Austria|Clinical Study Site, Dresden, Germany|Clinical Study Site, Leipzig, Germany|Clinical Study Site, Muenchen, Germany|Clinical Study Site, Brescia, Italy|Clinical Study Site, Milano, Italy|Clinical Study Site, Gdansk, Poland|Clinical Study Site, Krakow, Poland|Clinical Study Site, Lublin, Poland|Clinical Study Site, Opole, Poland|Clinical Study Site, Bournemouth, United Kingdom|Clinical Study Site, Leeds, United Kingdom",https://ClinicalTrials.gov/show/NCT02639910
291,Amgen,Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma,"Active, not recruiting",Has Results,Melanoma,Drug: Talimogene laherparepvec|Drug: Ipilimumab,Industry,Interventional,"Research Site, Tucson, Arizona, United States|Research Site, Beverly Hills, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, San Francisco, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Lakeland, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Louisville, Kentucky, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Morristown, New Jersey, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Charleston, South Carolina, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Richmond, Virginia, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Bordeaux, France|Research Site, Grenoble Cedex 9, France|Research Site, Lille, France|Research Site, Nantes Cedex 1, France|Research Site, Paris, France|Research Site, Göttingen, Germany|Research Site, Kiel, Germany|Research Site, Tübingen, Germany",https://ClinicalTrials.gov/show/NCT01740297
292,Acerta Pharma BV,"A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)","Active, not recruiting",Has Results,Glioblastoma Multiforme,Drug: ACP-196,Industry,Interventional,"UCLA Neurology-Oncology Program, Los Angeles, California, United States|Stanford Cancer Center, Palo Alto, California, United States|Beth Israel Deaconness Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Weill Cornell Medical College, New York, New York, United States|Northwest Cancer Specialists, Vancouver, Washington, United States",https://ClinicalTrials.gov/show/NCT02586857
293,Celgene,Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes,"Active, not recruiting",Has Results,Myelodysplastic Syndromes,Drug: Oral Azacitidine|Drug: Durvalumab,Industry,Interventional,"Yale University, New Haven, Connecticut, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|University of Chicago Medicine, Chicago, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|James Graham Brown Cancer Center, Louisville, Kentucky, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Hillman Cancer Institute at UPMC, Pittsburgh, Pennsylvania, United States|University of Texas- MD Anderson, Houston, Texas, United States|Cancer Care Centers of South Texas - HOAST, San Antonio, Texas, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Westmead Hospital, Westmead, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Cabrini Hospital, Malvern, Victoria, Australia|Royal Brisbane and Women's Hospital, Herston, Australia|Royal Perth Hospital, Perth, Australia|Universitair Ziekenhuis Brussel, Brussel, Belgium|Hopital Erasme, Bruxelles, Belgium|Centre Hospitalier Universitaire de Liege, Liège, Belgium|Clinique Saint-Pierre, Ottignies, Belgium|Institut Paoli Calmettes, Marseille Cedex 9, France|Hopital Saint-Louis, Paris, France|CHU Purpan, Toulouse, France|Universitatsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Germany|Marien Hospital, Dusseldorf, Germany|Universitatsklinikum Freiburg, Freiburg, Germany|Universitatsklinikum Halle Saale, Halle, Germany|Universitatsklinikum Leipzig, Leipzig, Germany|Medizinische Klinik III Klinikum der Universität München-Großhadern, München, Germany|Azienda Ospedaliera Santi Antonio Biagio E Cesare Arrigo, Allessandria, Italy|Azienda Ospedaliera Universitaria Policlinico Sant Orsola Malpighi, Bologna, Italy|Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy|Ospedale San Raffaele S.r.l., Milano, Italy|Azienda Ospedaliera Sant Andrea, Roma, Italy|Zaklad Opieki Zdrowotnej MSW z Warminsko-Mazurskim Centrum Onkologii, Olsztyn, Poland|MTZ Clinical Research Sp. z o.o., Warszawa, Poland|Uniwersytecki Szpital Kliniczny, Wroclaw, Poland|Institut Calatà d'Oncologia, L'Hospitalet, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Virgenes de las Nieves, Granada, Spain|Hospital General Gregorio Maranon, Madrid, Spain|Hospital Universitario Virgen De La Victoria, Malaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|CEIC Hospital Universitario La Fe, Valencia, Spain|United Lincolnshire Hospitals NHS Trust, Boston, United Kingdom|Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, United Kingdom|Broomfield Hospital, Chelmsford, United Kingdom|Saint James University Hospital, Leeds, United Kingdom|King's College HospitalSchool of Medicine, London, United Kingdom|Hammersmith Hospital, London, United Kingdom|University College London, London, United Kingdom|Northwick Park Hospital, Middlesex, United Kingdom|Southampton General Hospital, Southampton, United Kingdom",https://ClinicalTrials.gov/show/NCT02281084
294,"Janssen Research & Development, LLC",Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment,"Active, not recruiting",Has Results,Myelodysplastic Syndromes,Drug: Talacotuzumab|Drug: Daratumumab,Industry,Interventional,"Washington University School of Medicine, Saint Louis, Missouri, United States|University of Pennsylvania-Abramson Cancer Center, Philadelphia, Pennsylvania, United States|University of Texas, MD Anderson Cancer Center, Houston, Texas, United States|ZNA Stuivenberg, Antwerp, Belgium|Az Groeninge, Kortrijk, Belgium|UZ Leuven, Leuven, Belgium|AZ Turnhout, Turnhout, Belgium|Azienda Opedaliero-Universitaria Policlinico Sant'orsola Malpighi di Bologna, Bologna, Italy|Azienda Ospedaliero Universitaria Careggi, Firenze, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Pad. Marcora, Milano, Italy|Istituto Clinico Humanitas, Rozzano, Italy|Haga ziekenhuis, Den Haag, Netherlands|UMCG, Groningen, Netherlands|Erasmus MC, Rotterdam, Netherlands|City Clinical Hospital # 40, Moscow, Russian Federation|Nizhniy Novgorod Region Clinical Hospital, Nizhny Novgorod, Russian Federation|Saint Petersburg City Hospital #15, Saint-Petersburg, Russian Federation|Hosp. Univ. Vall D'Hebron, Barcelona, Spain|Hosp. Univ. de La Princesa, Madrid, Spain|Hosp. Clinico Univ. de Salamanca, Salamanca, Spain|Hosp. Univ. I Politecni La Fe, Valencia, Spain",https://ClinicalTrials.gov/show/NCT03011034
295,Hoffmann-La Roche,A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma,"Active, not recruiting",Has Results,"Lymphoma, Follicular",Drug: Atezolizumab (MPDL3280A) [TECENTRIQ]|Drug: Lenalidomide|Drug: Obinutuzumab,Industry,Interventional,"University of Alabama at Birmingham, Birmingham, Alabama, United States|University Miami, Miami, Florida, United States|Norton Medical Plaza II, Louisville, Kentucky, United States|Memorial Sloan-Kettering Cancer Center; Hematology/Oncology, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Hopital Henri Mondor; 51 Av Mal Lattre De Tassigny, Creteil, France|Hopital du Bocage, Dijon, France|Centre Jean Bernard, Le Mans, France|Centre Hospitalier Le Mans, Le Mans, France|CHRU de Lille - Hopital Claude Huriez, Lille, France|CHU Montpellier - Saint ELOI, Montpellier, France|CHU - Hôtel Dieu hematolgie clinique, Nantes, France|Centre Hospitalier Lyon Sud; Hematolgie, Pierre Benite, France|CHU de Rennes - Hopital de Pontchaillo, Rennes, France|Centre Henri Becquerel, Rouen, France|Chu Toulouse, Toulouse, France",https://ClinicalTrials.gov/show/NCT02631577
296,Amgen,Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma,"Active, not recruiting",Has Results,Unresected Stage IIIb to IVM1c Melanoma,Drug: Talimogene Laherparepvec,Industry,Interventional,"Research Site, Salt Lake City, Utah, United States|Research Site, Salzburg, Austria|Research Site, Wien, Austria|Research Site, Bruxelles, Belgium|Research Site, Bruxelles, Belgium|Research Site, Liege, Belgium|Research Site, Boulogne Billancourt, France|Research Site, Marseille cedex 05, France|Research Site, Nantes Cedex 1, France|Research Site, Paris, France|Research Site, Poitiers Cedex, France|Research Site, Essen, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Heraklion - Crete, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Pecs, Hungary|Research Site, Szeged, Hungary|Research Site, Bergamo, Italy|Research Site, Milano, Italy|Research Site, Siena, Italy|Research Site, Amsterdam, Netherlands|Research Site, Groningen, Netherlands|Research Site, Konin, Poland|Research Site, Warszawa, Poland|Research Site, Moscow, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Badalona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, San Sebastian, País Vasco, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, London, United Kingdom|Research Site, Wirral, United Kingdom",https://ClinicalTrials.gov/show/NCT02366195
297,Celgene,The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS),"Active, not recruiting",Has Results,Myelodysplastic Syndrome,Drug: Oral Azacitidine|Drug: Placebo|Other: Best Supportiv Care (BSC),Industry,Interventional,"Alta Bates Comprehensive Cancer Center, Berkeley, California, United States|Tower Hematology/Oncology Medical Group and Tower Cancer Research Found, Beverly Hills, California, United States|City of Hope, Duarte, California, United States|California Cancer Associates for Research and Excellence cCARE, Escondido, California, United States|Marin Oncology Associates, Greenbrae, California, United States|UCSD-Thornton Hospital, La Jolla, California, United States|University of Southern California Norris Cancer Center, Los Angeles, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|University of Florida Health Cancer Center at Orlando Health, Orlando, Florida, United States|Phoebe Cancer Center of Phoebe Putney Memorial Hospital, Albany, Georgia, United States|Robert H Lurie Comprehensive Cancer Center NW Univ, Chicago, Illinois, United States|University of Illinois at Chicago, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Loyola University Chicago, Maywood, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Louisville, J.G. Brown Cancer Center, Louisville, Kentucky, United States|Hematology and Oncology Specialists, LLC, Metairie, Louisiana, United States|Johns Hopkins Medicine, Baltimore, Maryland, United States|UMASS Memorial Hospital, Worcester, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Jackson Oncology Associates PLLC, Jackson, Mississippi, United States|Saint Luke's Cancer Institute, Kansas City, Missouri, United States|Kansas City VA Medical Center University of Kansas Medical Center, Kansas City, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Weill Cornell Medical College - New York - Presbyterian Hospital, New York, New York, United States|Icahn School of Medicine at Mount Sinai Medical Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Eastern Institute of Medical Sciences, Greenville, North Carolina, United States|University Hospitals of Cleveland Case Medical Center, Cleveland, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Kaiser Permanente Northwest Oncology Hematology, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Western Pennsylvania Cancer Institute, Pittsburgh, Pennsylvania, United States|Brooke Army Medical Center Francis Street Medical Center, Fort Sam Houston, Texas, United States|MD Anderson Cancer Center The University of Texas, Houston, Texas, United States|Michael Debakey VA Medical Center, Houston, Texas, United States|Millenium Oncology, Houston, Texas, United States|VA Commonwealth University Massey Cancer Center, Richmond, Virginia, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|Canberra Hospital, Garran, Australian Capital Territory, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Frankston Hospital, Frankston, Victoria, Australia|Royal Prince Alfred Hospital, Sydney Cancer Centre, Camperdown, Australia|The Northern Hospital, Epping, VIC, Australia|St Vincent's Hospital Melbourne, Fitzroy, Australia|St George Hospital, Kogarah, Australia|Cabrini Hospital, Malvern, Australia|Haematoloy and Oncology Clinics of Australia, Milton, Brisbane, Australia|Calvary Mater New Castle, Waratah, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|Algemeen Ziekenhuis Klina, Brasschaat, Belgium|AZ St-Jan Brugge Oostende AV, Brugge, Belgium|Grand Hopital de Charleroi, Charleroi, Belgium|UZ Leuven, Leuven, Belgium|Universidade Federal do Ceara, Fortaleza, Ceará, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Erasto Gaertner, Curitiba, Brazil|MS INCA HC I Hospital do Cancer I, Rio De Janeiro, Brazil|Hospital Albert Einstein Sociedade Beneficente Israelita Brasileira, Sao Paulo, Brazil|University of Alberta Hospital Adult Hematology Research, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Royal Victoria Hospital, Barrie, Barrie, Ontario, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Princess Margaret Hospital University Health Network, Toronto, Ontario, Canada|McGill University, Dept. Oncology Clinical Research Program, Montreal, Quebec, Canada|Hopital du Sacre-Coeur de Montreal, Montreal, Quebec, Canada|Fakultni nemocnice Brno, Brno, Czechia|University Hospital Hradec Kralove, Hradec Králové, Czechia|University Hospital Olomouc, Olomouc, Czechia|Vseobecna Fakultni Nemocnice v Praze, Praha, Czechia|Ustav hematologie a krevni transfuze, Praha, Czechia|Aarhus University Hospital, Aarhus, Denmark|Onk.Dep., Odense Universitets hospital, Odense C, Denmark|Roskilde Hospital, Roskilde, Denmark|Helsinki University Central Hospital, Helsinki, Finland|Turku University Hospital, Turku, Finland|CHRU de Lille-Hopital Claude Huriez Service des Maladies du Sang, Lille, France|Institute Paoli-Calmettes Service Haematology, Marseille Cedex 9, France|CHU Nantes Hotel Dieu, Nantes, France|Hospital Saint Louis, Paris, France|Centre Hospitalier Lyon Sud, Pierre-Bénite Cedex, France|CHRU Hôpital de Pontchaillou, Rennes Cedex, France|Centre Henri Becquerel, Rouen Cedex, France|Hopital Civil de Strasbourg, Strasbourg, France|Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse Cedex 9, France|Hopital Bretonneau, Tours, France|Gemeinschaftspraxis Haematologie-Onkologie, Dresden, Germany|Universitatsklinikum Carl Gustav Carus, Dresden, Germany|Marien Hospital, Duesseldorf, Germany|Universitatsklinkikum DusseldorfKlinik fur Hamatologie, Onkologie und klin. Immunoligie, Dusseldorf, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|Universitatsklinikum Schleswig-Holstein, Keil, Germany|Universitatsklinikum Leipzig, Leipzig, Germany|TU München - Klinikum rechts der Isar, München, Germany|University Hospital Tubingen, Tubingen, Germany|Universitatsklinikum Ulm, Ulm, Germany|Democritus University of Thrace, Alexandroupolis, Greece|Evangelismos General Hospital of Athens, Athens, Greece|Laiko General Hospital, Athens, Greece|Attikon General University Hospital of Athens, Athens, Greece|University General Hospital of Heraklion, Heraklion, Greece|University of Patras, Patras, Greece|Rambam Medical Center, Haifa, Israel|Rabin Medical Center, Petach Tikva, Israel|Sheba Medical Center, Tel Hashomer, Israel|Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel|Az. Osp. SS.Antonio e Biagio - SC Ematologia, Alessandria, Italy|Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari, Italy|Policlinico S. Orsola Malpighi, Bologna, Italy|U.O. Ematologia. Ospedale Oncologico di Riferimento Regionale Armando Businco, Cagliari, Italy|Azienda Ospedaliero Universitaria Careggi, Firenze, Italy|AUSL LE1 - Vito Fazzii Hospital Medical Oncology Department, Lecce, Italy|Opsedale Maggiore Policlinico and University, Milano, Italy|IRCCS - Istituo Clinico Humanitas - Humanitas Cancer Center, Milan, Italy|A.O.U. Maggiore della Carità, Novara, Italy|Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Ospedale S. Chiara, Pisa, Italy|Azienda Ospedaliera ""Bianchi-Melacrino-Morelli"", Reggio Calabria, Italy|IRCCS Centro di Riferimento Oncologico di Basilicata, Rionero in Vulture, Italy|Fondazione PTV Policlinico Tor Vergata, Roma, Italy|Policlinico Umberto I, Roma, Italy|Policlinico Universitario ""A. Gemelli"", Roma, Italy|AO Santa Maria, Terni, Italy|Azienda Ospedaliera San Giovanni Battista, Torino, Italy|Ospedale Umberto I, Torrette Di Ancona, Italy|Policlinico Univeristario di Udine, Udine, Italy|Ospedale dell Angelo di Mestre, Venezia - Mestre, Italy|Inje University Busan Paik Hospital, Busan, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul St Marys Hospital College of Medicine The Catholic University of Korea, Seoul, Korea, Republic of|Hospital Angeles Lomas - Consultorio 830, Huixquilucan de Degollado, Mexico|Hospital Universitario ""Dr. Jose E. Gonzalez"", Monterrey, Mexico|AVIX Investigacion Clinica, Monterrey, Mexico|Instituto Nacional de Cancerologia, Tlalpan, Mexico|VU University Medical Center, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|UMC St Radboud, Nijmegen, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|Helse Forde HF Central hospital, Førde, Norway|Oslo University Hospital, Rikshospitalet HF, Oslo, Norway|Szpital Uniwersytecki nr 2 im dr. Jana Biziela, Bydgoszcz, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Uniwersytet Jagiellonski Collegium Medicum, Krakow, Poland|Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi, Lodz, Poland|Specjalistyczny Szpital Miejski im. M. Kopernika w Toruniu, Torun, Poland|Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie, Warszawa, Poland|Instytut Hematologii i Transfuzjologii, Klinika Hematologii, Warszawa, Poland|Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie, Wroclaw, Poland|ULSBA (Unidade Local de Saúde do Baixo Alentejo, EPE) - Hospital de Beja, Beja, Portugal|Hospital Universitario de Coimbra, Coimbra, Portugal|Instituto Portugues de Oncologia de Lisboa, Lisboa, Portugal|Centro Hospitalar de Lisboa Central - Hospital de Santo António dos Capuchos, Lisboa, Portugal|Instituto Portugues de Oncologia do Porto, Porto, Portugal|Hospital Universitari Germans Trias i Pujol, Badalona (Barcelona), Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario Vall D Hebron, Barcelona, Spain|Complejo Hospitalario Universitario de Granada, Granada, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen de la Victoria, Malaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen del Rocio, Seville, Spain|Hospital Txagorritxu - Hospital Universitario de Álava, Vitoria-Gasteiz, Álava, Spain|SU/Sahlgrenska, Section of Haematology and Coagulation, Goeteborg, Sweden|University Hospital in Lund, Lund, Sweden|Karolinska Universitetssjukhuset - Huddinge, Stockholm, Sweden|Baskent University Medical Faculty Adana Practice and Research Center, Adana, Turkey|Antalya Egitim Arastirma, Antalya, Turkey|Istanbul University Cerrahpasa, Istanbul, Turkey|Istanbul University Faculty of Medicine, Istanbul, Turkey|Mersin University Medical Faculty, Mersin, Turkey|Karadeniz Teknik Universitesi Tip Fakultesi Farabi Hastanesi, Trabzon, Turkey|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|Birmingham Heartlands Hospital, Birmingham, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, United Kingdom|Addenbrookes Hospital, Cambridge, United Kingdom|University Hospital of Wales - Cardiff, Cardiff, United Kingdom|Northwick Park Hospital, Harrow Middlesex, United Kingdom|Queens Centre for Oncology & Haematology, Hull, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Royal Liverpool University Hospital, Prescot Street, Liverpool, United Kingdom|Barts and The London NHS Trust, London, United Kingdom|Guy's and St Thomas' Hospital - London, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|Nottingham City Hospital - Dept of Haematology, Nottingham, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|Kings Mill Hospital, Sutton in Ashfield, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom",https://ClinicalTrials.gov/show/NCT01566695
298,"Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Millennium Pharmaceuticals, Inc.","Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma","Active, not recruiting",Has Results,Mantle Cell Lymphoma,Drug: bortezomib,Other|NIH|Industry,Interventional,"UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Illinois CancerCare - Bloomington, Bloomington, Illinois, United States|St. Joseph Medical Center, Bloomington, Illinois, United States|Graham Hospital, Canton, Illinois, United States|Illinois CancerCare - Canton, Canton, Illinois, United States|Illinois CancerCare - Carthage, Carthage, Illinois, United States|Memorial Hospital, Carthage, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Eureka Community Hospital, Eureka, Illinois, United States|Illinois CancerCare - Eureka, Eureka, Illinois, United States|Galesburg Clinic, PC, Galesburg, Illinois, United States|Illinois CancerCare - Galesburg, Galesburg, Illinois, United States|Illinois CancerCare - Havana, Havana, Illinois, United States|Mason District Hospital, Havana, Illinois, United States|Illinois CancerCare - Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare - Macomb, Macomb, Illinois, United States|McDonough District Hospital, Macomb, Illinois, United States|Illinois CancerCare - Monmouth, Monmouth, Illinois, United States|OSF Holy Family Medical Center, Monmouth, Illinois, United States|BroMenn Regional Medical Center, Normal, Illinois, United States|Community Cancer Center, Normal, Illinois, United States|Illinois CancerCare - Community Cancer Center, Normal, Illinois, United States|Community Hospital of Ottawa, Ottawa, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Ottawa, Ottawa, Illinois, United States|Illinois CancerCare - Pekin, Pekin, Illinois, United States|Proctor Hospital, Peoria, Illinois, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF St. Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare - Peru, Peru, Illinois, United States|Illinois Valley Community Hospital, Peru, Illinois, United States|Illinois CancerCare - Princeton, Princeton, Illinois, United States|Perry Memorial Hospital, Princeton, Illinois, United States|Illinois CancerCare - Spring Valley, Spring Valley, Illinois, United States|Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, Saint Louis, Missouri, United States|Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Monter Cancer Center of the North Shore-LIJ Health System, Lake Success, New York, United States|CCOP - North Shore University Hospital, Manhasset, New York, United States|Don Monti Comprehensive Cancer Center at North Shore University Hospital, Manhasset, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States|SUNY Upstate Medical University Hospital, Syracuse, New York, United States|Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",https://ClinicalTrials.gov/show/NCT00310037
299,"Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Genentech, Inc.|Biologics, Inc.",Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,"Active, not recruiting",Has Results,Leukemia|Lymphoma,Biological: rituximab|Drug: busulfan|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: methotrexate|Drug: sirolimus|Drug: tacrolimus|Procedure: allogeneic stem cell transplant,Other|NIH|Industry,Interventional,"City of Hope Comprehensive Cancer Center, Duarte, California, United States|Tunnell Cancer Center at Beebe Medical Center, Lewes, Delaware, United States|CCOP - Christiana Care Health Services, Newark, Delaware, United States|Florida Hospital Cancer Institute at Florida Hospital Orlando, Orlando, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States|Union Hospital of Cecil County, Elkton, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, United States|Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, Saint Louis, Missouri, United States|UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, United States|Cancer Institute of New Jersey at Cooper - Voorhees, Voorhees, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Monter Cancer Center of the North Shore-LIJ Health System, Lake Success, New York, United States|CCOP - North Shore University Hospital, Manhasset, New York, United States|Don Monti Comprehensive Cancer Center at North Shore University Hospital, Manhasset, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States|New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Oklahoma University Cancer Institute, Oklahoma City, Oklahoma, United States",https://ClinicalTrials.gov/show/NCT01027000
300,"Ludwig Institute for Cancer Research|MedImmune LLC|Cancer Research Institute, New York City|Cure Brain Cancer Foundation, Australia",Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma,"Active, not recruiting",Has Results,Glioblastoma,Drug: Durvalumab|Radiation: Standard radiotherapy|Biological: Bevacizumab,Other|Industry,Interventional,"Research Facility, Los Angeles, California, United States|Research Facility, San Francisco, California, United States|Research Facility, Baltimore, Maryland, United States|Research Facility, Boston, Massachusetts, United States|Research Facility, Boston, Massachusetts, United States|Research Facility, Saint Louis, Missouri, United States|Research Facility, New York, New York, United States|Research Facility, Melbourne, Australia",https://ClinicalTrials.gov/show/NCT02336165
301,Dana-Farber Cancer Institute|Pharmacyclics LLC.|The Leukemia and Lymphoma Society|Blood Cancer Research Partnership,"A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia","Active, not recruiting",Has Results,Chronic Lymphocytic Leukemia|Leukemia,Drug: Ibrutinib|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Rituximab,Other|Industry,Interventional,"University of Miami Sylvester Comprehensive Cancer Center, Coral Gables, Florida, United States|University of Miami Sylvester Comprehensive Cancer Center, Deerfield Beach, Florida, United States|Unversity of Miami Sylvester Comprehensve Cancer Center, Miami, Florida, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Duke University Medical Center, Durham, North Carolina, United States",https://ClinicalTrials.gov/show/NCT02251548
